(19) World Intellectual Property Organization. International Bureau





(43) International Publication Date 12 July 2001 (12.07.2001)

(10) International Publication Number WO 01/49721 A2

- (51) International Patent Classification7: C07K 14/195, C12N 15/31, G01N 33/68, C12Q 1/68, A61K 48/00, 38/16, G01N 33/50
- (21) International Application Number: PCT/US00/35604

(22) International Filing Date:

29 December 2000 (29.12.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/174,089

30 December 1999 (30.12.1999)

- (71) Applicant (for all designated States except US): BRIS-TOL-MYERS SQUIBE COMPANY [US/US]; P.O. Box 4000, Lawrenceville-Princeton Road, Princeton, NJ 08543-4000 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): DOUGHERTY, Thomas, J. [US/US]; 791 Ives Row, Cheshire, CT 06410 (US). PUCCI, Michael, J. [US/US]; 182 Stocking Brook Road, Kensington, CT 06037 (US). DOUGHERTY, Brian, A. [US/US]; 10 Rosemary Lane, Killingworth, CT 06419 (US). DAVISON, Daniel, B. [US/US]; 37 Marks Court, Branford, CT 06405 (US). BRUCCOLERI,

Robert, E. [US/US]; 105 Corine Drive, Pennington, NJ 08543 (US). THANASSI, Jane, A. [US/US]; 552 Woodhouse Avenue, Wallingford, CT 06492 (US).

- (74) Agents: SHER, Audrey; Bristol-Myers Squibb Company, P.O. Box 4000, Lawrenceville-Princeton Road, Princeton, NJ 08543-4000 et al. (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL BACTERIAL GENES AND PROTEINS THAT ARE ESSENTIAL FOR CELL VIABILITY AND THEIR USES

(57) Abstract: The present invention provides novel bacterial genes and their encoded polypeptides thereof which are essential for bacterial cell viability, and their uses.

NOVEL BACTERIAL GENES AND PROTEINS THAT ARE ESSENTIAL FOR CELL VIABILITY AND THEIR USES

Throughout this application various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

FIELD OF THE INVENTION

15

5

The present invention relates generally to nucleotide sequences, and polypeptides encoded by the sequences, that are essential for bacterial viability, and to methods of using the nucleotide and polypeptide sequences.

20 BACKGROUND OF THE INVENTION

Bacterial genera, such as Streptococcus, Staphylococcus, Pseudomonas, Yersinia, Salmonella, and Enterobacter, are the cause of numerous afflictions in humans and animals. Bacterial infection can lead to serious health conditions, including pneumonia, osteomyelitis, meningitis, sinusitis, otitis, cystitis, and even food poisoning. Typically, these infections can be treated with standard antimicrobial agents such as antibiotics. However, the emergence of pathogenic bacterial strains that are resistant to antibiotics has risen alarmingly in the past two decades. This situation has created an urgent need for the development of new antimicrobial agents.

30

25

One strategy for developing new antimicrobial agents is to identify bacterial gene sequences that encode gene products that are essential for bacterial cell viability and

develop and/or identify agents which inhibit the function of the gene product. DNA sequencing technology has advanced from sequencing one gene at a time to sequencing entire genomes, the sum of all genes in an organism. With the recent arrival of bacterial genomic information, it is now possible to compare multiple bacterial genomes in an attempt to identify genes that encode conserved gene products. In this manner, one skilled in the art may identify a set of conserved bacterial genes, including a subset of genes that are essential for bacterial cell viability. The essential gene is then used as a starting point to develop therapeutic agents that inhibit or inactivate the product of the essential gene.

10

15

5

The availability of DNA sequence information for multiple microbial genomes is a recent development. The public release of the first complete genome, *Haemophilus influenzae* (Fleischmann, R.D., et al. 1995 *Science* 269:496-512), was followed in rapid succession by a number of public and private genome sequencing programs. Presently, some 20 completely sequenced bacterial genomes have been published, and over 100 other sequencing projects are underway (Blattner, F.R., et al., 1997 *Science* 277:1453-74; Ferretti, J.J., et al., 1997 *Adv Exp Med Biol* 418:961-963; Koonin, E.V., et al., 1996 *Methods Enzymol* 266:295-322). Analyses of these data indicate that approximately 46% of putative bacterial genes are of unknown function having no attributable function.

20

25

30

Others have pursued various strategies to identify bacterial genes that are essential for viability. These strategies include: identifying genes that are expressed by the bacteria when present in the infected host (Hensel, M., et al., 1995 Science 269:400-3), identifying essential genes by isolating temperature sensitive mutants (Schmid, M.B., et al., 1998 Curr Opin Chem Biol 2:529-34), and identifying genes in pathways known from prior physiological studies to be essential (Skarzynski, T. et al., 1996 Structure 1996 4:1465-74)

There continues to be a need to identify bacterial genes that encode gene products that are essential for cell viability, such as cell replication, growth, and survival. These genes and their encoded gene products can be used as a starting point towards identifying agents

that inhibit functions essential for cell viability, thereby causing bacterial cell stasis or death (e.g., antibacterial agents).

The present invention provides experimental identification of novel, conserved essential genes (ceg) from bacteria and their encoded protein products. The ceg genes are considered essential to cell viability because disruption of an endogenous ceg gene results in lethality of a bacterial cell (e.g., as determined by failure to recover viable chloramphenicol-resistant colonies, as described herein). Thus, the gene products encoded by these genes are potentially valuable targets for chemotherapeutic intervention of bacterial infections.

The ceg nucleotide sequences of the invention were obtained by large-scale computational comparisons of multiple genome sequences to identify conserved protein coding regions, followed by gene disruption to identify cegs. The conservation of protein sequences in many cases is believed to reflect the higher level conservation of common biochemical pathways essential for bacterial function and viability.

SUMMARY OF THE INVENTION

5

10

15

30

The acronyms "CEG" and "ceg" stand for Conserved Essential Gene. For convenience, the italicized term ceg refers herein to ceg nucleotide sequences. The capitalized term CEG refers herein to CEG polypeptide sequences.

Embodiments of the *ceg* nucleotide sequences and the CEG polypeptide sequences are
designated CFEs which stands for <u>CEG For Expression</u>. The CFEs are polypeptides resulting from expression of the *ceg* nucleotide sequence.

The present invention provides isolated nucleotide sequences of conserved essential genes from bacteria, designated *ceg*. The invention also provides recombinant nucleic acid molecules including the *ceg* sequences of the invention, and methods of uses thereof. Examples of nucleic acid molecules having *ceg* sequences are described in SEQ ID

NOS.: 1-113. The invention further provides isolated polypeptides and recombinant polypeptides having the CEG sequences of the invention, and methods of uses thereof. Examples of polypeptides having CEG sequences are described in SEQ ID NOS.:114-226.

5

The ceg sequences of the present invention are DNA or RNA. Further, the invention includes nucleic acid molecules that are identical or nearly identical (e.g., similar) with the ceg sequences of the invention. The invention additionally provides polynucleotide sequences that hybridize under stringent conditions to the ceg sequences of the invention.

A further embodiment provides polynucleotide sequences which are complementary to the ceg sequences of the invention. Yet another embodiment provides ceg nucleic acid molecules that are labeled with a detectable marker. Another embodiment provides recombinant nucleic acid molecules, such as a vector or a fusion molecule, including the ceg sequences of the invention.

15

30

10

The present invention provides various ceg sequences, fragments thereof having essential gene activity, and related molecules such as antisense molecules, oligonucleotides, peptide nucleic acids (PNA), fragments, and portions thereof.

- The present invention relates to the inclusion of the polynucleotides encoding CEG gene products, such as CEG polypeptides, in an expression vector which can be used to transform host cells or organisms. Such transgenic hosts are useful for the production of CEG gene products for the development of antibacterial agents such as antibiotics.
- 25 The invention further provides substantially purified CEG gene products, and uses thereof.

The invention also relates to pharmaceutical compositions comprising antisense molecules capable of disrupting expression of *ceg* sequences, agonists, antagonists or inhibitors of CEG gene products, and antibodies reactive against the CEG polypeptides.

These compositions are useful for preventing the growth or survival of bacteria, for example, in the treatment of conditions associated with bacterial infections.

BRIEF DESCRIPTION OF THE FIGURES

5

20

30

- Figure 1: A schematic representation of the gene disruption assay, as described in Example 3, *infra*. A) A recombinant vector undergoing homologous recombination with the host genome. B) The result of homologous recombination.
- Figure 2: A schematic representation of the polarity test for operons, as described in Examples 2 and 3, *infra*. A) The recombinant vector undergoing homologous recombination with the host genome. B) Case 1: one possible result of homologous recombination; the downstream Gene B has an independent promoter. C) Case 2; another possible result of homologous recombination; the downstream Gene B does not have an independent promoter.
 - Figure 3: Purification of 2CFE 75, as described in Example 6, *infra*. A) Fractionation profile of 2CFE 75 eluted from a Ni-NTA column. B) Gel electrophoresis of pooled fractions of CFE 75. C) Non-denaturing gel electrophoresis to determine oligo form of 2CFE 75.
 - Figure 4: Fractionation profile of 2CFE 3 eluted from a hydroxyapatite column, as described in Example 7, *infra*.
- 25 Figure 5: The biosynthesis pathway of Coenzyme A which starts with phosphorylation of pantothenate.
 - Figure 6: Circular dichroism spectra of 2CFE 101 and 103, as described in Example 10, infra. A) Circular dichroism spectra of 2CFE 101 and 103 at 25 degrees C. B) Circular dichroism thermal melt spectra of 2CFE 101 and 103 at a range of zero to 100 degrees C.

Figure 7: Circular dichroism spectra of aggregate and monomer pools of 2CFE 101 and 103, as described in Example 10, *infra*. A) Circular dichroism spectra of aggregate and monomer pools of 2CFE 101 and 103 at 25 degrees C. B) Circular dichroism thermal melt spectra of aggregate and monomer pools of 2CFE 101 and 103 at a range of zero to 100 degrees C.

5

Figure 8: Absorbance spectra of pantothenate-dependent production of ADP, as described in Example 10, *infra*.

Figure 9: The results of size exclusion chromatography and gel electrophoresis showing the oligomeric forms of 2CFE 21 and 39, as described in Example 11, *infra*. Lanes 1-6 contain 2CFE 21, lane 7 is a molecular weight marker, lanes 8-10 contain 2CFE 39.

Figure 10: Gel electrophoresis of a helicase reaction using 2CFE 21 and 39 and radiolabeled synthetic Holliday Junction template, as described in Example 11, *infra*. Lane 1 contains the synthetic Holliday Junction template; lane 2 contains the synthetic duplex; lane 3 contains a single-stranded template; lane 4 contains the helicase reaction using 2CFE 39; lane 5 contains the helicase reaction using 2CFE 21; lanes 6-8 contain the helicase reaction using 2CFE 39 and 21 at varying concentrations (e.g., 1, 2, and 3 μ M each); and lane 9 contains the helicase reaction using 2 μ M each 2CFE 39 and 21 in the presence of ethidium bromide.

20 bro

15

Figure 11: A graph depicting the results of the helicase reaction which were monitored by measuring the unquenching of the Holliday Junction templates with time, as described in Example 11, *infra*.

25

Figure 12: Capillary electrophoresis results of 2CFE 8 with and without ssDNA, as described in Example 12, *infra*. A) Electropherogram of 2CFE 8 alone. B) Electropherogram of 2CFE 8 in the presence of a 32-nucleotide single-stranded oligomer.

Figure 13: Gel mobility shift assay of 2CFE 8, and 2CFE 8 in the presence of a single-stranded 32-mer, as described in Example 12, infra. A) An ethidium bromide-stained,

native, polyacrylamide gel containing 2CFE 8, and 2CFE 8 in the presence of a 32-mer. B) The same native, polyacrylamide gel stained with Coomassie.

Figure 14: The N-acetyl glucosamine pathway putatively mediated by 2CFE 3 and 2CFE 86, as described in Example 13, *infra*.

Figure 15: Capillary electrophoresis results of 2CFE 3 with and without putative substrates, as described in Example 13, *infra*.. A) Electropherogram of 2CFE 3 with and without glucosamine-1-phosphate. B) Electropherogram of 2CFE 3 with and without D-glucose-1-phosphate. C) Electropherogram of 2CFE 3 alone, 2CFE 3 and glucose-1-phosphate, and 2CFE 3 and glucose-6-phosphate. D) Electropherogram of 2CFE 3 alone or in the presence of glucosamine-1-phosphate, glucosamine-6-phosphate, D-glucose, D(+) galactose, and α-D-glucose-1-phosphate.

Figure 16: Capillary electrophoresis results of FITC-derivitized 2CFE 3 polypeptide with and without D-glucosamine-6-phosphate (substrate) to produce the product D-glucosamine-1-phosphate, using laser-induced fluorescence, as described in Example 13, *infra*. Electropherogram of D-glucosamine-6-phosphate (putative substrate), 2CFE 3 reacted with D-glucosamine-6-phosphate, and the product glucosamine-1-phhosphate.

20

10

Figure 17: Gel electrophoresis of 2CFE 86 eluted from an Ni-NTA column, as described in Example 13, *infra*.

Figure 18: HPLC analysis of a coupled reaction including 2CFE 3, 2CFE 86, and D-glucosamine-6-phosphate to produce the product, UDP-N-acetylglucosamine-1-phosphate (UDPAG), as described in Example 13, *infra*.

Figure 19: A fatty acid biosynthesis pathway.

Figure 20: Size exclusion chromatography to determine the molecular weight and oligomeric form of 2CFE 34, as described in Example 14, *infra*.. Selected eluted samples were sized by gel electrophoresis.

- Figure 21: Gel electrophoresis of 2CFE 41 eluted from a Ni-NTA column, as described in Example 15, infra.
 - Figure 22: Capillary electrophoresis results of 2CFE 40, 41, and 46, as described in Example 15, *infra*.

Figure 23: Depicts a schematic diagram of a ligand which binds 2CFE 34. The ligand is 2-phenyl-N-(3 corboxyl-4hydroxyphenyl) azabicyclo [4.3.0] nona-2, 8-diene.

10

25

Figure 24: Depicts a schematic diagram of a ligand which binds 2CFE 43. The ligand is N-15 (3, 5-dinitrobenzyl)-7-trifluoromethyl benza diaza furanolactone.

Figure 25: Depicts a schematic diagram of a ligand which binds 2CFE 43. The ligand is 2-amino (N-para-methylphenyl sulfonamide)-3-phenylpropianic acid.

Figure 26: A nucleic acid sequence of 2CFE1 deposited with the American Type Culture Collection as ATCC designation ______ on December 20, 2000.

Figure 27: A nucleic acid sequence of 2CFE2 deposited with the American Type Culture Collection as ATCC designation ______ on December 20, 2000.

Figure 28: A nucleic acid sequence of 2CFE3 deposited with the American Type Culture Collection as ATCC designation ______ on December 20, 2000.

Figure 29: A nucleic acid sequence of 2CFE4 deposited with the American Type Culture


Collection as ATCC designation ______ on December 20, 2000.

	Figure 30: A nucleic acid sequence of 2CFE5 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
5	Figure 31: A nucleic acid sequence of 2CFE6 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
•	Figure 32: A nucleic acid sequence of 2CFE7 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
10	• • • • • • • • • • • • • • • • • • •
	Figure 33: A nucleic acid sequence of 2CFE8 deposited with the American Type Culture
•	Collection as ATCC designation on December 20, 2000.
	on December 20, 2000.
	Figure 34: A nucleic acid sequence of 2CFE9 deposited with the American Type Culture
15	Collection as ATCC designation on December 20, 2000.
	on December 20, 2000.
	Figure 35: A nucleic acid sequence of 2CFE10 deposited with the American Type Culture
Ŷ	Collection as ATCC designation on December 20, 2000.
	on December 20, 2000.
20	Figure 36: A nucleic acid sequence of 2CFE11 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
	on December 20, 2000.
	Figure 37: A nucleic acid sequence of 2CFE12 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
25	on December 20, 2000.
	Figure 38: A nucleic acid sequence of 2CFE13 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
	on December 20, 2000.
	Figure 39: A nucleic acid sequence of 2CFR14 James 12: 12: 12: 12: 12: 12: 12: 12: 12: 12:
30	Figure 39: A nucleic acid sequence of 2CFE14 deposited with the American Type Culture Collection as ATCC designation on December 20, 2000.
	Collection as ATCC designation on December 20, 2000.

	Figure 40: A nucleic acid sequence of 2CFE15 deposited with the American Type Culture
•	Collection as ATCC designation on December 20, 2000.
	Figure 41: A nucleic acid sequence of 2CFE16 deposited with the American Type Culture
5	Collection as ATCC designation on December 20, 2000.
	Figure 42: A nucleic acid sequence of 2CFE17 deposited with the American Type Culture
,	Collection as ATCC designation on December 20, 2000.
10	Figure 43: A nucleic acid sequence of 2CFE19 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
	Figure 44: A nucleic acid sequence of 2CFE21 deposited with the American Type Culture
15	Collection as ATCC designation on December 20, 2000.
	Figure 45: A nucleic acid sequence of 2CFE24 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
	Figure 46: A nucleic acid sequence of 2CFE25 deposited with the American Type Culture
20	Collection as ATCC designation on December 20, 2000.
	Figure 47: A nucleic acid sequence of 2CFE26 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
25.	Figure 48: A nucleic acid sequence of 2CFE27 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
	Figure 49: A nucleic acid sequence of 2CFE28 deposited with the American Type Culture
30	Collection as ATCC designation on December 20, 2000.

	Figure 50: A nucleic acid sequence of 2CFE29 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
	Figure 51: A nucleic acid sequence of 2CFE30 deposited with the American Type Culture
5	
	Figure 52: A nucleic acid sequence of 2CFE31 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
10	Figure 53: A nucleic acid sequence of 2CFE32 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
	Figure 54: A nucleic acid sequence of 2CFE33 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
15	Figure 55. A suplimental to the second secon
	Figure 55: A nucleic acid sequence of 2CFE34 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
	Figure 56: A nucleic acid sequence of 2CFE35 deposited with the American Type Culture
20	Collection as ATCC designation on December 20, 2000.
	0.2 2000mb01 20, 2000.
	Figure 57: A nucleic acid sequence of 2CFE36 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
25	Figure 58: A nucleic acid sequence of 2CFE37 deposited with the American Type Culture
,	Collection as ATCC designation on December 20, 2000.
	Figure 59. A nucleic acid sequence of 2CEE29 density 4. 4.
	Figure 59: A nucleic acid sequence of 2CFE38 deposited with the American Type Culture Collection as ATCC designation on December 20, 2000.
30	on December 20, 2000.

	Figure 60: A nucleic acid sequence of 2CFE39 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
	Figure 61: A nucleic acid sequence of 2CFE40 deposited with the American Type Culture
5	Collection as ATCC designation on December 20, 2000.
	Figure 62: A nucleic acid sequence of 2CFE41 deposited with the American Type Culture
•	Collection as ATCC designation on December 20, 2000.
10	2012 Additional action of 201242 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
	Figure 64: A nucleic acid sequence of 2CFE43 deposited with the American Type Culture
15	Collection as ATCC designation on December 20, 2000.
	Figure 65: A nucleic acid sequence of 2CFE44 deposited with the American Type Culture
٠.	Collection as ATCC designation on December 20, 2000.
,	Figure 66: A nucleic acid sequence of 2CFE45 deposited with the American Type Culture
. 20	Collection as ATCC designation on December 20, 2000.
	Figure 67: A nucleic acid sequence of 2CFE46 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
25	Figure 68: A nucleic acid sequence of 2CFE47 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
	Figure 69: A nucleic acid sequence of 2CFE48 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
30	






	Figure 90: A nucleic acid sequence of 2CFE70 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
	Figure 91: A nucleic acid sequence of 2CFE71 deposited with the American Type Culture
5	Collection as ATCC designation on December 20, 2000.
	Figure 92: A nucleic acid sequence of 2CFE72 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
10	Figure 93: A nucleic acid sequence of 2CFE75 deposited with the American Type Culture
•	Collection as ATCC designation on December 20, 2000.
	Figure 94: A nucleic acid sequence of 2CFE76 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
15	
	Figure 95: A nucleic acid sequence of 2CFE78 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
	Firmum OC A 1
- 20	Figure 96: A nucleic acid sequence of 2CFE79 deposited with the American Type Culture
- 20	Collection as ATCC designation on December 20, 2000.
	Figure 97: A pyoloic coid accuracy of CCVTD00 1
	Figure 97: A nucleic acid sequence of 2CFE80 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
25	Figure 98: A nucleic acid sequence of 2CFE81 deposited with the American Type Culture
-	Collection as ATCC designation on December 20, 2000.
	Figure 99: A nucleic acid sequence of 2CFE82 deposited with the American Type Culture
	Collection as ATCC designation on December 20, 2000.
30	on December 20, 2000.

Figure 100: A nucleic acid sequence of 2CFE83 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000. Figure 101: A nucleic acid sequence of 2CFE84 deposited with the American Type Culture Collection as ATCC designation ______ on December 20, 2000. 5 Figure 102: A nucleic acid sequence of 2CFE85 deposited with the American Type Culture Collection as ATCC designation ______ on December 20, 2000. Figure 103: A nucleic acid sequence of 2CFE86 deposited with the American Type Culture 10 Collection as ATCC designation ______ on December 20, 2000. Figure 104: A nucleic acid sequence of 2CFE87 deposited with the American Type Culture Collection as ATCC designation ______ on December 20, 2000. 15 Figure 105: A nucleic acid sequence of 2CFE88 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000. Figure 106: A nucleic acid sequence of 2CFE89 deposited with the American Type Culture Collection as ATCC designation ______ on December 20, 2000. 20 Figure 107: A nucleic acid sequence of 2CFE90 deposited with the American Type Culture Collection as ATCC designation ______ on December 20, 2000. Figure 108: A nucleic acid sequence of 2CFE91 deposited with the American Type Culture 25 Collection as ATCC designation _____ on December 20, 2000. Figure 109: A nucleic acid sequence of 2CFE92 deposited with the American Type Culture Collection as ATCC designation _____ on December 20, 2000. 30

	Figure 110: A nucleic acid sequence of 2CFE94 deposited with the American Type Culture Collection as ATCC designation on December 20, 2000.
	Figure 111: A nucleic acid sequence of 2CFE95 deposited with the American Type Culture Collection as ATCC designation on December 20, 2000.
	Figure 112: A nucleic acid sequence of 2CFE96 deposited with the American Type Culture Collection as ATCC designation on December 20, 2000.
. 10	Figure 113: A nucleic acid sequence of 2CFE97 deposited with the American Type Culture Collection as ATCC designation on December 20, 2000.
15	Figure 114: A nucleic acid sequence of 2CFE99 deposited with the American Type Culture Collection as ATCC designation on December 20, 2000.
	Figure 115: A nucleic acid sequence of 2CFE101 deposited with the American Type Culture Collection as ATCC designation on December 20, 2000.
20	Figure 116: A nucleic acid sequence of 2CFE102 deposited with the American Type Culture Collection as ATCC designation on December 20, 2000.
	Figure 117: A nucleic acid sequence of 2CFE103 deposited with the American Type Culture Collection as ATCC designation on December 20, 2000.
25	Figure 118: A nucleic acid sequence of 2CFE104 deposited with the American Type Culture Collection as ATCC designation on December 20, 2000.
30	Figure 119: A nucleic acid sequence of 2CFE105 deposited with the American Type Culture Collection as ATCC designation on December 20, 2000.

Figure 120: A nucleic acid sequence of 2CFE106 deposited with the American Type Culture Collection as ATCC designation on December 20, 2000.
Figure 121: A nucleic acid sequence of 2CFE107 deposited with the American Type 5 Culture Collection as ATCC designation on December 20, 2000.
Figure 122: A nucleic acid sequence of 2CFE108 deposited with the American Type Culture Collection as ATCC designation on December 20, 2000.
Figure 123: A nucleic acid sequence of 2CFE109 deposited with the American Type Culture Collection as ATCC designation on December 20, 2000.
Figure 124: A nucleic acid sequence of 2CFE111 deposited with the American Type Culture Collection as ATCC designation on December 20, 2000.
Figure 125: A nucleic acid sequence of 2CFE112 deposited with the American Type Culture Collection as ATCC designation on December 20, 2000.
Figure 126: A nucleic acid sequence of 2CFE113 deposited with the American Type Culture Collection as ATCC designation on December 20, 2000.
Figure 127: A nucleic acid sequence of 2CFE114 deposited with the American Type Culture Collection as ATCC designation on December 20, 2000.
Figure 128: A nucleic acid sequence of 2CFE115 deposited with the American Type Culture Collection as ATCC designation on December 20, 2000.
Figure 129: A nucleic acid sequence of 2CFE116 deposited with the American Type Culture Collection as ATCC designation on December 20, 2000.

Figure 130: A nucleic acid sequence of 2CFE117 deposited with the American Type Culture Collection as ATCC designation ______ on December 20, 2000.

Figure 131: Schematic structures of alkyloids which are ligands, for example, of 2CFE42.

5

DETAILED DESCRIPTION OF THE INVENTION

Definitions

All scientific and technical terms used in this application have meanings commonly used in the art unless otherwise specified. As used in this application, the following words or phrases have the meanings specified.

As used herein, a ceg nucleic acid molecule is said to be "isolated" when the nucleic acid molecule is substantially separated from contaminant nucleic acid molecules that encode polypeptides other than CEGs. Additionally, isolated nucleic acid molecule refers to any RNA or DNA sequence obtained from a natural source, or constructed by recombinant methods, or synthesized. A skilled artisan can readily employ nucleic acid isolation procedures to obtain an isolated nucleic acid molecule having ceg sequences.

20

25

30

15

The term "ceg" includes all isolated forms of ceg nucleotide and CEG amino acid sequences disclosed herein. The ceg sequences encode gene products that have essential biological functions in bacterial cells, such as, for example, nucleotide biosynthesis, amino acid biosynthesis, DNA replication, RNA transcription, protein translation, DNA recombination, DNA repair, biosynthesis of cofactors (e.g., Coenzyme A), biosynthesis of prosthetic groups, cellular processes (e.g., chaperones, cell division, and polypeptide secretion), energy metabolism (e.g., pentose phosphate pathway, glycolysis, gluconeogenesis), fatty acid biosynthesis, cell wall biosynthesis, and/or biosynthesis of purines, pyrimidines, nucleosides, and nucleotides. Accordingly, the gene products of the ceg nucleotide sequences are required for viability of bacterial cells. The term "ceg" also includes variants having nucleotide sequence similarity to the disclosed ceg sequences,

including sequences isolated from various bacterial genera and species, allelic variants, mutant variants, and ceg variants that encode conservative and non-conservative amino acid substitutions. The present invention also provides for all ceg sequences generated by recombinant DNA technology, including complementary sequences, ceg sequences that hybridize to the sequences of the invention at high stringency hybridization conditions, fusion genes comprising a ceg sequence, and codon usage variants.

The term "essential genes" refers to a nucleotide sequence that encodes a gene product having a function which is required for cell viability. The term "essential protein" refers to a polypeptide that is encoded by an essential gene and has a function that is required for cell viability. Accordingly, a mutation that disrupts the function of the essential gene or essential proteins results in a loss of viability of cells harboring the mutation.

10

25

30

"Non-essential genes" or "non-essential proteins" refer to genomic information or the
protein(s) or RNAs encoded therefrom which, when disrupted by a mutation, do not
result in a loss of viability of cells harboring said mutation under defined laboratory
conditions.

As used herein, a nucleotide sequence is said to be "identical" to another reference sequence when both nucleotide sequences are exactly alike.

As used herein, a nucleotide sequence is said to be "similar" to another reference sequence when a comparison of the two sequences shows that they have a low level of sequence differences. For example, two sequences are considered to be similar to each other when the percentage of nucleotides that are shared between the two sequences is between about 70 % to 99.99% over the entire length of the two sequences.

As used herein an amino acid sequence is said to be "similar" to another reference sequence when a comparison of the two sequences shows that they have a low level of sequence differences. For example, two sequences are considered to be similar to each

other when the percentage of amino acids that are shared between the two sequences may be between about 30% to 100% identity over the entire length of the two sequences.

As used herein, an "allele" or "allelic sequence" is an alternative form of the naturally-occurring ceg sequence. Alleles result from a mutation, that changes the nucleotide sequence, and generally produce altered mRNAs or polypeptides whose structure or function may or may not be altered.

"Substantially purified" as used herein means a specific isolated nucleic acid or protein, or fragment thereof, in which substantially all contaminants (i.e. substances that differ from said specific molecule) have been separated from said nucleic acid or protein.

In a host cell, an "endogenous" sequence as used herein means a nucleic acid sequence that is naturally-occurring and resides within the host genome.

15

5

In a host cell, an "exogenous" sequence as used herein means an isolated nucleic acid sequence that is introduced into the host cell, using any one of a variety of introduction methods, such as transfection, electroporation, cationic lipid or salt treatment methods.

20 "Knockout mutant" or "knockout mutation" as used herein refers to an in vitro engineered disruption of a region of endogenous chromosomal DNA (e.g., disruption of the genome), typically within a protein coding region. A knockout mutation can be generated by inserting an exogenous DNA sequence into the homologous endogenous sequence. A knockout mutation occurring in a protein coding region is expected to disrupt normal expression of the protein coding region. This usually leads to loss of the function provided by the protein.

In order that the invention herein described may be more fully understood, the following description is set forth.

A) MOLECULES OF THE INVENTION

1.) CEG NUCLEIC ACID MOLECULES

- The present invention provides isolated and recombinant ceg nucleic acid molecules and fragments thereof, and related molecules, such as sequences complementary to ceg sequences or a portion thereof, and those that hybridize to the nucleic acid molecules of the invention.
- The ceg polynucleotide sequences, also referred to herein as nucleic acid molecules of the invention, are preferably in isolated form, including DNA, RNA, DNA/RNA hybrids, and related molecules, and fragments thereof. Specifically contemplated are genomic DNA, ribozymes, and antisense molecules, as well as nucleic acid molecules based on an alternative backbone or including alternative bases, whether derived from natural sources or synthesized. Embodiments of particular ceg polynucleotide and amino acid sequences include, but are not limited to, the sequences described in Tables I and II (e.g., SEQ ID NOS:1-113, 114-226 and SEQ ID NOS: 227-339, 340-452, respectively). The ceg polynucleotide and amino acid sequences were designated cfe which stands for CEG For Expression.

20

Biological samples of the 2CFE nucleic acid molecules (e.g., SEQ ID NOS: 227-331) were deposited on December 20, 2000 with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA 20110-2209.

TABLE I

CFE Designation	SEQ. ID NO. (Nucleotide)	SEQ. ID NO. (Polypeptide)	POLARITY
CFE 1	1	114	<u>+</u>
CFE 2	. 2	115	
CFE 3	3	116	
CFE 4	4	117	
CFE 5	5	118	+
CFE 6			-
0.150	0	119	+

TABLE I

CFE Designation	SEQ. ID NO.	SEQ. ID NO.	POLARITY
	(Nucleotide)	(Polypeptide)	
CFE 7	7	120	
CFE 8	8	121	+
CFE 9	- 9	122	+
CFE 10	10	123	+
CFE 11	11	124	+
CFE 12	. 12	125	+
CFE 13	13	126	
CFE 14	14	127	+
CFE 15	15	128	-
CFE 16	16	129	
CFE 17	17	130	
CFE 19	18	131	+
CFE 21	19	132	<u> </u>
CFE 24	20	133	
CFE 25	• 21	134	+.
CFE 26	22	135	
CFE 27	23	136	+ -
CFE 28	. 24	137	
CFE 29	25	138	
CFE 30	26	139	
CFE 31	27	140	+
CFE 32	28	141	+
CFE 33	. 29	142	
CFE 34	30	143	+
CFE 35	. 31	144	+
CFE 36	32	145	+
CFE 37	33	146	
CFE 38	34	147	+ ·
CFE 39	35	148	
CFE 40	36	149	
CFE 41	37	150	
CFE 42	38	151	
CFE 43	39	152	
CFE 44	40	153	+
CFE 45	41	1:54	<u> </u>
CFE 46	42	155	

TABLE I

CFE Designation	SEQ. ID NO.	SEQ. ID NO.	POLARITY
	(Nucleotide)	(Polypeptide)	
CFE 47	43	156	
CFE 48	44	157	
CFE 49	45	158	+
CFE 50	46	159	+
CFE 51	47	160	+
CFE 52	48	161	
CFE 53	49	162	+
CFE 54	50	163	+
CFE 55	. 51	164	+
CFE 56	52	165	+
CFE 57	53	166	+
CFE 58	54	167	+
CFE 59	55	168	
CFE 60	56	169	+
CFE 61	57	170	+
CFE 62	58	171	
CFE 63	59	172	
CFE 64	60	173	+
CFE 65	61	174	+
CFE 66	62	175	+
CFE 67	63	176	+
CFE 68	64	177	
CFE 69	65	178	6+
CFE 70	66	179	+
CFE 71	67	180	<u> </u>
CFE 72	68	181	
CFE 73	69	182	+
CFE 74	70	183	<u> </u>
CFE 75	71	184	
CFE 76	72	185	+
CFE 77	73	186	
CFE 78	74	187	+
CFE 79	75	188	
CFE 80	76	189	
CFE 81	. 7 7 .	190	+
CFE 82	78	191	

TABLE I

CFE Designation	SEQ. ID NO.	SEQ. ID NO.	POLARITY
CFE 83	(Nucleotide)	(Polypeptide)	
	79	192	-
CFE 84	80	193	-
CFE 85	81	194	·-
CFE 86	82	195	-
CFE 87	83	196	_
CFE 88	84	197	<u> </u>
CFE 89	85	198	+
CFE 90	86	199	+
CFE 91	87	200	
CFE 92	88	201	
CFE 93	89	202	+
CFE 94	90	203	+
CFE 95	91	204	+
CFE 96	92	205	
CFE 97	93	206	· +
CFE 98	94	207	-
CFE 99	95	208	
CFE 100	. 96	209	+
CFE 101	97	210	
CFE 102	98	211	
CFE 103	. 99	. 212	+
CFE 104	100	213	
CFE 105	101	213	+
CFE 106	102		
CFE 107	103	215	-
CFE 108	103	216	-
CFE 109	105	217	+
CEE110	106	218	
CFE 111	. 107	219	-
CFE 112		220	
CFE 112	108	221	
CFE 114		222	<u> </u>
CFE 114 CFE 115	110 .	223	
CFE 116	111	224	-
CFE 117	112	225	-
CFE II/	113	226	-

TABLE II

SEQ. ID NO. (Nucleotide)	SEQ. ID NO.	FIGURE
	(1 olypeptide)	1 26
		26
		27
		28
		29
	· ·	30
		31
		32
	·	33
	· · · · · · · · · · · · · · · · · · ·	34
		35
		36
		37
		38
		39
		40
		41
		42
		43
		44
		45
	·	46
		47
· · · · · · · · · · · · · · · · · · ·		48
		49
		50
		51
		52
<u>-</u>		53
		54
		55
		56
		57
		58
		59 60
	(Nucleotide)	(Nucleotide) (Polypeptide)

CFE Designation	SEQ. ID NO.	SEQ. ID NO.	FIGURE
0.000	(Nucleotide)	(Polypeptide)	
2CFE 40			61
2CFE 41			62
2CFE 42			63
2CFE 43			64
2CFE 44		, .	65
2CFE 45			66
2CFE 46		•	67
2CFE 47			68
2CFE 48			69
2CFE 49			70
2CFE 50			71
2CFE 51			72
2CFE 52			73
2CFE 53			74
2CFE 54			75
2CFE 55			
2CFE 56			76
2CFE 57			77
2CFE 58			78
2CFE 59			. 79
2CFE 60			80
2CFE 61			81
2CFE 62			82
2CFE 64			83
2CFE 65			. 84
2CFE 66			85
2CFE 67			86
2CFE 68		· · · · · · · · · · · · · · · · · · ·	87
2CFE 69			88
2CFE 70	·		89
2CFE 71			90
2CFE 72			91
2CFE 75			92
2CFE 76			93
2CFE 78	· · · · · · · · · · · · · · · · · · ·		94
2CFE 79	<u> </u>		95
2CFE 80			96
			97

CFE Designation	SEQ. ID NO. (Nucleotide)	SEQ. ID NO. (Polypeptide)	FIGURE
2CFE 81		(1 orypeptide)	00
2CFE 82			98
2CFE 83		· .	- 99
2CFE 84			100
2CFE 85			101
2CFE 86			102
2CFE 87		· · · · · · · · · · · · · · · · · · ·	103
2CFE 88			104
2CFE 89			105
2CFE 90			106
2CFE 91			107
2CFE 92	··		108
2CFE 94			109
2CFE 95		· ·	110
2CFE 96			111
2CFE 97			112
2CFE 99	<u>-</u>		113
2CFE 101			114
2CFE 102			115
- 2CFE 103			116
2CFE 104			117
2CFE 105		· ·	118
2CFE 106			119 ·
2CFE 107		-	120
2CFE 108			121
2CFE 109			122
2CFE 111			123
2CFE 112			124
2CFE 113			125
2CFE 114			126
2CFE 115			127
2CFE 116			128 129
2CFE 117			130

a) Variant ceg Nucleotide Sequences

10

15

20

The present invention also provides nucleic acid molecules having a nucleotide sequence substantially identical or similar to the *ceg* sequences (SEQ ID NOS: 1-113, 227-331) disclosed herein.

The present invention provides nucleotide sequences which are similar to SEQ ID NOS:1-113 and/or SEQ ID NOS:227-331. The present invention provides nucleotide sequences which vary from SEQ ID NOS:1-113 or 227-331 by a range of about 1% to about 70%.

The present invention encompasses variations in polynucleotide sequences resulting from mutations and/or from transfer of genetic material from one cell to another (e.g., horizontal gene transfer or horizontal gene exchange).

The present invention also provides for variants of the polynucleotide *ceg* sequences disclosed herein, including variants isolated from naturally-occurring sources, those generated by recombinant DNA technology or other in vitro synthesis methodologies (e.g., PCR). The variant polynucleotide sequences of the invention encode polypeptides that exhibit the biological activity of naturally-occurring CEG polypeptides, such as activity required for bacterial cell viability.

In general, for example, a variant of ceg polynucleotide sequences may encode a polypeptide that differs by one or more amino acid substitutions. The variant may have conservative changes, wherein a substituted amino acid has similar structural or chemical properties, eg, replacement of leucine with isoleucine.

A polynucleotide sequence can encode conservative amino acid substitutions without altering either the conformation or the function of the polypeptide. Such changes include substituting any of isoleucine (I), valine (V), and leucine (L) for any other of these

hydrophobic amino acids; aspartic acid (D) for glutamic acid (E) and vice versa; glutamine (Q) for asparagine (N) and vice versa; and serine (S) for threonine (T) and vice versa. Other substitutions can also be considered conservative, depending on the environment of the particular amino acid and its role in the three-dimensional structure of the protein. For example, glycine (G) and alanine (A) can frequently be interchangeable, as can alanine (A) and valine (V). Methionine (M), which is relatively hydrophobic, can frequently be interchanged with leucine and isoleucine, and sometimes with valine. Lysine (K) and arginine (R) are frequently interchangeable in locations in which the significant feature of the amino acid residue is its charge and the differing pK's of these two amino acid residues are not significant. Still other changes can be considered "conservative" in particular environments.

A variant may also have nonconservative changes, eg, replacement of a glycine with a tryptophan. Other variations may also include amino acid deletions or insertions, or both. Guidance in determining which and how many amino acid residues may be substituted, inserted or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTAR software.

Another type of *ceg* sequence variant includes naturally-occurring allelic variants of *ceg* which share significant similarity (e.g., between about 30-99%) to the disclosed CEG polypeptide sequence. Allelic variants of the *ceg* sequences can encode conservative or non-conservative amino acid substitutions of the CEG polypeptide sequence herein described.

An example of allelic variants of ceg are mutant alleles of ceg polynucleotide sequences that encode a polypeptide having one or more changes in the polypeptide sequence, such as amino acid substitutions, deletions, insertions, frame shifts, or truncations. The mutant alleles of ceg may or may not encode a CEG polypeptide having the same biological functions as wild-type CEG proteins.

5

10

15

20

Variations in the bacterial genomic sequences can also arise from transfer of genetic material to another bacterial cell. The transfer of gene sequences can occur intraspecies or interspecies. Gene transfer can occur between bacterial cells which are members of the same or different populations. A population includes, but is not limited to, a serotype isolate, a clinical isolate, a naturally-occurring isolate, a strain, and a species. The transfer of genetic material can occur between cells within a population; for example transfer between serotype A to serotype A, or between S. pneumoniae and S. pneumoniae. The transfer of genetic material can occur between cells of different populations; for example, between serotype A to serotype B or S. pneumoniae and S. mutans.

5

10

15

Gene transfer can give rise to mutant or polymorphic variant genes sequences. In rare cases, gene transfer introduces new gene sequences that confer a new phenotype, such as antibiotic resistance. The transfer of genetic material includes transfer of large regions of genomic sequences which include partial gene sequences, whole single gene sequences, or multiple gene sequences. This mode of transfer can give rise to replacement of native whole gene sequences or introduction of new sequences in the recipient cell. This mode of transfer gives rise to mosaic gene sequences in the recipient cell.

The variation of genomic sequences resulting from gene transfer can be examined using molecular techniques, including: multilocus enzyme electrophoresis (Selander. R. K., et al., 1986 Appl. Environ. Microbiol. 51:837-884); and restriction endonuclease cleavage electrophoretic profiling (Coffey, T. J., et al., 1991 Mol. Microbio. 5:2255-2260); pulse-field gel electrophoresis fingerprinting (Bygraves, J. A. and Maiden, M. C. J. 1992 J. Gen. Microbiol. 138:523-531); and ribotyping (Stull, T. L., et al., 1988 J. Infect. Dis. 157:280-286). The degree of variation can vary greatly, and ranges from little or no variation as exemplified by gene sequences of E. coli (Caugant, d. A., et al., 1981 Genetics 98:467-490; Whittam, T. S., et al., 1983 Mol. Biol. Evol. 1:67-83; Souza, V., et al., 1992 Proc. Natl. Acad. Sci. USA 89:8389-8393) and Salmonella (Selander, R. K., et al., 1990 Infect. Immun. 58:2262-2275; Selander, R.K. and Smith, N. H. 1990 Rev. Med. Microbiol. 1:219-228; Smith, J. M., et al., 1993 Proc. Natl. Acad. Sci. USA 90:4384-

4388), to extensive gene transfer in *Neisseria gonorrhoeae* (Smith, J. M., et al., 1993 *Proc. Natl. Acad. Sci. USA* 90:4384-4388).

Gene transfer can be examined between various isolates of a particular microbial species which are antibiotic-sensitive or antibiotic-resistent (Coffey, T. J., et al., 1991 *Molec. Microbiol.* 5:2255-2260). Molecular biology techniques can be utilized to study the degree of transfer between populations, such as, for example, the degree of gene transfer between serotypes, isolates, strains, or species. The degree of transfer can be examined by comparing, for example, the penicillin binding proteins and numerous different loci which encode metabolic enzymes or capsular biosynthesis enzymes.

For example, intra-species, inter-serotype, gene transfer is possible (Coffey, T. J., et al., 1991 supra). Additionally, intraspecies gene transfer in S. pneumoniae (Coffey, T. J., et al., 1998 Mol. Microbiol. 27:73-83), Vibrio cholerae (Bik, E. M., et al., 1995 EMBO J. 14:209-216), and Haemophilus influenzae (Kroll, J. S. and Moxon, E. R. 1990 J. Bacteriol. 172: 1374-1379) are possible.

10

20

30

Interspecies gene transfer is also possible (Dowson, C. G., et al., 1989 Proc. Natl. Acad. Sci. USA 86:8842-8846; Laibl, G., et al., 1991 Mol. Microbiol. 5:1993-2002; Bourgoin, F., et al., 1999 Gene 233:151-161).

Variant gene sequences arising from gene transfer can be continually generated in transformable bacteria (e.g., transformation competent), such as *S. pneumoniae*. For example, the worldwide spread of varying degrees of antibiotic resistance has been documented and reviewed (Dowson, C. G., et al., 1994 *Trends Microbiol.* 2:361-366; Spratt, B. G. in *Bacterial Cell Wall*, eds Ghuysen J-M. and Hakenbeck, R. 1994 pp. 517-534; and reviewed in Maiden, M. C. J. 1998 *Clinic. Infect. Dis.* 27 (Supplement 1) S12-S20). For example, variant gene sequence arising from gene transfer can be tracked using a marker gene such as the gene which encodes the penicillin binding protein (Barcus, V. A., et al., 1995 *FEMS Microbiol. Lett.* 126:299-303). At the nucleotide level, gene sequences encoding the penicillin binding proteins in susceptible and resistant

strains differ by about 14% to 23% (Hakenbeck, R. 1995 Biochem. Pharmacol. 50:1121-1127; Spratt, B. G. in Bacterial Cell Wall, eds Ghuysen J-M. and Hakenbeck, R. 1994 pp. 517-534; Spratt, B. G., et al., 1991 Neisseria meningitidis and Streptococcus pneumoniae eds. Camisi, J., et al., pp. 73-83; Coffey, T. J., et al., 1995 Micro. Drug Resist. 1:29-34).

5

10

15

20

25

The ceg nucleotide sequences can be isolated from various species of Streptococcus including Streptococcus pneumoniae. Additionally, the ceg sequences can be isolated from other Steptococcal species, including S. mutans, S. pyogenes, and S. thermophila, The ceg polynucleotide sequences can also be isolated from strains of other bacterial genera including, but not limited to, Streptococcus, Escherichia, Bacillus, Pseudomonas, Yersinia, Salmonella, and Haemophilus.

The present invention additionally provides isolated codon-usage variants that differ from the disclosed ceg nucleotide sequences, yet do not alter the predicted CEG polypeptide sequence or function. The codon-usage variants may be generated by recombinant DNA technology. Codons may be selected to optimize the level of production of the ceg transcript or CEG polypeptide in a particular prokaryotic or eukaryotic expression host, in accordance with the frequency of codon utilized by the host cell. Alternative reasons for altering the nucleotide sequence encoding a CEG polypeptide include the production of RNA transcripts having more desirable properties, such as an extended half-life or increased stability. A multitude of variant ceg nucleotide sequences that encode the respective CEG polypeptide may be isolated, as a result of the degeneracy of the genetic code. Accordingly, the present invention contemplates selecting every possible triplet codon to generate every possible combination of nucleotide sequences that encode the disclosed CEG polypeptides. This particular embodiment provides isolated nucleotide sequences that vary from the sequences as described in SEQ ID NOs.: 1-113 or 227-331, such that each variant nucleotide sequence encodes a polypeptide having sequence identity with the amino acid sequences, as described in SEQ ID NOs.:114-226 or 332-436, respectively.

30

b) Complementary Sequences

The present invention includes polynucleotide sequences that are complementary to the sequences disclosed herein. The term "complementary" as used herein refers to the capacity of purine and/or pyrimidine nucleotides to associate through hydrogen bonding to form double stranded nucleic acid molecules. The following base pairs are related by complementarity: guanine and cytosine; adenine and thymine; and adenine and uracil. Complementary applies to all base pairs comprising at least two single-stranded nucleic acid molecules.

c) Sequences Capable of Hybridizing

Another embodiment provides nucleic acid molecules that will hybridize to ceg sequences under hybridization conditions. It is readily apparent to one skilled in the art that the stringency of the hybridization condition selected will depend upon the characteristics of the nucleic acid molecule to be hybridized, such as, the length, the degree of complementarity (e.g., exact or non-exact complementarity), the percent A/T content, and the objective of the hybridization experiment.

20

25

5

10

The hybridization procedure may by performed in low stringency hybridization conditions. Low stringency hybridization conditions will permit hybridization between two nucleic acid molecules that differ from exact complementarity by about 25% to 70%. Hybridization under standard high stringency conditions will occur between two complementary nucleic acid molecules (e.g., 100% exact complementarity) or two complementary nucleic acid molecules that differ from exact complementarity by about 1% to about 70%.

The high stringency hybridization conditions that disfavor non-homologous base pairing are well known in the art. Typically, high stringency hybridization conditions, includes but is not limited to, hybridizing at 50 °C to 65 °C in 5X SSPE, and washing at 50 °C to

65 °C in 0.5X SSPE. Typically, low stringency conditions, includes but is not limited to, hybridizing at 35 °C to 37 °C in 5X SSPE and 40% to 45% formamide and washing at 42 °C in 1-2X SSPE. The conditions and formulas for high stringency hybridization methods are well known in the art and can be readily obtained in *Molecular Cloning; A Laboratory Manual* (2nd edition, Sambrook, Fritch, and Maniatis 1989, Cold Spring Harbor Press) or in *Short Protocols in Molecular Biology* (Ausubel, F. M., et al., 1989, John Wiley & Sons).

d) Fragments of ceg Sequences

10

15

20

25

The invention further provides nucleic acid molecules having fragments of the *ceg* sequences, such as a portion of the *ceg* sequence (e.g., SEQ ID NOS:1-113, 227-331) disclosed herein. The size of the fragment will be determined by its intended use. For example, the length of the fragment to be used as a nucleic acid probe or PCR primer is chosen to obtain a relatively small number of false positives during probing or priming. Alternatively, a fragment of the *ceg* sequence may be used to construct a recombinant fusion gene having a *ceg* sequence fused to a non-*ceg* sequence.

The nucleic acid molecules, fragments thereof, and probes and primers of the present invention are useful for a variety of molecular biology techniques including, for example, hybridization screens of libraries, or detection and quantification of mRNA transcripts as a means for analysis of gene transcription and/or expression. Preferably, the probes and primers are DNA. A probe or primer length of at least 15 base pairs is suggested by theoretical and practical considerations (Wallace, B. and Miyada, G. 1987 "Oligonucleotide Probes for the Screening of Recombinant DNA Libraries" in: *Methods in Enzymology*, 152:432-442, Academic Press). Other lengths of fragments, probes, or primers are possible and routine to determine.

The probes and primers of this invention can be prepared by methods well known to those skilled in the art (Sambrook, et al. *supra*). In a preferred embodiment the probes

and primers are synthesized by chemical synthesis methods (ed. Gait, M. J. 1984 Oligonucleotide Synthesis, IRL Press, Oxford, England).

One embodiment of the present invention provides nucleic acid primers that are complementary to ceg sequences, which allow the specific amplification of nucleic acid molecules of the invention or of any specific parts thereof. Another embodiment provides nucleic acid probes that are complementary for selectively or specifically hybridizing to the ceg sequences or to any part thereof.

10 e) Derivative Nucleic Acid Molecules

The nucleic acid molecules of the invention include peptide nucleic acids (PNAs), or derivative molecules such as phosphorothicate, phosphotriester, phosphoramidate, and methylphosphonate, that specifically bind to single-stranded DNA or RNA in a base pair-dependent manner (Zamecnik, P. C., et al., 1978 *Proc. Natl. Acad. Sci.* 75:280284; Goodchild, P. C., et al., 1986 *Proc. Natl. Acad. Sci.* 83:4143-4146).

PNA molecules comprise a nucleic acid oligomer to which an amino acid residue, such as lysine, and an amino group have been added. These small molecules, also designated anti-gene agents, stop transcript elongation by binding to their complementary (template) strand of nucleic acid (Nielsen, P. E., et al., 1993 Anticancer Drug Des 8:53-63). For example, reviews of methods for synthesis of DNA, RNA, and their analogues can be found in: Oligonucleotides and Analogues, eds. F. Eckstein, 1991, IRL Press, New York; Oligonucleotide Synthesis, ed. M. J. Gait, 1984, IRL Press, Oxford, England. Additionally, methods for antisense RNA technology are described in U. S. patents 5,194,428 and 5,110,802. A skilled artisan can readily obtain these classes of nucleic acid molecules using the herein described ceg polynucleotide sequences, see for example Innovative and Perspectives in Solid Phase Synthesis (1992) Egholm, et al. pp 325-328 or U. S. Patent No. 5,539,082.

5

15

20

f) RNA Molecules

The present invention provides RNA molecules that encode the predicted ceg gene products. In particular, the RNA molecules of the invention may be isolated full-length or partial mRNA molecules or RNA oligomers that encode CEG gene products. The RNA molecules of the invention include the nucleotide sequences encoding all or portions of CEGs.

The RNA molecules of the invention also include antisense RNA molecules, peptide nucleic acids (PNAs), or non-nucleic acid molecules such as phosphorothioate derivatives, that specifically bind to the sense strand of DNA or RNA in a base pair-dependent manner. A skilled artisan can readily obtain these classes of nucleic acid molecules using the herein described *ceg* sequences.

15

20

5

g) Labeled Nucleic Acid Molecules

The nucleic acid molecules having *ceg* sequences can be labeled with a detectable marker. Examples of a detectable marker include, but are not limited to, a radioisotope, a fluorescent compound, a bioluminescent compound, a chemiluminescent compound, a metal chelator or an enzyme. Technologies for generating labeled DNA and RNA probes are well known in the art (See e.g. Sambrook et al., *supra*).

2.) RECOMBINANT NUCLEIC ACID MOLECULES

25

30

Also provided are recombinant nucleic acid molecules, such as recombinant DNA molecules (rDNAs) that comprise *ceg* sequences or fragments thereof. As used herein, a recombinant DNA molecule is a DNA molecule that has been subjected to molecular manipulation *in vitro*. Methods for generating rDNA molecules are well known in the art, for example, see Sambrook et al., *Molecular Cloning* (1989), *supra*.

a) Vectors

10

15

20

25

The nucleic acid molecules of the invention may be recombinant molecules each comprising the sequence, or portions thereof, of a ceg sequence linked to a non-ceg sequence. For example, the ceg sequence may be fused operatively to a vector to generate a recombinant molecule. The term vector includes, but is not limited to, plasmids, cosmids, and phagemids. A preferred vector includes an autonomously replicating vector comprising a replicon that directs the replication of the rDNA within the appropriate host cell. The preferred vectors can also include an expression control element, such as a promoter sequence, which enables transcription of the inserted ceg sequences and can be used for regulating the expression (e.g., transcription and/or translation) of an operably linked ceg sequence in an appropriate host cell such as Escherichia coli. Expression control elements are known in the art and include, but are not limited to, inducible promoters, constitutive promoters, secretion signals, enhancers, transcription terminators, and other transcriptional regulatory elements. Other expression control elements that are involved in translation are known in the art, and include the Shine-Dalgarno sequence, and initiation and termination codons. The preferred vector also includes at least one selectable marker gene that encodes a gene product that confers drug resistance such as resistance to ampicillin or tetracyline. The vector also comprises multiple endonuclease restriction sites that enable convenient insertion of exogenous DNA sequences.

The preferred vectors for generating *ceg* transcripts and/or the encoded CEG polypeptides are expression vectors which are compatible with prokaryotic host cells. Prokaryotic cell expression vectors are well known in the art and are available from several commercial sources. For example, a pET vectors (e.g., pET-21, Novagen Corp.) may be used to express CEG polypeptides in bacterial host cells.

b) Recombinant Vectors for Integration

The present invention provides recombinant vectors that may be used to integrate exogenously provided sequences into the genome of a host cell. The recombinant integration vectors of the present invention include a gene that encodes a selectable marker and ceg sequences; or fragments thereof. The integration vectors are used to integrate the ceg sequence into a target gene sequence that resides within the bacterial host genome (e.g., endogenous sequence), thereby disrupting the function of the target gene sequence within the bacterial cells. These integration vectors may be used in a gene disruption assay to screen candidate ceg nucleotide sequences, in order to identify the candidate sequences that encode a gene product that is required for bacterial cell viability.

Accordingly, these recombinant integration vectors include candidate ceg sequences that will be screened to determine if the candidate ceg sequences encode a gene product that is required for cell viability. The candidate ceg sequence that is included as part of the recombinant integration vector is the "exogenous" ceg sequence that is employed as the "disrupting" sequence in a gene disruption assay. The ceg sequence that resides within the host genome is the "endogenous" or "target" ceg sequence.

20

25

30

5

10

15

The integration event rarely occurs, for example, by non-homologous recombination in which a recombinant vector, that includes the exogenous ceg sequence, inserts the exogenous ceg sequence into a random location within the host genome. In a more preferred embodiment, the integration event inserts the exogenous ceg sequence into a specific target site within the host genome. The targeted integration event can involve homologous recombination in which the integration vector, that includes the exogenous ceg sequence, inserts the exogenous ceg sequence into its homologous target ceg sequence that resides within the host's genome (e.g., the endogenous ceg sequence) (Figure 1). Further, the exogenous ceg sequence can be used as a disrupting sequence whereby the homologous recombination event integrates the exogenous ceg sequence into the endogenous target ceg sequence resulting in disruption of the function of the

endogenous ceg sequence. For example, disrupting the function of the endogenous ceg sequence may result in the loss of bacterial cell viability.

An example of a recombinant vector that can be used as an integration vector in S. pneumoniae is the pEVP-3 vector (Jean-Pierre Claverys, et al. 1995 Gene 164: 123-128). The pEVP-3 vector integrates an exogenous sequence by homologous recombination involving a Campbell-type event (S. Adhya and A. Campbell 1970 J. Mol. Biol. 50:481-490). The pEVP-3 vector includes a replicon that functions only in gram-negative bacteria, such as E. coli. Therefore, the pEVP-3 vector cannot replicate in S. 10 pneumoniae. This vector also contains multiple cloning sites, and confers resistance to chloramphenicol in both a gram-negative and gram-positive bacteria, such as S. pneumoniae.

c) Fusion Gene Sequences

15

5

A fusion ceg gene is another example of a recombinant molecule of the invention. A fusion gene includes a ceg sequence operatively fused (e.g., linked) to a non-ceg sequence such as, for example, a tag sequence to facilitate isolation and/or purification of the expressed CEG gene product (Kroll, D.J., et al., 1993 DNA Cell Biol 12:441-53).

20

Alternatively, a recombinant fusion molecule has a ceg sequence of the invention fused to a ceg sequence isolated from a different microbial source. For example, the disclosed ceg sequences isolated from S. pneumoniae can be fused to a ceg sequence isolated from a different bacterial species.

25

30

3.) <u>CEG PROTEINS AND POLYPEPTIDE MOLECULES</u>

The invention additionally provides CEG proteins and peptide fragments thereof that are isolated or substantially purified. Embodiments of particular CEG amino acid sequences are disclosed in Tables I and II (SEQ ID NOS:114-226 and SEQ ID NOS:332-436, respectively).

The present invention also includes polypeptides having sequence variations from the predicted CEG polypeptide sequences disclosed herein, including mutant variants, conservative substitution variants, and similar CEG polypeptides from other prokaryotic organisms. For convenience, such proteins are referred to herein as "CEG proteins", "CEG polypeptides", or "proteins of the invention".

As used herein, CEG protein refers to a polypeptide having amino acid sequence identity or similarity to any one of the predicted amino acid sequences, as provided in SEQ ID NO.: 114-226 or 332-436. The variant CEG polypeptides can be allelic forms of CEG, such as mutant forms of CEG polypeptides. The present invention also provides conservative substitution-mutants of the CEG proteins that maintain functional activity of wild-type CEG (e.g., the CEG polypeptide is required for bacterial cell viability).

10

The CEG protein may be isolated from any source whether natural, synthetic, semi-synthetic, or recombinant. As used herein, "natural" refers to a polypeptide which is found in nature. Accordingly, the CEG proteins may be isolated from a prokaryotic organism, such as a bacterial strain including, but not limited to, Streptococcus, Escherichia, Bacillus, Pseudomonas, Yersinia, Salmonella, and Streptomyces. The CEG proteins of the invention, and fragments thereof, can also be generated by recombinant methods or chemical synthesis methods.

The CEG polypeptides of the invention are essential for the viability of a bacterial cell. Further, the CEG polypeptides can exhibit at least any one of the following functions: a pantothenate kinase, a Holliday Junction branch migration protein, a single stranded DNA binding protein, a phosphoglucosamine mutase, an acetyltransferase, an uridylyltransferase, a malonyl CoenzymeA:ACP transcylase, a 3-oxoacyl-ACP synthase II, a 3-oxoacyl-ACP reductase, a phosphomethylpyrimidine (HMP-P) kinase, a GTP binding protein, a ATP binding protein, or a 4-aminoimidazole carboxylase. Putative functions can include, but are not limited to, sugar transferase, techoic acid biosynthesis, ribosome recycling factor, response regulator, nicotinate phosphoribosyltransferase,

5

10

15

20

nitropropane dioxygenase, (3R)-hydroxymyristol acyl carrier protein dehydrase, sugar dehydrogenase, murein biosynthesis, cobalimin biosynthesis, ABC transporter, tRNA modification enzyme, arylsulfatase, 16S processing enzyme, tRNA methyl transferase, elongation factor P, signal recognition particle, protein export, undecaprenol kinase, SRP docking domain, diacyl glycerol kinase, dihydopicilinate reductase, HU-DNA binding protein, thiamine biosynthase, GreA transcription elongation factor, dTDP-L-rhamnose synthase, ATP-binding motif, ribose-5-p-3-epimerase-like activity, GTP pyrophosphokinase, acetyl-CoA carboxylase, O-sialoglycoprotein endopeptidase, glucosamine-fructose-6-phosphase aminotransferase, Strpn adhesion-associated ABCpermease, GTP pyrophosphokinase RelA, IMP dehydrogenase, DNA gyrase subunit B, acetyl-CoA carboxylase subunit AccD, phosphoglycerol kinase, acetyl-CoA carboxylase carbonyl transferase, phosphopanthetheine adenylyltransferase, oligopeptide transport permease subunit, translocation protein, perM permease, DNA pol III gamma and tau subunits, DNA pol III delta subunit, signal peptidase I, acetyl-coA carboxylase biotin carboxyl carrier protein, protein chain release factor-1, replicative DNA helicase, topoisomerase, pentapeptide-transferase, elongation factor G, spore coat polysaccharide biosynthesis protein C, protein release factor B, DNA polymerase III alpha subunit, phosphoprotein phosphatase, chaparonin, UDP-N-acetylmuramoylalanyl-D-glutamate-2, 6-diaminopimelate ligase, techuronic acid biosynthesis, UDP-glucose lipid carrier transferase, transcription termination factor, chromosome segregation factor, amino acid biosynthesis, HMG-CoA reductase, hypoxanthine-guanine phosphoribosyltransferase.

a) MODULATORS OF CEG POLYPEPTIDES

The invention provides compounds that modulate (e.g., activate or inhibit) the function of a CEG polypeptide. Such compounds can provide lead-compounds for developing drugs for diagnosing and/or treating conditions associated with bacterial infections. The modulator is a compound that may alter the function of the CEG polypeptide, such as activating or inhibiting the function of a CEG polypeptide. For example, the compound can act as agonist, antagonist, partial agonist, partial antagonist, cytotoxic agents,

inhibitors of cell proliferation, and cell proliferation-promoting agents. The activity of the compound may be known, unknown or partially known.

Suitable ligands include, but are not limited to, diazalactones, *N*-protected amino acid, azabicyclodiene, and alkaloids.

· An example of a diazalactone is:

An example of a N-protected amino acid is:

10

An example of an azabicyclodiene is:

Examples of alkaloids are:

5 B) METHODS FOR MAKING THE CEG PROTEINS AND POLYPEPTIDES

Recombinant methods are preferred if a high yield is desired. Recombinant methods involve expressing the cloned gene in a suitable host cell. For example, a host cell is introduced with an expression vector having the CEG sequence, then the host cell is cultured under conditions that permit *in vivo* production of the CEG protein. The recombinant vector can integrate the CEG sequence into the host genome. Alternatively, the CEG sequence can be maintained extra-chromosomally, as part of an autonomously replicating vector.

1. HOST-VECTOR SYSTEMS

10

15

The invention further provides a host-vector system comprising the vector, plasmid, phagemid, or cosmid comprising a *ceg* nucleotide sequence, or a fragment thereof, introduced into a suitable host cell. The host-vector system can be used to produce the

CEG polypeptides encoded by the *ceg* nucleotide sequences. The host cell can be prokaryotic or eukaryotic. Examples of suitable prokaryotic host cells include bacteria strains from genera such as *Escherichia, Bacillus, Pseudomonas, Streptococcus,* and *Streptomyces*. Examples of suitable eukaryotic host cells include a yeast cell, a plant cell, or an animal cell, such as a mammalian cell. A preferred embodiment provides a host-vector system comprising the pET21 vector having a *ceg* sequence introduced into an *E. coli* λ DE3 lysogen which is useful, for example for the production of the CEG protein, herein designated CFE polypeptides and CFE proteins.

- Introduction of the rDNA molecules of the present invention into an appropriate cell host is accomplished by well known methods that typically depend on the type of vector used and host system employed. For example, transformation of prokaryotic host cells by electroporation and salt treatment methods are typically employed, see for example, Cohen et al., 1972 Proc Acad Sci USA 69:2110; Maniatis, T., et al., 1989 Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. Transformation of vertebrate cells with vectors containing rDNAs, electroporation, cationic lipid or salt treatment methods are typically employed, see, for example, Graham et al., 1973 Virol 52:456; Wigler et al., 1979 Proc Natl Acad Sci USA 76:1373-76.
- Successfully transformed cells, i.e., cells that contain a rDNA molecule of the present invention, can be identified by well known techniques. For example, cells resulting from the introduction of a rDNA of the present invention can be selected and cloned to produce single colonies. Cells from those colonies can be harvested, lysed and their DNA content examined for the presence of the rDNA using a method such as that described by Southern,
 J Mol Biol (1975) 98:503, or Berent et al., Biotech (1985) 3:208, or the proteins produced from the cell assayed via a biochemical assay or immunological method.

Procaryotes are generally used as host cells for cloning and producing the products of exogenous DNA sequences. For example, the *Escherichia coli* K12 BL21 (λ DE3) (Novagen) is particularly useful for expression of foreign proteins. Other strains of *E. coli*, and bacilli such as *Bacillus subtilis*, Enterobacteriaceae such as *Salmonella*

typhimurium or Serratia marcescans, various Pseudomonas, Streptococcus, and Streptomyces species may also be employed as host cells in cloning and expressing the recombinant proteins of this invention.

In general terms, the production of recombinant CEG proteins may involve using a 5 host/vector system, or other methods may be used. The host/vector system may employ the following steps.

A nucleic acid molecule is obtained that encodes a CEG protein or a fragment thereof, such as any one of the polynucleotides disclosed in SEQ ID NOs.: 1-113 or 227-331. The CEG-10 encoding nucleic acid molecule is preferably inserted into an expression vector in operable linkage with suitable expression control sequences, to generate an expression vector including the CEG-encoding sequence. The expression vector is introduced into a suitable host, by standard transformation methods, and the resulting transformed host is cultured under conditions that allow the production of the CEG protein. For example, if expression of the CEG gene is under the control of an inducible promoter, then suitable growth conditions would include the appropriate inducer. The CEG protein (e.g., designated a CFE polypeptide or protein), so produced, is isolated from the growth medium or directly from the cells; recovery and purification of the protein may not be necessary in some instances where some impurities may be tolerated. A skilled artisan can readily adapt an appropriate host/expression system known in the art for use with CEG-encoding sequences to produce a CEG protein (Cohen, et al., supra; Maniatis et al., supra).

Host cells harboring the nucleic acids disclosed herein are also provided by the present invention. A preferred host is E. coli strain BL21(\(\lambda\)DE3) transfected or transformed with 25 a vector comprising a nucleic acid of the present invention. The invention also provides a host cell capable of expressing the ceg sequences described herein. The preferred host cell is any strain of E. coli that can accommodate high level expression of an exogenously introduced gene.

15

The proteins of the present invention can also be made by chemical synthesis. The principles of solid phase chemical synthesis of polypeptides are well known in the art and may be found in general texts relating to this area (Dugas, H. and Penney, C. 1981 Bioorganic Chemistry, pp 54-92, Springer-Verlag, New York). CEG polypeptides may be synthesized by solid-phase methodology utilizing an Applied Biosystems 430A peptide synthesizer (Applied Biosystems, Foster City, Calif.) and synthesis cycles supplied by Applied Biosystems. Protected amino acids, such as t-butoxycarbonyl-protected amino acids, and other reagents are commercially available from many chemical supply houses.

10

15

5

The polypeptides of the invention exhibit properties of a CEG protein, such as, for example, the ability to elicit the generation of antibodies that specifically bind an epitope associated with CEG polypeptides. Accordingly, the CEG polypeptide, or any oligopeptide thereof, is capable of inducing a specific immune response in appropriate animals or cells and binding with specific antibodies.

C) ANTIBODIES THAT RECOGNIZE AND BIND THE PROTEINS AND POLYPEPTIDES OF THE INVENTION

The invention further provides antibodies (e.g., polyclonal, monoclonal, chimeric, humanized, and human antibodies) that bind a CEG polypeptide. The most preferred antibodies will selectively bind a CEG polypeptide and will not bind (or will bind weakly) a non-CEG polypeptide. Antibodies that are particularly contemplated include monoclonal and polyclonal antibodies, as well as fragments thereof (e.g., recombinant proteins) which include the antigen binding domain and/or one or more complement determining regions of these antibodies. These antibodies can be from any source, for example, rabbit, sheep, rat, dog, cat, pig, horse, mouse, and human.

The invention encompasses antibody fragments that specifically recognize a CEG polypeptide. As used herein, an antibody fragment is defined as at least a portion of the variable region of the immunoglobulin molecule that binds to its target, i.e., the antigen binding region. Some of the constant region of the immunoglobulin may be included.

As will be understood by those skilled in the art, the regions or epitopes of a CEG polypeptide to which an antibody is directed may vary with the intended application. For example, antibodies intended for use in an immunoassay for the detection of membrane-bound CEG proteins on viable bacterial cells should be directed to an accessible epitope on membrane-bound CEG proteins. Antibodies that recognize other epitopes may be useful for the identification of CEG protein within damaged or dying cells, for the detection of secreted CEG protein or fragments thereof.

5

20

25

Various methods for the preparation of antibodies are well known in the art. For example, antibodies may be prepared by immunizing a suitable mammalian host using a CEG protein, peptide, or fragment, in isolated or immunoconjugated form (Harlow, 1989 Antibodies, Cold Spring Harbor Press, NY). In addition, fusion proteins comprising CEG polypeptides may also be used, such as a CEG protein/GST-fusion protein. Cells expressing or overexpressing a CEG polypeptide may also be used for immunizations. Similarly, any cell engineered to express CEG protein may be used. This strategy may result in the production of monoclonal antibodies with enhanced capacities for recognizing endogenous CEG protein.

The present invention contemplates chimeric antibodies that comprise a human and non-human immunoglobin portion. The antigen combining region (variable region) of a chimeric antibody can be derived from a prokaryotic source (e.g., bacteria) and the constant region of the chimeric antibody which confers biological effector function to the immunoglobulin can be derived from a eukaryotic source (e.g., human). The chimeric antibody should have the antigen binding specificity of the prokaryotic antibody molecule and the effector function conferred by the eukaryotic antibody molecule.

In one example, the procedure used to produce chimeric antibodies can involve the following steps:

a) Identifying and cloning the correct immunoglobin gene segment encoding the
 30 antigen binding portion of the antibody molecule. This gene segment is known as
 the VDJ, variable, diversity and joining regions for heavy chains or VJ, variable,

joining regions for light chains or simply as the V or variable region. This gene regions may be in either the cDNA or genomic form;

- b) Cloning the gene segments encoding the constant region or desired part thereof;
- c) Ligating the variable region with the constant region so that the complete chimeric antibody is encoded in a form that can be transcribed and translated:
- d) Ligating this construct into a vector containing a selectable marker and gene control regions such as promoters, enhancers and poly(A) addition signals;
- e) Amplifying this construct in bacteria;

5

10

.30

- f) Introducing this DNA into eukaryotic cells (transfection) most often mammalian lymphocytes;
- g) Selecting for cells expressing the selectable marker;
- h) Screening for cells expressing the desired chimeric antibody; and
- k) Testing the antibody for appropriate binding specificity and effector functions.
- 15 Chimeric antibodies of several distinct antigen binding specificities have been produced by protocols well known in the art, including anti-TNP antibodies (Boulianne et al., 1984 Nature 312:643); and anti-tumor antigen antibodies (Sahagan et al., 1986 J. Immunol. 137:1066). Likewise, several different effector functions have been achieved by linking new sequences to those encoding the antigen binding region. Examples of these include enzymes (Neuberger et al., 1984 Nature 312:604); immunoglobulin constant regions from another species and constant regions of another immunoglobulin chain (Sharon et al., 1984 Nature 309:364; Tan et al., 1985 J. Immunol. 135:3565-3567). Additionally, procedures for modifying antibody molecules and for producing chimeric antibody molecules using homologous recombination to target gene modification have been described (Fell et al., 1989 Proc. Natl. Acad. Sci. USA 86:8507-8511).

The predicted amino acid sequence of a CEG protein may be used to select specific regions of the CEG protein for generating antibodies. For example, hydrophobicity and hydrophilicity analyses of a CEG polypeptide may be used to identify hydrophobic and hydrophilic regions in the CEG protein. Regions of the CEG protein that show immunogenic structure, as well as other regions and domains, can readily be identified using

various other methods known in the art, such as Chou-Fasman, Garnier-Robson, Kyte-Doolittle, Eisenberg, Karplus-Schult or Jameson-Wolf analysis. Fragments that include the immunogenic regions are particularly suited for generating specific classes of antibodies.

Methods for preparing a protein for use as an immunogen and for preparing immunogenic conjugates of a protein with a carrier such as BSA, KLH, or other carrier proteins are well known in the art. In some circumstances, direct conjugation using, for example, carbodiimide reagents may be used; in other instances linking reagents such as those supplied by Pierce Chemical Co., Rockford, IL, may be effective. Administration of a CEG immunogen is conducted generally by injection over a suitable time period and with use of a suitable adjuvant, as is generally understood in the art. During the immunization schedule, titers of antibodies can be taken to determine adequacy of polyclonal antibody formation.

While the polyclonal antisera produced in this way may be satisfactory for some applications, for pharmaceutical compositions, monoclonal antibody preparations are preferred. Immortalized cell lines which secrete a desired monoclonal antibody may be prepared using the standard method of Kohler and Milstein (Nature 256: 495-497) or other techniques as described in Monoclonal Antibodies; A Manual of Techniques, CRC press, Inc., Boca Raton, Fla. (1987) ed. Zola. The immortalized cell lines secreting the desired antibodies are screened by immunoassay in which the antigen is the CEG polypeptide having binding activity, or a fragment thereof. When the appropriate immortalized cell culture secreting the desired antibody is identified, the cells can be cultured either in vitro or by production in ascites fluid.

The desired monoclonal antibodies are then recovered from the culture supernatant or from the ascites supernatant. Fragments of the monoclonal antibodies of the invention or the polyclonal antisera (e.g., Fab, F(ab')₂, Fv fragments, fusion proteins) which contain the immunologically significant portion (i.e., a portion that recognizes and binds a CEG protein) can be used as antagonists, as well as the intact antibodies. Humanized antibodies directed against a CEG polypeptide are also useful. The advantage of using humanized antibodies is that they are less immunogenic in humans. As used herein, a humanized antibody is an

immunoglobulin molecule which is capable of binding to a CEG polypeptide and which comprises a FR region having substantially the amino acid sequence of a human immunoglobulin and a CDR having substantially the amino acid sequence of non-human immunoglobulin or a sequence engineered to bind a CEG protein. Methods for humanizing murine and other non-human antibodies by substituting one or more of the non-human antibody CDRs for corresponding human antibody sequences are well known (Jones et al., 1986 Nature 321: 522-525; Riechmann et al., 1988 Nature 332: 323-327; Verhoeyen et al., 1988 Science 239: 1534-1536; Carter et al., 1993 Proc. Natl. Acad. Sci. USA 89: 4285; and Sims et al., 1993 J. Immunol. 151: 2296).

10

15

20

5

Use of immunologically reactive fragments, such as the Fab, Fab', or F(ab')2 fragments is often preferable, especially in a therapeutic context, as these fragments are generally less immunogenic than the whole immunoglobulin. Further, bi-specific antibodies specific for two or more epitopes may be generated using methods generally known in the art. Further, antibody effector functions may be modified so as to enhance the therapeutic effect of the antibodies of the invention. For example, cysteine residues may be engineered into the Fc region, permitting the formation of interchain disulfide bonds and the generation of homodimers which may have enhanced capacities for internalization, ADCC and/or complement-mediated cell killing (Caron et al., 1992 J. Exp. Med. 176: 1191-1195; Shopes, 1992 J. Immunol. 148: 2918-2922). Homodimeric antibodies may also be generated by cross-linking techniques known in the art (Wolff et al., Cancer Res. 53: 2560-2565). The invention also provides pharmaceutical compositions having the monoclonal antibodies or anti-idiotypic monoclonal antibodies of the invention.

The antibodies or fragments may also be produced, using current technology, by 25 recombinant means. Regions that bind specifically to the desired regions of the CEG protein can also be produced in the context of chimeric or CDR grafted antibodies of multiple species origin. The invention includes an antibody, e.g., a monoclonal antibody which competitively inhibits the immunospecific binding of any of the monoclonal 30 antibodies of the invention to a CEG protein.

Alternatively, methods for producing fully human monoclonal antibodies, include phage display and transgenic methods, are known and may be used for the generation of human monoclonal antibodies (reviewed in: Vaughan et al., 1998 Nature Biotechnology 16: 535-539). For example, fully human monoclonal antibodies may be generated using cloning technologies employing large human Ig gene combinatorial libraries (i.e., phage display) (Griffiths and Hoogenboom, "Building an in vitro immune system: human antibodies from phage display libraries", in: Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, Clark, M. (Ed.), Nottingham Academic, pp 45-64 (1993); Burton and Barbas, "Human Antibodies from combinatorial libraries" Id., pp 65-82). Fully human monoclonal antibodies may also be produced using transgenic mice engineered to contain human immunoglobulin gene loci as described in PCT Patent Application WO98/24893, Jakobovits et al., published December 3, 1997 (see also, Jakobovits, 1998 Exp. Opin. Invest. Drugs 7: 607-614). This method avoids the in vitro manipulation required with phage display technology and efficiently produces high affinity, authentic human antibodies.

5

10

15

20

The antibody or fragment thereof of the invention may be labeled with a detectable marker or conjugated to a second molecule, such as a therapeutic agent (e.g., a cytotoxic agent) thereby resulting in an immunoconjugate. For example, the therapeutic agent includes, but is not limited to, an anti-tumor drug, a toxin, a radioactive agent, a cytokine, a second antibody or an enzyme. Further, the invention provides an embodiment wherein the antibody of the invention is linked to an enzyme that converts a prodrug into a cytotoxic drug.

Examples of cytotoxic agents include, but are not limited to ricin, ricin A-chain, doxorubicin, daunorubicin, taxol, ethiduim bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin D, diphteria toxin, *Pseudomonas* exotoxin (PE) A, PE40, abrin, arbrin A chain, modeccin A chain, alpha-sarcin, gelonin, mitogellin, retstrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, sapaonaria officinalis inhibitor, and glucocorticoid and other chemotherapeutic agents, as well as radioisotopes such as ²¹²Bi, ¹³¹I, ¹³¹In, ⁹⁰Y, and ¹⁸⁶Re.

Suitable detectable markers for diagnostic used include, but are not limited to, a radioisotope, a fluorescent compound, a bioluminescent compound, chemiluminescent compound, a metal chelator or an enzyme. Antibodies may also be conjugated to an anticancer pro-drug activating enzyme capable of converting the pro-drug to its active form. See, for example, U.S. Patent Nos. 4,952,394 and 5,716,990.

Additionally, a recombinant protein of the invention comprising the antigen-binding region of any of the monoclonal antibodies of the invention can be made. In such a situation, the antigen-binding region of the recombinant protein is joined to at least a functionally active portion of a second protein having therapeutic activity. The second protein can include, but is not limited to, an enzyme, lymphokine, oncostatin or toxin. Suitable toxins include those described above.

10

25

30

Techniques for conjugating or joining therapeutic agents to antibodies are well known (Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in: Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56, Alan R. Liss, Inc. 1985; Hellstrom et al., "Antibodies For Drug Delivery", in: Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-53, Marcel Dekker, Inc. 1987; Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in: Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", in: Immunol. Rev., 62:119-58 (1982)). Techniques for joining detectable markers to antibodies are also known.

D) PHARMACEUTICAL COMPOSITIONS OF THE INVENTION

The invention includes pharmaceutical compositions for use in the treatment of microbial infections comprising a pharmaceutically effective amount of an anti-CEG antibody or a CEG polypeptide.

In one embodiment, the pharmaceutical compositions may comprise a CEG antibody, either unmodified, conjugated to a therapeutic agent (e.g., drug, toxin, enzyme or second antibody) or in a recombinant form (e.g., chimeric or bispecific). The compositions may additionally include other antibodies or conjugates (e.g., an antibody cocktail).

5

10

15

20

The pharmaceutical compositions also preferably include suitable carriers and adjuvants which include any material which when combined with the molecule of the invention (e.g., an anti-CEG antibody or a CEG protein) retains the molecule's activity and is nonreactive with the subject's immune systems. Examples of suitable carriers and adjuvants include, but are not limited to, human serum albumin, ion exchangers, alumina, lecithin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, and salts or electrolytes such as protamine sulfate. Other examples include any of the standard pharmaceutical carriers such as a phosphate buffered saline solution, water, emulsions such as oil/water emulsion, and various types of wetting agents. Other carriers may also include sterile solutions, tablets including coated tablets and capsules. Typically such carriers contain excipients such as starch, milk, sugar, certain types of clay, gelatin, stearic acid or salts thereof, magnesium or calcium stearate, talc, vegetable fats or oils, gums, glycols, or other known excipients. Such carriers may also include flavor and color additives or other ingredients. Compositions comprising such carriers are formulated by well known conventional methods. Such compositions may also be formulated within various lipid compositions, such as, for example, liposomes as well as in various polymeric compositions, such as polymer microspheres.

The pharmaceutical compositions of the invention can be administered using conventional modes of administration including, but not limited to, intravenous, intraperitoneal, oral, intralymphatic or administration directly into the tumor. Intravenous administration is preferred.

The pharmaceutical compositions of the invention may be in a variety of dosage forms which include, but are not limited to, liquid solutions or suspensions, tablets, pills, powders, suppositories, polymeric microcapsules or microvesicles, liposomes, and

injectable or infusible solutions. The preferred form depends upon the mode of administration and the therapeutic application.

The CEG polypeptides and proteins of this invention are found in common pathogenic bacterial species such as *Streptococcus pneumoniae*. This organism causes upper respiratory tract infections. Thus, the peptides and proteins of this invention can be used as immunogens in subunit vaccines for vaccination against a pathogenic bacteria such as *Streptococcus pneumoniae*. Additionally, the *ceg* sequences of the invention can be used as DNA vaccines (U.S. Patent No. 5,736,524 and U.S. Patent No. 5,989,553).

10

5

The polypeptides and proteins of this invention can be formulated as univalent and multivalent vaccines. The protein can be mixed, conjugated or fused with other antigens, including B or T cell epitopes of other antigens.

- 15 Further, when a haptenic peptide of the proteins of the invention is used, (i.e., a peptide which reacts with cognate antibodies, but cannot itself elicit an immune response), it can be conjugated to an immunogenic carrier molecule. Conjugation to an immunogenic carrier can render the oligopeptide immunogenic. Examples of carrier molecules are tetanus toxin or toxoid, diphtheria toxin or toxoid and any mutant forms of these proteins such as CRM.sub.197. Others include exotoxin A of *Pseudomonas*, the heat labile toxin of *E. coli* and rotaviral particles (including rotavirus and VP6 particles). Alternatively, a fragment or epitope of the carrier protein or other immunogenic protein can be used. For example, the happen can be coupled to a T cell epitope of a bacterial toxin.
- In formulating the vaccine compositions with the CEG polypeptides or proteins of the invention, alone or in the various combinations described, the immunogen is adjusted to an appropriate concentration and formulated with any suitable vaccine adjuvant. Suitable adjuvants include, but are not limited to: surface active substances, e.g., hexadecylamine, octadecylamine, octadecyl amino acid esters, lysolecithin, dimethyl-dioctadecylammonium bromide), methoxyhexadecylgylcerol, and pluronic polyols; polyamines, e.g., pyran, dextransulfate, poly IC, carbopol; peptides, e.g., muramyl

dipeptide, dimethylglycine, tuftsin; oil emulsions; and mineral gels, e.g., aluminum hydroxide, aluminum phosphate, etc. and immune stimulating complexes. The immunogen may also be incorporated into liposomes, or conjugated to polysaccharides and/or other polymers.

5

The vaccines can be administered to a human or animal in a variety of ways. These include intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, oral and intranasal routes of administration. Further, the vaccines can be live or inactivated vaccines.

10

The most effective mode of administration and dosage regimen for the compositions of this invention depends upon the severity and course of the disease, the patient's health and response to treatment and the judgment of the treating physician. Accordingly, the dosages of the compositions should be titrated to the individual patient.

15

E) <u>USES OF THE MOLECULES OF THE INVENTION</u>

1) MOLECULAR WEIGHT MARKERS

The nucleic acid molecules of the invention and their encoded proteins may be employed as molecular weight markers. For example, the molecular weight of each of the nucleic acid molecules having *ceg* sequences and their predicted polypeptides can be determined and can be used to compare against other gene sequences and proteins whose molecular weights are unknown.

25

30

2) DIAGNOSTICS

The nucleic acid molecules of the invention may be employed in diagnostic embodiments. For example, the presence of nucleotide sequences which are identical or similar to the *ceg* sequences of the invention may be detected within a biological sample.

The biological sample may include blood, serum or a swab from nose, ear or throat, may be determined by means of a nucleic acid detection assay.

Nucleic acid probes or primers having sequences complementary to ceg sequences may be used in a hybridization assay to detect the presence of the sequences which are identical or similar to the ceg sequences of the invention in the biological samples. Typically, nucleic acids molecules obtained from a suitable biological sample are hybridized with labeled probes or primers. The resulting hybridized molecules are detected and resolved by methods well known in the art, such as Northern or Southern blotting, micro-array technology, or amplifying with PCR technology. Other hybridization techniques and systems are known that can be used in connection with the detection aspects of the invention, including diagnostic assays such as those described in Falkow et al., U.S. Pat. No. 4,358,535.

Examples of the PCR technology are disclosed in U.S. Patent Nos. 4,683,202 and 4,965,188 (incorporated herein by reference). Generally, nucleic acid molecules are obtained from a suitable biological source and contacted with two primers corresponding to the *ceg* sequences disclosed herein, under conditions which allow for hybridization and polymerization to occur. A pair of probes, one corresponding to the 5' flanking region and the other corresponding to the 3' flanking region, would be sufficient to detect the nucleic acid molecules of the invention in a biological sample and may be used to indicate the amount of bacteria present.

Alternative methods of detecting nucleic acid molecules include, for example, in situ hybridization techniques, where a *ceg* probe is used to detect homologous sequences within one or more cells, such as cells within a clinical sample or even cells grown in tissue culture. As is well known in the art, the cells are prepared for hybridization by fixation, e.g. chemical fixation, and placed in conditions that allow for the hybridization of a detectable probe with nucleic acids located within the fixed cell.

The amount of ceg sequences present in a biological sample can be quantified and compared to the levels in a normal or "healthy" sample. For example, ceg sequences present in either increased or decreased levels, compared to the levels found in the control sample may indicate the presence of bacteria. This information is useful for diagnosis of a bacterial infection that requires treatment with an antibacterial agent.

Alternatively, the amount of CEG polypeptides present in a biological sample may be determined by means of an immunoassay. For example, labeled antibodies reactive against CEG polypeptides may be used in an immuno-reactive assay to detect the presence of CEG polypeptides in the biological samples.

3) SCREENING CANDIDATE CEG SEQUENCES

a) Gene Disruption Assay

15

20

25

10

The ceg nucleotide sequences of the invention can be used to identify nucleotide sequences which are identical or similar to the ceg sequences that are required for bacterial cell viability. For example, the ceg sequences can be used in a bacterial gene disruption assay to screen candidate nucleotide sequences to identify sequences required for bacterial cell viability.

The disruption assay can involve: introducing into a host cell a recombinant vector that is capable of integration into the host genome, where the recombinant vector includes a candidate sequence that putatively encodes a cell-viability gene product (e.g., the exogenous ceg sequence); the vector integrates the candidate sequence into a target sequence within the host's genome (e.g., the endogenous ceg sequence); and the host cell, so introduced, is screened for viability. The recombinant vector preferably includes a selectable marker so that the introduced host cell can be screened for viability in the presence of a selectable agent.

For example, Figure 1 shows a schematic representation of a gene disruption assay, within a bacterial host cell. In Figure 1A, the recombinant vector, pEVP3, includes the CAT gene (e.g., the selectable marker chloramphenical acetyl transferase) and an internal region of the *ceg* disrupting sequence; the internal region excludes the 5' and 3' ends of the *ceg* sequence. The "X" in Figure 1 indicates the recombinant pEVP3 vector undergoing homologous recombination with the target sequence (e.g., within the host genome). In Figure 1B, the resolved pEVP3 vector that is integrated into the host genome, is shown. Left to right are the following elements: the native promoter of the target gene; a 5' partial copy of the target gene; the body of the integrated pEVP3 vector including the disrupting gene and CAT; and, a 3' partial copy of the target gene. Thus, integration of the pEVP3 vector via homologous recombination results in two partial gene duplications flanking the integrated vector. If the target gene is not essential for survival, it is possible to recover chloramphenicol-resistant colonies of *S. pneumoniae*. Failure to recover chloramphenicol resistant colonies, in the presence of the proper controls as described below, indicates that the target gene may be essential for cell viability.

More particularly, the gene disruption assay for screening candidate ceg sequences can involve the following steps. The recombinant pEVP-3 vector encoding CAT resistance and having a fragment of a candidate ceg sequence, can be introduced into transformation-competent S. pneumoniae cells by methods that are well-known in the art (Lee, M.S., et al., 1998 Appl. Environ. Microbiol. 64:4796-4802). The preferred size of the ceg fragment can be between about 200 to about 500 bp in length. It is advantageous that the candidate ceg sequence does not include the 5' and 3' ends that encode the N-and C-terminal ends of the CEG polypeptide. This insures that the inserted ceg fragment and the disrupted endogenous ceg gene sequence are not capable of expression of a full-length, functional ceg gene product. The transformation-competent cells can be obtained by performing the transformation step in the presence of a heptadecapeptide that induces competence for transformation of S. pneumoniae (Havarstein, L. S., et al., 1995 Proc. Nat'l. Acad. Sci. 92:11140-11144), such as the CSP-1 peptide. The CSP-1 can be naturally-derived or synthetic. Additionally, the transformation step can be optimized by performing the transformation when the cells have reached a density which is optimal for

transformation (e.g., 3 X 10⁷ cells per ml.) (Havarstein, L. S. et al. *supra*). The recombinant vector can be introduced into the competent pneumococci and may undergo homologous recombination, whereby the candidate *ceg* fragment recombines with the corresponding endogenous *ceg* sequence, resulting in targeted integration of the vector into the pneumococcal genome and disruption of the endogenous *ceg*.

The transformed cells can be plated on or cultured in chloramphenicol-containing growth medium. The cells can be cultured under standard conditions, such as 37° C in 5% CO₂ for approximately 40 to 48 hours, for the purpose of selecting cells that carry the integrated vector.

Additionally, control samples can be run in parallel with the gene disruption assay, in order to determine whether the gene disruption procedure is working properly. example, the control samples can be used to calibrate the gene disruption experiment so that disruption of a known non-essential bacterial gene results in an approximate number of colonies per plate. Similarly, the disruption of a known essential gene can be calibrated to yield only zero or one colony per plate. The appearance of one colony is due to the rare illegitimate recombination into a non-homologous sequence. In particular, a known non-essential gene such as the lytA gene (Tomasz, A., et al., 1988 J. Bacteriol. 170:5931-5934) can be used so that between about 70 to 100 chloramphenicol-resistant colonies will grow per plate. Similarly, the ftsZ gene (Lutkenhaus, J. F., et al., 1980 J. Bacteriol. 143:1281-1288), a known essential gene, can be used to yield zero or, rarely, one colony per plate. As is well known in the art, specific parameters that are involved in any given gene disruption assay can be adjusted to calibrate the desired number of plated cells in the control samples. Experimental parameters that can be adjusted include, but are not limited to, the E. coli strain used to propagate the vector/insert, the fragment length of the sequence to be integrated, the amount of recombinant integration vector used to transform the cells, use of transformation-competent cells, and plating density of the transformed cells.

5

10

15

20

The transformed cells carrying the recombinant integration vector that disrupts expression of an endogenous essential gene (e.g., the target ceg gene) can be identified, based on a selectable phenotype such as non-viability. For example, the cells that carry a disrupted non-essential gene will be viable and, due to the integration of pEVP3, will grow on chloramphenicol-containing medium. In contrast, cells that carry a disrupted essential gene will not grow (e.g., non-viable) on the chloramphenicol-containing medium. Thus, the transformed cells that do not grow under these selective conditions carry an endogenous gene sequence that is essential for cell viability which has been disrupted by an exogenous candidate fragment, thereby identifying a ceg sequence. Steps one through three may be repeated in order to confirm that the ceg sequences, so identified, are essential for cell viability.

b) Autolysin Assay

10

It is advantageous to perform additional steps to determine whether the homologous recombination events result in disruption of the intended target gene sequence. The lytA transformation control can be used to confirm that the transformation system is functioning properly. For example, a phenotypic test for autolysin activity (lytA gene product) can be performed to determine that the exogenous lytA fragment is correctly integrated into the lytA site within the host genome. This typically involves flooding the culture plates containing transformants carrying the integrated lytA control vector with a solution of detergent, such as 0.1% deoxycholate, which triggers cell lysis in lytA-intact cells (e.g., the cells that have not undergone homologous recombination). After about 5-10 minutes the colonies with intact lytA will appear ghost-like due to cell lysis, and the

c) Polarity Analysis

The ceg sequences that are confirmed to be essential for cell viability can be examined further by performing a polarity analysis to determine if the corresponding endogenous ceg sequence is organized in an operon. Polarity is an effect unique to prokaryotes and is

the result of the operon organization of bacterial genomes. Many bacterial genes are arranged in operons in which multiple genes are under the control of a single regulatory sequence (e.g., a promoter) and are transcribed into a single mRNA transcript. With respect to the orientation of multiple genes within an operon, the genes that are proximal to the regulatory sequence are said to be "upstream" genes and the genes that are distal are said to be "downstream" genes. For example, many operons contain genes encoding different proteins that catalyze discrete steps of a common biochemical pathway. Thus, any of the proteins that catalyze the steps of the pathway may be essential for cell viability.

10

- 15

20

The presence of operons in a bacterial host genome may influence the interpretations of the gene disruption results. For example, disruption of an upstream gene may be erroneously interpreted as affecting the expression of the disrupted gene but may, in fact, have expression affects on the intact downstream genes. Therefore, it is advantageous to perform a polarity analysis to determine if a *ceg* sequence is part of an operon.

A polarity analysis can involve performing an *in vivo* gene disruption procedure using, as the disrupting sequence, a *ceg* sequence that includes the entire *ceg* coding sequence region but lacking expression regulatory sequences. This differs from the gene disruption assay, which involves the central region of the *ceg* sequence. The polarity analysis involves gene duplication via homologous recombination. For example, the pEVP-3 vector having the entire coding region of a *ceg* sequence can be used for the polarity analysis (Figure 2 A). The polarity analysis will yield different results depending on the organization of the endogenous target sequence within the host genome.

25.

30

For example, Figure 2 shows a schematic representation of the polarity test for operons, within a bacterial host cell. In Figure 2A, the recombinant vector, pEVP3, includes the CAT gene and the entire coding region of the *ceg* disrupting sequence. The "X" in Figure 2 indicates the recombinant pEVP3 vector undergoing homologous recombination with the target sequence. Two of the possible results of homologous recombination are shown in Figures 2 B and C.

In Figure 2 B, case 1, if the endogenous target sequence is not organized in an operon, the integration event may yield: a functional target sequence (e.g., it is capable of expression); a duplicate non-functional target sequence that lacks a promoter; and a functional downstream gene (e.g., Gene B) that is controlled by its own promoter. The cells carrying this type of integrated target sequence can be recovered as viable cells that grow in the presence of chloramphenicol; this condition is termed "polarity negative".

In Figure 2 C, case 2, if the target sequence is organized in an operon, then the integration event may yield an integration site that is similar to that described for case 1, including: a functional target sequence; and a duplicate non-functional target sequence which is not functional. However, this integration event may also yield a non-functional downstream gene (e.g., Gene B) because expression of this downstream gene is controlled by a promoter located upstream of the insertion site. The cells that carry this type of integrated target sequence will be non-viable; this condition is termed "polarity positive". Thus, the polarity analysis provides a method to determine whether integration of a recombinant vector into a target ceg sequence effects expression of downstream genes.

The ceg sequences disclosed herein (SEQ ID NOs.: 1-113, 227-331) encode gene products that are essential for viability in S. pneumoniae. Furthermore, many of these ceg sequences have been analyzed for the polarity effect and the results are presented in Table I. One subset of ceg sequences is classified as polarity negative (-), since the homologous recombination event did not effect the expression of downstream genes. Another subset of ceg sequences is classified as polarity positive (+), since the homologous recombination event did affect the expression of downstream genes. The ceg sequences that have not yet been classified as polarity positive or negative are indicated in Table I as a blank. For the ceg sequences that are classified as polarity positive, the genes downstream of the disrupted endogenous ceg sequences may or may not also be essential.

4) <u>ASSAYS FOR IDENTIFYING CEG LIGANDS AND OTHER BINDING AGENTS</u>

The present invention provides screening methods for identifying agents that interact and/or bind to the CEG proteins of the invention, such as a ligand. An agent can be, for example, a natural product, a derived or synthetic chemical molecule, a polypeptide, a nucleic acid molecule, or a metal. The agents that interact with CEG proteins may cause bacterial cell death by disrupting the functions of CEG proteins, including, but not limited to, nucleotide biosynthesis, DNA replication, RNA transcription, protein translation, and/or cell wall biosynthesis. Accordingly, the present invention provides screening methods for identifying agents having antibacterial activity, such as agents that cause bacterial cell death by interacting with the CEG proteins. These antibacterial agents are useful for treating diseases and afflictions associated with bacterial infections.

5

10

- Various methods can be used to discover agents having antibacterial activity, as determined by the ability of the binding agent to bind to a CEG protein and disrupt the function of the CEG protein. These screening methods include whole cell *in vivo* assays as well as *in vitro* assays with cellular components.
- An *in vivo* screening method for identifying ligands that bind CEG polypeptides can be performed in a whole cell assay. A typical method may be the use of whole bacterial cells to assess the antibacterial properties based on cell growth or viability. These methods can include methods for measuring cell growth and/or viability, for example, by optical density or zones of growth (Koch, A. L. et al., 1970 *Anal. Biochem.* 38:252-259; Biemer, J. J. et al., 1973 *Ann. Clin. Lab. Sci.* 2:135-140; *Manual of Clinical Microbiology*; 7th edition, Murray, P. R. (ed), ASM Press), by growth inhibition in an agar assay (Murray, P. R., *supra*), or other means of detecting cell metabolism
 - known to those skilled in the art. In addition, there are molecular biology-based detection methods for use with whole bacterial cells, such as gene reporter assays, to monitor the effect of the ligand on specific targets (Slauch, J. M., et al., 1991 *Methods Enzymol*. 204:213-248). Examples of the reporter genes include, but are not limited to, beta-

(Mychajlonka, M. et al., 1980 Antimicrob. Agents Chemother. 17:572-582), and are well

galactosidase, alkaline phosphatase, luciferase, and green fluorescent protein. For example, one embodiment provides a reporter system that monitors inhibition of DNA synthesis by fusing a reporter such as beta-galactosidase (*lacZ*) to genes known to be upregulated by the cessation of DNA synthesis as a result of the binding of ligands to the DNA synthetic apparatus. (Shurvinton, C. E., et al., 1982 *Mol. Gen. Genetics* 185:352-355; Rosato, A., et al., 1998 *Antimicrob. Agents Chemother.* 42:1392-1396).

Alternatively, the yeast two-hybrid system (Fields, S. and Song, O. 1989, *Nature* 340:245-246) may be adapted to screen for ligands that bind CEG polypeptides. Generally, the yeast two-hybrid system is performed in a yeast host cell carrying a reporter gene, and is based on the modular nature of the GAL transcription factor which has a DNA binding domain and a transcriptional activation domain. The yeast two-hybrid system relies on the physical interaction between a recombinant polypeptide that comprises the GAL DNA binding domain and another recombinant polypeptide that comprises the GAL transcriptional activation domain. The physical interaction between the two recombinant polypeptides reconstitutes the transcriptional activity of the transcription factor, thereby causing expression of the reporter gene. Either of the recombinant polypeptides used in the two-hybrid system can be generated to include a CEG polypeptide sequence to screen for binding partners of CEG.

20

25

10

15

Another method uses the bacterial CEG proteins as the basis for *in vitro* assay systems to detect binding agents. Typically, the *in vitro* screening method comprises: a) generating the CEG protein of the invention, or membranes enriched in the CEG protein; b) exposing the CEG protein or membranes to a candidate agent; and c) detecting the interaction of the CEG protein with the agent by any suitable means. Additionally, the screening methods may be adapted to automated high-throughput procedures, such as PANDEX.RTM Baxter-Dade Diagnostics, allowing for efficient high-volume screening of candidate agents.

30 An alternative method for screening potential ligands involves an *in vitro* binding procedure. Typically, the CEG proteins of the invention can be produced using

recombinant DNA technology and host-vector systems as described herein. A candidate agent is introduced into a reaction vessel containing the CEG protein, or fragment thereof; the candidate agents may be detectable by methods such as, but not limited to, radioisotope or chemical labeling. Binding of the CEG protein by a candidate agent can be determined by any suitable means, including, for example, quantifying bound label versus unbound label using any suitable method. Binding of a candidate agent may also be detected by methods similar to an alternative physical method disclosed in U.S. Patent No. 5,585,277. In this method, binding of a candidate agent to a protein is assessed by monitoring the ratio of folded protein to unfolded protein, for example by monitoring sensitivity of the protein to a protease, or amenability to binding of the protein by a specific antibody against the folded state of the protein, or binding to chaperone protein, or by binding to any suitable surface.

5

10

. 15

20

25

The invention provides methods of identifying compounds that modulate (e.g., activate or inhibit) the function of a CEG polypeptide. Essentially any compound can be used in the assays of the invention. The preferred compounds are those that are soluble in aqueous or organic solutions. It will be appreciated by those of skill in the art that there are many commercial suppliers of chemical compounds that can be used in the methods of the invention, including Sigma Chemical Co. (St. Louis, Mo.), Aldrich Chemical Co. (St. Louis, Mo.), Sigma-Aldrich (St. Louis, Mo.), Fluka Chemika-Biochemica Analytika (Buchs, Switzerland), and the like.

The present invention provides methods for detecting compounds which are identified as modulators of CEG function. The methods of the invention can be performed using isolated CEG polypeptides, or use whole cells expressing the CEG polypeptide. The steps of the method using isolated CEG polypeptides include: contacting the isolated CEG polypeptide with a candidate compound; and determining whether the function of the CEG polypeptide is altered. The steps of the method using whole cells include: contacting the whole cells with a candidate compound; and determining whether the cell dies, indicating the compound inhibited the function of a CEG polypeptide.

The preferred methods of the invention provide high-throughput screening assays for identifying compounds which modulate the function of a CEG polypeptide. The high throughput methods permit screening of large libraries of compounds. For example the high throughput methods can use automated assay steps. The assays can be performed in parallel on a solid support, as microtiter formats on microtiter plates in robotic assays are well known. A preferred embodiment of the methods includes adapting the methods to use microtiter plates or pico- nano- or micro-liter arrays. In high throughput assays it is desirable to run positive controls to ensure that the components of the assays are working properly.

. 10

15

The high throughput screening methods of the invention include providing a combinatorial library containing a large number of compounds (candidate modulator compounds) (Borman, S, C. & E. News, 1999, 70(10), 33-48). Such combinatorial chemical libraries can be screened in one or more assays to identify library members (particular chemical species or subclasses) that exhibit the ability to modulate the function of the CEG polypeptide (Borman, S., supra; Dagani, R. C. & E. News, 1999, 70(10), 51-60). The compounds, so identified, can serve as lead-compounds or can themselves be used as potential or actual therapeutics.

A combinatorial chemical library is a collection of diverse chemical compounds generated by using either chemical synthesis or biological synthesis, to combine a number of chemical building blocks, such as reagents. For example, a linear combinatorial chemical library, such as a polypeptide library, is formed by combining a set of chemical building blocks (amino acids) in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks.

Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Pat. No. 5,010,175, Furka, *Int. J. Pept. Prot. Res.*, 1991, 37:487-493 and

Houghton, et al., Nature, 1991, 354, 84-88). Other chemistries for generating chemical diversity libraries can also be used. Such chemistries include, but are not limited to, peptoids (PCT Publication No. WO 91/19735); encoded peptides (PCT Publication WO 93/20242); random bio-oligomers (PCT Publication No. WO 92/00091); benzodiazepines (U.S. Pat. No. 5,288,514); diversomers, such as hydantoins, benzodiazepines and dipeptides (Hobbs, et al., 5 Proc. Nat. Acad. Sci. USA, 1993, 90, 6909-6913); vinylogous polypeptides (Hagihara, et al., J. Amer. Chem. Soc. 1992, 114, 6568); nonpeptidal peptidomimetics with beta-D-glucose scaffolding (Hirschmann, et al., J. Amer. Chem. Soc., 1992, 114, 9217-9218); analogous organic syntheses of small compound libraries (Chen, et al., J. Amer. Chem. Soc., 1994, 116, 2661; Armstrong, et al. Acc. Chem. Res., 1996, 29, 123-131); or small organic molecule 10 libraries (see, e.g., benzodiazepines, Baum C&E News, 1993, Jan. 18, page 33,); oligocarbamates (Cho, et al., Science, 1993, 261, 1303); and/or peptidyl phosphonates (Campbell, et al., J. Org. Chem. 1994, 59, 658); nucleic acid libraries (see, Seliger, H et al., Nucleosides & Nucleotides, 1997, 16, 703-710); peptide nucleic acid libraries (see, e.g., U.S. Pat. No. 5,539,083); antibody libraries (see, e.g., Vaughn, et al., Nature Biotechnology, 1996, 15 14(3), 309-314 and PCT/US96/10287); carbohydrate libraries (see, e.g., Liang, et al., Science, 1996, 274, 1520-1522 and U.S. Pat. No. 5,593,853, Nilsson, UJ, et al., Combinatorial Chemistry & High Throughput Screening, 1999 2, 335-352; Schweizer, F; Hindsgaul, O. Current Opinion In Chemical Biology, 1999 3, 291-298); isoprenoids (U.S. Pat. No. 20 5,569,588); thiazolidinones and metathiazanones (U.S. Pat. No. 5,549,974); pyrrolidines (U.S. Pat. Nos. 5,525,735 and 5,519,134); morpholino compounds (U.S. Pat. No. 5,506,337); benzodiazepines (U.S. Pat. No. 5,288,514); and other similar art.

Devices for the preparation of combinatorial libraries are commercially available (see, e.g., 357 MPS, 390 MPS, Advanced Chem. Tech, Louisville Ky., Symphony, Rainin, Woburn, Mass., 433A Applied Biosystems, Foster City, Calif., 9050 Plus, Millipore, Bedford, Mass.). In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis, Mo., ChemStar, Ltd., Moscow, RU, 3D Pharmaceuticals, Exton, Pa., Martek Bio sciences, Columbia, Md., etc.).

In the high throughput methods of the invention, several thousand different candidate compounds can be screened in a relatively short period of time. For example, each well of a microtiter plate can be used to run a separate assay against a selected potential modulator, or if concentration or incubation time effects are to be observed, every 5-10 wells can test a single modulator. Thus, a single standard microtiter plate can assay about 100 (96) modulators. If 1536 well plates are used, then a single plate can easily assay from about 100 to about 1500 different compounds. It is possible to assay many different plates per day; assay screens for up to about 6,000-20,000, and even up to about 100,000-1,000,000 different candidate modulator compounds are possible using the methods of the invention.

The following examples are presented to illustrate the present invention and to assist one of ordinary skill in making and using the same. The examples are not intended in any way to otherwise limit the scope of the invention.

15

20

10

5

EXAMPLE 1

The following provides a general description of how a list of candidate *ceg* sequences was generated. The list was generated by selecting candidate *ceg* gene sequences from a Concordance web engine using the method described in: Bruccoleri, R.E., Dougherty, T.J., Davison, D.B. (1998) "Concordance analysis of microbial genomes" in: *Nucleic Acids Res* 26:4482-4486.

Microbial Genomics CEG Discovery Process Summary.

25

30

Microbial Concordance Analysis

The entire genomic sequence data of various bacteria was acquired from several public and proprietary sequence database sources, including GTC (Genome Therapeutics Corporation), and TIGR (The Institute for Genomic Research).

Predicted ORFs from the genomic data were identified, translated, and stored. The desirable ORFs were at least 90 amino acid residues in length. Concordance analysis was performed among bacteria and various parameters were used to filter out genes with high similarity to eukaryotes.

5

10

15

20

Concordance Analysis

The entire genomic sequence of various Eubacteria was acquired from several public and private sources. The proprietary PathoGenome System from Genome Therapeutics Corporation, Waltham, MA, USA contributed data. Public data was obtained from GenBank (http://ncbi.nlm.nih.gov), The Institute for Genomic Research (TIGR), the Yeast Proteome Database, from Proteome, Inc. of Beverly, MA, and the Sanger Center of the Medical Research Council of the United Kingdom (http://www.sanger.ac.uk). Additionally, the non-microbial sequence data used as a basis for comparison and data subtraction was obtained from a proprietary database, including the LifeSeq Database from Incyte Pharmaceuticals, Palo Alto, CA.

Where required, Incyte nucleotide sequences were translated into protein sequences in all six possible reading frames. GTC supplied predicted protein sequences with their data. In the case of other eubacterial nucleotide sequences, the program CRITICA (Badger, J. and Olsen, G., 1999 "CRITICA: coding region identification tool invoking comparative analysis" in: *Molecular Biology and Evolution* 16:512-524). The sequences were stored in flat files on a Unix computer system. Each predicted amino acid sequence had to be greater than 90 amino acids.

25

30

Each predicted protein sequence was compared to every other sequence (an "all-against-all" comparison). The program used was FASTA (Pearson, W.R., "Flexible sequence similarity searching with the FASTA3 program package." *Methods in Molecular Biology* 2000 132:185-219.) The parameters used were ktup=2, and all scores above the default cutoff were kept. The output was processed and stored in a PostGres 95 database (http://www.postgresql.org). Graphical user interfaces, using web browser technology, were constructed to query the database.

A Concordance Analysis was performed on the data. The question used to generate the dataset was show all *Streptococcus pneumoniae* open reading frames with a similarity greater than or equal to 30% overall protein sequence identity to both selected grampositive and/or gram-negative bacteria in the database. The data was further required not to match yeast or human sequences at greater than 30% overall protein sequence similarity. The resulting dataset included a list of more than 400 conserved amino acid sequences having known or unknown function. The amino acid sequences having unknown functions formed the basis of a list designated Conserved Unknown Reading Frames, or CURFs which is a subset of the total list of CEGs (e.g., CURFs includes known and unknown).

The resulting list of conserved genes (e.g., more than 400 sequences) was used as a basis for selecting and screening bacterial gene sequences that are essential for cell viability. The Concordance system was designed to permit high-throughput identification of conserved gene sequences in the database. (Bruccoleri, R, Dougherty, T, and Davison, D. 1998 "Concordance analysis of microbial genomes" *Nucleic Acids Res.* 26:4482-4486.)

20 Data Curation And Analysis

Exact N-terminal and C-terminal translational start sites of genes were identified by pairwise similarity searches, multiple sequence alignments. Ribosome binding sites, terminators, nearby genes, operons were identified.

25

30

5

10

15

The resulting list of conserved genes was used as a basis for selecting and screening bacterial gene sequences that are essential for cell viability. This Concordance system was designed to permit high throughput use of the conserved gene sequences contained on the list. A set of Knockout PCR primers were generated, based on the list of conserved genes, for the purpose of use in the gene disruption procedure described below. The PCR primers were designed to amplify a central 300-500 bp region of the ceg (to prevent generation of a functional copy of the ceg gene following integration),

ordered electronically, the primers were placed in a 96-well format, and used in the gene disruption procedure as described below.

EXAMPLE 2

5

The following provides a description of the procedure to generate recombinant vectors of pEVP-3 having inserts of candidate *ceg* nucleotide sequences. The Knockout primers generated by the method described in Example 1 above were used to generate DNA fragments comprising candidate *ceg* sequences.

10

15

20

Genomic PCR Knockout Target Fragment Generation

96-well plate format were set up (36 μl H₂O, 5 μl 10× VentTM buffer, 1 μl gene specific, knockout forward primer (0.5 μg/μl), 1 μl gene specific knockout reverse primer (0.5 μg/μl), 0.5 μl VentTM DNA polymerase (2000 U/ml New England Biolabs, Beverly, MA), 1.5 μl each dNTPs (10mM; 6.0 μl total), 0.5 μl S. pneumoniae chromosomal DNA (0.5 μg/μl), 50 μl total volume/reaction).

The nucleotide sequences of the forward and reverse knockout primer pairs were generated from the nucleotide sequence information obtained from the Genomic Therapeutics Corporation database for *Streptococcus pneumoniae*. The primer pairs were each used in a PCR reaction to generate a unique internal (e.g., central region) fragment of the candidate gene targeted for knockout.

The PCR program was set in the PCR machine (Initial 95 °C - 5 minutes: 30 Cycles of: 95 °C - 1 minute, 58 °C - 1 minute, 72 °C - 30 seconds; Final, 72 °C - 10 minutes, 4 °C - hold indefinitely). 5 μl of each reaction was run on an 0.8% agarose gel after purifying fragment over PCR purification kit (Qiagen) to visualize the fragments then ligation reactions were performed.

30

Ligation Reactions proceeded (set up in 96-well plate format (10.0 μl genomic PCR fragment (generated from step 2 above), 1.0 μl pEPV-3 SmaI-cut vector (1: 10 dilution of vector DNA at 50-100 ng/μl), 1.5 μl 10× ligation buffer (New England BiolabsTM), 1.0 μl T4 DNA Ligase (New England BiolabsTM 400,000 U/ml), 1.5 μl ddH₂O, 15.0 μl total reaction volume).

Reactions were allowed to incubate in 96-well plate at 14 °C overnight in the PCR machine. Transformations into E. coli for in vivo amplification were proceeded the following day.

10

15

5

The nucleotide sequences of the forward and reverse primer pairs used for the polarity test were generated in a similar manner, from the nucleotide sequence information obtained from the Genomic Therapeutics Corporation database for *Streptococcus pneumoniae*. The primer pairs were each used in a PCR reaction to generate a unique fragment of the candidate gene targeted for the polarity test. The fragment generated for the polarity test included the entire *ceg* coding sequence region but lacking the expression regulatory sequences.

Transformation into E. coli (strain LE392):

20

25

The next day, 3 μl of above ligation mix was used per transformation reaction plus 50 μl LE392 competent cells. Reactions were set up in 96-well plate format; incubated on ice for 30 minutes; heat-shocked at 42° C for 90 seconds; and incubated on ice 2 minutes; 100 μl SOC media (Gibco BRL) was added; then incubated at 37° C on platform shaker for 1 hour; plated on LB/chloramphenicol (13.0 μg/ml) agar plates for constructs over night at 37° C with plates inverted and proceeded with colony PCR to confirm constructs. The universal primers flanking the insert site in pEVP-3 were used for PCR amplification.

The colony PCR involved the following. 96-well plate format was set up (36.5 μl H₂O, 0.5 μl pEPV3 forward primer (0.25 μg/μl), 0.5 μl pEPV3 reverse primer (0.25 μg/μl), 1.5

 μ l each (6.0 μ l total) dNTPs (10 mM), 0.5 μ l VentTM DNA polymerase, 5 μ l 10× VentTM buffer, 1 μ l of a 1:50 cell dilution, 50 μ l total volume).

pEPV3 forward primer: 5' CATCAAGCTTATCGATACCGTCG 3' (SEQ ID NO:437)
p EPV3 reverse primer: 5' CACAGTAGTTCACCACCTTTTCCC 3' (SEQ ID NO:438)

Colonies of *E. coli* LE392 were picked onto a master plate of LB + 13 μ g/ml chloramphenicol (incubate throughout the day at 37° C) and then into 50 μ l H₂0 which has been placed into a 96-well plate. 1 μ l of this dilution was used in above PCR reaction (if the 96-well dilution plate is kept you will not need to prepare a master plate). Cultures for minipreps of plasmid candidates may be prepared directly from the cell dilutions.

The PCR program was run (95 °C - 5 minutes, 30 Cycles of: 95 °C - 1 minute, 58 °C - 1 minute, 72 °C - 30 seconds, 72 °C - 10 minutes, 4 °C - hold).

15

10

5

A 10 μ l/ reaction was run on a 1.0 % TBE gel. A gel designed for 96 well plates and a multichannel pipettor were used to ease loading of the sample rows. The gel was run and stained with ethidium bromide. The positive clones were identified with appropriate molecular size insert(s), amplified by the flanking pEVP-3 primers.

20

25

Minipreps Of Plasmids To Identify Cells Carrying The Pevp-3 Vector With An Insert

The constructs that carried an insert were identified. The constructs having an insert were inoculated into a 5 ml LB/Cm culture, and incubated over night at 37 °C with aeration. Miniprep plasmid DNA was prepared by a standard procedure. The miniprep DNA was digested with appropriate restriction enzymes to confirm the presence of the insert (enzymes flank SmaI site in pEVP-3) (10 μ l miniprep DNA, 2 μ l 10 × buffer, 1 μ l XbaI, 1 μ l XhoI, 6 μ l ddH20, 20 μ l total volume for digest).

To confirm the presence of an insert, the digest reactions were electrophoresed on an agarose gel and the gel was stained with ethidium bromide. The positive clones were used for the *S. pneumoniae* KNOCKOUTs procedure.

The confirmatory PCR reactions, using knock out-specific primers (quality control step) involved 35.5 μl H₂O, 5 μl 10 × VentTM buffer, 1 μl knockout forward primer (0.5 μg/μl), 1 μl knockout reverse primer (0.5 μg/μl), 0.5 μl VentTM (6.0 μl total) DNA Polymerase (2000 U/ml), 1.5 μl each dNTPs (10mM, 6.0 μl total), 1.0 μl miniprep DNA from test clone, 50 μl total reaction volume. The PCR program was as follows: 95 °C for 5 minutes, 30 Cycles of: 95 °C for 1 minute, 60 °C for 1 minute, 72 °C for 30 seconds, 72 °C for 10 minutes, hold at 4 °C. The presence of the correct-sized insert was confirmed by agarose gel electrophoresis and ethidium bromide staining. The confirmed clones were used for the *S. pneumoniae* gene KNOCKOUT procedure. Glycerol stocks were made of all positive *E. coli* LE392 constructs and frozen at – 80 degrees C.

15

20

EXAMPLE 3

The following provides a description of the high throughput gene disruption procedure used in *S. pneunomiae* strain (e.g., gene knockout procedure). The candidate *ceg* fragments that were generated by the method described in Example 2 were used in the gene disruption procedure in order to identify *ceg* nucleotide sequences that are required for cell viability.

Reactions were set up in a 1.5 ml eppendorf tubes or 96 well plate (1 µg total of miniprep pEVP-3 + insert DNA (usually 10 µl of Qiagen miniprep DNA); then 200 µl of S. pneumoniae (strain Rx-1) competent cells diluted 1:10 in competence media was added (1 ml of competence media = 980 µl Todd Hewitt (Difco Laboratories) with 0.5% yeast extract, 20 µl 10% BSA, 1 µl 10 % CaCl2, and 0.5 µl (200 µg/ml) Csp-1 competence peptide).

30

WO 01/49721 PCT/US00/35604.

Controls were run with each KNOCKOUT experiment and involved 1 μ g pEPV3 Lyt A construct = positive control (non-essential), or 1 μ g pEPV3 Fts Z construct = negative control (essential). Then the 96 well plates and controls were incubated at 37 °C for 2.5 to 3 hours in 37 °C room without shaking. The 200 μ l of the samples were plated on Todd Hewitt agar plates with 0.5% yeast extract and 2 μ g/ml chloramphenicol.

The samples were incubate over night at 37 °C in 5% CO₂ incubator. Control plates were checked for presence of colonies (pEVP-3::lytA) and no growth (pEVP-3::ftsZ). Plates were examined for growth (ca. 70-150 colonies) designating nonessentials and zero colonies designating essential genes.

The polarity test was performed in a similar manner, using the polarity fragments described in Example 3.

15

10

5

EXAMPLE 4

The following provides a description of the autolysin procedure used to determine that the non-essential control samples of *S pneumoniae* contain a disrupted *lytA* gene.

20

Phenotypic Autolysin Test

The culture plates containing transformants carrying the *lytA* control vector were flooded with 0.1% deoxycholate in H₂O. The plates were observed after 5-10 minutes. Plates with "ghosts" indicated intact *lytA* gene, or plates without "ghosts" indicated a disrupted *lytA* gene. The "ghost" phenomenon is due to detergent triggered autolysis of the cells, causing a gradual fading of the colonies.

The detergent treatment triggers the autolysin in *lytA* intact cells; it cannot trigger the autolysin (*lytA* gene product) in *lytA* disrupted cells. Colonies with intact *lytA* "ghost" in 5-10 minutes due to massive pneumococcal cell lysis.

EXAMPLE 5

5

15

20

25

The following provides a description of the procedure used to express the CEG proteins (e.g., designated CFE proteins) in *E. coli* cells.

CEG Protein Production

Full-length ceg gene were inserted into pET-21 expression vector using the E. coli BL21 10 \[\lambda DE3 \] expression system using the following method:

For each ceg, custom primers were used to insert N- and C- termini into vectors such that the 5' end (N-terminus of the CEG) is positioned properly for expression behind the T7 promoter and optimally placed with regard to the pET ribosome binding site. The pET vectors contain an Ndel site which allows positioning of ATG start site in the vector. In cases where the ceg sequence contains an internal Ndel site, blunt ligation of the ceg PCR fragment into the vector is accomplished via Klenow fill-in of the Ndel site. In many cases, primers were also designed such that the ceg 3' (C-terminus of the expressed protein) will contain an in-frame extension of 6X-histidine residues, encoded in the vector sequence of pET-21. The individual cegs were PCR amplified via custom designed primers as described above. Both ceg PCR and vector DNA were digested with appropriate restriction enzymes. The full-length ceg were ligated into the pET expression vector. The ligation mixture was transformed into competant E coli BL21 λ DE3 cells and selected for transformants on LB agar with 50 $\mu g/ml$ ampicillin. Positive insert bearing clones were screened via minipreps of the plasmids and size analysis on 0.8% agarose gels, with detection by ethidium bromide staining, as above.

Protein Production

The proper reading frame of each *ceg* inserted into pET-21 is verified by DNA sequencing.

A small (2-5 ml) test culture of *E. coli* BL21 λ DE3 with the insert-bearing plasmid is tested for protein expression by IPTG induction of the expression vector for 1-2 hours. The expression is verified by SDS-Polyacrylamide Gel Electrophoresis analysis of a whole cell extract (SDS extract of 0.5-1 ml of cells treated at 100 °C for 5 minutes) to determine whether the protein is over-expressed and migrates at the correct predicted molecular weight.

The protein is overproduced and purified via the following method. A large scale (500-1000ml) culture of *E. coli* is grown to early logarithmic phase in broth (e.g., LB broth) and protein expression induced for 2 hours with IPTG (isopropyl-D-thiogalactoside). The cells are harvested by centrifugation (8000 X G; 15 minutes) and the cell pellets resuspended in 20 ml. of buffer. The cells are lysed by sonication, and the supernatant fluid centrifuged at low speed (5000 X G, 15 min.) to remove unbroken cells. The supernatant fluid, containing the over-expressed protein is subjected to Ni-NTA affinity column chromatography (Quiagen, Inc., Chatsworth, CA). The 6X-histidine residues linked at the C-terminal end of the CEG proteins permit rapid protein purification via selective binding to a Ni-NTA resin column. The protein-bound Ni-NTA resin was to remove contaminants, and the bound proteins subsequently eluted with imidazole and recovered. It is possible to upscale this procedure to larger volumes for higher yields of proteins.

EXAMPLE 6

The following provides a description of the methods used to purify all 2CEG polypeptides (e.g., 2CFE polypeptides #19-117; SEQ ID NOS:349-436) having a histidine tag at their C-terminal ends. The 2CEG polypeptides having the his-tags were produced by the methods described in Example 5, supra. As an example, results of purification of 2CFE 75 polypeptide are presented.

10

15

20

Production Of The CFE Polypeptides

The BL21λDE3 cells harboring recombinant pET-21 vectors carrying a 2CFE nucleotide sequence (SEQ ID NOS:244-331) were cultured in LB broth containing ampicillin. When the A₆₀₀ reached approximately 0.6, protein production was induced by adding 1.0 mM of IPTG, the cells were cultured for an additional 2 hours. The cell pellet was collected by centrifugation, and the collected cell pellet was sonicated in Solution A (50 mM NaPO₄; 300 mM NaCl, pH 8.0). The sonicated cells were centrifuged at 10,000 RPM to remove the debris.

10

15

20

5

Purification Of The CFE Polypeptide

The supernatant was diluted with Solution A, loaded onto a Ni-NTA column (Quiagen) equilibrated with Solution A; the column bed size was 2.5 x 25 cm, and the flow rate was approximately 3.0 ml/minute. The 2CFE protein was eluted using a linear gradient of imidazole, using 0-250 mM in 450 ml, flow rate approximately 3.0 ml/minute. The eluted samples were collected as 22 ml fractions per tube and the eluted samples were monitored using spectrophotometry. The amount of protein in the eluted fractions was estimated using the Bradford method (Bradford, M. M., 1976 *Anal. Biochem.* 72:248) and the samples were run on an SDS-PAGE gel (Novex EC6008) (Figure 3 A). Fractions were selected for pooling based on the results of the SDS-PAGE gel. The pooled fractions were concentrated using a 10,000 MW Centricon (Amicon) to approximately 5 ml.

The 2CFE 75 polypeptide, a precipitate formed and was redissolved upon increasing the sample volume and removing the imidazole by repeated concentration in 50 mM Tris, 100 mM NaCl, pH 7.5. Varying amounts of the 2CFE 75 polypeptide were diluted in either 20 mM Tris, 20 mM KCl, pH 7.5 or 20 mM Tris, 20 mM MgCl₂, pH 7.5 at concentrations of 12, 24, or 36 ug/ml. The diluted samples were electrophoresed on an SDS-PAGE gel under non-reducing conditions (Figure 3 B). The results of Figure 3 B suggests that 2CFE 75 forms a multimer.

EXAMPLE 7

5

The following provides a description of the methods used to purify CEG polypeptides that lack a histidine tag (e.g., 2CFE polypeptides #1-17; SEQ ID NOS:332-348). As an example, the results of purification of CFE 3 polypeptide are presented.

Purification of the CFE 3 Polypeptide

The 2CFE 3 polypeptide was produced using the large scale IPTG-induced method described in Example 5, *supra*. The 2CFE 3 (SEQ ID NO:334) polypeptide lacks a Cterminal histidine tag. The 2CFE 3 polypeptide was purified using a 2-column procedure. The 2CFE 3 polypeptide preparation was eluted from a 26/10 Q Sepharose column (Pharmacia) using a 0-1.0 M NaCl gradient, 2 ml/minute flow rate, and the gradient size was 1 liter. Then the 2CFE 3 polypeptide was eluted from a hydroxyapatite Bio-gel column (Bio-Rad) using a 5-200 mM potassium phosphate (pH 8.0) gradient, the flow rate was 0.3 ml/minute, and the gradient size was 300 ml. A sample of the 2CFE 3 preparation was run on a polyacrylamide gel (Figure 4).

20 EXAMPLE 8

The following provides a description of the size exclusion chromatography methods used to estimate the molecular weight and determine whether the CEG polypeptides oligomerize. The CFE polypeptide may olimerize to form monomers, dimers, tetramers, hexameric rings, or other oligomeric forms.

Size exclusion chromatography was performed on all isolated 2CFE polypeptides #s 1-117 (e.g., SEQ ID NOS:332-436). This method was performed using various types of columns, depending on the particular 2CFE polypepeptide tested.

25

The Biosil SEC-125 HPLC Gel Filtration column (BioRad Laboratories, Inc) was used, for example, to characterize CFE 8. The mobile phase was 0.2 M KH₂PO₄, 0.9% NaCl pH 6.8.

The Phenomenex 600 x 7.5 mm Biosep SECS 3000 column was used, for example to characterize 2CFE 21 and 39. The mobile phase for size exclusion was 50 mM Na₂HPO₄, pH 7.0 and 150 mM NaCl run at 1 ml/minute in a Gilson HPLC system, with protein detection at 280 nm.

10 EXAMPLE 9

15

The following provides a description of the computer-aided methods used to search for similarities between the amino acid sequences of the CEG polypeptides and sequences available through public and proprietary databases. In many cases, the function of the CEG polypeptides was suggested by the results of the similarity searches. The function of some of these CEG polypeptides has been confirmed by performing additional analyses. Table V provides a list of the suggested and confirmed functions of CEG polypeptides designated CFEs #1-117.

The putative function of the CFE polypeptides were determined using computer-aided bioinformatic approaches, including distant homologies, motif searching, or predictions based on statistical rules. For example, the distant homology approach involved pairwise or multiple sequence alignments, employing tools such as FASTA, and Psi-BLAST. The motif searching approach involved using sophisticated hidden Markov models. The approach based upon predictions of statistical rules involved prediction of transmembrane regions, coiled-coil, and other structural motifs. These approaches have been reviewed in Computational Methods In Molecular Biology 1998, eds. Salxber, S.L., Searls, D.B. Searls, and Kasif, S., Elsevier, and in Bioinformatics: A Practical Guide To The Analysis Of Genes And Proteins 1998 eds Baxevanis, A. D. and Francis Ouellete, B.F., Wiley-Interscience.

Global sequence similarity searches were performed using the amino acid sequences of all the conserved essential gene sequences (e.g., CFEs 1-117; SEQ ID NOS:114-226) to search against a non-redundant protein database using the BLAST2 algorithm (Altschul S.F., et al., 1997 Nucleic Acids Res. 25(17):3389-3402). In a similar search, similar sequences were identified in the Concordance database using the "Neighbor" function (Bruccoleri R. E., Dougherty T.J., Davison D.B. 1998 Nucleic Acids Res. 26(19):4482-4486). To determine if the predicted amino acid sequences were full length and in the proper reading frame, BLAST-type searching and CLUSTAL multiple sequence alignments (Higgins D.G., et al., 1996 Methods Enzymol. 266:383-402) were used. Local sequence similarity searches were performed, by searching for Prosite (Hofmann K., et al., 1999 Nucleic Acids Res. 27(1):215-219) and Pfam motifs (Bateman A., et al., 2000 Nucleic Acids Res. 28(1):263-266). Additionally, the amino acid sequences of the CFEs were analyzed by performing protein threading analyses using the ProCeryon fold recognition program (Sippl, et al., 1992 Proteins 13:258-271; Sippl, J. 1993 J. Comp. Aided Mol. Design 7:473-501; www.proceryon.com) and Geneformatics.

5

10

15

20

25

30

In bacteria, many operons include genes encoding different proteins that catalyze discrete steps of a common biochemical pathway. Therefore, the operon structures in S. pneumoniae was compared with that in other bacteria in order to predict the function of CFE polypeptides.

Additionally, analysis of bacterial metabolic pathways were performed using Pathway Tools from DoubleTwist, based on the EcoCyc system (Karp P.D., et al., 1999 *Nucleic Acids Res.* 1999 27(1):55-58). This analysis was used to predict which CFEs mediate various steps of the pathways.

When the sequence identity between a CFE polypeptide and the annotated database (e.g., SwissProt, Genbank) was low (e.g., sequence identity less than about 30%), a Protein Threading (e.g., fold recognition) method was used to predict similarities in the folded protein structure of CFE polypeptides in the absence of a high level of sequence similarity with proteins in the databases (review by Teichmann, et al., 1999 Current Opinion in

Structural Biology 9:390-399). The Protein Threading method predicts the compatibility of a query sequence (e.g., CFE polypeptide sequences) with each of the folds in a library of known protein structures. The library of known protein structures as developed, maintained, and updated throughout the search process.

5

A list of potential structural folds, onto which each query was compatible, was generated for all CFE polypeptides (e.g., SEQ ID NOS:114-226). The fold assignments for each query were used to generate pairwise sequence alignments. The pairwise sequence alignments were used to generate protein models of the query polypeptide (e.g., CFE polypeptides).

10

15

The pairwise sequence alignments were also used to compare the position of critical residues of the structural template with the query polypeptide. The list of critical residues was generated by using multiple sequence alignments derived from a structural classification of proteins to generate a conservation profile which provided sequence-specific positions conserved across a homologous family of protein folds. Comparative modeling was used to search the model of the query polypeptide for the critical residues and determine whether the structural and functional motifs are conserved in the query protein. Conservation of structural and functional motifs permitted assignment of putative structure and function to a query polypeptide sequence.

20

The Protein Threading method was used to search for putative folded structure and function for all CFE polypeptides (SEQ ID NOS:114-226). The CFE polypeptides having significant sequence identity (e.g., more than 30%) to known proteins were assigned putative functions with a high level of confidence.

25

30

EXAMPLE 10

The following provides a description of the methods used to characterize purified, CFE 101 polypeptide. The 2CFE 101 polypeptide mediates the conversion of pantothenate to 4' phosphophantothenate, and is predicted to be a pantothenate kinase.

Computer-Aided Comparison

The computer-aided comparison, as described in Example 9 supra, suggests that the amino acid sequence of the CFE 101 polypeptide (SEQ ID NO:210) is 42% similar to the amino acid sequence of the coaA protein of E. coli. Thus, CFE 101 may be a pantothenate kinase, which mediates the conversion of pantothenate to 4' phosphophantothenate (Figure 5).

Circular Dichroism and Circular Dichroism Thermal Melt Analysis

10

Circular dichroism and circular dichroism melt methods were used to determine the folded structure of the expressed and isolated 2CFE polypeptides. For example, this method was used to characterize the folded structure of isolated 2CFE 101 (SEQ ID NO:421).

15

25

The starting concentration of the 2CFE 101 polypeptide was such that OD₂₀₅ was approximately 1.5, and the OD₂₈₀ was approximately 0.05 (e.g., 0.05 to 0.1 mg/ml). The starting concentration of 2CFE 101 was approximately 344 µM in 50% glycerol, 50 mM Tris, 100 mM NaCl, 5 mM MgCl₂, 0.5 mM EDTA, at pH 7.5. The polypeptide was 20 diluted to a final concentration of 7 μM, as determined by absorbance at A₂₈₀, in 20 mM Na-phosphate, 100 mM KCl, at pH 7.0. The circular dichroism analysis was performed using quartz cuvettes, the instrumentation was from JASCO (Model J-720), the readings were performed at 25 degrees C (Figure 6 A). The band width was 1 nm, the sensitivity was 20 mdeg, the response was 0.25 seconds, the scan speed was 50 nm/minute, and the step was 0.5. The circular dichroism thermal melt analysis was performed at a range of between 0 and 100 degrees C (Figure 6 B). Additionally, the circular dichroism was performed comparing monomer and aggregate pools of 2CFE 101.

Size Exclusion Analyses

Size exclusion chromatography methods were performed using the Biosil SEC column, as described in Example 8 *supra*. The results suggest that the 2CFE 101 polypeptide forms monomer (40,200 Da) and oligomers (194,000 Da). The specific activity of the monomer and oligomeric forms of 2CFE 101 were determined, as described below.

Biochemical Assays

5

30

The biochemical assays of the 2CFE 101 polypeptide was based on the PK/LDH coupled enzyme assays described by Vallari, D. S., et al. (1987 *J. Biol. Chem.* 262:2468-2471) and Song, W.-J., et al., (1994 *J. Biol. Chem.* 269:27051-27058).

Briefly, the assay was performed as follows. The reaction included: 885 μl of 0.1 M
Tris-HCl (pH 7.6), 25 μl NADH (14.1 mM), 20 μl ATP (10.7 mM), 50 μl phospho-enol-pyruvate (56 mM), 5 μl LDH/PK (lactose dehydrogenase/PK; Sigma, catalog # P-0294, 60 U/ ml PK, 1050 U/ml LDH), 5 μl of the 2CFE 101 polypeptide (9 mg/ml in 50 mM Tris-HCl, pH 7.5, 100 mM NaCl which was diluted to 4.5 mg/ml in 50% glycerol). The reaction was started by adding 10 μl pantothenate (100 mM; Sigma, catalog # P2250).
The production of ADP in the reaction was monitored by measuring the absorbance a 340 nm. The results in Figure 8 show that the 2CFE 101 polypeptide mediates ADP production in the presence of pantothenate and ATP. The K_m of pantothenate (n=4) was 144 (±16.5) μM, the V_{max} of the 2CFE 101 polypeptide (n=4) was 2.04 (±0.25) μM min⁻¹ mg⁻¹. The monomer form has a specific activity of approximately 1.7 μM min⁻¹ mg⁻¹.
The oligomeric form has a specific activity of 0.26 μM min⁻¹ mg⁻¹.

Alternatively, the 2CFE 101 polypeptide can be tested in an assay that monitors the conversion of pantothenate to 4'-phosphopantothenate. The same reaction described above can be used, except ¹⁴C-labeled pantothenate is used. The reaction can be monitored by measuring the amount of ¹⁴C-labeled 4'-phosphopantothanate produced.

EXAMPLE 11

The following provides a description of the methods used to characterize purified, CFE 39 and CFE 21 polypeptides, carrying a C-terminal histidine 6-tag. The methods include helicase reactions, in which synthetic Holliday Junction templates are resolved into duplex structures. In one method, helicase reaction was monitored using radiolabeled templates. In another method, the helicase assay was adapted for use in a high throughput assay employing fluorescence labeled templates.

10 Computer-Aided Comparison

The computer-aided comparison, as described in Example 9 *supra*, suggests that the CFE 39 polypeptide (SEQ ID NO: 148) is an RuvA homologue. The comparison also suggests that CFE 21 (SEQ ID NO:132) is an RuvB homologue.

15

30

5

Previous studies by Parsons and others have shown that RuvA and RuvB proteins, in E. coli, promote branch migration or movement of Holliday Junctions during genetic recombination and DNA repair (Parsons, C. A., et al., 1992 Proc. Natl., Acad. Sci. USA 89:5452-5456; Tsaneva, I. R., et al., 1993 Proc. Natl., Acad. Sci. USA 90:1315-1319; Muller, B., et al., 1993 J. Biol. Chem. 268:17179-17184; Mitchell, A. H. and S. C. West 1996 J. Biol. Chem. 271:19497-19502; Parsons, C. A. and S. C. West 1993 J. Molec. Biol. 232:397-405; Tsaneva, I. R., et al., 1992 Molec. Gen. Genet. 235:1-10; Mitchell, A. H. and S. C. West 1994 J. Molec. Biol. 1994 243:208-215).

25 Size Exclusion Chromatography

Size exclusion chromatography was performed on 2CFE 39 (SEQ ID NO:366) and 2CFE 21 (SEQ ID NO:350) using the Phenomenex 600 x 7.5 mm Biosep SECS 3000 column, as described in Example 8 *supra*. Protein standards (BioRad) were used to calibrate the column, including thyroglobulin (670,000 Da), gamma globulin (158,000 Da), ovalbumin (44,00 Da), myoglobin (17,00 Da), and B-12 (1350 Da).

The results indicate that 2CFE 39 (RuvA) forms tetramers and 2CFE 21 (RuvB) forms a hexameric ring structure. Selected eluted samples were electrophoresed on a polyacrylamide gel (Novagen) (Figure 9).

5

10

The Holliday Junction Analysis Using Radiolabeled Templates

The Holliday Junction analysis was performed using radiolabeled, synthetic, asymmetrical, Holliday Junction templates, as described in Hiom, K. and S. C. West 1995 *Cell* 80:787-793. The Holliday Junction templates were produced by annealing together four separate, single-stranded, oligonucleotide strands to form four-stranded structures (e.g., the Holliday Junction template). The Holliday Junction templates were reacted with the 2CFE 39 and 2CFE 21 polypeptides, in a helicase reaction, to test their ability to generate two duplex structures.

15

Producing the Synthetic Holliday Junction Templates

The asymmetrical Holliday Junction templates were produced by annealing the following oligonucleotide sequences:

20

Oligonucleotide strand 1:

5'-CCAGTGATCACATACGCTTTGCTAGGACATCTTGATATCAGCCCACGTT CACCCGCCTACCAGTGCCACGTTGTATGCCCACGTTGACC-3' (SEQ ID NO:438)

25 Oligonucleotide strand 2:

5'-GGGTCAACGTGGCATACAACGTGGCACTGGTAGGCGGGTGAACGTGGG CTGATATCAAGATGTCCATCTGTCCGTTCATCTATGACGT-3' (SEQ ID NO:439)

Oligonucleotide strand 3:

30 5'-AACGTCATAGATGAACGGACAGATCATGGTGCTTTTAAAGTCTAGAGAC TATCGAGCATTAGTACCAGTATCGAATCCGTCTTGTCAA-3' (SEQ ID NO:440)

Oligonucleotide strand 4:

5'-TTTGACAAGACGGATTCGATACTGGTACTAATGCTCGATAGTCTCTAGAC TTTAAAAGCACCATGTAGCAAAGCGTATGTGATCACTG-3' (SEQ ID NO:441)

5

10

15

20

25

30

Oligonucleotide strand 3 was labeled at the 5' end using approximately 300 ng of oligonucleotide strand 3, 1 μ l 10x Phosphate Buffer, 5 μ l ³²P ATP, 1 μ l T4 polynuclotide kinase (Gibco-BRL)), in a 10 μ l volume, and the reaction was performed at 37 degrees C for 30 minutes. The reaction was loaded onto a G50 column to remove the unincorporated radiolabel. The final concentration of the radiolabeled oligonucleotide strand 3 was approximately 15 ng per μ l.

Approximately equimolar amounts of the four oligonucleotide strands were annealed (e.g., hybridized). The annealing reaction included: 5 μl Annealing Buffer (200 mM Tris-Cl pH 8.0, 100 mM MgCl₂, 1 M NaCl, 10 mM DTT); 450 ng of radiolabeled oligonucleotide strand 3; and 1000 ng each of oligonucleotide strands 1, 2, and 4; in 50 μl total reaction volume. The control annealing reaction included: 5 μl Annealing Buffer, 60 ng radiolabeled oligonucleotide strand 3; 1000 ng oligonucleotide strand 4; in 50 μl total reaction volume. Annealing was performed at 95 degrees C for 5 minutes, 65 degrees C for 30 minutes, 42 degrees C for 30 minutes, and room temperature (e.g., between about 23 to 27 degrees C) for 30 minutes to generate the synthetic Holliday Junction templates. The synthetic Holliday Junction templates were gel or column-purified to remove the duplex and non-annealed products. As a control, oligonucleotide strands 3 and 4 were annealed to form duplex structures. The synthetic Holliday Junction templates and duplex structures were stored at –20 degrees C.

CFE 39 and CFE 21: The Helicase Reaction Using Radiolabeled Templates

The helicase reaction was performed to determine whether 2CFE 39 and 2CFE 21 resolved the synthetic Holliday Junction templates into duplex structures. The helicase reaction was performed as follows. A 50 µl total reaction volume included: 25 µl of 2x

Reaction Buffer (50 mM Tris-Cl pH8.0, 30 mM MgCl₂, 2 mM ATP); 1 µl synthetic Holliday Junction template (36 ng); 2 µl 2CFE 39 (1 µM); and 2 µl 2CFE 21 (1 µM). The reaction was incubated at 37 degrees for 30 minutes. The reaction was stopped by adding 5 µl Stop Buffer (100 mM Tris-Cl pH 7.5, 5 mg/ml Proteinase-K, 5% SDS). The stopped reaction was returned to 37 degrees C for 5 minutes. The helicase reaction was loaded onto and run on a non-denaturing, 12% PAGE, Tris-glycine gel.

The results shown in Figure 10, lanes 6, 7 and 8, indicate that the 2CFE 39 and 2CFE 21 polypeptides resolved the synthetic Holliday Junction templates into duplex structures.

CFE 39: The Helicase Reaction

10

15

20

It has been previously shown that *E. coli* RuvA binds to Holliday Junction templates (Parsons, C. A., et al., 1992 *Proc. Natl., Acad. Sci. USA* 89:5452-5456). The ability of *S. pneumoniae* CFE 39 to bind to a Holliday Junction template can be tested by employing the helicase assay described herein. The results of the helicase assay can be monitored by performing a gel shift assay and/or capillary electrophoresis. The presence of a Holliday Junction template bound to 2CFE 39, which migrates more slowly than the Holliday Junction template alone, would indicate that *S. pneumoniae* 2CFE 39 binds to Holliday Junction templates.

CFE 39 and CFE 21: Holliday Junction Analysis Using Fluorescent-Labeled Templates

The helicase reaction described herein was performed using Holliday Junction templates

having one oligonucleotide strand labeled with a fluorescent agent and another strand
labeled with a quenching agent. The 5' fluorescent end and the 3' quenching end of the
strands that make up the Holliday Junction templates are in proximity to each other,
resulting in a non-fluorescent template. When the Holliday Junction templates are
resolved into duplex structures, the fluorescent and quench ends are not in proximity to

each other, resulting in fluorescence.

The Holliday Junction templates used to perform this experiment comprised the following: the 5' end of oligonucleotide strand 1 was labeled with a fluorescein (e.g., the fluorescent agent), and the 3' end of oligonucleotide strand 4 was labeled with DABCYL (e.g., the quenching agent). The oligonucleotide strand 1 labeled with fluorescein and the oligonucleotide strand 4 labeled with DABCYL were custom synthesized (Gibco-BRL Life Technologies, Inc.).

The fluorescein and DABCYL labled oligonucleotides were annealed in a reaction, as described above, to generate synthetic Holliday Junction templates. The helicase reaction was performed as described above. The results of the helicase reaction were monitored by measuring the unquenching of the Holliday Junction templates with time (Figure 11).

The helicase assay using Holliday Junction templates labeled with fluorescent-quenching agents can be adapted for use in high throughput analyses to test 2CFE 39, 2CFE 21, and other polypeptides for their ability to resolve the templates into duplex structures.

EXAMPLE 12

5

10

15

The following provides a description of the methods used to characterize purified, CFE 8 polypeptide, which lacks a histidine tag. The CFE 8 is a putative DNA single-stranded binding protein.

Computer-Aided Comparison

The computer-aided comparison, as described in Example 9 supra, suggests that the CFE 8 polypeptide (SEQ ID NO:121) may be a single stand binding protein homologue, such as SSB.

Size Exclusion Chromatography

The 2CFE 8 polypeptide (SEQ ID NO:339) was characterized by size exclusion chromatography, using the Biosil SEC-125 HPLC Gel Filtration column as described in Example 8 supra. The chromatogram showed one peak corresponding to a molecular weight of approximately 89 kDa. Based on the nucleotide sequence, the predicted molecular weight of 2CFE 8 is 17,351 Da. In non-denaturing conditions, 2CFE 8 forms a multimer.

10 Binding Reaction

The 2CFE 8 polypeptide was reacted with a single-stranded oligonucleotide A. Briefly, the binding reaction included: $50 \mu M$ of 2CFE 8 polypeptide, $50 \mu M$ oligo strand A, $20 \mu M$ Tris/20 mM KCl pH 7.5. The binding reaction was performed at 37 degrees C, for 2 hours.

Oligonucleotide strand A:

5'-TTAGGGCCCGGGCTATCTTACAATCTCGTT-3' (SEQ ID NO:442)

20 Capillary Electrophoresis

The results of the binding reaction was monitored by capillary electrophoresis, following the methods described in "Handbook of Capillary Electrophoresis" 2nd Edition, 1997, ed. J. Landers.

25

15

Separation was performed using an uncoated capillary tube (360 μ m o.d., 50 μ m i.d., with a 50 cm effective separation length; Watrex International, Inc., Pittsford, NY) and 50 mM borate pH 9.3 as the mobile phase, at 25 kVolts, 20 minutes separation time.

The results indicate that 2CFE 8 alone elutes as a sharp peak, indicating little adsorption to the uncoated capillary wall (Figure 12 A). The shape of the peak and peak retention

time changed with 2CFE 8 in the presence of all oligonucleotides tested (Figure 12 B). As a negative control, MurB polypeptide (Pucci, M. J., L. F. Discotto, and T. J. Dougherty 1992 "Cloning and Identification of the Escherichia coli murB DNA sequence, which encodes UDP-N-acetylenolpyruvoylglucosamine reductase" *J. Bacteriol.* 174:1690-1693) was reacted with the same oligonucleotides. MurB reacted with or with out the oligonucleotides showed no change in peak shape or retention time.

After capillary electrophoresis analyses, the 2CFE8 alone and 2CFE plus oligonucleotide samples were run on native polyacrylamide gels to determine whether the polypeptide was intact. The results indicate that in all cases, 2CFE 8 was intact and had not degraded with time or storage.

Mobility Shift Assays

The ability of 2CFE 8 polypeptide to bind oligonucleotide strand A was tested in a mobility shift assay.

The results indicate that 2CFE 8 binds single stranded oligonucleotides (Figure 13 A and B). In Figure 13 A, the gel was stained with ethidium bromide. The unbound oligonucleotides appear near the bottom of the gel, while the bound oligonucleotides appear near the middle. The same gel was stained with Coomassie (Figure 13 B), revealing that 2CFE 8 polypeptide bound to the oligonucleotide migrated further than unbound 2CFE 8, due to the change in charge carried by the oligonucleotide. Various ratios of 2CFE8:oligo were tested. The optimal binding ratio was 2:1.

25

30

20

10

The Effect of MgCl₂

The 2CFE 8 polypeptide precipitated in the presence of 5 mM MgCl₂. The precipitation was reversible by the addition of 1 µM of the oligonucleotides tested. The observation indicates specific binding between 2CFE 8 polypeptide and the oligonucleotides tested.

Scintillation Proximity Assay

Scintillation proximity assay (SPA) methods can be used in a high throughput screening procedure to monitor, for example, a binding reaction. SPA utilizes beads (Amersham) which are coated on the surface with a particular compound or molecule. For example, the SPA bead may be coated with avidin to facilitate binding with any molecule having a biotin tag.

The binding reaction of the 2CFE 8 polypeptide and the oligonucleotide strand A can be monitored using SPA beads and a scintillation counter. The beads can be coated with avidin, the 2CFE 8 polypeptide can be tagged with biotin, and the oligonucleotide strand A can be radiolabeled.

EXAMPLE 13

15

25

The following provides a description of the methods used to characterize purified, 2CFE 3 (SEQ ID NO:334) and 2CFE 86 (SEQ ID NO:409) polypeptides.

The 2CFE 3 polypeptide catalyzes the conversion of D-glucosamine-6-phosphate to D-20 glucosamine-1-phosphate, indicating that 2CFE 3 mediates amino-sugar biosynthesis through the N-acetyl glucosamine pathway (Figure 14).

The 2CFE 86 polypeptide catalyzes the conversion of D-glucosamine-1-phosphate to N-acetylglucosamine-1-phosphate, and the conversion of N-acetylglucosamine-1-phosphate to UDP-N-acetylglucosamine-1-phosphate, which indicates that 2CFE 86 also mediates amino-sugar biosynthesis through the N-acetyl glucosamine pathway (Figure 14).

Computer-Aided Comparisons Of CFE 3

The computer-aided comparison, as described in Example 9 *supra*, suggested that the CFE 3 polypeptide (SEQ ID NO:116) is a phosphoglucosamine mutase, such as GlmM.

Purification of the CFE 3 Polypeptide

The 2CFE 3 polypeptide was produced using the large scale IPTG-induced method described in Example 5, *supra*. The 2CFE 3 polypeptide lacks a C-terminal histidine tag. The 2CFE 3 polypeptide was purified using a 2-column procedure. The 2CFE 3 polypeptide preparation was eluted from a 26/10 Q Sepharose column (Pharmacia) using a 0-1.0 M NaCl gradient, 2 ml/minute flow rate, and the gradient size was 1 liter. Then the 2CFE 3 polypeptide was eluted from a hydroxyapatite Bio-gel column (Bio-Rad) using a 5-200 mM potassium phosphate (pH 8.0) gradient, the flow rate was 0.3 ml/minute, and the gradient size was 300 ml. A sample of the 2CFE 3 preparation was electrophoresed on an SDS polyacrylamide gel (Figure 4).

Affinity Capillary Electrophoresis of CFE 3

10

15 Affinity capillary electrophoresis methods were used to determine whether the 2CFE 3 polypeptide binds to various glucose derivatives. Binding was performed under equilibrium conditions, in which the sugars were dissolved in the running buffer and reacts with 2CFE 3 during separation in the column. The affinity capillary electrophoresis method used to analyze 2CFE 3 follows the methods described in "Handbook of Capillary Electrophoresis" 2nd Edition, 1997, ed. J. Landers.

Briefly, 2CFE 3 polypeptide was reacted with increasing amounts of various glucose derivatives (e.g., substrate) at 25, 30 and 37 degrees C. The glucose derivatives included UDP-glucose, glucose-1-phosphate, glucose-6-phosphate, glucosamine-1-phosphate, and glucosamine-6-phosphate. The reaction included: 2CFE 3 polypeptide (2.0 mg/ml), separation buffer (25 mM Tris; 192 mM Glycine, pH 8.0; BupH Tris-Glycine Buffer Packs, Pierce). Separation was performed at 25 kVolts, separation time was 15 or 20 minutes.

30 The results shown in Figure 15 A indicate that at 25 degrees C, 2CFE 3 binds to D-glucose-1-phosphate in a dose-dependent manner, as the peak shape and/or the retention

time for 2CFE 3 changes in the presence of 100 and 500 μM D-glucose-1-phosphate compared to unreacted 2CFE 3.

The results shown in Figure 15 B indicate that at 25 degrees C, 2CFE 3 binds to D-glucosamine-6-phosphate in a dose-dependent manner, as the peak shape and/or the retention time for 2CFE 3 changes in the presence of 100 and 500 µM D-glucosamine-6-phosphate compared to unreacted 2CFE 3.

The results shown in Figure 15 C indicate that at 25 degrees C, the 2CFE 3 polypeptide also binds to glucose-6-phosphate.

A comparison of 2CFE 3 reacted with various glucose derivatives, at 30 degrees C, is shown in Figure 15 D. The results indicate that D-glucosamine-6-phosphate is a putative substrate for 2CFE 3, as this reaction exhibits the greatest change in peak shape and/or retention time.

CFE 3: Capillary Electrophoresis and Laser-Induced Fluorescence

5

15

In a further analysis of 2CFE 3 polypeptide, capillary electrophoresis was performed with laser-induced fluorescence in order to separate and detect interaction between the substrate (e.g., D-glucosamine-6-phosphate) and the product (e.g., D-glucosamine-1-phosphate) in a one dose, one time-point procedure.

The 2CFE 3 polypeptide was derivitized by reacting 10 mM FITC (fluorescein isothiocyanate dissolved in methanol; Calbiochem, San Diego, CA) with D-glucosamine-6-phosphate, at ambient temperature, in the dark, overnight. The FITC-derivatized 2CFE 3 polypeptide (2.0 mg/ml) was reacted with the substrate (D-glucosamine-6-phosphate and D-glucosamine-1-phosphate) for one hour.

Separation was performed using an uncoated capillary (360 μm o.d., 50 μm i.d., with a 50 cm effective separation length) and 50 mM borate (pH 9.3) as the mobile phase. The

argon-ion laser had an excitation wavelength of 488 nm and an emission filter of 520 nm (Beckman, Fullerton, CA). The results shown in Figure 16 indicate that 2CFE 3 binds and catalyzes the conversion of D-glucosamine-6-phosphate to D-glucosamine-1-phosphate.

5

10

15

20

Computer-Aided Comparison Of CFE 86

The comparison results, as described in Example 9 supra, suggested that the CFE 86 polypeptide (SEQ ID NO:195) is an acetyltransferase, such as GlmU which is a bifunctional enzyme in E coli. It has been previously shown that, in E coli, GlmU is a bifunctional protein having both the acetyltransferase and uridylyltransferase active sites (Mengin-Lecreulx, D. and J. van Heijennort 1994 J. Bacteriol. 176:5788-5795; Gehring, Al., et al., 1996 Biochemistry 35:579-585). The bifunctional enzyme catalyzes the conversion of D-glucosamine-1-phosphate to N-acetylglucosamine-1-phosphate (acetyltransferase), and catalyzes the conversion of N-acetylglucosamine-1-phosphate to UDP-N-acetylglucosmine-1-phosphate (uridylyltransferase). The Km of the acetyltransferase and uridylyltransferase reactions has been previously calculated (Mengin-Lecreulx, D. and J. van Heijennort 1994 supra). Additionally, the crystal structure of GlmU from E coli is known (Brown, K., et al., 1999 EMBO J. 18:4096-4107).

Purification of the CFE 86 Polypeptide

The 2CFE 86 polypeptide (SEQ ID NO:409) has a C-terminal histidine tag. The 2CFE 86 polypeptide was produced using the large scale IPTG-induced method described in Example 5, *supra*. The 2CFE 86 polypeptide was purified using the Ni-NTA affinity column method described in Example 6, *supra*. The eluted 2CFE 86 polypeptide was dialyzed against 50 mM Tris-Cl, 100 mM NaCl, 25% glycerol, pH 8.0. Samples of the purified 2CFE 86 polypeptide were electrophoresed on a polyacrylamide gel (Figure 17).

30

25

Coupling CFE 3 and CFE 86 to Produce UDPAG

A biochemical assay was performed, to determine whether 2CFE 3 and 2CFE 86 convert D-glucosamine-6-phosphate to UDP-N-acetylglucosamine-1-phosphate (e.g., UDPAG).

The 2CFE 3 and 2CFE 86 polypeptides were used in a coupled reaction based on the assays described in Jolly, L. P., et al., 1999 Eur. J. Biochem. 262:202-210.

A time-dependent and dose-dependent assay were performed. Briefly, the assay was performed in 96-well plates, each well including 100 μ l volume. The assay included: 1 mM D-glucosamine-6-phosphate (Sigma); 0.7 mM D-glucosamine-1,6-diphosphate (Sigma); 1.2 mM acetyl-Coenzyme A (Sigma); and 5 mM uridine-5'-phosphate (Sigma); 3 mM MgCl₂ (Sigma); 50 mM Tris-Cl, pH 8.0 (Life Technologies). The reaction was started by adding 1 μ g of 2CFE 3; and 10 μ g of 2CFE 86. The reaction was performed at room temperature. The reaction was stopped at 0, 15, 30, and 65 minutes, by filtering out the 2CFE polypeptides.

The results of the assay was monitored by HPLC (high pressure liquid chromatography) using an Optisil 10μ SAX column (250 x 4.6 mm), measuring at 262 nm, the mobile phase was 150 mM KH₂PO₄ (pH 3.5), and 1.5 ml/minute flow rate. The results shown in Figure 18 show the time-dependent assay and indicate that HPLC detected the presence of UDPAG.

CFE 86: The Uridylyltransferase Reaction

10

15

20

The 2CFE 86 polypeptide was tested in a uridylyltransferase reaction, in which N-acetyl-D-glucosamine-1-phosphate and UTP produce UDP-N-acetylglucosamine. The uridylyltransferase reaction was monitored using a malachite green/inorganic pyrophosphatase assay (e.g., malachite green-IPPAse assay) and/or monitored using HPLC. The malachite green-IPPAse assay was used to measure orthophosphate production from digestion of the pyrophosphate liberated in the uridylyltransferase reaction.

The malachite green reagent was prepared as follows. A 0.045 % solution of malachite green (Sigma; M9636) was prepared in water. A 4.2 % solution of ammonium molybdate (Mallinckrodt) was prepared in 4N HCl. The malachite green and ammonium molybdate were mixed in a 3:1 ratio, and stirred for about 20 minutes. The mixture was filtered, and stored at 4 degrees C. The inorganic pyrophosphatase (Sigma; I-2267) was diluted to 0.1 $U/\mu l$ in 50 mM Tris/3mM MgCl₂ ph 8.0, and stored at 4 degrees C.

The uridylyltransferase reaction was performed in 96-well plates. The coupled reaction described herein was performed, in the presence of 2CFE 3 alone or 2CFE 3 and 2CFE 86, and included the addition of 0.5 U/well of the diluted inorganic pyrophosphate. The reaction was mixed for 5 minutes at room temperature. The reaction was stopped by the addition of 240 μ l/well of the malachite green reagent and 30 μ l/well of 34% sodium citrate, and the reaction was mixed. The results of the uridylyltransferase reaction was monitored by spectrophotometry at 660 nm.

10

15

20

The results of separate uridylyltransferase reactions were monitored by HPLC, using a Phenosphere-NEXT C18 column (250 x 4.6 mm). The mobile phases included A and B as follows: A) methanol/10 mM potassium phosphate pH 6.5 (0:100); and B) methanol/10 mM potassium phosphate pH 6.5 (40:60). The mobile phases were run under the following conditions: 100% mobile phase A for 5 minutes, to 100% mobile phase B in 3 minutes; and hold 100% mobile phase B for 9 minutes. The retention time for the UDPAG product is approximately 5.75 to 6.0 minutes.

The results three uridylyltransferase reactions, monitored by HPLC are summarized in Table III below.

TABLE III

Purified CFE 86:	Specific Activity (nmol/min/µg):
2CFE 86-1	3.1
2CFE 86-2	3.4
2CFE 86-3	3.1

5

The results of the uridylyltransferase reactions, monitored by HPLC or HPLC and Malachite Green IPPAse assays are summarized in Table IV below.

10

TABLE IV

Reaction:	<u>Km (μM):</u>	Method:
Acetyltransferase reaction:	94	HPLC
Glucosamine-1-P Acetyl-coA	150	HPLC
Uridylytransferase reaction:		
N-acetylglucosamine-1-P UTP	48 79	HPLC and MG/IPPAse HPLC

EXAMPLE 14

15.

The following provides a description of the methods used to characterize various 2CFE polypeptides, including CFE 21, 34, 35, 39, and 90. The molecular weight of these 2CFE polypeptides were analyzed by size exclusion chromatography and gel electrophoresis. The 2CFE 34, 35, and 90 polypeptides putatively mediate fatty acid biosynthesis.

20

Computer-Aided Comparison

5

10

15

- 20

The computer-aided comparison, as described in Example 9 supra, suggests that CFE 34 (SEQ ID NO:143), CFE 35 (SEQ ID NO:144), and 90 (SEQ ID NO:199) are polypeptides which mediate a fatty acid biosynthesis pathway (Figure 19)

The comparison suggests that CFE 34 is a malonyl CoA:ACP transcylase, which catalyzes the reaction in which malonyl CoA and acyl carrier protein (ACP) are converted to malonyl-ACP and CoA. Thus, the CFE 34 polypeptide may be a homologue of *E. coli* FabD.

The comparison suggests that CFE 90 is a 3-oxoacyl-ACP synthase II (beta ketoacyl-ACP synthase II) which catalyzes the reaction in which malonyl-ACP is converted to beta aceto acetyl-ACP. Thus, the CFE 90 polypeptide may be a homologue of *E. coli* FabF.

The comparison suggests that CFE 35 is a 3-oxoacyl-ACP reductase (beta aceto acetyl ACP reductase) which catalyzes the reaction in which beta-keto-acetyl-ACP is converted to beta-hydroxy-acetyl-ACP. Thus, the CFE 35 polypeptide may be a homologue of *E. coli* FabG.

Size Exclusion Chromatography

The estimated molecular weights of 2CFE 34 (SEQ ID NO:361), 2CFE 35 (SEQ ID NO:362), and 2CFE 90 (SEQ ID NO:413) were determined using the Biosil SEC-125 HPLC Gel Filtration column as described in Example 8, supra.

The results suggest that 2CFE 34 polypeptide is a monomeric protein (33,093 Da), 2CFE 35 is a trimeric protein (25,758 Da; approximately 85%), and 2CFE 90 is a dimeric protein (43,930 Da). Selected eluted samples of 2CFE 34 were electrophoresed on a polyacrylamide gel (Figure 20).

Biochemical Assay: CFE 34

The function of 2CFE 34 was determined by performing various biochemical reactions.

To determine whether 2CFE 34 catalyzes the convertion of malonyl-CoA to malonyl and CoA, the following reaction was performed.

The biochemical reaction was performed in the presence of acyl carrier protein. The reaction included the following: 10 μM ¹⁴C labeled malonyl-CoA, 20 μM ACP, 30 μM 2CFE 34 (e.g., FabD) in 20 mM Tris-Cl, pH 8.0 and 5 mM DTT in 300 μl volume. The reaction was performed at room temperature (e.g., approximately 24 degrees C) for 30 minutes. The reaction was terminated with the addition of 45μl of 0.5% TFA. The labeled reaction was injected onto a MonoQ 5/5 column on a Gilson HPLC. Detection was performed by monitoring the radioactivity of the continuous flow-through of the HPLC effluent. Chromatography was performed using a buffer gradient for column elution. Buffer A included 20 mM Tris-Cl, pH 8.3. Buffer B was the same as Buffer A and included 1 M NaCl. The program was held at 90% A, 10% B for 10 minutes followed by a linear ramp to a final mix of 50% of each Buffer A and B over 10 minutes.

The substrate (e.g., ¹⁴C malonyl-CoA) eluted at 9.9 minutes, the product (e.g., ¹⁴C malonyl-ACP) eluted at 14.3 minutes. The results indicate that CFE 34 catalyzes the conversion of malonyl-CoA and acyl carrier protein (ACP) to malonyl-ACP and CoA.

EXAMPLE 15

25

10

15

The following provides a description of the methods used to characterize CFE polypeptides 40, 41, and 46.

Computer-Aided Comparison

The computer-aided comparison, as described in Example 9 supra, suggests that the CFE 40 polypeptide (SEQ ID NO:149) is a phosphomethylpyrimidine (HMP-P) kinase involved in thiamine biosynthesis.

The comparison, as described in Example 9 supra, suggests that the CFE 41 polypeptide (SEQ ID NO:150) has a GTP-binding motif and may be a protease.

10 The comparison, as described in Example 9 supra, suggests that the CFE 46 polypeptide (SEQ ID NO:155) has an ATP-binding motif.

Affinity Purification of CFE 41

The large-scale method described in Example 5 supra (e.g., IPTG-induced protein production) was used to prepare a sample of 2CFE 41 polypeptide (SEQ ID NO:368). The sample was affinity purified using the Ni-NTA method described in Example 6, supra. The eluted fractions were loaded onto and run on a 12% SDS-PAGE gel (Novex) (Figure 21).

20

5

Circular Dichroism and Circular Dichroism Thermal Melt Analysis

Circular dichroism and circular dichroism thermal melt methods were performed using JASCO instrumentation. The concentration of the isolated 2CFE 40 (SEQ ID NO:367) was approximately 21 µM, in a 0.1 cm pathlength cell at 210 nm. The circular dichroism spectrum suggests that this preparation of 2CFE 40 had mixed alpha and beta secondary structure. The circular dichroism thermal melt spectrum suggests that 2CFE 40 has a T_m of approximately 67 degrees C. The 2CFE 40 polypeptide precipitates at approximately the T_m.

The concentration of the isolated 2CFE 41 (SEQ ID NO:368) was approximately 70 μ M, in a 0.02 cm pathlength cell. The circular dichroism spectrum suggests that this preparation of 2CFE 41 had mixed alpha and beta secondary structure, with a greater percentage of alpha structures. The circular dichroism thermal melt spectrum suggests that 2CFE 41 has a T_m of approximately 38 degrees C. The 2CFE 41 polypeptide precipitates at approximately the T_m .

The concentration of the isolated 2CFE 46 (SEQ ID NO:373) was approximately 23 μ M, in a 0.1 cm pathlength cell at 280 nm. The circular dichroism spectrum suggests that this preparation of 2CFE 46 had mixed alpha and beta secondary structure. The circular dichroism thermal melt spectrum suggests that 2CFE 46 is highly stable at elevated temperatures. At 90 degrees C, the 2CFE 46 polypeptide exhibited only a 27% loss in signal and the polypeptide remained soluble.

15

10

5

Capillary Electrophoresis

Capillary electrophoresis was performed on samples of purified 2CFE 40, 41 and 46. The electropherograms of 2CFE 40, 41, and 46 are shown in Figure 22.

20

EXAMPLE 16

The following provides a description of methods that can be used to characterize CEG polypeptides (e.g., CFE polypeptides).

25

30

Computer-Aided Compilation

Computer-aided compilation of bacterial metabolic pathways may be analyzed using Pathway Tools from Doubletwist, based on the EcoCyc system (Karp P.D., et al., 1999 *Nucleic Acids Res.* 1999 27(1):55-58). This analysis may be used to predict which CFEs mediate various steps of the pathways. This information may be used in combination

with the results of a binding reaction which identifies a ligand or substrate that binds with a CFE polypeptide.

Identifying the Function of a CFE Polypeptide

5

The function of a CFE polypeptide may be identified by identifying a ligand or substrate which binds with the CFE polypeptide. The ligand or substrate may be identified using fractionation and affinity capillary electrophoresis methods. The following method is based upon the assumption that the bacterial cell lysate includes the ligand or substrate.

10

15

20

A bacterial host cells carrying an endogenous (e.g. native) CFE gene or carrying a recombinant vector which includes a CFE gene may be cultured so that the CFE polypeptide is produced by the cell. The cells may be ruptured in order to obtain the cell lysate. The cell lysate may be fractionated using HPLC technology. The HPLC fractions may be reacted with a CFE polypeptide in a binding reaction, and the binding reaction may be analyzed by affinity capillary electrophoresis methods. The ligand or substrate which reacts with the CFE polypeptide may be identified using mass spectrophotometry methods (in "Mass Spectrometry" 1990 eds. McCloskey, J. A., in Methods in Enzymology volume 193; Henion, J., et al., 1993 "Mass Spectrometric Investigations of Drug-Receptor Interactions" Ther. Drug Monit. 15:563-569; Loo, J. A., et al., 1999 "Application of Mass Spectrometry for Target Identification and Characterization" Med. Res. Rev. 19:307-319; Nguyen, D. N., et al., 1995 "Protein Mass Spectometry: Applications to Analytical Biotechnology J. Chromatogr. 705:21-45).

25 EXAMPLE 17

The following provides a description of nuclear magnetic resonance (NMR) spectroscopy methods that were used to characterize CFE polypeptides.

30 High resolution NMR spectroscopy was applied to ¹⁵N-labled, ¹³C/¹⁵N-labeled, ²H/¹³C/¹⁵N-labeled, and type-specifically isotopically labeled CFE polypeptide samples

in the solution state for the following purposes: to assess various aspects of the structural state, e.g., foldedness, structural integrity; to refine a previously determined experimental structure of a close sequence homologue; to refine a homology-modeled structure; to assess the potential for a CFE polypeptide to bind small molecules; and to identify small-molecule pharmacophoric fragments that bind specifically to the CFE polypeptide ("Nuclear Magnetic Resonance" 1994 eds. James, T. L. in *Methods in Enzymology* volume 239).

The NMR analysis includes screening both a compound deck of approximately 4,500 commercially available, structurally and chemically diverse compounds (the small-molecule pharmacophore deck) and a compound deck of proprietary, known, anti-microbial compounds (anti-microbial deck) against the CFE polypeptides (i.e., target polypeptides) to determine, either based upon perturbations to the chemical shifts of the amide proton and/or nitrogen resonances, as measured from a two-dimensional proton-nitrogen heteronuclear single-quantum correlation spectrum (2D screening method), or based upon increases in the linewidth of the compound's proton resonance(s), as measured by a one-dimensional T_{1p} spin-lock difference spectrum (1D screening method), both whether a compound binds to a CFE polypeptide and, in the case of the 2D screening method, where the compound binds on the CFE polypeptide.

20

25

30

10

15

Isotopic Labeling of CFE Polypeptides

BL21-DE3 *E. coli* bacteria are transformed with the CFE expression vectors. Expression takes place between 20°C and 37°C in minimal media containing [¹⁵N]-ammonium sulfate as the sole nitrogen source and either glucose, [²H]₁₃-glucose, or [¹³C]₆-glucose as the sole carbon source. Glucose is used for preparing uniformly ¹⁵N-labeled and ²H/¹⁵N-labeled CFE polypeptides. [²H]₁₃-glucose is used for preparing type-specifically ¹H/¹³C-labeled, uniformly ¹⁵N-labeled CFE polypeptides. [¹³C]₆-glucose is used for preparing ¹³C/¹⁵N-labeled CFE polypeptides. The minimal media is prepared in 100% H₂O for expressing both uniformly ¹⁵N-labeled and uniformly ¹³C/¹⁵N-labeled CFE polypeptides; the minimal media is prepared in 95% D₂O (deuterium oxide) and 5% H₂O for expressing

both type-specifically ¹H/¹³C-labeled, uniformly ¹⁵N-labeled and just uniformly ²H/¹⁵N-labeled CFE polypeptides. In the case of type-specifically ¹H/¹³C-labeled, uniformly ¹⁵N-labeled CFE polypeptides, 40 mg/L of protonated and uniformly ¹³C/¹⁵N-labeled isoleucine, valine and leucine amino acids are added to the minimal media.

5

10

15

20

25

30

NMR Screening

Compounds in the anti-microbial deck are pre-dissolved to a target concentration of 16 mM in deuterated DMSO (dimethylsulfoxide) with each deck well containing only one compound. Compounds in the small-molecule, pharmacophore deck are pre-dissolved in deuterated dmso to a target concentration of 50 mM in groups of 8, i.e., each deck well contains 8 unique compounds with each compound at a target concentration of 50 mM.

3.5 µl of compound is placed at the bottom of a well in a 96-well, screening plate. This well will be referred to as the compound screening well. Each compound screening well contains solution from only one deck well. 166.5 µl of buffer is added to each compound screening well. 170 µl of a CFE polypeptide solution, initially at a concentration ranging from 200-300 µM, is added to each compound screening well; the contents of that well are then thoroughly mixed. The control screening well contains only 3.5 µl of deuterated dmso. The screening plate is then centrifuged in a bucket rotor for 15 minutes at 3,500 rpm to insure that all particulate matter is at the bottom of the well.

The 2D screening method requires a single control screening well in which the compound solution consists only of deuterated DMSO. The 1D screening method requires a control screening well for each compound screening well. In the case of the 1D screening method, the control screening well is prepared identically to the compound screening well except that the 170 µl of a CFE polypeptide solution is replaced by 170 µl of buffer.

The screening plate is covered with aluminum foil and placed onto a rack of a Gilson liquid handler. The Gilson liquid handler, under computer control by the NMR host/data-acquisition software, is responsible for removing each sample from the screening plate,

injecting the sample into a high-resolution, ¹H/¹⁵N double-resonance NMR flow-probe, removing the sample from the flow-probe, and dispensing it back into the screening plate well from which the sample was originally removed. NMR data are collected on the sample while the sample resides in the NMR flow-probe. The type of NMR data collected depends upon whether the 2D or 1D screening method is being used.

Determining Structural Characteristics of a CFE Polypeptide

5

In assessing various aspects of the structural state of a CFE polypeptide, NMR was used to provide the following information. The proton 1D spectra and proton-nitrogen 2D correlation NMR spectra were used to assess the overall foldedness of a CFE polypeptide without actually describing in detail that folded state. Unfolded and substantially misfolded proteins produced distinct signatures in these two types of NMR spectra.

15 The chemical shift of most protein nuclei in either the set {H_N, H_α, H_β, C', C_α, C_β, N} or the set {H_N, C', C_α, C_β, N} for perdeuterated (e.g., ²H-labeled) proteins were determined by procedures well known in the art that involve collecting up to 10 triple-resonance NMR data sets. The protein secondary structure was delineated as either helical, turn or extended (e.g., β-sheet) by measuring Δ(δ_{Cα} - δ_{Cβ}), ΔδC', and Δδ_{Hα} where δ refers to the chemical-shift value and Δ refers to the difference between chemical-shift values measured in this protein and those measured for the same residue type in a random-coil (unstructured), tetrameric peptide.

This secondary-structure profile was generated in approximately 2-3 weeks per protein.

The secondary-structure profile was used to confirm the functional identity of a protein. It was also used to refine the list of possible functional identities of folds, predicted by various computational techniques including fold recognition which is associated with a protein or polypeptide.

NMR was used to generate folds of proteins or polypeptides for which both no structure was known of a sequence homologue and no structural homologue was discernible in the PDB by fold recognition techniques.

5 Refining a Structural Model

Nuclear Overhauser (NOE) data were used to refine both homology-modeled structured and previously determined experimental structures of close sequence homologues. This process took approximately 2-3 weeks per structure.

10

The CFE 88 polypeptide was characterized by NMR analysis to establish its secondary structure. The NMR data was used to filter the computer-aided threading analysis. The NMR-determined secondary structure for CFE 88 suggested that CFE 88 is structurally similar to 4-aminoimidazole carboxylase.

15

The characteristics of other CFE polypeptides were analyzed by NMR methods. A computer-aided threading analysis revealed that the N-terminal domain of the protein EGA, which both binds and hydrolyzes GTP, was both structurally similar and sufficiently similar in sequence to CFE 52 to suggest that CFE 52 had a similar function.

20

The NMR data of CFE 103 suggests that this polypeptide is unfolded. Circular dichroism spectra, as a function of temperature, also indicated that CFE103 was unfolded.

25 i

The CFEs 2, 42, 43, 68 and 88 polypeptides were tested for their ability to bind potential inhibitor molecules by screening both the anti-microbial deck and the small-molecule, pharmacophore deck. CFE 34 was tested for its ability to bind potential inhibitor molecules by screening the anti-microbial deck.

Characterizing Small-Molecule Binding

NMR-based screening was used to measure binding against both the small-molecule, pharmacophore deck and the anti-microbial deck. Binding data from these screens allowed assessment of the propensity of a protein to bind small molecules. The binding data was also used to identify sites on the protein which are capable of binding small molecules. The binding data was also used to identify common pharmacophores among the compounds which bind.

Reverse screening refers to a process whereby known anti-microbial compounds, the microbial target of which is unknown, are screened by a general method, e.g., binding as assessed by NMR, to find a physical interaction with polypeptide targets previously determined to be essential to the bacteria (i.e., the CFEs). The reverse screening method was used to determine which CFE polypeptides bind to which compounds in the antimicrobial deck. The reverse screening method included the following. The compounds in a proprietary compound deck were screened for Minimal Inhibitory Concentration (e.g., MIC). The compounds exhibiting antimicrobial activity were designated active compounds. The CFE polypeptides were screened to determine which polypeptide bind to which active compounds. The CFE polypeptides which bound to the active compound(s) were confirmed, where possible, i.e., in cases where an in-vitro assay was possible to construct, as being inhibited in their function as a polypeptide by the active compound(s) by examination of the inhibition profile of the compound(s) against the CFE polypeptides. For additional confirmation, the effect of the compound on the microorganism harboring the CFE polypeptide was monitored (e.g., whole cell assays). The structure of the active compound was used as a basis to generate chemically-related compounds by iterative synthesis. The chemically-related compounds were tested in a screening assay for binding with CFE polypeptides. The active compounds and the chemically-related compounds of interest were the compounds which exhibited an increase in binding affinity for a CFE polypeptide and/or exhibited drug-like properties.

25

5

10

15

The results of the reverse screening are as follows. 127 compounds from the proprietary compound deck exhibited anti-microbial activity. 94 of these active compounds were selected based upon both lack of cytotoxicity and lack of excessive hydrophobicity. These 94 compounds were soluble to 16 mM in deuterated DMSO; these compounds were also deemed to be sufficiently soluble in aqueous buffer for both the 2D and 1D NMR screening methods.

5

10

15

20

25

This subset of 94 compounds was used in an NMR-based screen to determine which compound binds to which CFE polypeptide. The CFE 42 polypeptide bound two different compounds with K_d 's in the range of 0.2 to 1 mM; the CFE 43 polypeptide bound one compound with $K_d \sim 30\text{--}50~\mu\text{M}$; the CFE 34 polypeptide bound 13 compounds, one of which inhibited the polypeptide function with $IC_{50} < 10~\mu\text{M}$.

The enzyme assay used to confirm the NMR results which suggested CFE 34 interaction with the compounds included the following: 10 μM ¹⁴C-labeled malonyl CoA; 20 μM ACP, 30 pM CFE 34; 20 mM Tris-Cl, pH 8.0; 5 mM DTT; in the presence of absence of 50 μM of a compound solubilized at 40 mM in 100% DMSO and dilute 100-fold into 10% DMSO and further diluted 8-fold for a final concentration of 50 μM in 1.25% DMSO. The reaction was performed at room temperature, the reaction was stopped with the addition of TFA. Two hundred μl of the reaction was injected onto a Mono Q 5/5 column. The chromatography conditions included: A) 20 mM Tris-Cl, pH 8.3; B) 20 mM Tris-Cl, pH 8.3, 1 M NaCl. Hold 10% B for 5 minutes, linear gradient from 10% B to 50%B in 10 minutes, back to 10% B in 1 minute, hold for 14 minutes to re-equilibrate. The reaction substrate (¹⁴C- malonyl CoA) eluted at 9.9 minutes, the reaction product (¹⁴C-malonyl ACP) eluted at 14.3 minutes.

What is claimed is:

1. An isolated nucleic acid molecule encoding a polypeptide which is (1) essential for the viability of a bacterial cell and (2) has at least any one of the functions of a pantothenate kinase, a Holliday Junction branch migration protein, a single stranded DNA binding protein, a phosphoglucosamine mutase, an acetyltransferase, an uridylyltransferase, a malonyl CoenzymeA:ACP transcylase, a 3-oxoacyl-ACP synthase II, a 3-oxoacyl-ACP reductase, a phosphomethylpyrimidine (HMP-P) kinase, a GTP binding protein, a ATP binding protein, or a 4-aminoimidazole carboxylase.

The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:97 or Figure 115 and wherein the polypeptide is a pantothenate kinase.

15

10

- 3. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:35, Figure 60, SEQ ID NO:19, or Figure 44, and wherein the polypeptide is a Holliday Junction branch migration protein.
- 4. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:8 or Figure 33 and wherein the polypeptide is a single stranded DNA binding protein.
- 5. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:3 or Figure 28 and wherein the polypeptide is a phosphoglucosamine mutase.
- The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule
 is shown in SEQ ID NO:82 or Figure 103 and wherein the polypeptide is a
 acetyltransferase.

7. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:82 or Figure 103 and wherein the polypeptide is a uridylyltransferase.

- 8. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:30 or Figure 55 and wherein the polypeptide is a malonyl CoenzymeA:ACP transcylase.
- 9. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:86 or Figure 107 and wherein the polypeptide is a 3-oxoacyl-ACP synthase II.

15

- 10. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:31 or Figure 56 and wherein the polypeptide is a 3-oxoacyl-ACP reductase.
- 11. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:36 or Figure 61 and wherein the polypeptide is a phosphomethylpyrimidine (HMP-P) kinase.
- 12. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:37, Figure 62, SEQ ID NO:48, or Figure 73, and wherein the polypeptide is a GTP binding protein.
- 25 13. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:42 or Figure 67 and wherein the polypeptide is a ATP binding protein.

14. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:84 or Figure 105 and wherein the polypeptide is a 4-aminoimidazole carboxylase.

- 5 15. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is shown in SEQ ID NO:48 or Figure 73 and wherein the polypeptide is a GTP binding protein.
- 16. An isolated nucleic acid molecule encoding a polypeptide which is essential for the viability of a bacterial cell, the nucleic acid molecule comprising a sequence shown in any one of SEQ ID NOS:1-113.
 - 17. An isolated nucleic acid molecule encoding a polypeptide which is essential for the viability of a bacterial cell, the nucleic acid molecule comprising a sequence shown in any one of Figures 26-130.
 - 18. An isolated nucleic acid molecule encoding any one of a polypeptide designated CFE 1-117 having the amino acid sequence shown in SEQ ID NO:114-226.
- 20 19. An isolated nucleic acid molecule comprising a nucleotide sequence which is complementary to the nucleotide sequence of claim 1, 16, 17 or 18.

15

- 20. The isolated nucleic acid molecule of claim 1, 16, 17 or 18 which is DNA or RNA.
- 21. The isolated nucleic acid molecule of claim 20, which is labeled with a detectable marker.
- 22. The isolated nucleic acid molecule of claim 21, wherein the detectable marker is selected from the group consisting of a radioisotope, a fluorescent compound, a

bioluminescent compound, a chemiluminescent compound, a metal chelator and an enzyme.

23. A vector comprising the nucleotide sequence of claim 1, 16, 17, or 18.

5

- 24. A host-vector system comprising the vector of claim 23, in a suitable host cell.
- 25. The host-vector system of claim 24, wherein the suitable host cell is selected from a group consisting of a yeast cell, a plant cell, and an animal cell.

10

20

- 26. The host-vector system of claim 24, wherein the suitable host cell is selected from a group consisting of an *Escherichia* cell, a *Bacillus* cell, a *Pseudomonas* cell, a *Streptococcus* cell, and a *Streptomyces* cell.
- 27. An isolated polypeptide which is essential for the viability of a bacterial cell comprising the amino acid sequence as shown in any one of SEQ. ID NOS: 114-226.
 - 28. An isolated polypeptide which is essential for the viability of a bacterial cell encoded by the isolated nucleic acid molecule of claim 1, 16, 17, or 18.
 - 29. The isolated polypeptide of claim 27 or 28 which is a fusion polypeptide.
- 30. A method for producing a polypeptide having the amino acid sequence of any one of SEQ ID NOS: 114-226 or a polypeptide encoded by the polynucleotide sequence as shown in any one of Figures 26-130, comprising:
 - a) culturing the host-vector system of claim 24 under suitable conditions so as to produce the polypeptide; and
 - b) recovering the polypeptide so produced.

- 31. A polypeptide produced by the method of claim 30.
- 32. A ligand which binds the polypeptide of claim 27 or 28.
- 5 33. The ligand of claim 32 which is an antibody or an immunologically active fragment thereof.
 - 34. The ligand of claim 33, wherein the antibody is a monoclonal antibody.
- 10 35. The ligand of claim 32 which is a diazalactone.
 - 36. The ligand of claim 35, wherein the diazalactone comprises the structure:

- 37. The ligand of claim 32 which is a N-protected amino acid.
- 38. The ligand of claim 37, wherein the N-protected amino acid comprises the structure:

39. The ligand of claim 32 which is an azabicyclodiene.

40. The ligand of claim 39, wherein the azabicyclodiene comprises the structure:

- 5 41. The ligand of claim 32 which is an alkaloid.
 - 42. The ligand of claim 41, wherein the alkaloid comprises the structure:

$$N \longrightarrow N$$

10

43. The ligand of claim 41, wherein the alkaloid comprises the structure:

44. The ligand of claim 41, wherein the alkaloid comprises the structure:

5 45. The ligand of claim 41, wherein the alkaloid comprises the structure:

46. The ligand of claim 41, wherein the alkaloid comprises the structure:

- 47. A method for detecting the presence of the polypeptide of claim 27 or 28 in a sample, comprising contacting the sample with a ligand which binds the polypeptide and detecting the binding of the polypeptide with the ligand in the sample.
- 10 48. The method of claim 47, wherein the detecting comprises:
 - a) contacting the sample with the ligand; and
 - b) determining whether a polypeptide-ligand complex is so formed.
- 49. The method of claim 47, wherein the sample is a cell, a tissue, or a biological fluid.
 - 50. The method of claim 47, wherein the sample is blood, serum, a swab from nose, a swab from ear, or a swab from throat.
- 20 51. The method of claim 47, wherein the ligand is a diazalactone.

52. The method of claim 51, wherein the diazalactone comprises the structure:

53. The method of claim 47, wherein the ligand is a N-protected amino acid.

54. The method of claim 53, wherein the N-protected amino acid comprises the structure:

55. The method of claim 47, wherein the ligand is an azabicyclodiene.

10

5

56. The method of claim 55, wherein the azabicyclodiene comprises the structure:

57. The ligand of claim 47 which is an alkaloid.

58. The ligand of claim 57, wherein the alkaloid comprises the structure:

$$N \longrightarrow N$$

5

59. The ligand of claim 57, wherein the alkaloid comprises the structure:

10

60. The ligand of claim 57, wherein the alkaloid comprises the structure:

61. The ligand of claim 57, wherein the alkaloid comprises the structure:

5

62. The ligand of claim 57, wherein the alkaloid comprises the structure:

10

63. A method for detecting the presence of a target nucleic acid molecule as shown in any one of SEQ ID NOS:1-113 in a sample, comprising contacting the sample with the complementary nucleic acid molecule of claim 19 and detecting the binding of the target nucleic acid molecule with the complementary nucleic acid molecule in the sample.

64. The method of claim 63, wherein the detecting comprises:

5

15

- a) contacting the sample with the complementary nucleic acid molecule; and
- b) determining whether a complex comprising the target nucleic acid molecule and the complementary nucleic acid molecule is so formed.
- 65. The method of claim 63, wherein the sample is a cell, a tissue, or a biological fluid.
- 10 66. The method of claim 63, wherein the sample is blood, serum, a swab from nose, a swab from ear, or a swab from throat.
 - 67. A pharmaceutical composition comprising the nucleic acid molecule of claim 1, 16, 17, or 18.
 - 68. A pharmaceutical composition comprising the polypeptide of claim 27 or 28.
 - 69. A pharmaceutical composition comprising the ligand of claim 32.
- 70. A method for determining whether a genomic nucleotide sequence of interest is essential for viability of a bacterial cell, comprising
 - a. integrating an exogenous nucleotide sequence into the genomic nucleotide sequence of interest, wherein the exogenous nucleotide sequence comprises a portion of an open reading frame of the genomic nucleotide sequence of interest, and
 - b. determining whether the cell having the genomic nucleotide sequence of interest so integrated is viable.
- 71. The method of claim 70, wherein the portion of the open reading frame comprises about 200 to 500 base pairs in length.

72. The method of claim 70, wherein the exogenous nucleotide sequence further comprises a nucleotide sequence conferring a selectable phenotype to the cell having the genome so integrated.

5 ·

- 73. The method of claim 70, wherein determining comprises selecting the cell having the genome so integrated in the presence of a selection agent.
- 74. The method of claim 73, wherein the selection agent is chloramphenicol.

10

20

- 75. A nucleotide sequence of interest which is essential for viability of a bacterial cell isolated by the method of claim 70.
- 76. A bacterial cell comprising an exogenous nucleotide sequence integrated into the genomic nucleotide sequence of interest, generated by the method of claim 70.
 - 77. A method for determining whether a genomic nucleotide sequence of interest resides within an operon, comprising
 - a) integrating an exogenous nucleotide sequence into the genomic nucleotide sequence of interest; and
 - b) determining whether the cell having the genomic nucleotide sequence of interest so integrated is viable, and wherein the exogenous nucleotide sequence lacks an expression regulatory sequence.
- 78. The method of claim 77, wherein the exogenous nucleotide sequence further comprises a nucleotide sequence conferring a selectable phenotype to the cell having the genome so integrated.
 - 79. The method of claim 77, wherein determining comprises selecting the cell having the genome so integrated in the presence of a selection agent.

80. The method of claim 79, wherein the selection agent is chloramphenicol.

5

- 81. A method for inhibiting a function of a CEG polypeptide which is essential for viability of a bacterial cell, the method comprising contacting the CEG polypeptide with the ligand of claim 32 under suitable conditions thereby inhibiting the function of the CEG polypeptide.
- 82. The method of claim 81, wherein the function of the CEG polypeptide is selected from a group consisting of a pantothenate kinase, a Holliday Junction branch migration protein, a single stranded DNA binding protein, a phosphoglucosamine mutase, an acetyltransferase, an uridylyltransferase, a malonyl CoenzymeA:ACP transcylase, a 3-oxoacyl-ACP synthase II, a 3-oxoacyl-ACP reductase, a phosphomethylpyrimidine (HMP-P) kinase, a GTP binding protein, a ATP binding protein, or a 4-aminoimidazole carboxylase.
 - 83. The method of claim 81, wherein the CEG polypeptide is selected from a group consisting of CFE1-113.
- 20 84. The method of claim 81, wherein the CEG polypeptide is 2CFE 34 shown in Figure 55.
 - 85. The method of claim 81, wherein the CEG polypeptide is 2CFE 43 shown in Figure 64.

86. The method of claim 81, wherein the CEG polypeptide is 2CFE 34 shown in Figure 55 and the ligand is:

87. The method of claim 81, wherein the CEG polypeptide is 2CFE 43 shown in Figure 64 and the ligand is:

$$O$$
 N
 NO_2
 NO_2

88. The method of claim 81, wherein the CEG polypeptide is 2CFE 43 shown in Figure 64 and the ligand is:

. 15

5

- 89. A method for identifying a ligand in a sample which specifically binds a CEG polypeptide, the method comprising:
 - a) contacting the CEG polypeptide with the sample under suitable conditions so that a complex having the CEG polypeptide and the ligand is formed;
 - b) recovering the complex so formed; and
 - c) separating the CEG polypeptide from the ligand in the complex and identifying the ligand so separated.
- 90. The method of claim 89, wherein the sample is a tissue or biological fluid.
- 91. The method of claim 89, wherein the ligand is an azabicyclodiene.
- 92. The method of claim 91, wherein the azabicyclodiene comprises the structure:

- 15
- 93. The method of claim 89, wherein the ligand is a diazalactone.
- 94. The method of claim 93, wherein the diazalactone comprises the structure:

$$CF_3$$
 N
 NO_2

- 20
- 95. The method of claim 89, wherein the ligand is a N-protected amino acid.

96. The method of claim 95, wherein the N-protected amino acid comprises the structure:

5

- 97. The method of claim 89, wherein the ligand is an alkoloid.
- 98. The ligand of claim 97, wherein the alkaloid comprises the structure:

$$N \longrightarrow N$$

10

99. The ligand of claim 97, wherein the alkaloid comprises the structure:

5

100. The ligand of claim 97, wherein the alkaloid comprises the structure:

101. The ligand of claim 97, wherein the alkaloid comprises the structure:

102. The ligand of claim 97, wherein the alkaloid comprises the structure:

Gene Disruption Assay






FIGURE 1

Polarity test for Operons



A.



204,000

B.

12 24 30

41,000

17,000 MW proteins

FIGURE 3





FIGURE 4

FIGURE 5

Α.



B.





FIGURE 6

Α.



B




FIGURE 7




FIGURE 8




FIGURE 9






FIGURE 10



11/60






FIGURE 13


N-Acetyl Glucosamine Pathway

fructose-6-P
glmS/CFE60

glucosamine-6-P
glmM/CFE3
glucosamine-1-P
+ Acetyl Coenzyme A
glmU/CFE86
N-acetylglucosamine-1-P
glmU/CFE86
UDP-N-acetylglucosamine-1-P
(releases pyrophosphate)

LPS
Murein/Peptidoglycan

FIGURE 14






FIGURE 15




FIGURE 15




FIGURE 16

WO 01/49721




FIGURE 17




FIGURE 18

Acyl Carrier Protein + malony (CoA

CFE 34 (Fab D)

(Palmitolyl ACP)

malonyl-ACP + COA

CFE 90 (Fab F)

B aceto acetyl ACP

NABOR CFE 35 (Fab 6)

B hydroxy acyl ACP





FIGURE 20



Fractions

ysalc

8 9 10 11 12 13

MW Markers




FIGURE 22

2 CFET "homologue of SEQ. ID NO. 1"
ATRATTATGCAGOAATTCTTGCCGGTGGAACTGGCACACGCATGGGGATCAGTAACTTGCCAAAACAAT
TITTAGAOCTAGGTGATCGACCTATTTTGATTCATACAATTGAAAAATTNGTCTTGGAGCCAAGTATTGAA
AAAATTDTAGTTGGTGTTCATGGAGACTGGGTTTCTCATGCAGAAGATCTTGTAGAAAAATATCTTCCTCT
TTATAAGGAACGTATCATCATACAAAGGGTGGTGCTGACCGCAATACAAGTATTAAGAACATCATTGAA
GCCATTGATGCTTATCGTCCGCTTACTCCAGAGGATATCGTTGTTACCCACGATTCTGTTCGTCCATTTATT
ACACTTCGCATGATTCAGGACAATATCCAACTTGCCCAAAATCATGACGCAGTGGACACAGTGGTAGAA
GCCGTTGATACTATCGTTGAAAGTACCAATGGTCAATTTATTACAGATATTCCAAATCGTGCTCACCTTTA
TCAAGGACAAACACCTCAAACATTCCGTTGCAAGGACTTCATGGACCTTTATGGATCTCTTTCTGATGAA
GAGAAATCTTGACAGATGCATGTAAAATCTTTTTTGATGAAAAAATCTTTGACAAAAGTATTGACAAA
GGTGAATACTCAAATCTGAAGATTACAACCGTAACAGATTTGAAGAATTGCAAAAAGTATGATTGACAAA
GACTAG

2CFE "homologue of SEQ. ID NO. 4"

2CFE 4 homologue of SEA 10 NO: 4

2 CFE6 "homologue of SEQ. ID NO. 6" AT TTATECAGATGATAGTTTGACATTGCACACGGACTTGTACCAGATCAACATGATGCAGGTTTACTTTG ACCAAGGGATTCACAATAAGAAGGCGGTCTTTGAGGTGTATTTCCGCCAACAGCCTTTTAAGAACGGCTA TGCGGTTTTGCAGGTTTGGAAAGAATTGTGAACTATCTTGAAGACTTGCGTTTTTCAGATAGTGATATAG CCTATTIGGAGTCGCTTGGTTATCATGGGGCGTTCTTGGATTACCTTCGCAATTTCAAGTTGGAGTTGACC OT CGT CTGCCCAAGAAGGGGATTTGGTTTTTGCTAATGAACCGATTGTGCAGGTGGAAGGACCTCTAG CCCAATETCAGTTGGTCGAAACGGCTCTTTTGAACATCGTCAACTACCAGACCTTGGTGGCGACGAAGGC AGCTCG TATTCGTTCGGTTATCGAAGATGAACCCTTGATGGAGTTTGGGACACGTCGGGCTCAAGAAATG GGTAAGCTCTTTGACATTCCTGTTTTGGGAACCCATGCCCATGCCTTGGTACAGGTTTATGGCAATGACTA GCATCGGTGTACCAGCTGCCATTCAGGTGGCGCGTGAGCTGGGTGATTAGATTAACTTTATGGGTGTGCGGATTGAGTCTGGGGATATTGCGTACATTTCTAAGAAAGTCCGTCAGCAACTGGACGAGGCTGGATTTACA GAGGCTAAGATTTATGCTTCTAATGATTTGGACGAAAATACTATCCTCAACCTCAAGATGCAAAAAGGCCA CAAGATTGTTGCAATCGAAGATGAAACTGGTCAGATGCGCAATACGATTAAGCTGTCTAATAATGCGGA AAAAGTOTCGACGCCAGGTAAGAAGCAGGTGTGGCGCATTACCAGTCGTGAAAAAGGCAAGTCAGAAG OTGACTACATCACTTATGATGGTGTGGATATTAGCGACATGACAGAAATCAAGATGTTCCATCCGACCTA TACATACATCAAGAAGACGGTTCGTAATTTTGATGCCGTTCCTCTTGGTGGATATCTTCAAAGAAGGTA TATFAGTFTACAACTTGCCTAGTTTGACTGACATTCAGGATTATGCCCGTAAGGAATTTGACAAGTTGTGG GATGAGTATAAGCGTGTGCTCAATCCGCAGCACTATCCAGTGGATTTGGCGCGTGATGTATGGCAAGATA AGATOGACTTGATTGATAAGATGCGCAAGGAAGCCCTTGGTGAAGGAGAAGAAGAATGA

2CFE 7 (conta)

2 OF 8 "homologue of SEO. ID NO. 8"
ATDATTA ACASTOTTOTACTOTAGGGCGTATGACACGTGACGCTGAGTTGCGTTATACCCCATCAAATG
TAGCAGTTGCACTTTTACTCTTGCAGTAAACCGTACATTTAAGAGTCAAAATGGTGAACGTGAGGCTGA
TITTATGAATGTCGTTATGTGGCGCCAACAGGCTGAAAATCTTGCTAACTGGGCTAAAAAAGGCTCACTT
ACGGGGTGACAGGTCGTATCCAGACTCGTAGTTACGATAACCAGCAAGGACAACGTGTCACGTGACA
CAGGTCGTGGCTQAGAATTTCCAAATGTTGGAAAGCCGTAGTGTGCGTGAGGGTCACACAGGTGGAGCT
TACTCTGCACCAACTGCAAACTATTCAGCACCTACAAATTCAGTACCAGACTTTTCACGTAATGAAAATC
CATTTGGAGCAACAAACCCATTGGATATTTCAGATGATGATTTACCATTCTAA

2CFEILIII homologue of SEQ. ID NO. 11"
ATGATTALTCAAATTTATCAACTAACTAAGCTAAGITTATCAATGTCAAATATCAGGAAGAGGCTATTG
ACCAAGAGTCATATCCTTATCCGTCCCAACTACATGGCTGTCTCTCATGCGGATCAGCGTTACTATCA
GGGAAAACGTGATCCCAAGATTTTGAATAAAAGCTTCCAATGGCAATGATTCACGAGTCATGTGGAAC
CGTCATTTCTGACCCGACCGGAACCTACGAGGTTGGTCAAAAAGTTGTCATGATTCCCAATCAGTCTCCT
ATGCAGAGTGATGAAGAATTCTATGAAAACTACATGACAGGGACCCATTTCTTGTCTAGTGGATTTGATG
GCTTTATGAGAGAGTTTGTTTCTCCCCTAAAGATCGTGTGGTGGCTTATGATGCTATTGACGATACGGTT
GCAGCCATTACAGAGTTTGTCAGTGTGGGCATGCACGCTATGAATCGTCTATTGACTCTTGCTCATAGCA
AGCGGGAGCGGATCGCCGTTATTGGAGATGGAAGTTTAGCTTTTTTGCCAAA

2 CFE // (CONTAL)

2 CFE12 "homologue of SEO. ID NO. 12"
ATGAACITAANACTACTTTGGGCCTTCTTGCTGGGCGTTCTTCCCACTTCGTTTTAAGCCGTCTTGGACG
TGDAACTACCTTCCCAGGGAAAGTCGCCCTTCAATTTGATAAAGATATTTTACAAAGCCTAGCTAAGAAC TALGAGATTGTCGTTGTCACTGGAACAAATGGAAAAACCCTGACAACTGCCCTCACTGTCGGCATTTTAA AADAGGTTTATGGTCAAGTTCTAACCAACCCAAGCGGTGCCAACATGATTACAGGGATTGCAACAACCTT CCTAACAGCCAAATCTTCAAAAACTGGGAAAAATATTGCCGTCCTCGAAATTGACGAAGCCAGTCTATCT CG|TATC|TGTGACTATATCCAGCCTAGTCTTTTTGTCATTACTAATATCTTCCGTGACCAGATGGACCGTTTC GDITGA ALATETATACTA CCTATAA CATGATATTGGATGCCATTCGAAAAGTTCCAACTGCTACTGTTCTCCT TANCGGAGACAGTCCACTTTTCTACAAGCCAACTATTCCAAACCCTATAGAGTATTTTGGTTTTGACTTGG AANAA GACCAGCCCAACTGGCTCACTACAATACCGAAGGGATTCTCTGTCCTGACTGCCAAGGCATCCT CALATATGAGCATAATACCTATGCAAACTTGGGTGCCTATATCTGTGAAGGTTGTGGATGTAAACGTCCT GATCTCGACTATCGTTTGACAAAACTGGTTGAGTTGACCAACAATCGCTCTCGCTTTGTCATAGACGGCC
AAGAATACGGTATCCAAATCGGCGGGCTCTATAATATCTATAACGCCCTAGCTGCTGTGGCCATCGCCCG TTTCCTAGGTGCCGATTCGCAACTCATCAAACAGGGATTTGACAAGAGCCGTGCTGTCTTTGGACGCCAA GANACCITTCATATCGGTGACAAGGAATGTACCCITGTCTTGATTAAAAATCCAGTCGGTGCAACCCAAG CTATCGAAATGATCAAACTAGCACCTTATCCATTTAGCCTATCTGTCCTCCTTAATGCCAACTATGCAGAT GGAAITTBACACTAGCTGGATCTGGGATGCAGACTTTGAACAAATCACTGACATGGACATTCCTGAAAATCA **ACCTGGCGGTGTTCGTCATTCTGAAATCGCTCGTCGCCTCCGAGTGACTGGCTATCCAGCTGAGAAAAT** CACTGRAACGAGTAATCTGGAGCAAGTTCTCAAGACCATTGAGAATCAAGACTGCAAGCATGCCTATATT CTGGCAACTTATACTGCCATGCTGGAATTTCGTGAACTGCTGGCTAGTCGTCAGATTGTTAGAAAGGAGA TGAACTAA-

ACTION TO THE PROPERTY OF A SEQUENTIAN SEQUENTIAL SEQUE

80

CFEI7 "homologue of SEQ. ID NO. 17"
ATGAGTAATATCAGTTTAACAACACTTGGTGGTGTGCGTGAGAATGGAAAAAATATGTACATTGCTGAAA TTGAGAGACTTTTTGTTTTGAATGTAGGGTTAAAATATCCTGAAAATGAACAATTAGGGGTCGATCT GG†GAT†CCAAACATGGATTACCTTTTTGAAAATAGCGACCGTATTGCTGGGGTTTTCTTGACCCACGGGC ATCOGATGCCATTGGTGCTCTACCTTATCTCTTGGCAGAGGCTAAAGTTCCTGTATTTGGGTCTGAGTTG ac¢att¢agt†ggcaaagctctttgtcaaaggaaatgatgccgttaagaaatttaatgatttccatgtca **GAPAGTETGGGAATTGTCTTGAAGACATCGGAAGGAAGCATCGTTTATACAGGTGACTTCAAATTTGACC** AAACGGCTAGTGAATCTTATGCAACTGATTTTGCTCGTTTTGGCAGAGATTGGTCGTGACGGCGTCCTGGC TCTCCTCAGTGATTCGGCCAATGCAGACAGCAATATTCAGGTGGCTAGTGAAAGTGAAGTTAGGGATGAA ATIAGCCIAAACTATTGCTOACTGGGAAGGTCGTATCATCGTTGCAGCTGTTTCCAGTAATCTTTCTCGTAT TQAGCAGATTTTTGACGCTGCGGATAAAACAGGTCGACGTATCGTCTTGACAGGATTTGATATTĞAAAAT ATGCTCGCACAGCGATTCGTCTTAAGAAGTTGTCTTTAGCCAACGAAATTCTCTTGATTAAGCCTAAAO ATATOTOTCGCTTTGAAGACCATGAGTTGATTATTCTTUAGACAGGTCGTATGGGTGAACCTATCAATGG ACTITECTIAGATGTCGATTGGTCGCCATCGTTATGTAGAAATCAAGGATGGGGACCTGGTCTATATTGCT TTGTGAAATTGATTACCCAAAGTTTACATGTATCAGGGCACGGAAATGTGCGTGATTTGGAGCTGATGAT CANTETTTTGCAACCTAAGTACCTCTTCCCTGTCCAAGGGGAGTATCGTGAGTTGGATGCTCACGCTAAGGCTGGCATGGCAGGATGTTGCCAGAACGCATCTTCATTCCTAAAAAGGGGACGACCATGGCTTACG TGA|TGTT|GGAAATGTTGTTCTTCGTGACCGTAAGGTCTTGTCAGAGGATGGAATTTTCATCGTGGCTATTA CACTCAACCGTCGTGAGAAAAATTGTGGCTAGAGCTCGTGTTCAGACGCGTGGATTTGTTTATCTCAA GA'AGAG'ICGCGATATTCTCCGTGAAAGTTCAGAATTGATTAACCAAACGGTAGAAGAGTATCTTCAAGG AGATGACTTTGACTGGCAGATCTCAAAGGTAAGGTTCGTGACAATCTGACCAAGTACCTCTTTGATCAA ACEAGGGCGECCAGCCATTTTACCAGTAGTCATGGAAGCAAAATAA

2 CF 14 "homologue of SEQ. ID NO. 20" | ATQAGTATGTTTTTTTTTTTAGATACAGCTAAGATTAAGGTCAAGGCTGGTAATGGTGGCGATGGTATGGTTGCCT TTCOTCCTGAAAATATGTCCCTAATGGAGGCCCTTGGGGTGGTGATGGTGGTCGTGGAGGCAATGTGGT CTICGTTETAGACGAAGGACTACGTACCTTGATGGATTTCCGCTACAATCGTCATTTCAAGGCTGATTCTO GTQAAAAAGGGATGACCAAAGGGATGCATGGTCGTGGTGCTGAGGACCTTAGAGTTCGAGTACCACAAG CONTROCCCACGOTGGTCGTGGACGTGGAAATATTCGTTTCGCGACACCAAAAAATCCTGCACCGGAA ATCTCTGAAAATGGAGAACCAGGTCAGGAACGTGAGTTACAATTGGAACTAAAAATCTTGGCAGATGTC GGTTTAATAGGATTCCCATCTGTAGGGAAGTCAACACTTTTAAGTGTTATTACCTCAGCTAAGCCTAAAAT TGGTGCCTACCACTTTACCACTATTGTACCAAATTTAGGTATGGTTCGCACCCAATCAGGTGAATCCTTTG DY CACTAGCCACTTGCCAGGTTTGATTGAAGGGGCTAGTEAAGGTGTTGGTTTGGGAAGTCAGTTCCTCCG TCACATCACCGTGTTATCCTTCACATCATTGATATGTCAGCTAGCGAAGCCCGTGATCCATATG AGGATTACCTAGCTATCAATAAAGAGCTGGAGTCTTACAATCTTCGCCTCATGGAGCGTCCACAGATTAT
TGTAACTAATAAGATGGACATGCCTGAGAGTCAGGAAAATCTTGAAGAATTTAAGAAAAATTGGCTGA ACACTITTAGATGCTACAGCTGAATTGTTAGACAAGACACCAGAATTTTTGCTCTACGACGAGTCCGATA TGGAAGAAGATTTACTATGGATTTGACGAAGAAGAAAAAGCCTTTGAAATTAGTCGTGATGACGATG CGACATGGGTAPTTTCTGGTGAAAAACTCATGAAACTCFTTAATATGACCAACTTTGATCGTGTGATGAATCT GTCATGAAATTTGCCCGTCAGCTTCGTGGTATGGGGGGTTGATGAAGCCCTTCGTGCGCGTGGAGCTAAAG ATGGGGATTGGTCGCATTGGTAAATTTGAGTTTGAATTTGTAGACCTCGAGCACCACCACCACCACCAC

2 CFE25 | "homologue of SEQ. ID.NO. 21"
ATGAACTACTTTAATGTTGGGAAAATCGTTAATACGCAGGGATTACAGGGTGAGATGCGAGTCTTGTCTO
TCACGGATTTTGCAGAAGAACGGTTTAAAAAAGGAGCTGAGCTTGGTTTGATGAAAAAAGATCAGTT
TGTGCAAACAGTGACCATCGCTAGCCACCGTAAACAGAAGAACTTTGACATTATTAAATTCAAAGATATO
TACCATATCAATACTATCGAAAAGTACAAGGGATACAGTCTCAAGGTCGCTGAGGAAGATTTGAATGAC
CTAGAGATGGTGAATTTTACTATCACGAGATTATCGGTTTGGAAGTCTATGAGGGTGATAGCTTGGTTG
GAACCATCAAGGAAATCCTGCAACCAGGTGCTAATGATGTCTGGGTGGTCAAACGAAAAGGCAAACGTG
ATTJGCTTTTACCTTATATCCCACCAGTGGTTCTCAATGTTGATATTCCAAATAAACGGGTCGATGTGGAA
ATTTAGAAGGGTTAGACGATGAAGATCTCGAGCACCACCACCACCACCACCACCACTGA

2CTH28 "homologue of SEQ. ID NO. 24" ATGCATTTGAAAGTTTAACAGAACGTTTGCAGAACGTCTTTAAAAATCTACGTAAAAAAGGAAAAATCT CTGAATGTGATGTCCAAGAGGCAACCAAAGAAATTCGCTTGGCCTTGCTCGAGGCCGACGTTGCCTTGCC TOTTOTALAGGACTITATCAAGAAAGTTAGTGAGCGTGCAGTCGGGCATGAGGTCATTGATACACTTAATCCGGCGGAACAGATTATTAAAATCGTTGATGAGGGAACTGACAGCCGTTTTAGGTTCTGATACGGCAGAAA TATCGTCCAGCTGCCATTGACCAGCTTAAGACCTTGGGACAACAGATTGATGTGCCTGTCTTTGCACTTGG AAQAGAAGTA&CAGCTGTTGAGATTGTACGTCAAGGTTTGQAGCAAGCCCAAACTAATCATAACGACTAT CATIGGCTCAACCAAATGAAATCTTGCTFGTCGTTGATGCTATGATTGGTCAGGAAGCAGCCAATGTTGC GCCTGACTTTAATGCTCACTTGGAAGTGACTGGGGTCATCCTTACCAAGATTGATGGCGATACTCGTGGT GGTGCTGCTCTGTTCGTCACATTACTGGAAAACCAATCAAGTTCACTGGTACAGGTGAAAAGATTA CGGACATTGAAACCTTCCACCCAGACCGCATGTCTAGCCGTATCCTTGGTATGGGGGATATGCTCACTTT GATITGAGAAAGCTTCTCAGGAATACGATGAACAAAAAGCCCTTGAAATGGCTGAGAAGATGCGCGAAAA CACCTTIGATTITAATGATTTCATCGATCAATTAGATCAGGTGCAAAATATGGGGCCGATGGAAGACTTG CTCAAGATGATICCAGGTATGGCCAACAATCCAGCCCTTCAAAACATGAAGGTGGATGAACGCCAGATT GCTCGTAAACGTGCCATTGTGTCTTCGATGACACCTGAAGAGCGTGAAAACCCAGATTTGTTAAATCCAA GCCCTCCCCCCTATTGCTGCTGGTTCTGGAAATACATTCGTCGAAGTCAATAAATTCATCAAGGACTTT AACCAGGCTAAACAGCTCATGCAGGGTGTTATGTCTGGGGATATGAATAAAATGATGAAGCAAATGGGG ATTAATCCAAATAACCTTCCTAAAAATATGCCAAATATGGGAGGAATGGATATGTCTGCCCTTGAAGGAA

2 CFE 28 (contd)

THATGEGACAAGGCGGTATGCCTGACTTATCAGCTCTCGGAGGAGCAGGAATGCCAGATATGAGCCAGA THATTTGTGGCGGTTTGAAAGGTAAAATTGGTGAATTTGCCATGAAACAGTCCATGAAACGTATGGCTAA CAAAATGAAGAAAAGGAAGAAACGCAAGGCGGCCGCACTCGAGCACCACCACCACCACCACTGA

2 CFES2, "homologue of SEQ. ID NO. 28"

ATGAGTAITCGAGTAATTATTGCCGGTTTTAAGGGAAAGATGGCCAGGCTGCTTGTCAGATGGTATTGA
CTGATCGAGACTTGGACTTGGTGCCAGTTTTGGATCCTTTTGAGTCTGAGTCAGAATGGCAGGTATTCCT
GTTTTCAAGGATAAGGCTGATTTAGCTGGTTTTGAAGCGGATGTCTGGGTAGATTTTACTACTCCAGCTGT
TGCTAGGAAAATACACGTTTTGCTCTTGAAAATGGCTTTGCTCCAGTAGTTTGAACGACTGGTTTCACGA

2CFE 32

2CIESS "homologue of SEQ. ID NO. 31" 35
ATGAAATTAGAACATAAAAATATCTTTATTACAGGTTCGIGGGAATTGGTCTTGCCATGCCCACA
ACTTTGTCAAGCAGGAGCCAACATTGTCTTAAACAGTCGTGGGGCAATTGGTCTTGCCATGCCCACA
ACTTTGTCAAGCAGGAGCCAACATTGTCTTAAACAGTCGTGGGGCAATTTTGCAGAAGATTTGCAGAAGATTTGCAGAAGATTTGCAGAAGTTTTGCAGAAGTTTTGCAGAAGTTTTGCAGAAGTTTTGCAGAAGTTTTGCAGAATTTGCAGAAGTTTTGCAGAAGTTTTGCAGAATTTTGCAGAAGTTTTAACAGAATTTGATTAATTTTTTAACAGAATTTGGTCAAGCTAAGTTTAACTTTAATTTTTAACAGAATTTAACTTGATTAATTTTTAACAGAATTTAACTTGATTAACTTAATTTTAACTTTAACTTGATTAACTTAATTTTAACTTTAACTTGATTAACTTAACTTTAACTTTAACTTTAACTTTAACTTTAACTTTAACTTTAACTTCAGATTTAACTTTAACTTTAACTTTAACTTTAACTTAACTTAACTTAACTTCAACTTTAACTAACTAACTTAACTTAACTTAACTTAACTAACTTAACTTAACTAACTTAACTAACTTAACTAACTTAACTA

2CFES6 | "homologue of SEQ. ID NO. 32"

ATGGGAGTGAAAAGAAACTAAAGTTGACTAGTTTGCTAGGACTGTCTCTGTTAATCATGACAGCCTOTG
CGACTAATGGGTAAACTAGCGATATTACAGCCGAATCGGCTGATTTTTGGAGTAAATTGGTTTACTTCTTT
GCGGAAATCATTCGCTTTTATCGTTTGATATTAGTATCGGAGTGGGGATTATTCTCTTTACGGTCTTGATT
CGTACAGTCCTCTTGCCAGTCTTTCAGGTGCAAATGGTGGCTTCTAGGAAAATGCAGGAAGCTCAGCCAC
GCATTAAGGCGCTTTCGAGAACAATATCCAGGTCGAGATATGGAAAGCAGAACCAAACTAGAGCAGAAA
TGCGTAAAGTATTAAAGAAATGGGTGTCAGACAGTCAGACTCTTTTGGCCGATTTTGATTCAGATGCC
GGTTATTTTGGCCCTGTTCCAAGCCCTATCAAGAGTTGACTTTTTAAAGACAGGTCATTTCTTATGGATTA
ACCTTGGTAGTGTGGATACAACCCTTGTTCTTCCGATTTTAGCAGCAGTATTCACCTTTTTTAAGTACTTGG
TTGTCCAACAAGCTTTGTCTOAGCGAAATGGCGCTACGACTGCGATGATGTATAGGGATTCCAGTCTTGA
TTTTTATGTTTGCAGTTTATGCGCCAGGTGGAGTCGCCCTATACTGGACAGTGTCTAATGCTTATCAAGTC

WO 01/49721

2 CFE 36

2CFE37 homologue of SEQ. ID NO. 33" ATGAADATTAGTAAGAGGCACTTATTAAATTATTCCATCTTGATTCCCTACTTGCTTTTATCTATTTTGGGC T GAT GTGGTCTATTCGACCACCAGTGCTATTTAATTGAAGAAGGCAAGAGCGCCTTGCAGTTGGTTCG AAACCAAGGAATCTTTTGGATTGGTAGTTTGATACTGATTGCCTTAATTTATAAATTGAGACTAGATTTTT TGAGALATGAGCGACTAATCATTTTAGTTATATTAATAGAAATGCTTTTATTGTTCTTGGCTCGTTTTATT THTCAAGTHTGACTCAAAATCAATGGCTTCCCCGTGCTTTTAATGATTGGCGATTCGTTCTCCTAGTTCT GATTGGAAGTTTGGGAATTTTCCCTGATTTAGGAAATGCGACTATTTTAGTCTTGGTTTCCTTGATTATGT ATACAOTTAGTGGAATCGCTTATCGCTGGTTTTCAACCATTCTGGCGCTCGTATGTGCCGCTTCTGTCTTTG TOTTGACCACTATCAGCCTAATCGGTGTTGAGACCTTTTCAAAAATTCCAGTATTTGGCTATGTAGCCAAA CGCTTAGTGCCTTTTTTAATCCTTTTGCCGATCGTGCTGATGCAGGTCACCAGTTAGCTAATTCTTATTTT ☼ GÓCATGGTCAATGGTGGTTGGTTTGGTCTAGGTCTTGGAAACTCGATTGAAAAACGAGGTTATTTGCCAG AAGCTGATACAGACTTTGTCTTTTCTATCGTGATTGAAGAATTTGGCTTTGTTGGTGCCAGTCTTATTTTAG CICTCIPITTTTCATGATTTTGCGGATTATCTTGGTCGGTATTCGAGCGGAGAATCCTTTCAATGCCATGG TICCATTCGGTGTCGGAGGGATGATGTTGGTTCAGGTATTTGTCAATATCGGAGGGATTTCGGGCTTGATT CCATCTACAGGAGTAACCTTCCCCTTCTTATCCCAGGGTGGAAATAGTCTTCTAGTCTTATCAGTGGCAGT ACCTIFGTCTTAAATATTGATGCCAGTGAAAAACGCGCTAAGTTGTACCGAGAATTGGAAAATCAACCA ATGAAGCTTCTGTTGAAGCTCGAGCACCACCACCACCACCACTGA

"homologue of SEQ. ID NO. 34" ATGCTCGGAATTTTAACCTTTATTCTGGTTTTCGGGATTATTGTAGTGGTGCACGAGTTCGGGGACTTCTA CITTOCCAAGAATCAGGGATTITAGTACGTGAATTTGCCATCGGTATGGGACCTAAAATTTTTGCTCACA TTPGCAAGGATGGAACGGCCTATACCATTCGAATCTTGCCTCTGGGTGGCTATGTCCGCATGGCCGGTTG GOOTG ATGATACAACTGAAATCAAGACAGGAACGCCTGTTAGTTTGACACTTGCTGATGATGGTAAGGTT TTGAAGACAAGCTCTTTATCAAAGGATTGGTTCTGGAAGAAGAAAAAACATTTGCAGTGGATCACGATGC AACGOTTGTGCAAGCAGATGGTACTGAGGTTCGGATTGCACCTTTAGATGTTCAATATCAAAATGCGACT A CTGGGGCAAACTGATTACCAATTTTGCAGGTCCTATGAACAATTTTATCTTAGGTGTCGTTGTTTTTTC GGITTTLATC/TTATGCAGGGTGTGTCAGAGATGTTGATACCAATCAGTTCCATATCATGCCCCAAGGTGCTTGGCCAAGGTAGGAGTAGCAGAAACGGCACAAATTACCAAGATTGGCTCACATGAGGTTAGCAACT GGGAAAGCTTGATCCAAGCTGTGGAAACAGAAACCAAAGATAAGACGGCACCGACTTTGGATGTGAETA TTICTG/AAAGGGGAGTGACAAACAAGTCACTGTTACACCCGAAGATAGTCAAGGTCGTTACCTTCTAGG TO TCAACCGGGGOTTAAGTCAGATTTTCTATCCATGTTTGTAGGTGGTTTTACAACTGCTGCTGACTCAG CTCTCCCAATTCTCTCAGCTCTGAAAAATCTGATTTTCCAACCGGATTTGAACAAGTTGGGTGGACCTGTT GCTATCTTAAGGCAAGTAGTGATGCTGCTAAAAATGGAATTGAGAATATCTTGTACTTCTTGGCAATGA TTICCATCAATATTGGGATTTTTAATCTTATTCCGATTCCAGCCTTGGATGGTGGTAAGATTGTGCTCAAT ATCTACAAGCCATCCGCCGCAAACCATTGAAACAAGAAATTGAAACCTATGTCACCTTGGCCGGAGTG GTGATC/TGGTTGTCTTGATGATTGCTGTGACTTGGAATGACATTATGCGACTCTTTTTTAGACTCGAGCA CCACCACCACCACTGA

ATOTACCATATTTAAAAGGAATCATTACCAAAATTACTGCCAAATACATTGTTCTTGAAACCAATGGTA
TTGGTTATATCGTGCATGTGGCCAATCCTTATGCCTATTCAGGTCAGGTTAATCAGGAGGCTCAGATTTAT
GTGCATCAGGTTGTGCGTGAGGACGCCCATTTGCTTTATGGATTTCGCTCAGAGGATGAGAAAAAGCTCT
TTCTTAGCTAATTTCGGTCTCTGGGATTGGTCCTGTATCAGCTCTTGCTATTATCGCTGCTGATGACAATG
CTGGCTTGGTTGAAGCCATTGAAACCAAGAACATTACCTACTTGACCAAGTTCCCTAAAATTGGCAAGAA
AACAGCCCAGCAGAGTGGTGCTGGACTTGGAAGGCAAGGTAGTAGTTGCAGGAGATGGCCTTCCTGCCAA
GGTCGCAGTGCAAGCAAGTGCTGAAAACCAAGAATTTGGAAGAAGCTATGGAAGCCATGTTGGCTCTGGG
CTACAAGGCAACAGAGCTCAAGAAAATCAAGAAATTCTTTGAAGGAACGACAGATACAGCTGAGAACTA
TATCAAGTCGGCCCTTAAAATGTTGGTCAAACTCGAGCACCACCACCACCACCACCACCACTGA

2 CTB40 "homologue of SEQ. ID NO. 36"
ATOAGRATAATCGTATTTTAGCACTTTCTGGAAATGATATTTTAGTGGTGGTGGACTGTCAGCTGATTT
GCCTACCTAJACCTTGAACGGCTTGCATGGGTTTGTAGCAGTGACTTGTTTGACAGCCTTGACAGAAAAA
GGATTTGAAGTCTTCCAACTGATGATACCATTTTTCAACATGAATTAGATAGCTTGCGTGATGTGGAATT
TGGGGGAATTAAGATTGGTCTTCTCCCTACTGTCAGTGGGCTGAGAAGGCCTTGGACTTTATCAAACAA
CCCCAGGAGTACCTGTGGTTTGGATCCTGTCTTGGTCTGCAAGGAAACGCATGATGTAGCTGTCAGTG
ACCTCTGCCAAGAGTTGATTCGCTTTTTCCCTTATGTCAGTGTGATTACGCCTAATCTCCCAGAAGCAGAA
TTATTATCCGGTCAGGAAATTAAAACCTTGGAAGACATGAAAAACTGCAGCGCAGAAATTGCATGATTTAG
GAGCGCCAGGAGTCATTATCAAGGGAGGCAATCGTCTTAGTCAGGACAAAGGCTGTGGATGTCTTTTATGA
TCGACAGACCTTTACTATCCTAGAAAATCCAGTTATCCAAGGCCAAAATGCTGGTGCAGGTTGTACCTTT
GCCTCTAGCATTGCCAGAGCAGAAAATCCAGTTATCCAAGGCCAAAATGCTGGTGCAGGTTGTACCTTT
TCGTTTATCGTGCTATTGCACAAGCAGATCAGTATGGAGTAAACCTTTTGCCAGCAGTAGAAAACAACC
TCGAGGACCACCACCACCACCACTGA

2 CFE41 "homologue of SEQ. ID NO. 37" ATGATTGAAAICGGAGAAAAAAGAGGAGCGAGTCCTGCTGATTGGTGTGGAATTGCAGGGTATGGACAGT TTGACCTCTCCATGGAAGAATTGGCTAGTTTAGCGAAAACGGCAGGGGCAGTCGTTGTAGATAGCTACA GACAAAAACGTGAAAAATATGATTCCAAGACCTTCGTCGGCTCTGGTAAGTTGGAAGAGATTGCGCTTAT GCTGGATGCAGAAGAAATCACTACTGTCATCGTCAACAACCGTCTGACCCCAAGGCAGAATGTCAATCTA CAGGAAGTTCTCCGTGTTAAGGTCATTGACCGTATGCAGTTGATTTTGGATATCTTTGCCATGCGGGCTCG GGOATTATGCTCAGCCGTCAGGCAGGGGOAATTGGTTCCCGTGGTCCTGGTGAAAGCCAACTGGAGCTO AACCGTCGTAGCGTTCGCAATCAAATCACGGATATCGAGCGCCAGCTTAAGGTGGTTGAGAAAAATCGT GCDACTOTCA GAGAAAAACGTTTGGAGTCTAGCACTTTTAAGATTGGTTTGATTGGTTATACTAATGCTG GDAAATCAACTATCATGAACATCTTGACCAGTAAGACCCAGTATGAAGCAGATGAGCTCTTTGCGACTCT GGATGCGACAACCAAGAGTATTCATCTGGGAGGCAACCTCCAAGTAACTTTGACAGATACCGTTGGCTTT TTCTGGTTCATGTTATCGATGCTAGCAATCCTTACCACGAGGAGCATGAAAAAACGGTTCTCTCCATCATG AAGACTGGACATGGAAGATATTCCTCACTTGACGCTTTATAATAAAGCGGATTTGGTGGAGGATTTCACCCTCATTTCTGCCAAGTCTGAGGACAGTCGTGAAAACTTGCAAGCATT ATTGCTAGATAAGATTAAGGAAATTTTTGAAGCATTTACCCTGCGAGTGCCTTTTTCAAAGTCCTACAAG ATTCATGATTTAGAGAGTGTTGCAATTCTGGAAGAACGTGATTATCAGGAAGACGGCGAAGTGATTACAG GCTACATTTCCGAGAAAAATAAATGGAGGTTAGAAGAATTTTATGACCTCGAGCACCACCACCACCACCA

2 CFF42 "homologue of SED. ID NO. 38"
ATGCAGAAAAAACATATCCTATGACCCTTGAGGAAAAGGAGAACTTGAAAAAGAATTAGAAGAATTG
AAATTGGTTCGTCGACCAGAAGTGGTAGAACGCCATTAAGATTGCCCGTTCATACGGTGATCTTTCAGAAA
AAATCCGCTATGCTGAAATCGTCAATAGCGACGCAGTTGCCCAGGACGAAGTAGCGATTGGTAAAACAG
TCACCATCCAAGAAATTGGTGAGGACGAAGAAGAAGTTTATATTATCGTAGGTTCAGCTGGTGCGGATGC
CTTTGCAGGTAAGGTTTCAAATGAAGCCCAATTGGGCAGGCCTTGATTGGCAAGAAAAAACAGGTGACAC
AGGAACCATTOAAACGCCTGTTGGTAGCTATGATGTAAAAAACTTTGAAGGTTGAAAAAAACAGCCCTCGA
GCACCACCACCACCACCACTGA

"homologue of SEQ. ID NO. 41" 2 CEE45 OTGGTGGCTATCTATATAGCCGTTAGTCATGATTATCCCAATAATATTCTGCCCATTTTAGGGCAGCAGGT CCCCCCCCTCGCCCTTGGGGCTTGTGATTGGTTTTGTGGTCATGCTCTTTAATACAGAATTTCTTTGGAAGG TGACCCCCTTTCTATATATTTTAGGCTTGGGACTTATGATCTTGCCGATTGTATTTTATAATCCAAGCTTAG TTGCATCAACGGGTGCCAAAAACTGGGTATCAATAAATGGAATTACCCTATTTCAACCGTCAGAATTTAT GAAGATATCCTATATCCTCATGTTGGCTCGTGTCATTGTCCAATTTACAAAGAAACATAAGGAATGGAGA CGCACGGTTCCGCTGGACTTTTTGTTAATTTTCTGGATGATTCTCTTTACCATTCCAGTCCTAGTTCTTTTA GCACTTCAAAGTGACTTGGGGACGGCTTTGGTTTTTGTAGCCATTTTCTCAGGAATCGTTTTATTATCAGG GGTTTCTTGGAAAATTATTATCCCAGTATTTGTGACTGCTGTAACAGGAGTTGCTGGTTTCTTAGCTATCT GGCTTGGCTCAATCCCTTTGAGTTTGCCCAAACAACGACTTACCAGCAGCAGGCTCAAGGGCAGATTGCCATT GGDAGTGGTGGCTTATTTTGTCAGGGATTTAATGCTTCGAATCTGCTTATCCCAGTTCGAGAGTCAGATAT GATTTTTACGGTTATTGCAGAAGATTTTGGCTTTATTGGCTCTGTCCTGGTTATTGCCCTCTATCTCATGTT GAPT, TAPCOTATOTTGAAGATTACTCTTAAATCAAATAACCAGTTCTACACTTATATTTCCACAGGTTTGA TTATGATGTTGCTCTTCCACATCTTTGAGAATATCGGTGCTGTGACTGGACTACTTCCTTTGACGGGGATT CCCTTGCTTTCATTTCGCAAGGGGGATCAGCTATTATCAGTAATCTGATTGGTTTGGTTTGCTTTTATCG ATO NOT TACCA GACTA AT CTAGCT GAAGAAA GAGCG GAAAAGT CCCATT CAAACGGAAAAAGGT TGTA TTAAAACAAATTAAACTCGAGCACCACCACCACCACCACCACTGA

QCFENT "homologue of SEQ. ID NO. 43"

ATCAGAAAAATTOTTATCAATGOTGGATTACCACTGCAAGGTGAAATCACTATTAGTGGTGCTAAAAATA
GTGTCGTTGCCTTAATTCCAGCTATTATCTTGGCTGATGATGTGGTGACTTTGGATTGCGTTCCAGATATTT

CGGATGTAGCCAGTCTTGTCGAAATCATGGAATTGATGGGAGCTACTGTTAAGCGTTATGACGATGTATT

GGAGATTGACCCAAGAGGTGTTCAAAATATTCCAATGCCTTATGGTAAAATTAACAGTCTTCGTGCATCT

TACTATTTTATGGGAGCCTCTTAGGCCGTTTTGGTGAAGCGACAGTTGGTCTACCGGGAGGATGTGATCT

TGGTCCTCGTCCGATTGACTTACACCTTAAGGCGTTTGAAGCTATGGGTGCCACTGCTAGCACGGGA

GATAACATGAAGTTATCTGCTAAAGATACAGGACTTCATGGTGCAAGTATTTACATGGATACGGTTAGTG

TGGGAGCAACGATTAATACGATGATTGCTGCGGTTAAAGCAAATGGTCGTACTATTATTGAAAATGCAGC

2 CFE 47 (contol)

"homologue of SEQ. ID NO. 45" AT BAGAAATATGGCTTTGACAGCAGGTATCGTTGGTTTGCCAAACGTTGGTAAATCAACACTATTTAATG Calattalaaaaagcaggagcagaggcagcaaactacccatttgcgactattgatccaaatgttggaatgg TGBAACITCCAGATGAACGCCTACAAAAACTAACTGAAATGATAACTCCTAAAAAGACAGTTCCCACAA CATTIGAATITACAGATATTGCAGGGATTGTAAAAGGAGCTTCAAAAGGAGAAAGGGCTAGGGAATAAATTCTTGGCAATATTCGTGAAGTAGATGCGATTGTTCACGTAGTTCGTGCTTTTGATGATGAAAATGTAATG CGCGAGCAAGGACGTGAAGACGCCTTTGTAGATCCACTTGCAGATATTGATACAATTAATCTGGAATTAA TT¢TTG¢TGAQTTAGAATCAGTGAACAAACGATATGCGCGTGTAGAAAAGATGGCACGTACGCAAAAAG ATAAAGAATCAGTAGCAGAATTCAATGTTCTTCAAAAGATTAAACCAGTCCTAGAAGACGGGAAATCAG CTGGTAGCATTGAATTAACAGATGAGGAACAAAAGGTTGTCAAAGGTCTTTTCCTTTTGACGACTAAACC AGTTCTTTATGTAGCTAATGTGGACGAGGATGTGGTTTCAGAACCTGACTCTATCGACTATGTCAAACAA ATTCTTGAATTTTGCAGCGACAGAAAATGCTGAAGTAGTCGTTATTTCTGCGCGTGCTGAGGAAGAAATTT CTGAATTOGATGATGAAGATAAAAAAGAGTTTCTTGAAGCCATTGGTTTGACAGAATCAGGTGTAGATAA GCTTGGACTTTICAAACGTGGTATGAAGGCTCCTCAAGCAGCTGGTATTATCCACTCAGACTTTGAAAAAG GGTTTATTCGTGCAGTAACCATGTCATATGAAGATCTAGTGAAATATGGATCTGAAAAGGCCGTAAAAGA AG¢TGG&CGCTTGCGTGAAGAAGGAAAGAATATATCGTTCAAGATGGCGATATCATGGAATTCCGCTTT AATGTCGTCGAGCACCACCACCACCACTGA

2.CFE11 "homologue of SEQ. ID NO. 47"

ATGACCTTAGANTGGGAAGAATTTCTAGATCCTTACATTCAAGCTGTTGGTGAGTTAAAGATTAAACTTC

GTGGTATTCGTAAGCAATATCGTAAGCAAAATAAGCATTCTCCAATTGAGTTTGTGACCGGTCGAGTCAA

GCCAATTGAGAGCATCAAAGAAAAAATGGCTCGTCGTGGCATTACTTATGCGACCTTGGAACACGATTTG

2 CFE 51 (conta) CAGGATATTGCTGCCTTACGTGTGATGGTTCAGTTTGTAGATGACGTCAAGGAAGTAGTGGATATTTTGC J A¢AAG¢GTCAGGATATGCGAATCATACAGGAGCGAGATTACATTACTCATAGAAAAGCATCAGGCTATC GTTCCTATCATGTGGTAGAATATACGGTTGATACCATCAATGGAGCTAAGACTATTTTGGCAGAAAT TOAAATTCGTACTTTGGCCATGAATTTCTGGGCAACGATAGAACATTCTCTCAACTACAAGTACCAAGGG S GATTTCCCAGATGAGATTAAGAAGCGACTGGAAATTACAGCTAGAATCGCCCATCAGTTGGATGAAGAA ATGGGTGAAATTCGTGATGATATCCAAGAAGCCCAGGCACTTTTTGATCCTTTGAGTAGAAAATTAAATG **A¢GÖT¢TAGĞAAAĆAGTGACGATACAGATGAAGAATACAGGCTCGAGCACCACCACCACCACCACTGA** 2 CRESZ / "homologue of SEQ. ID NO. 48" A 1GGA A CTTA A TACACA CAATGCTGAAATCTTGCTCAGTGCAGCTAATAAGTCCCACTATCCGCAGGATG AACTG&CAGAGATTGCCCTAGCAGGGCGTTCAAATGTTGGTAAATCCAGCTTTATCAACACTATGTTGAA COGTAGGATUTCGCCCGTACATCAGGAAAACCTGGTAAAACCCAGCTCCTGAACTTTTTTAACATTGAT GACAAGATGCGCTTTGTGGATGTGCCTGGTTATGGCTATGCTCGTGTTTCTAAAAAGGAACGTGAAAAGT GGGGGTGCATOATTGAGGAGTACTTAACGACTCGGGAAAATCTCCGTGCGGTTGTCAGTCTAGTTGACCT O TOGICATGACCOGTCAGCAGATGATGTGCAGATGTACGAATTTCTCAAGTATTATGAGATTCCAGTCATC
ATTGTGCGCGACCAAGGCGGACAAGATTCCTCGTGGTAAATGGAACAAGCATGAATCAGCAATCAAAAAG CTITGGGATGCAATCTTAGAAAAATTGGCGGCCGCACTCGAGCACCACCACCACCACTGA "homologue of SEQ. ID NO. 49" 2 OFE53 TCCCCATTGTCAAGAACAAGGAAGGACAAGTCTTTATTGATCCTACGGGCAAGGCCAATGGCCGCGGCG CTTATATCAAACTAGACAATGCAGAAGCCCTAGAGGCGAAAAAGAAGAAGGTCTTTAACCGCAGCTTTA `gcatggaagtggaagaagcttttatgacgagttgatcgcttatgtggatcacaaagtgaaaagaagag AGITTGGGACTTGAACTCGAGCACCACCACCACCACCACTGA "homologue of SEQ. ID NO. 50" APOTTALAACCCTCTATTGATACCTTGCTCGACAAGGTTCCTTCAAAATATTCACTCGTAATCTTGGAAGC <u>ANACCTGCCCACGAATTGGAAGCAGGTGCCCCAGCAACTCAAGGTTTCAAGTCTGAAAAATCAACTCTT</u> CGEGCTTTAGAAGAAATCGAATCAGGAAACGTTACAATTCACCAGATCCAGAAGGAAAACGTGAAGCA 2CFESS: "homologue of SEQ. ID NO. 51" ATOTCATTAACATCAAAACAACGTGCCTTCCTCAACAGCCAGGCACACCCTCAAAACTATCATCCAAA TCCCAAGATTTCTAAGAAAGTCAAAGAAATCCTCGAGCACCACCACCACCACCACCACTGA "homologue of SEQ. ID NO. 52" COTTCACATTTGGTATTGACCGTGCTATGAAGGAATTCCACTATGACAAAAAGGAAGTGGTCATGGTTGG COACCAGCTCATGACAGATATACGAGCAGCCCACCGTGCAGGGATTCGGTCAATTTTAGTCAAACCCTTG GTCCAACATGACTCAATCAAAACGCAGATTAACCGAACTCGTGAGCGTCGTGTTATGAGAAAAATCACTG

2CFE7 "homologue of SEQ. ID NO. 53"

ATEITTCBAAAAATTTTAATTGCCAATCOTGGTGAAATTGCGGTTCGTATTATCCGTGCGGCACGTGAATT
GGGGATTGCGACGGTAGGGGTTTATTCAACTGCTGATAAGGAAGCTCTTCATACGCTTTTTGGCAGATGAA

GCABTTTGTATTGGTCCTGGCAAGGCAACAGAGTCTTATCTCAATATTAATGCAGTTCTATCAGCTGCAGT
CTTGACTGAGGTAGAAGCTATTCACCCTGGTTTTGGATTTTCTCAGTGAAAATTCCAAATTTGCGACCATGT

aaaagtacgaccgattacatataaaaaaggaattctcgagcaccaccaccaccaccactga

12CFE 57

GTGAAGAAGTAGGTATCAAGTTTATCGGTCCATCTGGTCATGTTATGGATATGATGGGGGATAAGATCAA TOCOCCUTGCTCAGATGATTAAAGCAGGTGTGCCTGTTATACCAGGTTCAGATGGAGAAGTGCATAACTCT GAAGAAGCTT#GATTGTTGCTGAAAAAATTGGCTATCCTGTTATGCTCAAGGCTTCAGCAGGTGGAGGTG GTAAAGGGATTCGTAAGGTTGAAAAACCAGATGACCTCGTTTCTGCCTTTGAAACTGCCTCTAGTGAGGC CALATOCTAGOTGATGAGCATGGACATGTGATTCACTTGGGTGAACGGGATTGTTCTCTTCAAAGGAATA ACCAAAAGGTTTTGAAAGAAAGTCCCTCGATTGCAATCGGAAAAACGCTGCGTCATGAAATAGGTGCTG CTBCTGTTCGAGCGGCAGAGTTTGTTGGCTATGAGAATGCAGGAACCATTGAATTTCTTCTTGATGAAGC AAGTACAAATITTCTATTTCATGGAGATGAATACTCGTGTTCAGGTAGAACATCCAGTAACAGAGTTTGTT TCHGGTGTTGHTATCGTTAAGGAACAGATTTGCATTGCGGCAGGTCAGCCTTTGTCTGTTAAGCAAGAAG ATATTGTCCTACGCGGTCATGCCATCGAGTGTCGTATCAATGCAGAAAACCCAGCCTTTAACTTTGCTCCA ACTCCAGGTAAGATTACTAATCTCTATCTGCCAAGTGGTGGAGTTGGCTTGCGCGTGGATTCAGCAGTTT ATCCAGGTTA FACCATTCCGCCTTATTATGATAGTATGATTGCCAAAATCATAGTACACGGCGAAAATCG TITTOACGCCTTGATGAAAATGCAACGTGCCCTCTATGAATTAGAGATTGAAGGAGTGCAGACCAATGCA AACCTTCTTACCTAAATATCAAGAAAAAGAACTCGAGCACCACCACCACCACCACCACTGA

"homologue of SEQ. ID NO. 56" TTGAATACCGTGGCTATGATTCTGCGGGAATTTTTGTCCTAGATGGTGCTGATAACCATTTGGTGAAGGCT GTTOGTCGTATCGCAGAATTGTCTGCCAAGACAGCTGGTGTTGAGGGAACAACTGGTATCGGACATACTC OTTGGGGAACTCATGGGAAACCAACGGAAGACAATGCTCACCCACACCGCTCTGAGACAGAACGTTTTG TCTTGGTTCACAATGGGGTGATTGAAAACTACCTTGAAATTAAAGAAGAATACCTTGCTGGGCACCACTT CAMAGGGCAAACAGATACGGAAATCGCCGTACATTTGATTGGAAAATTTGCGGAAGAAGACGGTCTCTC AAAATCCAGATGTCATCTATGTAGCGAAAAACAAATCTCCACTTTTGATTGGTCTTGGGGAAGGCTACAA TATEGTCTGAGATGCTATGGCTATGATTCGTGAAACCAACCAATACATGGAAATTCATGACCAAGAG TTOPTAAICGTCAAGGCTGATAGCGTGGAAGTTCAAGACTATGATGGTAACAGTCGTGAACGTGCTAGCT ATACTOCOGAACTTGACTTGTCAGATATCGGTAAGGGAACTTATCCTTACTACATGCTTAAGGAAATTGA CCTGCTATCATTAAGGCTGTTCAAGACGCAGACCGCATCTACATCCTTGCAGCTGGAACATCTTACCATG CAGDATTINGCT ICTAAGAAAATGTTGGAAGAATTGACAGATACACCAGTTGAACTTGGCATCTGA GTGGGGGTACGGTATGCCACTTCTCAGCAAGAAACCACTCTTCATCTTTATCAGCCAATCTGGTGAAACA

2 CFE 60 (conda)

"homologue of SEQ. ID NO. 58" 2 CFE62 (ATOCCG|AAGAAGTGAATTTAACAGGCGAAGAAGTTGTCGCTTTAACCAAAGAATATTTAACGGAAGAG GAITGTTCATTTTGTCCATAAGGCCTTGGTCTATGCTGTTGAATGCCACAGTGGTCAATATCGCAAATCAGG CGAGCCITATATCATTCACCCTATCCAAGTGGCAGGTATTTTAGCTAAGCTAAAGCTGGATGCTGTAACA **GTAGCTTGTGGATTCTTGCATGATGTGGTGGAAGATACAGATGCGACTTTGGACGATTTGGAAAGAGAGT** GGAGCAATTAGCGGAAAATCATCGCAAGATGCTCATGGCCATGTCTGAGGACATCCGCGTTATTTTGGTC ANACTG CTGACCGCTTGCACAATATGCGGACCCTGAAACATCTTCGAAAAGACAAGCAGCAGGAGCGTATTT CCAAAGAAACCATGQAAATCTATGCCCGGCTTGCCCATCGTTTGGGGATTTCCAGTGTCAAATGGGAATT AGAAGACTTGTCTTTCCGTTATCTCAATCCAACGGAGTTTTACAAGATTACCCATATGATGAAGGAAAAG CGÇAGGGAGCGTGAGGCCTTGGTGGATGAGGTAGTCACAAAATTAGAGGAGTATACGACAGAACGTCAC TTGAMAGGGAAGATTTATGGTCGTCCCAAGCATATTTACTCAATTTTCCGCAAAATGCAGGACAAGAGAA AACOGTTTGAGGAAATCTATGATCTGATTGCTATTCGTTGTATTTTAGATACCCAAAGTGATGTTTATGCC ATCTTGTTACGTGCATGAATTTTGGAAACCGATGCCAGGTCGCTTCAAAGACTATATCGCCAACCGCA AGGCCAATGGTTATCAGTCTATCCATACGACTGTTTATGGACCAAAAGGGCCGATTGAATTCCAGATTCG AA¢CAA¢GAAATGCACGAGGTGGCTGAGTACGGGGTTGCGGCTCACTGGGCTTATAAGAAAGGTATAAA GGGGCAAGTTAACAGCAAGGAATCAGCTATTGGAATGAACTGGATCAAGGAGATGATGGAGCTCCAAGA CCAGGCTGATGATGCTAAGGAATTTGTGGACTCTGTTAAGGAAAACTATTTGGCTGAGGAGATTTACGTT TACAACGTCGGTGAAAAAGCAACTGGTGCCAAGGTCAATGGCCGCATGGTTCCACTGACAACCAAGTT AAAGACAGGGGATCAGGTTGAAATTATCGCCAACCCGAACTCCTTTGGACCTAGCCGTGACTGGCTCAAT ATGCCAGACTAGCAAGGCGCGCAATAAGATTCGCCAGTTCTTTAAAAACCAAGATAAGGAATTGTCT ACAAGCCCACATGGATCAAGTTCTGCAAAAGACCAGTTACAAGACAGAAGACTCCCTCTTTGCGGCCAT TGGTTTTBÖGGNAATCGGTGCGATTACCGTCTTAACCGTCTGACTGAAAAGGAGCGCCGTGAGGAAGAG CGTGCCAAGGCCAAGGCTGAGGCAGAGGAGCTTGTCAAAGGTGGCGAGGTCAAGGTTGAAAATAAAGA AACTCTCAAGCTCAAGCATGAGGGGGGGGGTGGTTATTGAAGGTGCTTCTGGTCTCCTAGTGCGGATTGCT AACTGTTGTAACCCCGTGCCTGGTGACGATATTGTTGGCTACATTACCAAGGGTCGTGGTGTGGCTATTC ACCUTGTUGACTOTATGAACCTGCGTGCCCAAGAAAACTACGAGCAACGTCTCCTTGATGTGGAATGGGA AGACCACTACTCTAGCTCAAATAAGGAGTATATGGCCCATATCGATATCTACGGTCTCAACCGTACAGGA

2 CFE 62 (conta)

2 CFE64 "homologue of SEQ. ID NO. 60" ANGACAGAAGAAATCAAAAATCTGCAGGCACAGGATTATGATGCCAGTCAAATTCAAGTTTTAGAGGGC TTAGAGGCTGTTCGTATGCGTCCAGGGATGTACATTGGATCAACCTCAAAAGAAGGTCTTCACCATCTAG DAGCCAGATDATTCGATTACTGTTGTGGATGATGGGCGTGGTATCCCAGTCGATATTCAGGAAAAAACAG GTCGTCTGCTGTTGAGACCGTCTTTACAGTCCTTCACGCTGGAGGAAAGTTCGGCGGTGGTGGATACAA GETTTCAGGTGGTCTCACGGGGTGGGGTCGTCAGTTGTTAATGCCCTTTCCACTCAATTAGACGTTCATG TCATAAAAACGGTAAGATTCATTACCAAGAATACCGTCGTGGTCATGTTGTCGCAGATCTTGAAATAGT T#GAGATACGGATAAAACAGGAACAACTGTTCACTTCACACCGGACCCAAAAATCTTCACTGAAACAAC AATCHTGATTTTGATAAATTAAATAAACGGATTCAAGAGTTGGCCTTTCTAAATCGCGGTCTTCAAATTT CTATCACTGATAAGCGCCAAGGTTTGGAACAAACCAAGCATTATCATTATGAAGGTGGGATTGCTAGTTA COTTCAATATATCAACGAGAACAAGGATGTAATCTTTGATACACCAATCTATACAGACGGTGAGATGGAT CATATCACAGTTGAGGTAGCCATGCAATACACAACGGGTTACCATGAAAATGTCATGAGTTTCGCCAATA ATATTGATACACATGAAGGTGGAACGCATGAACAAGGTTTCCGTACAGCCTTGACACGTGTTATCAACGA THATGITCGTAAGAATAAGTTACTGAAAGACAATGAAGACAATCTAACAGGGGAAGATGTTCGCGAAGG CITAACTGCAGTTATCTCAGTTAAACACCCCAAATCCACAGTTTGAAGGACAAACGAAGACCAAATTGGGA AATAG¢GAAGTGGTCAAGATTACCAATCGCCTCTTCAGTGAAGCCTTCTCCGATTTCCTCATGGAAAATC M CACAGATTGCCAAACGTATCGTAGAAAAAGGAATTTTGGCTGCCAAGGCTCGTGTGGCTGCCAAGCGTGC GGTGAGTCACACGTAAAÁAATCTGGTTTGGAAATTTCCAACCTTCCAGGGAAACTAGCAGACTGTTCT
TCTAATAACCCTGCTGAAACAGAACTCTTCATCGTCGAAGGAGACTCAGCTGGTGGATCAGCCAAATCTG
GTCGTAACCGTGAGATTTCAGCTATCCTTCCAATTCGCGGTAAGATTTTGAACGTTGAAAAAGCAAGTAT
GGATAAGATTCTAGCTAACGAAGAAATTCGTAGTCTTTTCACAGCCATGGGAACAGGATTTGGCGCAGAA
TTTGATGTTTCGAAAGCCCGTTACCAAAAACTCGTTTTGATGACGATGCCGATGCAGTGCAGAGCCCACA TEGTACCCTTCTTTAACCTTGATTTATCGTTATATGAAACCAATCCTAGAAGCTGGCTATGTTTATATTG CCAACCACCAATCTATGGTGTCAAGGTTGQAAGCGAGATTAAAGAATATATCCAGCCGGGTGCAGATC TANGGIGCTAGGTGAAATGGACGATCATCAGCTGTGGGAAACAACCATGGATCCCGAACATCGCTTGAT GGCTAGAGTTTCTGTAGATGATGCTGCAGAAGCAGATAAAATCTTTGATATGTTGATGGGGGATCGAGTA GAPCCTCGTCGTGAGTTTATCGAAGAAAATGCTGTCTATAGTACACTTGATGTCCTCGAGCACCACCACC ACCACCACTGA

2 CR65 ("homologue of SEQ ID NO. 61",
ATGGANTTACTGAAGAAACAGTACGTTTAAATTGGACGATTCCAATAAAAAAGAAATTAGCGAAACTT
TÜACAOATGTTTATGCTTCGTTGAACGATAAGGGTTACAACCCAATTAACCAAATCGTAGGTTACGTATT
GAGTGGACACCCTGCCTACGTTCCTCGTTATAATAATGCACGAAATCAAATCCGTAAGTATGAGCGTGAT
GAAATCGTTGAGGAATTGGTTCGCTACTATCTCAAAGGACAAGGAGTCGATCTACTCGAGCACCACCACC
ACCACCACTGA

2 CM66 (!homologue of SEQ. ID NO...62)"

ATGGTCAACTATCCACATAAAGTTTCATCACAAAAAAGACAAACATCTCTTTCTCAACCCAAAAATTTCG
CAAATCGAGAATGTCTTTTGAAAAGATGATCAATGCTACCAACGACTACTATTTGTCTCAGGGCTTGGC
TGTTATACATAAGAAACCAACTCCTATTCAAATCGTACAAGTGGACTATCCACAACGAAGTCGTGCCAAG
ATTGTTGAAGCCTATTTTCGACAAGCTTCAACGACGGACTATTCTGGCGTTTATAATGGATATTACATCGA
CTTTTGAAGTCAAGGAAACCAAAAAACGTGCGATTCCGATGAAAAATTTTCATCCACATCAGATTCAG
CATATGGAACAAGTCCTTGCCCAACAAGGAATCTGCTTTGTCCTTCTTCACTTTTCTTCTAGGCAAGAAAC
CTACTTATTGCCGGCATTCGATTTGATTCGCTTCTATCATCAAGATAAGGGACAAAAAATCAATGCCACTTO
AATATATTCGABAATATGGATATGAAATCAAGGCTGGTGCCTTCCCTCAAATTCCTTATCTCAATGTTATC
AAAGAACATTTATTAGGTGGTAAAACAAGACTCGAGCACCACCACCACCACCACCACCACCACTGA

2CFE 7 "homologue of SEQ. ID NO. 63"

2 CFE 67 homolyue of SER DNO: 63

- 2 CFE76 "homologue of SEQ. ID NO. 66"
 ATGITAMATCAGAMAACAATCACGTTATCAMATGITAMATGAGAATTGTCCTTCCTATTGGAAGGCG
 AAACCAATGITTTGGCTAATCTTTCCAACGCCAGTGCTCTCATAAAATCACGTTTTTCCTAATACCGTATTT

 OCAGCCTTTTATTTGTTCGATGGAAAGGAATTGGTTTTAGGCCCCTTCCAAGGAGGTGTTTCCTGCATCCG
 TATTGCACTAGGCAAGGGTGTTTGTGGTGAGGCACCTCACTTTCAGGAAACTGTTATTGTTGGAGATGTG
 ACCACCTATCTCAACTATATTTCTTGTGATAGTCTAAGAGTGAAAATTGTGGTGCCGATGATGAAGA
 ATGGTCAGTTAGTTGGAGTTCTGGATCTGGATCTTCAGAGATTGAGGATTACGATGCTATGGATCGAGA
 TTATTTGGAACAATTTGCCGCTATTTTGCTTGAAAAAGACAACATGGGACTTTACGATGTTTGAGGAAAAA
 TCTCTCGAGCACCACCACCACCACCACCACTGA
- 2 CRETI "homologue of SEQ. ID NO. 67"

 ATGRICA TOGALICA T

2 CFE 71 (contd)

TACGGÉAACAGTTGGGACTGGATCAAGTTCTTCTCATGCCTGAATACCAACCTCCTCACGTTGATAAAAA

6 GAAACCATCCCTGAACACCATCGTCTCAAGATGCTTGAGTTGGCAATTGAGGGGATTGACGGCCTAGTC

ATTGAAACCATTGAGTTGGAGCGCAAGGGTATTTCCTACACCTACGATACCATGAAGATTTTGACAGAGA

AGAATCCAGATACGGATTATTACTTTATCATCGGTGCCGACATGGTTGACTATCTGCCTAAGTGGTACCG

AATTGATGAACTGGTTGACATGGTTCAGTTTGTGGGGGGTTCAGCGTCCACGCTACAAGGTAGGGACTTCC

TATCCAGTTATCTGGGTGGACGTACCGCTCATGGATATCTCGTCCAGCATGGTGCGGGACTTCCTTGCCCA

AGGTCGGAAACCCACCACTTTCTCCTACCTCAGCCAGTGCTAGACTACATCGAGAAGGAGGGGCTCTACCTC

GAGCACACCACCACCACCACTGA

CCTTGTGTTGGTATCCTTGTCCCTTTTCGTAGTTGGTCAAAACTTAGCGGATGCTAGTGATCCACGTACAC ATAGAÇICGAGCACCACCACCACCACTGA 。 2 CFE79 "homologue of SEQ. ID NO. 75" ATOTATAACCTATTATTAACCATTTTATTAGTATTATCTGTTGTGATTGTGATTGCAATTTTCATGCAACCA OTTTTGAAGCTGTAATGCAGCGTTTGACAGGGATTTTAGTCTTTTCTGGCTAGCCATTGCCTTAGCATTG 2 CFE80 "homologue of SEQ. ID NO. 76" ATOTTT GTAGAAATAAATTATTTTTTT GGACCACAGAAATTTTACTCTTAACCATCATCTTTTACCTATGG AGACAGATGGGATCTTTGATTAACCCTTTTGTTAGCGTGCTTAATACAATTATGATTCCATTTTTATTAGG TG\$TATTTAATTACCTTGTGTACTTTGGTCTGGGGAATGGTCATAGGTGTTGTCTATCTCTTACCTATTTT GATTAATCAGFTATCTAGTTTGATTATATCTAGTCAAACTATTTATAGTCGAGTACAAGACTTAATCATAG ACTTATCTAATTATCCTGCGCTCCAGAATTTGGATGTAGAAGCTACAATTCAGCAGTTAAACTTATCCTAT TACTGTTTTGATTTTTGATTATGACTCCAGTTTTTTTTGGTTTATTTCTTATTAGATGGACATAAATTCTTGCCC AT CTT GAAA GAACGATTCTAAAGAGGGATCGCTTGCATATTGCAGGCTTATTAAAGAATTTAAATGCGA CGATTGCTCGCTATATTACTGCAGTTCCGATTGACGCAATCATTATAGGTTGTTTGGCTATATTGGCTAT AGGATTATTGGTTTAAAATATGCTTTAGTTTTTTGCCATTTTTTCTGGTGTAGCCAATTTAATTCCTTATGTG GGGCCAAGTATTGGTTTGATTCCTATGATCATCGCAAATATATTCACTGATCCCCATAGACTGCTGATTGC AG GAT TATATGCTTGTTGTTCAGCAGGTAGATGGCAATATCTTATATCCTCGAATTGTAGGAAGTGTTA TO A AGGIT CATCCAATCACGATTTTAGTTTTACTTTTGTTGTCAAGCAATATCTATGGTGTAGTTGGAATO ATTGTCCCAGTGCCAACCAATTCTATCTTGAAAGAAATTTCTAAGTTCTTATCCCGTTTGTATGAAAATCA "homologue of SEQ. ID NO. 77" CTAAGACTCTIJAAACAAGCGGTGGAGCAAGAGAAAATAAGTCACGCTTATCTTTTTTCTGGTCCTCGTGG ACCTTOCAATAACTGCTATATTTGTCAAGCAGTGACGGACGGTAGTTTAGAAGATGTCATTGAAATGGAT GC/GCT-CTAATAATGGGGTAGATGAAATTCGCGAAATTCGTGATAAATCTACCTATGCGCCTAGCCTTG CTCGTTATAAGGTTTATATCATAGATGAGGTTCACATGCTGTCTACAGGGGCTTTTAATGCCCTCTTAAAG ACCCTGCAAGAACCAACACAGAATGTAGTCTTTATTTTGGCCACTACTGAATTGCACAAGATTCCTGCTA GOTIGGA TIGCGGGACGCCTTGTCTATTTTGGATCAAGCCCTGAGTTTGACACAGGGAAATGAGCTGACGA CTOCTATCTCTGAAGAAATTACTGGCACCATTAGCCTACCAGCCTTGGATGATTATGTGGCGGCCTTGTCT CAACAGGATGTTCCCAAAGCTTTGTCTTGCTTGAATCTTCTTTTTGACAATGGTAAGAGCATGACTCGTTT TOTPACCIGATCTTTTGCACTATTTAAGAGACTTGTTAATTGTTCAAACAGGGGGAGAAAATACTCATCAT AGTICACTCTTTGTAGAAAATTTGGCACTTCCTCAAAAAAATCTGTTTGAAATGATTCGCTTAGCAACAGT GAAATCAAGTCCGAACCAGCTCTATCAGGAGCGGTTGAAAATGAAATTGCTACGCTGAGACAGGAAGTT GCCGTCTCAAACAAGAGCTTTCTAATGTAGGTGCGGTTCCTAAACAAGTTGCACCAGCTCCTAGTCGAC

2 CFE 2 "homologue of SEO. ID NO. 78"
ATELTIC GATTACCAATAAGTTAGCGGTATCGAACTTGATTAAAAACCGCAAACTCTACTATCGTTTTGC GCTGGCTGTTCTCTTGGCAGTCACTGTCACCTATCTCTTTTACTCTCAACCTTCAATCCTAAGATTGCGGA AATCCTTGAGGAACAACCATTCAGGCTACACTTGGATTTGGTATGTTTGTCGTCACCCTTGCGTCAGCC ATTATCGTTCTCTATGCCAATAGTTTTGTCATGAAGAACCGTTCCAAGGAACTAGGAATTTATGGCATGTT GGGCTTGDAGAAGCGTCATCTTATCAGTATGACCTTTAAGGAGTTAGTGGTATTTGGGATTCTAACTGTTG GAGCGGCTATCGGTATTGGAGCCTTGTTTGACAAGTTAATTTTCGCTTTCCTGCTCAAACTAATGAAATTG

GGTGGGGGGACAGCTCTGCCTCGAGCACCACCACCACCACCACTGA

AAATCCTGATTTAGCACGTCAAAATTTAATTCGTTTGCAGAATGCCTGGGGAGAGGTAATTGAAAGTCTA

2 CFE 82 (contd)

CCTAGGCCTCATGTTCCTGAATGCCCTTCGAATCGCCCGTATGAATGCCCTCCAGCTCTCTCGTGAGAAA(CTAGTGGAGAAAAAAGGTCGCTTCCTTCCTCCAAACCATTCTTGGTTCCATAAGTTTAGGAATTGG CT/TTA/CTTGCCCTTACGGTAAAAGATCCTCTTACAGCCTTAACAACCTTCTTCATAGCTGTTTTACTGGT TATCTTIGGGACTTATCTCTTGTTTAATGCAGGGATTACCGTTTTCCTCCAAATCTTAAAGAAAAATAAGA AATACTATTACCAACCAAATAACCTCATATCTGTTTCTAACTTGATTTTCCGTATGAAGAAAAATGCAGTT GGACTAGCCACCATCGCTATCTTGTCAACAATGGTTTTGGTAACCATGTCAGCAGCGACAAGCATTTTCA ATTCCTCAGAAAGCTTTAAAAAAGTTCTAAATCCTCATGATTTTGGGGTTTCAGGGCAAAATGTTGAAAA ATTCGTTACACTTACTTTGCTGTTGCGAATCAAGAAGGAACCAAGTTAACTATTTTTGAAAAAGGACAA AACCGTGTCCAACCAAAAACAGTTTTCATGGTATTTGACCAAAAAGATTATGAAAATATGACTGGTCAAA AACTOTICTCTATCAGGAAATGAGGTCGGACTCTTTGCAAAGAATGAGGGGGGTTAAAGAACAGAAAGCTC TAACTCHAAATGATCATCAATTTTCTGTAAAAGAAGAATTTACTAAAGATTTTATTGTCAACCATGTTCCA A AATCACTTTAATATTTTGACTGCTGATTACAATTACCTTGTTGTACCTGATTTACAAGCCTTTTTGGATCAA TTCCAGATTCGGCTATCTATAATCAGTTTTACGGTGGTATGAATGTAAATGCCAGTGAAGCAGAACAAC
TCAAGGTCGCTGAGGAGTATGAAAAATACTTACAAAAGTTTAATGCTCAATTAAACACTGAAGGTAACTA TGTGTATGGTAGCACTCTAGCAGATGCTAGTGCTCAGATGAGTGCCCTCTTTGGTGGTGTCTTCTTTATCG TATGAAGACCGTGAGCGCTTTATTATCTTGCAGAAAGTCGGTTTAGATCAAAGCAAATCAAGCAAACCA TOJACAJACAGGTTTTAACTGTATTCTTCCTTCCTTTGCTCTTTGCCTTCCTACATCTAGCCTTTGCCTACC ATATGCTTAGTCTGATTTTAAAAGTGATTGGTGTACTGGATACGACTATGATGTTGATTGTGACCTTGTCTATTGCGCTACCATGCCTATGTCTCATGCCTATGTCTCATGCCTATGTCTCATGATTTTCATGATTACTTCAAGAAGTTATCGCAAGATTGTCTCAAAAAGCTCCGAGCACCACCACCACCACCACTGA

2 CKES "homologue of SEQ.: ID NO. 81"

ATGGTAGTATTTACAGGTTCAACTGTTGAAGAAGCAATCCAGAAAGGATTGAAAGAATTAGATATTCCAA
GAAIGAAGGCTCATATCAAAGTCATTTCTAGGGAGAAAAAAGGCTTTCTTGGTCTATTTGGTAAAAAACC

2 CFE 85 (conta)

AGCCAAGTGGATATTGAAGCGATTAGTGAAACGACTGTTGTCAAAGCAAATCAACAGGTAGTAAAAGG
CGTTCCGAAAAAAATCAATGATTTGAACGAGCCTGTGAAGACGGTTAGTGAAGAAACCGTTGACCTTGGT
CATGTGGTTGATGCTATTAAAAAAAATAGAGGAAGAAGGTCAAGGTATTTCTGATGAAGTCAAGGCTGAA
ATCTTAAAACATGAAAGACATGCCAGCACTATCTTAGAAGAAACTGGTCACATTGAGATTTTAAATGAAC
TTCAAATCGAGGAAGCGATGAGGGAAGAAGCAGGCGCTGATGACCTTGAAACTGAGCAAGACCAAGCTG
AAAGTCAAGAACTAGAAGACTTGGGCTTGAAAGTTGAAACGAACTTTGATATTGAACAAGTAGCTACGG
AAAGTCAAGAACTAGAAACGATTATTGATGACATGATGTTGAGGCTACACTTTCAAATGATTATAA
CCGTCGTAGCATCAATCTACAAATTGACACCAACGAACCAGGTCGTATTATCCGGCTACCATGGTAAAGTC
TTGAAGGCCTTGCAACTGTTGGCTCAAAATTATCTTTTACAACCGCTATTCCAGAACCTTCTACGTTACAAT
CAATGTCAATGATTATGTCGAACACCGTGCAGAAGTCTTGCAGACCTTCTACGTTACCATCGT
CTTTCGAAGAAGGGCGCAGTCATAAAACAGATCCAATGTCAAATAGCGAACGCAAGATTATCCATCGT
ATTATTCACGTATGGATGGCTGACTAGTTACTCTGAAGGTGATGAGCCAAAATTCGCTATGTTGTAG
ATATTTCACGTATGGATGACCACCACCACCACCACCACCACGACGAAGATTATCCTTGTAG

2 CFT86 (homologue of SEQ. ID NO. 82"
ATGTCAAATTTTGCCAATTTTTAGCAGCGGGTAAAGGGACTCGCATGAAATCTGATTTGCCAAAAGTTTT CCATATGAATGATAAAAATGTGGCCACTATCTTGACTGCTGAAACGGATAATCCTTTTGGCTATGGACGA at git getaat gacaat get gaggt tett egtat tett gagcagaaggat get acagat tit gaaaagc CAATACCAATAACGCTCAAGGCGAATACTATATTACAGACGTCATTGGTATTTTCCGTGAAACTGGTGAAAAGTTTGGCGCTTATACTTTGAAAAGATTTTGATGAAAGTCTTGGGGGTAAATGACCGTGTGGCGCTTGCGA CAGCTGAGTCAGTTATGCGTCGCCATCAATCATAAACACATGGTCAACGGTGTTAGCTTTGTCAATCC AGAAGGAACTTATATCGATATTGATGTTGAGATTGCTCCGGAAGTTCAAATCGAAGCCAATGTTATCTTG AAAGGGCAAACGAAAATTGGTGCTGAGACTGTTTTGACAAACGGTACTTATGTAGTGGACAGCACTATC GGAGCAGGAGCGGTCATTACCAATTCTATGATTGAGGAAAGTAGTGTTGCAGACGGTGTGACAGTCGGT CCTTATCCTCACATTCCTCCAAATTCAAGTCTGGGTGCCCAAGTTCATATTGGTAACTTTGTTGAGGTGAA AGGATCTTCAATCCGTGAGAATACCAAGGCTGGTCATTTGACTTATATCGGAAACTGTGAAGTGGGAAGC AAGGTT/ATTTCGGTGCTGGAACTATTACAGTCAACTATGACGGCAAAAACAAATACAAGACAGTCATTG GAGACAATGTCTTTGTTGGTTCAAATTCAACCATTATTGCACCAGTAGAACTTGGTGACAATTCCCTCGTT GGTGCTGGTTCAACTATTACTAAAGACGTGCCAGCAGATGCTATTGCTATTGGTCGCGGTCGTCAGATCA ATAAAQACGAATATGCAACACGTCTTCCTCATCATCCTAAGAACCAGCTCGAGCACCACCACCACCACCA CTCA

2 CFE87. "homologue of SEQ. ID NO. 83"
ATCTCCAAGATTCTAGTATTTGGTCACCAAAATCCAGACTCAGATGCCATCGGGTCATCTGTAGCTTTTGC
CTACCTTCCAAAAGAAGCTTACGGTTTGGATACGGAAGCTGTTGCCCTTGGAACTCCAAATGAAGAAACA
GCCTTTGTCTTGAACTATTTTGGTGTGGAAGCACCACGTGTTATCACTTCTGCCAAAGCAGAGGGGCAG
AGCAAGTTATCTTGACTGACCACAATGAATTCCAACAATCTGTATCAGATATCGCTGAAGTAGAAGTTTA
CGGTTTGTAGACCACCACCGTGTGGCTAACTTTGAAACTGCAAGCCCACTTTACATGCGTTTGGAGCCA
GTTGGATCAGCGTCTTCAATCGTTTACCGTATGTTCAAAGAACATGGTGTAGCTGTGCCTAAAGAGATTG
CAGGTTTDATGCTTTCAGGTTTGATTTCAGATACCCTTCTTTTGAAATCACCAACAACACCCCAACAGAT
AAATCATTGCTCCTGAATTGGCTGAATTGGCTGGTGAAAACTTGATGACATCGATGCTAAGACTTTTGAACT
CAACGAAATAATGTCCGTGTTGCCCAAGTGAACACACACTCGATGCTAAGACTTTTGAACT
CAACGAAATAATGTCCGTGTTGCCCAAGTGAACACACACTCGATGCTTTTGTCTTGATGATTACAG
AAATTGAAGCTGCAAATCCAGAAATATTGGCTCTTGGTGCCAATATGGACAAGGTCGAAGCGCCTATCAA
TTTCAAACTTGAAAACAATCATGCCTTCCTTGCTGGTGCCAATATGGACAAGGTCGAAGCGCTTTCAA
TTTCAAACTTGAAAACAATCATGCCTTCCTTGCTGGTGCCAATATGGACAAGAAACAAGTGGTACCTCAAT
TAACTGAAAGCTTTAATACGCTCGAGCACCACCACCACCACCACCACCACTGA

2 CFESS "homologue of SEQ. ID NO. 84"
ATGATITCAAADAGATTAGAATTGGTAGCTTCCTTTGTGTCACAGGGGGCTATTTTACTAGATGTGGGAA
GTGACCAGGCTTATCTGCCTATCGAGTTGGTTGAGAGAGGGCCAAATCAAAAGCGCTATTGCAGGTGAGGT

2CFE 88 (contd)

2 CFE90 "homologue of SEQ. ID NO. 86"
ATQAAATCGAGTAGTGGTAACAGGTTATGGAGTAACATCTCCAATCGGAAATACACCAGAAGAA TTIIIGGAATAGTTTAGCAACTGGGAAAATCGGCATTGGTGGCATTACAAAATTTGATCATAGTGACTTTG ATCTGCATAATGCGGCAGAAATCCAAGATTTTCCGTTCGATAAATACTTTGTAAAAAAAGATACCAACCG TITIGATAACTATICTTTATATGCCTTGTATGCAGCCCAAGAGGCTGTAAACCATGCCAATCTTGATGTAG A GCTCTTAATAGGGATCGTTTTGGTGTTATCGTTGCATCTGGTATTGGTGGAATCAAGGAAATTGAAGA TCAGGTACTTCGCCTTCATGAAAAAGGACCCAAACGTGTCAAACCAATGACTCTTCCAAAAGCTTTACCA AATATGGCTTCTGGGAATGTAGCCATGCGTTTTGGTGCAAACGGTGTTTGTAAATCTATCAATACTGCCTG CICITICALCAANTGATGCGATTGGGGATGCCTTCCGCTCCATTAAGTTTGGTTTCCAAGATGTGATGTTGG TGGGAGGAACAGAAGCTTCTATCACACCTTTTGCCATCGCTGGTTTCCAAGCCTTAACAGCTCTCTACT ACAGAGATCGAACTCGTGCTTCGATCCCATTTGATAAGGATCGCAATGGGTTTGTTATGGGTGAAGGTTCAGGGATGTTGTTCTAGAAAGTCTTGAACACGCTGAAAAACGTGGAGCTACTATCCTGGCTGAAGTGGT TGTTACGGAAATACTTGTGATGCCTACCACATGACTTCTCCACATCCAGAAGGTCAGGGAGCTATCAAG GCCATCAAACTAGCCTTGGAAGAAGCTGAGATTTCTCCAGAGCAAGTAGCCTATGTTAATGCTCACGGAA CCTCAACTCCTGCCAATGAAAAAGGAGAAAGTGGTGCTATCGTAGCTGTTCTTGGTAAGGAAGTACCTGT ATCATCAACCAAGTCTTTTACAGGACATTTGCTGGGGGCTGCGGGTGCAGTAGAAGCTATCGTCACCATCGAAGCTATGCGTCAAACTTTGTACCAATGACAGCTGGGACAAGTGAAGTATCAGATTATATCGAAGCTA ATCTCGTFTATGGACAAGGTTTGGAGAAAGAAATTCCATACGCTATTTCAAATACTTTTGGTTTTGGAGGC CACAATCAGTTCTTGCTTTCAAACGTTGGGAGAATAGACTCGAGCACCACCACCACCACCACCACTGA

2CFE 91 (Contd)

COTCCAAAAACTAGATACGATTTTGTCTGGTAAATTGGACGAAGTTGTGGATGCCTTGGTGCTTTATQACC

2CHE92 "homologue of SEq. ID NO. 88" atiggcotacactcttaaacctgaagaagtcggcgtttttgccatcggtggtctaggagaaatcgggaaaa adactiacggaattgaataccaagacgagattatcatcgtcgatgctgggattaaattcccagaagatga CTTGCTTGGTATCGACTATGTCATTCCTGACTACTCTTACATCGTAGACAATATCGACCGCGTCAAGGCTG TAITTTAIGCTGGACCGCTTGCCTTGGCTTTGATCCGTGGGAAACTCGAAGAACACGGCCTCTTGCGCAAC qdcaaactttacgaaatcaaccacaacaccgagttgacctttaaaaatctcaaggcaactttcttagaa CHACTCHATTCCAGAGCCTTTGGGGATTGTCATTCATACTCCTCAAGGGAAAATCGTCTGTACGGGT **CACTITAAGTTCGACTTTACTCCAGTTGGAGAACCTGCGGACTTGCATCGTATGGCTGCGCTTGGTGAAG** AAGGCGTGCTCTCTCTCTCTGACTCGACAAATGCGGAAGTACCAACCTTTACCAACTCTGAAAAAGT CCTTGCTCAGTCCATTATGAAGATTATCCAAGGTATTGAAGGACGTATCATCTTTGCATCCTTTGCCTCAA ATATCTTCCGTCTCCAGCAGCAACAGAAGCTGCTGTTAAGACTGGACGCAAGATTGCGGTCTTTGGTCG TIPETATOGAAAAGGCCATTGTCAACGGAATCGATCTTGGCTACATCAAAGCTCCTAAGGGAACCTTTATC **GAUCCHAATGAAATCAAAGATTATCCTGCAGGAGAAGTTCTTATCCTCTGTACAGGTAGTCAGGGTGAGC** CTATGGLAGCCCTCTCTCGTATCGCCAACGGAACCCACCGTCAAGTACAATTACAACCAGGTGATACCGT TAPCPTOTTCTAGTCCCATCCCTGGAAACACTACTAGCGTCAACAAGCTGATTAACATCATTTCTGAAG CTBOTOTCGAAGTTATCCACGGTAAAGTGAACAATATCCATACATCTGGACACGGTGGCCAGCAAGAGC 🔊 AAAAAGTCATGCTCCGCTTGATTAAGCCAAAATACTTCATGCCTGTCCACGGTGAATACCGCATGCAAAA AGICCAPGCTGGACTAGCAGTGGATACTGGTGTTGTGAAGGACAATATCTTTATCATGAGCAATGGCGAT GT PCTT PCCCTTACTGCTGACTCAGCTCGTATCGCAGGTCATTTCAACGCCCAAGATATCTATGTCGATGG CTAGCABTCGCAACTGTTGACTTCAAATCGCAGATGATTCTGTCTGGCCCAGATATCCTCAGCCGAGGCT TTOTTCTACATGAGAGAGTCTGGAGACTTGATTCGCCAAAGCCAGCGTATCCTCTTCAATGCCATTCGTATC GCACTGAAAATAAGGATGCTAGCGTGCAATCTGTCAA~~ TCTATGAAAATACCGAACGTGAACCGATCATCATCCCG/ CCACCACCACCACTGA

2 CFE94

ATGGCTACGGCAACAAAAAAGAAAAAAATCAACAGTTA/ AAGGCCAAGACGATTGAAAAATATCTAGGCAGAAACTACAAGGTTTTAGCCAGTGTCGGGCATATCCGT GATTTOAAGAAATCCAGTATGTCCGTCGATATTGAAAATAATTATGAACCGCAATATATTAATATCCGAG GAAAAGCCCTCTTATCAATGACTTGAAAAAAGCTAAAAAAGCTAATAAAGTTTTTCTCGCGAGTO ACCCGGACCGTGAAGGAGAAGCGATTTCTTGGCATTTGGCCCATATTCTCAACTTGGATGAAAATGATGC CAACCGTGTGGTCTTCAATGAAATCACCAAGGATGCAGTCAAAAATGCTTTTAAAGAACCTCGTAAGATC GATATGGACTTGGTCGATGCCCAACAAGCTCGTCGGATCTTGGATCGCTTGGTAGGGTATTCGATTTCGC CTATTTTTTGGAAGAAGGTCAAGAAGGGCTTGTCAGCAGGTCGCGTTCAGTCCATTGCCCTTAAACTCAT CATTGACCTCAAAATCAATCCCTTCCAGCCAGAAGAATACTGGACAGTTGATGCTGTCTTTAAA AAGGAACCAAACAATTTCATGCTTCCTTCTATGGAGTAGATGGTAAAAAGATGAAACTGACCAGCAAT AAGGAAGTCAAGGAAGTCTTGTCTCGTCTGACGAGTAAAGACTTTTCAGTAGATCAGGTGGATAAGAAA ATTICCGTACTCGAAAAACCATGATGGTTGCCCAACAGCTCTATGAAGGAATTAATATCGGTTCTGGTGT TCAAGGTTTGATTACCTATATGCGTACCGATTCGACTCGTATCAGTCCTGTAGCGCAAAATGAGGCGGCA AGGTTCATTACGGATCGTTTTGGTAGCAAGTATTCTAAGCACGGTAGCAAGGTCAAAAACGCATCAGGTG CTCAGGATGCCCATGAGGCTATTCGTCCGTCAAGTGTCTTTAATACACCAGAAAGCATCGCTAAGTATCT GGACAAGGATCAGCTCAAGCTATATACCCTTATCTGGAATCGTTTTTGTGGCTAGCCAGATGACAGCGGCC GTTTTGATACCATGGCTGTTAAATTGTCTCAAAAAGGGGTTCAATTTGCTGCCAATGGTAGTCAGGTTAA GTTTGATGGTTATCTTGCCATTTATAATGATTCTGACAAGAATAAGATGTTACCGGACATGGTTGTTGGAG ATGTGGTCAAACAGGTCAATAGCAAACCAGAGCAACATTTCACCCAACCGCCTGCCCGTTATTCTGAAGCAACACTGATTAAAACCTTAGAGGAAAATGGGGTTGGACGTCCATCAACCTACGCGCCAACCATTGAAAC CATTCAGAAACGTTATTATGTTCGCCTGGCAGCCAAACGTTTTGAACCGACAGAGTTGGGAGAAATTGTCAAAACGTCACAGCTGAAATGGAAGGTAAACAACGTGACCTTCACAGCTGAAATGGAAGGTAAAC TGGATGATGTCGAAGTCGGAAAAGAGCAGTGGCGACGGGTCATTGATGCCTTTTACAAACCATTCTCTAA

1 JCFE 94 (contd)

"homologue of SEQ. ID NO. 91" 2 CFE95 ATTITITITITE ATCACTOCTOGGA ATTOTGA CATTTTACTA ACTITACTA GOA ATTCCGGCCTTTATCCA **ATTITATAGAAAGGCGCAAATTACAGGCCAGCAGATGCATGAGGATGTCAAACAGCATCAGGCAAAAGC** ACITAGCCAATICAGCAATAATGTGGGAATGATTTTGTTCATCTTGGTCTTGTATGGCTTGGTCGGATTTTT AGIATO ACTITUTO CAAGGTOTTTO GTAAAAT CAATO AGGGGOOTTAAT COTAAGCAAAAATTAGOTOTTCAG CITCATTTGGGATTTTTCTATATTTTCTTCGCTCTTTTCTGGCTAGTCGGTTTTTCAAACGCAGTAAACTTG TO GCA AGGTCAGA TGG ATATTCTTCTAGTGATTCTTGCCATGATTGGTGGTTTGCTCGGTTTCTTCATCTT TALCCATAAGCCTGCCAAGGTCTTTATGGGTGATGTGGGAAGTTTGGCCCTAGGTGGGATGCTGGCAGCT AFETCT/TGGCTCTCCACCAGGAATGGACTCTCTTGATTATCGGAATTGTGTATGTTTTTGAAACAACTTC TGTTATGATGCAAGTCAGTTATTTCAAACTGACAGGTGGTAAACGTATTTTCCGTATGACGCCTGTACATC ACCATTTGAGCTTGGGGGATTGTCTGGTAAAGGAAATCCTTGGAGCGAGTGGAAGGTTGACTTCTTCTT TTGGGGAGTTGGTCTTCTAGCAAGTCTCCTGACCCTAGCAATTTTATATTTGATGCTCGAGCACCACCACC ACCACCACTGA

"homologue of SEQ. ID NO. 92" AT&GCACGCGAATTTTCACTTGAAAAAACTCGTAATATCGGTATCATGGCTCACGTCGATGCCGGTAAAA CAACAACTACTGAGCGTATTCTTTACTACACTGGTAAAATCCACAAAATCGGTGAAACTCACGAAGGTGC GŤ¢ACAÅATGGACTGGATGGAGCAAGAGCAAGAACGTGGTATCACGATCACATCTGCTGCGACAACAGC TCAATGUAACAACCACCGCGTAAACATCATCGACACACCAGGACACGTGGACTTCACAATCGAAGTACA ACCTTCCTCCTCTATTGGATGGTGCGGTTACCGTTCTTGACTCACAATCAGGTGTTGAGCCTCAAACTG AAACAGTTTGGCGTCAAGCAACTGAGTACGGAGTTCCACGTATCGTATTTGCCAACAAAATGGACAAAAT CCCTTCACGACTTCCTTTACTCTGTAAGCACACTTCACGATCGTCTTCAAGCAAATGCACACCCAATCCAAT TOOCANTCOOTTCTGAAGATGACTTCCCTGGTATCATTGACTTGATCAAGATGAAAGCTGAAATCTATAC TAACGAGCTTGGTACGGATATCCTTGAAGAAGACATCCCAGCTGAATACCTTGACCAAGCTCAAGAATAC CCTGAAAAATTOATTGAAGCAGTTGCTGAAACTGACGAAGAATTGATGATGAAATACCTCGAAGGTGAA GAAATCACTAACGAAGAATTGAAAGCTGGTATCCGTAAAGCGACTATCAACGTTGAATTCTTCCCAGTAT TGT|GTGGTTCAGCCTTCAAAAACAAAGGTGTTCAATTGATGCTTGATGCGGTTATCGACTACCTTCCAAGT CCACTTGACATCCCAGCAATCAAAGGTATTAACCCAGATACAGACGCTGAAGAAATTCGTCCAGCATCTG ACQAAQAGCCATTTGCAGCTCTTGCCTTCAAGATCATGACTGACCCATTCGTAGGTCGTTTGACATTCTTC CGIGTT ACTCAGGTGTTCTTCAATCAGGTTCATACGTATTGAATACTTCTAAAGGTAAACGTGAACGTAT CGGACGTATCGTTCAAATGCACGCTAACAGCCGTCAAGAAATCGACACTGTTTACTCAGGTGATATCGCT GCTGGCTTTGGAAAGATACTACAACTGGTGACTCATTGACAGATGAAAAAGCTAAAATCATCCTTG AGICAAIICAAGGTTCCAGAACCAGTTATCCAATTGATGGTTGAGCCAAAATGTAAAGCTGACCAAGACAA GCTGAAACAGTTATCTCAGGTATGGGTGAACTTCACCTTGACGTCCTTGTTGATCGTATGCGTCGTGAGTT CAMAGTIGAAGCGAACGTAGGTGCTCCTCAAGTATCTTACCGTGAAACATTCCGCGCTTCTACTCAAGCA CGCGOAT/TCTTCAAACGTCAGTCTGGTGGTAAAGGTCAATTCGGTGATGTATGGATTGAATTTACTCCAA ACGAAGAAGGTAAAGGATTCGAATTCGAAAACGCAATCGTCGGTGGTGTGGTTCCTCGTGAATTTATCCC AGCGCTTCAAAAAAGGTTTGGTAGAATCTATGGCTAACGGTGTTCTTGCAGGTTACCCAATGGTTGACGTT AAAGCTAAGCT/TATGATGGTTCATATCACGATGTCGACTCATCTGAAACTGCCTTCAAGATTGCGGCTTC ACT||TCC¢TTAA|AGAAGCTGCTHAATCAGCACAACCAGCTATCCTTGAACCAATGATGCTTGTAACAATC **ACTOTTCCAGAGAAAAACCTTGGTGATGTTATGGGTCACGTAACTGCTCGTCGTGGACGTGTAGATGGTA** TGGAAGGACACGGTAACAGCCAAATCGTTCGTGCTTACGTTCCACTTGCTGAAATGTTCGGTTACGCAAC ACTICTECTTCTGCATCTCAAGGACGTGGTACATTCATGATGGTATTTGACCACTACGAAGATGTACCTA

2CFE 96 (costd)

AGICAGTACAAGAGAAATTATTAAGAAAAATAAAGGTGAAGACCTCGAGCACCACCACCACCACCACTG

CFE97 "homologue of SEQ. ID NO. 93"
ATDCCAAATTACAATATTCCATTTTCACCGCCTGATATCACAGAAGCAGAAATTGCTGAAGTAGCGGATA 2 CFE97 CCTTBCBTTCTGGTTGGATCACAACAGGTCCTAAAACAAAAGAACTGGAGCGCCGCTTGTCTCTTTACAC achgadaccthagactgtttgtctcaactctgcgacagccgctctggagttgattttacgcgttttggaag TOPGACTGGTGATGAAGTCATCGTTCCAGCCATGACCTATACGGCTTCATGTAGTGTCATTACGCACGT GGGAGGAACOCCTGTCATGGTGGATATCCAAGCAGATACGTTTGAGATGGACTATGACCTGCTTGAGCAA **CCHATCACTGAGAAAACTAAGGTGATTATCCCAGTAGAGCTCGCAGGGATTGTTTGCGATTATGACCGTT** CTPAITTTACTTCCTTCTCATTCCATGCTGTTAAGAACTTTACAACGGCAGAAGGTGGAAGTGCGACTTGG *a*akgccaatccagtgattgatgacgaagagatgtacaaggaattccaaatcctttcccttcacggcaaa CTAAGGATGCTCTTGCCAAGATGCAACTGGGGTCATGGGAATACGATATCGTTACACCAGCCTATAAGTO CANCATEACCGATATCATGGCTTCACTTGGTTTGGTACAATTGGACCGCTATCCAAGTTTGTTGCAACGCC **GRAGGACATTGTGGACCGCTATGATAGTGGTTTTGCAGGTTCTCGCATCCTTTGGCACACAAGAC** <u>Toaaactgtcgaatcttcacgccacctctacatcacccgtotagaaggagtaaggcctagaagaacgcaac</u> CT¢ATCATCCAAGAATTGGCTAAAGCAGGAATTGCAAGTAATGTTCACTACAAACCGCTTCCTCTTGA CAGCCTATAAGAATCTTGGATTTOATATGACGAACTATCCTAAGGCCTATGCCTTCTTTGAGAATGAAATT ADDETECTETTCATACTAAATTAAGCGATGAAGAAGTAGACTATATCATTGAGACTTTCAAAACAGTTT CTGAAAAAGTOCTAACTTTATCAAAAAAACTCGAGCACCACCACCACCACCACCACTG

2 CFE 02 "homologue of SEQ. ID NO. 98"

ATGGAAATTTCATTATTAACAGATGTTGGTCAGAAACGAACAAATAACCAAGACTATGTCAACCACTATG
TCAATAGAGCTGGACGTACCATGATTATTTTAGCTGATGGGATGGGAGGTCATCGCGCAGGAATATCGC

2 CFE 102 (cordd)

- 2 CFE104 "homologue of SEQ. ID NO. 100"
 ATGTCAAAAGAAATTAAATTTCATCAGATGCCCGTTCAGCCATGGTTCGTGGTGTCGATATCCTTGCAG ACACTGTTAAAGTAACCTTGGGACCAAAAGGTCGCAATGTCGTTCTTGAAAAGTCATTCGGTTCACCCTT GATTACEAATGACGGTGTGACCATTGCCAAAGAAATCGAATTGGAAGACCATTTTGAAAATATGGGTGCT AAGTTAGTATCAGAAGTAGCTTCTAAAACCAATGATATCGCAGGTGACGGGACTACGACCAGTCT TGACCCAAGCTATCGTCCGTGAAGGAATCAAAAACGTCACAGCAGGTGCAAATCCAATCGGTATTCGTCG TGGGATHGAAACAGCAGTTGCCGCAGCAGTCGAAGCTTTGAAAAACAACGCCATCCCTGTTGCCAATAA AGAAGGTATCGCTCAAGTTGCAGCCGTATCTTCTCGTTCTGAAAAAGTTGGTGAGTACATCTCTGAAGCA ATGGAAAAAGITTGCAAAGACGGTGTCATCACCATCGAAGAGTCACGTGGTATGGAAACAGAGCTTGAA GTGGTAGAAGGAATGCAGTTTGACCGTGGTTACCTTTCACAGTACATGGTGACTGATAGCGAAAAAATGGTGGCTGACCTTGAAAATCCGTACATTTTGATTACAGACAAGAAAATTTCCAATATCCAAGAAATCTTGCC ACTITIOGAAAGCATTCTCCAAAGCAATCGTCCACTCTTGATTATTGCGGATGATGTGGATGGCGAGGCTCTTCCAACTCTTGTTTTTGAACAAGATTCGTGGAACCTTCAACGTAGTAGCAGTCAAGGCACCTGGTTTTTGG TGACCGACGCAAAGCCATGCTTGAAGATATCGCCATCTTAACAGGCGGAACAGTTATCACAGAAGACCTT GCTCTTGAGTTGAAAGATGCGACAATTGAAGCTCTTGGTCAAGCAGCGAGAGTGACCGTGGACAAAGAT AGGACGETTATTGTAGAAGGTGCAGGAAATCCTGAAGCGATTTCTCACCGTGTTGCGGTTATCAAGTCAAGTCTCAAGTCTCAAGTCTCAAGTCAAGTCTCAAGTCTCAAGT TGTAGCCGTTATTAAGGTTGGAGCCGCAACTGAAACTGAGTTGAAGAAATGAAACTCCGCATTGAAGA TGCCTCAACGCTACTCGTGCAGCTGTTGAAGAAGGTATTGTTGCAGGTGGTGGAACAGCTCTTGCCAAT GTGATTCCAGCTGTTGCTACCTTGGAATTGACAGGAGATGAAGCAACAGGACGTAATATTGTTCTCCGTG AAAAATGCTGAGCTTGGTATAGGATTTAACGCAGCAACTGGCGAGTGGGTTAACATGATTAATCAAGGT ATCATTGATCCAGTTAAAGTGAGTCGTTCAGCCCTACAAAATGCAGCATCTGTAGCCAGCTTGATTTTGA CAACAGAAGCAGTCGTAGCCAATAAACCAGAACCAGTAGCCCCAGCTCCAGCAATGGATCGAAGTATGA TGGGGGGATGATGCTCGAGCACCACCACCACCACCACCACTGA

2 CTE 105 homologue of SEQ 10 NO: 101 (contd)

AGECATEAGTTTGATTGCCATGGAGTTCTATGGTAATCCACAAGAGAAACTCAAACTCCTTGCCTTTACT GGTACTAAGGGTAAGACAACAGCAACCTATTTCGCCTATAACATCTTATCTCAAGGGCATAGACCTGCTA TATTGACCTCTTTGACATGATGAATCAGGCTGTGCAAAATGACCGTACCCACCTCATCATGGAAGTCTCC TGACCATATCGGCCCGATTGAACACCCTAGCTTTGAAGACTATTTCTACCACAAGCGTCTCTTGATGGAA AATAGCCGAGCAGTCATCATTAACAGTGACATGGACCACTTCTCAGTCTTGAAAGAACAGGTTGAAGATC AA\$ACCATGATTTCTATGGTAGCCAATTTGATAACCAAATCGAGAATTCCAAAGCCTTTAGCTTTTCAGCT ACCOGTA AACTCGCTGGAGATTATGATATCCAACTCATTGGCAACTTCAACCAAGAAAATGCAGTTGCTG CTGGACTTGTCTCCGTCTCGGAGCAAGTCTTGAGGACATCAAAAAAGGCATCGCTGCAACCCGCGT TCTTGGTCGTATGGAAGTCCTCACTCAGAAAAATGGAGCCAAGGTCTTCATCGACTATGCCCACAATGGG GATAGTETGAAAAAACTCATCAATGTGGTTGAAACTCATCAAACCGGAAAGATTGCTCTGGTTCTGGGAT CAACAGDAAACAAGGGAGAAAGTCGTCGTAAGGACTTTGGCCTCCTCCAATCAACACCCTGAGATTC AAGTCTTTCTGACTGCTGATGACCCTAACTATGAAGACCCAATGGCCATTGCAGATGAAATTAGTAGCTA CATCANTCATCCTGTTGAAAAGATTGCGGATCGCCAAGAAGCCATCAAGGCGGCAATGGCTATCACAAA TCACGAATTAGATGCAGTTATTATTGCGGGTAAGGGAGCCGATTGTTACCAAATCATCCAGGGCAAGAAA GA TECTACCEAGGAGATACAGCCGTCGCAGAAAATTATTTACTCGAGCACCACCACCACCACCACCACTGA

2 CFELO6 "homologue of SEQ. ID NO. 102"
ATGATCGAAATCGGCAAGATTTTTGCCGGACGCTATCGGATTGTCAAACAGATTGGTCGAGGAGGCATGG CGGATGTCTACCTAGCCAAAGACTTAATCTTAGATGGGGAAGAAGTGGCAGTGAAGGTTCTGAGGACCA ACTACCAGACGGACCCGATAGCTGTAGCTCGTTTTCAGCGTGAAGCGAGAGCTATGGCAGATCTAGACCA TCGTCATATCCTTCGGATAACAGATATTGGTGAGGAAGACGGTCAACAGTATCTTGCAATGGAGTATCTT GCTGGA¢TAGACCTCAAACGCTATATCAAGGAACATTATCCTCTTTCTAATGAAGAAGCAGTCCGTATCA TGGGACAAATTCTCTTGGCTATGCGCTTGGCCCATACTCGAGGAATTGTTCACAGGGACTTGAAACCTCA ALATATCTTTTGACACCAGATGGGACTGCCAAGGTCACAGACTTTGGGATTGCTGTAGCCTTTGCAGAG ACAAGT CTGACCCAGACTAACTCGATGTTGGGCTCAGTTCATTACTTGTCACCAGAGCAGGCGCGTGGTT CGAAGGCGACTGTGCAGAGTGATATCTATGCCATGGGGATTATTTTCTATGAGATGTTGACAGGCCATAT CCCTTATGACGGGGATAGCGCGGTGACCATTGCCCTCCAGCATTTCCAGAACCCCCTGCCGTCATTTC CAGAAAATTCATCTGTACCTCAGGCTTTAGAAAATGTTATTATCAAGGCAACTGCTAAAAAGKTGACCAA TOGCTATCGCTCGGTTTCAGAGATGTATGTAGACTTGTCTAGTAGCTTGTCCTACAATCGTAGAAATGAAA GTAAGTTAATOTTTGATGAAACGAGCAAGGCAGATACCAAGACCTTGCCGAAGGTTTCTCAGAGTACCTT ACAGGAAACTTACCAACCACAAGCACCGAAAAAACATAGATTTAAGATGCGTTACCTGATTTTGTTGGCC AGCTTGTATTGGTGGCAGCTTCTCTTATTTGGATACTATCCAGAACTCCTGCAACCATTGCCATTCCAGA TGTGGCAGGTCAGACAGTTGCAGAGGCCAAGGCAACGCTCAAAAAAAGCCAATTTTGAGATTGGTGAGGA GAAGACAGAGGCTAGTGAAAAGGTGGAAGAAGGGCGGATTATCCGTACAGATCCTGGCGCTGGAACTGG TCGAAAAGAAGGAACGAAAATTAATCTGGTTGTCTCATCAGGCAAACAATCCTTCCAAATTAGTAATTAT GTCGGCCGGAAATCTTCTGATGTTATCGCGGAATTAAAAGAGAAAAAAGTTCCAGATAATTTGATTAAAA TTGAGGAAGAAGAGTCGAATGAAAGTGAGGCTGGAACGGTCCTGAAGCAAAGTCTACCAGAAGGTACG ACCITATGACITGAGCAAGGCAACTCAAATTGTTTTGACAGTAGCTAAAAAAGCTACGACGATTCAATTAG GGACTATATTGGACGGAACTCTACAGAAGTAATCTCAGAACTCAAGCAGAAGAAGAAGGTTCCTGAGAATT
TGATTAAGATAGAGGAAGAAGAGTCCAGCGAAAGCGAACCAGGAACGATTATGAAACAAAGTCCAGGT GCCGGAACGACTTATGATGTGAGTAAACCTACTCAAATTGTCTTGACAGTAGCTAAAAAAGTTACAAGTG TTOCCATGCCGAGTTACATTGGTTCCAGCTTGGAGTTTACTAAGAACAATTTGATTCAAATTGTTGGGATT AAGGAAGCTAATATAGAAGTTGTAGAAGTGACGACAGCGCCTGCAGGTAGTGTAGAAGGCATGGTTGTT GAACAAAGTCCTAGAGCAGGTGAAAAGGTAGACCTAAATAAGACTAGAGTCAAGATTTCAATCTACAAA CCTAMAACAACTTCAGCTACTCCTGCGGCCGCACTCGAGCACCACCACCACCACTGA

2CFE 107 (contd)

2 CFE109 "homologue of SEQ. ID NO. 105".
ATGACTÁGTCCACTATTAGAATCTAGACGCCAACTCCGTAAATGCGCTTTTCAAGCTCTCATGAGCCTTGA
GTTCGGTACGGATGTCGAAACTGCTTGTCGTTTCGCCTATACTCATGATCGTGAAGATACGGATGTACAA
CTTCCAGCCTTTTTGATAGACCTCGTTTCTGGTGTTCAAGCTAAAAAGGAAGAACTAGATAAGCAAATCA
CTCAGCATTTAAAAGCAGGTTGGACCATTGAACGCTTAACGCTGGGAGAGAACCTCCTTCGCTTGGG
AGTCTTTGAAATCACTTCATTTGACACTCCTCAGCTGGTTGTTAATGAAGCTATCGAGCTTGCAAAGG
ACTTCTCCGATCAAAAATCTGCCCGTTTTATCAATGGACTGCTCAGCCAGTTTGTAACAGAAGAACAACT
CGAGCACCACCACCACCACCACTGA

2 CFELLI "homologue of SEQ. ID NO. 107" ATGACAAAACGTGTAACGATTATTGATGTAAAAGACTATGTTGGTCAGGAAGTGACGATTGGCGCTTGGG TTGCCAACAAATCAGGAAAAGGGAAAAATCGCTTTCTTACAATTGCGTGATGGAACAGCCTTCTTTCAAGGTGGAACTTTTAAACCAAACTTTGTCGAAAAATTTGGTGAAGAAGTTGGGGACTTGAGAAGTTTGATGTTATC AAACGCTTGAGCCAAGAAACGTCTGTTTATGTGACAGGTATTGTCAAAGAGGACGAACGTTCTAAATTTG GCTATGAGTTGGACATCACAGACATCGAAGTGATCGGTGAATCTCAAGACTACCCAATCACACCAAAAG AAGACGGAACAGACTTTTTGATGGATAACCGTCACTTGTGGCTACGCTCTCGTAAGCAAGTAGCTGTGTT GCAAATCCGTAACGCTATTATCTATGTAACTTATOAGTTCTTTGACAAGAATGGTTTTATGAAGTTTGACA GCCCAATTCTTCAGGAAATGCGGCAGAAGATTCTACAGAACTCTTTGAAACTGACTACTTCGGAACGCC AGGCTAGTTGAGCCAATCAGGTCAGCTTTACCTAGAAGCAGGGGCTATGGCTCTTGGTCGTCTTTGACT TGAGTIACTCATACTTGACACATGATGAGTCGCTTGACTTGCAAGAAGCTTATGTGAAAGCTCTTCTACAA GGTGTTCITTGACCGCGCGCCTCAAGCCTTGGAAACCTTGGAACGTGATACAGAACTCTTGAAACGCTACA TTGCAGAGCCATTCAAACGTATCACTTACGATCAAGCCATTGACCTCTTGCAAGAGCATGAAAATGATGA AGATGCTGACTACGAGCATCTTGAGCATGGTGATGACTTTGGGTCACCACGAAACTTGGATTTCAAAC CACITTGGTGTGCCAACATTTGTCATGAACTATCCAGCAGCCATCAAGGCCTTCTACATGAAACCAGTTCC ATCAAACEACTEGAGCACCACCACCACCACTGA

CACCTGAGTGAGAATGTGGTGGGAACTTTTTCTCTGCCTTATTCGCTGGTTCCGGAGGTACTTGTCAACGG TCAGGAATACACCGTTCCCTATGTGACAGAAGAACCCTCTGTGGTTGCGGCGGCCAGCTATGCCAGCAAA ATCATCAGCCTCCAGGTTCTTTACTCCACAAGTCCATCAGCCCCAGATGATTGGCCAGGTAGCCCTTT ATGAAGTTGCTJAATCCTAAACTAGCGCAAGAGAAGATTGCCAGCAAGAAAGCGGAGCTCTTGGAGCTTG CIGTCC/ACTA/CGCGACTGATTCTCTGGTGACTGCAAGCTGTCGCATCGCCTTTCGCTACTTGAGCCGCCA AAAGGA†CAA&GACGAGAGATTGCGGAGAAAATTGCGTTGGCTAGTCAGTTTGCGCAGGCTGATCCTTA CCCAGCTGCTACTCATAATAAAGGAATTTTTAATGGTATTGATGCGATTTTGATTGCCACTGGTAATGACT GGCGTGCCATCGAAGCTGGGGCCCATGCCTTTGCCAGTCGAGATGGACGCTATCAAGGTCTTAGCTGCTG GAGGCTGGACCTTGAAAGAGAAGAATTGGTCGGTGAGATGACCCTGCCCATGCCTGTAGCGACTAAGGG TGGCTGTATCGGCCTCAACCCACGTGTAGCTCTCAGTCATGATCTACTAGGAAATCCTTCTGCCAGAGAAT TACCCAGATTATCGTGTCCATCGGTCTTGCTCAAAATTTTGCAGCCCTCAAAGCCTTGGTAAGTACGGGC aticagiaaggccacatgaaactacaggccaaatccctagctcctagctggggctagtgaatctgaag TTCCTCCCTAGTAGAGCGCCTCATCTCAGATAAAACCTTTAACCTAGAGACAGCCCAGCCCTATCTCGA AAATTTAAGATCAGCGGCCGCACTCGAGCACCACCACCACCACCACTGA

 2CFE 115 (conta)

CCGTGAATGGAATCAAAAATGGGTCGATTTATCTCTCAACTCTTTTGCCGATATTGAAAATAATCTCTTTG AABCABAAGGCTATAACCATTCATTTCGTTTTCTCAAGGCCAGTCATCAAATTGACCAAATTGAGAGTCA *AA*TTACTTTGATTGAAGAAGATATTGCGGCAATTCGCAATGCTTTGGCAGACTTAGAGAAGCAAGAATCT AAAAATAGTGGTCGTGTTCTTCATGCTTTGGATTTATTTGAGGAACTTCAGCATAGAGTTGCTGAAAATTC aghacastatggtcaagccttggatgaaattgaaaaaacaattagaaaatatccaatctgaattttcacaa TTTGTAACCTTGAATTCATCGGGTGACCCTGTGGAAGCCGCAGTGATTTTGGATAATACAGAAAATCACA TTTTGGCCTTA'AGTCATATTGTGGATCGTGTTCCAGCCTTGGTTACGACGCTTTCTACAGAATTGCCAGAT CAATTACAGGATTTGGAAGCCGGTTATCGTAAACTAATTGATGCTAATTATCATTTTGTTGAAACGGATAT TGARGEBOGTTTCCACTTGCTTTATGAAGCATTCAAGAAAAACCAAGAGAATATTCGTCAGTTGGAATTG **GATAATECCGAATATGAGAATGGACAGGCACAAGAGGAAATCAATGCCTTGTATGATATTTTTACTCGAG** AAATTGCTGCTCAGAAAGTAGTGGAAAATCTACTTGCAACTCTCCAACTTACCTTCAACATATGAAAGA GANTAANACTITATTGGGAGAAGATATTGCACGTTTOAACAAGACCTATTTACTTCCTGAGACAGCTGCA AGCATOTTCGTCGTATTCAGACAGAATTAGAGAGTTTTTGAGGCAGCTATTGTTGAGGTAACTTCAAATC *AAAAAGAACCAACCCAAGCTTATTCAGTTCTTGAAGAAAATCTTGAGGATTTACAAACTCAACTAAAAG* ATATTCAAGATGAGCAAATTTCAGTTAGTGAGCGCCTGACACAAATTGAGAAAGATGATATTAATGCAC SGT GAAAAGGCCAATGTTTATGTCAATCGTCTCCATACTATCAAGCGATACATGGAAAAACGCAATCTGCC TT#AGA#ACGGAAACTTATAATATTGTACAATATGCAACTTTGACAGAGCAACTCTTGCAATATTCTAAC CGCTATCGCTCATTTGATGAACGCATTCAAGAAGCATTTAACGAAGCTTTAGATATTTTTGAAAAAGAAT TTGATTATCACGCTTCATTTGACAAGATTTCTCAAGCATTGGAAGTGGCAGAGCCTGGTGTAACCAATCG CTITGTTACCTCATATGAGAAAACACGTGAAACGATTCGTTTTGCGGCCGCACTCGAGCACCACCACCAC CACCACTGA |

2 CFR116 "homologue of SEQ. ID NO.112" ATOCTTATATCTTATÁAATGGTTAÄAAGAATTGGTGGACATTGATGTGCCATCACAAGAGTTGGCTOAAA AAATGT¢AACTACAGGAATCGAGGTAGAGGGTGTCGAATCACCAGCTGCTGGTCTCTCAAAAATTGTCGT CGGTGAGGTCTTGTCTTGCGAAGATGTGCCAGAGACTCACCTCCATGTTTGTCAGGTTAACGTTGGCGAA GAAGAGEGTCAGATCGTTTGTGGTGCCCCAAATGTGCGTGCTGGGATCAAGGTCATGGTGGCTCTTCCAG GAGCTCGTATOGCTGATAACTACAAAATCAAAAAAGGAAAAATCCGTGGTTTGGAGTCACTTGGAATGA TCIGTTCACTTGGTGAATTGGGAATTTCTGACTCAGTTGTGCCTAAGGAATTCGCAGATGGCATCCAAATC TTGCCTGAAGATGCCGTGCCAGGTGAGGAAGTCTTTTCTTACCTAGACTTGGATGATGAAATCATCGAAC TTTCCATCACCAAACCGTGCAGATGCCCTTTCTATGTGTGGAGTGGCTCACGAAGTGGCAGCCATCTA TGACAAGGCAGTCAACTTTAAAGAATTTACTCTAACAGAAACTAATGAAGCTGCGGCAGATGCCCTTTCT GTCAGCATTGAGACAGACAAGGCGCCTTACTATGCAGCTCGTATCTTGGACAATGTGACCATCGCACCAA GTCCACATGCTTCCATCACCAACCATCAATAACCTAGTGGACCTGAC CAACTACATCCTCCTCTATTTTGGTCAACCAATGCATGCCTTTGACTTGGATAACTTTGAAGGGACTGACA TCCGTGTGCGTGAAGCGCGTGCTGGTGAAAAATTGGTGACCTTGGACGTGAAGAACGTGACTTGGACGT GAATGA¢CTAGTCATCACTGTCGCAGACAAGCCAGTAGCCCTTGCAGGTGTCATGGGTGGTCAAGCAACA GAAATCTCTGAAAAATCTAGTCGTGTTGTCCTTGAAGCTGCTGTTTTCAATGGCAAATCTATCCGTAAGAC AAGTGGTCGCCTGAACCTTCGTTCTGAGTCATCTTCTCGCTTTGAAAAAGGAATTAATGTGGCAACAGTT AATGAAGCCCTTGATGCGGCAGCTAGCCTGATTGCGGAACTTGCAGGTGCGACGGTGGGTAAGGGCATC GTTTCAGCGGGTGAGCTTGATACTTCAGATGTAGAAGTTTCTTCAACCCTTGCTGATGTTAACCGTGTCCT CCCAACTGAGCTGTCTTATGCTGATGTAGAAGACGTCTTCCGTCGTCTTTGGCTTTTGGTCTTTCTGGAAATG CACACCACTTACAGTCAGAGTCCCACGTCGTCGTTGGGATATCACAATCGAAGCTGACCTCTTTGAAGA AATTGCTCGTATCTATGGTTATGACCGCTTGCCAACTAGTCTACCAAAAGACGATGGTACAGCAGGTGAA TTGACAGCACACAAAAACTCCGCCGTCAAGTTCGTACTATTGCTGAAGGAGCAGGTTTGACAGAAATCA TCAECTAFACTCTAACAACTCCTGAAAAAGCAGTTGAGTTTACGGCTCAACCAAGTAACCTTACGGAACT CATGTGGCCAATGACTGTGGATCGTTCAGTCCTCCGTCAAAATATGATTTCAGGTATCCTTGATACCGTTG TAATCCAAAAGAAGAACTTCCAAATGAAATCAACAGTTTTGCCTTTGCCTTGACAGGCTTGGTTGCTQAA AAAGATHTCCAAACAGCAGCAGTTCCAGTTGATTTCTTCTATGCTAAGGGAATCCTTGAAGCCCTATTTAC TCGTTTGGGACTCCAAGTAACCTATACAGCAACATCTGAAATCGCTAGCCTTCATCCAGGTCGTACAGCC GTGATT| CACTOGGTGACCAAGTTCTTGGTTTCCTTGGCCAAGTGCATCCAGTCACTGCCAAGGCTTACGA TTTGTAGAAATTCCCGGCAGTCAGCCGTGACGTTGCCCTTCTCCTCAAGGCAGAAGTGACTC

2CFE 116 (conta)

2 CEE177 "homologue of SEO. ID NO. 113"
ATOTTAGAAAACGATATTAAAAAAGTCCTCGTTTCACACGATGAAATTACAGAAGCAGCTAAAAAACTA
GCTGCTCAATTAACTAAAGACTATGCAGGAAAAAATCCAATCTTAGTTGGGATTTTAAAAGGATCTATTC
CATGGTGGAACGAAGTAGTGGTGTATACAATATTAAACAAGATGTGCTCAAGATATCAAAGGAAGA
CATGTTTATTTGTAGAAGATATCATTGATACAGGTCAAACTTTGAAGAATTTGCGAGATATCAAAGGAAGA
AAAGAAAGCAGCTTCTGTTAAAATTGCAACCTTGTTGGATAAACCAGAAGTATTGCGAGATATTTAAAG
AGGCAAACTATACCTGCTTTACTATCCCAAATGAGTTTGTAGTAGGTTATTGGTTTAGACTACAAAGAAAA
TTATCGTAATCTTCCTTATATTGGAGTATTGAAAGAGGAAGTGTTTCAAATCTCGAGCACCACCAC

闰

SEQUENCE LISTING

```
<110> Dougherty, Thomas J.
            Pucci, Michael J.
  5
            Dougherty, Brian A.
            Davison, Daniel B.
            Bruccoleri, Robert E.
            Thanassi, Jane A.
 10
      <120> NOVEL BACTERIAL GENES AND PROTEINS THAT ARE ESSENTIAL
            FOR CELL VIABILITY AND THEIR USES
      <130> 30436.44USU1
 15
      <140> Not yet known
      <141> 2000-12-30
      <160> 226
 20
      <170> PatentIn Ver. 2.0
      <210> 1
      <211> 708
      <212> DNA
 25
     <213> Streptococcus pneumoniae
      <400> 1
     atgatttatg caggaattct tgccggtgga actggcacac gcatgggaat cagtaacttg 60
     ccaaaacaat ttttagagct aggtgatcga cctattttga ttcatacaat tgaaaaattt 120
30
     gtcttggaac caagtattga aaaaattgta gttggggttc atggagactg ggttttacat 180
     gcagaagate ttgtagataa atatetteet etteataagg aacgtattat cattacaaag 240
     ggtggtgctg accgcaatac aagtattgag aacatcattg aagccattga tgcttatcgc 300
     cogettacte cagaggatat cgttgttace cacgattetg ttcgtccatt tattacgett 360
     cgcatgattc aagacagtat caaacttgct caaaatcatg acgcagtgga tacagtagta 420
35
     gaagcagtgg atactatcgt tgaaagtacc aatggtcaat tcattacagg tattccaaat 480
     cgtgctcacc tctatcaggg acaaacacct caaacattcc gttgcaagga cttcatggac 540
     ctttatggat ctctttctga tgaagagaag gaaatcttga cagatgcatg taaaatcttt 600
     gtgatcaaag gaaaagatgt agccttggcc aaaggcgaat actcaaatct gaagattaca 660
     accytaacay atttgaagat tycaaaaagt atgattgaga aagactag
40
     <210> 2
     <211> 558
     <212> DNA
     <213> Streptococcus pneumoniae
45
     <400> 2
     atggctaacg taattattga aaaagctaaa gagagaatga cccagtctca ccaatcactt 60
     gctcgtgaat ttggtggtat ccgtgctggt cgtgccaatg caagcttgct tgaccgtgta 120
     catgtagaat actatggagt cgaaactcct cttaaccaaa tcgcttcaat tacgattcca 180
50
     gaagegegtg ttttgttggt aacaccattt gacaagtett cattgaaaga categaaegt 240
     geettgaaeg ettetgatet tygtateaea eeggetaatg aeggttetgt gattegettg 300
     gttateceag etettacaga agaaactegt egtgacettg etaaagaagt gaagaaggte 360
    ggcgaaaatg ctaaagtggc tgtccgcaat atccgtcgcg atgctatgga cgaagctaag 420
    aaacaagaaa aagcacaaga aatcactgaa gacgaattga agactcttga aaaagatatt 480
55
    caaaaagtaa cagacgatgc tgttaaacac atcgacgaca tgactgctaa caaagagaaa 540
    gaacttttgg aagtctaa
```

```
<210> 3
       <211> 1353
       <212> DNA
       <213> Streptococcus pneumoniae
  5
      atgggtaaat attttgggac tgatggagtc cgtggagaag ctaacctaga actaacacca 60
      gaattageet ttaaactagg acgttttgga ggetatgtte ttagtcaaca tgaaacggaa 120
      gegeegaaag tetttgtagg aegtgacaea egtattteag gggaaatget ggaateggee 180
 10
      ttggtggcag gtctcctttc agtagggatt cacgtataca aacttggtgt ccttgcaaca 240
      ccagcagtag cttacttggt tgaaactgaa ggagcaagtg ccggtgtcat gatttctgct 300
      agccacaacc cagcccttga taacggaatc aagttctttg gcggtgatgg cttcaaacta 360
      gatgatgaaa aagaagcaga aattgaagcc ttgctagatg ctgaggaaga cactcttcct 420
      cgtccaagtg cagaaggctt aggaattttg gtagattatc cagaaggctt gcgtaagtat 480
      gaaggatacc gtgtgtcaac tggaactcct cttgatggaa tgaaggttgc cttggataca 540
 15
      gctaatggag cagcttctac cagtgcccgt caaatctttg cagaccttgg tgcccaattg 600
      acggttatcg gggaaacacc agacggtctt aacatcaacc ttaatgttgg ttcaacacat 660
      ccagaagccc ttcaagaagt ggtcaaagaa agtgggtcag ctattggttt ggcctttgat 720
      ggagacagtg accepttgat tgctgttgat gagaatggtg acatcgtcga tggtgacaag 780
 20
      attatgtaca tcatcggaaa atacctttct gaaaaaggac aattggctca aaatacaatt 840
      gtgacaactg ttatgtctaa ccttggtttc cacaaggcct tgaatcgcga aggtattaac 900
      aaggcagtta ctgcagttgg tgaccgctac gttgttgaag aaatgagaaa atcaggctac 960
      aaccttggtg gtgaacagtc tggtcacgtt atcttgatgg attacaatac cacaggtgat 1020
      ggtcaattat cagcagttca attgactaaa atcatgaagg aaactggtaa gagcttatca 1080
 25
      gagttggcgg cagaagtaac gatttatcca caaaaattag ttaatatccg agtggaaaac 1140
      gtcatgaagg aaaaggccat ggaagtgcca gctatcaagg ccatcatcga gaagatggaa 1200
      gaagaaatgg cggggaacgg ccgtatcctt gttcgtccaa gtggaacaga gcccctcttg 1260
     cgtgttatgg cagaagcgcc tacaacagaa gaagtggact actatgttga taccatcaca 1320
      gatgtagttc gtgctgaaat tgggattgac taa
30
      <210> 4
     <211> 705
     <212> DNA
     <213> Streptococcus pneumoniae
35
     atgaaaaaaa tactaattgt agatgatgag aaaccaatct cggatattat caagtttaat 60
     atgaccaagg aaggttatga agttgtaact gcttttaatg gtcgtgaagc gctagagcaa 120
     tttgaagcag agcaaccaga tattattatt ctggatttga tgcttccaga aattgatggt 180
     ttagaagttg ctaagaccat tcgtaagaca agcagtgtgc ccattcttat gctttcagcc 240
     aaagatagtg aatttgataa ggttatcggt ttggaacttg gggcagatga ctatgtaacg 300
     aaacccttct ccaatcgtga gttgcaggcg cgtgttaaag ctcttctgcg tcgttctcaa 360
     cctatgccag tagatggtca ggaagcagat agtaaacctc aacctatcca aattggggat 420
     ttagaaattg ttccagacgc ctacgtggct aaaaaatatg gcgaagaact agacttaacc 480
45
     catcgtgaat ttgagctttt gtatcattta gcatcgcata caggtcaagt catcacgcgc 540
     gaacacttgc ttgagactgt ctggggttat gactattttg gtgatgtccg cacagttgat 600
     gtgactgtac gacgtctgcg tgagaagatt gaagatacgc ccagccgacc agagtatatc 660
     ttgacgcgcc gtggtgtagg gtattacatg agaaataatg cttga
50
     <210> 5
     <211> 1107
    <212> DNA
    <213> Streptococcus pneumoniae
55
    atggaagaaa ttctctgtat tggttgtgga gcaaccattc agacgacaga taaagctggt 60
    cttggtttta cccccagtc ggcacttgaa aaaggtttgg agactggcga agtctattgc 120
```

```
caacgetgtt teegteteeg ceactacaat gaaateacag atgteeagtt gaegaacgat 180
       gatttcctca agctcttgca cgaggtggga gacagtgatg ctttagtggt caatgtcatt 240
       gatatetttg attttaatgg atetgteate ceaggtttae caegtttegt etegggeaat 300
       gatgtcctct tggtaggaaa taaaaaagat atccttccta agtcagttaa gtctggtaag 360
      attagecagt ggeteatgaa acgtgeceat gaagaaggte ttegteeagt egatgtggte 420
      ctaacttcag cacaaaataa acatgccatt aaggaagtca ttgacaagat tgaacactac 480
      cgtaagggcc gcgatgtcta tgtggtcggt gtgaccaacg ttggaaaatc aactctaatc 540
      aatgctatta tccaagaaat cacgggtgat cagaatgtca tcactacttc acgcttccca 600
      gggacaacet tggacaaaat agagatteeg ettgacgacg gatettatat ttacgatacg 660
      ccgggaatta tocaccgcca ccagatggct cactacttga cggccaaaaa cctcaagtat 720
      gtcagtccta aaaaggaaat caagcctaag acctatcagc ttaatcctga gcaaacccta 780
      tttttaggtg gtttgggacg ctttgacttt atagcaggag aaaagcaagg atttactgct 840
      ttetttgata atgaacteaa acteeategt ageaagettg aaggagetag tgetttetae 900
      gataagcacc tgggaactct tctgacacca ccaaatagca aggaaaaaga agatttccca 960
      aggetagtee ageatgtett taccattaaa gataagacag acetagteat etcaggeeta 1020
 15
      ggatggattc gtgtaacagg cacagcaaaa gtcgccgtct gggcaccaga aggcgtcgcc 1080
      gtcgtcacac gaaaagcaat tatttaa
      <210> 6
 20
      <211> 1461
      <212> DNA
      <213> Streptococcus pneumoniae
      <400> 6
 25
      atgtatccag atgatagttt gacattgcac acggacttgt accagatcaa catgatgcag 60
      gtttactttg accaagggat tcacaataag aaggeggtet ttgaggtgta tttccgccaa 120
      cagcetttta agaacggeta tgeggttttt geaggtttgg aaagaattgt gaactatett 180
      gaagacttgc gtttttcaga tagtgatata gcctatttgg agtcgcttgg ttatcatggg 240
      gcgttcttgg attaccttcg caatttcaag ttggagttga ccgttcgttc tgcccaagaa 300
30
      ggggatttgg tttttgctaa tgaaccgatt gtgcaggtgg aaggacctct agcccaatgt 360
      cagttggtcg aaacggctct tttgaacatc gtcaactacc agaccttggt ggcgacgaag 420
      gcagctcgta ttcgttcggt tatcgaagat gaaccettga tggagtttgg gacacgtcgg 480
      getcaagaaa eggatgegge catetgggga acaegegeag eggtgattgg tggegecaat 540
      ggaaccagca acgtgcgtgc gggtaagctc tttgacattc ctgttttggg aacccatgcc 600
35
     catgeettgg tacaggttta tggcaatgac tatgaggett tcaaggetta cgctgcgacc 660
     cacaaaaatt gtgtctttct tgtggatacc tatgataccc ttcgcatcgg tgtaccagct 720
     gccattcagg tggcgcgtga gctgggtgat cagattaact ttatgggtgt gcggattgac 780
     tctggggata ttgcctacat ttctaagaaa gtccgtcagc aactggacga ggctggattt 840
     acagaggeta agatttatge ttetaatgat ttggaegaaa ataetateet caateteaag 900
     atgcaaaagg ccaagattga tgtctggggt gtgggtacca agctgattac agcctatgac 960
     cageeggete ttggggeggt ttacaagatt gttgcaateg aagatgaaac tggtcagatg 1020
     cgcaatacga ttaagctgtc taataatgcg gaaaaagtgt cgacgccagg taagaagcag 1080
     gtgtggcgca ttaccagtcg tgaaaaaggt aagtcagaag gtgattacat cacttatgat 1140
     ggtgtggata ttagcgacat gacagaaatc aagatgttcc atccgaccta tacatacatc 1200
     aagaagacgg ttcgtaattt tgatgccgtt cctctttgg tggatatctt caaagaagga 1260
     atattagttt acaacttgcc tagtttgact gacattcagg attatgcccg taaagaattt 1320
     gacaagttgt gggatgagta taagcgtgtg ctcaatccgc agcactatcc agtggatttg 1380
     gcgcgtgatg tatggcaaga taagatggac ttgattgata agatgcgcaa ggaagccctt 1440
     ggtgaaggag aagaagaatg a
50
     <210> 7
     <211> 852
     <212> DNA
     <213> Streptococcus pneumoniae
55
```

3

atggctacta ttcaatggtt teetggtcac atgtctaaag ctcgtcgaca ggtgcaggag 60

```
aatttaaaat ttgttgattt tgtgacgatt ttagtagatg cacgcttgcc tctatctagt 120
       caaaatceta tgttgaccaa gattgttggt gataaaccaa aactettgat tttaaacaag 180-
       gccgacttgg ctgatccagc aatgaccaag gaatggcgtc agtattttga atcacaagga 240
       atccagacgc tagctatcaa ctccaaagag caagtgactg taaaagttgt aacagatgcg 300
       gccaagaagc tcatggctga taagattgct cgccagaaag aacgtgggat tcagattgaa 360
       accttgcgta ctatgattat cgggattcca aacgctggta aatcaactct gatgaaccgt 420
       ttggctggta aaaagattgc tgttgttgga aacaagccag gggtcacaaa aggtcaacaa 480
       tggcttaaaa ccaataaaga cctggaaatc ttggatacac cggggattct ctggcctaag 540
       tttgaggatg aaactgttgc acttaagttg gcattgactg gagctatcaa ggatcagttg 600
  10
       cttcctatgg atgaggttac catttttggt atcaattatt tcaaagaaca ttatccagaa 660
       aagctggctg aacgcttcaa acaaatgaaa attgaagaag aaccgtctgt gattattatg 720
       gatatgacec gegeeetegg ttteegtgat gactatgace gtttttacag tetettegtg 780
       aaggaagtte gtgatggcaa acteggtaae tatacettag atacattgga agacetegat 840
       ggcaacgatt aa
  15
      <210> 8
      <211> 471
      <212> DNA
      <213> Streptococcus pneumoniae
 20
      <400> 8
      atgattaaca atgttgtact tgtagggcgt atgacacgtg acgctgagtt gcgttatacc 60
      ccatcaaatg tagcagttgc gacttttact cttgcagtaa accgtacatt taagagtcaa 120
      aatggtgaac gtgaggctga ttttatcaat gtcgttatgt ggcgccaaca ggctgaaaat 180
 25
      cttgctaact gggctaaaaa aggctcactt atcggggtga caggtcgtat ccagactcgt 240
      agttacgata accagcaagg acaacgtgtc tacgtgacag aggtcgtggc tgagaatttc 300
      caaatgttgg aaagccgtag tgtgcgtgag ggccacacag gtggagctta ctctgcacca 360
      actgcaaact attcagcacc tacaaattca gtaccagact tttcacgtaa tgaaaatcca 420
      tttggagcaa caaacccatt ggatatttca gatgatgatt taccattcta a
 30
      <210> 9
      <211> 975
      <212> DNA
      <213> Streptococcus pneumoniae
 35
     <400> 9
     atgaaaacgc gtattacaga attattgaag attgattatc ctattttcca aggagggatg 60
     gcctgggttg ctgatggtga tttggcaggg gctgtttcca aggctggagg attaggaatt 120
     40
     ttgactgata aaccetttgg ggtcaacatc atgetettat etecetttgt ggaagatate 240
     gtggatctcg ttattgaaga aggtgttaaa gttgtcacaa caggagcagg aaatccaage 300
     aagtatatgg aacgtttcca tgaagctggg ataatcgtta ttcctgttgt tcctagtgtc 360
     getttageta aacgeatgga aaaaateggt geagaegetg ttattgeaga aggaatggaa 420
     gctggggggc atatcggtaa attaacaacc atgaccttgg tgcgacaggt agccacagct 480
45
     atatctatte etgttattge tgeaggagga attgeggatg gtgaaggtge tgeggetgge 540
     tttatgctag gtgcagaggc tgtacaggtg gggacacggt ttgtagttgc aaaagagtcg 600
     aatgeceate caaactacaa ggagaaaatt ttaaaagcaa gggatattga cactacgatt 660
     teageteage actttggtea tgetgttegt getattaaaa ateagttgae tagagatttt 720
     gaactggctg aaaaagatgc ctttaagcag gaagatcctg atttagaaat ctttgaacaa 780
    atgggagcag gtgccctagc caaagcagtt gttcacggtg atgtggaggg tggctctgtc 840
    atggcaggtc aaatcgcagg gcttgtttct aaagaagaaa cagctgaaga aatcctaaaa 900
    gatttgtatt acggagccgc taagaaaatt caagaagaag cctctcgctg gacaggagtt 960
    gtaagaaatg actaa
                                                                      975
55
    <210> 10
    <211> 423
    <212> DNA
```

<213> Streptococcus pneumoniae <400> 10 atgategata tteaaggaat caaagaagee etteeceace gttateetat gettetagtg 60 gaccgtgtet tggaggtgag cgaggatacc attgttgcta tcaaaaatgt gaccatcaac 120 gagcetttet ttaacggcca ettteetcaa tacccagtta tgccaggtgt tetgattatg 180 gaageettgg egeaaactge eggtgtgttg gagttateaa aacetgaaaa taaaggaaaa 240 ctggtctttt acgctggtat ggataaggtt aagttcaaga agcaagttgt accaggcgac 300 caattggtta tgacagcgac ttttgtaaaa cgtcgtggca ccatagctgt ggttgaagca 360 aaggetgaag tggatggcaa gettgeagee agtggtaeee ttaettttge aattgggaae 420 10 <210> 11 <211> 1023 15 <212> DNA <213> Streptococcus pneumoniae <400> 11 atgattaatc aaatttatca actaactaaa cctaagttta tcaatgtcaa atatcaggaa 60 20 gaggetattg accaagagaa tcatateett ateegteeca actacatgge tgtetgteat 120 geggateage gttactacea gggaaaaegt gateceaaga ttttgaataa aaagetteea 180 atggcaatga ttcacgagtc atgtggaatc gtcatttctg acccgagcgg aacctacgag 240 gttggtcaaa aagttgtcat gattcccaat cagtctccta tgcagagtga tgaagaattc 300 tatgaaaact acatgacagg gacccatttc ttgtctagtg gatttgatgg ctttatgaga 360 25 gagtttgttt ctctccctaa agatcgtgtg gtggcttatg atgctattga agatacggtt 420 geagecatta cagagitigi cagigigge atgeacgeta tgaategiet attgactett 480 geteatagea agegggageg gateceegtt attggagatg gaagtttage ttttgtggtt 540 gccaatatta tcaactatac tttgccagaa gcagagattg tggttattgg tcgtcattgg 600 gaaaagttgg aactettete atttgeeaaa gaatgetata ttaeggataa tatteetgaa 660 gagttggcct ttgaccatgc ttttgaatgt tgtggtggtg atggtactgg accagctatt 720 aatgacttga ttcgctacat tcgtcctcag ggaacaattc tcatgatggg agttagcgaa 780 tataaagtca atctcaatac tegegatgee ttagaaaagg gettgetett ggttgggtca 840 tctcgttctg gtcgcattga ttttgaaaat gctatccaaa tgatgaaagt caagaaattt 900 gccaatcgtc ttaaaaatat cctttatcta gaagaacctg taagagaaat taaagatatt 960. 35 caccgtgtct ttgcaaccga tttaaacaca gcctttaaaa cagtgtttaa gtgggaagta 1020 <210> 12 <211> 1344 40 <212> DNA <213> Streptococcus pneumoniae atgaacttaa aaactacttt gggccttctt gctggacgtt cttcccactt cgttttaagc 60 cgtcttggac gtggaagtac gctcccaggg aaagtcgccc ttcaatttga taaagatatt 120 ttacaaaacc tagctaagaa ctacgagatt gtcgttgtca ctggaacaaa tggaaaaacc 180 ctgacaactg ccctcactgt cggcatttta aaagaggtct atggtcaagt tctaaccaat 240 ccaageggtg ccaacatgat tacagggatt gcaacaacct tectaacage caaatettet 300 aaaactggga aaaatattgc cgtcctcgaa attgacgaag ccagtctatc tcgtatctgt 360 gactatatcc agcctagtct ttttgtcatt actaatatct tccgtgacca gatggaccgt 420 50 ttcggtgaaa tctatactac ctataacatg atattggatg ccattcggaa agttccaact 480 gctactgttc tccttaacgg agacagtcca cttttctaca agccaactat tccaaaccct 540 atagagtatt ttggttttga cttggaaaaa ggaccagccc aactggctca ctacaatacc 600 gaagggattc tctgtcctga ctgccaaggc atcctcaaat atgagcataa tacctatgca 660 aacttgggtg cctatatctg tgagggttgt ggatgtaaac gtcctgatct cgactatcgt 720 ttgacaaaac tggttgagtt gaccaacaat cgctctcgct ttgtcataga cggccaagaa 780 tacggtatec aaatcggcgg getetataat atctataacg ecetagetge tgtggccate 840

```
gcccgtttcc tcggcgcaga ttcccaactc atcaaacagg gatttgacaa gagccgtgct 900
       gtetttggac gecaagaaac ettteatate ggtgacaagg aatgtaceet tgtettgatt 960
      aaaaatccag teggtgeaac ecaagetate gaaatgatea aactageace ttatecattt 1020
      agcetatetg tecteettaa tgecaactat geagatggaa ttgacactag etggatetgg 1080
      gatgcagact ttgagcaaat cactgacatg gacattcctg aaatcaacgc tggcggtgtt 1140
     . cgtcattctg aaatcgctcg tcgcctccga gtgactggct atccagctga gaaaatcact 1200
      gaaacgagta atctggagca agttctcaag accattgaga atcaagactg caagcatgce 1260
      tatattctgg caacttatac tgccatgctg gaatttcgtg aactgctggc tagtcgtcag 1320
      attgttagaa aggagatgaa ctaa
 10
      <210> 13
      <211> 783
      <212> DNA
      <213> Streptococcus pneumoniae
 15
      <400> 13
      atggtttata cttcactttc ctcaaaagat ggcaattacc cctatcagct caacattgcc 60
      cacctetacg gaaateteat gaatacetae ggggacaatg gaaacateet catgeteaag 120
      tatgtggctg aaaaactggg agcccatgtg accgttgaca tcgtttctct ccatgatgac 180
 20
      tttgatgaaa atcactacga catcgccttt ttcggtggtg gtcaagactt tgaacaaagt 240
      atcattgcag acgacctacc tgctaaaaaa gagagcattg acaactacat ccaaaacgac 300
      ggtgtagtte tggetatetg eggtggttte caactattgg gteaatatta tgttgaaget 360
      tcaggaaaac gtatcgaagg gctaggggtc atgggacact acacgctcaa ccagaccaat 420
     aaccgtttta tcggtgacat caagattcac aatgaagatt tcgatgaaac ctactatgga 480
 25
     tttgaaaatc accaaggtcg taccttcctc tctgatgacc aaaaaccgct gggacaggtt 540
     gtctatggaa atggaaacaa cgaagaaaag gtcggtgaag gggttcatta taagaatgtc 600
     tttggttcct acttccacgg gcctatcctc tctcgtaatg ccaatctggc ttatcgccta 660
     gttactactg ccctcaagaa gaaatatggt caggacatcc aactccctgc ctatgaggac 720
     atteteagee aagaaatege tgaagagtae agtgaegtea aaageaagge tgaetttet 780
30
     <210> 14
     <211> 276
     <212> DNA
35
     <213> Streptococcus pneumoniae
     atggcaaaca aacaagattt gatcgctaaa gtagcagaag ctacagaatt aactaagaaa 60
     gactcagcag cagcagttga agctgtattt gcagcagtag ctgactatct tgcagctggt 120
     gaaaaagtte agttgategg ttttagtaae tttgaagtte gtgagegege agaacgtaaa 180
     ggtcgcaacc cacaaactgg taaagaaatg acaattgcag cttctaaagt accagcattc 240
     aaagctggta aagctcttaa agacgctgtt aaataa
     <210> 15
45
     <211> 840
     <212> DNA
     <213> Streptococcus pneumoniae
     <400> 15
50
    atgggaattg ctctagaaaa tgtgaatttt acatatcaag aaggtactcc cttagcttca 60
    gcagettigt eggatgitte titgaegatt gaagatgget ettatacage titaatiggg 120
    cacacaggta gtggtaaatc aactattta caactettaa atggtttatt ggtgccaagt 180
    caagggagtg tgagggtttt tgatacctta atcacctcga cttctaaaaa taaagatatt 240
    cgtcaaatta gaaaacaggt tggcttggta tttcagtttg ctgaaaatca gatttttgaa 300
    gaaacggttt tgaaggacgt tgcttttgga ccgcaaaatt ttggagtttc tgaagaagat 360
    getgtgaaga etgegegtga gaaactgget etggttggaa ttgatgaate actttttgat 420
    cgtagtccgt ttgagctgtc agggggacaa atgagacgtg ttgccattgc aggcatactt 480
```

6

```
gccatggage cagetatatt agtettagat gagecaacag etggtetaga teetetaggg 540
      agaaaagagt tgatgaccct gttcaaaaaa ctccaccagt cagggatgac catcgtcttg 600
      gtaacgcatt tgatggatga tgttgctgaa tatgcgaatc aagtctatgt aatggaaaag 660
      ggacgtttag taaagggggg caaaccaagt gatgtctttc aagacgttgt ttttatggaa 720
  5
      gaagttcagt tgggagtace taaaattacg geettttgta aacgattgge tgatagagge 780
      gtgtcattta aacgattacc ggttaagata gaggagttca aggagtcgct aaatggatag 840
      <210> 16
      <211> 930
 10
      <212> DNA
      <213> Streptococcus pneumoniae
      <400> 16
      atggatattc aattittagg aacgggggct ggtcagccct ctaaagcccg caacgtttca 60
 15
      agtetegeee tgaaactttt ggatgagatt aacgaagttt ggetetttga etgtggagaa 120
      ggtacgcaaa atcgcattct ggaaaccaca attcgaccac gtaaggtcag caaaatcttt 180
      attacccate tgcatggaga ccacattttt ggtttgccag gtttcctttc tagccgtgcc 240
      tttcaggcca atgaagagca gacagatttg gaaatctacg gacctcaagg aatcaagtca 300
      tttgtettaa ccagcetteg tgtgteaggt tetegtetge ectaeegeat teattteeat 360
 20
      gagtttgacc aagattctct aggtaaaatt cttgaaatcg ataaattcac tgtgtatgca 420
      gaggagetgg accacactat titetgtgtt ggetategtg teatgeaaaa ggatetagaa 480
      gggacgetgg atgetgaaaa actcaagget getggtgtte egtteggeee getttttggt 540
      aaaatcaaaa atggccagga tcttgttttg gaagacggaa ctgaaatcaa ggcagcagac 600
     tatateteag egecaegtee aggtaagatt ateactattt taggagaeac tegaaaaaeg 660
     gatgccagtg tgcgtctggc tgtcaatgca gatgtcctag ttcatgagtc cacttatggc 720
25
     aagggtgatg aaaaaattgc tcgtaaccat ggtcactcaa ctaatatgca agctgcacaa 780
     gtageggtag aageaggtge caaacgcete ctactcaace atateagtge cegtiteete 840
     tcaaaagata ttagcaaact caagaaagac gctgccacaa tttttgaaaa tgtccatgtg 900
     gtcaaagact tggaagaagt ggaaatctag
30
     <210> 17
     <211> 1662
     <212> DNA
     <213> Streptococcus pneumoniae
35
     <400> 17
     atgagtaata tcagtttaac aacacttggt ggtgtgcgtg agaatggaaa aaatatgtac 60
     attgctgaaa ttggagagtc catttttgtt ttgaatgtag ggttaaaata tcctgaaaat 120
     gaacaattag gggtcgatgt ggtgattcca aacatggatt acctttttga aaatagcgac 180
     cgtattgctg gggttttctt gacccacggg catgcggatg cgattggtgc tctaccttat 240
     ctcttggcag aggctaaagt tcctgtattt gggtctgagt tgaccattga gttggcaaag 300
     ctctttgtca aaggaaatga tgccgttaag aaatttaatg atttccatgt cattgatgag 360
     aatacggaga ttgattttgg tgggacagtg gtttccttct tccctacgac ttactccgtt 420
     ccagagagte tgggaattgt cttgaagaca tcggaaggaa gcatcgttta tacaggtgac 480
.45
    ttcaaatttg accaaacggc tagtgaatct tatgcaactg attttgctcg tttggcagag 540
     attggtcgtg acggcgtcct ggctctcctc agtgattcgg ccaatgcaga cagcaatatt 600
    caggtggcta gtgaaagtga agttagggat gaaattaccc aaactattgc tgactgggaa 660
    ggtcgtatca tcgttgcagc tgtttccagt aatctttctc gtattcagca gatttttgac 720
    gctgcggata aaacaggtcg acgtatcgtc ttgacaggat ttgatattga aaatatcgtc 780
50
    cgcacagcga ttcgtcttaa gaagttgtct ttagccaacg aaattctctt gattaagcct 840
    aaagatatgt ctcgctttga agaccatgag ttgattattc ttgagacagg tcgtatgggt 900
    gaacctatca atggacttcg taagatgtcg attggtcgcc atcgttatgt agaaatcaag 960
    gatggggacc tggtctatat tgctacggct ccgtctattg ctaaagaagc ctttgttgcg 1020
    cgtgtagaaa atatgattta tcaggcaggt ggggttgtca aattgattac ccaaagttta 1080
    catgtatcag ggcacggaaa tgtgcgtgat ttgcagctga tgatcaatct tttgcaacct 1140
    aagtacetet teeetgteea aggggagtat egtgagttgg atgeteaege taaggetgee 1200
    atggcagttg ggatgttgcc agaacgcatc ttcattccta aaaaggggac gaccatggct 1260
```

```
tacgagaatg gagactttgt tccagctgga tcggtttcag caggagatat cttaattgat 1320
       gggaatgcca ttggtgatgt tggaaatgtt gttcttcgtg accgtaaggt cttgtcagag 1380
       gatggaattt tcatcgtggc tattacagtc aaccgtcgtg agaagaaaat tgtggctaga 1440
       getegtgtte acacgegtgg atttgtttat etcaagaaga gtegegatat teteegtgaa 1500
       agttcagaat tgattaacca aacggtagaa gattatcttc aaggagatga ctttgactgg 1560
       gcagatetta aagggaaggt tegagataat ttgaccaagt atetetttga ccaaaccaag 1620
       cgtcgtccag ctattttacc agtagtcatg gaagcaaaat aa
       <210> 18
  10
       <211> 951
       <212> DNA
       <213> Streptococcus pneumoniae
      <400> 18
 15
      atgacaaaag aatttcatca tgtaacggtc ttactccacg aaacgattga tatgcttgac 60
      gtaaaacctg acggtatcta cgttgatgcg actttgggtg gagcaggcca tagcgagtat 120
      ttattaagta aattaagtga aaaaggccat ctctatgcct ttgaccagga tcagaatgcc 180
      attgacaatg cgcaaaaacg cttggcacct tacattgaga agggagtggt gacctttate 240
      aaggataact teegteatti acaggeaegt ttgegegaag etggtgttea ggaaattgat 300
      ggaatttgtt atgacttggg agtgtctagt cctcaattgg accagegtga gegtggtttt 360
      tettataaaa aggatgegee actggacatg eggatgaate aggatgetag tetgacagee 420
      tatgaagtgg ttaatcatta tgactatcat gatttggttc gtattttctt caaatacggt 480
      gaggataaat tototaaaca gattgogogt aagattgago aagogogtga agtgaagoog 540
      attgagacaa cgactgagtt agcagagatt atcaagttgg tcaaacctgc caaggaactc 600
 25
      aagaagaagg gtcatcctgc taagcagatt ttccaggcta ttcgaattga agtcaatgat 660
      gaactggggg cggcagatga gtccatccag caggctatgg atatgttggc tctggatggt 720
      agaattteag tgattacett teatteetta gaagaeeget tgaccaagea attgtteaag 780
      gaagetteaa eagttgaagt teeaaaagge ttgeetttea teecagatga teteaageee 840
      aagatggaat tggtgtcccg taagccaatc ttgccaagtg cggaagagtt agaagccaat 900
 30
     aaccgctcgc actcagccaa gttgcgcgtg gtcagaaaaa ttcacaagta a
      <210> 19
      <211> 999
      <212> DNA
35
     <213> Streptococcus pneumoniae
     atgagtagaa ttttagataa tgagataatg ggggatgagg agttagtaga acgcacgctc 60
     cgtcctcagt atttacgtga atatatcgga caggataagg tcaaggacca gctacaaatc 120
40
     tttattgaag ctgccaaaat gcgggatgaa gcgctggatc atgtgctctt atttgggcct 180
     ccaggteteg ggaaaacgae catggeettt gttattgeea acgaactggg agtcaatett 240
     aagcagacgt cgggtccagt cattgaaaaa gccggagatc tggtagctat tttgaatgag 300
     ttagageetg gggatgtact ttttattgat gagateeate gtttgeeaat gteagtggaa 360
     gaggtgettt atagtgetat ggaggaette tacategata ttatgattgg ggetggtgag 420
45
     ggtagtegta gtgttcattt ggagttacca ccttttacct tgattggtgc gacgactcgg 480
     getggtatge tetecaatee getaegggea egttttggga ttacaggeca tatggagtat 540
     tatgcccatg ctgacttgac agaaattgtc gagcggacgg cagatatttt tgagatggaa 600
     atcactcatg aggcagcatc tgagttggcc ctacgtagtc gtgggacccc tcgtattgcc 660
     aatcgtctcc tcaagcgcgt gcgcgatttt gcccagataa tggggaatgg ggtaattgat 720
    gatattatta ccgataaggc tttgactatg ctggatgttg accatgaagg tttggactat 780
50
    gtggatcaaa aaatcetteg taceatgatt gagatgtaca gtggaggace tgttggteta 840
    ggaactettt etgtgaatat egeegaagag egtgagaeag ttgaagaeat gtatgageet 900
    tacttgattc aaaaaggttt tatcatgcgg acacggtctg gacgggtggc gactgctaag 960
    gcatatgagc acttaggtta tgaatacagt gaaaaataa
55
    <210> 20
    <211> 1311
```

```
<212> DNA
       <213> Streptococcus pneumoniae
      atgagtatgt ttttagatac agctaagatt aaggtcaagg ctggtaatgg tggcgatggt 60
      atggttgcct ttcgtcgtga aaaatatgtc cctaatggag gcccttgggg tggtgatggt 120
      ggtcgtggag gcaatgtggt cttcgttgta gacgaaggac tacgtacctt gatggatttc 180
      cgctacaatc gccatttcaa ggctgattct ggtgaaaaag ggatgaccaa agggatgcat 240
      ggtcgtggtg ctgaggacct tagagttcga gtatcacaag gtacgactgt tcgtgatgcg 300
 10
      gagactggca aggttttaac agatttgatt aaacatgggc aagaatttat cgttgcccac 360
      ggtggtcgtg gtggacgtgg aaatattcgt tttgcgacac caaaaaatcc tgcaccggaa 420
      atctctgaaa atggagaacc aggtcaggaa cgtgagttac aattggaact aaaaatcttg 480
      gcagatgtcg gtttagtagg attcccatct gtagggaagt caacactttt aagtgttatt 540
      acctcagcta agcctaaaat tggtgcctac cactttacca ctattgtacc aaatttaggt 600
 15
      atggttcgca cccaatcagg tgaatccttt gcagtagccg acttgccagg tttgattgaa 660
      ggggctagtc aaggtgttgg tttgggaact cagttcctcc gtcacatcga gcgtacacgt 720
      gttatccttc acatcattga tatgtcagct agcgaaggcc gtgatccata tgaggattac 780
      ctagctatca ataaagagct ggagtcttac aatcttcgcc tcatggagcg tccacagatt 840
      attgtagcta ataagatgga catgcctgag agtcaggaaa atcttgaaga atttaagaaa 900
 20
      aaattggctg aaaattatga tgaatttgaa gagttaccag ctatcttccc aatttctgga 960
      ccagaatttt tgctctacga cgagtccgat atggaagaag aagcttacta tggatttgac 1080
      gaagaagaaa aagcetttga aattagtegt gatgaegatg egacatgggt actttetggt 1140
      gaaaaactca tgaaactctt taatatgacc aactttgatc gtgatgaatc tgtcatgaaa 1200
 25
      tttgcccgtc agettcgtgg tatgggggtt gatgaagccc ttcgtgcgcg tggagctaaa 1260
      gatggggatt tggtccgcat tggtaaattt gagtttgaat ttgtagacta g
      <210> 21
      <211> 519
. 30
      <212> DNA
      <213> Streptococcus pneumoniae
     <400> 21
     atgaactact ttaatgttgg gaaaatcgtt aatacgcagg gattacaggg tgagatgcga 60
35 gtettgtetg tgacggattt tgcagaagaa cggtttaaaa aaggagetga getggetttg 120
     tttgatgaaa aagatcagtt tgtccaaaca gtgaccatcg ctagccaccg taaacagaag 180
     aactttgaca ttattaaatt caaagatatg taccatatca atactatcga aaagtacaag 240
     ggatacagtc tcaaggtcgc tgaggaagat ttgaatgacc tagacgatgg tgaattttac 300
     tatcacgaga ttatcggttt ggaagtctat gagggtgata gcttggttgg aaccatcaag 360
40
     gaaatcctgc aaccaggtgc taatgatgtc tgggtggtca aacgaaaagg caaacgtgat 420
     ttgcttttac cttatatccc accagtggtt ctcaatgttg atattccaaa taaacgggtc 480
     gatgtggaaa tcttagaagg gttagacgat gaagattga
     <210> 22
45
     <211> 720
     <212> DNA
     <213> Streptococcus pneumoniae
     <400> 22
50
     atgaagattg atattttaac cctctttcca gagatgtttt ctccactgga gcactcaatc 60
     gttggaaagg ctcgagaaaa agggctcttg gatatccagt atcataattt tcgagaaaat 120
     gctgaaaagg cccgtcatgt agatgatgag ccctacggag gcggtcaggg catgttgctc 180
     agagcacaac ctattttcga ttcctttgat gctattgaaa agaaaaatcc gcgcgttatt 240
     ctcctcgatc ctgctggaaa gcagtttgat caggcttatg ctgaagattt ggctcaagag 300.
55
    gaagagctaa tetttatetg tgggcactat gagggttatg atgagcgcat taagacettg 360
    gtaacagatg agatttccct aggcgactat gtcctcactg gtggagaatt ggcagctatg 420
    accatgattg atgctacagt tcgcctgatt ccagaagtga ttggcaagga gtctagccac 480
```

```
caagatgata gtttttette aggtetttta gaatateate agtacacacg teectatgat 540
        tategaggea tggtegtgee agatgtattg atgagtggee atcatgaaaa gattegteag 600
       tggcgattgt acgagagttt aaagaaaacc tacgagcgca gaccggattt acttgaacat 660
       tatcaactga cagtagaaga agaaaaaatg ctggcagaaa tcaaagaaaa caaagaataa 720
   5
       <210> 23
       <211> 561
       <212> DNA
       <213> Streptococcus pneumoniae
  10
       <400> 23
       atgattgaag caagtaaatt aaaagctggt atgacctttg aaacagctga cggcaaattg 60
       attegegttt tggaagetag teaceacaaa ceaggtaaag gaaacacgat catgegtatg 120
       aaattgegtg atgteegtae tggttetaea tttgacacaa getaeegtee agaggaaaaa 180
  15
       tttgaacaag ctattatcga gactgtccca gctcaatact tgtacaaaat ggatgacaca 240
       gcatacttca tgaatacaga aacttacgac cagtacgaaa tccctgtagt caatgttgaa 300
       aacgaattgc tttacatcct tgaaaactct gatgtgaaaa tccaattcta cggaactgaa 360
      gtgatcggtg tcaccgttcc tactactgtt gagttgacag ttgctgaaac tcaaccatct 420
      atcaaaggtg ctactgttac aggttctggt aaaccagcaa cgatggaaac tggacttgtc 480
      gtaaacgttc cagacttcat cgaagcagga caaaaactcg ttatcaacac tgcagaagga 540
  20
      acttacgttt ctcgtgccta a
      <210> 24
      <211> 1572
 25
      <212> DNA
      <213> Streptococcus pneumoniae
      <400> 24
      atggcatttg aaagtttaac agaacgtttg cagaacgtct ttaaaaaatct acgtaaaaaa 60
 30
      ggaaaaatet etgaatetga tgteeaagag gcaaccaaag aaattegett ggeettgete 120
      gaggeegaeg ttgeettgee tgttgtaaag gaetttatea agaaagtteg tgagegtgea 180
      gtegggeatg aggteatiga tacaéttaat éetgegeaac agattattaa aategttgat 240
      gaggaactga cagccgtttt aggttctgat acggcagaaa ttatcaagtc acctaagatt 300
      ccaaccatca tcatgatggt tggtttacaa ggggctggta aaacaacctt tgctggtaaa 360
 35
      ttggccaaca aactcaagaa agaagaaaat gctcgtcctt tgatgattgc ggcggatatt 420
     tatogtocag etgecattga coagettaag acettgggac aacagattga tgtgcetgte 480
     tttgcacttg gaacagaagt accagctgtt gagattgtac gtcaaggttt ggagcaagcc 540
     caaactaatc ataacgacta tgtcttgatt gatactgcgg gtcgtttgca gattgatgag 600
     ctcctcatga atgagcttcg tgatgtgaaa acattggctc aaccaaatga aatcttgctt 660
     gtcgttgatg ctatgattgg tcaggaagca gccaatgttg cgcgtgagtt taatgctcag 720
     ttggaagtga ctggggtcat cettaccaag attgatggcg atactcgtgg tggtgctgct 780
     ctgtctgttc gtcacattac tggaaaacca atcaagttca ctggtacagg tgaaaagatt 840
     acggacattg aaaccttcca cccagaccgc atgtctagcc gtatccttgg tatgggggat 900
     atgeteactt tgattgagaa agetteteag gaatacgatg aacaaaaage cettgaaatg 960
     gctgagaaga tgcgcgaaaa cacctttgat tttaatgatt tcatcgatca attagatcag 1020
     gtgcaaaata tggggccgat ggaagacttg ctcaagatga ttccaggtat ggcaaacaat 1080
     ccagccette aaaacatgaa ggtggatgaa cgccagattg ctcgtaaacg tgccattgtg 1140
     tettegatga cacetgaaga gegtgaaaac ceagatttgt taaateeaag eegtegeegt 1200
     cgtattgctg ctggttctgg aaatacattc gtcgaagtca ataaattcat caaggacttt 1260
50
    aaccaggeta aacageteat geagggtgtt atgtetgggg atatgaataa aatgatgaag 1320-
    caaatgggga ttaatccaaa taaccttcct aaaaatatgc caaatatggg aggaatggat 1380
    atgtetgeec ttgaaggaat gatgggacaa ggeggtatge etgaettate agetetegga 1440
    ggagcaggaa tgccagatat gagccagatg tttggtggcg gtttgaaagg taaaattggt 1500
    gaatttgcta tgaaacagtc catgaaacgt atggctaaca aaatgaagaa agcgaagaag 1560
55
    aaacgcaagt aa
                                                                       1572
```

<210> 25

```
<211> 846
      <212> DNA
      <213> Streptococcus pneumoniae
  5
      <400> 25
      atgtatetta ttgaaatttt aaaatetate ttetteggga ttgttgaagg aattaeggaa 60
      tggttgccga tttccagtac aggtcatttg attttagcag aggagtttat ccaataccaa 120
      aatcaaaatg aagcetttat gteeatgttt aatgtegtga tteagettgg tgetatttta 180
      gcagttatgg tgatttattt taacaagete aateetttta aacegactaa ggacaaacag 240
 10
      gaagttcgta agacttggag actatggttg aaggtcttga ttgctacttt acctttactt 300
      ggtgtcttta aatttgatga ttggtttgat acccacttcc ataacatggt ttcagttgct 360
      ctcatgttga ttatctacgg ggttgccttc atctatttgg aaaagcgcaa taaagcqcgt 420
      gctatcgagc caagtgtaac agagttggac aagcttcctt atacgaccgc tttctatatc 480
      ggactettee aagttettge tettttacca gggactagee gtteaggtge aacgattgte 540
 15
      ggtggtttgt taaatggaac cagtcgttca gttgtgacag aatttacctt ctatcttggg 600
      attoccgtta tgtttggagc tagtgcctta aagattttca aatttgtgaa agccggagaa 660
     ctcttgagct ttgggcaatt gtttttgctc ttggtcgcga tgggagtagc ttttgcggtc 720
      agcatggtgg ctattegett ettgaceage tatgtgaaaa aacacgactt caccettitt 780
      ggtaaatacc gtatcgtgct tggtagtgtt ttgctacttt acagttttgt ccgtttattt 840
20
     gtataa
     <210> 26
     <211> 1290
     <212> DNA
25
     <213> Streptococcus pneumoniae
     <400> 26
     atgggattat ttgaccgtct attcggaaaa aaagaagaac ctaaaatcga agaagttgta 60
     aaagaagete tggaaaatet tgatttgtet gaagatattg ageetgeett cacagaaget 120
30
     gaggaagttt ctcaagaaga agcagaggtt gaaagttctg aagaatctgt gttccaagaa 180
     qaqqataqtc aagacacagt cgaagaaaat ctggatttag agccagttgt agaggtttct 240
     caagaagaag tagaagaatt tccaaactca caagaagtca cagaggaaga gaagcttgag 300
     cacgaaggaa ctgtagaaga aaataatttt gaagtgcttg aaccagaagc tcctcaaaca 360
     gaagaaactg ttcaggaaaa atatgaccgc agtcttaaga aaactcgcac aggtttcggt 420
35
     gecegettga atgeettett tgetaactte egetetgttg acgaagaatt tttegaggaa 480
     ctggaagaac tgttgattat gagtgatgtt ggtgtccaag tcgcttctaa cttaacggag 540
     gaactacgtt acgaagccaa gcttgaaaat gccaagaaac ctgatgcact tcgtcgtgtc 600
     atcattgaga aattggttga gctttatgaa aaggatggta gctacgatga aagcatccac 660
     ttccaagata acttgacagt tatgctcttt gttggtgtga atggtgttgg gaaaacaact 720
40
     tetateggaa aactageeea eegetacaaa egagetggta agaaggteat getggttgea 780
     gcagatacet teegtgeggg tgcagtaget cagetagetg aatggggeeg acgagtagat 840
     gttccagtag taactggacc tgaaaaagct gatccagcca gcgtggtctt tgatggtatg 900
     gaacgtgccg tggctgaagg tatcgatatt ctcatgattg atactgctgg tcgtctgcaa 960
     aataaggata accttatggc tgagttggaa aagattggtc gtattatcaa acgtgttqtq 1020
45
     ccagaagcac cacatgaaac cttcttggca cttgatgcat caacaggtca aaatgcccta 1080
     gtacaggcca aagaattttc gaaaatcaca cctttaacgg gaattgtttt gactaagatt 1140
     gatggaactg ctcgaggagg tgtggttcta gccattcgtg aagaactcaa tattcctgta 1200
     aaattgattg gttttggtga aaaaatcgat gatattggag agtttaactc agaaaacttc 1260
     atgaaaggtc tcttggaagg tttaatctaa
                                                                       1290
50
    <210> 27
    <211> 498
    <212> DNA
    <213> Streptococcus pneumoniae
55
    <400> 27
```

atgtatattg aaatggtaga tgaaactggt caagtttcaa aagaaatgtt gcaacaaacc 60

```
caagaaattt tggaatttgc agccaaaaaa ttaggaaaag aagacaagga gatggcagtc 120
      acttttgtga ccaatgagcg tagtcatgaa cttaatctgg agtaccgtga caccgaccgt 180
      ccgacagatg tcatcagcct tgagtataaa ccagaattgg aaattgcctt tgacgaagag 240
      gatttgcttg aaaatccaga attggcagag atgatgtctg agtttgatgc ctatattggg 300
      gaattgttca tototatoga taaggotcat gagcaggoog aagaatatgg toacagottt 360
      gagcgtgaga tgggcttctt ggcagtacac ggctttttac atattaacgg ctatgatcac 420
      tatactccgg aagaagaagc ggagatgttc ggtttacaag aagaaatttt gacagcctat 480
      ggactcacaa gacaataa
 10
      <210> 28
      <211> 768
      <212> DNA
      <213> Streptococcus pneumoniae
 15
      <400> 28
      atgagtattc gagtaattat tgccggtttt aagggaaaga tgggccaggc tgcttgtcag 60
      atggtattga ctgatccaga cttggacttg gtggcagttt tggatccttt tgagtctgag 120
      tcagaatggc agggtattcc tgttttcaag gataaggctg atttagctgg ttttgaagcg 180
      gatgtctggg tagattttac tactccagct gttgcctacg aaaatacacg ttttgctctt 240
 20
      gaaaatggct ttgctccagt agttggaacg actggtttca cgagtgaaga aattgcagag 300
      ctaaaagaat tttctcgtgc ccaagacttg ggtggcctga ttgcccctaa ctttgccttg 360
      ggtgctgtct tactcatgca atttgcgacg caggctgcca aatatttccc aaatgtggag 420
      attattgage tecateatga caagaaaaag gatgeteega gtggaacage cattaaaaca 480
      gctgagttga tggcagaggt tcgagagtca attcagcaag gtgcagcaga tgaggaagag 540
 25
      ctgattgctg gtgctcgtgg tgctgacttt gatggtatgc gcatccactc agttcgtttg 600
      ccaggettgg tagetcatca ggaagtcate tttggcaatc agggagaagg gttgaccete 660
      cgtcatgact cctatgatcg catctccttc atgacaggag tcaatttggg aattaaagaa 720
      gttgtcaagc gtcatgagct tgtctatgga ttagaacact tattatga
 30
      <210> 29
      <211> 276
      <212> DNA
     <213> Streptococcus pneumoniae
35
     <400> 29
     atggcaaaca aacaagattt gatcgctaaa gtagcagaag ctacagaatt aactaagaaa 60
     gactcagcag cagcagttga agctgtattt gcagcagtag ctgactatct tgcagctggt 120
     gaaaaagttc agttgatcgg ttttagtaac tttgaagttc gtgagcgcgc agaacgtaaa 180
     ggtcgcaacc cacaaactgg taaagaaatg acaattgcag cttctaaagt accagcattc 240
40
     aaagctggta aagctcttaa agacgctgtt aaataa
     <210> 30
     <211> 921
     <212> DNA
45
     <213> Streptococcus pneumoniae
     <400> 30
     atgactaaaa cagcettttt atttgetggt caaggtgeee agtatetagg gatgggaegg 60
     gatttctatg atcagtatcc gattgttaaa gaaacgattg atcgagcgag tcaggtgctc 120
50
     ggttatgatt tgcgttatct catcgatacg gaagaggaca aactcaatca gacccgctat 180
     acgcaaccag ccattctagc gacttcggtt gctatctacc gtttattgca agaaaagggc 240
     tatcagcetg atatggtcgc tggtttgtct cttggagaat actctgcctt ggtggcaagc 300
     ggcgccttgg attitgaaga tgcggttgcc ttggtagcta agcgtggagc ctatatggaa 360
     gaageggete etgetgaete tggeaagatg gtageagtte teaataegee agtagaggte 420
55
     attgaagaag cetgtcaaaa agettetgaa ettggagtgg ttactccage caactataac 480
     acacctgcac aaatcgtcat tgctggagaa gtggttgcag ttgatcgagc ggttgaactt 540
     ttgcaagaag caggtgccaa acgcttgatt cctcttaagg tgtcaggtcc ctttcacacc 600
```

```
gctctccttg agccagctag ccagaaacta gctgaaactc tagctcaggt aagtttttca 660
       gattttactt gtcccctagt cggcaataca gaagctgctg tgatgcaaaa agaggacatt 720
       geteagetet tgacgegtea ggteaaggaa eeegttegtt tetatgaaag tattggggte 780
       atgcaagaag caggcataag caactttatc gagattggac cggggaaagt cttgtcaggt 840
       tttgttaaaa aaattgatca aactgctcac ttagctcatg tggaagatca agcgagttta 900
       gtagcacttt tagaaaaata g
       <210> 31
       <211> 732
  10
       <212> DNA
       <213> Streptococcus pneumoniae
       <400> 31
       atgaaactag aacataaaaa tatctttatt acaggttega gtegtggaat tggtettgee 60
 15
      ategeceaea agtttgetea ageaggagee aacattgtet taaacagteg tggggeaate 120
      tcagaagaat tgctcgctga gttttcaaac tatggtatca aggtggttcc catttcagga 180
      gatgtatcag attttgcaga cgctaagcgt atgattgatc aagctattgc agaactgggt 240
      teagtagatg ttttggteaa caatgeaggg attacceaag atactettat geteaagatg 300
      acagaagcag attttgaaaa agtgctcaag gtcaatctga ctggtgcctt taatatgaca 360
 20
      caatcagtct tgaaaccgat gatgaaagcc agagaaggtg ctatcattaa tatgtctagt 420
      gttgttggtt tgatggggaa tattggtcaa gctaactatg ctgcttctaa ggctggcttg 480
      attggettta ccaagtetgt ggeacgegag gtegetagte ggaatataeg agteaatgtg 540.
      attgctccag gaatgattga gtctgatatg accgctatct tatcagataa gattaaggaa 600
      gctacactag ctcagattcc gatgaaagaa tttgggcagg cagagcaggt tgcagatttg 660
      acagtatttt tagcaggcca agattatcta actggtcaag tggttgccat tgatggtggc 720
 25
      ttaagtatgt ag
      <210> 32
      <211> 831
 30
      <212> DNA
      <213> Streptococcus pneumoniae
      <400> 32
     atgggagtga aaaagaaact aaagttgact agtttgctag gactgtctct gttaatcatg 60
35
     acagectgtg cgactaatgg ggtaactage gatattacag ccgaategge tgatttttgg 120
     agtaaattgg titacttcti tgcggaaatc attcgcttti tatcgtttga tattagtatc 180
     ggagtgggga ttattctctt tacggtcttg attcgtacag tcctcttgcc agtcttcag 240
     gtgcaaatgg tggcttctag gaaaatgcag gaagctcagc cacgcattaa ggcgcttcga 300
     gaacaatato caggtogaga tatggaaago agaaccaaac tagagcagga aatgogtaaa 360
40
     gtatttaaag aaatgggtgt cagacagtca gactctcttt ggccgatttt gattcagatg 420
     ceggttattt tggccctgtt ccaagcccta tcaagagttg actttttaaa gacaggtcat 480
     ttettatgga ttaacettgg Gagtgtggat acaaceettg ttetteegat tttageagea 540
     gtattcacct ttttaagtac ttggttgtcc aacaaagctt tgtctgagcg aaatggcgct 600
     acgactgcga tgatgtatgg gattccagtc ttgattttta tctttgcagt ttatgcgcca 660
45
     ggtggagtcg ccctatactg gacagtgtct aatgcttatc aagtcttgca aacctatttc 720
     ttgaataatc cattcaagat tatcgcagag cgcgaggccg tagtacaggc acaaaaagat 780
     ttggaaaata gaaaaagaaa agccaagaaa aaggctcaga aaacgaaata a
     <210> 33
50
     <211> 1230
     <212> DNA
     <213> Streptococcus pneumoniae
     <400> 33
55
     atgaagatta gtaagaggca cttattaaat tattccatct tgattcccta cttactttta 60
     totattttgg gettgattgt ggtctattcg accaccagtg ctattttaat tgaagaagge 120
    aagagcgcct tgcagttggt tcgaaaccaa ggaatctttt ggattgttag tttgatactg 180
```

```
attgccttaa tttataaatt gagactagat tttttgagaa atgagcgact aatcatttta 240
      gttatattaa tagaaatgot tttattgtto ttggctcgtt ttattggtat ttcagtaaac 300
      ggggcatacg gttggatttc ggttgcagga gtaactattc agccagctga gtacttaaaa 360
      atcattatta tittggtatti ageteacega tieteeaaac ageaagaaga aatagetaet 420
      tatgattttc aagttttgac tcaaaatcaa tggcttcccc gtgcttttaa tgattggcga 480
      ttcgttctcc tagttctgat tggaagtttg ggaattttcc ctgatttagg aaatgcgact 540
      attttagtct tggtttcctt gattatgtat acagttagtg gaatcgctta tcgctggttt 600
      tcaaccattc tggcgctcgt atctgccact tctgtctttg tcttgaccac tatcagccta 660
      atcggtgttg agaccttttc aaaaattcca gtatttggct atgtagccaa gcgctttagt 720
      goottitta atcottitge egategiget gatgeaggie accagitage taattottat 780
      tttgccatgg tcaatggtgg ttggtttggt ctaggtcttg gaaactcgat tgaaaaacga 840
      ggttatttgc cagaagctca tacagacttt gtcttttcta tcgtgattga agaatttggc 900
      tttgttggtg ccagtcttat tttagctctc ttgtttttca tgattttgcg gattatcttg 960
      gtcggtatcc gagcggagaa tcctttcaat gccatggttg cactcggtgt cggagggatg 1020
      atgitggttc aggiattigt caatategga gggattiegg gettgattee atctacagga 1080
 15
      gtgactttcc ctttcttatc ccagggtgga aatagtcttc tagtcttatc agtggcagta 1140
      gcctttgtct taaatattga tgccagtgaa aaacgcgcta agttgtaccg agaattggaa 1200
      aatcaaccaa tgaaccttct gttgaagtag
 20
      <210> 34
      <211> 1260
      <212> DNA
      <213> Streptococcus pneumoniae
25
     <400> 34
     atgeteggaa ttttaacett tattetggtt tttgggatta ttgtagtggt geacgagtte 60
     gggcacttct actttgccaa gaaatcaggg attttagtac gtgaatttgc catcggtatg 120
     ggacctaaaa totttgctca cattggcaag gatggaacgg cotataccat togaatottg 180
     cctctgggtg gctatgtccg catggccggt tggggtgatg atacaactga aatcaagaca 240
30
     ggaacgeetg ttagtttgac acttgetgat gatggtaagg ttaaacgeat caatctetea 300
     ggtaaaaaat tggatcaaac agccctccct atgcaggtga cccagtttga ttttgaagac 360
     aagctcttta tcaaaggatt ggttctggaa gaagaaaaaa catttgcagt ggatcacgat 420
     gcaacggttg tggaagcaga tggtactgag gttcggattg cacctttaga tgttcaatat 480
     caaaatgcga ctatctgggg caaactgatt accaattttg caggtcctat gaacaatttt 540
35
     atcttaggtg tcgttgtttt ttgggtttta atctttatgc agggtggtgt cagagatgtt 600
     gataccaatc agttccatat catgccccaa ggtgccttgg ccaaggtagg agtaccagaa 660
     acggcacaaa ttaccaagat cggctcacat gaggttagca actgggaaag cttgatccaa 720
     gctgtggaaa cagaaaccaa agataagacg gcaccgactt tggatgtgac tatttctgaa 780
     aaggggagtg acaaacaagt cactgttaca cccgaagata gtcaaggtcg ttaccttcta 840
40
     ggtgttcaac cgggggttaa gtcagatttt ctatccatgt ttgtaggtgg ttttacaact 900
     gctgctgact cagctctccg aattctctca gctctgaaaa atctgatttt ccaaccggat 960
     ttgaacaagt tgggtggacc tgttgctatc tttaaggcaa gtagtgatgc tgctaaaaat 1020
     ggaattgaga atatottgta ottottggca atgatttoca toaatattgg gatttttaat 1080
     cttattccga ttccagcctt ggatggtggt aagattgtgc tcaatatcct agaagccatc 1140
45
     cgccgcaaac cattgaaaca agaaattgaa acctatgtca cettggccgg agtggtcatc 1200
    atggttgtct tgatgattgc tgtgacttgg aatgacatta tgcgactctt ttttagataa 1260
     <210> 35
     <211> 594
50
    <212> DNA
    <213> Streptococcus pneumoniae
    <400> 35
    atgtacgcat atttaaaagg aatcattacc aaaattactg ccaaatacat tgttcttgaa 60
    accaatggta ttggttatat cctgcatgtg gccaatcctt atgcctattc aggtcaggtt 120
    aatcaggagg ctcagattta tgtgcatcag gttgtgcgtg aggacgccca tttgctttat 180
    ggattteget cagaggatga gaaaaagete tttettagte taattteggt etetgggatt 240
```

```
ggtcctgtàt,cagctcttgc tattatcgct gctgatgaca atgctggctt ggttcaagcc 300
       attgaaacca agaacatcac ctacttgacc aagttcccta aaattggcaa gaaaacagcc 360
       cagcagatgg tgctggactt ggaaggcaag gtagtagttg caggagatga ccttcctgcc 420
       aaggtegeag tgeaageaag tgetgaaaac caagaattgg aagaagetat ggaageeatg 480
       ttggctctgg gctacaaggc aacagagctc aagaaaatca agaaattctt tgaaggaacg 540
       acagatacag ctgagaacta tatcaagtcg gcccttaaaa tgttggtcaa atag
       <210> 36
       <211> 774
 10
       <212> DNA
      <213> Streptococcus pneumoniae
      <400> 36
      atgaagaata atcgtatttt agcactttct ggaaatgata tttttagtgg tggtggactg 60
 15
      tcagctgatt tggctaccta taccttgaac ggcttgcatg ggtttgtagc agtgacttgt 120
      ttgacagcet tgacagaaaa aggatttgaa gtetttecaa etgatgatae cattttecaa 180
      catgaattag atagcttgcg tgatgtggaa tttgggggaa ttaagattgg tcttctccct 240
      actgtcagtg tggctgagaa ggccttggac tttatcaaac aacgcccagg agtacctgtg 300
      gtgttggatc ctgtcttggt ctgcaaggaa acgcatgatg tagctgtcag tgagctctgc 360
 20
      caagagttga ttcgcttctt cccttatgtc agtgtgatta cgcctaatct cccagaagca 420
      gaattattat coggtcagga aattaaaacc ttggaagaca tgaaaactgc agcgcagaaa 480
      ttgcatgatt taggagcgcc agcagtcatt atcaagggag gcaatcgtct tagtcaggac 540
      aaggetgtgg atgtetttta tgatggacag acetttaeta teetagaaaa teeagttate 600
      caaggccaaa atgctggtgc aggttgtacc tttgcctcta gcattgccag tcacctggtt 660
 25 aaaggtgata aatttttgcc agcagtagaa agctctaagg ctttcgttta tcgtgctatt 720
      gcacaagcag atcagtatgg agtaagacaa tatgaagcaa acaaaaacaa ctaa
      <210> 37
      <211> 1239
 30
      <212> DNA
      <213> Streptococcus pneumoniae
      <400> 37
     atgattgaaa cggagaaaaa agaggagcga gtcctgctga ttggtgtgga attgcagggt 60
35
     atggacagtt ttgacctctc catggaagaa ttggctagtt tagcgaaaac ggcaggggca 120
     gtcgttgtag atagctacag acaaaaacgt gaaaaatatg attccaagac cttcgtcggc 180
     tetggtaagt tggaagagat tgegettatg gtggatgeag aagaaateae tactgteate 240
     gtcaacaate gtctgaccce aaggcagaat gtcaatctag aggaagttct cggtgttaag 300
     gtcattgacc gtatgcagtt gattttggat atctttgcca tgcgggctcg aagccatgaa 360.
     gggaagetee aagteeacet ageceaatte aaatacetet tgeetegett ggttggteag 420
40
     gggattatgc tcagccgtca ggcaggggga attggttccc gtggtcctgg tgaaagccaa 480
     ctggagctga accgtcgtag cgttcgcaat caaatcacgg atatcgagcg ccagcttaag 540
     gtggttgaga aaaatcgtgc gactgtcaga gaaaaacgtt tggagtctag cacttttaag 600
     attggtttga ttggttatac taatgctggg aaatcaacta tcatgaacat cttgaccagt 660
45
     aagacccagt atgaagcaga tgagctcttt gcgactctgg atgcgacaac caagagtatt 720
     catctgggag gcaatctcca agtaactttg acagataccg ttggctttat ccaagatttg 780
     ccgacagagt tggtgtccag tttcaagtca accttggaag aaagcaagca tgtggacctt 840
     ctggttcatg ttatcgatgc tagcaatcct taccacgagg agcatgaaaa aacggttctc 900
     tccatcatga aagacctgga catggaagat attcctcact tgacgcttta taataaagcg 960
50
     gatttggtgg aggatttcac gcctacccaa acgccatata ccctcatttc tgccaagtct 1020
     gaggacagtc gtgaaaactt gcaagcatta ttgctagata agattaagga aatttttgaa 1080
    gcatttaccc tgcgagtgcc tttttcaaag tcctacaaga ttcatgattt agagagtgtt 1140
    gcaattetgg aagaacgiga ttatcaggaa gacggcgaag tgattacagg ctacattice 1200
    gagaaaaata aatggaggtt agaagaattt tatgactga
55
    <210> 38
```

<211> 483

```
<212> DNA
      <213> Streptococcus pneumoniae
      atggcagaaa aaacatatcc tatgaccctt gaggaaaagg aaaaacttga aaaagaatta 60
      gaagaattga aattggttcg tcgaccagaa gtggtagaac gcattaagat tgcccgttca 120
      tacggtgacc tttcagaaaa cagtgagtac gaagcagcta aggatgaaca agcctttgtc 180
      gaaggacaaa tetetagett agaaacaaaa ateegetatg etgaaategt caatagegae 240
      geagttgeec aggacgaagt agegattggt aaaacagtca ccatccaaga aattggtgag 300
 10
      gacgaagaag aagtttatat tatcgtaggt tcagctggtg cggatgcctt tgcaggtaag 360
      gtttcaaatg aaagcccaat tgggcaggcc ttgattggca agaaaacagg tgatacagca 420
      accattgaaa cgcctgttgg tagctatgat gtaaaaatct tgaaggttga aaaaacagcc 480
      <210> 39
      <211> 570
      <212> DNA
      <213> Streptococcus pneumoniae
 20
      <400> 39
      atgaccaaat tacttgtagg cttgggaaat ccaggggata aatattttga aacaaaacac 60
      aatgttggtt ttatgttgat tgatcaacta gcgaagaaac agaatgtcac ttttacacac 120
      gataagatat ttcaagctga cctagcatcc tttttcctaa atggagaaaa aatttatctg 180
      gttaaaccaa cgacctttat gaatgaaagt ggaaaagcag ttcatgcttt attaacttac 240
 25
      tatggtttgg atattgacga tttacttatc atttacgatg atcttgacat ggaagttggg 300
      aaaattegtt taagageaaa aggeteagea ggtggteata atggtateaa gtetattatt 360
      caacatatag gaactcaggt ctttaaccgt gttaagattg gaattggaag acctaaaaat 420
      ggtatgtcag ttgttcatca tgttttgagt aagtttgaca gggatgagta tatcggtatt 480
      ttacagtctg ttgacaaagt tgacgattct gtaaactact atttacaaga gaaaaatttt 540
30
     gagaaaacaa tgcagaggta taacggataa
                                                                        570
     <210> 40
     <211> 852
     <212> DNA
35
     <213> Streptococcus pneumoniae
     <400> 40
     atgattttaa ttacaggggc aaatggccaa ttaggaacgg aacttcgcta tttattggat 60
     gaacgtaatg aagaatacgt ggcagtagat gtggctaaga tggacattac caatgaagaa 120
40
     atggttgaga aagtttttga agaggtgaaa ccgactttag tctaccattg tgcagcctac 180
     accgctgttg atgcagcaga ggatgaagga aaagagttgg acttcgccat caatgtgacg 240
     gggacaaaaa atgtcgcaaa agcatctgaa aagcatggtg caactctagt ttatatttct 300
     acggactatg tctttgacgg taagaaacca gttggacaag agtgggaagt tgatgaccga 360
     ccagatccac agacagaata tggacgcact aagcgtatgg gggaagagtt agttgagaag 420
45
     catgtgtcta atttctatat tatccgtact gcctgggtat ttggaaatta tggcaaaaac 480
     ttcgttttta ccatgcaaaa tcttgcgaaa actcataaga ctttaacagt tgtaaatgat 540
     cagtacggtc gtccgacttg gactcgtacc ttggctgagt tcatgaccta cctagctgaa 600
     aatcgtaagg aatttggtta ttatcatttg tcaaatgatg cgacagaaga cacaacatgg 660
     tatgattttg cagttgaaat tttgaaagat acagatgtcg aagtcaagcc agtagattcc 720
50
     agtcaatttc cagccaaagc taaacgtccg ctaaactcaa cgatgagcct ggccaaagcc 780
     aaagctactg gatttgttat tccaacttgg caagatgcat tgcaagaatt ttacaaacaa 840
     gaagtgagat aa
    <210> 41
55
    <211> 1224
    <212> DNA
    <213> Streptococcus pneumoniae
```

```
<400> 41
       atgaaacgtt ctctcgactc aagagtcgat tacagtttgc tcttgccagt attttttcta 60
       ctggtcatcg gtgtggtggc tatctatata gccgttagtc atgattaccc caataatatt 120
       ctgcccattt tagggcagca ggtcgcctgg attgccttgg ggcttgtgat tggttttgtg 180
       gtcatgetet ttaatacaga atttetttgg aaggtgacce cetttetata tattttagge 240
       ttgggactta tgatcttgcc gattgtattt tataatccaa gcttagttgc atcaacgggt 300
       gccaaaaact gggtatcaat aaatggaatt accctattcc aaccgtcaga atttatgaag 360
       atateetata teeteatgtt ggetegtgte attgteeaat ttacaaagaa acataaggaa 420
      tggagacgca cggttccgct ggactttttg ttaattttct ggatgattct ctttaccatt 480
  10
       ccagtectag ttettttage actteaaagt gaettgggga eggetttggt ttttgtagee 540
      attttctcag gaatcgtttt attatcaggg gtttcttgga aaattattat cccagtattt 600
      gtgactgctg taacaggagt tgctggtttc ttagctatct ttattagcaa ggacggacga 660
      gettttette accagattgg aatgeegace taccaaatca ateggatttt ggettggete 720
      aatccctttg agtttgccca aacaacgact taccagcagg ctcaagggca gattgccatt 780
 15
      gggagtggtg gettatttgg teagggattt aatgettega atetgettat eecagttega 840
      gagtcagata tgatttttac ggttattgca gaagattttg gctttattgg ctctgtcctg 900
      gttattgccc tetateteat gttgatttac egtatgttga agattactet taaatcaaat 960
      aaccagttet acaettatat ttecacaggt ttgattatga tgttgetett ceacatettt 1020
      gagaatateg gtgetgtgae tggactaett cetttgaegg ggatteeett geettteatt 1080
 20
      tegeaagggg gateagetat tateagtaat etgattggtg ttggtttget tttategatg 1140
      agttaccaga ctaatctagc tgaagaaaag agcggaaaag ttccattcaa acggaaaaag 1200
      gttgtattaa aacaaattaa ataa
 25
      <210> 42
      <211> 609
      <212> DNA
      <213> Streptococcus pneumoniae
 30
      <400> 42
     atgggaaaaa tcatcggaat cactggggga attgcctcag gtaagtcaac tgtgacaaat 60
     tttctaaaac accaagggct ttcaagcagt ggattgccga cgcagtgttc caccaactac 120
     agaaaacctg gtggtcgtct gtttgaggct ttagtacagc actttgggca agaaatcatt 180
     cttgaaaacg gagaactcaa tcgccctctc atagctagtc tcatcttttc aaatcctgaa 240
35
     gagcaaaaat ggtctaatca aattcaaggg gagattatcc gtgaggaact ggctactttg 300
     agagaacagt tggctcagac agaagagatt ttcttcatgg atattcccct actttttgaa 360
     caggactaca gegattggtt tgctgagact tggttggtct atgtggaceg agatgeecaa 420
     gtagaacgct taatgaaaag ggaccagttg tccaaagatg aagctgagtc tcgtatggca 480
     gcccagtggc ctttagaaaa aaagaaagat ttggccagcc aggttcttga taataatggc 540
     aatcagaacc agcttcttaa tcaagtgcat atcettcttg agggaggtag gcaagatgac 600
40
     agagattaa
     <210> 43
     <211> 1260
45
     <212> DNA
     <213> Streptococcus pneumoniae
   . <400> 43
     atgagaaaaa ttgttatcaa tggtggatta ccactgcaag gtgaaattac tattagtggt 60
50
     gctaaaaata gtgttgtggc cttaattcca gctattatat tggctgatga tgtggtgact 120
    ttggattgtg ttccagatat ttcggatgta gccagtcttg tcgaaatcat ggaattgatg 180
    ggagctactg ttaagcgtta tgacgatgtc ttggagattg atccaagagg tgttcaaaat 240
    attecaatge ettatggtaa aattaacagt ettegtgeat ettaetattt ttatgggage 300
    ctcttaggcc gttttggtga agcgacagtt ggtctaccgg gaggatgtga tcttggtcct 360
55
    cgtccgattg acttacacct taaggcgttt gaagctatgg gtgccactgc tagctacgag 420
    ggagataaca tgaagttatc tgctaaagat acaggacttc atggtgcaag tatttacatg 480
    gatacggtta gtgtgggagc aacgattaat acgatgattg ctgcagttaa agcaaatggt 540
```

```
cgtactatta ttgaaaatgc agcccgtgaa cctgagatta ttgatgtagc tactctcttg 600
       aataatatgg gtgcccatat ccgtggggca ggaactaata tcatcattat tgatggtgtt 660
       gaaagattac atgggacacg tcatcaggtg attccagacc gcattgaagc tggaacatat 720
       atatetttag etgetgeagt tggtaaagga attegtataa ataatgttet ttaegaacae 780
   5
       ctggaagggt ttattgctaa gttggaagaa atgggagtga gaatgactgt atctgaagac 840
       agcattittg tegaggaaca gtetaatttg aaagcaatea atattaagae ageteettae 900
       ccaggetttg caactgattt gcaacaaccg ettaccecte ttttactaag agegaatggt 960
       cgtggtacaa ttgtcgatac gatttacgaa aaacgtgtaa atcatgtttt tgaactagca 1020
       aagatggatg cggatatttc gacaacaaat ggtcatattt tgtacacggg tggacgtgat 1080
  10
      ttacgtgggg ccagtgttaa agcgaccgac ttaagagctg gggctgcact agtcattgct 1140
      gggcttatgg ctgaaggtaa aactgaaatt accaatattg agtttatctt acgtggttat 1200
      totgatatta togaaaaatt acgtaattta ggagoggata ttagacttgt tgaggattaa 1260
      <210> 44
 15
      <211> 696
      <212> DNA
      <213> Streptococcus pneumoniae
      <400> 44
 20
      atgtcaagaa ttgaattttc accatctttg atgaccatgg atttggacaa attcaaagag 60
      cagattactt ttttgaatga taaagtagca tcttatcata tcgatattat ggatggccat 120
      tttgttccca atattacctt gtctccttgg ttcattcaag aagttcaaaa aattagtgac 180
      acacctttat cagttcatct gatggtcaca gacccaacct tttgggtaga tcaagttctc 240
      gatttacaat gtgagtatat ttgtattcat gctgaagttc tgaatggtct tgcttttcgt 300
 25
      ttgattgata aaattcatga tgcaggtcta aaggctggtg ttgtccttaa tcctgaaaca 360
      cctgtttcta caatctttcc ctacattgat ttacttgaca aagtaactat tatgactgta 420
      gatccaggtt ttgcaggaca acgetttttg gagtctacet tgtataaaat ccaagaacte 480
     cgtcagctta gagttcagaa tggttatcac tacatcattg agatggatgg ttcttcgagt 540
     cgtaagactt tcaaacaaat tgatgtggca ggaccagata tttatgttat aggtcgcagt 600
 30
     ggattatttg gtttggatga cgatattgcc aaagcctggg atatctgttc tagagattac 660
      gaagaaatga ccggaaaaac aatgccaatc aaataa
     <210> 45
     <211> 1125
35
     <212> DNA
     <213> Streptococcus pneumoniae
     <400> 45
     atgagaaata tggctttgac agcaggtatc gttggtttgc caaacgttgg taaatcaaca 60
     ctatttaatg caattacaaa agcaggagca gaggcagcaa actacccatt tgcgactatt 120
40
     gatccaaatg ttggaatggt ggaagatcca gatgaacgcc tacaaaaact aactgaaatg 180
     ataacteeta aaaagacagt teecacaaca tttgaattta eggatattge agggattgta 240
     aaaggagett caaaaggaga agggetaggg aataaattet tggecaatat tegtgaagta 300
     gatgcgattg ttcacgtagt tcgtgctttt gatgatgaaa atgtgatgcg cgagcaagga 360
45
     cgtgaagacg cetttgtaga tecaettgea gatattgata caattaatet ggaattaatt 420
     cttgctgact tagaatcagt gaacaaacga tatgcgcgtg tagaaaagat ggcacgtacg 480
     caaaaagata aagaatcagt agcagaattc aatgttcttc aaaagattaa accagtccta 540
     gaagacggga aatcagctcg taccattgaa tttacagatg aggaacaaaa ggttgtcaaa 600
     ggtcttttcc ttttgacgac taaaccagtt ctttatgtag ctaatgtgga cgaggatgtg 660
50
    gtttcagaac ctgactctat cgactatgtc aaacaaattc gtgaatttgc agcgacagaa 720
    aatgetgaag tagtegttat ttetgegegt getgaggaag aaatttetga attggatgat 780
    gaagataaaa aagagtttct tgaagccatt ggtttgacag aatcaggtgt agataagttg 840
    acgegtgeag ettaceaett gettggattg ggaacttact teacagetgg tgaaaaagaa 900
    gttcgcgctt ggactttcaa acgtggtatg aaggctcctc aagcagctgg tattatccac 960
55
    tcagactttg aaaaaggett tattegtgea gtaaccatgt catatgaaga tetagtgaaa 1020
    tacggatetg aaaaggeegt aaaagaaget ggacgettge gtgaagaagg aaaagaatat 1080
    atcgttcaag atggcgatat catggaattc cgctttaatg tctaa
                                                                       1125
```

```
<210> 46
      <211> 333
     <212> DNA
  5
     <213> Streptococcus pneumoniae
      <400> 46
      atggaaatcg aaaaaaccaa tcgtatgaat gcgctctttg aattttatgc ggcgcttttg 60
      acagataagc aaatgaatta tatagagctt tactacgctg atgattacag tcttgctgag 120
 10
      atagctgagg agtttggtgt tagtcgtcag gctgtctatg acaatatcaa gcgaacagaa 180
      aagattctgg aagattatga gatgaaattg cacatgtact cggactacat tgtccgtagt 240
      cagatttttg accaaatctt ggagcgctat cccaaggatg attttctgca ggagcagata 300
      gaaattttaa caagcattga taatagagaa taa
 15
      <210> 47
      <211> 672
      <212> DNA
      <213> Streptococcus pneumoniae
 20
      atgacettag aatgggaaga atttetagat cettacatte aagetgttgg tgagttaaag 60
     attaaacttc gtggtattcg taagcaatat cgtaagcaaa ataagcattc tccaattgag 120
     tttgtgaccg gtcgagtcaa gccaattgag agcatcaaag aaaaaatggc tcgtcgtggc 180
     attacttatg cgaccttgga acacgatttg caggatattg ctggcttacg tgtgatggtt 240
25
     cagtttgtag atgacgtcaa ggaagtagtg gatattttgc acaagcgtca ggatatgcga 300
     atcatacagg agcgagatta cattactcat agaaaagcat caggctatcg ttcctatcat 360
     gtggtagtag aatatacggt tgataccatc aatggagcta agactatttt ggcagaaatt 420
     caaattcgta ctttggccat gaatttctgg gcaacgatag aacattctct caactacaag 480
     taccaagggg atttcccaga tgagattaag aagcgactgg aaattacagc tagaatcgcc 540
30
     catcagttgg atgaagaaat gggtgaaatt cgtgatgata tccaagaagc ccaggcactt 600
     tttgatcctt tgagtagaaa attaaatgac ggtgtaggaa acagtgacga tacagatgaa 660
     gaatacaggt aa
     <210> 48
35
     <211> 588
     <212> DNA
     <213> Streptococcus pneumoniae
     <400> 48
40
     atggaactta atacacacaa tgctgaaatc ttgctcagtg cagctaataa gtcccactat 60
     ccgcaggatg aactgccaga gattgcccta gcagggcgtt caaatgttgg taaatccagc 120
     tttatcaaca ctatgttgaa ccgtaagaat ctcgctcgta catcaggaaa acctggtaaa 180
    acceagetee tgaacttttt taacattgat gacaagatge getttgtgga tgtgeetggt 240
     tatggctatg ctcgtgtttc taaaaaggaa cgtgaaaagt gggggtgcat gattgaggag 300
45
   tacttaacga ctcgggaaaa tctccgtgcg gttgtcagtc tagttgacct tcgtcatgac 360
     ccgtcagcag atgatgtgca gatgtacgaa tttctcaagt attatgagat tccagtcatc 420
     attqtqqcqa ccaagqcqqa caaqattcct cgtqgtaaat ggaacaagca tgaatcagca 480
     atcaaaaaga aattaaactt tgacccaagt gacgatttca tcctcttttc atctgtcagc 540
     aaggcaggga tggatgaggc ttgggatgca atcttagaaa aattgtga
50
     <210> 49
     <211> 294
     <212> DNA
     <213> Streptococcus pneumoniae
55
    <400> 49
    atgaaaacaa gaaaaatccc tttgcgcaag tctgttgtgt ctaacgaagt gattgataag 60
```

```
cgtgatttgc tccgcattgt taagaacaag gaaggacaag tctttattga tcctacgggc 120
      aaggccaatg geegeggege ttatateaaa etagacaatg cagaageeet agaggegaaa 180
      aagaagaagg tctttaaccg cagctttagc atggaagtgg aagaaagctt ttatgacgag 240
      ttgatcgctt atgtggatca caaagtgaaa agaagagagt tgggacttga ataa
      <210> 50
      <211> 312
      <212> DNA
      <213> Streptococcus pneumoniae
10
      <400> 50
      atgttaaaac cctctattga taccttgctc gacaaggttc cttcaaaata ttcactcgta 60
      atcttggaag caaaacgtgc ccacgaattg gaagcaggtg ccccagcaac tcaaqqtttc 120
      aagtotgaaa aatcaactot togogottta gaagaaatog aatcaggaaa ogttacaatt 180
 15
      cacccagatc cagaaggaaa acgtgaagca gtgcgtcgcc gtatcgaaga agaaaaacgc 240
      cgcaaagaag aagaagaaaa gaaaatcaaa gagcaaattg ctaaagaaaa agaagatggt 300
      gaaaaaattt aa
      <210> 51
20
      <211> 312
      <212> DNA
      <213> Streptococcus pneumoniae
25
     atgtcattaa catcaaaaca acgtgccttc ctcaacagcc aggcacacac cctcaaacct 60
      atcatccaaa tcgggaaaaa tggactcaac gaccaaatca aaaccagcgt ccgtcaagct 120
     cttgatgcgc gtgaattaat caaggttact ctcttacaaa acacagatga aaacatccac 180
     gaagtagetg aaattttgga agaagaaate ggtgtggata cagtecaaaa aataggaege 240
     atcttgattt tgtttaaaca atctagcaag aaagaaaatc gcaagatttc taagaaagtc 300
30
     aaagaaatct aa
     <210> 52
     <211> 528
     <212> DNA
35
     <213> Streptococcus pneumoniae
     <400> 52
     atggcgattg aaaattatat accagatttt gctgtggaag cagtctatga tctgacagtc 60
     ccaagcctgc aggcgcaggg aatcaaggct gttttggtcg atttggataa taccctcatt 120
40
     gcttggaaca accctgatgg aacgccagag atgaagcaat ggctacatga ccttcgggac 180
     gegggtattg geattategt agtgteaaat aacaccaaaa aacgegttea acgageagtt 240
     gagaaatttg ggattgatta cgtttactgg gccttgaagc ccttcacatt tggtattgac 300
     cqtqctatga aggaattcca ctatgacaaa aaggaagtgg tcatggttgg tgaccagete 360
     atgacagata tacgagcagc ccaccgtgca gggattcggt caattttagt caaacccttg 420
45
     gtccaacatg actcaatcaa aacgcagatt aaccgaactc gtgagcgtcg tgttatgaga 480
     aaaatcactg aaaagtacgg accgattaca tataaaaaag gaatttaa
     <210> 53
     <211> 1368
50
     <212> DNA
     <213> Streptococcus pneumoniae
     atgtttcgaa aaattttaat tgccaatcgt ggtgaaattg cggttcgtat tatccgtgcg 60
55
     gcacgtgaat tggggattgc gacggtagcg gtttattcaa ctgctgataa ggaagctctt 120
     catacgctgt tggcagatga agcagtttgt attggtcctg gcaaggcaac agagtcttat 180
    ctcaatatta atgcagttct atcagctgca gtcttgactg aggcagaagc tattcaccct 240
```

```
ggttttggat ttctcagtga aaattccaaa tttgcgacca tgtgtgaaga aataggtatc 300
      aagtttatcg gtccatctgg tcatgttatg gatatgatgg gggataaaat caatgcgcgt 360
      gctcagatga ttaaagcagg tgtgcctgtt ataccaggtt cagatggaga agtgcataac 420
      tctgaagaag ctttgattgt tgctgaaaaa attggctatc ctgttatgct caaggcttca 480
    gcaggtggag gtggtaaagg gattcgtaag gttgaaaaac cagatgacct cgtttctgcc 540
      tttgaaactg cctctagtga ggccaaggcc aattatggca atggtgccat gtacatagaa 600
      cgggttatct atccagctcg gcacattgag gttcaaatcc taggtgatga gcatggacat 660
      gtgattcact tgggtgaacg ggattgttct cttcaaagga ataaccaaaa ggttttggaa 720
      gaaagtccct cgattgcaat cggaaaaacg ctgcgtcatg aaataggtgc tgctgctgtt 780
 10
      cgagcggcag agtttgttgg ctatgagaat gcaggaacca ttgaatttct tcttgatgaa 840
      gcaagtagca atttctattt catggagatg aatactcgtg ttcaggtaga acatccagta 900
      acagagtttg tttcaggtgt tgatatcgtt aaggaacaga tttgcattgc ggcaggtcag 960
      cctttgtctg ttaagcaaga agatattgtc ctacgcggtc atgccatcga gtgtcgtatc 1020
      aatgcagaaa acccagcett taactttget ecaagtecag gtaagattae taatetetat 1080
 15
      ctgccaagtg gtggagttgg cttgcgcgtg gattcagcag tttatccagg ttataccatt 1140
      cogcettatt atgatagtat gattgccaaa atcatagtac acggcgaaaa tcgttttgac 1200
      gccttgatga aaatgcaacg tgccctctat gaattagaaa ttgaaggagt gcagaccaat 1260
      gcagatttcc agcttgacct catttcagat cgcaatgtca ttgctgggga ttatgatact 1320
      tgcttcttga tggaaacctt cttacctaaa tatcaagaaa aagaataa
 20
      <210> 54
      <211> 234
      <212> DNA
      <213> Streptococcus pneumoniae
25
      <400> 54
     atgatttaca aagtttttta tcaagaaaca aaagaacgta gcccacgccg tgaaacaaca 60
     cgcgcgcttt acctagacat cgataccagc tcagaacttg agggccgtat cactgctcgc 120
     caacttgtcg aagaaaatcg cccagagtac aatatcgaat atatcgaact cttgtctgac 180
30
     aaattgctcg attacgaaaa agaaactggc gccttcgaaa ttacggagtt ctaa
     <210> 55
     <211> 1011
     <212> DNA
35
     <213> Streptococcus pneumoniae
     <400> 55
     atgaaggata gatatatttt agcatttgag acatcctgtg atgagaccag tgtcgccgtc 60
     ttgaaaaacg acgatgagct cttgtccaat gtcattgcta gtcaaattga gagtcacaaa 120
40
     cgttttggtg gcgtagtgcc cgaagtagcc agtcgtcacc atgtcgaggt cattacagcc 180
     tgtatcgagg aggcattggc agaagcaggg attaccgaag aggacgtgac agctgttgcg 240
     gttacctacg gaccaggctt ggtcggagcc ttgctagttg gtttgtcagc tgccaaggcc 300
     tttgcttggg ctcacggact tccactgatt cctgttaatc acatggctgg gcacctcatg 360
     gcagctcaga gtgtggagcc tttggagttt cccttgctag ccctcttggt cagcggcgga 420
     cacacagagt tggtctatgt ttctgaggct ggcgattaca agattgttgg ggagacacga 480
     gatgacgcgg ttggcgaggc ctatgataag gtcggccgtg tcatgggctt gacctatcct 540
     gcaggtcgtg agattgacga gctggctcat caggggcagg atatttatga tttcccccgt 600
     gccatgatta aggaagataa tctggagttt tcattctctg gtttgaagtc agcctttatc 660
     aatetteate acaatgeega geaaaaggga gaaageetgt etacagaaga tttgtgtget 720
50
     tccttccaag cagcagttat ggacattctc atggcaaaaa ccaagaaggc tttggaggaa 780
    tatcctgtta aaaccctatt tgtggcaggt ggtgtggcag ccaataaagg tctcagagaa 840
    cgcttagcag ccgaaatcac agatgtcaag gttatcatcc cccctctgcg actctgcgga 900
    qacaatgcag qtatgattgc ctatgccagc gtcagcgagt ggaacaaaga aaacttcgca 960
    ggctgggacc tcaatgccaa accaagtctt gcctttgata ccatggaata a
55
    <210> 56
     <211> 1809
```

<212> DNA 213> Streptococcus pneumoniae

```
atgtgtggaa ttgttggtgt tgttggaaac acaaatgcaa ctgatatttt gattcaaggg 60
      cttgaaaagc ttgaataccg tggctatgat tctgcgggaa tttttgtcct agatggtgct 120
      gataaccatt tggtgaaggc ggttggtcgt attgcagaat tgtctgccaa gacagctggt 180
      gttgagggaa caactggtat cggacatact cgttgggcta ctcacggaaa accaactgag 240
      gacaatgete acceacaceg etetgagaca gaacgttttg tettggtgca taatggggtg 300
      attgagaact atcttgaaat caaggaagaa taccttgcag gtcaccactt caaggggcag 360
      acagatactg aaatagccgt tcatttgatt ggaaaatttg cggaagaaga agggctctca 420
      gttcttgaag cctttaaaaa agctcttcat attatccgtg gttcatatgc ctttgccttg 480
      attgactetg aaaateeaga tgtcatetat gtagegaaaa acaaatetee aettttgatt 540
      ggtcttgggg aaggctacaa tatggtctgc tcagatgcta tggctatgat tcgtgaaacc 600
 15
      aaccaataca tggaaattca tgaccaagag ttggtaatcg tcaaggctga tagcgtggaa 660
      tcagatatcg gtaagggaac ttatccttac tacatgctta aggaaattga tgagcaacca 780
      actgttatgc gtaaactcat tcaagcctac acggatgatg ctggtcaagt agtggttgct 840
      cetgetatea ttaaggetgt teaagaegea gacegeatet acateettge agetggaaca 900
- 20
      tettaccatg caggatttgc ttetaagaaa atgttggaag aattgacaga tacaccagtt 960
      gaacttggaa tctcatctga gtggggctac ggtatgccac ttctcagcaa gaaaccactc 1020
      ttcatcttta tcagccaatc tggtgaaaca gcggatagtc gtcaagtttt ggtcaaggct 1080
      aatgaaatgg gaattccaag cttaacagtg acaaatgttc caggttcaac cctctcacgt 1140
      gaagecaact ataccatget cetteacgea ggaectgaaa ttgeegtgge atcaactaaa 1200
 25
      gcctatacag cgcaaatcgc agcccttgcc ttccttgcaa aagcagtcgg agaagcaaat 1260
     ggtaatgeta aagcgcaagc cittgacctg gttcatgaat tgtcaatcgt agctcagtct 1320
      attgaatcaa etettteaga gaaagaaace attgaageea aggttegtga aettettgaa 1380
     acaactegta acgeetttta categgaegt ggtcaagatt actaegtage catggaagea 1440
     agteteaaac teaaagagat ttettatate eagtgtgaag gttttgegge aggagaacte 1500
 30
     aagcacggaa ccattgcctt gattgaagaa ggaacgcctg ttttggctct cttgtcagat 1560
     ccagttettg ccaaccatac tcgtggaaat atccaagagg tcgcagcccg tggtgccaaa 1620
     gtcctcacta tcgcagaaga gaatgtagcc aaagataccg acgatatcgt ccttacgacc 1680
     gtacatecat accteteace aattteaatg gtegtaceaa egeaattagt egettacttt 1740
     gcaaccetee accetegeet egatetegae aaaccaeeta accttegeeaa etcaetaaee 1800
 35
     gtagaataa
     <210> 57
     <211> 723
     <212> DNA
40
     <213> Streptococcus pneumoniae
     atgatacgta tcgaaaatct cagtgtctcc tacaaagaaa cgttggcact taaggatatt 60
     tcactagtgc tccatggacc aacaattacc ggcatcattg gtccaaacgg cgctgggaaa 120
45
     tcaacactat taaaaggtat gctgggaatt atcccacatc aaggtcaggc atttctcgat 180
     gacaaggaag ttaaaaaatc cttacaccga attgcctatg tcgaacaaaa aatcaatatc 240
     gactacaact ttcccatcaa ggtcaaggaa tgcgtctcgt taggactatt tccctctatt 300
     cetetette gaagtttaaa ggetaaacat tggaagaaag tgcaagagge cettgaaate 360
     gtcggcctag ctgactacgc tgaacgtcaa attagtcaac tgtctggagg tcaattccag 420
50
    cgggtcttga ttgccagatg tttggtgcag gaagccgact atatcctctt ggatgaaccc 480
    tttgctggga ttgactctgt cagtgaggaa atcatcatga atacgctgag agatttgaaa 540
    aaagetggga agaeggttet categtteae caegaeetea geaagattee eeaetaette 600
    gatcaagtct tacttgtcaa tcgagaagtg attgcctttg gtccaacaaa agaaactttt 660
    accgaaacca atctaaaaga agcttacggt aatcaactct ttttcaatgg aggtgaccta 720
55
    tga
                                                                     723
```

<210> 58

<211> 2223 <212> DNA

```
<213> Streptococcus pneumoniae
      <400> 58
      atgccgaaag aagtgaattt aacaggcgaa gaagttgtcg ctttaaccaa agaatattta 60
      acggaagagg atgttcattt tgtccataag gccttggtct atgctgttga atgccacagt 120
      ggtcaatatc gcaaatcagg cgagccttat atcattcacc ctatccaagt ggcaggtatt 180
      ttagctaagc taaagctgga tgctgtaaca gtagcttgtg gattcttgca tgatgtggtg 240
 10
      gaagatacag atgcgacctt ggacgatttg gaaagagagt ttggtcctga tgtgcgggtg 300
      attgttgacg gagttaccaa gcttggcaag gtcgagtaca aatcgatcga ggagcaatta 360
      geggaaaate ategeaagat geteatggee atgtetgagg acateegegt tattttggte 420
      aaactgtetg accgettgea caatatgegg accetgaaac atettegaaa agacaageag 480
      gagegtattt ccaaagaaac catggaaatc tatgccccac ttgcccatcg tttggggatt 540
15
      tccagtgtca aatgggaatt agaagacttg tctttccgtt atctcaatcc aacggagttt 600
      tacaagatta cccatatgat gaaggaaaag cgcagggagc gtgaggcctt ggtggatgag 660
      gtagtcacaa aattagagga gtatacgaca gaacgtcact tgaaagggaa gatttatggt 720
      cgtcccaagc atatttactc aattttccgc aaaatgcagg acaagagaaa acggtttgag 780
      quaatctatg atctgattgc tattcgttgt attttagata cccaaagtga tgtttatgcc 840
 20
      atgcttggtt acgtgcatga attttggaaa ccgatgccag gtcgcttcaa agactatatt 900
      gccaaccgca aggccaatgg ttatcagtct atccatacga ctgtttatgg accaaaaggg 960
      ccgattgaat tccagattcg aaccaaggaa atgcacgagg tggctgagta cggggttgcg 1020
      gctcactggg cttataagaa aggtataaag gggcaagtta acagcaagga atcagctatt 1080
      ggaatgaact ggatcaagga gatgatggag ctccaagacc aggctgatga tgctaaggaa 1140
 25
      tttgtggact ctgttaagga aaactatctg gctgaggaga tttacgtttt taccccagat 1200
      ggagetgtee gtteeettee caaagattea ggacegattg attttgeeta egaaateeat 1260
      accaaggteg gtgaaaaage aactggtgee aaggteaatg geegeatggt teeactgaea 1320
      accaagttaa agacagggga tcaggttgaa attatcgcca acccgaactc ctttggacct 1380
      agccgtgact ggctcaatat ggtcaagact agcaaggcgc gcaataagat tcgccagttc 1440
30
     tttaaaaacc aagataagga attgtctgtc aacaagggtc gtgagatgct gatggctcag 1500
     ttccaagaaa atggctatgt ggcaaataaa tttatggaca agcgccacat ggatcaagtt 1560
     ctgcaaaaga ccagttacaa gacagaagac tccctctttg cggccattgg ttttggggaa 1620
     atcggtgcga ttaccgtctt taaccgtctg actgaaaagg aacgccgtga ggaagagcgt 1680
     gccaaggcca aggctgaggc agaggagctt gtcaaaggtg gcgaggtcaa ggttgaaaat 1740
35
     aaagaaactc tcaaggtcaa gcatgagggg ggagtggtta ttgaaggtgc ttctggtctc 1800
     ctagtgcgga ttgctaagtg ttgtaacccc gtgcctggtg acgatattgt tggctacatt 1860
     accaagggtc gtggtgtggc tattcaccgt gtggactgta tgaacctgcg tgcccaagaa 1920
     aactacgage aacgteteet tgatgtggaa tgggaagaee agtactetag etcaaataag 1980
     gagtatctgg cccatatcga tatctacggt ctcaaccgta caggactgtt gaacgatgta 2040
40
     ctgcaagttc tttcaaatac aaccaagaat atttcaacgg tcaatgccca accaaccaag 2100
     gatatgaagt ttgctaatat ccatgtgtcc ttcggtattg ccaacctctc tacactgacc 2160
     acggttgtcg ataaaattaa gagtgtgcca gaagtttact ctgtcaaacg gaccaacggc 2220
     tag
                                                                        2223
45
     <210> 59 .
     <211> 1479
     <212> DNA
     <213> Streptococcus pneumoniae
50
     <400> 59
     atgtctaatt gggacactaa atttttgaaa aaaggtttta cctttgatga tgtattgctt 60
     attccagctg aaagtcatgt gttgcctaac gatgcagatt taacaactaa attggcagat 120
     aatttgactt taaatatccc aattattacc gctgccatgg acacagttac agagagtcaa 180
    atggccattg ctattgctcg tgcaggcggt ctcggagtta tccataaaaa catgtcaatt 240
55
    gctcaacaag cagacgaggt tcgtaaggta aaacgttctg aaaatggagt tattattgat 300
    ccgttcttct tgacgcctga acatacaatt gctgaagcag atgagcttat gggtcgttac 360
```

cgcatcagtg gtgttccagt tgttgaaaca cttgaaaatc gtaaattggt tggtattttg 420

```
acaaaccgag atcttcgttt tatttcagat tataatcaac caatttcaaa ccatatgact 480
      agtgaaaatc ttgttactgc tcctgtgggt acggatcttg caacggctga gagtattctt 540
      caagagcatc gtattgaaaa acttccgttg gtcgatgaag aaggcagtct ttctggtttg 600
      atcactatca aagatattga aaaagttatt gagtttccaa atgcggctaa agatgagttt 660
      ggtcgtcttc tagttgcagg tgcagtaggt gttacttcag atacatttga acgtgcagag 720
      gctctttttg aggcaggagc ggatgcgatt gttattgata ctgcacatgg tcattctgca 780
      ggtgtcttgc gtaaaattgc cgagattcgt gctcatttcc cagatcggac tttgattgct 840
      ggaaatattg ctactgctga aggtgcacgt gccctttatg aagcgggtgt agacgttgtt 900
      aaggttggta ttggaccagg ttctatctgt actactcgtg tgattgctgg tgttggtgtt 960
 10
      ccgcaagtaa cagctatcta cgatgctgca gctgttgcgc gcgaatatgg taaaacgatt 1020
      attgctgacg gtgggatcaa gtattctgga gatattgtaa aagcacttgc tgcaggtgga 1080
      aatgctgtta tgcttggatc tatgtttgct ggaactgatg aagctccagg cgaaactgaa 1140
      atcttccaag gacgtaaatt caagacttac cgtggtatgg gatcaattgc tgctatgaag 1200
      aaaggttcaa gcgaccgtta tttccaaggt tctgtcaatg aagcaaacaa gcttgttcca 1260
 15
      gaaggaattg aaggtcgtgt tgcttataaa ggagcggcag ctgatattgt tttccaaatg 1320
      attggtggta ttcgctctgg tatgggttac tgtggtgcag ctaaccttaa agaactacac 1380
      gataatgctc aatttattga aatgtctggt gctggtttga aagaaagcca tcctcatgat 1440
      gtgcaaatta ctaatgaggc accaaattat tctatgtaa
 20
      <210> 60
      <211> 1947
     <212> DNA
     <213> Streptococcus pneumoniae
25
     <400> 60
     atgacagaag aaatcaaaaa totgoaggoa caggattatg atgocagtoa aattoaagtt 60
     ttagagggct tagaggctgt tcgtatgcgt ccagggatgt acattggatc aacctcaaaa 120
     gaaggtette accatetagt etgggaaatt gttgataact caattgacga ggeettggea 180
     ggatttgcca gccatattca agtttttatt gagccagatg attcgattac tqttqtqqat 240
30
     gatgggcgtg gtatcccagt cgatattcag gaaaaaacag gccgtcctgc tgttgagacc 300
     gtctttacag tccttcacgc tggaggaaag ttcggcggtg gtggatacaa ggtttcaggt 360
     ggtcttcacg gggtggggtc gtcagtagtt aatgcccttt ccactcaatt agacgttcat 420
     gttcacaaaa atggtaagat tcattaccaa gaataccgtc gtggtcatgt tgtcgcagat 480
     35
     aaaatottoa otgaaacaac aatotttgat tttgataaat taaataaacg gattcaagag 600
     ttggcctttc taaatcgcgg tcttcaaatt tcaattacag ataagcgcca aggtttggaa 660
     caaaccaagc attatcatta tgaaggtggg attgctagtt acgttgaata tatcaacgag 720
     aacaaggatg taatctttga tacaccaatc tatacagacg gtgagatgga tgatatcaca 780
     gttgaggtag ccatgcagta cacaactggt taccatgaaa atgtcatgag tttcgccaat 840
40
     aatattcata cacatgaagg tggaacgcat gaacaaggtt tccgtacagc cttgacacgt 900
     gttatcaatg attatgctcg taaaaataag ttactgaaag acaatgaaga caacctaaca 960
     ggggaagatg ttcgcgaagg cttaactgca gttatctcag ttaaacaccc aaatccacag 1020
     tttgaaggac aaaccaagac caaattggga aatagcgaag tggtcaagat taccaatcgc 1080
     ctcttcagtg aagccttctc cgatttcctc atggaaaatc cacagattgc caaacgtatc 1140
45
     gtggaaaaag ggattttage tgccaagget egtgtggetg ecaagegtge gegtgaagte 1200
     acacgtaaaa aatctggttt ggaaatttcc aaccttccag ggaaactagc agactgttct 1260
     tetaataace etgetgaaac agaactette ategtegaag gagacteage tggtggatea 1320
     gccaaatctg gtcgtaaccg tgagtttcag gctatccttc caattcgcgg taagattttg 1380
     aacgttgaaa aagcaagtat ggataagatt ctagctaacg aagaaattcg tagtcttttc 1440
50
    acagccatgg gaacaggatt tggcgcagaa tttgatgttt cgaaagcccg ttaccaaaaa 1500
    ctcgttttga tgaccgatgc cgatgtcgat ggagcccaca ttcgtaccct tcttttaacc 1560
    ttgatttatc gttatatgaa accaatccta gaagctggtt atgtttatat tgcccaacca 1620
    ccaatctatg gtgtcaaggt tggaagcgag attaaagaat atatccagcc gggtgcagat 1680
    caagaaatca aactccaaga agctttagcc cgttatagtg aaggtcgtac caaaccgact 1740
55
    attcagcgtt ataaggggct aggtgaaatg gacgatcatc agctgtggga aacaaccatg 1800
    gatcccgaac atcgcttgat ggctagagtt tctgtagatg atgctgcaga agcagataaa 1860
    atctttgata tgttgatggg ggatcgagta gagcctcgtc gtgagtttat cgaagaaaat 1920
```

```
gctgtctata gtacacttga tgtctaa
                                                                         1947
       <210> 61
       <211> 267
       <212> DNA
       <213> Streptococcus pneumoniae
      atgggattta ctgaagaaac agtacgtttt aaattggacg attccaataa aaaagaaatt 60
      agcgaaactt tgacagatgt ttatgcttcg ttgaacgata agggttacaa cccaattaac 120
      caaatcgtag gttacgtatt gagtggagac cctgcctacg ttcctcgtta taataatgca 180
      cgaaatcaaa tccgtaagta tgagcgtgat gaaatcgttg aggaattggt tcgctactac 240
      ctcaaaggac aaggagtcga tctataa
 15
      <210> 62
      <211> 597
      <212> DNA
      <213> Streptococcus pneumoniae
 20
      <400> 62.
      atggtcaact atccacataa agtttcatca caaaaaagac aaacatctct ttctcaaccc 60
      aaaaaatttcg caaatcgagg aatgtctttt gaaaagatga tcaatgctac caacgactac 120
      tatttgtctc agggcttggc tgttatacat aagaaaccaa ctcctattca aatcgtacaa 180
      gtggactatc cacaacgaag tcgtgccaag attgttgaag cctattttcg acaagcttca 240
25
      acgacggact attctggcgt ttataatgga tattacatcg actttgaagt caaggaaaca 300
      aaacaaaaac gtgcgattcc gatgaaaaat tttcatccac atcagattca gcatatggaa 360
      caagteettg cecaacaagg aatetgettt gteettette aettttette teageaagaa 420
      acctacttat tgccggcatt cgatttgatt cgcttctatc atcaagataa gggacaaaaa 480
      tcaatgccac ttgaatatat tcgagaatat ggatatgaaa tcaaggctgg tgccttccct 540
30
     caaattcctt atctcaatgt tatcaaagaa catttattag gtggtaaaac aagatga
     <210> 63
     <211> 867
     <212> DNA
35
     <213> Streptococcus pneumoniae
     <400> 63
     atggctctat ttagtaaaaa agataagtat attcgaatca atcccaatcg ttcggttagg 60
     gaaaaacctc aagctaagcc agaggttcca gatgaattat tttcccagtg tccaggctgt 120
40
     aagcatacca totatcagaa ggatotggga agtgaacgta totgtocgca otgtagctat 180
     acctttcgta tttctgccca agaacgcttg gctttgacga ttgatatggg aaccttcaaa 240
     gaattgttta cagggattga aagcaaggat cccttgcatt tccctggtta ccaaaagaaa 300
     ctggcatcta tgcgtgaaaa aacaggtctg catgaagccg ttgtgacagg aactgctctt 360
     attaaaggtc agactgtggc tcttgggatt atggattcta actttatcat ggcttctatg 420
45
     ggtacggttg taggtgaaaa aatcactcgt ttgtttgagt atgcgactgt cgaaaaattg 480
     ccagttgtcc tattcacagc ctctggtgga gcccgtatgc aggaaggaat catgagtctc 540
     atgcagatgg ctaagatctc tgcggcggtt aaacgccatt caaatgctgg tctcttttac 600
     ctgaccattt tgacagatcc aacgactggt ggtgtgacag cttctttcgc tatggaaggc 660
     gatatcattc tggctgaacc acagagettg gttggttttg ctggacgtcg tgtgattgaa 720
50
     aatacggttc gtgaaagctt gcctgaggat ttccaaaagg cagaattcct attagaacat 780
     ggctttgtgg atgctattgt caaaagaaga gacttaccag atacgattgc tagcctagtc 840
     agattgcatg gagggagtcc tagatga
     <210> 64
55
     <211> 420
     <212> DNA
     <213> Streptococcus pneumoniae
```

```
<400> 64
      atgagaatta tgggattgga cgtcggttca aaaacggtag gggtggcgat tagcgatccg 60
      cttggtttta cagctcaagg gcttgaaatc atccagataa atgaagaaca aggccaattt 120
      ggttetgace gegttaagga attggttgat acttacaagg tggaacgatt tgtagtggge 180
      ttgcctaaaa acatgaacaa tacaagtgga ccgcgcgtag aagctagtca agcatacgga 240
      gcaaagctag aagagttttt tggtttacca gtagactatc aggatgaacg cttgacaaca 300
      gtggctgctg agcgcatgtt gattgaacaa gcagatatca gtcgcaataa gcgcaagaaa 360
      gtcattgata agttagcagc tcagctgatt ttacaaaatt atttagatag aaaattttaa 420
 10
      <210> 65
      <211> 1197
      <212> DNA
      <213> Streptococcus pneumoniae
 15
      atggcaaaac ttactgttaa agacgttgac ttgaaaggta aaaaagtcct cgttcgtgtt 60
      gacttcaacg taccattgaa agatggcgta atcactaacg ataaccgtat cacagcagct 120
      cttccaacta ttaagtacat catcgaacaa ggtggacgtg caattctttt ctctcacctt 180
 20
      ggacgtgtga aagaagaagc tgataaagct ggtaaatcac ttgctcctgt agcagcagac 240
      ttggcagcaa aacttggtca agatgttgtt ttcccaggtg tcactcgtgg tgctgaattg 300
      gaageggeaa teaacgetet tgaagatgga caagttetet tggttgaaaa caetegttae 360
      gaagatgttg acggcaagaa agaatctaaa aacgatcctg aacttggtaa atactgggca 420
      tcacttggag atggtatett egtaaaegat geatteggta eageteaeeg tgeaeaegea 480
 25
      tctaacgttg gtatctcagc aaacgttgaa aaagcagttg ctggtttcct tcttgaaaac 540
      gaaattgcct acatccaaga agcagttgaa actccagaac gtccattcgt ggctatcctt 600
      ggtggttcaa aagtttcaga caagatcggt gttatcgaaa acttgcttga aaaagctgat 660
      aaagteetta teggtggtgg gatgaettae acattetaea aageacaagg tategaaate 720
      ggtaactcac ttgtagaaga agacaaattg gatgttgcga aagctcttct tgaaaaagca 780
 30
     aatggtaaat tgatcttgcc agttgactca aaagaagcta acgcatttgc tggttacact 840
     gaagtgcgtg acactgaagg tgaagcagtt tctgaaggct tccttggtct tgacatcggt 900
     ccaaaatcta tcgccaaatt tgacgaagct ttgactggtg ccaaaacagt tgtatggaac 960
     ggacctatgg gtgtatttga aaacccagat ttccaagctg gtacaatcgg tgtgatggac 1020
     gctatcgtga aacaaccagg agttaaatca atcatcggtg gtggtgactc agctgccgca 1080
35
     gcgattaacc ttggccgtgc agacaagttc tcatggatta gtacgggtgg tggagcatca 1140
     atggaacttc ttgaaggtaa ggttcttcca caacttgcag ccttgacaga aaaataa 1197
     <210> 66
     <211> 498
40
     <212> DNA
     <213> Streptococcus pneumoniae
     <400> 66
     atgttaaaat cagaaaaaca atcacgttat caaatgttaa atgaagaatt gtccttccta 60
45
     ttggaaggcg aaaccaatgt tttggctaat ctttccaacg ccagtgctct cataaaatca 120
     cgttttccta ataccgtatt tgcaggcttt tatttgttcg atggaaagga attggtttta 180
     ggccccttcc aaggaggtgt ttcctgcatc cgtattgcac taggcaaggg tgtttgtggt 240
     gaggcagete aettteagga aactgttatt gttggagatg tgaegaeeta teteaactat 300
     atttcttgtg atagtctagc taaaagtgaa attgtggtgc cgatgatgaa gaatggtcag 360
50
     ttacttggag ttctggatct ggattcttca gagattgagg attacgatgc tatggatcga 420
     gattatttgg aacaatttgt cgctattttg cttgaaaaga cagcatggga ctttacgatg 480
     tttgaggaaa aatcttaa
                                                                       498
    <210> 67
55
    <211> 630
    <212> DNA
    <213> Streptococcus pneumoniae
```

```
atgacaatcg aactattgac tccctttacc aaggtagagt tggagccaga aatcaaggag 60
       aaaaaaacgca aacaagttgg gattttaggg gggaatttta accctgttca caatgcccat 120
       ctcattgttg cggatcaagt acggcaacag ttgggactgg atcaagttct gctcatgcct 180
       gaataccaac ctcctcacgt tgataaaaag gaaaccatcc ctgaacacca tcgtctcaag 240
       atgettgagt tggcaattga gggaattgae ggeetagtea ttgaaaccat tgagttggag 300
       cgcaagggta tttcctacac ctacgacacc atgaagattt tgacagagaa gaatccagat 360
       acggattatt actttatcat cggtgccgac atggttgact atctgcctaa gtggtaccga 420
  10
      attgatgaac tggttgacat ggttcagttt gtgggggttc agcgtccacg ctacaaggta 480
      gggacttect atccagttat etgggtggac gtaccgetca tggatatete gtecageatg 540
      gtgcgtgcct tccttgccca aggtcggaaa cccaactttc tcctacctca gccagtgcta 600
      gactacatcg agaaggaggg gctctactga
 15
      <210> 68
      <211> 768
      <212> DNA
      <213> Streptococcus pneumoniae
 20
      atgaatattg caaaaatagt cagagaagcg cgtgagcaga gtcgcttgac aaccttggac 60
      tttgcgacag gcatttttga tgaatttatc caattacatg gtgaccgttc ttttcgtgat 120
      gatggtgcag ttgttggtgg tattggttgg cttggagacc aagctgtaac agtggttggt 180
      atccaaaaag gcaagagttt gcaagacaac ctcaaacgga attttggcca accacatcca 240
      gaaggetace gaaaggeact geggttgatg aaacaggetg agaaatttgg ccgtccagtt 300
 25
      gtgaccttta tcaatacage aggtgcttat cctggtgteg gagcggaaga acgtggtcaa 360
      ggggaageta ttgctcgcaa tctcatggaa atgagtgacc tgaaagttcc tattatcgcc 420
      attattatcg gtgaaggtgg ttcaggcggg gctctggctc tagctgtcgc ggaccgtgtc 480
      tggatgctgg aaaattctat ctatgccatt ctcagtccag aaggctttgc ttccattta 540
 30
      tggaaggacg gtactcgcgc catggaagca gcagaactga tgaaaatcac ttcgcatgaa 600
      ctgttagaaa tggacgtggt ggataaggtg atttctgaag taggactttc tagtaaagaa 660
     ctgattaaga gtgtcaaaaa agaactccaa acggagctgg ctagactttc acaaaaaccg 720
      ctagaagagt tgctggaaga acgctatcaa cgatttagaa aatactaa
35
     <210> 69
     <211> 510
     <212> DNA
     <213> Streptococcus pneumoniae
40
     <400> 69
     atgattataa aagtagaaat ggcagatgtt gaggtgttgg ctaaaattgc caaacaaacc 60
     tttcgtgaaa cctttgcgta tgataatacg gaagagcagt tacaggaata ctttgaagag 120
     gettatagte tgaaaacttt gteaactgag ttgggaaate etgaetetga aacetattte 180
     attatgcatg aggaggagat agctggtttt ctcaaagtca actggggaag tgctcaaact 240
45
     gagagagaat tagaggacgc ttttgaaatt caacgcctct atgtgctaca aaaattccaa 300
     ggatttggac taggtaagca actgtttgaa ttcgcacttg aacttgctac aaaaaatagt 360
     ttttcttggg cttggctagg tgtttgggag cataatacaa aagctcaagc cttttataat 420
     cgatatggtt ttgaaaaatt tagccaacat cattttatgg ttggtcaaaa agtagatacg 480
     gattggttac tgagaaagaa attaaggtaa
50
     <210> 70
     <211> 1590
     <212> DNA
     <213> Streptococcus pneumoniae
55
    <400> 70
    atgttacggg ggactgcttt gctaacggct agtaacttta tcagtcgcct actcggggct 60
```

```
gtttacatta tecettggta catetggatg ggggettatg cagetaagge aaatggtete 120
       tttaccatgg gttacactat ctatgcttgg ttcttgttgg tttcaacagc ggggattcca 180
       gttgcggtgg ccaagcaagt tgccaagtat aataccatgc gagaagaaga gcatagcttt 240
       geoctgatte ggagettett aggetttatg acaggactag geotggtttt tgetttagte 300
      ttgtatgtet ttgctccttg gctagcagac ttgtctggcg tgggcaaaga cttgatccca 360
      atcatgcaaa gcttggcttg gggagtcttg attttcccgt ctatgagtgt tatccgagga 420
      tttttccaag ggatgaataa cctcaaaccc tatgccatga gccaaattgc tgagcaggtc 480
      attcgtgtta tctggatgct cctagcaacc tttatcatta tgaagctcgg ttcaggagat 540
      tatctagcag ccgttaccca atcaaccttt gctgcctttg tcggtatggt agccagtttt 600
 10
      gcagtettga tttattteet tgeecaagaa agtteactea aaagagtett tgaaacagga 660
      gataagatta acagtaagcg tetettggtt gataccatta aggaagccat teettttate 720
      ctgacagggt ctgccatcca gatcttccag attttggatc agctgacctt tatcaatagt 780
      atgagetggt ttaccaacta cagcaatgag gacttggttg tcatgttttc ttatttctca 840
      gccaatccta ataaaatcac gatgattttg atttctgtag gggtttcgat tgggagtgtt 900
 15
      ggtttgccac ttttgacgga aaactatgtc aagggggact tgaaagcggc ttctcgtctc 960
      gttcaggaca gtctcaccct actctttatg ttcttgctac cagcaacggt tggagtggtt 1020
      atggtaggag aacctettta tacggtette tatggtaage cagatagttt ggetetggge 1080
      ttatttgtct ttgcagtttt gcagtctatt attttaggct tgtacatggt cttgtctcca 1140
      atgcttcagg ccatgttccg caaccgcaag gccgttctct attttatcta tggttctatt 1200
 20
      gccaagctag tcttgcaact acctaccatc gccctcttcc acagttatgg tcctttgatt 1260
      tcaacaacca ttgctctcat cattcctaac gtcttgatgt atcgggatat ttgtaaagta 1320
      actggtgtca agcgcaaggt gattttgaag cgaaccattt taatcagttt gctgacccta 1380
      gtcatgtttc tgttaatagg aaccatccag tggctgttag gatttttctt ccaaccaagt 1440
      ggacgtttgt ggagcttctt ttatgtagct cttgtcggtg ccatgggggg tggactttat 1500
 25
      atggttatga gtctgcgtac ctatttatta gataaggtaa taggaaaagc ccaagcagat 1560
     .cgcctgcgag caaaatttaa gctttcgtaa
      <210> 71
      <211> 468
 30
      <212> DNA
      <213> Streptococcus pneumoniae
      <400> 71
      atgtcagata agattggctt attcacaggc tcatttgatc cgatgacaaa tgggcatctg 60
     gatatcattg aacgggcgag cagactcttt gataagctct atgtcggtat tttttttaat 120
     ccccacaaac aaggatttct tcctatcgaa aatcgtaaac gggggctaga aaaggctttg 180
     ggacatctgg aaaatgttga agtcgtggct tctcatgatg aattggtggt cgatgttgca 240
     aaaagattgg gtgctacttg tctagtgcgt ggtttgagga atgcgtcgga tttgcaatat 300
     gaagccagtt ttgattacta caatcatcag ctgtcttctg atatagagac tatttattta 360
40
     catagtcgac ctgaacatct ctatatcagt tcatcaggcg ttagagagct tttgaagttt 420
     ggtcaggata ttgcctgcta tgttcccgag agtatttgga ggaaataa
     <210> 72
     <211> 432
45.
     <212> DNA
     <213> Streptococcus pneumoniae
     atgacgattt tgtttgtggt tatcagtgct tcctttctgt atatggtttc tcttagcatg 60
50
     aaaccctatc aaacagctaa aagtgaagga gaaaaattag ctcagcagta tgcaggatta 120
     gagcaggccg atcaggttga tttatacaat ggcttggaat cttattacag cgttcttggt 180
     cgtaataaac agcaagaagc acttgctgtt ctgattggaa aagatgatca taagatttac 240
     gtttatcagc taaatcaggg tgtttcacaa gaaaaagcag aaacggtttc taaggaaaag 300
     ggagctggcg aaattgacaa gattatcttt ggtcgttatc aagataagcc aatctgggaa 360
55
    gtcaagtcag gatctgattt ttatctagta gattttgaaa caggagcatt ggtcaacaag 420
     gagggcctat ga
                                                                       432
```

```
<210> 73
      <211> 732
      <212> DNA
      <213> Streptococcus pneumoniae
      <400> 73
      atgattgata ttcattcgca cattgtcttt gatgtagatg atggtcccaa gtcaagagag 60
      gaaagtaagg ctctcttgac agaagcctac aggcaggggg tgcgaaccat tgtctctacc 120
      teteacegte geaagggeat gtttgaaact eeagaagaga agatageaga aaactttett 180
 10
      caggttcggg aaatagctaa ggaagtcgcg agtgacttgg tcattgctta tggggctgaa 240
      atttactaca cgccagatgt tttggataag ctggaaaaca atcggattcc gaccctcaat 300
      aatagtcgtt atgccttgat agagtttagt atgaacactc cttatcgcga tattcatagt 360
      gccttgaata aaatattgat gttgggaatt actcccgtca ttgcccacat agagcqctat 420
      gatgttcttg aaaataatga aaaacgcgtt cgagagctga tcgatatggg ctgttacacg 480
 15
      caaataaata gttcacatgt cctcaaatcc aaactttttg gagaacctta taaattcatg 540
      aaaaaaagag cgcagtattt cttggagcgt gatttggttc atatcattgc aagtgatatg 600
      cataatgtgg acggcagacc cccccatatg gcagaagcat atgaccttgt ttcccaaaaa 660
      tacggagaag cgaaggctca ggaacttttt atagacaatc ctcgaaaaat tgtaatggat 720
     caactaattt ag
20
     <210> 74
     <211> 927
     <212> DNA
     <213> Streptococcus pneumoniae
25
     <400> 74
     atgtctacaa tcgataaaga aaaatttcag tttgtaaaac gtgacgattt tgcctctgaa 60
     actattgatg cgccagcata ttcttactgg aaatcagtgt ttaaacaatt tatgaagaaa 120
     aaatcaactg tagtcatgtt gggaatcttg gtagccatca ttttgataag tttcatctac 180
30
     ccaatgtttt ctaagtttga tttcaatgat gtcagcaagg taaacgactt tagtgttcgt 240
     tatatcaagc caaatgcgga gcattggttc ggtactgaca gtaacggtaa atcgctcttt 300
     gacggtgtct ggttcggagc tcgtaactcc atcctcattt ctgtgattgc gacagtgatt 360
     aacttggtta teggtgtttt tgteggtggt atttggggta tttcaaaate agttgaeegt 420
     gtcatgatgg aagtttacaa cgtcatctca aacatcccac ctcttttgat tgttattgtc 480
35
     ttgacttact caatcggagc tggattctgg aatctgattt ttgccatgag cgtaacaaca 540
     tggattggta ttgccttcat gatccgtgtg caaatcttgc gctatcgtga cttggaatac 600
     aacttggcgt cacgtacttt gggaacacca accttgaaga ttgttgccaa aaatatcatg 660
     cctcaattgg tatctgttat tgtgacaacc atgactcaaa tgcttccaag ctttatctca 720
     tacgaageet tettgtettt etteggtett ggattacega ttacagtgee aagtttgggt 780
40
     cgtttgattt cggattattc acaaaacgta acaaccaatg cttacttgtt ctggattcca 840
     ttgacaaccc ttgtcttggt atccttgtcc cttttcgtag ttggtcaaaa cttagcggat 900
     gctagtgatc cacgtacaca tagatag
                                                                        927
     <210> 75
45
     <211> 234
     <212> DNA
     <213> Streptococcus pneumoniae
     <400> 75
50
     atgtataacc tattattaac cattttatta gtattatctg ttgtgattgt gattgcaatt 60
     ttcatgcaac caaccaaaaa ccaatccagc aatgtatttg atgccagttc aggtgatttg 120
     tttgaacgca gtaaagctcg cggttttgaa gctgtaatgc agcgtttgac agggatttta 180
     gtctttttct ggctagccat tgccttagca ttgacggtat tatcaagtag ataa
55
    <210> 76
    <211> 1110
```

<212> DNA

<213> Streptococcus pneumoniae

```
<400> 76
       atgtttcgta gaaataaatt attttttgg accacagaaa ttttactctt aaccatcatc 60
       ttttacctat ggagacagat gggatctttg attaaccctt ttgttagcgt gcttaataca 120
       attatgattc catttttatt agggggcttt ctttattatt tgacaaaccc tattgttact 180
       ttcttaaata aagtctgtaa actcaatcgt ttgcttggta ttttaattac cttgtgtact 240
       ttggtctggg gaatggtcat aggtgttgtc tatctcttac ctattttgat taatcagtta 300
       tctagtttga ttatatctag tcaaactatt tatagtcgag tacaagactt aatcatagac 360
  10
      ttatctaatt atcctgcgct ccagaatttg gatgtagaag ctacaattca gcagttaaac 420
      ttatcctatg ttgatattct tcaaaatatc ctaaatagcg tatcaaatag tgtggggagc 480
      gtcttgtcag ctcttatcag tactgttttg attttgatta tgactccagt ttttttggtt 540
      tattettat tagatggaca taaattettg eccatgettg aaagaaegat tetaaagagg 600
      gatcgcttgc atattgcagg cttattaaag aatttaaatg cgacgattgc tcgctatatt 660
      agtggagttt cgattgacgc aatcattata ggttgtttgg cttatattgg ctatagtatt 720
      attggtttaa aatatgcttt agtttttgcc attttttctg gtgtagccaa tttaattcct 780
      tatgtggggc caagtattgg tttgatteet atgateateg caaatatatt caetgtacee 840
      catagactgc tgattgcagt gatttatatg cttgttgttc agcaggtaga tggcaatatc 900
      ttatatcctc gaattgtagg aagtgttatg aaggttcatc caatcacgat tttagtttta 960
      cttttgttgt caagcaatat ctatggtgta gttggaatga ttgtcgcagt gccaacctat 1020
 20
      tctatcttga aagaaatttc taagttctta tcccgtttgt atgaaaatca taaaataatg 1080
      aaagaacgag aaagagaatt agctaagtaa
                                                                        1110
      <210> 77
 25
      <211> 1356
      <212> DNA
      <213> Streptococcus pneumoniae
      <400> 77
 30
      atgtatcaag cactttatcg aaaatataga agtcaaaact tctcccagtt agttggtcaa 60
      gaagttgtgg ctaagactct taaacaagcg gtggagcaag agaaaataag tcacgcttat 120
      cttttttctg gtcctcgtgg aacgggaaaa accagtgttg ctaaaatctt tgccaaggct 180
     atgaactgtc ccaatcaagt gggtggcgaa ccttgcaata actgctatat ttgtcaagca 240
     gtgacggacg gtagtttaga agatgtcatt gaaatggatg cagcttctaa taatggggta 300
35
     gatgaaattc gcgaaattcg tgataaatct acctatgcgc ctagccttgc tcgttataag 360
     gtttatatca tagatgaggt tcacatgctg tctacagggg cttttaatgc cctcctaaag 420
     acgetggaag aaccaacaca gaatgtagte tttattttgg ceactactga attgeacaag 480
     attectgeta etattetate cegtgtgeaa egttttgagt ttaaateaat taagacacag 540
     gatattaagg aacatattca ctatatctta gaaaaagaaa atatcagttc tgaaccagag 600
40
     gctgtggaaa tcattgccag acgggcggaa ggtggaatgc gggacgcctt gtctattttg 660
     gatcaageee tgagtttgac acagggaaat gagetgaega etgetatete tgaagaaatt 720
     actggcacca ttagcctatc agccttggat gattatgtgg cggccttgtc tcaacaggat 780
     gttcccaaag ctttgtcttg cttgaatctt ctttttgaca atggtaagag catgactcgt 840
     tttgtgaccg atcttttgca ctatttaaga gacttgttaa ttgttcaaac agggggagaa 900
45
     aatactcatc atagttcagt ctttgtagaa aatttggcac ttcctcaaaa aaatctgttt 960
     gaaatgattc gcttagcaac agtgaattta gcagatatta agtctagttt gcagcccaag 1020
     atttatgctg aaatgatgac cgtccgtttg gcggaaatca agcccgaacc agctctatca 1080
     ggagcggttg aaaatgaaat tgctacgctg agacaggaag ttgcccgtct caaacaagag 1140
     ctttctaatg caggtgcggt tcctaaacaa gttgcaccag ctcctagtcg accagctacg 1200
     ggcaaaacag totatogtgt cgatogcaat aaagtgcaat ctatottaca agaggcogto 1260
50
     gaaaatcctg atttaacacg tcaaaatcta attcgtttgc agaatgcatg gggagaggta 1320
     attgaaagtc taggtgggcc ggacaagctc tgctag
     <210> 78
55
     <211> 1989
     <212> DNA
    <213> Streptococcus pneumoniae
```

```
<400> 78
       atgtttcgat taaccaataa gttagcggta tcgaacttga ttaaaaaccg caaactctac 60
       tateettitg egetggetgt tetettggea gteactetea ectatetet ttaeteteta 120
       accttcaatc ctaagattgc ggaaatccgt ggaggaacaa ccattcaggc tacacttgga 180
       tttggtatgt ttgtcgtcac ccttgcgtca gccattatcg ttctctatgc caatagtttt 240
       gtcatgaaga aacgttccaa ggaactagga atttatggca tgttgggctt ggagaagcgt 300
      catcttatca gtatgacctt taaggagtta gtggtatttg ggattctaac tgttggagcg 360
      ggtatcggta ttggagcctt gtttgacaag ttaattttcg ctttcctgct caaactaatg 420
      aaattgaagg ttgagctggt tgctaccttc cagacgaaag ttgtcattac agtgcttgtt 480
  10
      gtetteggtt tgatttteet aggeeteatg tteetgaatg ecettegaat egeeegtatg 540
      aatgccctcc agctctctcg tgagaaagct agtggagaga aaaaaggtcg cttccttcct 600
      ctccaaacca ttcttggttc cataagttta ggaattggct attatcttgc ccttacggta 660
      aaagateete ttacageett aacaacette tteatagetg ttttactggt tatetttggg 720
 15 acttatetet tgtttaatge agggattace gtttteetee aaatettaaa gaaaaataag 780
      aaatactatt accaaccaaa taacctcata tetgttteta acttgatttt cegtatgaag 840
      aaaaatgcag ttggactagc aactatcgct attttgtcaa caatggtttt ggtaaccatg 900
      tcagcagcga caagcatttt caattccgca gaatccttta aaaaagttct aaatcctcat 960
      gattttgggg tttcaggaca aaatgttgaa aaagaagatt tggacaaact cttgagccag 1020
 20
      tttgcaagtg acaatggtta taagattaaa gaaaaagaag tgtttcgtta cacttacttt 1080
      ggtgttgcga accaagaagg aaataagtta accttttttg aaaaaggaca aaatcgtgtc 1140
      caacccacaa cagttttcat ggtatttgac caaaaagatt atgaaaatat gactggtcaa 1200
      aaactgtete tatcaggaaa tgaggteggt etetttgeea aaaatgaegg aetgaaagga 1260
      cagaaaactc taattetgaa tgatcatcaa ttttetgtaa aagaagaatt taataaagat 1320
 25
      tttattgtca accatgtccc aaatcagttt aatattttga ctgctgatta caattacctt 1380
      gttgtacetg atttacaage etttttgaac caatteecag atteggatat etataateag 1440
      ttttacggtg gtatgaatgt aaatgtcagt gaagaagaac aactcaaggt cgctgaggag 1500
      tatgaaaact acctcaatca atttaatgct caattagaca cagaaggtag ctatgtttat 1560
      ggtagcaatc tagcagatgc tagttctcag atgagtgccc tctttggtgg tgtcttcttt 1620
      atcggtattt tcctatccat tatetttatg gtcggaactg ttctggtcat ctactacaaa 1680
      caaatttetg aaggetacga agacegtgaa egetttatta tettgeagaa agteggtttg 1740
      gaccaaaage aaatcaagea aaccatecae aaacaggttt taactgtttt etteetteet 1800
      ttgctctttg ccttcataca tctcgccttt gcctaccata tgcttagcct gattttaaaa 1860
      gtgattggtg tactggatac gactatgatg ttgattgtga ccttgtctat ctgcgctatc 1920
 35
     tteeteateg cetatgtget gatttteatg attactteaa gaagttateg caagattgtg 1980
     caaatgtaa
                                                                        1989
     <210> 79
     <211> 891
40
     <212> DNA
     <213> Streptococcus pneumoniae
     <400> 79
     atgaaacaag atcaactaaa ggcttggcaa ccagctcagt ttgaccgttt tgtccgtatc 60
45
     ttagaacaag accageteaa teaegeetat etettteag gtttetttgg aagettggaa 120
     atggcgcaat ttttagctaa gagcctcttt tgtacggata aagttggcgt cttaccatgt 180
     gagaaatgcc gaagttgcaa gctgattgaa caggaagagt ttccagatgt caccttgatt 240
     aagccagtca atcaggtcat caagacagaa cgcattcggg aattggtggg acagttttct 300
     caagcaggga ttgaaagcca gcaacaggtc tttattatcg agcaagcgga taaaatgcat 360
50
     cccaacgcag ccaattetet geteaaggte ategaagaac eccagagtga agtttatatt 420
     ttettettga etagegatga ggaaaagatg ttacegacaa teegaagteg gaeteagate 480
     ttccacttta aaaagcaaga agaaaaactt atcttactct tagaacaaat gggacttgtt 540
     aagaaaaaag cgactctttt agctaagttt agtcaatcgc gagctgaagc agaaaagttg 600
     gctaatcagg caagtttttg gaccttggtc gatgaaagtg aacgcctgct gacttggtta 660
55
    gtagctaaga aaaaagaaag ttatctacag gttgccaaat tagccaactt ggcagatgat 720
     aaggaaaaac aggatcaggt tttacggatt cttgaagttc tctgtgggca ggacctcttg 780
    caggtaagag taagagtgat tctacaagat ttactagaag ctagaaaaat gtggcaagct 840
```

```
aatgtcagct ttcaaaatgc catggaatat ctggtcttga aagaaatata a
                                                                           891
       <210> 80
       <211> 615
       <212> DNA
       <213> Streptococcus pneumoniae
       <400> 80
      atgaattcat ttaaaaattt cttaaaagag tggggactgt tcctcctaat tctgtcatta 60
  10
      ctagetttaa gtegtatett tttttggage aatgttegeg tagaaggaea tteeatggat 120
      ccgaccctag cggatggcga aattctcttc gttgtaaaac accttcctat tgaccgtttt 180
      gatatcgtgg tggcccatga ggaagatggc aataaggaca tcgtcaagcg cgtgattgga 240
      atgeetggeg acaccatteg ttacgaaaat gataaactet acatcaatga caaagaaacg 300
      gacgagcett atetagcaga etatateaaa egetteaagg atgacaaact ecaaagcact 360
 15
      tactcaggca agggctttga aggaaataaa ggaactttct ttagaagtat cgctcaaaaa 420
      geceaageet teacagttga tgtcaactac aacaccaact ttagetttae tgttccagaa 480
      ggagaatacc ttctcctcgg agatgaccgc ttggtttcga gcgacagccg ccacgtaggt 540
      acettcaaag caaaagatat cacaggggaa gctaaattcc gcttctggcc aatcacccgt 600
      atcggaacat tttaa
 20
      <210> 81
      <211> 987
      <212> DNA
      <213> Streptococcus pneumoniae
 25
      atggtagtat ttacaggttc aactgttgaa gaagcaatcc agaaaggatt gaaagaatta 60
      gatattccaa gaatgaaggc tcatatcaaa gtcatttcta gggagaaaaa aggctttctt 120
      ggtctatttg gtaaaaaacc agcccaagtg gatattgaag cgattagtga aacgactgtt 180
 30
      gtcaaagcaa atcaacaggt agtaaaaggc gttccgaaaa aaatcaatga tttgaacgag 240
      cctgtgaaga cggttagtga agaaaccgtt gaccttggtc atgtggttaa tgctattaaa 300
     aaaatagagg aagaaggtca aggtatttct gatgaagtca aggctgaaat cttaaaacat 360
     gaaagacatg ccagcactat cttagaagaa actggtcaca ttgagatttt aaatgaactt 420
     caaatcgagg aagcgatgag ggaagaagca ggcgctgatg accttgaaac tgagcaagat 480
35
     caaactgaaa atcaagactt gaaagagatg ggcttgaagg tcgagcaaag ttatgatatt 540
     gcccaggtgg ctacggatgt gactgcctat gttcaagcga ttgtggatga catggatgtt 600
     gaagetacae tttcaaatga ttataaccgt cgtagcatca atctacaaat tgacaccaac 660
     gaaccaggtc gtattatcgg ctaccatggt aaagtcttga aggccttgca actgttggct 720
     caaaattate tttacaaccg ctattccaaa accttctacg ttacaatcaa tgtcaatgat 780
     tatgtcgaac accgtgcaga agtcttgcag acctatgcgc aaaaattggc gaatcgtgtt 840
     ttggaagaag gtcgcagtca taaaacagat ccaatgtcaa atagcgaacg caagattatc 900
     categtatta tttcaegtat ggatggegtg actagttact etgaaggtga tgagecaaat 960
     cgctatgttg ttgtagatac agaataa
45
     <210> 82
     <211> 1383
     <212> DNA
     <213> Streptococcus pneumoniae
50
     <400> 82
     atgtcaaatt tttgccattat tttagcagcg ggtaaaggga ctcgcatgaa atctgatttg 60
     ccaaaagttt tgcacaaggt tgcgggtatt tctatgttgg aacatgtttt ccgtagtgtg 120
     ggagctatcc aacctgaaaa gacagtaaca gttgtaggac acaaggcaga attggttgag 180
    gaggtettgg etggacagae agaatttgtg acteaatetg aacagttggg aactggteat 240
55
    gcagttatga tgacagaacc tatcttagaa ggtgtgtcag gacacacctt ggtcattgca 300 ggagatactc ctttaatcac tggtgaaagc ttgaaaaact tgattgattt ccatatcaat 360
    cataaaaatg tggccactat cttgactgct gaaacggata atccttttgg ctatggacga 420
```

```
attgttcgta atgacaatgc tgaggttctt cggtcattgt tgagcagaag gatgctacag 480
      attttgaaaa gcaaatcaag gaaatcaaca ctggtaacat acgtctttga caacgagcgt 540
      ttgtttgagg ctttgaaaaa tatcaatacc aataacgctc aaggcgaata ctatattaca 600
      gacgtcattg gtattttccg tgaaactggt gaaaaagttg gcgcttatac tttgaaagat 660
      tttgatgaaa gtcttggggt aaatgaccgt gtggcgcttg cgacagctga gtcagttatg 720
      cgtcgtcgca tcaatcataa acacatggtc aacggtgtta gctttgtcaa tccagaagca 780
      acttatatcg atattgatgt tgagattgct ccggaagttc aaatcgaagc caatgttatc 840
      ttgaaagggc aaacgaaaat tggtgctgag actgttttga caaacggtac ttatgtagtg 900
      gacagcacta teggageagg ageggteatt accaatteta tgattgagga aagtagtgtt 960
 10
      gcagacggtg tgacagtcgg teettatget cacattcgte caaattcaag tetgggtgee 1020
      caagttcata ttggtaactt tgttgaggtg aaaggatctt caatcggtga gaataccaag 1080
      gctggtcatt tgacttatat cggaaactgt gaagtgggaa gcaacgttaa tttcggtgct 1140
      ggaactatta cagtcaacta tgacggcaaa aacaaataca agacagtcat tggagtcaat 1200
      gtctttgttg gttcaaattc aaccattatt gcaccagtag aacttggtga caattccctc 1260
 15
      gttggtgctg gttcaactat tactaaagac gtgccagcag atgctattgc tattggtcgc 1320
      ggtcgtcaga tcaataaaga cgaatatgca acacgtcttc ctcatcatcc taagaaccag 1380
      tag
      <210> 83
 20
      <211> 936
      <212> DNA
      <213> Streptococcus pneumoniae
      <400> 83
25
      atgtccaaga ttctagtatt tggtcaccaa aatccagact cagatgccat cggatcatct 60
      gtagettttg cetacettge aaaagaaget taeggtttgg ataeggaage tgttgeeett 120
     ggaactccaa atgaagaaac agcctttgtc ttgaactatt ttggtgtgga agcaccacgt 180
     gttatcactt ctgccaaagc agagggggca gagcaagtta tcttgactga ccacaatgaa 240
     ttccaacaat ctgtatcaga tatcgctgaa gtagaagttt acggtgttgt agaccaccac 300
30
     cgtgtggcta actttgaaac tgcaagccca ctttacatgc gtttggagcc agttggatca 360
     gcgtcttcaa tcgtttaccg tatgttcaaa gaacatggtg tagctgttcc taaagagatt 420
     gcaggtttga tgctttcagg tttgatttca gatacccttc ttttgaaatc accaacaaca 480
     cacccaacag ataaaatcat tgctcctgaa ttggctgaat tggctggtgt aaacttggaa 540
     gaatatggtt tggcaatgtt gaaagctggt accaacttgg ctagcaaatc tgctgaagaa 600
     ttgattgaca tcgatgctaa gacttttgaa ctcaacggaa ataatgtccg tgttgcccaa 660
     gtgaacacag ttgacatcgc tgaagttttg gaacgccaag cagaaattga agctgcaatg 720
     caagetgeea acgaateaaa eggetaetet gaetttgtet tgatgattae agatategte 780
     aactcaaact cagaaatatt ggctcttggt gccaatatgg acaaggtcga agcggctttc 840
     aatttcaaac ttgaaaacaa tcatgccttc cttgctggtg ccgtttcacg taagaaacaa 900
40 gtggtacctc aattaactga aagetttaat acgtaa
                                                                       936
     <210> 84
     <211> 678
     <212> DNA
45
     <213> Streptococcus pneumoniae
     <400> 84
     atgatttcaa agagattaga attggtagct teetttgtgt cacagggggc tattttacta 60
    gatgtgggaa gtgaccatgc ttatctgcct atcgagttgg ttgagagagg ccaaatcaaa 120
50
    agcgctattg caggtgaggt ggtggaaggt ccctatcagt ctgcggttaa aaatgttgag 180
    getcaeggee taaaggagaa aatecaagte egtttageea atggettgge agettttgaa 240
    gagactgacc aagtgtctgt cattaccatt gctggcatgg gtggtcgttt gattgctagg 300
    attttagaag aaggtttggg gaagttagct aatgtagagc gtttgatcct ccagcccaat 360
    aatcgtgaag acgacttgcg tatctggcta caggatcatg gattccagat tgtagcagaa 420
    agcatettag aagaagetgg aaagttttat gagattttgg tggtggaage aggacaaatg 480
    aagctatcag ccagtgatgt tcgctttggt cccttcttgt ccaaagaagt cagtccagta 540
    tttgtccaaa aatggcaaaa agaagctgag aagctagagt tcgccctcgg acaaatccca 600
```

```
gaaaaaaatc tggaagaacg tcaagttcta gtagataaga ttcaagctat caaggaggtg 660
       ctccatgtta gcaagtga
       <210> 85
       <211> 486
       <212> DNA
       <213> Streptococcus pneumoniae
       <400> 85
      atgaatttaa acgatattaa agacttgatg actcaatttg accagtcaag tttgagagaa 60
  10
      ttttettata aaaatgggac ggatgagttg cagtttagca agaatgaage gagacetgtg 120
      cetgaagttg caactcaagt egetecagea eccettetag caacacegag tecagtaget 180
      cctacatetg etccagcaga gactgtagca gaagaagtte cagetccage tgaagcaagt 240
      gtggctagtg agggaaatct tgtagagagt ccacttgttg gagtggttta cttggctgct 300
 15
      ggaccagata aacctgeett egttacagtt ggtgatagtg teaaaaaagg teaaacattg 360
      gtaattatcg aagccatgaa agtcatgaat gaaatcccag ctcctaagga tggtgtggta 420
      acggaaatte tegtetetaa egaagaaatg gttgagtttg gtaaaggatt ggtacgtate 480
      aaatga
 20
      <210> 86
      <211> 1236
      <212> DNA
      <213> Streptococcus pneumoniae
 25
      <400> 86
      atgaaactaa atcgagtagt ggtaacaggt tatggagtaa catctccaat cggaaataca 60
      ccagaagaat tttggaatag tttagcaact gggaaaatcg gcattggtgg cattacaaaa 120
      tttgatcata gtgactttga tgtgcataat gcggcagaaa tccaagattt tccgttcgat 180
      aaatactttg taaaaaaaga taccaaccgt tttgataact attctttata tgccttgtat 240
      gcagcccaag aggctgtaaa tcatgccaat cttgatgtag aggctcttaa tagggatcgt 300
      tttggtgtta tcgttgcatc tggtattggt ggaatcaagg aaattgaaga tcaggtactt 360
      cgccttcatg aaaaaggacc caaacgtgtc aaaccaatga ctcttccaaa agctttacca 420
      aatatggett etgggaatgt agecatgegt tttggtgeaa aeggtgtttg taaatetate 480
      aatactgeet getetteate aaatgatgeg attggggatg cetteegete cattaagttt 540
     ggtttccaag atgtgatgtt ggtgggagga acagaagctt ctatcacacc ttttgccatc 600
     getggtttee aageettaac agetetetet actacagagg atecaacteg tgettegate 660
     ccatttgata aggatcgcaa tgggtttgtt atgggtgaag gttcagggat gttggttcta 720
     gaaagtettg aacacgetga aaaacgtgga getactatee tggetgaagt ggttggttae 780
     ggaaatactt gtgatgccta ccacatgact tctccacatc cagaaggtca gggagctate 840
    -aaggccatea aactagcctt ggaagaagct gagatttctc cagagcaagt agcctatgtc 900
     aatgctcacg gaacgtcaac tcctgccaat gaaaaaggag aaagtggtgc tatcgtagct 960
     gttcttggta aggaagtacc tgtatcatca accaagtctt ttacaggaca tttgctgggg 1020
     gctgcgggtg cagtagaagc tatcgtcacc atcgaagcta tgcgtcataa ctttgtacca 1080
     atgacagetg ggacaagtga agtateagat tatategaag etaatgtegt ttatggacaa 1140
     ggcttggaga aagaaattcc atacgctatt tcaaatactt ttggttttgg aggccacaat 1200
     gcagttcttg ctttcaaacg ttgggagaat agataa
                                                                       1236
     <210> 87
     <211> 1080
50
     <212> DNA
     <213> Streptococcus pneumoniae
     <400> 87
    atgaacatct atgatcaact acaagttgta gaagaccgtt atgaagaatt aggagaattg 60
55
    ctgagtgacc ctgatgtcgt ttcagacacc aagcgtttta tggagctttc aaaagaagaa 120
    gettecaate gtgacaccgt aatageetac cgtgagtata aacaagteet teaaaatate 180
    gtcgatgccg aagagatgat taaggaatca ggcggagatg cggacttgga agaattggcc 240
```

```
aagcaagaac tcaaagatgc caaggctgaa aaagaagaat atgaagaaaa actgaaaatt 300
       ttgctccttc caaaggatcc aaacgatgac aagaatatca tccttgaaat ccgtggagca 360
       gctggtggag acgaagcggc acttttcgct ggagatttgc taactatgta ccaaaagtat 420
       gcggaagccc aaggttggcg ctttgaagtc atggaagcct ctatgaatgg tgtcggtggt 480
       tttaaagaag tggttgctat ggtttcaggt cagtctgtat actctaagct taagtatgaa 540
       tcaggtgccc accgtgtgca acgtgttcct gtgacagaaa gccaaggccg tgttcatact 600
       tcgacagcga cagttcttgt tatgccagaa gttgaagagg ttgaatacga cattgatcca 660
       aaagacette gtgtegacat etateaegee tetggtgetg gtggacagaa egtcaataag 720
       gttgcgactg ccgttcgtat cgttcacttg ccaaccaata tcaaggttga gatgcaggaa 780
       gaacgtacce agcagaagaa cegegagaag getatgaaga ttateegtge aegegteget 840
  10
       gaccactttg ctcagattgc tcaggatgaa caagacgctg agcgtaagtc gacaatcggt 900
       actggtgace gttcagaacg gatccgaact tataacttcc cacaaaaccg tgtcacagac 960
       caccgtatcg gettgaccet ecaaaacta gatacgattt tgtetggtaa attggacgaa 1020
      gttgtggatg cettggtget ttatgaccaa acacaaaaac tagaagaatt aaacaaataa 1080
  15
      <210> 88
      <211> 1680
      <212> DNA
      <213> Streptococcus pneumoniae
 20
      <400> 88
      atggcctaca ctcttaaacc tgaagaagtt ggtgtttttg ccatcggtgg tctaggagaa. 60
      atcgggaaaa acacttacgg aattgaatac caagacgaga ttatcatcgt cgatgctggg 120
      attaaattcc cagaagatga cttgcttggt atcgactatg tcattcctga ctactcttac 180
 25
      atcgtagaca atatcgaccg cgtcaaggct gttttaatca cacacggaca cgaggaccac 240
      attggtggga ttccgttcct actcaagcaa gcaaatgtcc ctatttatgc tggaccgctt 300
      geettggett tgateegtgg gaaactegaa gaacaeggee tettgegeaa egeeaaactt 360
      tacgaaatca accacaacac cgagttgacc tttaaaaatc tcaaggcaac tttctttaga 420
      acgactcact ctattccaga gcctttgggg attgtcattc atactcctca agggaaaatc 480
 30
     gtctgtacgg gtgactttaa gttcgacttt actccagttg gagaacctgc ggacttgcat 540
     egtatggetg egettggtga agaaggegtg etetgtetee tgtetgaete gacaaatgeg 600
     gaagtaccaa cctttaccaa ctctgaaaaa gtcgttggtc agtccattat gaagattatc 660
     caaggtattg aaggacgtat catctttgca tcctttgcct caaatatctt ccgtctccag 720
     caggcaacag aagctgctgt taagactgga cgcaagattg cggtctttgg tcgttctatg 780
 35
     gaaaaggcca ttgtcaacgg aatcgatctt ggctacatca aagctcctaa gggaaccttt 840
     atcgagccaa atgaaatcaa agattateet gcaggagaag ttettateet etgtacaggt 900
     agtcagggtg agcctatggc agccctctct cgtatcgcca acggaaccca ccgtcaagta 960
     caattacaac caggtgatac cgttatcttc tcttctagtc ccatccctgg aaacactact 1020
     agogtoaaca agotgattaa catcatttot gaagotggtg togaagttat coacggtaaa 1080
     gtgaacaata tccatacatc tggacacggt ggtcagcaag agcaaaaact catgctctgc 1140
     ttgattaage caaaataett catgeetgte caeggtgaat acegeatgea aaaagteeae 1200
     gctggactag cagtggatac tggtgttgag aaggacaata tctttatcat gagcaatggc 1260
     gatgtgcttg cccttactgc tgactcagct cgtatcgcag gtcatttcaa cgcccaagat 1320
     atctatgtcg atggaaatcg tatcggtgaa attggcgcag ctgtcctcaa agatcgtcgc 1380
     gatctatctg aagacggtgt cgttctggca gtcgcaactg ttgacttcaa atcgcagatg 1440
45
     attetgtetg geceagatat ceteageega ggetttgtet acatgagaga gtetggagae 1500
     ttgattcgcc aaagccagcg tatcctcttc aatgccattc gtatcgcact gaaaaataag 1560
     gatgctagcg tgcaatctgt caatggtgcc attgtcaacg ctattcgccc cttcctctat 1620
     gaaaataccg aacgtgaace gatcatcate ccgatgatce tcacaccaga tgaagaataa 1680
50
     <210> 89
     <211> 1362
     <212> DNA
     <213> Streptococcus pneumoniae
55
    <400> 89
    atggcagaag tagaagagtt acgagtacaa cctcaagata tcttagctga gcaatccgtt 60
```

```
ttaggggcta tctttattga tgagagtaaa cttgtttttg tgcgagaata cattgagtct 120
      cgggactttt ttaagtatgc ccatcgtttg attttccaag ccatggtcga tttatccqat 180
      cgtggtgatg ccatagatgc aacaacggtt cgtactatcc ttgataatca aggtgattta 240
      cagaatattg gtggcttgtc ttacttggtt gagattgtta attctgtgcc aacttctgct 300
      aatgcggagt attatgctaa gattgttgca gaaaaagcaa tgctacgtcg tttaattgcc 360
      aagttgacag agtctgtcaa ccaagcttac gaagcgtcac aaccagctga tgaaattatt 420
      gctcaggcag aaaaagggtt gattgatgtc agtgaaaatg caaatcgaag cgqqtttaag 480
      aacattcgag atgtgttgaa tctcaacttt ggaaatctgg aagctcgctc gcaacaaacg 540
     accgatatta caggtattgc gacaggttat cgtgatttgg atcatatgac aacaggactt 600
10
     catgaggagg agttgattat cttagcagct cgtccagcag ttggtaagac agcatttgcc 660
     ttgaatatcg ctcagaacat tgggactaag ttggacaaaa cggttgctat tttttcactc 720
     gaaatgggtg cggaaagctt ggtagatcgt atgttagctg cagaaggctt ggtggagtca 780
     cattetatee gtacagggca attgacagat gaggagtggc aaaaatatac tattgeteag 840
     ggtaatctag ctaacgccag tatctatatc gatgatacgc caggtattcg gattacagag 900
15
     attegttete qttetegtaa attggeteaa gaaactggaa atettggttt gattgtgata 960
     gactatttqc aacttatcac gggaactggt cgagaaaatc gtcaacaaga agtttctqaa 1020
     attteteqte aqttqaaaat actaqceaaq qaattqaaqq tteeaqtaat eqetetqaqt 1080
     cagctttctc qtqqtqtaqa acaacqtcaq qacaaqaqac cqqtcttqtc tqatattcqt 1140
     gaatctgggt ctattgagca ggacgctgat atcgtagctt ttctctatcg cgatgactac 1200
20
     tatgaacqtq qtqqtqaaqa aqaqqaqqt atcccaaata ataaqqtqqa aqttattatc 1260
     gagaaaaacc qtagtggagc tcgtggaaca gtggaattga ttgtccaaaa agaatacaat 1320
     aaattcttca agtattcaag tatctcaaag agggaggcat aa
     <210> 90
25
     <211> 693
     <212> DNA
     <213> Streptococcus pneumoniae
     <400> 90
30
     atggcgtata aatatttagt gattgtagaa tcacctgcaa aagccaagac aattgagaaa 60
     tatcttggac gaaactataa agtaatggcc agtgttggcc atataagaga tttaccgaaa 120
     agtaaaatgg gtatcgattt tgaaaacaat tatgaacccc attatatttc tatacgcgga 180
     aaaggcgatg tcatcaaaag cctgaaagcc gcagcaaaaa aagctcaaaa agtttacttg 240
     gcaagtgacc cggatagaga aggagaagcg attgcttggc atttagcgta cctacttggg 300
35
     ttggatctqa aagaaaaaaa tcgggtggtc ttcaatgaaa tcacaaaaga cgcagtcaaa 360
     gcagctttta aggaaccaag aacgatcgat gtagatttag tagatgcaca gcaagctcqt 420
     cqtaccttaq acaqaatcqt tqqttattcq atcaqtccta ttctctqqcq taaqqtcaaq 480
     aaagggttaa qtgcaggacg tgtccaatct gtcgctttaa aaattattat tgaccgtgaa 540
     aaagagatcc gagaatttgt tccagaagaa tattggagca tcgacggtaa ttttaaaaaa 600
40
     gctcgcaaga aattcaaagc aaatttctgg ggaatcgacg gtaagaaaaa gaaattacca 660
     gatgcacaaa gtgtaaaaag aagtcactgc tag
                                                                       693
     <210> 91
     <211> 981
45
     <212> DNA
     <213> Streptococcus pneumoniae
     atgtttattt ccatcagtgc tggaattgtg acatttttac taactttagt aggaattccg 60
50
     gootttatcc aattttatag aaaggegeaa attacaggec agcagatgea tgaggatgte 120
     aaacagcatc aggcaaaagc tgggactcct acaatgggag gtttggtttt cttgattact 180
     tctgttttgg ttgctttctt tttcgcccta tttagtagcc aattcagtaa taatgtggga 240
     atgattttgt tcatcttggt cttgtatggc ttggtcggat ttttagatga ctttctcaag 300
     gtctttcgta aaatcaatga ggggcttaat cctaagcaaa aattagctct tcagcttcta 360
55
     ggtggagtta tcttctatct tttctatgag cgcggtggcg atatgctttc tgtctttggt 420
     tatcaagtge atctagggat tttctatatt gttttegete ttttetgget agteggtttt 480
```

tcaaacgcag taaacttgac agacggtgtt gacggtttag ctagtatttc cgttgtgatt 540

```
agtttgtctg cctatggagt tattgcctat gtgcaaggtc agatggatat tcttctagtg 600
      attetggeca tgattggtgg tttgeteagt ttetteatet ttaaccataa geetgetaag 660
      atctttatgg gtgatgtggg aagtttggct ttaggtggaa tgctggcagc tatctctatg 720
      gctctccacc aagaatggac tctcttgatt atcggaattg tgtatgttt tgaaacaact 780
      tetgttatga tgcaagtcag ttatttcaaa etgacaggtg gtaaacgtat ttteegtatg 840
      acgcetgtae atcaccattt tgagettggg ggattgtetg gtaaaggaaa teettggage 900
      gagtggaagg ttgacttctt cttttgggga gttgggcttc tagcaagtct cctgacccta 960
      gcaattttat atttgatgta a
 10
      <210> 92
      <211> 2082
      <212> DNA
      <213> Streptococcus pneumoniae
 15
      <400> 92
      atggcacgcg aattttcact tgaaaaaact cgtaatatcg gtatcatggc tcacgtcgat 60
      geeggtaaaa caacaactae tgagegtatt etttactaca etggtaaaat ccacaaaate 120
      ggtgaaactc acgaaggtgc gtcacaaatg gactggatgg agcaagagca agaacgtggt 180
      atcacgatca catctgctgc gacgacagct caatggaaca accaccgcgt aaacatcatc 240
 20
      gacacaccag gacacgtgga cttcacaatc gaagtacaac gttctcttcg tgtattggat 300
     ggtgcggtta ccgttcttga ctcacaatca ggtgttgagc ctcaaactga aacagtttgg 360
     cgtcaagcaa ctgagtacgg agttccacgt atcgtatttg ccaacaaaat ggacaaaatc 420
      ggtgctgaet teetttacte tgtaageaca etteaegate gtetteaage aaatgeacae 480
     ccaatccaat tgccaatcgg ttctgaagat gacttccgtg gtatcattga cttgatcaag 540
25
     atgaaagctg aaatctatac taacgacctt ggtacggata teettgaaga agacateeca 600
     gctgaatacc ttgaccaagc tcaagaatac cgtgaaaaat tgattgaagc agttgctgaa 660
     actgacgaag aattgatgat gaaatacctc gaaggtgaag aaatcactaa cgaagaattg 720
     aaagctggta tccgtaaagc gactatcaac gttgaattct tcccagtatt gtgtggttca 780
     gccttcaaaa acaaaggtgt tcaattgatg cttgatgcgg ttatcgacta ccttccaage 840
     ccacttgaca teccageaat caaaggtatt aacceagata cagaegetga agaaattegt 900
30
     ccagcatetg acgaagagee atttgcaget ettgcettea agateatgae tgacccatte 960
     gtaggtcgtt tgacattctt ccgtgtttac tcaggtgttc ttcaatcagg ttcatacgta 1020
     ttgaatactt ctaaaggtaa acgtgaacgt atcggacgta teettcaaat gcacgctaac 1080
     agcegteaag aaategacae tgtttactea ggtgatateg etgetgeegt tggtttgaaa 1140
35
     gatactacaa ctggtgactc attgacagat gaaaaagcta aaatcatcct tgagtcaatc 1200
     aacgttccag aaccagttat ccaattgatg gttgagccaa aatctaaagc tgaccaagac 1260
     aagatgggta tcgcccttca aaaattggct gaagaagatc caacattccg cgttgaaaca 1320
     aacgttgaaa ctggtgaaac agttatctca ggtatgggtg aacttcacct tgacgtcctt 1380
     gttgatcgta tgcgtcgtga gttcaaagtt gaagcgaacg taggtgctcc tcaagtatct 1440
     taccgtgaaa cattccgcgc ttctactcaa gcacgtggat tcttcaaacg tcagtctggt 1500
     ggtaaaggtc aattcggtga tgtatggatt gaatttactc caaacgaaga aggtaaagga 1560
     ttcgaattcg aaaacgcaat cgtcggtggt gtggttcctc gtgaatttat cccagcggtt 1620
     gaaaaaggtt tggtagaatc tatggctaac ggtgttcttg caggttaccc aatggttgac 1680
     gttaaagcta agctttatga tggttcatat cacgatgtcg actcatctga aactgccttc 1740
45
     aagattgegg etteacttte eettaaagaa getgetaaat eageacaace agetateett 1800
    gaaccaatga tgcttgtaac aatcactgtt ccagaagaaa accttggtga tgttatgggt 1860
    cacgtaactg ctcgtcgtgg acgtgtagat ggtatggaag cacacggtaa cagccaaatc 1920
    gttcgtgctt acgttccact tgctgaaatg ttcggttacg caacagttct tcgttctgca 1980
    teteaaggae gtggtacatt catgatggta tttgaccact acgaagatgt acctaagtea 2040
50
    gtacaagaag aaattattaa gaaaaataaa ggtgaagact aa
                                                                       2082
    <210> 93
    <211> 1227
    <212> DNA
    <213> Streptococcus pneumoniae
    <400> 93
```

```
atgccaaatt acaatattcc attttcaccg cctgatatca cagaagcaga aattgctgaa 60
       gtagcggata ccctgcgttc tggttggatc acaacaggtc ctaaaacaaa agaactggag 120
       egeogettgt etetttacae acagacacet aagactgttt gteteaacte tgegacagee 180
       getetggagt tgattttacg cgttttggaa gtgggaeetg gtgatgaagt categtteea 240
       gccatgacet atacggette atgtagtgte attacgeaeg tgggageaac ccctgteatg 300
       gtggatatec aagcagatac gtttgagatg gactatgaec tgettgagea agctateact 360
       gagaaaacta aggtgattat cccagtagag ctcgcaggga ttgtttgcga ttatgaccgt 420
       ttgttccaag tcgtggagaa aaaacgtgac ttctttaccg cttcaagcaa gtggcaaaag 480
      gcctttaacc gtattgtcat tgtctctgat agtgcccacg ctttgggatc tacttataaa 540
  10
      ggacaacett etggttetat egetgatttt actteettet eatteeatge egttaagaac 600
      tttacaacgg cagaaggtgg aagtgcgact tggaaagcca atccagtgat tgatgacgaa 660
      gagatgtaca aggaattcca aatcetttee etteacggge aaactaagga tgetettgee 720
      aagatgcaac tggggtcatg ggaatacgat atcgttacac cagcctataa gtgcaacatg 780
      accgatatca tggcttcact tggtttggta caattggacc gctatccaag tttgttgcaa 840
 15
      cgccgtaagg acattgtgga ccgctatgat agtggttttg caggttctcg catccatcct 900
      ttggcacaca agactgaaac tgtcgaatct tcacgccacc tctacatcac ccgtgtagaa 960
      ggagcaagcc tagaagaacg cagcctcatc atccaagaat tggctaaagc aggaattgca 1020
      agtaatgtte actacaaace getteetete ttgacageet ataagaatet tggatttgat 1080
      atgacgaact atcctaagge ctatgeette tttgagaatg aaattaceet ecetetteat 1140
 20
      actaaattaa gcgatgaaga agtagactat atcattgaga ctttcaaaac agtttctgaa 1200
      aaagtgctaa ctttatcaaa aaaatga
      <210> 94
      <211> 978
 25
      <212> DNA
      <213> Streptococcus pneumoniae
      <400> 94
      atgacagaac ctgatttttg gaacgataat attgcggccc aaaaaacgtc gcaagaattg 60
     aatgtattta aaaacactta caatacette cataagatgg aagagttgca ggatgaagte 120
30
     gaaattttat tggatttttt ggctgaagac gagtcagtgc atgatgaact ggtagcgcag 180
     ttagecgaac ttgataagat aatgaccage tacgagatga etttactett gteagaacet 240
     tatgaccaca acaatgccat cttggaaatc catccaggtt ctggtggtac tgaggcgcag 300
     gactggggtg atatgttgct tcgtatgtat actcgttatg gtaatgctaa aggctttaaa 360
     gtggaagtgt tggattacca agcaggtgat gaggctggta ttaagtcggt aactttatca 420
35
     tttgaaggge ctaatgeeta tggteteete aagteagaaa tgggtgttea cegettagtg 480
     cgaatctcac catttgactc tgccaaacgt cgccatacct ctttcacatc tgtagaagtg 540
     atgccagaat tggatgatac tattgaagtg gaaatccgtg aagatgatat caagatggat 600
     accttccgtt caggtggtgc cggtggacaa aacgtcaata aagtttcaac aggtgtacgt 660
40
     ttaacccaca ttccaactgg aattgttgtc caatcaacag tggatcgtac ccagtatgga 720
     aatagagatc gtgccatgaa gatgttgcag gctaagctct atcaaatgga gcaagagaag 780
     aaggetgegg aggtagatte teteaaaggt gagaaaaagg agattaettg gggaageeaa 840
     atcogttett atgtetteae geettataet atggtaaaag atcacegaae tagetttgag 900
     gttgctcagg tagataaggt tatggatggg gacctagatg gttttatcga tgcttatctc 960
45
     aagtggcgaa ttagctaa
     <210> 95
     <211> 750
     <212> DNA
50
    <213> Streptococcus pneumoniae
    atgttttata cttatttgcg tggattagtt gtattgctct tatggtccat caatggcaat 60
    gctcactate ataatactga taaaatteet aatcaagatg aaaattatat tttagttgcg 120
    ceteacegta cetggtggga teetgtttat atggeetttg egaccaagee aaaacagtte 180
    atotttatgg caaaaaaga actotttacc aaccgtatct ttggttggtg gattcgtatg 240
    tgtggcgcct ttcccatcga ccgtgaaaat cccagcgcct cagccatcaa atatcctatc 300
```

```
aacgttetea aaaaaagtga eegetetete ateatgttte eaagtggtag eegecaetea 360
       aacgatgtca agggggggc agcactgatt gccaaaatgg ccaaggtccg tatcatgccg 420
       gttacctaca coggtoccat gactttgaag ggcttgatta gccgtgaacg tgtcgatatg 480
       aactttggaa atccaatcga tatctcagat atcaagaaaa tgaatgatga aggcattgaa 540
       acagtegeca ategtattea aacagaatte caacgtetgg acgaagaaac gaaacaatgg 600
       cacaatgata aaaaaccaaa tccactctgg tggtttatcc gcatccctgc cctcatcctt 660
       gctattatcc tegetatect aaccateate titagettta tegeaagett catetggaac 720
       ccagataaga aaagagaaga acttgcatag
  10
       <210> 96
       <211> 3102
       <212> DNA
       <213> Streptococcus pneumoniae
  15
       <400> 96
       ttgatcgcac aactagatac aaaaacagtc tatagtttta tggaaagcgt catttcgatc 60
       gaaaagtatg tgagagcagc taaagaatac ggctacactc atttggctat gatggatatt 120
       gacaatettt atggegettt egacttteta gagattacaa aaaaataegg catteateet 180
       ttgctagggc ttgaaatgac agtgtttgta gatgatcagg gagtaaattt gcgcttttta 240
      getetateta gtgtgggeta teageagttg atgaagettt egacageeaa gatgeagggg 300
 20
      gagaaaactt ggtcagtcct gtcccagtac ctggaggata tcgcggtcat tgtgccttat 360
      tttgatagag ttgagtcgtt agaactaggc tgtgattact atataggggt ttatccagaa 420
      acactagcaa gogaattica toatectate tiacetetti ategggteaa egettitgaa 480
      agcagggata gagaagttet teaagtttta acagegatta aagaaaatet acegeteaga 540
 25
      gaagttccct tgcgttcgag acaagatgtc tttatatcag caagttcttt agagaaacta 600
      ttccaagage gttttccgca agetttggac aatttagaaa agettatttc aggcatttct 660
      tacgacttgg atactagtct gaaactgcct cgttttaatc cagctagacc agcagtagag 720
      gagttgagag agegtgetga actggggett gttcagaagg ggttgactag taaagaatat 780
      caagatagac tagaccaaga attgtctgtt attcatgata tgggctttga tgattatttc 840
      ttggttgttt gggatttgtt gcgttttgga cgatcgaatg gctattatat gggaatggga 900
 30
      aggggttctg cagtaggcag tttggtttct tatgccttag acatcacggg gattgaccca 960
      gtagagaaaa atctgatttt tgaacgettt ettaategtg aacgetatae catgeetgat 1020
      attgatattg atatcccaga tatttatcgt ccagatttta tcagatatgt tggtaataaa 1080
     tatggtagta aacatgcggc acaaatcgtt actttttcaa cctttggagc caagcaagct 1140
 35
     cttcgagatg tcttgaaacg ctttggtgtg ccagagtatg aattatctgc aattactaag 1200
     aaaatcagtt ttcgtgacaa tcttaagtcg gcctatgagg gcaatctcca gtttcgtcag 1260
     caaatcaata gtaagttaga ataccaaaaa gcttttgaga ttgcttgcaa gatagagggc 1320
     tatccaagge aaacetetgt ceatgegget ggtgttgtaa ttagtgacca agatttaace 1380
     aactacatto ototaaagta tggtgatgaa attocactga otoagtatga tgotoatgga 1440
40
     gttgaggcta gcggactttt gaagatggac tttctgggac tacgaaattt gacctttgtc 1500
     cagaagatgc aagagttgct tgctgaaata gaaggtattc accttaaaat tgaagaaata 1560
     gatttggaag acaaagaaac gttagattta tttgcctctg gaaatacaaa aggtatcttt 1620
     caattigage aacciggige tattegettg cicaaacgig ticaaccagi cigittigaa 1680
     gatgtegtag caactactte tetaaatega eegggtgeta gtgaetatat caataatttt 1740
45
     gtggcaagaa agcatgggca ggaagaagtg actgttctgg atccagtact ggaggatatt 1800
     ttggctccaa cctacggcat aatgctctat caggagcagg ttatgcaggt tgcccagcga 1860
     tttgccggat ttagtcttgg gaaagccgat attttgcgtc gggctatggg gaaaaaggat 1920
     gcctctgcca tgcatgagat gagggcttcc tttattcaag gttcattaga agctggtcat 1980
     actgtggaaa aagcagagca ggtctttgat gttatggaga agtttgcagg ctatggtttt 2040
     aacaggtcac acgcctatgc ctactcagca ttggccttcc agttggctta ttttaaaaca 2100
50
     cattatccag ccatatttta tcagatcatg ttgaattctg ccaacagtga ttacttaata 2160
    gatgcacttg aagcaggttt tgaagtggeg cctctgtcca tcaacacgat tccctatcac 2220
    gataaaattg ccaacaaggc catctatcta ggtttgaaat ccattaaagg agtcagtaat 2280
    gatttagete tetggattat tgaacataga eettatteta atattgaaga tittataget 2340.
55
    aaattacctg agaattatct gaaactteet etgetagaae etttggtaaa agttggtett 2400
    ttcgattcat ttgaaaaaaa tcgtcaaaaa gtatttaata acttagctaa tctatttgaa 2460
    tttgtgaaag agttgggaag tttgtttgga gatgctattt atagttggca ggaatcggaa 2520
```

```
gattggacgg aacaagaaa attttatatg gaacaagagc ttttagggat aggtgtcagc 2580
       aaacatccac tacaagctat tgcaagtaag gctatttacc cgattacccc aatcggaaat 2640
       ttgtcagaaa atagctatgc tattattttg gttgaagttc agaaaataaa agtgattcgt 2700
       accaaaaagg gtgaaaatat ggccttctta caggcagatg atagtaagaa aaaattggat 2760
       gtcactctct tttcagactt atatcgtcag gttggacagg aaataaaaga gggagccttc 2820
       tactatgtaa aaggaaaaat acaatcacgt gatggccgtc tgcaaatgat tgcacaagaa 2880
       ataagagaag cagttgctga acgcttttgg atacaggtga aaaatcatga atcggatcaa 2940
       gaaatttcac gtattttaga acaatttaaa ggcccaatcc cagtcatcat ccggtatgaa 3000
       gaggaacaga aaaccatcgt ttctccccat cattttgtag ctaaatccaa tgaattagag 3060
  10
       gagaaattga atgaaatcgt tatgaaaacg atttatcgct aa
       <210> 97
       <211> 921
       <212> DNA
 15
      <213> Streptococcus pneumoniae
      <400> 97
      atgaccaacg aatttttaca ttttgaaaaa atcagccgcc agacttggca atctttacat 60
      cgaaagacaa cacctccttt gacagaagaa gaattggaat ctatcaagag ttttaatgac 120
      caaatcagte tecaagaegt tacagatate tateteeet tggeteatet gatteagatt 180
      tacaagcgaa ctaaggaaga tttagccttt tcaaaaggaa ttttcctcca acgtgaaagt 240
      aaatetcaac ettttattat tggggtttet gggagtgttg cegttggaaa atccacaacc 300
      agtegectae tteaaateet actgteeegt acgtttacag atgetaeggt tgagttggtt 360
      acaactgatg gttttctcta tcccaatcaa accttgattg agcagggaat tttaaatcgt 420
 25
      aaaggattto otgaaagota tgatatggaa gotottotoa acttottgga cogoatcaaa 480
      aatggacaag atgtagatat teetgtetat teteatgaag tttacgacat egtacecaaa 540
      aagaaacaaa gtgtcaaagc tgctgatttt gtaatcgttg agggaattaa tgtctttcaa 600
      aatccacaaa acgatcgtct ctatatcact gacttctttg acttttccat ctatgtagat 660
      gctggagtgg atgatattga aagttggtat ctggaccgtt tcttgaaaat gctgagtcta 720
      geceaaaaeg accetgatag etactattat egitttaete agatgeegat tggggaagtg 780
 30
      gagteetttg eccateaggt etggaceagt ateaatetea caaatetgea aaattatatt 840
     gaaccaacca gaaatcgtgc agaagtgatt cttcataaaa gcaagaacca tgaaatcgat 900
      gaaatttact taaaaaagta a
35
     <210> 98
      <211> 741
     <212> DNA
     <213> Streptococcus pneumoniae
40
     <400> 98
     atggaaattt cattattaac agatgttggt cagaaacgaa caaataacca agactatgtc 60
     aaccactatg teaatagage tggacgtace atgattattt tagetgatgg gatgggaggt 120
     categtgeag ggaatatege tagtgaaatg geggteacag acetgggtgt agettgggtt 180
     gatacccaga tcgatacagt caatgaagtg cgtgaatggt tcgcccatta cctagaaatt 240
45
     gaaaatcaaa agattcacca gcttggtcag gatgaagctt acagaggcat gggaactact 300
     ttggaagtee ttgetattat tgataateag getatetatg eteatattgg tgattegegt 360
     ateggettga ttegtggaga agaataccat cagttgacga gegateatte ettggttaat 420
     gaattgetea aggetggtea attgacacca gaagaggeag aageteatee geaaaaaaat 480
     attatcaccc agtotattgg gcaaaaagat gaaattcagc ctgattttgg gacagttatc 540
     cttgagtcag gtgactatct cttgctcaat agtgacggct tgaccaacat gatttcaggc 600
     agtgagattc gtgatattgt aaccagtgat attectttag cagataaaac ggagacactt 660
    gttcgttttg ctaacaatgc aggaggttta gacaacatta cggttgccct tgtttctatg 720
    aacgaggagg atgaagaatg a
                                                                       741
55
    <210> 99
    <211> 831
    <212> DNA
```

<213> Streptococcus pneumoniae

```
gtgacgatac agatgaagaa tacaggtaaa cgaattgatc tgatagccaa tagaaaaccg 60
  5
      cagagtcaaa gggtcttgta tgaattgcga gatcgtttga agagaaatca gtttatactc 120
      aatgatacca atccggatat tgtcatttcc attggcgggg atggtatgct cttgtcggcc 180
      tttcataagt acgaaaatca gcttgacaag gtccgcttta tcggtcttca tactggacat 240
      ttgggcttct atacagatta tcgtgatttt gagttggaca agctagtgac taatttgcag 300
      ctagatactg gggcaagggt ttcttaccct gttctgaatg tgaaggtctt tcttgaaaat 360
      ggtgaagtta agattttcag agcactcaac gaagccagca tccgcaggtc tgatcgaacc 420
      atggtggcag atattgtaat aaatggtgtt ccctttgaac gttttcgtgg agacgggcta 480
      acagtttcga caccgactgg tagtactgcc tataacaagt ctcttggcgg tgctgtttta 540
      caccetacea ttgaagettt geaattaaeg gaaattgeea geettaataa tegtgtetat 600
      cgaacactgg gctcttccat tattgtgcct aagaaggata agattgaact tattccaaca 660
 15
      agaaacgatt atcatactat ttcggttgac aatagcgttt attctttccg taatattgag 720
      cgtattgagt atcaaatcga ccatcataag attcactttg tcgcgactcc tagccatacc 780
      agtttctgga accgtgttaa ggatgccttt atcggtgagg tggatgaatg a
      <210> 100
 20
      <211> 1623
      <212> DNA
      <213> Streptococcus pneumoniae
      <400> 100
25
     atgtcaaaag aaattaaatt ttcatcagat gcccgttcag ccatggttcg tggtgtcgat 60
     attettgcag acactgttaa agtaacettg ggaccaaaag gtcgcaatgt cgttettgaa 120
     aagtcattcg gttcaccctt gattaccaat gacggtgtga ccattgccaa agaaatcgaa 180
     ttggaagacc attttgaaaa tatgggtgct aagttagtat cagaagtagc ttctaaaacc 240
     aatgatateg caggtgaegg aactaegaet geaacagtet tgaeceaage tategteegt 300
30
     gaaggaatca aaaacgtcac agcaggtgca aatccaatcg gtattcgtcg tgggattgaa 360
     acagcagttg ccgcagcagt tgaagctttg aaaaacaacg ccatccctgt tgccaataaa 420
     gaagetateg eteaagttge ageagtatet tetegttetg aaaaagttgg tgagtacate 480
     tetgaagcaa tggaaaaagt tggcaaagae ggtgteatea eeategaaga gteacgtggt 540
     atggaaacag agcttgaagt cgtagaagga atgcagtttg accgtggtta cctttcacag 600
35
     tacatggtga cagatagcga aaaatggtg gctgaccttg aaaatccgta cattttgatt 660
     acagacaaga aaatttccaa catccaagaa atcttgccac ttttggaaag cattctccaa 720
     agcaategte cactettgat tattgeggat gatgtggatg gtgaggetet tecaactett 780
     gttttgaaca agattcgtgg aaccttcaac gtagtagcag tcaaggcacc tggttttggt 840
     gaccgtcgca aagccatgct tgaagatatc gccatcttaa caggcggaac agttatcaca 900
40
     gaagacettg gtettgagtt gaaagatgeg acaattgaag etettggtea ageagegaga 960
     gtgaccgtgg acaaagatag cacggttatt gtagaaggtg caggaaatcc tgaagcgatt 1020
     teteacegtg ttgeggttat caagteteaa ategaaacta caacttetga atttgacegt 1080
     gaaaaattgc aagaacgctt ggccaaattg tcaggtggtg tagcggttat taaggtcgga 1140
     geogeaactg aaactgagtt gaaagaaatg aaacteegea ttgaagatge ceteaacget 1200
     actogtgcag ctgttgaaga aggtattgtt gcaggtggtg gaacagctct tgccaatgtg 1260
     attccagctg ttgctacctt ggaattgaca ggagatgaag caacaggacg taatattgtt 1320
     ctccgtgctt tggaagaacc cgttcgtcaa attgctcaca atgcaggatt tgaaggatct 1380
     atcgttatcg atcgtttgaa aaatgctgag cttggtatag gattcaacgc agcaactggc 1440
     gagtgggtta acatgattga tcaaggtatc attgatccag ttaaagtgag tcgttcagcc 1500
50
     ctacaaaatg cagcatctgt agccagcttg attttgacaa cagaagcagt cgtagccaat 1560
     aaaccagaac cagtagcccc agctccagca atggatccaa gtatgatggg cgggatgatg 1620
     taa
                                                                       1623
    <210> 101
```

55 <211> 101 <221> 1446 <212> DNA

<213> Streptococcus pneumoniae

```
<400> 101
      atgattaaga ttgaaaccgt attagatatt ttaaagaaag atggcctttt tcgcgaaatt 60
      attgaccaag gtcattacca ctacaactac agcaaagtta tttttgatag catcagctac 120
      gacageegaa aagtaacaga agacaetett tittitgeaa aaggegetge eittaaaaaa 180
      gaatacette titetgetat aacacaaggt ttagettggt atgtagetga aaaggactae 240
      gaagtegata teeetgteat cattgtgaac gatataaaga aageeatgag tttgattgee 300
      atggagttet atggtaatee acaagagaaa eteaaaetee ttgeetttae tggtaetaag 360
      ggtaagacaa cagcaaccta tttcgcctat aacatcttat ctcaggggca tagacctgct 420
  10
      atgttgtcga ccatgaacac aactettgat ggcgagactt tetttaagte agcgttgaca 480
      acccctgaga gtattgacct ctttgacatg atgaatcagg ctgtgctaaa tgaccgtacc 540
      cacctcatca tggaagtctc cagtcaagcc tatctagtcc atcgagtcta tggactgacc 600
      tttgatgtag gagtctttct taacatcact cctgaccata tcggcccgat tgaacaccct 660
      agetttgaag actatttcta ccacaagegt ctettgatgg aaaatageeg ageagteate 720
 15
      attaacagtg acatggacca cttctcagtc ttgaaagaac aggttgaaga tcaagaccat 780
      gatttctatg gtagccaatt tgataaccaa atcgagaatt ccaaagcctt tagcttttca 840
      gctacgggta aactcgctgg agattatgat atccaactca ttggcaactt caaccaagaa 900
      aatgcagttg ctgctggact tgcttgtctc cgtctcggag caagtcttga ggacatcaaa 960
      aaaggcatcg ctgcaacccg cgttcctggt cgtatggaag tcctcactca gaaaaatgga 1020
 20
      gccaaggtct tcatcgacta tgcccacaat ggggatagtc tgaaaaaact catcaatgtg 1080
      gttgaaactc atcaaaccgg aaagattgct ctggttctgg gatcaacagg aaacaaggga 1140
      gaaagtcgtc gtaaggactt tggcctcctc ctcaatcaac accctgagat tcaagtcttt 1200
      ctgactgctg atgaccctaa ctatgaagac ccaatggcca ttgcagatga aattagtagc 1260
      tacatcaatc atcctgttga aaagattgcg gatcgccaag aagccatcaa ggcggcaatg 1320
 25
      gctatcacaa atcacgaatt agatgcagtt attattgcgg gtaagggagc cgattgttac 1380
      caaatcatce agggcaagaa agaatcctac ccaggagata cagccgtcgc agaaaattat 1440
      ttataa
     <210> 102
 30
     <211> 1980
      <212> DNA
     <213> Streptococcus pneumoniae
     <400> 102
35
     atgatccaaa tcggcaagat ttttgccgga cgctatcgga ttgtcaaaca gattggtcga 60
     ggaggtatgg cggatgtcta cctagccaaa gacttaatct tagatgggga agaagtggca 120
     gtgaaggttc tgaggaccaa ctaccagacg gacccgatag ctgtagctcg ttttcagcgt 180
     gaagcgagag ctatggcaga tctagaccat cctcatatcg ttcggataac agatattggc 240
     tatatcaagg aacattatcc tetttetaat gaagaagcag teegtatcat gggacaaatt 360
     ctcttggcta tgcgcttggc ccatactcga ggaattgttc acagggactt gaaacctcaa 420
     aatateetet tgacaecaga tgggactgee aaggteacag aetttgggat tgetgtagee 480
     tttgcagaga caagtctgac ccagactaac tcgatgttgg gctcagttca ttacttgtca 540
     ccagagcagg cgcgtggttc gaaggcgact gtgcagagtg atatctatgc catggggatt 600
45
     attttctatg agatgctgac aggccatatc ccttatgacg gggatagcgc ggtgaccatt 660
     gecetecage atttccagaa acceetgeeg teegttattg cagaaaatce atetgtacet 720
     caggetttag aaaatgttat tateaaggea actgetaaaa agttgaccaa tegetacege 780
     teggttteag agatgtatgt ggaettgtet agtagettgt cetacaateg tagaaatgaa 840
    agtaagttaa totttgatga aacgagcaag gcagatacca agacottgcc gaaggtttot 900
50
    cagagtacet tgacatetat teetaaggtt caagegeaaa cagaacacaa atcaatcaaa 960
    aacccaagcc aggctgtgac agaggaaact taccaaccac aagcaccgaa aaaacataga 1020
    tttaagatgc gttacctgat tttgttggcc agccttgtat tggtggcagc ttctcttatt 1080
    tggatactat ccagaactcc tgcaaccatt gccattccag atgtggcagg tcagacagtt 1140
    gcagaggcca aggcaacgct caaaaaagcc aattttgaga ttggtgagga gaagacagag 1200
55
    gctagtgaaa aggtggaaga agggcggatt atccgtacag atcctggcgc tggaactggt 1260
    cgaaaagaag gaacgaaaat caatttggtt gtctcatcag gcaagcaatc tttccaaatt 1320
    agtaattatg tcggtcggaa atcctctgat gtcattgcgg aattaaaaga gaaaaaagtt 1380
```

```
ccagataatt tgattaaaat tgaggaagaa gagtcgaatg agagtgaggc tggaacggtc 1440
       ctgaagcaaa gtctaccaga aggtacgacc tatgacttga gcaaggcaac tcaaattgtt 1500
       ttgacagtag ctaaaaaagc tacgacgatt caattaggga actatattgg acggaactct 1560
       acagaagtaa totoagaact caagcagaag aaggttootg agaatttgat taagatagag 1620
       gaagaagagt ccagcgaaag cgaaccagga acgattatga aacaaagtcc aggtgccgga 1680
       acgaettatg atgigagtaa acctaeteaa atigtettga cagtagetaa aaaagttaca 1740
       agtgttgcca tgccgagtta cattggttct agcttggagt ttactaagaa caatttgatt 1800
       caaattgttg ggattaagga agctaatata gaagttgtag aagtgacgac agcgcctgca 1860
      ggtagtgcag aaggcatggt tgttgaacaa agtcctagag caggtgaaaa ggtagacctc 1920
  10
      aataagacta gagtcaagat ttcaatctac aaacctaaaa caacttcagc tactccttaa 1980
      <210> 103
      <211> 1176
      <212> DNA
 15
      <213> Streptococcus pneumoniae
      <400> 103
      atgaaacatt ttgatactat tgtcatcggt gggggacctg ctggtatgat ggctacgatt 60
      tccagtaact tttatggaca gaaaaccctc ctcatcgaaa aaaatcggaa acttggaaaa 120
 20
      aaattagctg ggactggtgg gggacgttgc aatgtgacca acaatggtag cttagacaac 180
      ctgctagctg gaattcctgg aaacggacgc tttctttaca gtgttttctc ccagttcgat 240
      aatcatgaca tcatcaactt ttttacagaa aatggtgtta aacttaaggt cgaagaccac 300
      ggacgcgtct ttccagccag tgacaagtct cggactatta tcgaagcttt ggaaaagaaa 360
      atcactgaac taggtggtca agttgctact caaatagaaa tcgtttctgt taaaaaagta 420
 25
      gatgaccagt ttgtccttaa gtcagcggat caaaccttca cttgtgagaa actcattgtc 480
      acaacaggtg gtaagtetta teettegact ggttegactg gttttggtea egagattget 540
      cgccatttta agcataccat caccgatctt gaggctgctg aaagtccttt attaacagat 600
      tttccacata aagcettaca agggatttct ctggacgatg tgaccctaag ttatggtaag 660
      catgtcatca ctcatgattt actctttacc cactttggtt tgtcaggtcc tgctgcccta 720
 30
      cgcatgtcta gctttgtcaa aggtggggag gttctctcac tcgatgtttt gcctcaactt 780
      tetgagaagg acttggttac atttetagaa gaaaateggg aaaaateett gaaaaaeget 840
      ttaaaaaacct tgttaccaga acgcttggcc gaattttttg tacaaggata tcctgaaaaa 900
      gtcaaacagc tgactgaaaa ggaacgagaa caacttgtcc agtccattaa agaacttaaa 960
     attectgtaa etggaaaaat gteeettgea aagteetttg ttaccaaggg tggagteagt 1020
35
     ctcaaggaaa tcaatcctaa aaccettgaa agtaagetgg tacetggcet ccactttgca 1080
     ggcgaagtta tggatatcaa tgcccacacg ggtggcttta acatcacttc tgccctctgt 1140
     accggctggg tggcgggaag tctgcattat gattaa
     <210> 104
40
     <211> 696
     <212> DNA
     <213> Streptococcus pneumoniae
     <400> 104
45
     atgctgaaat gggaagactt gcctgtggaa atgaaatcaa gcgaggttga gtcttactac 60
     cagcitgtct ctaaaaggaa gggttcgctg attttcaagc gttgcttgga ctgggttttg 120
     gccttggtgc ttacatgggt tctaacttct cccatctttc tcatcttgag catttggatc 180
     aagttggata gcaaggggcc agtgatttac aagcaagagc gtgtgaccca gtacaaccgt 240
     cggttcaaga tttggaagtt ccgtaccatg gtgacggatg cggataaaaa aggaagtctg 300
50
     gtgacttctg ctaacgatag ccgtattacc aaggttggaa atttcatccg acgtgtccgt 360
     ttggacgaac tgcctcagtt ggtcaatgtc cttaaaggtg agatgtcctt tgtcggtaca 420
     cgacctgaag tgccacgtta tacagagcag tatagccctg aaatgatggc aaccttgctc 480
    ttgcaagcag gaattacctc tccagccagc atcaactaca aggatgagga caccatcatc 540
    agtcaaatga cggagaaagg totgtcagtt gatcaggoot atgtggagca tgttottoot 600
55
    gaaaagatgc gctataacct cgcctatctc cgagagttta gtttctttgg ggacatcaaa 660
     atcatgtttc aaaccgtgtt tgaggtacta aaataa
                                                                       696
```

```
<210> 105
       <211> 423
       <212> DNA
       <213> Streptococcus pneumoniae
      <400> 105
      atgactagtc cactattaga atctagacgc caactccgta aatgcgcttt tcaagctctc 60
      atgagcettg agttcggtac ggatgtcgaa actgcttgtc gtttcgccta tactcatgat 120
      cgtgaatata cggatgtaca acttccagcc tttttgatag acctcgtttc tggtgttcaa 180
 10
      gctaaaaagg aagaactaga taagcaaatc actcagcatt taaaagcagg ttggaccatt 240
      gaacgettaa egetegtgga gagaaacete ettegettgg gagtetttga aateaettea 300
      tttgacactc ctcagctggt tgctgttaat gaagctatcg agcttgcaaa ggacttctcc 360
      gatcaaaaat etgecegitt tateaatgga etgeteagee agtttgtaac agaagaacaa 420
 15
      <210> 106
      <211> 3540
      <212> DNA
      <213> Streptococcus pneumoniae
 20
      <400> 106
      atgtatttaa aggaaatcga aattcagggg ttcaagtctt ttgctgataa gaccaaggtc 60
      gtttttgacc aaggtgtgac ggcagttgtt ggacccaatg gatctggaaa gtccaatatt 120
      acagaaagte tgegttggge tittgggggag tetagtgtea agagteteeg tgggggeaag 180
 25
      atgeeggatg teatettige tggaacagaa agtegeaaac egeteaatta tgettetgta 240
     gttgtgactc tggataatca tgacggattt atcaaggatg caggtcaaga aatcagggtg 300
     gaacgccata tctatcgtag tggagatagc gaatacaaga ttgacggcaa gaaagtccgt 360
     ctgcgtgata ttcatgacct cttcttggat actggattgg gacgagattc cttctctatt 420
     atttcccaag ggaaggttga ggagatttt aattccaagc ctgaggaacg acgagctatt 480
30
     tttgaagaag ctgctggagt tttaaaatac aagactcgca gaaaagaaac cgagagtaaa 540
     ctgcagcaga ctcaggataa tctggaccgc ttagaggaca ttatctacga gttggataat 600
     caaatcaagc ctcttgagaa gcaagctgag aatgcccgta agtttttaga cttggaagga 660
     caacgtaagg ctatttattt agacgttctg gttgctcaaa tcaaggaaaa taaggcagaa 720
     ctagagtcga cagaagaaga gttggctcag gttcaagaac tcttgatgag ttattaccaa 780
     aagcgtgaaa aattagaaga agaaaatcaa actcttaaaa agcaacgcca agatttacag 840
     gctgaaatgg ccaaagacca aggcagtttg atggacttga ctagtctgat tagtgattta 900
     gaaagaaaat tagccctatc gaaactggag tccgagcaag tggccctgaa tcaacaggag 960
     gcacaagete gtitggetge titggaggat aagagaaatt cacteageaa agaaaagtat 1020
     gataaagaaa getetttage tetgttagag ggaaatetag tecaaaataa teaaaaacte 1080
     aatcgtttag aagctgaatt gctggctttc tcagacgatc ctgatcagat gattgagctc 1140
40
     ttacgtgaac getttgtage tettttacaa gaagaagegg atgtetcaaa ecagttgace 1200
     cgtattgaga atgagttgga aaatagtcgt cagctttctc aaaaacaagc agatcaacta 1260
     gaaaagctga aagagcaatt agctacagct aaagagaagg ctagtcagca aaaagacgag 1320
     cttgaaactg ccaaggtgca ggttcagaaa ttattggctg actatcaagc tattgccaag 1380
45
     gagcaagagg agcagaaaac ttcctatcaa gctcaacaaa gtcaactctt tgaccgtctg 1440
     gatagtetea aaaacaagca ggeeagaget caaagtttgg aaaatateet gagaaateat 1500
    agtaactttt atgcaggtgt taagagtgtt ctccaagaaa aagatcgcct aggtgggatt 1560
    attggtgcag tcagtgagca tctgaccttt gatgtttatt atcaaactgc cctagagatt 1620
    gccttagggg caagtagcca gcatatcatc gtagaagatg aagagtcggc aaccaaagct 1680
50
    attgatttcc tcaaacgaaa cagagtcggt cgtgcaacct ttcttccttt gaccactatt 1740
    aaggogogta cgatttetag toagaaccaa gatgotatog otgtaagooc aggtttoott 1800
    gggatggcag atgagttggt gacttttgat actagactgg aagccatttt caagaacttg 1860
    ctagctacga eggetatett tgatacegta gaacatgege gtgaagetge tegacaagtt 1920
    cgttatcagg ttcgtatggt gacattggat gggacagaat tacgcacggg tggttcctat 1980
    gegggtggtg ceaategeea aaataacagt atttteatea ageeagaaet ggagcaatta 2040
    caaaaagaaa ttgctgcaga tgaagcaagc ttgggttcag aagaagcggc tttgaagacc 2100
    ttgcaagacc agatggctgc attgacagaa agattagaag ccatcaaatc tcaaggagag 2160
```

```
caggeacgta ttcaggagca aggettgtcc ctcgcttatc agcaaactag tcagcaagtt 2220
       gaagaactgg aaactctttg gaaactccaa gaagaggaaa tagatcgtct ttctgaggga 2280
       gattggcaag cggataagga aaaatgtcaa gagagccttg ctactatcgc cagtgacaag 2340
       caaaatctgg aagctgagat tgaagaaatt aagtctaata aaaacgccat ccaagaacgc 2400
       tatcaaaatt tgcaggaaga ggtggcgcaa gctcgcttgc ttaagacaaa actgcaaggg 2460
       caaaaacgtt atgaagtagc tgatattgag cgtttaggca aggaattgga caatcttaat 2520
      atcgaacaag aagaaattca gcgcatgctc caagaaaaag ttgacaatct tgagaaggtt 2580
      gatacagaat tgctcagtca acaggcggaa gaatccaaaa ctcagaaaac aaatctccaa 2640
      caaggtttga ticgcaagca gtttgagttg gatgatatag aaggtcaact ggatgatatt 2700
  10
      gccagtcact tggatcaagc tcgccagcag aatgaggagt ggattcgcaa gcaaacacgt 2760
      gctgaagcca agaaagaaaa ggtcagcgag cgcttgcgcc atctacaaaa tcaattaaca 2820
      gaccagtace agattageta taetgaagea etagaaaagg cacatgaatt ggaaaacete 2880
      aatctggcag agcaagaggt gcaggattta gagaaggcta ttcgctcatt gggacctgtc 2940
      aacttggaag ctattgacca gtacgaagaa gttcacaacc gtctggactt tctaaatagt 3000
15
      cagcgagatg atattttgtc agcgaaaaat ctgctccttg aaaccattac agagatgaat 3060
      gatgaggtca aggaacgctt taaatcaacc tttgaagcta ttcgtgagtc ctttaaagtg 3120
      accttcaage agatgtttgg eggaggteag geagaettga tattgaetga gggegaeett 3180
      ttaacagetg gtgtggagat ttctgttcaa cctccaggta agaaaatcca gtcgcttaac 3240
      ctcatgagtg gtggtgaaaa agctctatcg gctcttgcct tgcttttctc cattattcgt 3300
      gtcaagacca ttccttttgt catcttggat gaggtggaag ctgcgctgga tgaagccaat 3360
 20
      gttaaacgtt ttggggatta cctcaaccgc tttgacaagg acagccagtt tatcgtcgta 3420
      acceacegta agggaaceat ggeagegget gattecatet atggagtgae catgeaagaa 3480
      tcaggtgtct caaaaattgt ttcggttaag ttaaaagatt tagaaagtat tgaaggatga 3540
 25
      <210> 107
      <211> 1344
      <212> DNA
      <213> Streptococcus pneumoniae
 30
      <400> 107
      atgacaaaac gtgtaacgat tattgacgta aaagactatg ttggtcagga agtgacgatt 60
      ggcgcttggg ttgccaacaa atcaggaaaa ggaaaaatcg ctttcttaca attgcgtgat 120
      ggaacageet tettteaagg tgtggetttt aaaccaaact ttgtegaaaa atttggtgaa 180
     gaagtgggac ttgagaagtt tgatgttatc aaacgcttga gccaagaaac gtctgtttat 240
 35
     gtgacaggta ttgtcaaaga ggacgaacgt tctaaatttg gctatgagtt ggacatcaca 300
     gacategaag tgateggtga ateteaagae taceeaatea caceaaaaga acaeggaaca 360
     gactttitga tggataaccg teacttgtgg ctacgetete gtaagcaagt agetgtgttg 420
     caaatccgta acgctattat ctatgcaact tatgagttct ttgacaagaa cggttttatg 480
     aagtttgaca gcccaattct ttcaggaaat gcggcagaag attctacaga actctttgaa 540
40
     actgactact tcggaacgcc agcctacttg agccaatcag gtcagcttta cctagaagca 600
     ggggctatgg ctcttggtcg tgtctttgac tttggtccag ttttccgtgc tgaaaaatca 660
     aaaacacgcc gtcacttgac tgagttctgg atgatggatg ctgagtactc atacttgaca 720
     catgatgagt cgcttgactt gcaagaagct tatgtgaaag ctcttctaca aggtgttctt 780
     gaccgcgcgc ctcaagcctt ggaaaccttg gaacgtgata cagaactctt gaaacgctac 840
     attgcagage cattcaaacg tatcacttac gatcaagcca ttgacctctt gcaagagcat 900
     gaaaatgatg aagatgctga ctacgagcat cttgagcatg gtgatgactt tgggtcacca 960
     cacgaaactt ggatttcaaa ccactttggt gtgccaacat ttgtcatgaa ctatccagca 1020
     gccatcaagg ccttctacat gaaaccagtt cctggaaatc cagagegegt gctttgtgca 1080
     gacttgcttg ctccagaagg ctatggagaa attatcggtg ggtctatgcg tgaggaagat 1140
50
     tacgatgccc ttgtcgctaa gatggatgaa cttggcatgg atcgtacaga atatgaattc 1200
     taccttgacc ttcgtaaata cggtacagtt ccacacggag gatttggtat cggtatcgaa 1260
     cgtatggtaa ccttcgcagc aggaacaaaa catatccgtg aagctattcc attcccacgt 1320
     atgttgcacc gtatcaaacc ataa
                                                                       1344
55
     <210> 108
     <211> 927
```

<212> DNA

<213> Streptococcus pneumoniae

```
atgtctgaaa aattagtaga aatcaaagat ttagaaattt ccttcggtga aggaagtaag 60
  5
      aagtttgtcg cggttaaaaa tgctaacttc tttatcaaca agggagaaac tttctcgctt 120
      gtaggtgagt ccggtagtgg gaaaacaact attggtcgtg ctatcatcgg tctaaatgat 180
      acaagtaatg gagatatcat ttttgatggt caaaagatta atggtaagaa atcgcgtgaa 240
      caagetgegg aattgatteg tegaateeag atgattttee aagaecetge egeaagtttg 300
      aatgaacgtg cgactgttga ttatattatt tctgaaggtc tttacaatca ccgtttattt 360
 10
      aaggatgaag aagaacgtaa agagaaagtt caaaatatta teegtgaagt aggtettett 420
      gctgagcact tgactcgtta ccctcatgaa ttctcaggcg gtcaacgtca acgtatcggt 480
      attgcccgtg ccttggtcat gcaaccagac tttgttattg cagatgagcc aatttcagcc 540
      ttggacgttt ctgtacgtgc ccaagtcttg aacttgctca aaaaattcca aaaagagctc 600
      ggcctgacct atctcttcat cgcccatgac ttgtcggttg ttcgctttat ttcagatcgt 660
 15
      atcgcagtta tttacaaggg tgttattgta gaggttgcag aaacagaaga attgtttaac 720
      aatccaattc acccatatac tcaagccttg ctttcagcgg taccaatccc agatccaatc 780
      ttggaacgta agaaggtctt gaaggtttac gacccaagtc aacacgacta tgagactgat 840
      aagccgtcta tggtagaaat ccgtccaggt cactatgttt gggcgaacca aaccgaattg 900
      gcacgttatc aaaaaggact aaactag
 20
      <210> 109
      <211> 1275
      <212> DNA
      <213> Streptococcus pneumoniae
 25
      <400> 109
      atgaagataa gttggaatgg attttctaaa aaatcatacc aagagcgcct cgagctgcta 60
     aaageteagg egeteettag teetgagaga caagetagte tggagaagga tgaacagatg 120
     agtgtgactg tggcagacca gctgagtgag aatgtggtgg gaactttttc tctgccttat 180
30
     tegetggtte eggaggtact tgtcaaeggt caggaataca eegtteeeta tgtgacagaa 240
     gaaccetetg tggttgegge ggccagetat gccagcaaaa teateaageg tgcaggtggt 300
     tttactgcac aagtccatca gcgccagatg attgggcagg tagcccttta tcaaattgct 360
     aatectaaac tagegeaaga gaagattgee ageaagaaag eggagetett ggagettgee 420
     aatcaagcct atcettetat egttaaaegt gggggtgggg egegtgatet geatgtegag 480
35
     cagataaaag gcgaaccaga ctttctcgtt gtttatattc atgtcgatac ccaggaagcc 540
     atgggtgcca atatgctcaa caccatgctg gaagccttga aaccagtctt agaagaactc 600
     agtcagggac agagtctcat gggaatcctg tccaactacg cgactgattc tctggtgact 660
     gcaagctgtc gcatcgcctt tegetacttg agccgccaaa aggatcaagg acgagagatt 720
     gcggagaaaa ttgcgttggc tagtcagttt gcgcaggctg atccttaccg agctgctact 780
     cataataaag gaatttttaa tggtattgat gcgattttga ttgccactgg taatgactgg 840
     cgtgccatcg aagctggggc ccatgccttt gccagtcgag atggacgcta tcaaggtctt 900
     agctgctgga cgctggacct tgaaagagaa gaattggtcg gtgagatgac cctgcccatg 960
     cctgtagcga ctaagggtgg ctctatcggc ctcaacccac gtgtagctct cagtcatgat 1020
     ctactaggaa atccttctgc cagagaatta gcccagatta tcgtgtccat cggtcttgct 1080
45
     caaaattttg cagccctcaa agccttggta agtacgggca tccagcaagg ccacatgaaa 1140
     ctacaggcca aatccctagc tctcctagct ggggctagtg aatctgaagt tgctcccta 1200
     gtagagegee teateteaga taaaaeettt aacetagaga eageeeageg etatetegaa 1260
     aatttaagat cataa
50
     <210> 110
     <211> 789
     <212> DNA
     <213> Streptococcus pneumoniae
55
     <400> 110
    atgccaatta catcattaga aataaaggac aagacttttg gaactcgatt cagaggtttt 60
    gatccagaag aagtcgatga atttttagat attgtggttc gtgattacga agatcttgtg 120
```

```
cgtgcgaatc atgataaaaa tttgcgtatt aagagtttag aagagcgttt gtcttacttt 180
        gatgaaataa aagattcatt gagccagtct gtattgattg ctcaggatac agctgagaga 240
       gtgaaacagg cggcgcatga acgttcaaac aatatcattc atcaagcaga gcaagatgcg 300
       caacgettgt tggaagaage taaatataag gcaaacgaga ttettegtea agcaactgat 360
       aatgctaaga aagtcgctgt tgaaacagaa gaattgaaga acaagagccg tgtcttccac 420
       caacgtctca aatctacaat tgagagtcag ttggctattg ttgaatcttc agattgggaa 480
       gatattetee gtecaacage tacttatett caaaccagtg atgaageett taaagaagtg 540
       gttagcgaag tacttggaga accgattcca gctccaattg aagaagaacc aattgatatg 600
       acacgtcagt tetetcaage agaaatggea gaattacaag etegtattga ggtageegat 660
       aaagaattgt ctgaatttga agctcagatt aaacaggaag tggaagctcc aactcctgta 720
  10
       gtgagtcctc aagttgaaga agagcctctg ctcatccagt tggcccaatg tatgaagaac 780
       cagaagtag
       <210> 111
  15
       <211> 1728
       <212> DNA
       <213> Streptococcus pneumoniae
       <400> 111
  20
       atgtctaatg gacaactaat ttatttaatg gttgcaattg cagtcatttt agttctggct 60
       tatgtagtgg caatctttct acgtaagcga aacgagggga gattagaggc gctagaagaa 120
      agaaaagaag aactatacaa tottocagta aatgatgaag tagaagotgt aaaaaatatg 180
      cacttgattg gacaaagtca agtggctttc cgtgaatgga atcaaaaatg ggtcgattta 240
      teteteaact ettttgeega tattgaaaat aatetetttg aageagaagg ttataaccat 300
      tcatttcgtt ttctcaaggc cagtcatcaa attgaccaaa ttgagagtca aattactttg 360
      attgaagaag atattgcggc aattcgcaat gctttggcag acttagagaa gcaagaatct 420
      aaaaatagtg gtcgtgttct tcatgctttg gatttatttg aggaacttca gcatagagtt 480
      gctgaaaatt cagaacagta tggtcaagcc ttggatgaaa ttgaaaaaca attagaaaat 540
      atccaatctg aattttcaca atttgtaacc ttgaattcat cgggtgaccc tgtggaagcc 600
      gcagtgattt tggataatac agaaaatcac attttggcct taagtcatat tgtggatcgt 660
      gttccagect tggttacgac getttctaca gaattgccag atcaattaca ggatttggaa 720
      gccggttatc gtaaactaat tgatgctaat tatcattttg ttgaaacgga tattgaagcg 780
      cgtttccact tgctttatga agcattcaag aaaaaccaag agaatattcg tcagttggaa 840
      ttggataatg ccgaatatga gaatggacag gcacaagagg aaatcaatgc cttgtatgat 900
      attittacte gagaaattge tgeteagaaa gtagtggaaa atetaettge aactetteea 960
     acttaccttc aacatatgaa agagaataat actttattgg gagaagatat tgcacgtttg 1020
     aacaagacct atttacttcc tgagacagct gcaagccatg ttcgtcgtat tcagacagaa 1080
     ttagagagtt ttgaggcagc tattgttgag gtaacttcaa atcaagaaga accaacccaa 1140
     gottattcag ttcttgaaga aaatcttgag gatttacaaa ctcaactaaa agatattgaa 1200
 40
     gatgagcaaa tttcagttag tgagcgcctg acacaaattg agaaagatga tattaatgca 1260
     cgtcaaaagg ccaatgttta tgtcaatcgt ctccatacta tcaagcgata catggaaaaa 1320
     cgcaatctgc caggtattcc acaaactttc ttgaagttat tctttacggc aagcaataat 1380
     accgaggatt taatggttga gttagaacaa aaaatgatta acattgaatc tgttacccga 1440
     gttcttgaaa ttgcaacgaa tgatatggaa gctttagaaa cggaaactta taatattgta 1500
45
     caatatgcaa ctttgacaga gcaactcttg caatattcta accgctatcg ctcatttgat 1560
     gaacgcattc aagaagcatt taacgaagct ttagatattt ttgaaaaaga atttgattat 1620
     cacgetteat ttgataagat tteteaagea ttggaagtgg cagageetgg tgtaaccaat 1680
     cgctttgtta cctcatatga gaaaacacgt gaaacgattc gtttttaa
50
     <210> 112
     <211> 2403
     <212> DNA
     <213> Streptococcus pneumoniae
55
    <400> 112
    atgettatat ettataaatg gttaaaagaa ttggtggaca ttgatgtgee atcacaagag 60 ·
    ttggctgaaa aaatgtcaac tacaggaatc gaggtagagg gtgtcgaatc accagctgct 120
```

```
ggtctctcaa aaattgtcgt cggtgaggtc ttgtcttgcg aagatgtgcc agagactcac 180
       ctccatgttt gtcaggttaa cgttggcgaa gaagagcgtc agatcgtttg tggtgcccca 240
       aatgtgcgtg ctgggatcaa ggtcatggtg gctcttccag gagctcgtat cgctgataac 300
       tacaaaatca aaaaaggaaa aatccgtggt ttggagtcac ttggaatgat ctgttcactt 360
       ggtgaattgg gaatttctga ctcagttgtg cctaaggaat tcgcagatgg catccaaatc 420
      ttgcctgaag atgccgtgcc aggtgaggaa gtcttttctt acctagactt ggatgatgaa 480
      atcatcgaac tttccatcac accaaaccgt gcagatgccc tttctatgtg tggagtggct 540
      cacgaagtgg cagccatcta tgacaaggca gtcaacttta aagaatttac tctaacagaa 600
      actaatgaag ctgcggcaga tgccctttct gtcagcattg agacagacaa ggcgccttac 660
 10
      tatgcagete gtatettgga caatgtgace ategcaceaa gtecacaatg gttgcaaaac 720
      cttctcatga acgaaggaat ccgtcccatc aataacgtag tggacgtgac caactacatc 780
      ctgctctatt ttggtcaacc aatgcatgcc tttgacttgg ataactttga agggactgac 840
      atccgtgtgc gtgaagcgcg tgctggtgaa aaattggtga ccttggacgg tgaagaacgt 900
      gacttggacg tgaatgacct agtcatcact gtcgcagaca agccagtagc ccttgcaggt 960
 15
      gtcatgggtg gtcaagcaac agaaatctct gaaaaatcta gtcgtgttgt ccttgaagct 1020
      gctgttttca atggcaaatc tatccgtaag acaagtggtc gcctgaacct tcgttctgag 1080
      tcatcttctc gctttgaaaa aggaattaat gtggcaacag ttaatgaagc ccttgatgcg 1140
      gcagctagcc tgattgcgga acttgcaggt gcgacggtgc gtaagggcat cgtttcagcg 1200
      ggtgagettg atacttcaga tgtagaagtt tettcaaece ttgetgatgt taaecgtgte 1260
 20
      ctcggaactg agctgtctta tgctgatgta gaagacgtct tccgtcgtct tggctttggt 1320
      ctttctggaa atgcagacag ctttacagtc agagtcccac gtcgtcgttg ggatatcaca 1380
      atcgaagetg acctetttga agaaattget egtatetatg gttatgaceg ettgecaact 1440
      agtetaceaa aagacgatgg tacagcaggt gaattgacag ccacacaaaa actccgccgt 1500
      caagttegta etattgetga aggageaggt ttgacagaaa teateaceta taetetaaea 1560
 25
      actcctgaaa aagcagttga gtttacggct caaccaagta accttacgga actcatgtgg 1620
      ccaatgactg tggatcgttc agtcctccgt caaaatatga tttcaggtat ccttgatacc 1680
      gttgcctaca acgtggctcg taagaataaa aacttggccc tttacgagat tggaaaagtc 1740
      tttgaacaaa caggtaatcc aaaagaagaa cttccaaatg aaatcaacag ttttgccttt 1800
      gccttgacag gcttggttgc tgaaaaagat ttccaaacag cagcagttcc agttgatttc 1860
 30
     ttctatgcta agggaatcct tgaagcccta tttactcgtt tgggactcca agtaacctat 1920
     acagcaacat ctgaaatcgc tagccttcat ccaggtcgta cagccgtgat ttcactcggt 1980
     gaccaagtte ttggttteet tggccaagtg catcaagtea etgccaagge ttacgatatt 2040
     ccagaaacgt atgtggctga gcttaacctt tcagctatcg aagctgcgct tcagccagcg 2100
     actecattig tagaaateac caaatteeeg geagteagee gtgaegttge cetteteete 2160
35
     aaggcagaag tgactcatca agaagttgta gatgctatcc aagctgccgg cgtgaaacgt 2220
     ttgacagata tcaaactett tgacgtette tcaggtgaga aattgggact tggtatgaag 2280
     tcaatggett atagettgae ettecaaaat eeagaagata gettaaegga egaagaagte 2340
     gcacgctata tggaaaaaat ccaagcatcg ctcgaagaaa aagtcaatgc agaagtgcgt 2400
     taa
40
     <210> 113
     <211> 543
     <212> DNA
     <213> Streptococcus pneumoniae
45
     atgttagaaa acgatattaa aaaagtcctc gtttcacacg atgaaattac agaagcagct 60
     aaaaaactag gtgctcaatt aactaaagat tatgcaggaa aaaatccaat cttagttggg 120
     attttaaaag gatctattcc ttttatggct gaattggtca aacatattga tacacatatt 180
50
     gaaatggact tcatgatggt ttctagctac catggtggaa cagcaagtag tggtgttatc 240
     aatattaaac aagatgtgac tcaagatatc aaaggaagac atgttctatt tgtagaagat 300
     atcattgata caggtcaaac tttgaagaat ttgcgagata tgtttaaagc aagagaagca 360
     gcttctgtta aaattgcaac cttgttggat aaaccagaag gacgtgttgt agaaattgag 420
     gcagactata cetgetttae tateccaaat gagtttgtag taggttatgg tttagactae 480
55
     aaagaaaatt atcgtaatct teettatatt ggagtattga aagaggaagt gtattcaaat 540
                                                                       543
```

	<2 <2	10> 11> 12> 13>	235	ptoc	occu:	s pn	eumo	niae								
5	<4 Me	00>							a Gl	y Gl		Gl _y	y Thi	r Ar	g Met 15	
-10	. 11	e Se	r Ası	ı Lei 20	ı Pro	Ly:	s Glı	n Phe	Let 25	ı Glı	ı Lei	ı Gly	/ Asp	Arg 30) I l
15	Lei	ı Il	e His	Thr	: Ile	e Glu	ı Lys	Phe 40	· Va]	Leu	ı Glu	Pro	Ser 45		e Glu	Ĺу
	Ile	9 Va:	l Va]	. Gly	/ Val	. His	Gl ₃ 55	Asp	Trp	Val	. Leu	His		Glu	1 Asp	Le
20	Va] 65	l Asp) Lys	Tyr	Leu	Pro 70	Leu	His	Lys	Glu	Arg 75	Ile	Ile	Ile	Thr	Ly:
	Gl	, Gl?	/ Ala	Asp	Arg 85	Asn	Thr	Ser	Ile ,	Glu 90		Ile	Ile	Glu	Ala 95	Ile
25			Tyr	100					105					110		
30			. Arg 115					120					125			
		130					135					140				
35	145		Val			150					155					160
40			His		165					170					175	
40			Met	180					185					190		
45			Asp 195					200					205			
		210	Lys				215					Thr 220	Thr	Val	Thr	Asp
50	Leu 225	Lys	Ile	Ala		Ser 230	Met	Ile (Glu	_	Asp 235					
55	<210 <211 <212 <213	> 18 > PR	5	:	711S 7	າກອນ	non i									

<4(00>	115

Met Ala Asn Val Ile Ile Glu Lys Ala Lys Glu Arg Met Thr Gln Ser 1 5 10 15

- 5 His Gln Ser Leu Ala Arg Glu Phe Gly Gly Ile Arg Ala Gly Arg Ala
 20 25 30
 - Asn Ala Ser Leu Leu Asp Arg Val His Val Glu Tyr Tyr Gly Val Glu 35 40 45
- Thr Pro Leu Asn Gln Ile Ala Ser Ile Thr Ile Pro Glu Ala Arg Val
 50 55 60
- Leu Leu Val Thr Pro Phe Asp Lys Ser Ser Leu Lys Asp Ile Glu Arg
 65 70 75 80
 - Ala Leu Asn Ala Ser Asp Leu Gly Ile Thr Pro Ala Asn Asp Gly Ser 85 90 95
- 20 Val Ile Arg Leu Val Ile Pro Ala Leu Thr Glu Glu Thr Arg Arg Asp
 100 105 110
 - Leu Ala Lys Glu Val Lys Lys Val Gly Glu Asn Ala Lys Val Ala Val 115 120 125
- Arg Asn Ile Arg Arg Asp Ala Met Asp Glu Ala Lys Lys Gln Glu Lys 130 135 140
- Ala Gln Glu Ile Thr Glu Asp Glu Leu Lys Thr Leu Glu Lys Asp Ile 145 150 155 160
 - Gln Lys Val Thr Asp Asp Ala Val Lys His Ile Asp Asp Met Thr Ala 165 170 175
- 35 Asn Lys Glu Lys Glu Leu Leu Glu Val 180 185
- <210> 116 40 <211> 450

25

- 40 <211> 450 <212> PRT
 - <213> Streptococcus pneumoniae

<400> 116

- 45 Met Gly Lys Tyr Phe Gly Thr Asp Gly Val Arg Gly Glu Ala Asn Leu 1 5 10 15
- Glu Leu Thr Pro Glu Leu Ala Phe Lys Leu Gly Arg Phe Gly Gly Tyr 20 25 30
 - Val Leu Ser Gln His Glu Thr Glu Ala Pro Lys Val Phe Val Gly Arg
 35 40 45
- Asp Thr Arg Ile Ser Gly Glu Met Leu Glu Ser Ala Leu Val Ala Gly 55 50 60
 - Leu Leu Ser Val Gly Ile His Val Tyr Lys Leu Gly Val Leu Ala Thr

	65					7	0				7	5				80)
. 5	Pro	Ala	a Va	1 A1	а Ту: 8:	r Le 5	u Va	1 G1	u Th	r Gl 9	u Gl O	y Al	a Se	r Al	a Gl 9	y Val 5	
	Met	Ile	e Se:	r Al.	a Sei O	c Hi	s As	n Pr	0 Al	a Le	u As	p As	n Gl	y Il 11		s Phe	ļ
10	Phe	Gly	/ Gl:	y As _l 5	p Gly	y Ph	e Ly	s Lei 120	u Ası O	p As	p Gl	u Ly:	s Gl 12		a Gl	u Ile	;
	Glu	Ala 130	Let	ı Lei	u Asp	Ala	a Gl:	u Glu 5	ı Ası	o Thi	r Lei	Pro 140		g Pro	Se:	r Ala	
15	Glu 145	Gly	Leu	ı Gly	/ Ile	Let 150	ı Val	l Asp	Туі	r Pro	Glu 155		/ Lei	u Arg	J Lys	Tyr 160	
20	Glu	Gly	Туг	Arç	y Val 165	Sei	Thi	Gly	Thr	Pro 170		ı Asp	Gly	y Met	Lys 175	Val	
	Ala	Leu	Asp	Thr 180	Ala	Asn	Gly	/ Ala	Ala 185		Thr	Ser	Ala	190		lle	
25	Phe	Ala	Asp 195	Leu	Gly	Ala	Gln	Leu 200		Val	Ile	Gly	Glu 205		Pro	Asp	
	Gly	Leu 210	Asn	Ile	Asn	Leu	Asn 215	Val	Gly	Ser	Thr	His 220		Glu	Ala	Leu	
30	Gln (225	Glu	V _a l	Val	Lys	Glu 230	Ser	Gly	Ser	Ala	Ile 235	Gly	Leu	Ala	Phe	Asp 240	
35	Gly	Asp	Ser	Asp	Arg 245	Leu	Ile	Ala	Val	Asp 250		Asn	Gly	Asp	Ile 255	Val	
	Asp (Gly	Asp	Lys 260	Ile	Met	Tyr	Ile	Ile 265	Gly	Lys	Tyr	Leu -	Ser 270	Glu	Lys	
40	Gly	Sln	Leu 275	Ala	Gln	Asn	Thr	Ile 280	Val	Thr	Thr	Val	Met 285	Ser	Asn	Ļeu	
	Gly F	Phe 290	His	Lys	Ala	Leu	Asn 295	Arg	Glu	Gly	Ile	Asn 300	Lys	Ala	Val	Thr	
45	Ala V 305	al	Gly	Asp	Arg	Tyr 310	Val	Val	Glu	Glu	Met 315	Arg	Lys	Ser	Gly	Tyr 320	
. 50	Asn L	eu	Gly	Gly	Glu 325	Gln	Ser	Gly	His-	Val 330	Ile	Leu	Met	Asp	Tyr 335	Asn	
	Thr T	hr (Gly	Asp 340	Gly	Gln	Leu		Ala 345	Val	Gln	Leu	Thr	Lys 350	Ile	Met	
55	Lys G	lu 3	Thr 355	Gly	Lys :	Ser		Ser 360	Glu	Leu	Ala .		Glu 365	Val	Thr	Ile	
	Tvr P	ro G	71n	T.vs	7.611 1	7-1	N an	Tla T	71	17 7	C2	.			_		

370 375 380 Lys Ala Met Glu Val Pro Ala Ile Lys Ala Ile Ile Glu Lys Met Glu 5 Glu Glu Met Ala Gly Asn Gly Arg Ile Leu Val Arg Pro Ser Gly Thr Glu Pro Leu Leu Arg Val Met Ala Glu Ala Pro Thr Thr Glu Glu Val 10 425 Asp Tyr Tyr Val Asp Thr Ile Thr Asp Val Val Arg Ala Glu Ile Gly 15 Ile Asp 450 <210> 117 20 <211> 234 <212> PRT <213> Streptococcus pneumoniae <400> 117 25 Met Lys Lys Ile Leu Ile Val Asp Asp Glu Lys Pro Ile Ser Asp Ile Ile Lys Phe Asn Met Thr Lys Glu Gly Tyr Glu Val Val Thr Ala Phe 30 Asn Gly Arg Glu Ala Leu Glu Gln Phe Glu Ala Glu Gln Pro Asp Ile Ile Ile Leu Asp Leu Met Leu Pro Glu Ile Asp Gly Leu Glu Val Ala 35 Lys Thr Ile Arg Lys Thr Ser Ser Val Pro Ile Leu Met Leu Ser Ala 40 Lys Asp Ser Glu Phe Asp Lys Val Ile Gly Leu Glu Leu Gly Ala Asp Asp Tyr Val Thr Lys Pro Phe Ser Asn Arg Glu Leu Gln Ala Arg Val 105 45 Lys Ala Leu Leu Arg Arg Ser Gln Pro Met Pro Val Asp Gly Gln Glu 120 Ala Asp Ser Lys Pro Gln Pro Ile Gln Ile Gly Asp Leu Glu Ile Val 50 135

Pro Asp Ala Tyr Val Ala Lys Lys Tyr Gly Glu Glu Leu Asp Leu Thr

His Arg Glu Phe Glu Leu Leu Tyr His Leu Ala Ser His Thr Gly Gln

170

165

55

Val Ile Thr Arg Glu His Leu Leu Glu Thr Val Trp Gly Tyr Asp Tyr 180 185 190

- Phe Gly Asp Val Arg Thr Val Asp Val Thr Val Arg Arg Leu Arg Glu

 5 200 205
 - Lys Ile Glu Asp Thr Pro Ser Arg Pro Glu Tyr Ile Leu Thr Arg Arg 210 215 220
- 10 Gly Val Gly Tyr Tyr Met Arg Asn Asn Ala 225 230

25

40

- - Asp Lys Ala Gly Leu Gly Phe Thr Pro Gln Ser Ala Leu Glu Lys Gly
 20 25 30
- Leu Glu Thr Gly Glu Val Tyr Cys Gln Arg Cys Phe Arg Leu Arg His 35 40 45
- Tyr Asn Glu Ile Thr Asp Val Gln Leu Thr Asn Asp Asp Phe Leu Lys
 50 55 60
 - Leu Leu His Glu Val Gly Asp Ser Asp Ala Leu Val Val Asn Val Ile
 65 70 75 80
- Asp Ile Phe Asp Phe Asn Gly Ser Val Ile Pro Gly Leu Pro Arg Phe
 85 90 95
 - Val Ser Gly Asn Asp Val Leu Leu Val Gly Asn Lys Lys Asp Ile Leu 100 105 110
 - Pro Lys Ser Val Lys Ser Gly Lys Ile Ser Gln Trp Leu Met Lys Arg 115 120 125
- Ala His Glu Glu Gly Leu Arg Pro Val Asp Val Val Leu Thr Ser Ala
 45 130 135 140
 - Gln Asn Lys His Ala Ile Lys Glu Val Ile Asp Lys Ile Glu His Tyr 145 150 155 160
- 50 Arg Lys Gly Arg Asp Val Tyr Val Val Gly Val Thr Asn Val Gly Lys 165 . 170 . 175
- Ser Thr Leu Ile Asn Ala Ile Ile Gln Glu Ile Thr Gly Asp Gln Asn 180 185 190
 - Val Ile Thr Thr Ser Arg Phe Pro Gly Thr Thr Leu Asp Lys Ile Glu
 195 200 205

	13	le E	Pro	Le	u As	sp A	g g	ly	Ser 215	Ty	r I	le '	Гуr	As	P Th 22		ro	Gly	y I1	e Il
5	Hi 22	.s A	rg	Hi	s Gl	.n Me	et A 2	la 30	His	ту	r Le	eu ?	Thr	Ala 235	a Ly	s A	sn	Let	ı Ly	s Ty:
10	Va	ıl S	er	Pro	ь Гу	rs Ly 24	/s G 5	lu	Ile	ь Гу	s Pı		ys 250		ту	r G	ln	Leu	As 25	n Pro 5
	G1	uG	ln	Thi	с Le 26	u Ph O	e L	eu	Gly	Gl;	y Le 26		Зly	Arg	Ph	e A		Phe 270		e Ala
15	Gl	уG	lu	Lys 275	G1	n Gl	y P	he '	Thr	Ala 280	a Ph	e F	he	Asp	As:	n G]		Leu	Ly.	s Leu
	Hi	s A:	rg 90	Ser	Ly.	s Le	u G	lu (Gly 295	Ala	a Se	r A	.la	Phe	Ту: 300		p	Lys	His	s Leu
20	30:	5					31	LO						315						Pro 320
25						32.	5					3.	30						335	
					340)					34	5					3	350		. Ala
30	Va]	. Tr	p .	Ala 355	Pro	Glı	ı Gl	у۷	al	Ala 360	Va.	L Va	al	Thr	Arg	Ъу 36		Ala	Ile	. Įle
35														•						
33	<21 <21 <21		48€	ŝ																
40		3> ,	Str	ept	oco	ccus	pn	eum	oni	ae		•								
	Met 1	Ту	r F	ro	Asp	Asp 5	Se	c Le	eu '	Thr	Leu		s 1	'hr	Asp	Leu	T ,	yr	Gln 15	Ile
45	Asn	Met	: M	let	Gln 20	Val	Туз	Pì	ne A	Asp	Gln 25	Gl	y I	le	His	Asn		ys : 30	Lys	Ala
50	Val	Phe	e G	1u 35	Val	Tyr	Phe	e Ar	:g (40	Gln	Pr	o P	he :	Lys	Asn 45		ly :	Tyr	Ala
	Val	Phe 50	A	la (Gly	Leu	Glu	·Ar 5	g I 5	le	Val	Ası	n T	yr 1	Leu 60	Glu	As	sp I	Leu	Arg
55 .	Phe 65						70						•	75						80
	Ala	Phe	Le	eu Æ	4sp	Tyr	Leu	Ar	g A	sn :	Phe	Lys	Le	eu G	Slu	Leu	Th	ır V	al.	Arg.

	WU	U1/4)	9/21												P	CT/US
					8	5				9	0				9	5 .
5	Se	r Al	a Gl	n Gl 10	u Gl; 0	y Ası	e Le	u Va	1 Pho		a Ası	n Gli	ı Pr	0 Ile 110		l Gln
-	Va.	1 G1	u Gl 11	y Pr 5	o Le	u Ala	a Gl	n Cys 120	s Gli	n Le	u Val	l Glı	1 Th:		a Lei	u Leu
10	Ası	n Il 13	e Va O	l As	n Tyi	r Glr	13!		ı Val	l Ala	a Thi	Lys 140		a Ala	a Ar	g Ile
	Arg 145	g Se	r Va	l I1e	e Glu	150	Glı	ı Pro	Lev	Met	Glu 155		e Gly	/ Thr	Arg	Arg 160
. 15	Ala	a G1:	n Gl	u Thi	r Asp 165	Ala S	Ala	a Ile	Trp	Gl ₃		Arg	Ala	a Ala	Val	Ile
20	Gly	/ G1	y Ala	a Asr 180	n Gly	Thr	Ser	Asn	Val 185	Arg	, Ala	Gly	Lys	Leu 190		e Asp
	Ile	Pro	Va]	Leu i	ı Gly	Thr	His	Ala 200		Ala	Leu	Val	Gln 205		Tyr	Gly
25	Asn	Asp 210	Tyr)	Glu	Ala	Phe	Lys 215		Tyr	Ala	Ala	Thr 220		Lys	Asn	Cys
٠	Val 225	Phe	e Leu	val	. Asp	Thr 230	Tyr	Asp	Thr	Leu	Arg 235	Ile	Gly	Val	Pro	Ala 240
30	Ala	Ile	Gln	Val	Ala 245	Arg	Glu	Leu	Gly	Asp 250		Ile	Asn	Phe	Met 255	Gly
35	Val	Arg	Ile	Asp 260	Ser	Gly	Asp	Ile	Ala 265	Tyr	Ile	Ser	ГÀЗ	Lys 270	Val	Arg
	Gln	Gln	Leu 275	Asp	Glu	Ala	Gly	Phe 280	Thr	Glu	Ala	Lys	Ile 285	Tyr	Ala	Ser
40	Asn	Asp 290	Leu	Asp	Glu	Asn	Thr 295	Ile	Leu	Asn	Leu	Lys 300	Met	Gln	Lys	Ala
	Lys 305	Ile	Asp	Val	Trp	Gly 310	Val	Gly	Thr	Gln	Leu 315	Ile	Thr	Ala	Tyr	Asp 320
45	Gln	Pro	Ala	Leu	Gly 325	Ala	Val	Tyr	Lys	Ile 330		Ala	Ile	Glu	Asp 335	Glu
50	Thr	Gly	Gln	Met 340	Arg	Asn	Thr		Lys 345	Leu	Ser	Asn	Asn	Ala 350	Glů	Lys
	Val	Ser	Thr	Pro	Gly	Lyś	Lys	Gln	Val	Trp	Arg	Ile	Thr	Ser	Arg	Glu

Lys Gly Lys Ser Glu Gly Asp Tyr Ile Thr Tyr Asp Gly Val Asp Ile 370 380

Ser Asp Met Thr Glu Ile Lys Met Phe His Pro Thr Tyr Thr Tyr Ile

55

	38	35				3	90				3	95					400
5	Ly	/s L	ys T	hr V	al·A: 40	rg As D5	sn Pl	he A	sp Al	la V 4	al P: 10	ro L	eu L	eu V		.sp 15	Ile
	Pł	ne L	ys G	lu G. 42	ly II 20	le Le	eu Va	al Ty	/r As 42	sn L	eu Pi	ro Se	er L		hr A 30	sp	Ile
10	Gl	n A	sp T 4	yr A. 35	la Ai	g Ly	rs G]	lu Ph 44	ne As 10	sp L	ys Le	eu Ti		sp G:	lu T	yr	Lys
	Ar	g Va 45	al L 50	eu As	sn Pr	o G1	n Hi 45	s Ty 55	r Pr	o Va	al As	p Le 46		la Ai	g A	sp	Val.
15	Tr 46	p G: 5	ln A.	sp L	s Me	t As 47	p Le 0	u Il	e As	p L	s Me		g Ly	s Gl	u A	la	Leu 480
20	G1	y G]	Lu Gi	ly Gl	u Gl 48		u										
25	<2: <2:	10> 11> 12> 13>	283 PRT	ptoc	occu	s pne	eumo:	niae		-							
30		00> : Al		r Il	e Gli	n Trp	> Phe	e Pro	o Gl	ү Ні 1		t Se	г Ьу	s Al		g 1 5	Arg
	Glr	ı Va	1 G1	n Gli 20	a Asr	ı Let	ı Lys	s Phe	25 25	l Asj	Phe	e Val	l Th:	r Ile 30		u I	/al
35	Asp	Al:	a Ar 3	g Lei 5	ı Pro	Leu	Ser	Ser 40	Glr	Ası	n Pro	Met	Let 45		r Ly	s I	le
	Val	G1 ₃	y Asj	p Lys	Pro	Lys	Leu 55	Leu	Ile	Let	a Asn	Lys 60		Asp	Le	u A	la
40	Asp 65	Pro	Ala	a Met	Thr	Lys 70	Glu	Trp	Arg	Glr	Tyr 75		Glu	Ser	Gl		ly 80
45	Ile	Glr	Thi	. Leu	Ala 85	Ile	Asn	Ser	Lys	Glu 90		Val	Thr	Val	95 PA		al
	Val	Thr	Asp	Ala 100	Ala	Lys	Lys	Leu	Met 105	Ala	Asp	Lys	Ile	Ala 110		g G.	ln
50	Lys	Glu	Arg	Gly	Ile	Gln	Ile	Glu 120	Thr	Leu	Arg	Thr	Met 125	Ile	Ile	G.	ly
	Ile	Pro 130	Asn	Ala	Gly	Lys	Ser 135	Thr	Leu	Met	Asn	Arg 140	Leu	Ala	Gly	. Г 7	/S .
55	Lys 145	Ile	Ala	Val	Val	Gly 150	Asn	Lys	Pro	Gly	Val 155	Thr	Lys	Gly	Gln	G1 16	

Trp Leu Lys Thr Asn Lys Asp Leu Glu Ile Leu Asp Thr Pro Gly Ile Leu Trp Pro Lys Phe Glu Asp Glu Thr Val Ala Leu Lys Leu Ala Leu 5 185 Thr Gly Ala Ile Lys Asp Gln Leu Leu Pro Met Asp Glu Val Thr Ile 200 10 Phe Gly Ile Asn Tyr Phe Lys Glu His Tyr Pro Glu Lys Leu Ala Glu Arg Phe Lys Gln Met Lys Ile Glu Glu Glu Pro Ser Val Ile Ile Met 15 Asp Met Thr Arg Ala Leu Gly Phe Arg Asp Asp Tyr Asp Arg Phe Tyr Ser Leu Phe Val Lys Glu Val Arg Asp Gly Lys Leu Gly Asn Tyr Thr 20 Leu Asp Thr Leu Glu Asp Leu Asp Gly Asn Asp 280 25 <210> 121 <211> 156 <212> PRT <213> Streptococcus pneumoniae 30 <400> 121 Met Ile Asn Asn Val Val Leu Val Gly Arg Met Thr Arg Asp Ala Glu 5 35 Leu Arg Tyr Thr Pro Ser Asn Val Ala Val Ala Thr Phe Thr Leu Ala Val Asn Arg Thr Phe Lys Ser Gln Asn Gly Glu Arg Glu Ala Asp Phe 40 Ile Asn Val Val Met Trp Arg Gln Gln Ala Glu Asn Leu Ala Asn Trp Ala Lys Lys Gly Ser Leu Ile Gly Val Thr Gly Arg Ile Gln Thr Arg 45 Ser Tyr Asp Asn Gln Gln Gly Gln Arg Val Tyr Val Thr Glu Val Val ··· 90 Ala Glu Asn Phe Gln Met Leu Glu Ser Arg Ser Val Arg Glu Gly His 50 Thr Gly Gly Ala Tyr Ser Ala Pro Thr Ala Asn Tyr Ser Ala Pro Thr 55 Asn Ser Val Pro Asp Phe Ser Arg Asn Glu Asn Pro Phe Gly Ala Thr 135

Asn Pro Leu Asp Ile Ser Asp Asp Leu Pro Phe 150 5 <210> 122 <211> 324 <212> PRT <213> Streptococcus pneumoniae 10 Met Lys Thr Arg Ile Thr Glu Leu Leu Lys Ile Asp Tyr Pro Ile Phe Gln Gly Gly Met Ala Trp Val Ala Asp Gly Asp Leu Ala Gly Ala Val 15 Ser Lys Ala Gly Gly Leu Gly Ile Ile Gly Gly Gly Asn Ala Pro Lys 20 Glu Val Val Lys Ala Asn Ile Asp Lys Ile Lys Ser Leu Thr Asp Lys Pro Phe Gly Val Asn Ile Met Leu Leu Ser Pro Phe Val Glu Asp Ile 25 Val Asp Leu Val Ile Glu Glu Gly Val Lys Val Val Thr Thr Gly Ala 30 Gly Asn Pro Ser Lys Tyr Met Glu Arg Phe His Glu Ala Gly Ile Ile Val Ile Pro Val Val Pro Ser Val Ala Leu Ala Lys Arg Met Glu Lys . 120 35 Ile Gly Ala Asp Ala Val Ile Ala Glu Gly Met Glu Ala Gly Gly His Ile Gly Lys Leu Thr Thr Met Thr Leu Val Arg Gln Val Ala Thr Ala 40 Ile Ser Ile Pro Val Ile Ala Ala Gly Gly Ile Ala Asp Gly Glu Gly 45 Ala Ala Ala Gly Phe Met Leu Gly Ala Glu Ala Val Gln Val Gly Thr Arg Phe Val Val Ala Lys Glu Ser Asn Ala His Pro Asn Tyr Lys Glu 50 Lys Ile Leu Lys Ala Arg Asp Ile Asp Thr Thr Ile Ser Ala Gln His Phe Gly His Ala Val Arg Ala Ile Lys Asn Gln Leu Thr Arg Asp Phe 55 Glu Leu Ala Glu Lys Asp Ala Phe Lys Gln Glu Asp Pro Asp Leu Glu

245 250 255

Ile Phe Glu Gln Met Gly Ala Gly Ala Leu Ala Lys Ala Val Val His 260 265 270

Gly Asp Val Glu Gly Gly Ser Val Met Ala Gly Gln Ile Ala Gly Leu 275 280 285

Val Ser Lys Glu Glu Thr Ala Glu Glu Ile Leu Lys Asp Leu Tyr Tyr 10 290 295 300

Gly Ala Ala Lys Lys Ile Gln Glu Glu Ala Ser Arg Trp Thr Gly Val 305 310 315 320

15 Val Arg Asn Asp

25 Met Ile Asp Ile Gln Gly Ile Lys Glu Ala Leu Pro His Arg Tyr Pro

1 5 10 15

Met Leu Leu Val Asp Arg Val Leu Glu Val Ser Glu Asp Thr Ile Val 20 25 30

Ala Ile Lys Asn Val Thr Ile Asn Glu Pro Phe Phe Asn Gly His Phe 35 40 45

Pro Gln Tyr Pro Val Met Pro Gly Val Leu Ile Met Glu Ala Leu Ala 50 55 60

Gln Thr Ala Gly Val Leu Glu Leu Ser Lys Pro Glu Asn Lys Gly Lys
65 70 75 80

40 Leu Val Phe Tyr Ala Gly Met Asp Lys Val Lys Phe Lys Lys Gln Val 85 90 95

Val Pro Gly Asp Gln Leu Val Met Thr Ala Thr Phe Val Lys Arg Arg 100 105 110

Gly Thr Ile Ala Val Val Glu Ala Lys Ala Glu Val Asp Gly Lys Leu 115 120 125

Ala Ala Ser Gly Thr Leu Thr Phe Ala Ile Gly Asn 130 135 140

<210> 124

<211> 340

55 <212> PRT

30

45

<213> Streptococcus pneumoniae

	<4	.00>	124													٠
		t I		sn Gl	n Il	е Ту: 5	c Gl	n Le	u Th:	r Ly		o Lys	s Ph	e Ile	e As 1	n Val 5
5	Ly	s Ty	yr Gl	n Gl 2	u Gl O	u Ala	a Il	e Ası	p Gli 25	n Gli	u Ası	n His	s Ile	e Lei 30		e Arg
10	Pr	o As	n Ty 3	r Me 5	t Al	a Vä]	Су	s His	s Ala	a Asp	o Glr	n Arg	Ty:		Gl:	n Gly
	Lу	s Ar 5	g As	p Pr	o Ly	s Ile	Let 5	u Ası 5	n Lys	. Lys	s Lev	Pro 60		: Ala	Me	t Ile
15	Ні 6	s Gl 5	u Se	r Cy	s Gl	y Ile 70		l Ile	e Ser	Asp	75		Gly	Thr	ту	r Glu 80
	Va.	l Gl	y Gl	n Lys	8 Val	l Val	Met	t Ile	Pro	Asn 90		Ser	Pro	Met	Glr 95	s Ser
20	Ası	Gl	u Gl	u Phe 100	Tyr	Glu	Asr	ı Tyr	Met 105		Gly	Thr	His	Phe 110		Ser
25	Sei	Gl	y Pho 11:	e Asp 5	Gly	Phe	Met	120	Glu	Phe	Val	Ser	Leu 125	Pro	ГЛа	Asp
	Arc	Vá. 13	l Va:	l Ala	Tyr	Asp	Ala 135	Ile	Glu	Asp	Thr	Val 140	Ala	Ala	Ile	Thr
30	Glu 145	Phe	e Val	l Ser	Val	Gly 150	Met	His	Ala	Met	Asn 155	Arg	Leu	Leu	Thr	Leu 160
	Ala	His	s Ser	: Lys	Arg 165	Glu	Arg	Ile	Pro	Val 170	Ile	Gly	Asp	Gly	Ser 175	Leu
35	Ala	Phe	e Val	Val 180	Ala	Asn	Ile	Ile	Asn 185	Tyr	Thr	Leu	Pro	Glu 190	Ala	Glu
40	Ile	Val	Val 195	Ile	Gly	Arg	His	Trp 200	Glu	Lys	Leu	Glu 、	Leu 205	Phe	Ser	Phe
٠	Ala	Lys 210	Glu	Суз	Tyr	Ile	Thr 215	Asp	Asn	Ile		Glu 220	Glu	Leu	Ala	Phie
45	Asp 225	His	Ala	Phe	Glu	Cys 230	Суѕ	Gly	Gly	Asp	Gly 235	Thr	Gly	Pro	Ala	Ile 240
	Asn	Asp	Leu	Ile	Arg 245	Tyr	Ile	Arg		Gln 250	Gly	Thr	Ile		Met 255	
50	Gly	Val	Ser	Glu 260	Tyr	Lys '	Val		Leu 7 265	Asn	Thr	Arg i		Ala : 270	Leu	Glu
55	Lys	Gly	Leu 275	Leu	Leu	Val (Ser : 280	Ser 1	Arg	Ser (Arg : 285	Ile Z	Asp	Phe
	Glu	Asn 290	Ala	Ile	Gln	Met N	1et 295	Lys '	Val I	Lys 1		Phe A	Ala A	Asn A	Arg	Leu

Lys Asn Ile Leu Tyr Leu Glu Glu Pro Val Arg Glu Ile Lys Asp Ile His Arg Val Phe Ala Thr Asp Leu Asn Thr Ala Phe Lys Thr Val Phe 330 Lys Trp Glu Val 10 <210> 125 <211> 447 <212> PRT 15 <213> Streptococcus pneumoniae <400> 125 Met Asn Leu Lys Thr Thr Leu Gly Leu Leu Ala Gly Arg Ser Ser His 20 Phe Val Leu Ser Arg Leu Gly Arg Gly Ser Thr Leu Pro Gly Lys Val Ala Leu Gln Phe Asp Lys Asp Ile Leu Gln Asn Leu Ala Lys Asn Tyr 25 40 Glu Ile Val Val Val Thr Gly Thr Asn Gly Lys Thr Leu Thr Thr Ala 30 Leu Thr Val Gly Ile Leu Lys Glu Val Tyr Gly Gln Val Leu Thr Asn Pro Ser Gly Ala Asn Met Ile Thr Gly Ile Ala Thr Thr Phe Leu Thr 35 Ala Lys Ser Ser Lys Thr Gly Lys Asn Ile Ala Val Leu Glu Ile Asp 105 Glu Ala Ser Leu Ser Arg Ile Cys Asp Tyr Ile Gln Pro Ser Leu Phe 40 Val Ile Thr Asn Ile Phe Arg Asp Gln Met Asp Arg Phe Gly Glu Ile 130 45 Tyr Thr Thr Tyr Asn Met Ile Leu Asp Ala Ile Arg Lys Val Pro Thr 150 Ala Thr Val Leu Leu Asn Gly Asp Ser Pro Leu Phe Tyr Lys Pro Thr 50 Ile Pro Asn Pro Ile Glu Tyr Phe Gly Phe Asp Leu Glu Lys Gly Pro Ala Gln Leu Ala His Tyr Asn Thr Glu Gly Ile Leu Cys Pro Asp Cys 55 200.

Gln Gly Ile Leu Lys Tyr Glu His Asn Thr Tyr Ala Asn Leu Gly Ala

		21	.0			215						220					
5	44	r Il 5	е Су	s Gl	u Gl	y Cy 23	s Gl	у Су:	s Ly:	s Ar	g Pro 235	As _i	p Le	u Asp	у Ту	r Ar	
		u Th	г Ьу	s Le	u Val 24!	l Gl	u Lei	u Thi	r Ası	n Asr 250	n Arç	g Se:	r Ar	g Phe	25		
10	As	p Gl	y Gl	n Gla 260	и Ту з О	Gly	y Ile	e Glr	11e 265	e Gly	/ Gly	Let	з Ту	270		Ty:	
	Ası	n Ala	a Let 275	ı Ala	a Ala	a Val	l Ala	280	Ala	Arg	Phe	. Let	Gl ₃ 285		Asp	Sei	
15	Glr	290	ı Ile	e Lys	s Gln	Gly	7 Phe 295	Asp	Lys	Ser	Arg	Ala 300		. Phe	Gly	Arg	
20	Glr 305	ı Gli	Thr	Phe	His	Ile 310	e Gly	' Asp	Lys	Glu	Cys 315		Leu	Val	Leu	Ile 320	
	Lys	Asn	Pro	Val	. Gly 325	Ala	Thr	Gln	Ala	Ile 330	Glu	Met	Ile	Lys	Leu 335	Ala	
25				340					345					350			
			355		Ser			360					365				
30		370			Pro		375					380					
35	363				Leu	390			٠		395					400	
•					Leu 405	•				410					415		
40				420	Tyr				425					430		Phe	
45	Arg	Glu	Leu 435	Leu	Ala	Ser	Arg	Gln 440	Ile	Val .	Arg	Lys	Glu 445	Met	Asn		
45	<210 <211 <212	> 26 > PR	0 · T														
50	<400	> 12	6		cus j				_								
55	Met 1				5					10					15		
55	Leu 1	asn .	тте 1	41a 1 20	mıs I	eu 1	ryr 0	SLY A	sn I 25	eu M	let A	sn 1	Thr T	7yr G 30	Sly A	Asp	

	Ası	n Gl	y As 3	n Il 5	.e Le	u Met	Le	1 Ly:	з Туі)	c Val	l Ala	a Glu	Lys 45		ı Gl	y Ala
5	His	5 Va.	l Th O	r Va	l As	p Ile	• Va:	Se:	: Let	ı His	s Asp	Asp 60		e Asp	Gl:	a Asn
	His 65	T y 1	c As	p Il	e Ala	a Phe	Phe	e Gly	/ Gly	/ Gly	/ Glr 75		Phe	Glu	ı Glı	Ser 80
10	Ile	: Ile	e Al	a As	p Ası 85	p Leu 5	Pro	Ala	Lys	Lys 90		Ser	Ile	Asp	Ası 95	Tyr
15	Ile	Gln	a Ası	n As 10	p Gly O	y Val	Val	. Lev	Ala 105		Cys	Gly	Gly	Phe 110		Leu
	Leu	Gly	Gl:	n Ty. 5	г Туг	. Val	Glu	Ala 120		Gly	Ьys	Arg	Ile 125		Gly	Leu
20	Gly	Val 130	Met	t Gl	y His	Tyr	Thr 135	Leu	Asn	Gln	Thr	Asn 140	Asn	Arg	Phe	Ile
	Gly 145	Asp	Ile	E Lys	3 Ile	His 150	Asn	Glu	Asp	Phe	Asp 155	Glu	Thr	Tyr	Tyr	Gly 160
25	Phe	Glu	Asn	n His	Gln 165	Gly	Arg	Thr	Phe	Leu 170	Ser	Asp	Asp	Gln	Lys 175	
30	Leu	Gly	Gln	Val 180	. Val	Tyr	Gly	Asn	Gly 185	Asn	Asn	Glu	Glu	Lys 190	Val	Gly
	Glu	Gly	Val 195	His	Tyr	Lys	Asn	Val 200	Phe	Gly	Ser	Tyr	Phe 205	His	Gly	Pro
35	Ile	Leu 210	Ser	Arg	Asn	Ala	Asn 215	Leu	Ala	Tyr	Arg	Leu 220	Val	Thr	Thr	Ala
	225					Gly 230					235					240
40	·Ile	Leu	Ser	Gln	Glu 245	Ile	Ala	Glu		Tyr 250	Ser	Asp	Val	Lys	Ser 255	Lys
45	Ala .	Asp	Phe	Ser 260											٠	
50	<210: <211: <212: <213:	> 22 > PR	3 · T	cococ	ccus	pneu	noni	a e	٠		,					
55	<4000 Met <i>I</i>			Lys	Glu . 5	Asn 1	Phr (Glu 1	Lėu V	/al 1 10	Phe <i>l</i>	Arg G	Slu V	/al /	Ala 15	Glu
	Ala S	Ger 1	Leu	Ser 20	Ala	Asn A	lrg (Glu S	Ser (Sly S	Ser V	al S	er V	/al] 30	ile	Ala

Val Thr Lys Tyr Val Asp Val Pro Thr Ala Glu Ala Leu Leu Pro Leu 5 Gly Val His His Ile Gly Glu Asn Arg Val Asp Lys Phe Leu Glu Lys Tyr Glu Ala Leu Lys Asp Arg Asp Val Thr Trp His Leu Ile Gly Thr 10 Leu Gln Arg Arg Lys Val Lys Asp Val Ile Gln Tyr Val Asp Tyr Phe His Ala Leu Asp Ser Val Lys Leu Ala Gly Glu Ile Gln Lys Arg Ser 15 Asp Arg Val Ile Lys Cys Phe Leu Gln Val Asn Ile Ser Lys Glu Glu Ser Lys His Gly Phe Ser Arg Glu Glu Leu Leu Glu Ile Leu Pro Glu 20 135 Leu Ala Gly Leu Asp Lys Ile Glu Tyr Val Gly Leu Met Thr Met Ala 155 25 Pro Phe Glu Ala Ser Ser Glu Gln Leu Lys Glu Ile Phe Lys Ala Ala Gln Asp Leu Gln Arg Glu Ile Gln Glu Lys Gln Ile Pro Asn Ile Pro 30 Met Thr Glu Leu Ser Met Gly Met Ser Arg Asp Tyr Lys Glu Ala Ile 35 Gln Phe Gly Ser Thr Phe Val Arg Ile Gly Thr Ser Phe Phe Lys 215 <210> 128 40 <211> 279 <212> PRT <213> Streptococcus pneumoniae <400> 128 45 Met Gly Ile Ala Leu Glu Asn Val Asn Phe Thr Tyr Gln Glu Gly Thr Pro Leu Ala Ser Ala Ala Leu Ser Asp Val Ser Leu Thr Ile Glu Asp 50 Gly Ser Tyr Thr Ala Leu Ile Gly His Thr Gly Ser Gly Lys Ser Thr Ile Leu Gln Leu Leu Asn Gly Leu Leu Val Pro Ser Gln Gly Ser Val 55 Arg Val Phe Asp Thr Leu Ile Thr Ser Thr Ser Lys Asn Lys Asp Ile

	65	5					70				. 7	5				8(
5	Arg	g Gl	n Il	e Ai	g Ly	ys G: 35	ln V	al Gl	ly Le		l Pho	e Glı	n Phe	≥ Ala	Gl:	
	Gln	ıIl	e Ph	e Gl	.u G])0	lu Tì	nr Va	al Le	eu Ly 10	s As	p Vai	l Ala	a Ph∈	Gly 110		o Glr
10	Asn	Ph	e Gl 11	y Va 5	ıl Se	er Gl	lu Gi	lu As 12	sp Al	a Va	l Lys	s Thi	Ala 125		Glu	ı Lys
	Ĺeu	Ala 13	a Le	u Va	.1 G1	y Il	le As	sp G1 35	u Se	r Le	u Phe	Asp 140		Ser	Pro	Phe
15 -	Glu 145	Let	ı Se:	r Gl	y Gl	y Gl 15	л Ме 0	t Ar	g Ar	g Val	l Ala 155		Ala	Gly	Ile	Leu 160
20	Ala	Met	: Glu	ı Pr	o Al 16	a Il 5	e Le	u Va	l Le	1 Asp	o Glu	Pro	Thr	Ala	Gly 175	
	Asp	Pro	Let	18	y Ar	д Гу	s Gl	u Le	u Met 185	Thr	Leu	Phe	Lys	Lys 190	Leu	His
25	Gln	Ser	Gl ₃	Me	t Th	r Il	e Va	l Lei 200	u Val O	. Thr	His	Leu	Met 205	Asp	Asp	Val
•	Ala	Glu 210	Tyr	Ala	a Ası	n Gli	n Va. 21	1 Ty:	r Val	Met	Glu	Lys 220	Gly	Arg	Leu	Val
30	Lys 225	Gly	Gly	Lys	Pro	230	r Ası	o Val	l Phe	Gln	Asp 235	Val	Val	Phe	Met	Glu 240
35	Glu	Val	Gln	Leu	Gl ₃ 245	Val	L Pro	Lys	Ile	Thr 250	Ala	Phe	Cys	Lys	Arg 255	Leu
	Ala	Asp	Arg	Gly 260	Val	Ser	Phe	. Lys	Arg 265	Leu	Pro	Val	Lys	Ile 270	Glu	Glu
40	Phe	Lys	Glu 275	Ser	Leu	Asn	Gly	,	-							
45	<210: <211: <212: <213:	> 30 > PF)9 RT .	:oco	ccus	pne	umon	iae					:			
50	<4000 Met A			Gln	Phe 5	Leu	Gly	Thr	: Gly	Ala 10	Gly	Gln :	Pro :	Ser 1	Lys 1	Ala
	Arg A	Asn	Val	Ser 20	Ser	Leu	Ala	Leu	Lys 25	Leu	Leu <i>l</i>	Asp (Glu I	Ile <i>P</i> 30	ne)	Glu
55	Val I	rp :	Leu	Phe	Asp	Cys	Gly	Glu	Glv	Thr :	Gln /	Asn Z	Ara 1	le I	.eu (27.11

Thr Thr Ile Arg Pro Arg Lys Val Ser Lys Ile Phe Ile Thr His Leu His Gly Asp His Ile Phe Gly Leu Pro Gly Phe Leu Ser Ser Arg Ala 5 Phe Gln Ala Asn Glu Glu Gln Thr Asp Leu Glu Ile Tyr Gly Pro Gln 10 Gly Ile Lys Ser Phe Val Leu Thr Ser Leu Arg Val Ser Gly Ser Arg Leu Pro Tyr Arg Ile His Phe His Glu Phe Asp Gln Asp Ser Leu Gly 120 15 Lys Ile Leu Glu Ile Asp Lys Phe Thr Val Tyr Ala Glu Glu Leu Asp 135 His Thr Ile Phe Cys Val Gly Tyr Arg Val Met Gln Lys Asp Leu Glu 20 Gly Thr Leu Asp Ala Glu Lys Leu Lys Ala Ala Gly Val Pro Phe Gly 170 Pro Leu Phe Gly Lys Ile Lys Asn Gly Gln Asp Leu Val Leu Glu Asp 25 Gly Thr Glu Ile Lys Ala Ala Asp Tyr Ile Ser Ala Pro Arg Pro Gly 30 Lys Ile Ile Thr Ile Leu Gly Asp Thr Arg Lys Thr Asp Ala Ser Val Arg Leu Ala Val Asn Ala Asp Val Leu Val His Glu Ser Thr Tyr Gly 35 Lys Gly Asp Glu Lys Ile Ala Arg Asn His Gly His Ser Thr Asn Met Gln Ala Ala Gln Val Ala Val Glu Ala Gly Ala Lys Arg Leu Leu 40 Asn His Ile Ser Ala Arg Phe Leu Ser Lys Asp Ile Ser Lys Leu Lys 280 45 Lys Asp Ala Ala Thr Ile Phe Glu Asn Val His Val Val Lys Asp Leu 290 295 Glu Glu Val Glu Ile 50 <210> 130 <211> 553 55 <212> PRT <213> Streptococcus pneumoniae

	<pre><400> 130 Met Ser Asn Ile Ser Leu Thr Thr Leu Gly Gly Val Arg Glu Asn Gly 1</pre>
5	5 Lys Asn Met Tyr Ile Ala Glu Ile Gly Glu Ser Ile Phe Val Leu Asn 20 25 30
10	Val Gly Leu Lys Tyr Pro Glu Asn Glu Gln Leu Gly Val Asp Val Val 35 40 45
	Ile Pro Asn Met Asp Tyr Leu Phe Glu Asn Ser Asp Arg Ile Ala Gly 50 55 60
15	75 80
	Leu Leu Ala Glu Ala Lys Val Pro Val Phe Gly Ser Glu Leu Thr Ile 85 90 95
20	100 105 110
25	Asn Asp Phe His Val Ile Asp Glu Asn Thr Glu Ile Asp Phe Gly Gly 115 120 125
	Thr Val Val Ser Phe Phe Pro Thr Thr Tyr Ser Val Pro Glu Ser Leu 130 135 140
30	Gly Ile Val Leu Lys Thr Ser Glu Gly Ser Ile Val Tyr Thr Gly Asp 145 150 155 160
25	Phe Lys Phe Asp Gln Thr Ala Ser Glu Ser Tyr Ala Thr Asp Phe Ala 165 170 175
35	Arg Leu Ala Glu Ile Gly Arg Asp Gly Val Leu Ala Leu Leu Ser Asp 180 185 190
40	Ser Ala Asn Ala Asp Ser Asn Ile Gln Val Ala Ser Glu Ser Glu Val 195 200 205
	Arg Asp Glu Ile Thr Gln Thr Ile Ala Asp Trp Glu Gly Arg Ile Ile 210 215 220
45	Val Ala Ala Val Ser Ser Asn Leu Ser Arg Ile Gln Gln Ile Phe Asp 225 230 235 240
50	Ala Ala Asp Lys Thr Gly Arg Arg Ile Val Leu Thr Gly Phe Asp Ile 245 250 255
30	Glu Asn Ile Val Arg Thr Ala Ile Arg Leu Lys Lys Leu Ser Leu Ala 260 265 270
55	Asn Glu Ile Leu Leu Ile Lys Pro Lys Asp Met Ser Arg Phe Glu Asp 275 280 285
	His Glu Leu Ile Ile Leu Glu Thr Gly Arg Met Gly Glu Pro Ile Asn 290 295 300

	G1 30	у) 5	Leu	Arg	J Ly:	s Me	t Se 31	r Ile O	e Gl	y Ar	g His	315	ј Туг 5	va:	l Glı	ı Ile	2 Ly
5	As	p (Sly	Asp	Lei	ı Va. 32.	1 Ty:	r Ile	e Ala	a Th	r Ala 330	a Pro	Ser	: Ile	e Ala	335	
10		a E	?he	Val	Ala 340	a Ar	g Vai	l Glu	ı Ası	n Me 34	t Il∈ 5	e Tyr	Gln	Ala	Gly 350		/ Vai
,	۷a	1 I	ys,	Leu 355	Ile	Thi	c Glr	n Ser	Let 360	ı Hi:	s Val	. Ser	Gly	His 365		/ Asn	val
15	Ar	д А З	sp 70	Leu	Gln	Leu	ı Met	375	Asr	ı Let	ı Leu	Gln	Pro 380		Tyr	Leu	Phe
	Pro 385	o V	al	Gln	Gly	Glu	390	Arg	Glu	ı Leı	ı Asp	Ala 395	His	Ala	Lys	Ala	Ala 400
20	Met	: A	la	Val	Gly	Met 405	Leu	Pro	Glu	ı Arg	Ile 410	Phe	Ile	Pro	Lys	Lys 415	Gly
25	Thr	T)	hr	Met	Ala 420	Tyr	Glu	Asn	Gly	Asp 425	Phe	Val	Pro	Ala	Gly 430	Ser	Val
	Ser	A .	la	Gly 435	Asp	Ile	Leu	İle	Asp 440	Gly	Asn	Ala	Ile	Gly 445	Asp	Val	Gly
30	Asn	Va 45	al 50	Val	Leu	Arg	Asp	Arg 455	Lys	Val	Leu	Ser	Glu 460	Asp	Gly	Ile	Phe
	Ile 465	Vá	al.	Ala	Ile	Thr	Val 470	Asn	Arg	Arg	Glu	Lys 475	Lys	Ile	Val	Ala	Arg 480
35	Ala	Ar	g	Val	His	Thr 485	Arg	Gly	Phe	Val	Tyr 490	Leu	Lys	Lys	Ser	Arg 495	Asp
40					500					505	Asn				510		
			. :	015					520	·	Asp			525			
.45	Asp	As: 53	n I O	ieu '	Thr	Lys	Tyr	Leu 535	Phe	Asp	Gln		Lys . 540	Arg .	Arg	Pro.	Ala
	Ile 545	Le	u E	?ro '	Val		Met 550	Glu .	Ala	Lys							
50	<210 <211 <212 <213	> 3 > I	316 PRT	.:	coc	cus j	pneu	monia	ie	٠,	٠						
55	<400 Met	> 1	.31							Thr '	Val _. I	eu I	eu H	lis G	Slu I	hr 1	lle

		1				5				1	0				1	5
5	As	sp Me	et Le	eu As 2	p Va 90	l Ly	s Pr	o As	p Gl;		е Ту	r Va	l As	p Al	_	r Leu
	Gl	y GI	Ly Al	.a Gl 85	y Hi	s Se	r Gl	u·Ty 4	r Lei	ı Le	u Se	r Ly	s Le 4		r Gl	u Lys
10	Gl	y Hi	s Le	u Ty	r Al	a Phe	Asj	p Gli 5	n Asg	Gl:	n Asi	n Ala		e Ası	o Ası	n Ala
	G1 6	n .Ly 5	s Ar	g Le	u Ala	a Pro	э Ту:)	r Ile	e Glu	Lys	s Gl ₂		l Va	l Thi	r Phe	e Ile 80
15	Ly	s As	p As	n Ph	e Arq	g His	: Le	ı Ğlr	n Ala	Arg 90		ı Arç	Glı	u Ala	a Gly 95	y Val
20	Gli	n Gl	u Il	e Ası	p Gly	/ Ile	су:	з Туг	Asp 105		1 Gl	/ Val	. "Sei	Ser 110		Gln
	Lei	ı As	p Gl 11	n Arg	g Glu	Arg	Gl)	Phe 120		Tyr	Lys	. Lys	125		Pro	Leu
25	. Asp	Ме 13	t Ar	g Met	Asn	Gln	Asp 135		Ser	Leu	Thr	Ala 140		Glu	Val	Val
,	Asr 145	n Hi:	ту :	r Asp	Tyr	His 150	Asp	Leu	Val	Arg	Ile 155		Phe	Lys	Tyr	Gly 160
30	Glu	ı Asp	b Lys	s Phe	Ser 165	Гуз	Gln	Ile	Ala	Arg 170	Lys	Ile	Glu	Gln	Ala 175	
35	Glu	Va]	Lys	Pro 180	Ile	Glu	Thr	Thr	Thr 185	Glu	Leu	Ala	Glu	Ile 190	Ile	Lys
	Leu	Va]	. Lys 195	Pro	Ala	Lys	Glu	Leu 200	Lys	Lys	Lys	Glÿ	His 205	Pro	Ala	Lys
40	Gln	Ile 210	Phe	Gln	Ala	Ile	Arg 215	Ile	Glu	Val	Asn	Asp 220	Glu	Leu	Gly	Ala
	Ala 225	Äsp	Glu	Ser	Ile	Gln 230	Gln	Ala	Met	Asp	Met 235	Leu	Ala	Leu	Asp	Gly 240
45	Arg	Ile	Ser	Val	Ile 245	Thr	Phe	His		Leu 250	Glu	Asp	Arg	Leu	Thr 255	Lys
50-	Gln	Leu	Phe	Lys 260	Glu	Ala	Ser	Thr	Val 265	Glu	Val	Pro	Lys	Gly 270	Leu	Pro
	Phe	Ile	Pro 275	Asp	Asp	Leu		Pro 280	Lys	Met	Glu		Val 285	Ser	Arg	Lys
55	Pro	Ile 290	Leu	Pro	Ser		Glu 295	Glu	Leu (Glu /		Asn . 300	Asn	Arg	Ser	His
	Ser	Ala	Lys	Leu	Arg	Val '	Val .	Arg :	Lys J	[le	His :	Lys		-		

305 310 315

<210> 132
5 <211> 332
 <212> PRT
 <213> Streptococcus pneumoniae

<400> 132

30

45

10 Met Ser Arg Ile Leu Asp Asn Glu Ile Met Gly Asp Glu Glu Leu Val 1 5 10 15

Glu Arg Thr Leu Arg Pro Gln Tyr Leu Arg Glu Tyr Ile Gly Gln Asp
20 25 30

Lys Val Lys Asp Gln Leu Gln Ile Phe Ile Glu Ala Ala Lys Met Arg
35 40 45

Asp Glu Ala Leu Asp His Val Leu Leu Phe Gly Pro Pro Gly Leu Gly 50 55 60

Lys Thr Thr Met Ala Phe Val Ile Ala Asn Glu Leu Gly Val Asn Leu 65 70 75 80

25 Lys Gln Thr Ser Gly Pro Val Ile Glu Lys Ala Gly Asp Leu Val Ala 85 90 95

Ile Leu Asn Glu Leu Glu Pro Gly Asp Val Leu Phe Ile Asp Glu Ile 100 105 110

His Arg Leu Pro Met Ser Val Glu Glu Val Leu Tyr Ser Ala Met Glu 115 120 125

Asp Phe Tyr Ile Asp Ile Met Ile Gly Ala Gly Glu Gly Ser Arg Ser 130 135 140

Val His Leu Glu Leu Pro Pro Phe Thr Leu Ile Gly Ala Thr Thr Arg 145 150 155 160

40 Ala Gly Met Leu Ser Asn Pro Leu Arg Ala Arg Phe Gly Ile Thr Gly 165 170 175

His Met Glu Tyr Tyr Ala His Ala Asp Leu Thr Glu Ile Val Glu Arg 180 185 190

Thr Ala Asp Ile Phe Glu Met Glu Ile Thr His Glu Ala Ala Ser Glu 195 200 205

Leu Ala Leu Arg Ser Arg Gly Thr Pro Arg Ile Ala Asn Arg Leu Leu 50 210 215 220

Lys Arg Val Arg Asp Phe Ala Gln Ile Met Gly Asn Gly Val Ile Asp 235 230 235

55 Asp Ile Ile Thr Asp Lys Ala Leu Thr Met Leu Asp Val Asp His Glu 245 250 255

Gly Leu Asp Tyr Val Asp Gln Lys Ile Leu Arg Thr Met Ile Glu Met Tyr Ser Gly Gly Pro Val Gly Leu Gly Thr Leu Ser Val Asn Ile Ala 5 Glu Glu Arg Glu Thr Val Glu Asp Met Tyr Glu Pro Tyr Leu Ile Gln 10 Lys Gly Phe Ile Met Arg Thr Arg Ser Glý Arg Val Ala Thr Ala Lys Ala Tyr Glu His Leu Gly Tyr Glu Tyr Ser Glu Lys 15 <210> 133 <211> 436 <212> PRT 20 <213> Streptococcus pneumoniae <400> 133 Met Ser Met Phe Leu Asp Thr Ala Lys Ile Lys Val Lys Ala Gly Asn 25 Gly Gly Asp Gly Met Val Ala Phe Arg Arg Glu Lys Tyr Val Pro Asn Gly Gly Pro Trp Gly Gly Asp Gly Gly Arg Gly Gly Asn Val Val Phe 30 Val Val Asp Glu Gly Leu Arg Thr Leu Met Asp Phe Arg Tyr Asn Arg 35 His Phe Lys Ala Asp Ser Gly Glu Lys Gly Met Thr Lys Gly Met His Gly Arg Gly Ala Glu Asp Leu Arg Val Arg Val Ser Gln Gly Thr Thr 40 Val Arg Asp Ala Glu Thr Gly Lys Val Leu Thr Asp Leu Ile Lys His Gly Gln Glu Phe Ile Val Ala His Gly Gly Arg Gly Arg Gly Asn 45 Ile Arg Phe Ala Thr Pro Lys Asn Pro Ala Pro Glu Ile Ser Glu Asn 135 Gly Glu Pro Gly Gln Glu Arg Glu Leu Gln Leu Glu Leu Lys Ile Leu 50 Ala Asp Val Gly Leu Val Gly Phe Pro Ser Val Gly Lys Ser Thr Leu 55 Leu Ser Val Ile Thr Ser Ala Lys Pro Lys Ile Gly Ala Tyr His Phe 180 185

	Th	r T	nr I	1e 95	Va]	l Pro	o Ası	n Lei	u G1 20	у Ме 0	t Vai	l Ar	g Th:	r Gl: 20:		c Gly	y Glı
5	Se.	r Pl 2:	ne A LO	la	Val	Ala	a Asp	215	u Pr	o Gl	у Let	ı Ile	220		y Ala	s Sei	Gli
10	G1; 22!	y Va 5	ıl G	ly	Leu	ı Gly	7 Thi 230	Glr	n Pho	e Le	u Arg	7 His 235	: Ile	e Glu	ı Arç	Thr	240
	Va.	l I]	e L	eu .	His	11e 245	Ile	e Asp	Met	t Sei	r Ala 250	Ser	Glu	1 Gl	/ Arg	Asp 255	
15	Туз	: G1	u A	sp '	Tyr 260	Leu	Ala	ı Ile	e Asr	265	s Glu	Leu	Glu	Ser	Tyr 270		Leu
			2	/5					280) .	e Val			285			
20		29	U					295			Phe		300				
25	303						310				Ala	315					320
						325					Leu 330					335	
30				3	40					345	Tyr				350		
35			35	5					360		Glu			365			
33	•	370	1					375			Leu		380				
40	385						390				Arg	395			•		400
				•		405		•			Val 410					415	
45		٠		42	20	Asp	GIA.	Asp	Leu	Val- 425	Arg	Ile	Gly		Phe 430	Glu	Phe
50	Glu	rne	435		sp						•						•
55	<210 <211 <212 <213	> 1' > P	72 RT	toc		us p	pneur	monia	1e				٠				
<i>JJ</i>	<400 Met A			Ph	e A	sn V	/al (Sly I	ys .	Ile V	Val A	Asn T	hr G	Sln G	Sly I	eu G	ln

		1					5					10					1	5
5		уG	lu I	1et	Arg 20	y Vai	l Le	u Se	er Va	1 Th	r As	sp P	he A	la	Glu	Gl: 30		g Phe
		s L	ys (35	Ala	Gl:	ı Let	ı Al	a Le 4	u Ph O	e As	sp G	lu L	ys .	Asp 45		n Ph	e Val
10		•	υ					5	5				•	60				p Ile
	Ile 65	e Ly 5	/s F	he	Lys	Asp	Met 70	Ty	r Hi	s Il	e As	n Th	r I:	le (Glu	Lys	ту:	r Lys 80
15	Gl7	/ Ту	r S	er	Leu	Lys 85	Val	Ala	a Glu	ı Glı		p Le 0	u As	sn A	Asp	Leu	Ası 9	Asp
20	Gly	/ G1	u P	he	Туг 100	Tyr	His	Glı	ılle	105 105	e G1	y Le	u Gl	u V	/al	Tyr 110		ı Gly
	Asp	Se	r L 1	eu 15	Val	Gly	Thr	Ile	Lys 120	Gl:	ıIl	e Le	u Gl		Pro .25	Gly	Ala	Asn
25	Asp	Va 13	1 T: O	rp '	Val	Val	Lys	Arg 135	Lys	Gly	Ly:	s Ar	g Às 14		eu	Leu	Leu	Pro
	Tyr 145	11	e Pi	o i	Pro	Val	Val 150	Leu	Asn	Val	Asp	15:		о A	sn	Lys	Arg	Val 160
30	Asp	Va:	l G	.u :	Ile	Leu 165	Glu	Gly	Leu	Asp	Asp 170		ı As	p				
35	<210 <211 <212 <213	1> 2 2> E	239 PRT	ptc	coc	cus	pneu	mon:	iae									
40	<400 Met 1			e A	rsb	Ile 5	Leu	Thr	Leu	Phe	Pro 10		Met	: Pł	ne S	Ser	Pro 15	Leu
45	Glu	His	Se.	r I	le ' 20	Val	Gly	Lys	Ala	Arg 25	Glu	Lys	Gly	Le	eu I	eu 30	Asp	Ile
	Gln	Tyr	Hi:	з А 5	sn 1	Phe 1	Arg (Glu	Asn 40	Ala	Glu	Lys	Ala		g H 5	lis	Val	Asp
50	Asp	Glu 50	Pro	э Т:	yr (Sly (Gly (51y 55	Gln	Gly	Met	Leu	Leu 60	Ar	g A	la (Gln	Pro
•	Ile 1 65	Phe	Asp	S S e	er F	he <i>F</i>	sp <i>1</i> 70	\la	Ile	Glu	Lys	Lys .75	Asn	Pr	о А	rg V	/al	Ile 80
55	Leu I	Leu	Asp	Pr	o A	la G 85	ly I	ys (Gln :	Phe 1	Asp 90	Gln	Ala	ту	r A		31u /	Asp

Leu Ala Gln Glu Glu Leu Ile Phe Ile Cys Gly His Tyr Glu Gly Tyr Asp Glu Arg Ile Lys Thr Leu Val Thr Asp Glu Ile Ser Leu Gly Asp Tyr Val Leu Thr Gly Gly Glu Leu Ala Ala Met Thr Met Ile Asp 10 Ala Thr Val Arg Leu Ile Pro Glu Val Ile Gly Lys Glu Ser Ser His Gln Asp Asp Ser Phe Ser Ser Gly Leu Leu Glu Tyr His Gln Tyr Thr 165 170 15 Arg Pro Tyr Asp Tyr Arg Gly Met Val Val Pro Asp Val Leu Met Ser 185 Gly His His Glu Lys Ile Arg Gln Trp Arg Leu Tyr Glu Ser Leu Lys 20 Lys Thr Tyr Glu Arg Arg Pro Asp Leu Leu Glu His Tyr Gln Leu Thr 25 Val Glu Glu Lys Met Leu Ala Glu Ile Lys Glu Asn Lys Glu 30 <210> 136 <211> 186 <212> PRT 35 <213> Streptococcus pneumoniae <400> 136 Met Ile Glu Ala Ser Lys Leu Lys Ala Gly Met Thr Phe Glu Thr Ala 40 Asp Gly Lys Leu Ile Arg Val Leu Glu Ala Ser His His Lys Pro Gly 45 Lys Gly Asn Thr Ile Met Arg Met Lys Leu Arg Asp Val Arg Thr Gly Ser Thr Phe Asp Thr Ser Tyr Arg Pro Glu Glu Lys Phe Glu Gln Ala 55 50 Ile Ile Glu Thr Val Pro Ala Gln Tyr Leu Tyr Lys Met Asp Asp Thr Ala Tyr Phe Met Asn Thr Glu Thr Tyr Asp Gln Tyr Glu Ile Pro Val 55

Val Asn Val Glu Asn Glu Leu Leu Tyr Ile Leu Glu Asn Ser Asp Val

				10	0				10	5				11	0	
5	Ъγ	s Il	e Gl 11	n' Ph	е Ту	r Gl	y Th	r Gl 12		1 Il	e Gl	y Va	l Th 12		l Pr	o Thr
	Th	r Va 13	1 G1 0	u Le	u Th	r Va	1 Al	a Gl	u Th	r Gl	n Pro	Se:		е Гу	s Gl	y Ala
10	Th:	r Va 5	l Th	r Gl	y Se:	r Gly 150		s Pr	o Ala	a Th	r Met		u Th	r Gl	y Le	ı Val 160
	Va	l As:	n Va	l Pro	165		e Ilo	e Glı	ı Ala	a Gl;		ı Ly:	s Lei	ı Vai	l Ile 175	e Asn
15	Th:	r Ala	a Gli	ı Gly 180		Туг	· Val	l Sei	185		a					
		•														
20	<21 <21	.0> : .1> : .2> :	523 PRT					•								
				otoco	ccus	pne	umor	ııae								
25				: Glu	Ser 5		Thr	Glu	Arg	Leu 10		Asn	Val	Phe	Lys 15	
30	Leu	Arg	Lys	Lys 20		Lys	Ile	Ser	Glu 25		Asp	Val	Gln	Glu 30		Thr
	Lys	Glu	Ile 35	Arg	Leu	Ala	Leu	Leu 40		Ala	Asp	Val	Ala 45		Pro	Val
35	Val	Lys 50		Phe	Ile	Lys	Lys 55		Arg	Glu	Arg	Ala 60	Val	Gly	Hìs	Glu
40	Val 65	Ile	Asp	Thr	Leu	Asn 70	Pro	Ala	Gln	Gļn	Ile 75	Ile	Lys	Ile	Val	Asp 80
	Glu	Glu	Leu	Thr	Ala 85	Val	Leu	Gly	Śer	Asp 90	Thr	Ala	Glu	Ile	Ile 95	Lys
45	Ser	Pro	Lys	Ile 100	Pro	Thr	Ile	Ile	Met 105	Met	Val	Gly	Leu	Gln 110	Gly	Ala
	Gly	Lys	Thr 115	Thr	Phe	Ala	Gly	Lys 120		Ala	Asn	Lys	Leu 125	Lys	Lys	Glu
50	Glu	Asn 130	Ala	Arg	Pro	Leù	Met 135	Ile	Ala	Ala	Asp	Ile 140	Tyr	Arg	Pro	Ala
	Ala	Ile	Asp	Gln	Leu	Lys	Thr	Leu	Gly	Gln	Gln	Ile	Asp	Val	Pro	Val

Phe Ala Leu Gly Thr Glu Val Pro Ala Val Glu Ile Val Arg Gln Gly 165 170 175

55

	Le	eu G	lu G	ln A	la G: 80	ln Th	nr As	n Hi	s As	n As 5	р Ту	r Val	l Le	u Il 19		o Thr
. 5	Al	a G	ly A	rg Le 95	eu Gl	ln Il	.e As	p G1 20	u Le	u Le	u Met	t Asr	1 G1: 20:		u Arg	g Asp
10		۷.	LU	•			21	5				220)			Ala
	Me 22	t II 5	le Gi	Ly Gl	ln Gl	u Al 23	a Al O	a As	n Val	L Ala	235		Phe	e Asr	n Ala	Gln 240
15	Le	u Gl	.u Va	al Th	r Gl 24	y Va 5	1 11	e Le	u Thi	Lys 250	s Ile	Asp	Gly	Asp.	Thr 255	Arg
	Gl:	y Gl	y Al	a Al 26	a Le 0	u Se:	r Va	l Arq	g His 265	Ile	Thr	Gly	Lys	Pro 270		Lys
20	Phe	∋ Th	r Gl 27	y Th 5	r Gl	y Gli	ı Lys	3 Ile 280	Phr	Asp	Ile	Glu	Thr 285		His	Pro
25	Asp	29	g Me O	t Se	r Se	r Ar	7 Ile 295	e Leu	ı Gly	Met	Gly	Asp 300	Met	Leu	Thr	Leu
	Ile 305	Gl:	u Ly	s Al	a Sei	Glr 310	ı Glu	Tyr	Asp	Glu	Gln 315	Lys	Ala	Leu	Glu	Met 320
30	Ala	Glı	a Ly	s Me	325	g Glu	Asn	Thr	Phe	Asp 330	Phe	Asn	Asp	Phe	Ile 335	Asp
,	Gln	Let	ı Ası	9 Glr 340	n Val	. Gln	Asn	Met	Gly 345	Pro	Met	Glu	Asp	Leu 350	Leu	Lys
35	Met	Ile	9 Pro	Gly	/ Met	Ala	Asn	Asn 360	Pro	Ala	Leu		Asn 365	Met	Lys	Val
40	Asp	Glu 370	Arc	g Glm	Ile	Ala	Arg 375	Lys	Arg	Ala		Val 380	Ser	Ser	Met	Thr
	Pro 385	Glu	Glu	Arg	Glu	Asn 390	Pro	Asp	Leu	Leu	Asn 395	Pro	Ser	Arg		Arg 400
45	Arg	Ile	Ala	Ala	Gly 405	Ser	Gly	Asn	Thr	Phe 410	Val (Glu '	Val .		Lys 415	Phe
	Ile	Lys	Asp	Phe 420	Asn	Gln	Ala ,	Lys	Gln 425	Leu	Met (Gln		Val 1 430	Met	Ser
. 50	Gly	Asp	Met 435	Asn	Lys	Met	Met	Lys 440	Gln i	Met (Gly 1		lsn 1	Pro I	Asn A	Asn
55	Leu	Pro 450	Lys	Asn	Met	Pro	Asn 455	Met	Gly (Gly I		Asp M	let S	Ser A	Ala I	eu
	Glu 465	Gly	Met	Met	Gly	Gln 470	Gly	Gly 1	Met I	Pro P	Asp L	eu S	er A	la I		1.y 80

Gly Ala Gly Met Pro Asp Met Ser Gln Met Phe Gly Gly Leu Lys 5 Gly Lys Ile Gly Glu Phe Ala Met Lys Gln Ser Met Lys Arg Met Ala 505 Asn Lys Met Lys Lys Ala Lys Lys Lys Arg Lys 10 <210> 138 <211> 281 <212> PRT 15 <213> Streptococcus pneumoniae <400> 138 Met Tyr Leu Ile Glu Ile Leu Lys Ser Ile Phe Phe Gly Ile Val Glu 20 Gly Ile Thr Glu Trp Leu Pro Ile Ser Ser Thr Gly His Leu Ile Leu Ala Glu Glu Phe Ile Gln Tyr Gln Asn Gln Asn Glu Ala Phe Met Ser 25 40 Met Phe Asn Val Val Ile Gln Leu Gly Ala Ile Leu Ala Val Met Val 30 Ile Tyr Phe Asn Lys Leu Asn Pro Phe Lys Pro Thr Lys Asp Lys Gln Glu Val Arg Lys Thr Trp Arg Leu Trp Leu Lys Val Leu Ile Ala Thr 35 Leu Pro Leu Gly Val Phe Lys Phe Asp Asp Trp Phe Asp Thr His Phe His Asn Met Val Ser Val Ala Leu Met Leu Ile Ile Tyr Gly Val 40 Ala Phe Ile Tyr Leu Glu Lys Arg Asn Lys Ala Arg Ala Ile Glu Pro 45 Ser Val Thr Glu Leu Asp Lys Leu Pro Tyr Thr Thr Ala Phe Tyr Ile Gly Leu Phe Gln Val Leu Ala Leu Leu Pro Gly Thr Ser Arg Ser Gly 50 Ala Thr Ile Val Gly Gly Leu Leu Asn Gly Thr Ser Arg Ser Val Val 185

Thr Glu Phe Thr Phe Tyr Leu Gly Ile Pro Val Met Phe Gly Ala Ser

Ala Leu Lys Ile Phe Lys Phe Val Lys Ala Gly Glu Leu Leu Ser Phe

55

		2	10				2	15				. 2	20			
5	22	у G. 5	ln L	eu Pl	he Le	eu Le 23	eu Lo 30	eu V	al A	la M		ly Va 35	al A	la Pi	ne A.	la Val 240
		r Me	et V	al Al	la II 24	le Ai	g Pl	ne Le	eu Ti	nr Se 25	er Ty 50	yr Va	al Ly	ys L <u>y</u>		is Asp 55
10	Ph	e Tł	ır L	eu Ph 26	ne Gl 50	y Ly	s Ty	r Ai	rg II 26	le Va 55	al Le	eu Gl	Ly Se	er Va 27		eu Leu
	Lei	u Ty		er Ph	ie Va	l Ar	g Le	u 'Ph 28								
15	<21 <21	10>	429 PRT													
20				ptoc	occu	s pn	eumo	niae								
		00> : Gl		u Ph	e Ası	Arg	g Le	u Ph	e Gl	у Ly 1	s Ly. O	s Gl	u Gl	u Pr	o Ly 1	s Ile 5
25	Glu	Gl	u Va	1 Va:	l Lys O	s Glu	ı Ala	a Le	u Gli 2!	u Ası 5	n Lei	ı Ası	D Lei	u Sei		u Asp
30			3.	5				4 ()				4.5	5		ı Ala
		31	,				55)				. 60)			Gln
35	65					70				•	75	i				Ser 80
40				ı Val	85					90					95	;
40				Glu 100	•				105					110		
45			113					120					125			
		130		Leu			135		• .			140				
50	145			Ala		150					155					160
5.5	Leu				165					170					175	
55	Asn 1	Leu	Thr	Glu 180	Glu	Leu	Arg	Tyr	Glu 185	Ala	Lys	Leu	Glu	Asn 190	Ala	Lys

	Lys	s Pr	o As 19	p Al 5	a Leu	Arg	Arg	7 Val 200	Ile	lle	Glu	Lys	Let 205		1 G1	u Leu
5	Туз	21	и L y 0	s As	p Gly	Ser	Tyr 215	Asp	Glu	Ser	Ile	His 220		Glr	n Asj	p Asn
	Leu 225	Th:	r Va	l Me	t Leu	Phe 230	Val	. Gly	Val	Asn	Gly 235	Val	Gly	' Lys	Thi	r Thr 240
10	Ser	: Ile	e Gl	у Гу:	s Leu 245	Ala	His	Arg	Tyr	Lys 250	Arg	Ala	Gly	Lys	Lys 255	
15	Met	Leu	ı Val	1 Ala 260	a Ala	Asp	Thr	Phe	Arg 265	Ala	Gly	Ala	Val	Ala 270		Leu
	Ala	Glu	275	Gly	/ Arg	Arg	Val	Asp 280	Val	Pro	Val	Val	Thr 285	Gly	Pro	Glu
20	Lys	Ala 290	Asp	Pro	Ala	Ser	Val 295	Val	Phe	Asp		Met 300	Glu	Arg	Ala	Val
	Ala 305	Glu	Gly	' Ile	Asp	Ile 310	Leu	Met	Ile	Asp	Thr .	Ala	Gly	Arg	Leu	Gln 320
25	Asn	Lys	Asp	Asn	Leu 325	Met	Ala	Glu	Leu	Glu 330	Lys	Ile	Gly	Arg	Ile 335	Ile
30	Lys	Arg	Val	Val 340	Pro	Glu	Ala	Pro	His 345	Glu	Thr	Pḥe	Leu	Ala 350	Leu	Asp
	Ala	Ser	Thr 355	Gly	Gln	Asn .	Ala	Leu 360	Val	Gļn.	Ala I		Glu 365	Phe	Ser	Lys
35	Ile	Thr 370	Pro	Leu	Thr	Gly	Ile 375	Val	Leu '	Thr :		le 1 880	Asp	Gly	Thr	Ala
	Arg 385	Gly	Gly	Val	Val	Leu 1 390	Ala	Ile .	Arg (Glu (Glu I 395	eu 1	Asn	Ile	Pro	Val 400
40	Lys	Leu	Ile	Gly	Phe (Gly (3lu :	Lys :		Asp <i>I</i> 110	lsp I	le (Sly(Phe 415	Asn
45	Ser (Glu	Asn	Phe 420	Met I	∵ys (Gly :		Leu (Slu G	Sly L	eu I	le			
50	<210: <211: <212: <213:	> 16 > PR	5 T	ococ	cus p	neum	onia	ıe	• • •							
55	<400> Met T			Glu i	Met V 5	al A	sp G	lu T	hr G	ly G 10	ln Va	al S	er L	ys G	Slu N 15	l et
	Leu G	ln C	Sln S	Thr (Sln G	lu I	le L	eu G	lu Pi 25	he Al	la Al	a L	ys L	ys I	eu G	Sly

Lys Glu Asp Lys Glu Met Ala Val Thr Phe Val Thr Asn Glu Arg Ser 40 His Glu Leu Asn Leu Glu Tyr Arg Asp Thr Asp Arg Pro Thr Asp Val Ile Ser Leu Glu Tyr Lys Pro Glu Leu Glu Ile Ala Phe Asp Glu Glu 10 Asp Leu Leu Glu Asn Pro Glu Leu Ala Glu Met Met Ser Glu Phe Asp Ala Tyr Ile Gly Glu Leu Phe Ile Ser Ile Asp Lys Ala His Glu Gln 15 Ala Glu Glu Tyr Gly His Ser Phe Glu Arg Glu Met Gly Phe Leu Ala 20 Val His Gly Phe Leu His Ile Asn Gly Tyr Asp His Tyr Thr Pro Glu Glu Glu Ala Glu Met Phe Gly Leu Gln Glu Glu Ile Leu Thr Ala Tyr 150 25 Gly Leu Thr Arg Gln 30 <210> 141 <211> 255 <212> PRT <213> Streptococcus pneumoniae 35 <400> 141 Met Ser Ile Arg Val Ile Ile Ala Gly Phe Lys Gly Lys Met Gly Gln Ala Ala Cys Gln Met Val Leu Thr Asp Pro Asp Leu Asp Leu Val Ala 40 Val Leu Asp Pro Phe Glu Ser Glu Ser Glu Trp Gln Gly Ile Pro Val Phe Lys Asp Lys Ala Asp Leu Ala Gly Phe Glu Ala Asp Val Trp Val 45 Asp Phe Thr Thr Pro Ala Val Ala Tyr Glu Asn Thr Arg Phe Ala Leu 50 Glu Asn Gly Phe Ala Pro Val Val Gly Thr Thr Gly Phe Thr Ser Glu 90 Glu Ile Ala Glu Leu Lys Glu Phe Ser Arg Ala Gln Asp Leu Gly Gly 55

Leu Ile Ala Pro Asn Phe Ala Leu Gly Ala Val Leu Leu Met Gln Phe

				11.	5				1	20					12	5		
5	Al	a	Thr 130	Gl	n Al	a Al	a Ly	s Ty	/r P) 35	ne P	ro	Asn	va:	l Gl: 140		e Il	e Gl	u Leu
	Hi 14	s . 5	His	Ası	o Ly	s Ly	s Ly 15	s As O	sp A	La P	ro	Ser	G1 ₃	y Thi	r Al	a Il	е Ly	s Thr 160
10						16	5					170					17	
	As	p (Slu	Glu	18	u Le [.] 0	u Il	e Al	a G]	y A. 18	la 2 35	Arg	Gly	/ Ala	ı Ası	Ph 19		pGly
15	Me	t A	Arg	Ile 195	Hi:	s Se	r Vai	l Ar	g Le 20	u Pi	co (Gly	Leu	Val	Ala 205		s Gl	n Glu
20	Val	2	le 10	Phe	Gly	y Ası	n Glr	21.	y G1 5	u Gl	.y 1	Ĺeu	Thr	Leu 220	Arg	g His	s Asp	Ser
	Туг 225	: A	sp	Arg	Ile	e Sei	230	e Mei	t Th	r Gl	γV	/al	Asn 235		Gly	/ Ile	e Lys	Glu 240
25	Val	. V	al	Lys	Arg	His 245	Glu	ı Lei	บ Va	1 Ту	r 0	51y 250	Leu	Glu	His	Lev	Leu 255	
30	<21 <21 <21 <21	1> 2>	91 PR	Т	coco	ccus	pne	umon	iiae		·							
35	<40 Met 1				Lys	Gln 5	Asp	Leu	Ile	Al:		ys 10	Val	Ala	Glu	Ala	Thr 15	Glu
	Leu	Tì	nr I	Lys	Lys 20	Asp	Ser	Ala	Ala	Ala 25		al (Glu	Ala	Val	Phe 30	Ala	Ala
40	.Val	A)	la A	Asp 35	Tyr	Leu	Ala	Ala	Gly 40		ı Ly	ys V	Val	Gln	Leu 45	Ile	Gly	Phe
45	Ser	As 5	n E	?he	Glu	Val	Arg	Glu 55	Arg	Ala	G]	lu <i>I</i>	Arg	Lys 60	Gly	Arg	Asn	Pro
	Gln 65	Th	r G	Sly	Lys	Glu	Met 70	Thr	Ile	Ala	Al	a S	Ser :	Lys '	Val	Pro	Ala	Phe [.] 80
50 .	Lys	Al	a G	ly:	Lys	Ala 85	Leu	Lys	Asp	Ala		1 L	ys					
55	<210 <211 <212	> :	306		•													

<213> Streptococcus pneumoniae

		100> et T 1			s Th	r Al	.a P	he	Let	ı Ph	e A.	la	Gl ₃		n Gl	у А	.la	Gl		r I	eu
5	G1	y M	et	Gly	y Ar 2	g As O	p P	he	Туг	As	p Gi	ln 25	Туг	Pr	o Il	e v	al	Lу 3		u T	'hr
10	Il	e A	sp	Arç 35	g Al	a Se	r G	ln	Val	. Le:	u G:	lу	Tyr	As	p Le		rg 45	Ty:	r Le	u I	le
	As	рТ	hr 50	Glu	ı Glı	u As	рЬ	ys :	Leu 55	Ası	n Gl	ln	Thr	Ar	g Ту 6		hr	Gli	n Pr	o A	la
15	I1 6	e L	eu	Ala	Thi	r Se	r Va	1 7	Ala	Ile	э Ту	r	Arg	Let 75	ı Le	u G	lņ	Glı	ı Ly		80 80
	Ty.	r G	ln	Pro	Asp	Me 8	t Va 5	1 7	Ala	Gly	/ Le	u	Ser 90	Leu	ı Gl	y G	Lu	Tyr	Se.		la
. 20	Le:	u Va	al,	Ala	Ser 100	Gl _e	y Al	a I	Seu	Asp	Ph 10		Glu	Asp	Al:	a Va	1	Ala 110		ı Va	al
. 25	Ala	a Ly	s i	Arg 115	Gly	/ Ala	а Ту	r M	let	Glu 120	G1	u.	Ala	Ala	Pro	Al 12		Asp	Sei	G]	Ly
	Lys	3 Me	t T	Val	Ala	Va]	Le	u A 1	sn 35	Thr	Pr	ο '	Val	Glu	Val		е	Glu	Glu	ı Al	la
30	Cys 145	Gl	n, I	Бys	Ala	Ser	G1 15	ц L О	eu	Gly	Va.	l v	Val	Thr 155	Pro	Al	a <i>i</i>	Asn	Tyr	As 16	
	Thr	Pr	o <i>P</i>	Ala	Gln	Ile 165	Va.	lI	le	Ala	Gly		31u 170	Val	Val	Al	a .1	Val	Asp 175		g
35	Ala	۷a	1 G	ilu	Leu 180	Leu	Glı	n G.	lu	Ala	Gl ₃ 185	7 F	Ala	Lys	Arg	Le		Ile 190	Pro	Le	u
40	Lys	Va.	1 S	er 95	Gly	Pro	Ph∈	H:	is	Thr 200	Ala	ı I	eu	Leu	Glu	Pro 205		la	Ser	Gl:	n
		210	}			Thr		21	15						220					_	
45	225					Asn	230							235			•.			240	0
						Thr 245						2	50 _.						255		
50	Ser	Ile	G]	Ly Y	Val 260	Met.	Gln	Gl	u A	\la	Gly 265	I	le S	Ger .	Asn	Phe		le 70	Glu	Ile	;
55	Gly	Pro	G1 27	.y I 75	.ys	Val	Leu	Se	r G 2	ly 1 80	Phe	Va	al L	ys :		Ile 285	A	sp (Gln	Thr	
,	Ala	His 290	Le	u A	Mla 1	His	Val	G1: 29:	uA 5	sp (Gln	Al	la S		Leu 300	Val	A.	la 1	Leu	Leu	

	G] 30	u Ly)5	γs													
5	<2 <2	10> 11> 12>	243 PRT													
10		00>		ptoc	occu	s · pn	eumo	niae								
•	Me	t Ly 1	's Le	u∙Gl	u His	з Гу: 5	s Ası	n Ile	e Phe	e Il		r Gl	y Se	r Se	r Ar	
15	Il	e Gl	y Le	u Ala 20	a Ile O	e Ala	a His	s Lys	s Phe		a Glr	n Ala	a Gl	y Ala		n Ile
20	۷a	l Le	u As:	n Sei	r Arg	gly	/ Ala	a Ile 40		c Gli	ı Glu	ı Leı	1 Le: 4:		a Glu	ı Phe
	Se	r As	п Ту: 0	r Gly	/ Ile	Lys	5 Val	l Val	. Pro) Ile	e Ser	Gl ₃		Val	Sei	: Asp
25	Phe 6	e Ala	a Asp	o Ala	Lys	Arg	Met	: Ile	Asp	Glr	Ala 75		e Ala	a Glu	Leu	Gly 80
	Sei	· Vai	l Asp	Val	Leu 85	Val	Asn	Asn	Ala	Gly 90		Thr	Glr	Asp	Thr 95	
30	Met	: Le	ı Lys	Met 100	Thr	Glu	Ala	Asp	Phe 105		Lys	Val	Leu	Lys 110		Asn
35	Leu	Thr	Gly 115	Ala	Phe	Asn	Met	Thr 120	Gln	Ser	Val	Leu	Lys 125		Met	Met
	Lys	Ala 130	Arg	Glu	Gly	Ala	Ile 135		Asn	Met	Ser	Ser 140	Val	V.al	Gly	Leu
40	Met 145	Gly	Asn	Ile	Gly	Gln 150	Ala	Asn	Tyr	Ala	Ala 155	Ser	Lys	Ala	Gly	Leu 160
	Ile	Gly	Phe	Thr	Lys 165	Ser	Val	Ala	Arg	Glu 170	Val	Ala	Ser	Arg	Asn 175	Ile
45	Arg	Val	Asn	Val 180	Ile	Ala	Pro	Gly	Met 185	Ile	Glu	Ser	Asp	Met 190	Thr	Ala
50	Ile	Leu	Ser 195	Asp	Lys	Ile	Lys	Gl <u>u</u> 200	Ala	Thr	Leu	Ala	Gln 205	Ile	Pro	Met
	Lys	Glu 210	Phe	Gly	Gln	Ala	Glu 215	Gln	Val	Ala	Asp	Leu 220	Thr	Val	Phe	Leu
55	Ala 225	Gly	Gln	Asp	Tyr	Leu 230	Thr	Gly	Gln	Val	Val 235	Ala	Ile	Asp	Gly	Gly 240

Leu Ser Met

5	<: <:	211> 212>	145 276 PRT Str		cocci	ıs pr	neumo	niae								
10			145 ly V	al Ly	ys Ly	rs Ly 5	s Le	u Ly:	s Le		r Sei	r Le	u Le	u G1	_	u Se .5
15	Le	eu L	eu I	le Me	et Th	r Al	а Су	s Ala	2 Th	r As 5	n Gly	y Vai	l Th	r Se 3		p Il
	Th	ır A.	la G	lu Se 35	r Al	a As	p Ph	e Trr		c Ly	s Leu	ı Val	1 Ty		e Ph	e Al
20	G1	u I	le I] 50	le Ar	g Ph	e Le	u Ser	r Phe	e Asp	o Ile	e Ser	: Ile		y Va.	l Gl	y Ile
	I1 6	е Le 5	eu Ph	e Th	r Va	l Le:	ı Ile	arg	Thr	' Val	Leu 75		Pro	Va:	l Ph	e Glr 80
25	Va	1 G1	n Me	t Va	1 Ala 8	a Sei 5	r Arg	Lys	Met	Glr 90	Glu	Ala	Glr	Pro	9:	
30	Ly	s Al	a Le	u Ar	g Gli O	ı Glr	Tyr	Pro	Gly 105	Arg	Asp	Met	Glu	Ser 110		g Thr
	Lys	s Le	u Gl 11	u Glı 5	n Glu	ı Met	Arg	Lys 120	Val	Phe	Lys	Glu	Met 125		v Val	Arg
35	Glr	13	r Asj	p Sei	Leu	Trp	Pro 135	Ile	Leu	Ile	Gln	Met 140	Pro	Val	Ile	Leu
	Ala 145	Le	u Phe	e Glr	a Ala	Leu 150	Ser	Arg	Val	Asp	Phe 155	Leu	Lys	Thr	Gly	His 160
. 40	Phe	Le	ı Trp) Ile	165	Leu	Gly	Ser	Val	Asp 170	Thr	Thr	Leu	Val	Leu 175	
45	Ile	Let	ı Ala	180	Val	Phe	Thr	Phe	Leu 185	Ser	Thr	Trp	Leu	Ser 190	Asn	Lys
•	Ala	Let	Ser 195	Glu	Arg	Asn	Gly	Ala 200	Thr		Ala	Met	Met 205	Tyr	Gly	Ile
50	Pro	Val 210	Leu	ılle	Phe	Ile	Phe 215	Ala	Val	Tyr		Pro 220	Gly	Gly	Val	Ala
	Leu 225	Tyr	Trp	Thr	Val	Ser 230	Asn	Ala '	Tyr (Val 1 235	Leu	Gln	Thr	Tyr	Phe 240
55	Leu	Asn	Asn	Pro	Phe 245	Lys	Ile	Ile 1		Glu . 250	Arg (Slu /	Ala		Val 255	Gln

Ala Gln Lys Asp Leu Glu Asn Arg Lys Arg Lys Ala Lys Lys Lys Ala 260 265

Gln Lys Thr Lys 5 275

<210> 146

<211> 409

10 <212> PRT

25

40

55

<213> Streptococcus pneumoniae

<400> 146

Met Lys Ile Ser Lys Arg His Leu Leu Asn Tyr Ser Ile Leu Ile Pro 15 1 5 10 15

Tyr Leu Leu Ser Ile Leu Gly Leu Ile Val Val Tyr Ser Thr Thr
20 25 30

20 Ser Ala Ile Leu Ile Glu Glu Gly Lys Ser Ala Leu Gln Leu Val Arg 35 40 45

Asn Gln Gly Ile Phe Trp Ile Val Ser Leu Ile Leu Ile Ala Leu Ile 50 55 60

Tyr Lys Leu Arg Leu Asp Phe Leu Arg Asn Glu Arg Leu Ile Ile Leu 65 70 75 80

Val Ile Leu Ile Glu Met Leu Leu Leu Phe Leu Ala Arg Phe Ile Gly 85 90 95

Ile Ser Val Asn Gly Ala Tyr Gly Trp Ile Ser Val Ala Gly Val Thr

35 Ile Gln Pro Ala Glu Tyr Leu Lys Ile Ile Ile Ile Trp Tyr Leu Ala 115 120 125

His Arg Phe Ser Lys Gln Gln Glu Glu Ile Ala Thr Tyr Asp Phe Gln 130 135 140

Val Leu Thr Gln Asn Gln Trp Leu Pro Arg Ala Phe Asn Asp Trp Arg 145 150 155 160

Phe Val Leu Leu Val Leu Ile Gly Ser Leu Gly Ile Phe Pro Asp Leu 45

Gly Asn Ala Thr Ile Leu Val Leu Val-Ser Leu Ile Met Tyr Thr Val

50 Ser Gly Ile Ala Tyr Arg Trp Phe Ser Thr Ile Leu Ala Leu Val Ser 195 200 205

Ala Thr Ser Val Phe Val Leu Thr Thr Ile Ser Leu Ile Gly Val Glu 210 215 220

Thr Phe Ser Lys Ile Pro Val Phe Gly Tyr Val Ala Lys Arg Phe Ser 225 230 235 240

	_					247						250					255	
		٠		•	.00					2	65					270		Gly
10		u G)	ly A 2	sn 5 75	Ser	Ile	Glu	L Lys	8 Ar 28	g G. 0	ly	Tyr	Leu	Pro	Glu 285	Ala	His	Thr
		~ .	, 0					295)					300				Ala
15	Ser 305	Le	eu I	le L	eu i	Ala	Leu 310	Leu	Pho	e Pl	ne i	Met	Ile 315	Leu	Arg	İle	Ile	Leu 320
	Val	Gl	y II	le A	rg <i>P</i>	Ala 325	Glu	Asn	Pro	Ph	ie i	Asn 330	Ala	Met	Val	Ala	Leu 335	Gly
20	Val	G1	y Gl	.у М З	et M 40	let .	Leu	Val	Glr	Va 34	1 1	Phe	Val	Asn	Ile	Gly 350	Gly	Ile
25			23	J					360						Phe 365			
		370	,					3/5						380	Ala			
30	Asn 385	Ile	As;	p Al	a S	er d	31u 390	Lys	Arg	Ala	a L	ys i	Leu 395	Tyr .	Arg	Glu :		Glu 400
	Asn	Gln	Pro) Me		sn L)5	eu :	Leu	Leu	Lys	3							
35	<210 <211	> 4	19															
40	<212 <213	> S	trep	toc	occu	ıs p	neur	noni	ae									
	<400 Met :			Ile	e Le	u Tl 5	nr F	he :	Ile	Leu	Va 1	al Pi LO	he G	ly I	le I		al V 15	'al
45	Val i	His	Glu	Phe 20	Gl	у Н.	is P	he 1	ľyr	Phe 25	Al	a L	ys L	ys S	er G	ly I 30	le L	eu
50	Val A	Arg	Glu 35	Phe	Al.	a Il	.e G	ly M	1et (Gly	Pr	.o	ys I		he A 45	la H	is I	le.
30	Gly I	ys 50	Asp	Gly	Thi	c Al	а Т	yr T 55	hr I	[le	Ar	g Il		eu P:	ro Le	eu G	ly G	ly
55	Tyr V 65	al	Arg	Met	Ala	G1 7	у Т: 0	rp G	ly P	Asp	Ası		r Ti 5	nr G	lu II	Le Ly	/s Tl	
	Gly T	hr :	Pro	Val	Ser	Le	u Tł	ır L	eu A	la	Asp) As	p Gl	.у L <u>У</u>	vs Va	ıl Ly	s Ax	g

					85	5				9(1		•		95	<u>.</u>
	7.1		_	_			_	_								
5	116	AS1	n Lei	100	r GI3	/ Lys	з Гу:	s Lei	1 Asp 105		ı Thi	: Ala	a Lei	110		: G1
,	Val	LThi	r Gli	n Phe	e Asp	Phe	e Gli	120	b Lys	Let	ı Phe	e Ile	≥ Lys 125		Λ΄ Γe <i>r</i>	ı Va
10	Lev	i Ġli 130	ı Glu	1 Gl _i i	ı Lys	Thi	Phe 135	e Ala	val	Asp	His	140		Thi	val	. Va
	Glu 145	a Ala	a Asp	Gly	y Thr	Glu 150		l Arg	, Ile	e Ala	Pro 155		ı Asp	Val	l Glm	Ty:
15	Gln	Asn	n Ala	Thr	11e		Gly	/ Lys	Leu	170		Asn	Phe	: Ala	Gly 175	
20	Met	Asn	Asn	Phe 180	e Ile	Leu	Gly	v Val	Val 185		Phe	Trp	Val	Leu 190		Phe
20	Met	Gln	Gly 195	Gly	Val	Arg	Asp	Val 200		Thr	Asn	Gln	Phe 205		Ile	Met
25	Pro	Gln 210	Gly	Ala	Leu	Ala	Lys 215	Val	Gly	Val	Pro	Glu 220		Ala	Gln	Ile
	Thr 225	Lys	Ile	Gly	Ser	His 230	Glu	Val	Ser	Asn	Trp 235	Glu	Ser	Leu	Ile	Gln 240
30	Ala	Val	Glu	Thr	Glu 245		Lys	Asp	Lys	Thr. 250	Ala	Pro	Thr	Leu	Asp 255	Val
35	Thr	Ile	Ser	Glu 260		Gly	Ser	Asp	Lys 265	Gln	Val	Thr	Val	Thr 270	Pro	Glu
	Asp	Ser	Gln 275	Gly	Arg	Tyr	Leu	Leu 280	Gly	Val	Gln	Pro	Gly 285	Val	Lys	Ser
40	Asp	Phe 290	Leu	Ser	Met	Phe	Val 295	Gly	Gly	Phe	Thr	Thr 300	Ala	Ala	Asp	Ser
	Ala 305	Leu	Arg	Ile	Leu	Ser 310	Ala	Leu	Lys	Asn	Leu 315	Ile	Phe	Gln	Pro	Asp 320
45	Leu	Asn	Lys	Leu	Gly 325	Gly	Pro	Val	Ala	Ile 330	Phe.	Lys	Ala	Ser	Ser 335	Asp
	Ala	Ala	ГЛЗ	Asn 340	Gly	Ile	Glu	Asn	Ile 345	Leu	Tyr	Phe	Leu	Ala 350	Met	Ile

Ser Ile Asn Ile Gly Ile Phe Asn Leu Ile Pro Ile Pro Ala Leu Asp

Gly Gly Lys Ile Val Leu Asn Ile Leu Glu Ala Ile Arg Arg Lys Pro 370 380

Leu Lys Gln Glu Ile Glu Thr Tyr Val Thr Leu Ala Gly Val Val Ile

355 360

50

55

385 390 395 400

Met Val Val Leu Met Ile Ala Val Thr Trp Asn Asp Ile Met Arg Leu
405 410 415

Phe Phe Arg

- 10 <210> 148 <211> 197 <212> PRT <213> Streptococcus pneumoniae
- 15 <400> 148

 Met Tyr Ala Tyr Leu Lys Gly Ile Ile Thr Lys Ile Thr Ala Lys Tyr

 1 5 10 15
- Ile Val Leu Glu Thr Asn Gly Ile Gly Tyr Ile Leu His Val Ala Asn 20 25 30
 - Pro Tyr Ala Tyr Ser Gly Gln Val Asn Gln Glu Ala Gln Ile Tyr Val 35 40 45
- 25 His Gln Val Val Arg Glu Asp Ala His Leu Leu Tyr Gly Phe Arg Ser 50 .55 60
- Glu Asp Glu Lys Lys Leu Phe Leu Ser Leu Ile Ser Val Ser Gly Ile 65 70 75 80
 - Gly Pro Val Ser Ala Leu Ala Ile Ile Ala Ala Asp Asp Asn Ala Gly
 85 90 95
- Leu Val Gln Ala Ile Glu Thr Lys Asn Ile Thr Tyr Leu Thr Lys Phe 100 105 110
 - Pro Lys Ile Gly Lys Lys Thr Ala Gln Gln Met Val Leu Asp Leu Glu 115 120 125
- 40 Gly Lys Val Val Val Ala Gly Asp Asp Leu Pro Ala Lys Val Ala Val 130 135 140
- Gln Ala Ser Ala Glu Asn Gln Glu Leu Glu Glu Ala Met Glu Ala Met 145 150 155 160
 - Leu Ala Leu Gly Tyr Lys Ala Thr Glu Leu Lys Lys Ile Lys Lys Phe
 165 170 175
- Phe Glu Gly Thr Thr Asp Thr Ala Glu Asn Tyr Ile Lys Ser Ala Leu 180 180 180

·Lys Met Leu Val Lys 195

55 <210> 149 <211> 257

<212> PRT <213> Streptococcus pneumoniae

Gly Gly Leu Ser Ala Asp Leu Ala Thr Tyr Thr Leu Asn Gly Leu 20 25 30

His Gly Phe Val Ala Val Thr Cys Leu Thr Ala Leu Thr Glu Lys Gly
35 40 45

Phe Glu Val Phe Pro Thr Asp Asp Thr Ile Phe Gln His Glu Leu Asp 50 55 60 .

Ser Leu Arg Asp Val Glu Phe Gly Gly Ile Lys Ile Gly Leu Leu Pro 65 70 75 80

20 Thr Val Ser Val Ala Glu Lys Ala Leu Asp Phe Ile Lys Gln Arg Pro 85 90 95

Gly Val Pro Val Val Leu Asp Pro Val Leu Val Cys Lys Glu Thr His 100 105 110

Asp Val Ala Val Ser Glu Leu Cys Gln Glu Leu Ile Arg Phe Pro 115 120 125

Tyr Val Ser Val Ile Thr Pro Asn Leu Pro Glu Ala Glu Leu Leu Ser 130 135 140

Gly Gln Glu Ile Lys Thr Leu Glu Asp Met Lys Thr Ala Ala Gln Lys
145 . 150 155 160

35 Leu His Asp Leu Gly Ala Pro Ala Val Ile Ile Lys Gly Gly Asn Arg 165 170 175

Leu Ser Gln Asp Lys Ala Val Asp Val Phe Tyr Asp Gly Gln Thr Phe
180 185 190

Thr Ile Leu Glu Asn Pro Val Ile Gln Gly Gln Asn Ala Gly Ala Gly 195 200 205

Cys Thr Phe Ala Ser Ser Ile Ala Ser His Leu Val Lys Gly Asp Lys 210 215 220

Phe Leu Pro Ala Val Glu Ser Ser Lys. Ala Phe Val Tyr Arg Ala Ile 225 230 235 240

50 Ala Gin Ala Asp Gin Tyr Gly Val Arg Gin Tyr Glu Ala Asn Lys Asn 245 250 255

Asn

55

40

25

<210> 150

•	<211> 412 <212> PRT <213> Streptococcus pneumoniae
	5 <400> 150 Met Ile Glu Thr Glu Lys Lys Glu Glu Arg Val Leu Leu Ile Gly Val 1 5 10 15
10	Glu Leu Gln Gly Met Asp Ser Phe Asp Leu Ser Met Glu Glu Leu Ala 20 25 30
1.5	Ser Leu Ala Lys Thr Ala Gly Ala Val Val Val Asp Ser Tyr Arg Gln 35 40 45
15	Lys Arg Glu Lys Tyr Asp Ser Lys Thr Phe Val Gly Ser Gly Lys Leu 50 60
20	Glu Glu Ile Ala Leu Met Val Asp Ala Glu Glu Ile Thr Thr Val Ile 65 70 75 80
•	Val Asn Asn Arg Leu Thr Pro Arg Gln Asn Val Asn Leu Glu Glu Val 85 90 95
25	Leu Gly Val Lys Val Ile Asp Arg Met Gln Leu Ile Leu Asp Ile Phe 100 105 110
	Ala Met Arg Ala Arg Ser His Glu Gly Lys Leu Gln Val His Leu Ala 115 120 125
30	Gln Phe Lys Tyr Leu Leu Pro Arg Leu Val Gly Gln Gly Ile Met Leu 130 135 140
35	Ser Arg Gln Ala Gly Gly Ile Gly Ser Arg Gly Pro Gly Glu Ser Gln 145 150 155 160
	Leu Glu Leu Asn Arg Arg Ser Val Arg Asn Gln Ile Thr Asp Ile Glu 165 170 175
40	Arg Gln Leu Lys Val Val Glu Lys Asn Arg Ala Thr Val Arg Glu Lys 180 185 190
٠	Arg Leu Glu Ser Ser Thr Phe Lys Ile Gly Leu Ile Gly Tyr Thr Asn 195 200 205
45	Ala Gly Lys Ser Thr Ile Met Asn Ile Leu Thr Ser Lys Thr Gln Tyr 210 215 220
50	Glu Ala Asp Glu Leu Phe Ala Thr Leu Asp Ala Thr Thr Lys Ser Ile 225 230 235 240
•	His Leu Gly Gly Asn Leu Gln Val Thr Leu Thr Asp Thr Val Gly Phe 245 250 255
55	Ile Gln Asp Leu Pro Thr Glu Leu Val Ser Ser Phe Lys Ser Thr Leu 265 270
	Glu Glu Ser Lys His Val Asp Leu Leu Val His Val Ile Asp Ala Ser

				27	75					28	30					2	85			
5	As	n I	Pro 290	TJ	r H:	is G	lu (lu	Hi 29	s G1 5	.u L	ys	Thi	r Va	l Le 30	eu S	er	11	e Me	et Lys
	As 30	р I 5	eu	As	p Me	et Gi	lu <i>F</i>	1sp 110	Il	e Pr	о н	is	Let	1 Th		u T	yr	Ası	а Ьу	's Ala 320
10	As	ρI	eu	Va	1 G1	.u As 32	sp F !5	'he	Th	r Pr	о Т	hr	Gln 330	Th:	r Pr	o T	yr	Thi	Le 33	u Ile 5
	Se	r A	.la	ЪΆ	s Se 34	r Gl O	u A	.sp	Sea	r Ar	g G: 3	lu 45	Asn	Le	ı Gl	n A	la	Le:		u Leu
15	Ası	o L	ys	11 35	e Ly 5	s Gl	u I	le	Phe	36	u A: 0	la	Phe	Thi	Le		rg 65 _.	Va1	Pr	o Phe
20	Sei	3 1	ys 70.	Se	с Ту	r Ly	s I	le	His 375	: As _l	o Le	eu	Glu	Ser	Va.		la	Ile	Lei	u Glú
	Glu 385	1 A:	rg	Ası	ту.	r Gl	n G.	lu 90	Asp	Gly	y∙Gl	.u	Val	Ile 395		r Gl	у.	Tyr	Ile	Ser 400
25	Glu	L	/S	Asr	Ly:	40		:g	Leu	Glu	Gl		Phe 410	Tyr	Asp	•			•	
30	<21 <21 <21 <21	1> 2>	16 PR'	0 T	tocc	ccus	pn	.eur	non:	iae								•		
35	<40 Met 1				Lys	Thr 5	Ту	r I	?ro	Met	Th	r I	eu 10	Glu	Glu	Lу	s G	Slu	Lys 15	Leu
	Glu	Lу	s G	lu	Leu 20	Glu	G1	u I	eu	Lys	Let 25	ı V	al .	Arg	Arg	Pro		1u 30	Val	Val
40 _	Glu	Ar	g I	1e 35	Lys	Ile	Al	a A	rg	Ser 40	Туг	: G	ly .	Asp	Leu	Ser 45		lu	Asn	Ser
45	Glu	Ту: 5(r G)	lu	Ala	Ala	Lу	s A	.sp` 55	Glu	Gln	A	la 1	Phe	Val 60	Glu	ı G.	ly	Gln	Ile
•	Ser 65	Sei	L	eu	Glu	Thr	Lys 70	s I	le.	Arg	Tyr	A	la (31u 75	Ile	Val	A	sn i	Ser	Asp 80
50 .	Ala	Val	. A.	la	Gln	Asp 85	Glu	ı V	al 1	Ala	Ile		ly I 90	Lys '	Thr	Val	Tì	nr :	Ile 95	Gln
	Glu	Ile	G.	Lу	Glu 100	qeA	Glu	G.	lu (Glu	Val 105	ту	/r I	le :	Ile	Val	G1 11		Ser	Ala

Gly Ala Asp Ala Phe Ala Gly Lys Val Ser Asn Glu Ser Pro Ile Gly 115 120 125

55

Gln Ala Leu Ile Gly Lys Lys Thr Gly Asp Thr Ala Thr Ile Glu Thr 130 $$135\$

- Pro Val Gly Ser Tyr Asp Val Lys Ile Leu Lys Val Glu Lys Thr Ala 5 145 150 155 160
- 10 <210> 152
 - <211> 189
 - <212> PRT
 - <213> Streptococcus pneumoniae
- 15 <400> 152

25

- Met Thr Lys Leu Leu Val Gly Leu Gly Asn Pro Gly Asp Lys Tyr Phe 1 5 10 15
- 20 Glu Thr Lys His Asn Val Gly Phe Met Leu Ile Asp Gln Leu Ala Lys 20 25 30
 - Lys Gln Asn Val Thr Phe Thr His Asp Lys Ile Phe Gln Ala Asp Leu 35 40 45
- Ala Ser Phe Phe Leu Asn Gly Glu Lys Ile Tyr Leu Val Lys Pro Thr
 50 55 60
- Thr Phe Met Asn Glu Ser Gly Lys Ala Val His Ala Leu Leu Thr Tyr 70 75 80
 - Tyr Gly Leu Asp Ile Asp Asp Leu Leu Ile Ile Tyr Asp Asp Leu Asp 85 90 95
- 35 Met Glu Val Gly Lys Ile Arg Leu Arg Ala Lys Gly Ser Ala Gly Gly 100 105 110
- His Asn Gly Ile Lys Ser Ile Ile Gln His Ile Gly Thr Gln Val Phe 115 120 . 125
 - Asn Arg Val Lys Ile Gly Ile Gly Arg Pro Lys Asn Gly Met Ser Val 130 135 140
- Val His His Val Leu Ser Lys Phe Asp Arg Asp Glu Tyr Ile Gly Ile
 45 145 150 155 160
 - Leu Gln Ser Val Asp Lys Val Asp Asp Ser Val Asn Tyr Tyr Leu Gln
 165 170 175
- 50 Glu Lys Asn Phe Glu Lys Thr Met Gln Arg Tyr Asn Gly
 180 185
- <210> 153
- 55 <211> 283
 - <212> PRT
 - <213> Streptococcus pneumoniae

			153															
5		t II	le L	eu I.	le T	hr G 5	ly F	lla	As	n Gl		ln L 10	eu G	ly	Thr	Gl	u Le 1	u Arg 5
_		r Le	eu L	eu As 2	sp G. 20	lu A	rg A	sn	Gl	ມ Gl 2	u Ty 5	yr V	al A	la '	Val	Asp 30		l Ala
10	Ly	s Me	et As	sp I] 35	le Th	ar A	sn G	lu.	.Glı 40	i Me	t Va	al G	lu L	ys '	Val 45	Phe	e Gl	u Glu
٠	Va.	l Ly · 5	s Pi	co Tr	ır Le	eu Va	al Ț	yr 55	His	з Су	s Al	a A		yr : 60	ľhr	Ala	va.	l Asp
15	Ala 65	a Al	a Gl	u As	p Gl	u Gl 7	.у L	ys	Glu	Le	u As	p Pi	ne Al	la']	le	Asn	Va]	Thr 80
. 20	G1,	y`Th	r Ly	's As	n ya 8	1 Al 5	a Ly	ys	Ala	Sei	r Gl 9		s Hi	s G	ly	Ala	Thr 95	Leu
	Val	. Ту:	r Il	e Se 10	r Th O	r As	р Ту	/r	Val	Phe 105	e Asj	p Gl	у Гу	s L	ys	Pro 110	'Val	Gly
25	Gln	. Gli	ı Tr	p G1 5	u Va.	l As	p As	ър 1 :	Arg 120	Pro	As _l	p Pr	o Gl		hr 25	Glu	Tyr	Gly
	Arg	Th:	: Ly:	s Ar	g Met	t Gl	y Gl 13	u (G1u	Leu	Va]	L G1	u Ly 14		is	Val	Ser	Asn
30 -	Phe 145	Туг	: Ile	e Ile	e Aro	7 Th:	r Al	a 1	rp • •	Val	Phe	Gl ₂ 15	y Ası	n T	yr (Gly	Lys	Asn 160
35	,			∋ Thr	165	•	•				170	1					175	
				180			•			185					1	190		
40	•		193					2	00					20	5			
		210		Asn			215)					220					
45	Val 225					230						235			٠.			240
50	Ser				245						250 ·					2	255	
	Leu i	Ala	Lys	Ala 260	Lys	Ala	Thr	G1	Ly E	he 165	Val	Ile	Pro	Thi		rp 0	Sln i	Asp
55	Ala 1	Leu	Gln 275	Glu	Phe	Tyr	Lys	G1 28		lu '	Val	Arg				-		•

5	<2 <2	211> 212>	154 40 PRI Str	7 !	toc	occu	ıs pr	neum	oni	iae											
10			154 ys #		Ser	r Le	u As 5	sp S	er	Arg	g Va	1 As	sp T .0	'yr	Sei	: Le	u Le	u Le	u F .5	ro,	
	Va	1 P	he F	'he	Leu 20	ı Le	u Va	1 1	le	G17	/ Va.		l A	la	Ile	ту		e Al O	a V	al	
15	Se	r H	is A	sp 35	Туг	Pr	o As	n As	sn	Ile 40	e Lei	ı Pr	o I	le	Leu	Gly 45		n Gl	n V	al	
20	Al	a T:	rp I 50	le	Ala	Le:	u Gl	у Le	eu 55	Val	Il€	e Gl	у Р	he	Val 60		L Me	t Le	u P	he	
	As:	n Tl 5	ır G	lu	Phe	Let	ı Tr	o D F?	/S	Val	Thr	Pr		he 75	Leu	Tyr	: 11	e Le		80 BO	
25	Le	u G]	y L	eu	Met	11e 85	e Lei	ı Pr	0	Ile	Val	. Ph		yr	Asn	Pro	Sei	Lei 95	_	al	
	Ala	a Se	r Tl	ır	Gly 100	Ala	Ly:	s As	n :	Trp	Val 105	Se	r II	Le	Asn	Gly	Ile 110	e Thi	: Le	eu	
30	Phe	e G1	n Pi 11	5	Ser	Glu	Phe	e Me	t 1	նys 120	Ile	Sea	с Ту	r	Ile	Leu 125		Leu	ı Al	la	
35	Arg	7 Va 13	1 II 0	.e '	Val	Gln	Phe	тh: 13	r I	'nуs	Lys	His	з Ьу		Glu 140	Trp	Arg	Arg	Th	ır	
•	Val 145	Pr	o Le	u I	Asp	Phe	Leu 150	Lei	ı I	le	Phe	Trp	Ме 15	t 1 5	Ile	Leu	Phe	Thr	11 16		
40	Pro	Va.	l Le	u 1	Val	Leu 165	Leu	Ala	a L	eu	Gln	Ser 170		pΙ	Leu	Gly	Thr	Ala 175		u	
	Val	Phe	e Va	1 7	Ala 180	Ile	Phe	Ser	G		Ile 185	Val	Le	u I	eu	Ser	Gly 190	Val	Se	r	
45	Trp	Lys	11 19	e I 5	lle	Ile	Pro	Val		he 00	Val	Thr	Ala	a.V		Thr 205	Gly	Val	Ala	a	
50	Gly	Phe 210	e Le	ı A	la	Ile	Phe	Ile 215	S	er :	Lýs	Asp	Gly		rg . 20	Ala	Phe	Leu	Hi:	3	
	Gln 225	Ile	Gly	γM	let	Pro	Thr 230	Tyr	G.	ln :	Ile	Asn	Arg 235		le 1	Leu	Ala	Trp	Le: 240		
55	Asn	Pro	Phe	e G	lu i	Phe 245	Ala	Gln	Th	ır 1	lhr :	Thr 250	Tyr	G.	ln (Sln .	Ala	Gln 255	Gl	7	
	Gln	Ile	Ala	ı I	le (Gly	Şer	Gly	G1	y I	Leu i	Phe.	Gly	· G.	ln G	Sly :	Phe	Asn	Ala	ι	

				26	50				2	65					27	0	
5	Sei	: As:	n Le 27	u Le 5	u Il	.ę Pi	ro Va	al A: 20	rg G 30	lu S	er	Asp	Met	I I 1 28		e Th	ır Val
	Ile	290	a Gl	u As	p Ph	e GJ	ly Pi 29	ne II 95	Le G	ly S	er	Val	Let 300		1 11	e Al	a Leu
10	Tyr 305	Let	ı Me	t Le	u Il	e Ty 31	r Ar .0	g Me	et Le	eu L	ys	Ile 315	Thr	Le	u Ly	s Se	r Asn 320
	Asn	Glr	n Phe	∍ Ту	r Th 32	r Ty 5	r Il	e Se	r Tl		ly 1 30	Leu	Ile	· Me	t Me	t Le 33	u Leu 5
15	Phe	His	: Ile	Ph 34	e Gl O	u As	n Il	e Gl	y Al	.a V	al ?	Thr	Gly	Le	1 Le		O Leu
20	Thr	Gly	7 Ile 355	Pr	o Le	u Pr	o Ph	e Il 36	e Se O	r G	ln (Sly	Gly	Se:		a Ile	e Ile
	Ser	Asn 370	Leu	. Ile	e Gly	y Va	1 G1 37	y Le	u Le	u Le	eu S	Ser	Met 380	Ser	туі	r Glr	n Thr
25	Asn 385	Leu	Ala	Glı	ı Glı	1 Ly: 39	s Se:	r Gl	y Ly	s Va		Pro 195	Phe	Lys	Arç	J Lys	Lys 400
	Va1	Val	Leu	Lys	Glr 405		e Lys	\$									
30	<210)> 11·1	55											•			
25	<211 <212 <213	> 20 > PI	02 RT	toco	ccus	pn∈	umon	ıiae'								•	
35	<400			T1-	T1 -	61			~-			_					
	Met 1	сту	т Ха	TIE	11e 5	сту	TIE	Tņr	. GT2	/ G1 1		le i	Ala	Ser	Gly	Lys 15	Ser
40	Thr	Val	Thr	Asn 20	Phe	Leu	Lys	His	Glr 25	Gl;	y Le	eu s	Ser	Ser	Ser 30	Gly	Leu
45	Pro !	Thr,	Gln 35	Суз	Ser	Thr	Asn	Tyr 40	Arg	Ьy	s Pi	ćo (Sly	Gly 45	Arg	Leu	Phe
	Glu 1	Ala 50	Leu	Val	Gln	His	Phe 55	Gly	Gln	Glı	1 Il		le : 60	Leu	Glu	Asn	Gly
50	Glu I 65			•		70					7	5					.80
	Glu G	3ln :	Lys	Trp	Ser .85	Asn	Gln	Ile	Gln	Gly 90		u I	le i	[le	Arg	Glu 95	Glu
55	Leu A	la :	Thr :	Leu 100	Arg	Glu	Gln	Leu	Ala 105	Gln	Th	r G	lu G		Ile 110	Phe	Phe

Met Asp Ile Pro Leu Leu Phe Glu Gln Asp Tyr Ser Asp Trp Phe Ala 115 120 125

- Glu Thr Trp Leu Val Tyr Val Asp Arg Asp Ala Gln Val Glu Arg Leu 130 135 140
 - Met Lys Arg Asp Gln Leu Ser Lys Asp Glu Ala Glu Ser Arg Met Ala 145 150 155 160
- 10 Ala Gln Trp Pro Leu Glu Lys Lys Lys Asp Leu Ala Ser Gln Val Leu 165 170 175
 - Asp Asn Asn Gly Asn Gln Asn Gln Leu Leu Asn Gln Val His Ile Leu 180 185 190
- Leu Glu Gly Gly Arg Gln Asp Asp Arg Asp 195 200

15

- 25 <400> 156

 Met Arg Lys Ile Val Ile Asn Gly Gly Leu Pro Leu Gln Gly Glu Ile

 1 5 10 15
- Thr Ile Ser Gly Ala Lys Asn Ser Val Val Ala Leu Ile Pro Ala Ile 20 25 30
 - Ile Leu Ala Asp Asp Val Val Thr Leu Asp Cys Val Pro Asp Ile Ser 35 40 45
- 35 Asp Val Ala Ser Leu Val Glu Ile Met Glu Leu Met Gly Ala Thr Val 50 55
- Lys Arg Tyr Asp Asp Val Leu Glu Ile Asp Pro Arg Gly Val Gln Asn 65 70 75 80
 - Ile Pro Met Pro Tyr Gly Lys Ile Asn Ser Leu Arg Ala Ser Tyr Tyr 85 90 95
- Phe Tyr Gly Ser Leu Leu Gly Arg Phe Gly Glu Ala Thr Val Gly Leu 45
 - Pro Gly Gly Cys Asp Leu Gly Pro Arg Pro Ile Asp Leu His Leu Lys 115 120 125
- 50 Ala Phe Glu Ala Met Gly Ala Thr Ala Ser Tyr Glu Gly Asp Asn Met 130 135 140
- Lys Leu Ser Ala Lys Asp Thr Gly Leu His Gly Ala Ser Ile Tyr Met 145 150 155 160
 - Asp Thr Val Ser Val Gly Ala Thr Ile Asn Thr Met Ile Ala Ala Val 165 170 175

	т7	ys A	ıта	Asr	18	у А <u>1</u> О	g Ti	nr I	le I	le	Gl: 185	u As	n Al	a Al	a Ar		lu P: 90	ro Glu
5	. 11	e I	le	Asp 195	Va	1 A1	a Tì	ır Le	eu L 2	eu 00	Asr	n Ası	n Me	t Gl	y Al 20	.a H: 15	is I	le Arg
10		у А 2	la 10	Gly	Th	r As	n Il	e I] 21	.e I .5	le	Ile	e Asp	o Gl	y Va 22	l G1 0	u Ar	g Le	eu His
	G1 22	у Т1 5	nr	Arg	His	s Gl	n Va 23	1 I1 0	e P	ro	Asp	Arg	23	e Gl 5	u Al	a Gl	y Th	r Tyr 240
15	Il	e Se	er	Leu	Ala	24	a Al 5	a Va	1 G.	ly	Lys	Gly 250	/ Ile	e Ar	g Il	e As	n As 25	n Val 5
	Le	u T	r (Glu	His 260	Lei	ı Gl	u Gl	y Pł	ne	Ile 265	Āla	Lys	5 Le	ı Glı	u Gl 27		t Gly
20	Va:	l Ar	g t	Met 275	Thr	Va]	Se:	r Gl	u As 28	5p	Ser	Ile	Ph∈	val	Glu 285	1 G1:	u Gl	n Ser
25	Asr	1 Le 29	u I 0	ъ́уѕ	Ala	Ile	e Asr	11e 295	e Ly	's	Thr	Ala	Pro	Туг 300	Pro	Gl:	y Ph	e Ala
	Thr . 305	As	рΙ	eu	Gln	Gln	Pro 310	Let	ı Th	r	Pro	Leu	Leu 315	Leu	Arg	Ala	a Ası	Gly 320
30	Arg	G1;	у Т	hr	Ile	Val 325	Asp	Thr	. II	e 1	Гуr	Glu 330	Lys	Arg	Val	Asr	His 335	Val
	Phe	Glı	ı L	eu .	Ala 340	Lys	Met	Asp	Ala	a <i>I</i>	Asp 845	Ile	Ser	Thr	Thr	Asn 350	Gly	His
35	Ile	Leu	1 T;	yr '	Thr	Gly	Gly	Arg	As ₁	o I	eu .	Arg	Gly	Ala	Ser 365	Val	Lys	Ala
40	Thr	Asp 370	Le	eu A	Arg	Ala	Gly	Ala 375	Ala	a L	eu '	Vál	Ile	Ala 380	Gly	Leu	Met	Ala
	Glu 385	Gly	. L	ys T	hr	Glu	Ile 390	Thr	Asn	ıI	le (Glu	Phe 395	Ile	Leu	Arg	Gly	Tyr 400
45	Ser	Asp	11	e I	le	Glu 405	Lys	Leu	Arg	A	sn I	Leu (Gly	Ala	Asp	Ile	Arg 415	Leu
	Val	Glu	As	p														
50	<210 <211 <212	> 2:	31													,		
55	<212 <213	> St	re	pto	cocc	cus j	pneu	moni	ae									
	<400: Met :			g I	le G	Slu 1	Phe .	Ser	Pro	Se	r L	eu M	let 1	hr N	10t 1	aen.	I 011	7 cn

		1				5				10	. 0				1	5
5	Lys	s Ph	ie Ly	s Gl 2	u Gli O	n Ile	e Th:	r Phe	e Lei 25	ı Ası	n Asp	э Ьу	s Va.	1 Ala 30		т Туі
-	His	s Il	e As	p Il	e Met	t Asp	o Gly	y His 40	Phe	e Val	Pro	Ası	n Ile		Le	u Ser
. 10	Pro	Tr 5	p Ph 0	e Il	e Glr	Glu :	ı Val	l Glr	Lys	Ile	Ser	Asp 60		Pro	Le	u Ser
	Val 65	Hi	s Le	u Met	: Va:l	Thr 70	Asp	Pro	Thr	Phe	Trp 75		l Asp	Gln	Va:	Leu 80
15	Asp	Le	u Gl	n Cys	85 85	Tyr	lle	Cys	Ile	His 90	Ala	Glu	. Val	Leu	Asr 95	Gly
20	Leu	Ala	a Pho	Arc 100	, Leu	Ile	Asp	Lys	Ile 105	His	Asp	Ala	Gly	Leu 110		Ala
	Gly	Val	l Vai	l Leu	Asn	Pro	Glu	Thr 120	Pro	Val	Ser	Thr	Ile 125	Phe	Pro	Tyr
25	Ile	Asp 130	Let	Leu	Asp	Lys	Val 135	Thr	Ile	Met	Thr	Val 140	Asp	Pro	Gly	Phe
	Ala 145	Gly	Gln	Arg	Phe	Leu 150	Glu	Ser	Thr	Leu	Tyr 155	Lys	Ile	Gln	Glu	Leu 160
30	Arg	Gln	Leu	Arg	Val 165	Gln	Asn	Gly	Tyr	His 170	Tyr	Ile	Ile	Glu	Met 175	Asp
35	Gly	Ser	Ser	Ser 180	Arg	Lys	Thr	Phe	Lys 185	Gln	Ile	Asp	Val	Ala 190	Gly	Pro
	Asp	Ile	Туr 195	Val	Ile	Gly	Arg	Ser 200	Gly	Leu	Phe	Gly	Leu 205	Asp	Asp	Asp
40	Ile	Ala 210	Lys	Ala	Trp	Asp	Ile 215	Cys	Ser	Arg		Tyr 220	Glu	Glu	Met	Thr
	Gly 225	Lys	Thr	Met		Ile 230	Lys									
45	<210	> 15	S.R.					•						ŕ		
	<211	> 37	4	٠									÷			•
50	<212: <213:			осос	cus j	pneur	nonia	ae								
30	<4000 Met 7			Met .	Ala 1 5	Leu 1	Thr A	Ala G	Sly 1	lle V	al e	Sly 1	Ĺe _, u I	?ro <i>}</i>	lsn 15	Val
55	Gly I	bys	Ser	Thr 1	Leu E	he F	Asn A	la I	le 1 25	'hṛr L	ys A	la (Sly A	Ala 6	Slu i	Ala

•	Ala	a As	n Ty 3	r Pr 5	o Ph	e Ala	a Th	r Il 4		p Pr	o Ası	n Va	l Gl 4		t Va	l Glu
5	Asp	Pr 5	o As O	p Gl	u Arq	g Leu	1 Gl: 5.	n Ly	s Le	u Th	r Glı	ı Mei		e Th	r Pr	o Lys
	Lys 65	Th	r Va	l Pr	o Thi	70	Pho	e Gl	u Phe	e Th	r Ası 75		e Ala	a Gl	y Il	e Val 80
10	Lys	. Gl	y Al	a Se	r Lys 85	Gly	Glı	ı Gl	y Let	3 Gly 90		ı Lys	s Phe	e Lev	1 Ala 9	a Asn 5
15	Ile	Ar	g Gl	u Vai	l Asp	Ala	Ile	e Val	l His	val	l Val	. Arg	Ala	110	_	o Asp
	Glu	Ası	n Va:	l Met	Arg	Glu	Glr	120		g Glu	a Asp	Ala	Phe 125		. Asp	Pro
20	Leu	Ala 130	a Asp)	o Ile	Asp	Thr	Ile 135	Aşn	Leu	Glu	1 Leu	Ile 140		Ala	Asp	Leu
	Glu 145	Ser	· Val	l Asn	Lys	Arg 150	Tyr	Ala	Arg	Val	Glu 155	Lys	Met	Ala	Arg	Thr 160
25	Gln	Lys	Asp	Lys	Glu 165	Ser	Val	Ala	Glu	Phe 170		Val	Leu	Gln	Lys 175	
30	Lys	Pro	Val	. Leu 180	Glu	Asp	Gly	Lys	Ser 185	Ala	Arg	Thr	Ile	Glu 190	Phe	Thr
	Asp	Glu	Glu 195	Gln	Lys	Val	Val	Lys 200	Gly	Leu	Phe	Leu	Leu 205	Thr	Thr	Lys
35	Pro	Val 210	Leu	Tyr	Val	Ala	Asn 215	Val	Asp	Glu	Asp	Val 220	Val	Ser	Glu	Pro
	225				Tyr	230					235					240
40					Val 245					250					255	
45				260	Glu				265		•		•	270	_	
			275		Val			280					285			
50	Gly :	Leu 290	Gly	Thr	Tyr		Thr 295	Ala	Gly	Glu		Glu 300	Val	Arg	Ala	Trp
<u>:</u> _	Thr 1					310					315	•	•			320
55	Ser A	Asp	Phe	Glu	Lys (325	Gly E	Phe	Ile		Ala 330	Val '	Thr 1	Met		Tyr 335	Glu

Asp Leu Val Lys Tyr Gly Ser Glu Lys Ala Val Lys Glu Ala Gly Arg 345

Leu Arg Glu Glu Gly Lys Glu Tyr Ile Val Gln Asp Gly Asp Ile Met 5 360

Glu Phe Arg Phe Asn Val 370

10

<210> 159

<211> 110

<212> PRT

<213> Streptococcus pneumoniae

15

25

<400> 159

Met Glu Ile Glu Lys Thr Asn Arg Met Asn Ala Leu Phe Glu Phe Tyr

20 Ala Ala Leu Leu Thr Asp Lys Gln Met Asn Tyr Ile Glu Leu Tyr Tyr

Ala Asp Asp Tyr Ser Leu Ala Glu Ile Ala Glu Glu Phe Gly Val Ser

Arg Gln Ala Val Tyr Asp Asn Ile Lys Arg Thr Glu Lys Ile Leu Glu

Asp Tyr Glu Met Lys Leu His Met Tyr Ser Asp Tyr Ile Val Arg Ser 30

Gln Ile Phe Asp Gln Ile Leu Glu Arg Tyr Pro Lys Asp Asp Phe Leu

35 Gln Glu Gln Ile Glu Ile Leu Thr Ser Ile Asp Asn Arg Glu 100 105

<210> 160 40

<211> 223

<212> PRT

<213> Streptococcus pneumoniae

<400> 160

45 Met Thr Leu Glu Trp Glu Glu Phe Leu Asp Pro Tyr Ile Gln Ala Val

Gly Glu Leu Lys Ile Lys Leu Arg Gly Ile Arg Lys Gln Tyr Arg Lys

50 Gln Asn Lys His Ser Pro Ile Glu Phe Val Thr Gly Arg Val Lys Pro

Ile Glu Ser Ile Lys Glu Lys Met Ala Arg Arg Gly Ile Thr Tyr Ala 55

Thr Leu Glu His Asp Leu Gln Asp Ile Ala Gly Leu Arg Val Met Val

	6	5				7	0				7	5				80
. 5	G1	n Pł	ne Va	ıl As	p Asj 8	p Vai	l Ly	s Gl	u Va	1 Va.		o Ile	e Le	ı His	s Lys 95	Arg
J	Gl	n As	p Me	t Ar 10	g Ile O	e Ile	e Gl	n Gl	u Ar		р Ту	r Ile	Thi	His 110		Lys
10	Al	a Se	r Gl 11	у Ту 5	r Ar	g Sei	r Ty:	r Hi		l Vai	l Val	L Glu	тул 125		. Val	Asp
	Th	r Il 13		n Gl	y Ala	a Lys	Th:		e Lei	ı Ala	a Glu	11e		ı.Ile	Arg	Thr
15	Le:	u Al 5	a Me	t Ası	n Ph∈	Trp	Ala	a Thi	c Ile	e Glu	155		Leu	Asn	Tyr	Lys 160
20	Ty	c Gl	n Gl	y Ası	Phe 165		Asp	o Glu	ı Ile	Lys 170		Arg	Leu	Glu	11e 175	
20	Ala	a Ar	g Il	e Ala 180	a His	Gln	. Le	ı Asp	Glu 185		Met	Gly	Glu	Ile 190		Asp
25	Asp) Il	e Gl: 19:		ı Ala	Gln	Ala	Leu 200		Asp	Pro	Leu	Ser 205	Arg	Lys	Leu
	Asn	Asp 210	Gly	y Val	. Gly	Asn	Ser 215		Asp	Thr	Asp	Glu 220	Glu	Tyr	Arg	
30		0> 1 1> 1														
35	<21	2> E	RT.	toco	ccus	pne	umon	iae								
		0> 1 Glu		Asn	Thr 5	His	Asn	Ala	Glu	Ile 10	Leu	Leu	Ser	Ala		Asn
40	Lys	Ser	His	Tyr 20	Pro	Gln	Asp	Glu	Leu 25		Glu	Ile	Ala	Leu 30	15 Ala	Gly
	Arg	Ser	Asn 35	Val	Gly	Lys	Ser	Ser 40		Ile	Asn	Thr	Met 45		Asn	Arg
:45	Lys	Asn 50		Ala	Arg	Thr	Ser 55		Lys	Pro	Gly	Lys 60		Gln	Leu	Leu
50	Asn 65	Phe	Phe	Asn	Ile	Asp 70	Asp	Lys	Met	Arg	Phe 75		Asp	Val	Pro	Gly 80
	Tyr	Gly	Tyr	Ala	Arg 85	Val	Ser	Lys	Lys	Glu 90	Arg	Glu :	Lys	Trp	Gly 95	Cys
55	Met	Ile	Glu	Glu 100	Tyr	Leu	Thr		Arg 105	Glu	Asn	Leu i		Ala 110	Va:l '	Val

Ser Leu Val Asp Leu Arg His Asp Pro Ser Ala Asp Asp Val Gln Met Tyr Glu Phe Leu Lys Tyr Tyr Glu Ile Pro Val Ile Ile Val Ala Thr 5 Lys Ala Asp Lys Ile Pro Arg Gly Lys Trp Asn Lys His Glu Ser Ala 145 10 Ile Lys Lys Lys Leu Asn Phe Asp Pro Ser Asp Asp Phe Ile Leu Phe Ser Ser Val Ser Lys Ala Gly Met Asp Glu Ala Trp Asp Ala Ile Leu 15 Glu Lys Leu 195 20 <210> 162 <211> 97 <212> PRT <213> Streptococcus pneumoniae 25 <400> 162 Met Lys Thr Arg Lys Ile Pro Leu Arg Lys Ser Val Val Ser Asn Glu Val Ile Asp Lys Arg Asp Leu Leu Arg Ile Val Lys Asn Lys Glu Gly 30 Gln Val Phe Ile Asp Pro Thr Gly Lys Ala Asn Gly Arg Gly Ala Tyr 35 Ile Lys Leu Asp Asn Ala Glu Ala Leu Glu Ala Lys Lys Lys Val Phe Asn Arg Ser Phe Ser Met Glu Val Glu Glu Ser Phe Tyr Asp Glu 40 Leu Ile Ala Tyr Val Asp His Lys Val Lys Arg Arg Glu Leu Gly Leu Glu 45 ્ર <210> 163 <211> 103 50 <212> PRT <213> Streptococcus pheumoniae <4001163 Met Leu Lys Pro Ser Ile Asp Thr Leu Leu Asp Lys Val Pro Ser Lys 55 10

Tyr Ser Leu Val Ile Leu Glu Ala Lys Arg Ala His Glu Leu Glu Ala

20 25. 30 Gly Ala Pro Ala Thr Gln Gly Phe Lys Ser Glu Lys Ser Thr Leu Arg 5 Ala Leu Glu Glu Ile Glu Ser Gly Asn Val Thr Ile His Pro Asp Pro Glu Gly Lys Arg Glu Ala Val Arg Arg Arg Ile Glu Glu Glu Lys Arg 10 Arg Lys Glu Glu Glu Lys Lys Ile Lys Glu Gln Ile Ala Lys Glu Lys Glu Asp Gly Glu Lys Ile 100 <210> 164 20 <211> 103 <212> PRT <213> Streptococcus pneumoniae <400> 164 25 Met Ser Leu Thr Ser Lys Gln Arg Ala Phe Leu Asn Ser Gln Ala His Thr Leu Lys Pro Ile Ile Gln Ile Gly Lys Asn Gly Leu Asn Asp Gln 25 30 Ile Lys Thr Ser Val Arg Gln Ala Leu Asp Ala Arg Glu Leu Ile Lys Val Thr Leu Leu Gln Asn Thr Asp Glu Asn Ile His Glu Val Ala Glu 35 55 -Ile Leu Glu Glu Glu Ile Gly Val Asp Thr Val Gln Lys Ile Gly Arg 40 Ile Leu Ile Leu Phe Lys Gln Ser Ser Lys Lys Glu Asn Arg Lys Ile Ser Lys Lys Val Lys Glu Ile 100 45 <210> 165 <211> 175 <212> PRT 50 <213> Streptococcus pneumoniae <400> 165 Met Ala Ile Glu Asn Tyr Ile Pro Asp Phe Ala Val Glu Ala Val Tyr

Asp Leu Thr Val Pro Ser Leu Gln Ala Gln Gly Ile Lys Ala Val Leu 20 25 30

Val Asp Leu Asp Asn Thr Leu Ile Ala Trp Asn Asn Pro Asp Gly Thr Pro Glu Met Lys Gln Trp Leu His Asp Leu Arg Asp Ala Gly Ile Gly Ile Ile Val Val Ser Asn Asn Thr Lys Lys Arg Val Gln Arg Ala Val 10 Glu Lys Phe Gly Ile Asp Tyr Val Tyr Trp Ala Leu Lys Pro Phe Thr Phe Gly Ile Asp Arg Ala Met Lys Glu Phe His Tyr Asp Lys Lys Glu 15 105 Val Val Met Val Gly Asp Gln Leu Met Thr Asp Ile Arg Ala Ala His 20 Arg Ala Gly Ile Arg Ser Ile Leu Val Lys Pro Leu Val Gln His Asp Ser Ile Lys Thr Gln Ile Asn Arg Thr Arg Glu Arg Arg Val Met Arg 150 25 Lys Ile Thr Glu Lys Tyr Gly Pro Ile Thr Tyr Lys Lys Gly Ile 30 <210> 166 <211> 455 <212> PRT <213> Streptococcus pneumoniae 35 <400> 166 Met Phe Arg Lys Ile Leu Ile Ala Asn Arg Gly Glu Ile Ala Val Arg Ile Ile Arg Ala Ala Arg Glu Leu Gly Ile Ala Thr Val Ala Val Tyr 40 Ser Thr Ala Asp Lys Glu Ala Leu His Thr Leu Leu Ala Asp Glu Ala 45 Val Cys Ile Gly Pro Gly Lys Ala Thr Glu Ser Tyr Leu Asn Ile Asn Ala Val Leu Ser Ala Ala Val Leu Thr Glu Ala Glu Ala Ile His Pro 50 Gly Phe Gly Phe Leu Ser Glu Asn Ser Lys Phe Ala Thr Met Cys Glu Glu Ile Gly Ile Lys Phe Ile Gly Pro Ser Gly His Val Met Asp Met 55 Met Gly Asp Lys Ile Asn Ala Arg Ala Gln Met Ile Lys Ala Gly Val

				13	15						12	0						12	5			
5		ro	Va)	l Il	e P	ro G	ly	Se	r A	sp 35	Gly	y G.	lu	Va]	l Hi		sn 40		r G	lu G	lu	Ala
	Le 14	eu :	Ile	e Va	l A	la G	lu	Ly:	s I:	le	Gl	/ Ty	yr	Pro	Va 15	1 M 5	et	Le	u L	/s A	la	Ser 160
10	Al	.a (Gly	G1	y GI	ly G 1	1 y 65	Lys	s G]	У	Ile	: A1	g	Lys 170	Va	1 G	lu	Lys	s Pr		sp 75	Asp
		u V	/al	Se	r Al 18	a P.	he	Glu	ı Th	r i	Ala	S∈ 18	r 5	Ser	G1	u A	la	Lyś	8 Al 19		sn	Tyr
15	G1	уД	Asn	G1 19	y Al 5	a Mo	et	Tyr	: 11	e (51 u 200	Ar	g	Val	Il	e Ty	γr	Pro 205		a A	rg	His
20	Il	e G 2	1u 10	Va:	l Gl	n I	le :	Leu	G1 21	у <i>Р</i> 5	Asp	Gl	u I	His	Gly	y Hi 22	.s ?0	Val	Il	e H	is	Leu
	G1 22	y G 5	lu	Arg	j As	p C	7s :	Ser 230	Le	u G	ln	Ar	g 1	Asn	Asr 235	n G1	n i	Lys	Va.	l Le	eu	Glu 240
25	Glt	ı S	er	Pro	Se:	r Il 24	e 1 5	Ala	Ile	e G	lу	Ly	s 1	hr 250	Leu	Ar	g i	His	Gli	ı II 25		Gly
	Ala	а А.	la	Ala	Va. 260	L Ar)	g Æ	Ala	Ala	a G	lu	Ph 6	e V 5	'al	Gly	Ту	r (Glu	Asr 270		a	Gly
30	Thr	: I	le	Glu 275	Phe	e Le	u I	eu	Asp) G.	lu 80	Ala	a S	er	Ser	As		Phe 285	Tyr	Ph	e l	Met
35	Glu	Me 29	et 90	Asn	Thr	Ar	g V	al	Gln 295	Vá	al	Glu	ı H	is	Pŗo	Va:		hr	Glu	Ph	e V	/al
	Ser 305	G1	У	Val	Asp	Ile	∍ V 3	al 10	Lys	G]	lu	Gln	ı I.	le	Cys 315	Ile	e A	la	Ala	G1;		51n 320
40					Val	323)						3.	30						33	5	
1_					Ile 340							345							350			•
· 45	Pro	G1	y I	Lys 355	Ile	Thr	As	sn :	Leu	Ту 36	r 1 0	Geu	Pr	:o S	Ser	Gly		ly ' 65	Val	Gly	L	eu
50	Arg	Va:	1 <i>P</i>	sp	Ser	Ala	Va	1 5	Tyr 375	Pr	0 0	lу	Ту	r T		Ile 380	Pı	ro 1	Pro	Tyr	T	yr
	Asp 385						39	U						3	95						4 (00 .
55	Ala	Leu	ı M	et :	Lýs	Met 405	G1	n A	lrg	Ala	a L	eu	Ту. 41	r G.	lụ 1	Leu	Gl	u I		Glu 415	G]	ГĀ
	Val '	Gln	T)	hr 1	Asn	Ala	Asj	рΡ	he	Glr	ı L	eu .	Ası	o Le	eu]	île	Se	r A	sp .	Arg	As	in

420 425 430

Val Ile Ala Gly Asp Tyr Asp Thr Cys Phe Leu Met Glu Thr Phe Leu 435 440 445

Pro Lys Tyr Gln Glu Lys Glu 450 455

10 <210> 167 <211> 77 <212> PRT <213> Streptococcus pneumoniae

15 <400> 167
Met Ile Tyr Lys Val Phe Tyr Gln Glu Thr Lys Glu Arg Ser Pro Arg
1 5 10 15

Arg Glu Thr Thr Arg Ala Leu Tyr Leu Asp Ile Asp Thr Ser Ser Glu 20 25 30

Leu Glu Gly Arg Ile Thr Ala Arg Gln Leu Val Glu Glu Asn Arg Pro
35 40 45

25 Glu Tyr Asn Ile Glu Tyr Ile Glu Leu Leu Ser Asp Lys Leu Leu Asp 50 55 60

Tyr Glu Lys Glu Thr Gly Ala Phe Glu Ile Thr Glu Phe 65 70 75

<210> 168 <211> 336

30

40

55

<212> PRT
35 <213> Streptococcus pneumoniae

<400> 168 Met Lys Asp Arg Tyr Ile Leu Ala Phe Glu Thr Ser Cys Asp Glu Thr

1 5 10 15

Ser Val Ala Val Leu Lys Asn Asp Asp Glu Leu Leu Ser Asn Val Ile

Ala Ser Gln Ile Glu Ser His Lys Arg Phe Gly Gly Val Val Pro Glu
45 40

Val Ala Ser Arg His His Val Glu Val Ile Thr Ala Cys Ile Glu Glu 50 55 60

50 Ala Leu Ala Glu Ala Gly Ile Thr Glu Glu Asp Val Thr Ala Val Ala 65 70 75 80

Val Thr Tyr Gly Pro Gly Leu Val Gly Ala Leu Leu Val Gly Leu Ser 85 90 95

Ala Ala Lys Ala Phe Ala Trp Ala His Gly Leu Pro Leu Ile Pro Val 100 105 110

	Ası	n Hi	s Met 115	t Ala	a Gly	/ His	Let	120	Ala	a Ala	a Gln	Ser	Va)	l Glu	ı Pr	Leu
5	Glı	130	e Pro	Let	ı Lev	Ala	Leu 135	Let	ı Val	. Sei	Gly	Gly		Th:	Glı	ı Leu
10	Val 145	. Туі 5	. Val	. Ser	Glu	Ala 150	Gly	Asp	Tyr	Lys	11e 155		Gly	/ Glu	Thr	Arg 160
	Asp	Asp	Ala	Val	. Gly 165	Glu	Ala	Tyr	Asp	Lys 170	Val	Gly	Arg	Val	Met 175	Gly
15	Leu	Thr	Tyr	Pro 180	Ala	Gly	Arg	Gľu	Ile 185		Glu	Leu	Ala	His 190		Gly
	Gln	Asp	Ile 195	Туг	Asp	Phe	Pro	Arg 200	Ala	Met	Ile	Lys	Glu 205	Asp	Asn	Leu
20	Glu	Phe 210	Ser	Phe	Ser	Gly	Leu 215	Lys	Ser	Ala	Phe	Ile 220	Asn	Leu	His	His
25	Asn 225	Ala	Glu	Gln	Lys	Gly 230	Glu	Ser	Leu	Ser	Thr 235	Glu	Asp	Leu	Суз	Ala 240
	Ser	Phe	Gln	Ala	Ala 245	Val	Met	Asp	Ile	Leu 250	Met	Ala	Lys	Thr	Lys 255	Lys
30	Ala	Leu	Glu	Glu 260	Tyr	Pro	Val	Lys	Thr 265	Leu	Phe	Val	Ala	Gly 270	Gly	Val
	Ala	Ala	Asn 275	Lys	Gly	Leu	Arg	Glu 280	Arg	Leu	Ala		G1u 285	Ile	Thr	Asp
35	Val	Lys 290	Val	Ile	Ile	Pro	Pro 295	Leu	Arg	Leu	Cys	Gly . 300	Asp	Asn	Ala	Gly
40	Met 305	Ile	Ala	Tyr	Ala	Ser 310	Val	Ser	Glu	Trp	Asn : 315	Lys (Glu	Asn	Phe	Ala 320
	Gly	Trp	Asp	Leu	Asn 325	Ala i	Ĺуs	Pro		Leu 330	Ala i	Phe A	Asp		Met 335	Glu
45																
50	<210: <211: <212: <213:	> 60: > PR'	2 Г	ococo	cus p	oneum	onia	1e	• -							
55 .	<400> Met 0			le V	/al 6	Sly V	al V	al G	Sly A	sn 1	hr A	sn A	la T	Thr A	Asp :	Ile .
	Leu I	le 0	Sln G	ly I	eu G	lu L	ys L	eu G	lu T	yr A	rg G	ly T	yr A	sp S	er 1	Ala

WO 01/49721 US00/35604

	***	J 01/	47/	21														PCT/U	5
					2	0.					2	5					30		
5		Ly 1	le	Phe 3	e Va 5	ıl Le	eu As	sp G	lу.	Ala 40	As _l	P As	n Hi	s L	eu V	al L 45	ys A	la Val	
•		.у А	rg 50	Ile	Al	a Gl	u Le	u S	er 1 55	Ala	Lys	3 Th	r Al		Ly V 50	al G	lu G	ly Thr	
10	Th	r G	ly	Il€	e Gl	y Hi	s·Th 7	r Ai	rg :	rp	Ala	Th	r Hi 7	s G1 5	y L	ys P	ro T	hr Glu 80	
	As	рA	sn	Ala	Hi.	s Pr 8	o Hi 5	s Aı	rg S	Ser	Glu	Th:	r Gl	u Ar	g Pi	ne Va		eu Val 95	
15	Hi.	s A	sn	Gly	Va:	1 I1	e Gl	u As	in I	`yr	Leu 105	Glı	ı I1	e Ly	s G]	lu G]		r Leu	
20	Al	a G	lу	His 115	His	s Phe	e Ly:	s Gl	у G 1	ln 20	Thr	Asp	Th:	r Gl	บ์ II 12		a Va	ıl His	
	Lei	u II 13	Le 30	Gly	Lys	s Phe	Ala	Gl 13	ս G 5	lu	Glu	Gly	Let	1 Se.		l Le	u Gl	u Ala	
25	Phe 145	e Ly 5	s.	Lys	Ala	Leu	His 150	Il.	e I.	le	Arg	Gly	Ser 155		r Al	a Ph	e Al	a Leu 160	
	Ile	e As	p:	Ser	Glu	Asn 165	Pro	As	o Va	al	Île	Tyr 170	Val	Ala	а Ly	s As	n Ly 17	s Ser 5	
30	Pro	Le	น 1	Leu	Ile 180	Gly	Leu	Gly	y GI	Lu	Gly 185	Tyr	Asn	Met	. Va.	l Cy:		r Asp	
35	Ala	Ме	t <i>I</i>	11a 195	Met	Ile	Arg	Glu	2 Th	er i	Asn	Gln	Tyr	Met	Glv 205		e His	s Asp	
	Gln	Gİ:	u I O	eu	Val	Ile	Val	Lys 215	Al	.a 2	Asp	Ser	Val	Glu 220		Glr	n Asp	Tyr	
40	Asp 225	Gly	γA	sn	Ser	Arg	Glu 230	Arg	Al	a 9	Ser '	Tyr	Thr 235	Ala	Glu	Let	Asp	Leu 240.	
	Ser	Asp) I	le (Gly	Lys 245	Gly	Thr	Ту	r E	?ro	Tyr 250	Tyr	Met	Leu	Lys	Glu 255	Ile	
45	Asp	Glu	ı G.	ln 1	Pro 260	Thr	Val	Met	Ar	g I 2	ys I :65	Leu	Ile	Gln	Ala	Tyr 270	Thr	Asp	
50	Asp	Ala	G: 2	ly (Sln	Val	Val	Val	Ala 280	a P	ro A	lla	Ile	Ile	Lys 285	Ala	Val	Gln	
	Asp	Ala 290	As	sp A	lrg	Ile	Tyr	Ile 295	Let	ı A	la A	la (Gly	Thr 300	Ser	Tyr	His	Ala	

Gly Phe Ala Ser Lys Lys Met Leu Glu Glu Leu Thr Asp Thr Pro Val 305 310 315 320

Glu Leu Gly Ile Ser Ser Glu Trp Gly Tyr Gly Met Pro Leu Leu Ser

					325	5				330)				335	5
. 5	Lys	Lys	Pro	Leu 340	. Phe	· Ile	Phe	Ile	Ser 345		Ser	Gly	Glu	Thr 350		Asp
	Ser	Arg	Gln 355	Val	Leu	Val	Lys	Ala 360	Asn	Glu	Met	Gly	Ile 365		Ser	Leu
10	Thr	Val 370	Thr	Asn	Val	Pro	Gly 375	Ser	Thr	Leu	Ser	Arg 380	Ġlu	Ala	Asn	Tyr
	Thr 385	Met	Leu	Leu	His	Ala 390	Gly	Pro	Glu	Ile	Ala 395	Val	Ala	Ser	Thr	Lys 400
15	Ala	Tyr	Thr	Ala	Gln 405	Ile	Ala	Ala	Leu	Ala 410	Phe	Leu	Ala	Lys	Ala 415	Val
20	Gly	Glu	Ala	Asn 420	Gly	Asn	Ala	Lys	Ala 425	Gln	Ala	Phe	Asp	Leu 430	Val	His
	Glu	Leu	Ser 435	Ile	Val	Ala	Gln	Ser 440	Ile	Glu	Ser	Thr	Leu 445	Ser	Glu	Lys
25	Glu	Thr 450	Ile	Glu	Ala	Lys	Val 455	Arg	Glu	Leu	Leu	Glu 460	Thr	Thr	Arg	Asn
•	Ala	Phe	Tyr	Ile	Gly	Arg	Gly	Gln	Asp	Tyr	Tyr	Val	Ala	Met	Glu	Ala

470 475

30 Ser Leu Lys Leu Lys Glu Ile Ser Tyr Ile Gln Cys Glu Gly Phe Ala 490

Ala Gly Glu Leu Lys His Gly Thr Ile Ala Leu Ile Glu Glu Gly Thr

Pro Val Leu Ala Leu Leu Ser Asp Pro Val Leu Ala Asn His Thr Arg 515 520

Gly Asn Ile Gln Glu Val Ala Ala Arg Gly Ala Lys Val Leu Thr Ile 40

Ala Glu Glu Asn Val Ala Lys Asp Thr Asp Asp Ile Val Leu Thr Thr 545 550 ` 555

45 Val His Pro Tyr Leu Ser Pro Ile Ser Met Val Val Pro Thr Gln Leu 570

Val Ala Tyr Phe Ala Thr Leu His Arg Gly Leu Asp Val Asp Lys Pro

Arg Asn Leu Ala Lys Ser Val Thr Val Glu 600

55 <210> 170 <211> 240 <212> PRT

35

<213> Streptococcus pneumoniae

<400> 170

Met Ile Arg Ile Glu Asn Leu Ser Val Ser Tyr Lys Glu Thr Leu Ala

1 10 15

Leu Lys Asp Ile Ser Leu Val Leu His Gly Pro Thr Ile Thr Gly Ile 20 25 30

- 10 Ile Gly Pro Asn Gly Ala Gly Lys Ser Thr Leu Leu Lys Gly Met Leu 35 40 45
- Gly Ile Ile Pro His Gln Gly Gln Ala Phe Leu Asp Asp Lys Glu Val
 50 55 60
- Lys Lys Ser Leu His Arg Ile Ala Tyr Val Glu Gln Lys Ile Asn Ile 65 70 75 80
- Asp Tyr Asn Phe Pro Ile Lys Val Lys Glu Cys Val Ser Leu Gly Leu 85 90 95
- 25 Lys Val Gln Glu Ala Leu Glu Ile Val Gly Leu Ala Asp Tyr Ala Glu 115 120 125
- Arg Gln Ile Ser Gln Leu Ser Gly Gly Gln Phe Gln Arg Val Leu Ile 130 135 140
 - Ala Arg Cys Leu Val Gln Glu Ala Asp Tyr Ile Leu Leu Asp Glu Pro 145 150 155 160
- Phe Ala Gly Ile Asp Ser Val Ser Glu Glu Ile Ile Met Asn Thr Leu 165 170 175
 - Arg Asp Leu Lys Lys Ala Gly Lys Thr Val Leu Ile Val His His Asp 180 185 185
- 40 Leu Ser Lys Ile Pro His Tyr Phe Asp Gln Val Leu Leu Val Asn Arg
 195 200 205
 - Glu Val Ile Ala Phe Gly Pro Thr Lys Glu Thr Phe Thr Glu Thr Asn 210 215 220
 - Leu Lys Glu Ala Tyr Gly Asn Gln Leu Phe Phe Asn Gly Gly Asp Leu 225 230 235 240

50

45

<210> 171

<211> 740

55 <212> PRT

<213> Streptococcus pneumoniae

•		
	<pre><400> 171 Met Pro Lys Glu Val Asn Leu Thr Gly Glu Glu Val Val Ala Leu 1 5 10 15</pre>	
5	5 Lys Glu Tyr Leu Thr Glu Glu Asp Val His Phe Val His Lys Ala 20 25 30	Leu
10	Val Tyr Ala Val Glu Cys His Ser Gly Gln Tyr Arg Lys Ser Gly (35 40 45	Glu
	Pro Tyr Ile Ile His Pro Ile Gln Val Ala Gly Ile Leu Ala Lys I 50 60	Leu
15	Lys Leu Asp Ala Val Thr Val Ala Cys Gly Phe Leu His Asp Val V 65 70 75	/al 80
	Glu Asp Thr Asp Ala Thr Leu Asp Asp Leu Glu Arg Glu Phe Gly F 85 90 95	ro.
20	Asp Val Arg Val Ile Val Asp Gly Val Thr Lys Leu Gly Lys Val G 100 105 110	lu
25	Tyr Lys Ser Ile Glu Glu Gln Leu Ala Glu Asn His Arg Lys Met L 115 120 125	eú
	Met Ala Met Ser Glu Asp Ile Arg Val Ile Leu Val Lys Leu Ser As 130 135 140	qe
30	Arg Leu His Asn Met Arg Thr Leu Lys His Leu Arg Lys Asp Lys Gl 145 150 155 16	ln 50
	Glu Arg Ile Ser Lys Glu Thr Met Glu Ile Tyr Ala Pro Leu Ala Hi 165 170 175	.s
35	Arg Leu Gly Ile Ser Ser Val Lys Trp Glu Leu Glu Asp Leu Ser Ph 180 185 190	e
40	Arg Tyr Leu Asn Pro Thr Glu Phe Tyr Lys Ile Thr His Met Met Ly 195 200 205	s
	Glu Lys Arg Arg Glu Arg Glu Ala Leu Val Asp Glu Val Val Thr Ly 210 215 220	
45	Leu Glu Glu Tyr Thr Thr Glu Arg His Leu Lys Gly Lys Ile Tyr Gly 225 235 246	
	Arg Pro Lys His Ile Tyr Ser Ile Phe Arg Lys Met Gln Asp Lys Arg 245 250 255	j
50	Lys Arg Phe Glu Glu Ile Tyr Asp Leu Ile Ala Ile Arg Cys Ile Leu 260 265 270	ì
55	Asp Thr Gln Ser Asp Val Tyr Ala Met Leu Gly Tyr Val His Glu Phe 275 280 285	
ń.	Trp Lys Pro Met Pro Gly Arg Phe Lys Asp Tyr Ile Ala Asn Arg Lys 290 295 300	

		3(La A O S	sn G	ly T	'yr	Gln	Ser 310	r I]	le H	lis	Th	r Th	ır V 3	al 15	Tyr	G1	y P	ro	Ьγ	s Gly 320
	5					•	325						33	10						33	
	10				3	40						345	•					3!	50		y Gln
				٥.	33					3	60						36	5			1 Met
	15		3 /	0					37	5					•	380			•		Ser
		Va. 38:	1 Ь _ў 5	rs Gi	lu A	șn T	'yr	Leu 390	Al	a G	lu	Glu	I10	e T <u>y</u> 39		Val	Phe	e Th	r	Pro	Asp 400
	20	Gl	y Al	a, Va	al Ai	cg S 4	er 05	Leu	Pr	o ľ	/S	Asp	Se:	r Gl	.у І	Pro	Ile	e As		Phe 415	Ala
	25	Тул	c Gl	u Il	e Hi 42	.s T 20	hr :	Lys	Va:	l G1	у (Glu 425	Lys	s Al	a T	hr	Gly	/ Al 43		Lys	Val
		Asr	ı Gl	y Ar 43	g Me 5	t V	al 1	Pro	Leu	1 Th 44	r : 0	Fhr	Lys	Le	u I	ys	Thr 445		y F	4sp	Gln
3	30	Val	. Gl: 45	u Il O	e Il	e A.	la A	Asn	Pro 455	As	n S	Ser	Phe	G1;		ro 60	Ser	Ar	g A	sp	Trp
		Leu 465	Ası	n Me	t Va	l Ly	/s 1	hr 170	Ser	гЪ	s į	Ala	Arg	47!		ys	Ile	Arg	g G	ln	Phe 480
3	35	Phe	Lys	s Ası	n Gl	n As 48	sp I 85	ys	Glu	Le	u S	er	Val 490	Ası	n L	ys '	Gly	Arg		1u 95	Met
. 4	0	Leu	Met	: Ala	500	n Ph	ie G	ln	Glu	Ası	n G 5	1y 05	Tyr	Val	L A	la 2	Asn	Lys 510		he	Met
		Asp	Lys	515	y His	. Me	t A	sp (Gln	Va] 520	L L	eu	Gln	Lys	T		Ser 525	Tyr	L	ys	Thr
4	5	Glu	Asp 530	Ser	Let	ı Ph	е A.	la A	Ala 535	Ile	e G.	ly.	Phe	Gly	G1 54	.u] !0	lle	Gly	A.	la	Ile
		Thr 545	Val	Phe	Asn	Ar	g Le 5:	eu 1 50	Phr	Glu	L	ys (Glu	Arg 555	Ar	g G	Slu	Glu	G]		Arg 560
5(0	Ala	Lys	Ala	Lys	Ala 56	a G1	lu A	Ala	Glu	G.	Lu I	Leu 570	Val	Ly	s G	lу	Gly	G1 57		Val
55	5	Lys	Val	Glu	Asn 580	Lys	s G]	lu T	'hr	Leu	L <u>y</u> 58	/s \ 85	/al	Lys	Hi	s G		Gly 590	Gl	у (/al
		Val	Ile	Glu 595	Gly	Ala	s Se	r G	ly	Leu 600	Le	u V	al.	Arg	Il	e A	la :	Lys	Су	s C	:ys

Asn Pro Val Pro Gly Asp Asp Ile Val Gly Tyr Ile Thr Lys Gly Arg Gly Val Ala Ile His Arg Val Asp Cys Met Asn Leu Arg Ala Gln Glu Asn Tyr Glu Gln Arg Leu Leu Asp Val Glu Trp Glu Asp Gln Tyr Ser 10 Ser Ser Asn Lys Glu Tyr Leu Ala His Ile Asp Ile Tyr Gly Leu Asn Arg Thr Gly Leu Leu Asn Asp Val Leu Gln Val Leu Ser Asn Thr Thr 15 Lys Asn Ile Ser Thr Val Asn Ala Gln Pro Thr Lys Asp Met Lys Phe 20 Ala Asn Ile His Val Ser Phe Gly Ile Ala Asn Leu Ser Thr Leu Thr Thr Val Val Asp Lys Ile Lys Ser Val Pro Glu Val Tyr Ser Val Lys 25 Arg Thr Asn Gly 30 <210> 172 <211> 492 <212> PRT <213> Streptococcus pneumoniae 35 <400> 172 Met Ser Asn Trp Asp Thr Lys Phe Leu Lys Lys Gly Phe Thr Phe Asp Asp Val Leu Leu Ile Pro Ala Glu Ser His Val Leu Pro Asn Asp Ala 40 Asp Leu Thr Thr Lys Leu Ala Asp Asn Leu Thr Leu Asn Ile Pro Ile 40 45 Ile Thr Ala Ala Met Asp Thr Val Thr Glu Ser Gln Met Ala Ile Ala Ile Ala Arg Ala Gly Gly Leu Gly Val Ile His Lys Asn Met Ser Ile 50 Ala Gln Gln Ala Asp Glu Val Arg Lys Val Lys Arg Ser Glu Asn Gly Val Ile Ile Asp Pro Phe Phe Leu Thr Pro Glu His Thr Ile Ala Glu

Ala Asp Glu Leu Met Gly Arg Tyr Arg Ile Ser Gly Val Pro Val Val

				11	15					12	20					1	.25				
5		lu	Th:	c L∈	eu G.	lu A	sn A	rg	Lys 135	s Le	u V	al (Gly	, Il	e Le	eu T 10	hr	As	n Aı	g i	Asp
		u 5	Arç	, Ph	e I	Le Se	er A 1	sp 50	Туг	As	n G	ln 1	Pro	I1 15		er A	sn	Hi	s M∈		Thr 160
10	Se	r	Glu	As	n Le	eu Va 16	al T 55	hr	Ala	Pr	o Va	al (31 y 170	Th	r As	p L	eu	Al.	a Th		Ala
	G1	u,	Ser	Il	e Le 18	u G] 0	.n G	lu	His	Ar	g Il 18	.e .6	Slu	Lys	s Le	u P.	ro	Le: 190		1 <i>P</i>	Asp
15	Gl	u (Glu	G1 19	y Se 5	r Le	u S	er (Gly	Le:	u I1 O	e I	hr	Ile	e Ly		sp 05	Ile	e Gl	u I	ys
. 20	Va.	1 :	Ile 210	G1	u Ph	e Pr	o A	sn i	Ala 215	Ala	а Ьу	s A	sp	Glu	Ph 22		Ly	Arç	J Le	u L	eu
	Va. 22!	1 <i>7</i> 5	Ala	Gl:	y Al	a Va	1 GI 23	30 JY 1	/al	Thr	: Se	r A	ga.	Thr 235		e G]	.u	Arg	Al		lu 40
25	Ala	a I	Leu	Ph€	e Gli	Al 24	a Gl 5	y F	Ala	Asp	Al.		le 50	Val	Ile	e As	p '	Thr	A1a		is
	Gl7	, H	lis	Ser	260	a Gl;	y Va	11	eu	Arg	Ъу: 265	s I:	le	Ala	Glu	1 I I		Arg 270		a H	is
30	Ph∈	P	ro	Asp 275	Arg	Th:	c Le	u I	le	Ala 280	Gly	y As	sn	Ile	Ala	Th 28		Ala	Glu	G]	ly
35	Ala	A 2	rg 90	Ala	Leu	туг	G1	u A 2	1a 95	Gly	Val	. As	g q	Val	Val 300		s V	al	Gly	11	le
	Gl [·] y 305	P	ro	Gly	Ser	Ile	Cy:	s T:	hr	Thr	Arg	v Va	1 :	Ile 315	Ala	Gl:	y V	al	Glÿ	Va 32	
40	Pro	G.	ln '	Val	Thr	Ala 325	Ile	e Ty	yr i	Asp	Ala	A1 33	a <i>I</i>	Ala	Val	Ala	a A	rg	Gl _u 335	Ту	r
	Gly	r2	ys '	Fhr	Ile 340	Ile	Ala	a As	sp (Gly	Gly 345	11	e I	ys	Tyr	Sei		ly 50	Asp	11	е
45	Val	L	ys A	Ala 355	Leu	Ala	Ala	G]	Ly (Gly 360	Asn	Al.	a V	al	Met	Let 365		ly	Ser	Ме	t
50	Phe	A1 37	a (Sly	Thr	Asp	Glu	A1 37	a I	?ro	Glÿ	Gli	u T		Glu 380	Ile	Pl	ne i	Gln	G1	У
	Arg 385	Lу	s P	he	Lys	Thr	Tyr 390	Ar	g C	Sly	Met	Gl	γ S 3	er : 95.	Ile	Ala	A]	La i	Met	Lys 400	
55	Lys	G1	y S	er	Ser	Asp	Arg	Ту	r P	he (Gln	Gl ₃	7 S	er V	/al	Asn	G1	.u 2	Ala	Asn	1

Lys Leu Val Pro Glu Gly Ile Glu Gly Arg Val Ala Tyr Lys Gly Ala

																1 (1/0	
				42	20				42	25				4	30		
. 5	Al	a A	la A 4	sp II 35	le Va	al Ph	ie Gl	ln Me	et II 10	Le G	ly Gl	y Il		rg Se 15	er G	ly Me	t
. J	Gl	у Т	yr C 50	ys Gl	ly Al	a Al	.a As	sn Le	eu Ly	/s G]	Lu Le	u Hi 46		sp As	sn A]	la Glı	n
10	Ph 46	e I:	le G	lu M∈	et Se	r Gl 47	у Al О	a Gl	y Le	u Ly	ıs Gl 47	u Se 5	r Hi	.s Pr	O Hi	.s Asp 48(
	Va	1 G	ln I	le Th	r As 48		u Al	a Pr	o As	n Ty 49		r Me	t.				
15.			173													·	
20	<2:	11> 12> 13>	PRT	ptoc	occu	s pne	eumo≀	niae									
		00> : Th		u Glı	u Ile	∍ Lys	s Ası	n Lei	ı Glı	n Ala		n Ası	э Ту	r Ası	o Ala	a Ser 5	
25	Gln	ıIl	e Gl	n Val	L Leu)	ı Glu	Gly	/ Let	ı Glu 25	ı Ala	a Val	. Arg	g Mei	t Arg		o Gly	
30	Met	Ту	r Il	e Gl <u>j</u> 5	/ Ser	Thr	Ser	Lys 40	Glu	ı Gly	/ Leu	His	His 45		ı Val	Trp	
	Glu	11e 50	e Vai	l Asp	Asn	Ser	Ile 55	Asp	Glu	Ala	Leu	Ala 60		Phe	Ala	Ser	
35	His 65	Ile	e Glr	n Val	Phe	Ile 70	Glu	Pro	Asp	Asp	Ser 75	Ile	Thr	Val	Val	Asp 80	
	Asp	Gly	Arg	Gly	Ile 85	Pro	Val	Asp	Ile	Gln 90		Lys	Thr	Gly	Arg 95		
40	Ala	Val	Glu	Thr 100	Val	Phe	Thr	Val	Leu 105	His	Ala	Gly	Gly	Lys 110	Phe	Gly	
45	Gly	Gly	Gly 115	Tyr	Lys	Val	Ser	Gly 120	Gly	Leu	His	Gly	Val 125	Gly	Ser	Ser	
15	Val	Val 130	Asn	Ala	Leu	Ser	Thr 135	Gln	Leu	Asp	Val	His 140	Val	His	Lys	Asn	
50	Gly 145	Lys	Ile	His	Tyr	Gln 150	Glu	Tyr	Arg	Arg	Gly	His	Val	Val	Ala	Asp	

Leu Glu Ile Val Gly Asp Thr Asp Lys Thr Gly Thr Thr Val His Phe

Thr Pro Asp Pro Lys Ile Phe Thr Glu Thr Thr Ile Phe Asp Phe Asp 180 185 190

55

	Ly	s I	eu	Asr 195	ь Ly ; .	s Ar	g Il	e Gl	n G1 20	u L	eu A	la	Phe	Lev	20		g Gl	y Leu
5	G1	n I 2	le 10	Ser	: I1	e Th	r As	р L y 21	s Ar 5	g G	Ln G	ly	Leu	Glu 220		n Th	r Ly	s His
	Ту 22	r H 5	is	Tyr	· Gl	u Gly	y Gly 230	y Il O	e Al	a Se	er T		Val 235	Glu	Ту	r Il	e As	n Glu 240
10	As	n L	ys	Asp	Va.	1 Ile 245	e Phe	e As	p Th	r Pr		1e 50	Tyr	Thr	Asp	G1	y Gl 25	u Met 5
15	As	рΑ	sp	Ile	Th:	val	Glu	ı Va	l Al	a Me 26		ln '	Tyr	Thr	Thr	G1 27		r His
	Gl	u A	sņ	Val 275	Met	Ser	Phe	Ala	a As 28	n As O	n I	le i	His	Thr	His 285		ı Gl	y Gly
20	Thi	r H: 29	is 90	Glu	Glr	Gly	Phe	295	g Th	r Al	a Le	eu 1	ſhr	Arg 300	Val	. Ile	e Ası	n Asp
	Ту1 305	A]	La .	Arg	Lys	Asn	Lys 310	Let	ı Lei	а Ly	s As		Asn 315	Glu	Asp	Asr	Let	Thr 320
25	G17	, G]	.u /	Asp	Val	Arg 325	Glu	Gly	Let	ı Th	r Al		/al	Ile	Ser	Va)	Lys 335	His
30	Pro	As	n l	Pro	Gln 340	Phe	Glu	Gly	Glr	Th:		s I	hr.	Lys	Leu	Gly 350		Ser
	Glu	. Va	1 3	Val 355	Lys	Ile	Thr	Asn	Arg 360	Lei	ı Ph	e S	er	Glu	Ala 365	Phe	Ser	Asp
35	Phe	Le 37	u N O	1et	Glu	Asn	Pro	Gln 375	Ile	Ala	Ly	s A		Ile 380	Val	Glu	Lys	Gly
	Ile 385	Le	u <i>I</i>	Ala	Ala	Lys	Ala 390	Arg	Val	Ala	Al		ys 1 95	Arg	Ala	Arg	Glu	Val 400
40	Thr	Ar	g L	ys	Lys	Ser 405	Gly	Leu	Glu	Ile	Se:		sn 1	Leu	Pro	Gly	Lys 415	Leu
45	Ala	Ası	o C	ys	Ser 420	Ser	Asn	Asn	Pro	Ala 425		ı Tl	hr C	lu :	Leu	Phe 430	Ile	Val
	Glu	Gly	, A 4	sp : 35	Ser	Ala	Gly	Gly	Ser 440	Ala	Lys	s Se	er G		Arg 145	Asn	Arg	Glu
50	Phe	Glr 450	1 A.	la 1	lle	Ļeu	Pro	Ile 455	Arg	Gly	Lys	; Il		eu <i>I</i> 60	Asn	Val	Glu	Lys
	Ala 465	Ser	Me	et A	lsp	Lys :	Ile : 470	Leu	Ala	Asn	Glu	Gl 47		le A	Arg :	Ser	Leu	Phe 480
55	Thr	Ala	Me	et G	ly	Thr (Gly 1	Phe	Gly	Ala	Glu 490	Ph	e A	sp V	al :	Ser	Lys 495	Ala

	Ar	g Ty	r Gl	ln Ly 50	s Le 0	u Va	l Le	u Met	505	Asp	Ala	Asp	Va]	1 Asp 510		y Ala
5	Hi	s Il	e Ar 51	g Th	r Le	u Le	u Le	u Thi 520	r Leu	ılle	. Tyr	Arg	Tyr 525		Lys	s Pro
	Ile	E Le 53	u G1 0	u Al	a Gl	у Ту:	r Va: 535	L Tyr	: Ile	. Ala	Gln	Pro 540	Pro	Ile	Туг	Gly
10	Va] 545	L Ly	s Va	1 G1	y Se	550	ı Ile	e Lys	Glu	Tyr	Ile 555		Pro	Gly	Ala	Asp 560
15	Glr	ı Gl	u Il	e Ly	5 Let	ı Glr	n Glu	a Ala	Leu	Ala 570		Tyr	Ser	Glu	Gly 575	Arg
	Thr	Ly:	s Pr	o Th: 580	r Ile	Glr	Arg	Tyr	Lys 585	Gly	Leu	Gly	Glu	Met 590	Asp	Asp
20	His	Glı	59:	u Trị	Glu	Thr	Thr	Met 600	Asp	Pro	Glu	His	Arg 605	Leu	Met	Ala
	Arg	Va]	Se:	r Val	. Asp	Asp	Ala 615	Ala	Glu	Ala	Asp	Lys 620	Ile	Phe	Asp	Met
25	Leu 625	Met	: Gly	y Asp	Arg	Val 630	Glu	Pro	Arg	Arg	Glu 635	Phe	Ile	Glu	Glu	Asn 640
30	Ala	Val	Туз	: Ser	Thr 645	Leu	Asp	Val								
35	<213 <213		8 RŢ	toco	ccus	pneı	imoni	ae							*	
40	1	Gly	Phe		Glu 5					10					15	
	Lys	Lys	Glu	Ile 20	Ser	Glu	Thr	Leu	Thr . 25	Asp '	Val '	Tyr <i>I</i>	Ala :	Ser 1	Leu	Asn
45	Asp	Lys	G1y 35	Tyr	Asn	Pro	Ile	Asn 40	Gln :	Ile V	Val (Sly T	'yr \ 45	Val 1	Seu	Ser
	Gly .	Asp 50	Pro	Ala	Ťyr	Val	Pro . 55	Arg'	Tyr- 1	Asn A	Asn A	11a A 60	rg 1	Asn (Sln :	Ile .
50	Arg :	Lys	Tyr	Glu	Arg .	Asp 70	Glu :	Ile '	Val (Slu G	Slu L 75	eu V	al A	Arg T	'yr '	Tyr 80
55	Leu]	Lys	Gly	Gln	Gly '	Val 1	Asp 1	Leu	•							
	<210	. 17	5													

<211> 198 <212> PRT <213> Streptococcus pneumoniae <400> 175 Met Val Asn Tyr Pro His Lys Val Ser Ser Gln Asp Arg Gln Thr Ser Leu Ser Gln Pro Lys Asn Phe Ala Asn Arg Gly Met Ser Phe Glu Lys 10 Met Ile Asn Ala Thr Asn Asp Tyr Tyr Leu Ser Gln Gly Leu Ala Val 15 Ile His Lys Lys Pro Thr Pro Ile Gln Ile Val Gln Val Asp Tyr Pro 55 Gln Arg Ser Arg Ala Lys Ile Val Glu Ala Tyr Phe Arg Gln Ala Ser 20 Thr Thr Asp Tyr Ser Gly Val Tyr Asn Gly Tyr Tyr Ile Asp Phe Glu 90 Val Lys Glu Thr Lys Gln Lys Arg Ala Ile Pro Met Lys Asn Phe His 25 Pro His Gln Ile Gln His Met Glu Gln Val Leu Ala Gln Gln Gly Ile Cys Phe Val Leu Leu His Phe Ser Ser Gln Gln Glu Thr Tyr Leu Leu 30 135 Pro Ala Phe Asp Leu Ile Arg Phe Tyr His Gln Asp Lys Gly Gln Lys 150 35 Ser Met Pro Leu Glu Tyr Ile Arg Glu Tyr Gly Tyr Glu Ile Lys Ala 170 Gly Ala Phe Pro Gln Ile Pro Tyr Leu Asn Val Ile Lys Glu His Leu 40 Leu Gly Gly Lys Thr Arg 195 45 <210> 176 <211> 288 <212> PRT <213> Streptococcus pneumoniae 50 <400> 176 Met Ala Leu Phe Ser Lys Lys Asp Lys Tyr Ile Arg Ile Asn Pro Asn

Arg Ser Val Arg Glu Lys Pro Gln Ala Lys Pro Glu Val Pro Asp Glu
20 25 30

	Le	u Pl	he Se	er Gl 35	n Cy.	s Pro	Gl;	y Cy:	s Lys	s Hi	s Thi	r Ile	∋ Ty 4		n Ly	s Asp
5	Le	u G	ly Se 50	er Gl	u Ar	g Ile	Cy:	s Pro	o His	з Суя	s Sei	ту: 60		r Ph	e Ar	g Ile
	Se 6	r Al 5	la Gl	n Gl	u Ar	J Leu 70	Ala	a Leu	ı Thr	: Ile	e Asp 75	Met i	: Gl	y Thi	r Ph	e Lys 80
10	Gl	u Le	u Ph	e Th	r Gly 85	/ Ile	Glu	ı Ser	Lys	Asp 90	Pro	Leu	His	s Phe	9:	o Gly
15	Ту	r Gl	n Ly	s Ly:	s Leu O	Ala	Ser	Met	Arg 105	Glu	Lys	Thr	G13	/ Leu		∃ Glu
	Ala	a Va	l Va 11	1 Th:	c Gly	Thr	Ala	Leu 120	Ile	Lys	Gly	Gln	Thr 125		Ala	ı Leu
20	Gly	/ Il 13	e Met O	t Asp	Ser	Asn	Phe 135	Ile	Met	Ala	Ser	Met 140	Gly	Thr	Val	. Val
	Gly 145	Gl:	u Lys	s Ile	Thr	Arg 150	Leu	Phe	Glu	Tyr	Ala 155	Thr	Val	Glu	Lys	Leu 160
25	Pro	Va.	l Val	Leu	Phe 165	Thr	Ala	Ser	Gly	Gly 170	Ala	Arg	Met	Gln	Glu 175	
30	Ile	Met	Ser	Leu 180	Met	Gln	Met	Ala	Lys 185	Ile	Ser	Ala	Ala	Val 190	Lys	Arg
	. His	Ser	Asn 195	Ala	Gly	Leu	Phe	Tyr 200	Leu	Thr	Ile	Leu	Thr 205	Asp	Pro	Thr
35	Thr	Gly 210	Gly	Val	Thr	Ala	Ser 215	Phe	Ala	Met	Glu	Gly 220	Asp	Ile	Ile	Leu
	Ala 225	Glu	Pro	Gln	Ser	Leu ' 230	Val	Gly	Phe .	Ala	Gly 235	Arg .	Arg	Val	Ile	Glu 240
40	Asn	Thr	Val	Arg	Glu 245	Ser]	ieu	Pro	Glu i	Asp 250	Phe (Gln :	Lys		Glu 255	Phe ·
45	Leu	Leu	Glu	His 260	Gly	Phe V	/al /	Asp i	Ala 1 265	Ile	Val 1	rys)		Arg . 270	Asp	Leu
<i>-</i> U	Pro	Asp	Thr 275	Ile	Ala :	Ser I	eu 1	Val <i>1</i> 280	Arg I	Leu l	His (Sly 285	Ser :	Pro	Arg
															•	

50 -

<210> 177 <211> 139 55 <212> PRT <213> Streptococcus pneumoniae

<400> 177

10

25

Met Arg Ile Met Gly Leu Asp Val Gly Ser Lys Thr Val Gly Val Ala 1 5 10 15

- 5 Ile Ser Asp Pro Leu Gly Phe Thr Ala Gln Gly Leu Glu Ile Ile Gln 20 25 30
 - Ile Asn Glu Glu Gln Gly Gln Phe Gly Ser Asp Arg Val Lys Glu Leu 35 40 45
- Val Asp Thr Tyr Lys Val Glu Arg Phe Val Val Gly Leu Pro Lys Asn 50 55 60
- Met Asn Asn Thr Ser Gly Pro Arg Val Glu Ala Ser Gln Ala Tyr Gly 65 70 75 80
 - Ala Lys Leu Glu Glu Phe Phe Gly Leu Pro Val Asp Tyr Gln Asp Glu 85 90 95
- 20 Arg Leu Thr Thr Val Ala Ala Glu Arg Met Leu Ile Glu Gln Ala Asp 100 105 110
 - Ile Ser Arg Asn Lys Arg Lys Lys Val Ile Asp Lys Leu Ala Ala Gln
 115. 120 125
- Leu Ile Leu Gln Asn Tyr Leu Asp Arg Lys Phe 130 135
- 35 <400> 178

 Met Ala Lys Leu Thr Val Lys Asp Val Asp Leu Lys Gly Lys Lys Val

 1 5 10 15
- Leu Val Arg Val Asp Phe Asn Val Pro Leu Lys Asp Gly Val Ile Thr 20 25 30
 - Asn Asp Asn Arg Ile Thr Ala Ala Leu Pro Thr Ile Lys Tyr Ile Ile 35 40 45
- 45 Glu Gln Gly Gly Arg Ala Ile Leu Phe Ser His Leu Gly Arg Val Lys
 50 55 60
- Glu Glu Ala Asp Lys Ala Gly Lys Ser Leu Ala Pro Val Ala Ala Asp
 65 70 75 80
 - Leu Ala Ala Lys Leu Gly Gln Asp Val Val Phe Pro Gly Val Thr Arg
 85 90 95
- Gly Ala Glu Leu Glu Ala Ala Ile Asn Ala Leu Glu Asp Gly Gln Val 100 105 110
 - Leu Leu Val Glu Asn Thr Arg Tyr Glu Asp Val Asp Gly Lys Lys Glu

		11	.5				12	0			12	125				
5		ys As 30	n Ası	Pro	Glu	Le:	u Gl 5	у Ьу	s Ty	r Tr	p Al. 14		r Le	u Gl	y Asp	
	Gly I 145	le Ph	e Val	l Asn	Asp 150	Ala	a Phe	e Gl	y Th	r Al	a Hi: 5	s Ar	g Al	a Hi	s Ala 160	
10	Ser A	sn Va	l _. Gly	/ Ile 165	Ser	Ala	a Ası	n Vai	1 G1:	u Ly: 0	s Ala	a Va	l Ala	a Gl		
	Leu Le	eu Gl	u Asn 180	Glu	Ile	Ala	а Туг	11e	e Gli	n Glı	ı Ala	Va.	l Gli 190		r Pro	
. 15	Glu Ar	g Pro 195	Phe	Val	Ala	Ile	Let 200	Gly	/ Gly	y Ser	Lys	Va. 205		: Asp	Lys	
20	Ile Gl 21	y Val 0	lle	Glu	Asn	Leu 215	Leu	Glu	Lys	s Ala	Asp 220		Val	. Leu	ı Ile	
	Gly Gl 225	y Gly	Met	Thr	Tyr 230	Thr	Phe	Tyr	Lys	Ala 235	Gln	G17	' Ile	Glu	Ile 240	
25	Gly As	n Ser	Leu	Val 245	Glu	Glu	Asp	Lys	Leu ,250	Asp	Val	Ala	Lys	Ala 255		
	Leu Gl	u Lys	Ala 260	Asn	Gly	Lys	Leu	Ile 265	Leu	Pro	Val	Asp	Ser 270	Lys	Glu	
30	Ala Ası	n Ala 275	Phe	Ala	Gly	Tyr	Thr 280	Glu	Val	Arg	Asp	Thr 285	Glu	Gly	Glu	
35	Ala Val 290	l Ser	Glu	Gly 1	Phe 1	Leu 295	Gly	Leu	Asp	Ile	Gly 300	Pro	Lys	Ser	Ile	
	Ala Lys 305	Phe	Asp	Glu A	Ala I 310	Lėu	Thr	Gly	Ala	Lys 315	Thr	Val	Val	Trp	Asn .	
40	Gly Pro	Met	Gly	Val F 325	Phe G	Glu	Asn	Prò	Asp 330	Phe	Gln	Ala	Gly	Thr 335	Ile	
	Gly Val	Met	Asp 2 340	Ala I	le V	al :	Lys	Gln 345	Pro	Gly	Val	Lys	Ser 350	Ile	Ile	
45	Gly Gly	Gly 355	Asp S	Ser A	la A	la i	Ala . 360	Ala	Ile	Asn		Gly 365	Arg .	Ala	Asp	
50	Lys Phe 370	Ser	Trp 1	le S	er T 3	hr (Gly	Glý (Gly		Ser 1 380	1et	Glu :	Leu	Leu	
•	Glu Gly 385	Lys	Val I	eu Pi	ro G. 90	ln I	Leu A	Ala A		Leu 1 395	Thr (Slu :	Lys			
55	<210> 17 <211> 16 <212> PF	55				•										

<213> Streptococcus pneumoniae

<400> 179

15

30

55

Met Leu Lys Ser Glu Lys Gln Ser Arg Tyr Gln Met Leu Asn Glu Glu
5 1 5 10 15

Leu Ser Phe Leu Leu Glu Gly Glu Thr Asn Val Leu Ala Asn Leu Ser 20 25 30

- 10 Asn Ala Ser Ala Leu Ile Lys Ser Arg Phe Pro Asn Thr Val Phe Ala 35 40 45
 - Gly Phe Tyr Leu Phe Asp Gly Lys Glu Leu Val Leu Gly Pro Phe Gln
 50 55 60
- Gly Gly Val Ser Cys Ile Arg Ile Ala Leu Gly Lys Gly Val Cys Gly 65 70 75 80
- Glu Ala Ala His Phe Gln Glu Thr Val Ile Val Gly Asp Val Thr Thr 85 90 95
 - Tyr Leu Asn Tyr Ile Ser Cys Asp Ser Leu Ala Lys Ser Glu Ile Val 100 105 110
- 25 Val Pro Met Met Lys Asn Gly Gln Leu Leu Gly Val Leu Asp Leu Asp 115 120 125
 - Ser Ser Glu Ile Glu Asp Tyr Asp Ala Met Asp Arg Asp Tyr Leu Glu 130 135 140
 - Gln Phe Val Ala Ile Leu Leu Glu Lys Thr Ala Trp Asp Phe Thr Met 145 150 155 160
- Phe Glu Glu Lys Ser

<210> 180

<211> 209

40 <212> PRT

<213> Streptococcus pneumoniae

<400> 180

- Met Thr Ile Glu Leu Leu Thr Pro Phe Thr Lys Val Glu Leu Glu Pro
 1 5 10 15
 - Glu Ile Lys Glu Lys Lys Arg Lys Gln Val Gly Ile Leu Gly Gly Asn
 20 25 30
- 50 Phe Asn Pro Val His Asn Ala His Leu Ile Val Ala Asp Gln Val Arg
 - Gln Gln Leu Gly Leu Asp Gln Val Leu Leu Met Pro Glu Tyr Gln Pro
 50 55 60
 - Pro His Val Asp Lys Lys Glu Thr Ile Pro Glu His His Arg Leu Lys 65 70 75 80

Met Leu Glu Leu Ala Ile Glu Gly Ile Asp Gly Leu Val Ile Glu Thr Ile Glu Leu Glu Arg Lys Gly Ile Ser Tyr Thr Tyr Asp Thr Met Lys Ile Leu Thr Glu Lys Asn Pro Asp Thr Asp Tyr Tyr Phe Ile Gly 10 Ala Asp Met Val Asp Tyr Leu Pro Lys Trp Tyr Arg Ile Asp Glu Leu 135 . Val Asp Met Val Gln Phe Val Gly Val Gln Arg Pro Arg Tyr Lys Val 15 Gly Thr Ser Tyr Pro Val Ile Trp Val Asp Val Pro Leu Met Asp Ile Ser Ser Ser Met Val Arg Ala Phe Leu Ala Gln Gly Arg Lys Pro Asn 20 185 Phe Leu Leu Pro Gln Pro Val Leu Asp Tyr Ile Glu Lys Glu Gly Leu 25 Tyr 30 <210> 181 <211> 255 <212> PRT <213> Streptococcus pneumoniae 35 <400> 181 Met Asn Ile Ala Lys Ile Val Arg Glu Ala Arg Glu Gln Ser Arg Leu Thr Thr Leu Asp Phe Ala Thr Gly Ile Phe Asp Glu Phe Ile Gln Leu 40 His Gly Asp Arg Ser Phe Arg Asp Asp Gly Ala Val Val Gly Gly Ile 45 Gly Trp Leu Gly Asp Gln Ala Val Thr Val Val Gly Ile Gln Lys Gly Lys Ser Leu Gln Asp Asn Leu Lys Arg Asn Phe Gly Gln Pro His Pro 50 Glu Gly Tyr Arg Lys Ala Leu Arg Leu Met Lys Gln Ala Glu Lys Phe . 90 Gly Arg Pro Val Val Thr Phe Ile Asn Thr Ala Gly Ala Tyr Pro Gly 55

Val Gly Ala Glu Glu Arg Gly Gln Gly Glu Ala Ile Ala Arg Asn Leu

	115								120								125				
:	Met 5	G1 13	u 1	let	Ser	Asp	Le	u L 1	ys 35	Val	Pro) Ile	e Il	.e A	11a 40	Il∈	e Il	e Î	le	Gly	
	Glu 145	G1	уЭ	ly	Ser	Gly	Gly	у А. Э	la :	Leu	Ala	Let	Al 15	a V 5	al.	Ala	As	рA	rg	Val 160	
10	Trp	Мe	t L	eu (Glu	Asn 165	Sei	r II	le :	lyr	Ala	Ile 170	Le	u S	er :	Pro	Gl		ly 75	Phe	
	Ala	Se	r I	le 1	Leu 180	Trp	Lys	s As	sp G	lу	Thr 185	Arg	Ala	a M	et (Glu	Ala 190		la	Glu	
15	Leu	Met	1 .	ys 1 95	le	Thr	Ser	Hi	.s G	1u 00	Leu	Leu	Glı	א נ-	et A	Asp 205	Val	. Va	ıl	Asp	
20	Lys	Val 210	. []	le S	er (Glu	Val	Gl 21	у L 5	eu	Ser	Ser	Lys	G1 22	u I	eu	Ile	Ĺу	s ;	Ser	
	Va1 225	Lys	Ь	's G	lu l	Leu	Gln 230	Th	r G	lu :	Leu	Ala	Arg 235	Le	u S	er	Gln	Ly		Pro 240	
25	Leu	Glu	Gl	u L	eu I 2	Leu 245	Glu	Glı	u Ai	eg !	ſyr	Gln 250	Arg	Ph	e A	rg	Lys	Ту: 25			
30	<210: <211: <212: <213:	> 10 > PI	59 RT	ptod	cocc	us Į	Элец	mon	iae	•											
35	<400> Met I 1	> 18 ∶le	12 I1e	э Ьу	s V	al (Slu 1	Met	Al	a A	sp V	/al (10	Slu	Val	. Le	eu A	Ala	Lys 15		le	
	Ala L	ys	Gln	Th 2	r Pl O	ne A	rg (Glu	Th:	r Pi	he A 25	la T	'yr	Asp	As	n T	'hr 30	Glu	G]	lu .	
40	Gln L		••						4(,					4	5					
45		- •						23						60						•	
	Glu G 65						, 0			•			/5	•					8	0	
50	·Glu Ar				•	_					2	10						95 ·			
	Gln Ly									10.	5					11	.0				
55	Leu Gl	u L 1	eu 15	Ala	Thr	. Ly	s As	sn S	Ser 120	Phe	e Se	r Tr	рA	la	Trp 125	Le	u G.	ly '	Val		

Trp Glu His Asn Thr Lys Ala Gln Ala Phe Tyr Asn Arg Tyr Gly Phe Glu Lys Phe Ser Gln His His Phe Met Val Gly Gln Lys Val Asp Thr Asp Trp Leu Leu Arg Lys Lys Leu Arg 165 10 <210> 183 <211> 529 <212> PRT <213> Streptococcus pneumoniae 15 <400> 183 Met Leu Arg Gly Thr Ala Leu Leu Thr Ala Ser Asn Phe Ile Ser Arg 5 20 Leu Leu Gly Ala Val Tyr Ile Ile Pro Trp Tyr Ile Trp Met Gly Ala Tyr Ala Ala Lys Ala Asn Gly Leu Phe Thr Met Gly Tyr Thr Ile Tyr 25 Ala Trp Phe Leu Leu Val Ser Thr Ala Gly Ile Pro Val Ala Val Ala Lys Gln Val Ala Lys Tyr Asn Thr Met Arg Glu Glu Glu His Ser Phe 30 Ala Leu Ile Arg Ser Phe Leu Gly Phe Met Thr Gly Leu Gly Leu Val 90 Phe Ala Leu Val Leu Tyr Val Phe Ala Pro Trp Leu Ala Asp Leu Ser 35 Gly Val Gly Lys Asp Leu Ile Pro Ile Met Gln Ser Leu Ala Trp Gly 120 40 Val Leu Ile Phe Pro Ser Met Ser Val Ile Arg Gly Phe Phe Gln Gly Met Asn Asn Leu Lys Pro Tyr Ala Met Ser Gln Ile Ala Glu Gln Val 45 Ile Arg Val Ile Trp Met Leu Leu Ala Thr Phe Ile Ile Met Lys Leu Gly Ser Gly Asp Tyr Leu Ala Ala Val Thr Gln Ser Thr Phe Ala Ala 180 Phe Val Gly Met Val Ala Ser Phe Ala Val Leu Ile Tyr Phe Leu Ala . 200 55

220

Gln Glu Ser Ser Leu Lys Arg Val Phe Glu Thr Gly Asp Lys Ile Asn

		er I 25	ys i	Arg	Let	ı Le	u V 2	al 2 30	Asp	Th	ır 1	île	Lys	s G:	lu <i>P</i> 35	lla	Ile	e P:	ro I	?he	Ile 240
	L∈	eu T	hr (∃ly	Sea	24	a I 5	le (Gln	Il	e E	he	G1r 250	n II	le I	eu	Asp) G.		eu 255	Thr
10		e I	le A	lsn	Ser 260	Me	t S	er T	ľrp	Ph	e T 2	hr 65	Asn	т Ту	r S	er	Asr	G] 27		sp	Leu
	Va	1 V	al M	let 175	Phe	.Se	r Ty	r F	he	Se 28	r A O	la	Asn	ı Pr	о А	sn	Lys 285		e T	hr	Met
15	11	e Le 29	eu I 90	le	Ser	Va.	l Gl	y V 2	al 95	Se	r I	le	Gly	Se	r Va	al 00	Gly	Le	u P	ro	Leu
	Le: 30:	u Tl 5	ir G	lu	Asn	Туз	7 Va 31	1 L	ys	Gl	y A:	sp	Leu	Ly:	s A.	la.	Ala	Se	r A	rg	Leu 320
20	Va]	l G1	n A	sp	Ser	Let 325	Th	r L	eu	Let	a Pł	ne	Met 330	Phe	e Le	eu I	Leu	Pr		La 35	Thr
25	Val	. G1	y Va	al :	Val 340	Met	. Va	1 G.	lу	Glu	Pr 34	5	Leu	Туз	Th	r V	/al	Phe 350		/r	Gly
	Lys	Pr	o As 35	sp :	Ser	Leu	Ala	a Le	eu !	Gly 360	Le	u l	Phe	Val	. Ph	e <i>F</i>	Ala 865	Va]	L Le	eu (Gln
30	Ser	I1 37	e Il O	e I	Leu	Gly	Let	1 Ту 37	r 1'5	Met	Va	1 1	Leu	Ser	Pr 38	0 M 0	let	Let	G1	n A	Ala
	Met 385	Ph	e Ar	g P	Asn	Arg	Lуs 390	A1	.a 7	Val	Le	u I	yr	Phe 395	Il	еТ	yr	Gly	' Se		le 100
35	Ala	Lys	s Le	u V	al	Leu 405	Gln	Le	u E	Pro	Th:	r I 4	le . 10	Ala	Let	1 P	he	His	Se 41		'yr
40	Gly	Pro	Le	u I 4	le . 20	Ser	Thr	Th	r I	le	Ala 425	a L	eu :	Ile	Ile	• P:		Asn 430	Va.	l L	eu
	Mėt	Tyr	43	g A 5	sp :	Ile	Cys	Lys	s V 4	al 40	Thr	G	ly V	Val	Lys	A)		Ŀÿs	Va:	LI	le
45	Leu	Lys 450	Arg	g Tl	hr 1	lle	Leu	Ile 455	e S	er	Ĺeu	L.	eu 1	Thr	Leu 460		l N	1et	Ph€	e L	eu
	Leu 465	Iľe	Gly	7 Th	nr I	le	Gln 470	Trp	L	eu	Leu	G]	Ly F	he 75	Phe	Ph	e G	ln	Pro		er 30
50	Gly 2	Arg	Leu	Tr	rp S 4	er : 85	Phe	Phe	Ty	yr '	Val	A1	a L 90	eu	Val	Gl	уА	la	Met 495		Ŋ
55	Gly (Gly	Leu	Ту 50	r M	et 1	/al	Met	Se	er 1	Leu 505	Ar	g T	hr '	Tyr	Le		eu 10	Asp	Lу	'S
	Val 1	le	Gly 515	Ly	s A	la G	Sln	Ala	As 52	р <i>Р</i> 10	Arg	Le	u A	rg /	Ala	Ly:	s Pl	he :	Lys	Le	u

Ser

<400> 184

20

35

Met Ser Asp Lys Ile Gly Leu Phe Thr Gly Ser Phe Asp Pro Met Thr 1 5 10 15

Asn Gly His Leu Asp Ile Ile Glu Arg Ala Ser Arg Leu Phe Asp Lys
20 25 30

Leu Tyr Val Gly Ile Phe Phe Asn Pro His Lys Gln Gly Phe Leu Pro 35 40 45

Ile Glu Asn Arg Lys Arg Gly Leu Glu Lys Ala Leu Gly His Leu Glu 50 55 60

Asn Val Glu Val Val Ala Ser His Asp Glu Leu Val Val Asp Val Ala 65 70 75 80

Lys Arg Leu Gly Ala Thr Cys Leu Val Arg Gly Leu Arg Asn Ala Ser

30 Asp Leu Gln Tyr Glu Ala Ser Phe Asp Tyr Tyr Asn His Gln Leu Ser 100 105 110

Ser Asp Ile Glu Thr Ile Tyr Leu His Ser Arg Pro Glu His Leu Tyr 115 120 125

Ile Ser Ser Ser Gly Val Arg Glu Leu Leu Lys Phe Gly Gln Asp Ile 130 135 140

Ala Cys Tyr Val Pro Glu Ser Ile Trp Arg Lys 145 155

<210> 185

<211> 143

45 <212> PRT

<213> Streptococcus pneumoniae

<400> 185

Met Thr Ile Leu Phe Val Val Ile Ser Ala Ser Phe Leu Tyr Met Val

50 1 5 10 15

Ser Leu Ser Met Lys Pro Tyr Gln Thr Ala Lys Ser Glu Gly Glu Lys
20 25 30

55 Leu Ala Gln Gln Tyr Ala Gly Leu Glu Gln Ala Asp Gln Val Asp Leu
35 40 45

Tyr Asn Gly Leu Glu Ser Tyr Tyr Ser Val Leu Gly Arg Asn Lys Gln
50 55 60

- Gln Glu Ala Leu Ala Val Leu Ile Gly Lys Asp Asp His Lys Ile Tyr
 5 65 70 75 80
 - Val Tyr Gln Leu Asn Gln Gly Val Ser Gln Glu Lys Ala Glu Thr Val 85 90 95
- 10 Ser Lys Glu Lys Gly Ala Gly Glu Ile Asp Lys Ile Ile Phe Gly Arg
 100 105 110
 - Tyr Gln Asp Lys Pro Ile Trp Glu Val Lys Ser Gly Ser Asp Phe Tyr 115 120 125
 - Leu Val Asp Phe Glu Thr Gly Ala Leu Val Asn Lys Glu Gly Leu 130 135 140

- 25 <400> 186

 Met Ile Asp Ile His Ser His Ile Val Phe Asp Val Asp Asp Gly Pro

 1 5 10 15
- Lys Ser Arg Glu Glu Ser Lys Ala Leu Leu Thr Glu Ala Tyr Arg Gln
 20 25 30
 - Gly Val Arg Thr Ile Val Ser Thr Ser His Arg Arg Lys Gly Met Phe 35 40 45
- 35 Glu Thr Pro Glu Glu Lys Ile Ala Glu Asn Phe Leu Gln Val Arg Glu
 50 55 60
- Ile Ala Lys Glu Val Ala Ser Asp Leu Val Ile Ala Tyr Gly Ala Glu 65 70 75 80
 - Ile Tyr Tyr Thr Pro Asp Val Leu Asp Lys Leu Glu Asn Asn Arg Ile 85 90 95
- Pro Thr Leu Asn Asn Ser Arg Tyr Ala Leu Ile Glu Phe Ser Met Asn 45
 - Thr Pro Tyr Arg Asp Ile His Ser Ala Leu Asn Lys Ile Leu Met Leu 115 120 125
- 50 Gly Ile Thr Pro Val Ile Ala His Ile Glu Arg Tyr Asp Val Leu Glu 130 135 140
- Asn Asn Glu Lys Arg Val Arg Glu Leu Ile Asp Met Gly Cys Tyr Thr 145 150 155 160
 - Gln Ile Asn Ser Ser His Val Leu Lys Ser Lys Leu Phe Gly Glu Pro 165 170 175

Tyr Lys Phe Met Lys Lys Arg Ala Gln Tyr Phe Leu Glu Arg Asp Leu Val His Ile Ile Ala Ser Asp Met His Asn Val Asp Gly Arg Pro Pro 200 His Met Ala Glu Ala Tyr Asp Leu Val Ser Gln Lys Tyr Gly Glu Ala 10 Lys Ala Gln Glu Leu Phe Ile Asp Asn Pro Arg Lys Ile Val Met Asp Gln Leu Ile 15 <210> 187 <211> 308 20 <212> PRT <213> Streptococcus pneumoniae <400> 187 Met Ser Thr Ile Asp Lys Glu Lys Phe Gln Phe Val Lys Arg Asp Asp 25 Phe Ala Ser Glu Thr Ile Asp Ala Pro Ala Tyr Ser Tyr Trp Lys Ser 30 Val Phe Lys Gln Phe Met Lys Lys Lys Ser Thr Val Val Met Leu Gly Ile Leu Val Ala Ile Ile Leu Ile Ser Phe Ile Tyr Pro Met Phe Ser 35 Lys Phe Asp Phe Asn Asp Val Ser Lys Val Asn Asp Phe Ser Val Arg 70 Tyr Ile Lys Pro Asn Ala Glu His Trp Phe Gly Thr Asp Ser Asn Gly 40 Lys Ser Leu Phe Asp Gly Val Trp Phe Gly Ala Arg Asn Ser Ile Leu 45 Ile Ser Val Ile Ala Thr Val Ile Asn Leu Val Ile Gly Val Phe Val 120 Gly Gly Ile Trp Gly Ile Ser Lys Ser Val Asp Arg Val Met Met Glu 50 Val Tyr Asn Val Ile Ser Asn Ile Pro Pro Leu Leu Ile Val Ile Val 155 Leu Thr Tyr Ser Ile Gly Ala Gly Phe Trp Asn Leu Ile Phe Ala Met 55 Ser Val Thr Thr Trp Ile Gly Ile Ala Phe Met Ile Arg Val Gln Ile

. 180 185 . 190 Leu Arg Tyr Arg Asp Leu Glu Tyr Asn Leu Ala Ser Arg Thr Leu Gly 200 5 .Thr Pro Thr Leu Lys Ile Val Ala Lys Asn Ile Met Pro Gln Leu Val Ser Val Ile Val Thr Thr Met Thr Gln Met Leu Pro Ser Phe Ile Ser 10 230 Tyr Glu Ala Phe Leu Ser Phe Phe Gly Leu Gly Leu Pro Ile Thr Val 15 Pro Ser Leu Gly Arg Leu Ile Ser Asp Tyr Ser Gln Asn Val Thr Thr . 260 265 Asn Ala Tyr Leu Phe Trp Ile Pro Leu Thr Thr Leu Val Leu Val Ser 20 Leu Ser Leu Phe Val Val Gly Gln Asn Leu Ala Asp Ala Ser Asp Pro 295 Arg Thr His Arg 25 <210> 188 <211> 77 <212> PRT - <213> Streptococcus pneumoniae <400> 188 Met Tyr Asn Leu Leu Thr Ile Leu Leu Val Leu Ser Val Val Ile 35 10 Val Ile Ala Ile Phe Met Gln Pro Thr Lys Asn Gln Ser Ser Asn Val 40 Phe Asp Ala Ser Ser Gly Asp Leu Phe Glu Arg Ser Lys Ala Arg Gly Phe Glu Ala Val Met Gln Arg Leu Thr Gly Ile Leu Val Phe Phe Trp 45 Leu Ala Ile Ala Leu Ala Leu Thr Val Leu Ser Ser Arg 70 50 <210> 189 <211> 369 <212> PRT

	Le	u Ti	nr II	le Il 2	e Ph	е Ту	r Le	u Tr	p Ar 2		n Me	t Gl	y Se		u I1 0	e As
_. 5	Pr	o Ph	ne Va	al Se 85	r Va	l Le	u As	n Th 4	r Il	e Me	t Il	e Pr		e Le	u Le	u Gl
10	Gl	y Ph	e Le 0	u Ty	r Ty	r Le	u Th	r As: 5	n Pr	o Il	e Va	1 Th		e Le	u As	n Lys
	Va 6	1 Cy 5	s Ly	s Le	u Ası	n Ar	g Le	u Lei	u Gly	y Il	e Le		e Th	r Le	и Су	s Thi
15	. Le	u Va	l Tr	p Gl	y Me	t Vai	l Ile	e Gly	y Val	l Va. 9		r Le	u Le	u Pro	o Il. 9:	e Let 5
	Ile	e As	n Gl	n Le	u Sei O	r Sei	r Let	ı Ile	105	e Se:	r Se	r Glr	n Th	r Ile 110		r Ser
20	Arg	y Va.	l Gl 11	n Ası 5	p Leu	ı Ile	e Ile	2 Asp	Leu)	Sei	Asr	туг	Pro 125		ı Leı	ı Gln
25	Asr	130	u As _l	p Val	l Glu	a Ala	Thr 135	: Ile	: Gln	Glr	Lev	140		Ser	Туг	val (
23	Asp 145	Ile	e Le	ı Glr	n Asn	11e 150	Leu	Asn	Ser	Val	Ser 155		Ser	Val	Gly	/ Ser 160
30	Val	Let	ı Sei	c Ala	Lėu 165	Ile	Ser	Thr	Val	Leu 170		Leu	Ile	Met	Thr 175	Pro
	Val	Phe	e Let	Val 180	Tyr	Phe	Leu	Leu	Asp 185	Gly	His	Lys	Phe	Leu 190	Pro	Met
35	Leu	Glu	195	Thr	Ile	Leu	Lys	Arg 200	Asp	Arg	Leu	His	Ile 205	Ala	Gly	Leu
40	Leu	Lys 210	Asn	Leu	Asn	Ala	Thr 215	Ile	Ala	Arg	Tyr	Ile 220	Ser	Gly	Val	Ser
	Ile 225	Asp	Ala	Ile	Ile	Ile 230	Gly	Суз	Leu	Ala	Tyr. 235	Ile	Gly	Tyr	Ser	Ile 240
45	Ile	Gly	Leu	Lys	Tyr 245	Ala	Leu	Val	Phe	Ala 250	Ile	Phe	Ser	Gly	Val 255	Ala
	Asn	Leu	Ile	Pro 260	Tyr	Val	Gly	Pro	Ser 265	Ile	Gly	Leu	Ile	Pro 270	Met	Ile
50	Ile	Ala	Asn 275	Ile	Phe	Thr	Val	Pro 280		Arg	Leu	Leu	Ile 285	Ala	Val	Ile
55	Tyr	Met 290	Leu	Val	Val	Gln	Gln 295	Val	Asp	Gly	Asn	Ile 300	Leų	Tyr	Pro	Arg
	Ile 305	Val	Gly	Ser	Val	Met 310	Lys	Val	His	Pro	Ile 315	Thr	Ile	Leu		Leu 320

Leu Leu Leu Ser Ser Asn Ile Tyr Gly Val Val Gly Met Ile Val Ala 325 330 335

- 5 Val Pro Thr Tyr Ser Ile Leu Lys Glu Ile Ser Lys Phe Leu Ser Arg
 - Leu Tyr Glu Asn His Lys Ile Met Lys Glu Arg Glu Arg Glu Leu Ala 355 360 365

10 Lys

- 15 <210> 190 <211> 451 <212> PRT
 - <213> Streptococcus pneumoniae
- 20 <400> 190

 Met Tyr Gln Ala Leu Tyr Arg Lys Tyr Arg Ser Gln Asn Phe Ser Gln

 1 5 10 15
- Leu Val Gly Gln Glu Val Val Ala Lys Thr Leu Lys Gln Ala Val Glu
 25 20 25 30
 - Gln Glu Lys Ile Ser His Ala Tyr Leu Phe Ser Gly Pro Arg Gly Thr 35 40 45
- 30 Gly Lys Thr Ser Val Ala Lys Ile Phe Ala Lys Ala Met Asn Cys Pro 50 55 60
- Asn Gln Val Gly Gly Glu Pro Cys Asn Asn Cys Tyr Ile Cys Gln Ala 65 70 75 80
 - Val Thr Asp Gly Ser Leu Glu Asp Val Ile Glu Met Asp Ala Ala Ser 85 90 95
- Asn Asn Gly Val Asp Glu Ile Arg Glu Ile Arg Asp Lys Ser Thr Tyr
 100 105 110
 - Ala Pro Ser Leu Ala Arg Tyr Lys Val Tyr Ile Ile Asp Glu Val His 115 120 125
- 45 Met Leu Ser Thr Gly Ala Phe Asn Ala Leu Leu Lys Thr Leu Glu Glu 130 135 140
- Pro Thr Gln Asn Val Val Phe Ile Leu Ala Thr Thr Glu Leu His Lys 145 150 155 160
 - Ile Pro Ala Thr Ile Leu Ser Arg Val Gln Arg Phe Glu Phe Lys Ser 165 170 175
- Ile Lys Thr Gln Asp Ile Lys Glu His Ile His Tyr Ile Leu Glu Lys
 180 185 190
 - Glu Asn Ile Ser Ser Glu Pro Glu Ala Val Glu Ile Ile Ala Arg Arg

195 200 205 Ala Glu Gly Gly Met Arg Asp Ala Leu Ser Ile Leu Asp Gln Ala Leu 215 5 Ser Leu Thr Gln Gly Asn Glu Leu Thr Thr Ala Ile Ser Glu Glu Ile 235 Thr Gly Thr Ile Ser Leu Ser Ala Leu Asp Asp Tyr Val Ala Ala Leu 10 Ser Gln Gln Asp Val Pro Lys Ala Leu Ser Cys Leu Asn Leu Leu Phe Asp Asn Gly Lys Ser Met Thr Arg Phe Val Thr Asp Leu Leu His Tyr 15 Leu Arg Asp Leu Leu Ile Val Gln Thr Gly Gly Glu Asn Thr His His 20 Ser Ser Val Phe Val Glu Asn Leu Ala Leu Pro Gln Lys Asn Leu Phe 310 315 Glu Met Ile Arg Leu Ala Thr Val Asn Leu Ala Asp Ile Lys Ser Ser Leu Gln Pro Lys Ile Tyr Ala Glu Met Met Thr Val Arg Leu Ala Glu 345 30 Ile Lys Pro Glu Pro Ala Leu Ser Gly Ala Val Glu Asn Glu Ile Ala 360 Thr Leu Arg Gln Glu Val Ala Arg Leu Lys Gln Glu Leu Ser Asn Ala 35 Gly Ala Val Pro Lys Gln Val Ala Pro Ala Pro Ser Arg Pro Ala Thr 390 395 Gly Lys Thr Val Tyr Arg Val Asp Arg Asn Lys Val Gln Ser Ile Leu 40 410 Gln Glu Ala Val Glu Asn Pro Asp Leu Thr Arg Gln Asn Leu Ile Arg 425 Leu Gln Asn Ala Trp Gly Glu Val Ile Glu Ser Leu Gly Gly Pro Asp 45 440 Lys Leu Cys 450 50 <210> 191 <211> 662 <212> PRT 55 <213> Streptococcus pneumoniae <400> 191

	Ме	t P 1	he	Arg	, Le	u Th	r As 5	sn L	ys I	eu	Ala	1 Vai		r A	sn 1	Leu	Il	_	rs Asn .5	ı
5	Ar	g L	ys	Leu	ту: 2	т Ту 0	r Pr	co Pl	he A	la	Leu 25	Ala	a Va	1 L	eu I	eu	A1 3		1 Thr	
	Le	u T	hr	Tyr 35	Le	u Ph	е Ту	r Se	er L	eu 40	Thr	Phe	e As	n Pi	co I	ys 45	Il	e Al	a Glu	
10	11	e A	rg 50	Gly ·	Gly	y Th	rˈTh	r II	le G 55	ln	Ala	Thr	Le		y P 50	'he	Gl	y Me	t Phe	
15	Va. 65	l Va 5	al'	Thr	Leu	ı Ala	a Se 7	r Al O	a I	le	Ile	Val	. Le: 7:		r A	la	Ası	n Se	r Phe 80	
	Val	L M∈	et I	Lys	Lys	Arq 85	g Se.	r Ly	s G	lu	Leu	Gly 90	Ile	∋ Ту	r G	ly	Met	Let 9	u Gly 5	
20	Let	ı Gl	.u]	Ĺуs	Arg 100	His	Le	u Il	e S	er i	Met 105	Thr	Phe	₽ Ly	s G	lu	Leu 110		l Val	
	Phe	Gl	у I 1	le 15	Leu	Thr	Va.	l Gl	y Al 12	La (20	Sly	Ile	Gly	, Il	e G:		Ala	Let	Phe	
. 25	Asp	Ly 13	s I O	eu	Ile	Phe	Ala	Pho 13	е Le 5	u I	Seu	Lys	Leu	Me1		/S	Leu	Lys	Val	
30	Glu 145	Le	u V	al	Ala	Thr	Phe 150	Gli	n Th	r I	ys	Val	Val 155		e Th	r '	Val	Leu	Val 160	
	Val	Phe	e G	ly	Leu	Ile 165	Phe	Lei	ı Gl	y I	ėu i	Met 170	Phe	Let	ı As	n A	Ala	Leu 175	Arg	
35	·				180					1	85					1	90		Gly	
		•	13	95		Arg			20	0					20.	5		•		
40		210	,			Gly		215						220						
45	Thr 225						230					:	235						240	
	Thr	Tyr	Le	u I	eu	Phe 245	Asn	Ala	Gl)	, II	le I	hr \ 50	Val	Phe	Leu	ı G		Ile 255	Leu	
50	Lys			2	60					26	55					2	70			
	Ser i		21	5					280						285					
55 [.]	Ile 1	Ala 290	Il	e L	eu S	Ser '	Thr	Met 295	Val	Le	u V	al T	hr i	Met 300	Ser	A]	la A	Ala	Thr	

	Ser Ile 305	e Phe A	sn Ser	Ala (Glu Se -	r Phe	Lys Ly	ys Val 15	Leu	Asn 1	Pro His 320
5	Asp Phe	Gly V	al Ser 325	Gly (Sln As	n Val	Glu Ly 330	ys Glu	Asp		Asp Lys 335
••	Leu Leu	J.	40			345				350	
10	Glu Val	Phe A: 355	rg Tyr	Thr T	yr Phe 360	e Gly	Val Al	a Asn	Gln (365	Glu G	ly Asn
15	Lys Leu 370	Thr Ph	ne Phe	Glu L 3	ys Gly 75	/ Gln	Asn Ar	g Val 380	Gln I	Pro T	hr Thr
	Val Phe 385	Met Va	l Phe	Asp G 390	ln Lys	Asp	Tyr G1 39		Met 1	hr G	ly Gln 400
20	Lys Leu	Ser Le	u Ser 405	Gly A	sn Glu	Val (Gly Le	u Phe	Ala I		sn Asp 15
	Gly Leu	Lys Gl 42	y Gln O	Lys Ti	ır Leu	Ile 1 425	Leu Ası	n Asp		ln Pl 30	ne Ser
25	Val Lys	Glu Gla 435	u Phe	Asn Ly	s Asp 440	Phe 1	Ile Val		His V 445	al Pr	o Asn
30	Gln Phe 450	Asn Ile	e Leu '	Phr Al 45	a Asp 5	Tyr A	Asn Tyr	Leu 1	Val V	al Pr	o Asp
	Leu Gln 465	Ala Phe	E Leu A	Asn Gl 170	n Phe	Pro A	sp Ser 475	Asp :	lle Ty	yr As	n Gln 480
35	Phe Tyr	Gly Gly	Met A 485	lsn Va	l Asn	Val S	er Glu 90	Glu (Glu Gl	ln Le 49	
	Val Ala (Glu Glu 500	Tyr G	lu Ası	n Tyr	Leu A 505	sn Gln	Phe A	sn Al		n Leu
40	Asp Thr (Glu Gly 515	Ser T	yr Val	1 Tyr 520	Gly S	er Asn		la As 25	p Ala	a Ser
45	Ser Gln N 530	Met Ser	Ala L	eu Phe 535	e Gly	Gly Va	al Phe	Phe I 540	le Gl	y Ile	e Phe
	Leu Ser I 545	le Ile	Phe M	et Val 50	. Gly	Thr Va	al Leu 555	Val I	le Ty	r Tyr	Lys.
50	Gln Ile S	er Glu	Gly Ty 565	yr Glu	Asp i	Arg Gl 57	u Arg	Phe I	le Ile	E Leu 575	
	Lys Val G	ly Leu 580	Asp Gl	ln Lys	Gln 1	le Ly 185	s Gln	Thr II	le His		Gln
55	Val Leu Ti	hr Val 95	Phe Ph	e Leu	Pro I 600	eu Le	u Phe .	Ala Ph 60		His	Leu .

Ala Phe Ala Tyr His Met Leu Ser Leu Ile Leu Lys Val Ile Gly Val 610 $\,$ 615 $\,$ 620 $\,$

- Leu Asp Thr Thr Met Met Leu Ile Val Thr Leu Ser Ile Cys Ala Ile 625 630 635 635 640
 - Phe Leu Ile Ala Tyr Val Leu Ile Phe Met Ile Thr Ser Arg Ser Tyr 645 650 655
- 10 Arg Lys Ile Val Gln Met 660
- <210> 192
- 15 <211> 296

25

40

- <212> PRT
- <213> Streptococcus pneumoniae
- <400> 192
- 20 Met Lys Gln Asp Gln Leu Lys Ala Trp Gln Pro Ala Gln Phe Asp Arg
 1 5 10 15
 - Phe Val Arg Ile Leu Glu Gln Asp Gln Leu Asn His Ala Tyr Leu Phe 20 25 30
 - Ser Gly Phe Phe Gly Ser Leu Glu Met Ala Gln Phe Leu Ala Lys Ser 35 40 45
- Leu Phe Cys Thr Asp Lys Val Gly Val Leu Pro Cys Glu Lys Cys Arg
 50 55 60
 - Ser Cys Lys Leu Ile Glu Gln Glu Glu Phe Pro Asp Val Thr Leu Ile 65 70 75 80
- 35 Lys Pro Val Asn Gln Val Ile Lys Thr Glu Arg Ile Arg Glu Leu Val 85 90 95
 - Gly Gln Phe Ser Gln Ala Gly Ile Glu Ser Gln Gln Gln Val Phe Ile 100 . 105 110
 - Ile Glu Gln Ala Asp Lys Met His Pro Asn Ala Ala Asn Ser Leu Leu 115 120 125
- Lys Val Ile Glu Glu Pro Gln Ser Glu Val Tyr Ile Phe Phe Leu Thr
 130 135 140
 - Ser Asp Glu Glu Lys Met Leu Pro Thr Ile Arg Ser Arg Thr Gln Ile 145 150 155 160
- 50 Phe His Phe Lys Lys Gln Glu Glu Lys Leu Ile Leu Leu Glu Gln 165 170 175
- Met Gly Leu Val Lys Lys Lys Ala Thr Leu Leu Ala Lys Phe Ser Gln 180 185 190
 - Ser Arg Ala Glu Ala Glu Lys Leu Ala Asn Gln Ala Ser Phe Trp Thr 195 200 205

	Le	eu Y	Val 210	As	p G.	lu S	er G	lu	Ar 21	g Le 5	eu L	eu	Th	r Tr	ър L	eu 20	Va]	l Al	a L	ys	Lys
5	-	ys (25	3lu	Se	r T	/r L	eu G 2	1n 30	Va.	1 A)	a L	ys	Le	u Al 23	a A:	sn I	Let	ı Al	a A	sp	Asp 240
10	Lζ	s C	Slu	Lу	s Gl	n As	sp G 15	ln	Va:	l Le	u A	rg	I16 250	e Le	u G	Lu V	Val	. Le		ys 55	Gly
	G1	n A	sp	Let	ь 26	u G1 10	n V	al	Arg	g Va	1 A	rg 65	Val	l Il	e Le	eu (Sln	As 27		∍u	Leu
15	G1	u A	la	Arg 275	g Ly	з Ме	t T	rp	Glr	n Al 28	a A:	sn	Val	. Se	r Ph		31n 285		n Al	a	Met
	Gl		yr 90	Leu	ı Va	l Le	u Ly	ys	Glu 295		е										
20																					
	<2: <2:	10> 11> 12> 13>	20 PR	4 T	toc	occu	s pr	ieui	mon	iae									•		
25				•																	
		>00												•							
	Met	: As	sn :	Ser	Phe	E Ly:	s As	n l	Phe	Let	ı Ly	s (Glu 10	Trp	Gl:	УL	eu	Phe	Le 1		Leu
30 -	Ile	e Le	eu S	Ser	Let 20	ı Lei	ı Al	a I	Leu	Ser	Ar 2	g] 5	le	Phe	Phe	∍ Ti	rp	Ser 30		n V	/al
35	•			33		His				40					•	4	15				
		Э	U			Lys			55						60	1					
40	0.5	٠.				Asp	/(J						75							80
						Thr 85							90			•		•	95		
45	Asp	Ly	s G	lu	Thr 100	Asp	Glu	ı P	ro	Tyr	Leu 105	A.	la .	Asp	Tyr	Il		Lys 110	Arg	P	he
50	Lys	Ası) A	sp 15	Lys	Leu	Glr	ı S	er	Thr 120	Tyr	S	er (Gly	Lys	G1 12		Phe	Glu	G.	ly
	Asn	130	,					1.	35						140						
55	Thr 145	Val	. As	gp 1	Val	Asn	Tyr 150	As	n 1	Thr	Asn	Ph		Ser 155	Phe	Thi	r V	al	Pro	G1 16	
	Gly	Glu	Ту	r I	eu	Leu	Leu	Gl	y P	qsŀ	Asp	Ar	g I	Leu '	Val	Ser	: s	er	Asp	Se	r

165 170 175

Arg His Val Gly Thr Phe Lys Ala Lys Asp Ile Thr Gly Glu Ala Lys
180 185 190

Phe Arg Phe Trp Pro Ile Thr Arg Ile Gly Thr Phe 195 200

- 10 <210> 194 <211> 328 <212> PRT <213> Streptococcus pneumoniae
- 15 <400> 194

 Met Val Val Phe Thr Gly Ser Thr Val Glu Glu Ala Ile Gln Lys Gly

 1 5 10 15
- Leu Lys Glu Leu Asp Ile Pro Arg Met Lys Ala His Ile Lys Val Ile
 20 25 30
 - Ser Arg Glu Lys Lys Gly Phe Leu Gly Leu Phe Gly Lys Lys Pro Ala 35 40 45
- 25 Gln Val Asp Ile Glu Ala Ile Ser Glu Thr Thr Val Val Lys Ala Asn 50 55 60
- Gln Gln Val Val Lys Gly Val Pro Lys Lys Ile Asn Asp Leu Asn Glu $65 \ 70 \ 75 \ 80$
 - Pro Val Lys Thr Val Ser Glu Glu Thr Val Asp Leu Gly His Val Val 85 90 95
- Asn Ala Ile Lys Lys Ile Glu Glu Glu Gly Gln Gly Ile Ser Asp Glu 100 105 110
 - Val Lys Ala Glu Ile Leu Lys His Glu Arg His Ala Ser Thr Ile Leu 115 120 125
- 40 Glu Glu Thr Gly His Ile Glu Ile Leu Asn Glu Leu Gln Ile Glu Glu 130 135 140
- Ala Met Arg Glu Glu Ala Gly Ala Asp Asp Leu Glu Thr Glu Gln Asp 145 150 155 160
- Gln Thr Glu Asn Gln Asp Leu Lys Glu Met Gly Leu Lys Val Glu Gln
 165 170 175
- Ser Tyr Asp Ile Ala Gln Val Ala Thr Asp Val Thr Ala Tyr Val Gln 180 185 190
 - Ala Ile Val Asp Asp Met Asp Val Glu Ala Thr Leu Ser Asn Asp Tyr 195 200 205
- Asn Arg Arg Ser Ile Asn Leu Gln Ile Asp Thr Asn Glu Pro Gly Arg 210 215 220

							230						235					eu Ala 240
4						243						250		•			25	r Ile
				•	.00					2	65					270	1	r Tyr
10) A.	la G	ln L 2	ys I :75	eu <i>l</i>	Ala	Asn	Arg	Va. 28	1 L	eu (Glu	Glu	Gly	Arg 285	Ser	Hi	s Lys
15		r A	sp P 90	ro M	let S	Ser	Asn	Ser 295	Glı	ı Aı	ŗg]	Lys	Ile	Ile 300	His	Arg	Il	e Ile
	Se 30	r A	rg M	et A	sp G	ly :	Val 310	Thr	Ser	: T)	yr S	Ser	Glu 315	Gly	Asp	Glu	Pro	Asn 320
20	Ar	g T	yr Va	al V	al V 3	al 1 25	Asp	Thr	Glu	l								
25	<2 <2	11> 12>	195 460 PRT Stre	eptod	cocci	ıs p	neur	noni	ae									
30		00> : Se		n Ph	ie Al	la I 5	le 1	le:	Leu	Ala	a A	la G 10	Sly 1	.ys (Sly	Thr .	Arg 15	Met
			r As	2						25)					30		
35			u Hi: 3!						40						45			
40								J J						60	•			
•			Thr			. '	U				•	•	/5					80
45			Met		0.	,					9	U					95	
50			Ile	100						105					1	10		
50			Ile 115					1.4	20					12	5			
55							13	J .					14	0				
	Asp . 145	Asn	Ala	Glų	Val	Let 150	ı Ar	g Se	r L	eu	Leu	Ser 155	Ar	g Ar	g Me	t Le		31n .60

	Ile	Leu 1	Lys S	Ser 1	∴ys 165	Ser	Arg	l PÀ	s Se	er T	hr :	Leu	Val	Thi	т Ту	r Va	al Phe
	5 Asp	Asn (Slu A	Arg I .80	Leu	Phe	Glu	Ala	a Le 18	u L 5	ys i	Asn	Ile	Asn	Th.		n Asn
10	}	_						200	J					205			g Glu
	•	-10					213						220				u Ser
15					2	30					2	35					1 Met 240
20	Arg A			2.	* 3					. 25	0					25	5
20	Asn F		21	,0					265	1					270		
25	Val G	2 1	5					280						285			
		30				2	90					3	00				
30	Gly A				٥,	. U					31	.5					320
35	Ala As			32.	3					330						335	
33	Ser Le		541	,					345					3	350		
40	Ser Se	55.	•				3	60					3	65			
	Asn Cy 37	Ū				31)					38	0				
45	Val As:				350	,					395	j					400
50	Val Phe			405					,	410					4	115	
	Asp Asr	•	120					4	25					4:	30		
55	Ala Asp						44	U					44		ys A	.sp (Slu
	Tyr Ala 450		ary	nen	E'T O	455	, ні	3 P:	ro L	ys .	Asn	Gln 460		•			

		5 <	<211 <212	> 19 > 31 > PR' > St:	1 T	ococ	cus	pneu	mon:	iae								
	10	O M	let :		Lys :		Ū					10)	n Pro			15	
											25)		a Lys		30		
	15									40) Asn	45			
	20	Pł	ne V	al L 50	eu A	sn T	'yr E	Phe (51y 55	Val	Glu	Ala	Pro	Arg 60	Val	Ile	Thr	Ser
		A1 6	.a L _j 55	ys A	la G	lu G	ly A	la 6 70	lu (Gln	Val	Ile	Leu 75	Thr	Asp	His	Asn	Glu 80
	25											90		Glu			95	
		Va	l As	iH q	ls Hi	s Ai	rg V	al A	la A	sn	Phe 105	Glu	Thr	Ala	Ser	Pro :	Leu '	Tyr
	30	Met	t Ar	g Le 11	u G1 5	u Pr	70 V	al G	ly S 1	er 1 20	Ala	Ser ·	Ser	Ile	Val '	Tyr /	Arg N	l et
	35	Phe	13	s Gl O	u Hi	s Gl	y Va	1 Al	la V 85	al E	oro :	Lys	Glu	Ile <i>1</i> 140	Ala (Gly I	eu M	let
								v				•	155	Lys S			1	60
	40						-				1	. 70		Ala G		1	75	
		Val	Asn	Leu	180	ı Glı	ту:	r Gl	y Le	u A.	la M 85	let I	eu I	ys A		ly T 90	hr A	sn
	15	Leu	Ala	Ser 195	Lys	Ser	Ala	a Gla	1 Gl 20	ս Le 0	eu I	le A	sp _. I	le A	sp A. 05	la Ly	ys Tł	nr .
5	0	Phe	Glu 210	Leu	Asn	Gly	Asn	Asr 215	va.	l Ar	g V	al A	la G 2:	ln Va 20	al As	sn Th	ır. Va	1
		Asp 225	Ile	Ala	Glu	Val	Leu 230	Glu	Ar	g G1	n Al	la G1 23	Lu II 35	le Gl	lu Al	a Al	a Me 24	
5.	5	Gln .	Ala	Ala	Asn	Glu 245	Ser	Asn	G17	ту	r Se 25	er As	p Ph	ne Va	l Le	u Me 25		e
		Thr 1	Asp	Ile	Val	Asn	Ser	Asn	Ser	Gl	ı Il	e Le	u Al	a Le	u G1	υ Δ1·	- Ac-	_

260 265 270

Met Asp Lys Val Glu Ala Ala Phe Asn Phe Lys Leu Glu Asn Asn His 275 280 285

Ala Phe Leu Ala Gly Ala Val Ser Arg Lys Lys Gln Val Val Pro Gln 290 295 300

Leu Thr Glu Ser Phe Asn Thr 305 310

<210> 197

<211> 225

15 <212> PRT

30

45

· <213> Streptococcus pneumoniae

<400> 197

Met Ile Ser Lys Arg Leu Glu Leu Val Ala Ser Phe Val Ser Gln Gly

1 5 10 15

Ala Ile Leu Leu Asp Val Gly Ser Asp His Ala Tyr Leu Pro Ile Glu 20 25. 30

25 Leu Val Glu Arg Gly Gln Ile Lys Ser Ala Ile Ala Gly Glu Val Val
35 40 45

Glu Gly Pro Tyr Gln Ser Ala Val Lys Asn Val Glu Ala His Gly Leu
50 55 60

Lys Glu Lys Ile Gln Val Arg Leu Ala Asn Gly Leu Ala Ala Phe Glu 65 70 75 80

Glu Thr Asp Gln Val Ser Val Ile Thr Ile Ala Gly Met Gly Gly Arg 85 90 95

Leu Ile Ala Arg Ile Leu Glu Glu Gly Leu Gly Lys Leu Ala Asn Val

40 Glu Arg Leu Ile Leu Gln Pro Asn Asn Arg Glu Asp Asp Leu Arg Ile 115 120 125

Trp Leu Gln Asp His Gly Phe Gln Ile Val Ala Glu Ser Ile Leu Glu 130 135 140

Lys Leu Ser Ala Ser Asp Val Arg Phe Gly Pro Phe Leu Ser Lys Glu
165 170 175

Val Ser Pro Val Phe Val Gln Lys Trp Gln Lys Glu Ala Glu Lys Leu 180 185 190

55 Glu Phe Ala Leu Gly Gln Ile Pro Glu Lys Asn Leu Glu Glu Arg Gln 195 200 205

Val Leu Val Asp Lys Ile Gln Ala Ile Lys Glu Val Leu His Val Ser Lys 5 225 <210> 198 <211> 161 10 <212> PRT <213> Streptococcus pneumoniae <400> 198 Met Asn Leu Asn Asp Ile Lys Asp Leu Met Thr Gln Phe Asp Gln Ser 15 Ser Leu Arg Glu Phe Ser Tyr Lys Asn Gly Thr Asp Glu Leu Gln Phe Ser Lys Asn Glu Ala Arg Pro Val Pro Glu Val Ala Thr Gln Val Ala 20 Pro Ala Pro Val Leu Ala Thr Pro Ser Pro Val Ala Pro Thr Ser Ala 25 Pro Ala Glu Thr Val Ala Glu Glu Val Pro Ala Pro Ala Glu Ala Ser Val Ala Ser Glu Gly Asn Leu Val Glu Ser Pro Leu Val Gly Val Val 30 Tyr Leu Ala Ala Gly Pro Asp Lys Pro Ala Phe Val Thr Val Gly Asp 105 Ser Val Lys Lys Gly Gln Thr Leu Val Ile Ile Glu Ala Met Lys Val Met Asn Glu Ile Pro Ala Pro Lys Asp Gly Val Val Thr Glu Ile Leu 40 . Val Ser Asn Glu Glu Met Val Glu Phe Gly Lys Gly Leu Val Arg Ile 150 155 Lys 45 <210> 199 <211> 411 50 <212> PRT <213> Streptococcus pneumoniae <400> 199 Met Lys Leu Asn Arg Val Val Val Thr Gly Tyr Gly Val Thr Ser Pro 55 Ile Gly Asn Thr Pro Glu Glu Phe Trp Asn Ser Leu Ala Thr Gly Lys

																	PCT/US
					2	20				2	25				3	80	
5	IJ	е (31 y	, II 3	e G1 5	.у G1	y Il	.e Tł	nr L	ys Pl 10	ne As	sp Hi	s Se		p Ph 5	e As	sp Val
-	Ні	.s 7	lsn 50	Al	a Al	a Gl	u Il	e G]	ln As 55	sp Pi	ne Pr	o Ph		р L y 0	з Ту	r Ph	e Val
10	L у 6	s I 5	уs	Asj	p Th	r As	n Ar 7	g Ph O	ne As	sp As	n Ty	r Se 7	r Le 5	u Ty	r Al	a Le	u Tyr 80
	Al	a A	la	Glı	n Gl	u Al 8	a Va 5	l As	n Hi	s Al		n Le	u As	p Va	1 G1	u Al 9	a Leu 5
15	As	n A	rg	Asp	100	g Ph	e Gl	y Va	1 11	e Va 10	1 A1 5	a Se	r Gl	y Il	e Gl		y Ile
20	Ly.	s G	lu	Ile 115	e Glı	ı Ası	o Gli	n Va	1 Le 12	u Ar O	g Le	u His	s Gli	1 Lys		y Pro	o Lys
	Ar	y V. 1:	al 30	Lys	Pro	Met	Thi	Le:	u Pr 5	o Ly	s Al	a Leu	1 Pro		Met	Ala	a Ser
25	Gl ₃ 145	/ A:	sn	Val	Ala	Met	150	p Phe	e Gl	y Ala	a Ası	n Gly 155	Val	. Cys	Lys	Ser	Ile 160
	Asr	Tì	nr	Ala	Суs	Ser 165	Ser	Sei	Ası	n Asp	Ala 170	a Ile	Gly	Asp	Ala	Phe 175	Arg
30	Ser	. I]	.e	Lys	Phe 180	Gly	Phe	Glr.	Asp	Val 185	Met	Leu	Val	Gly	Gly 190		Glů
35	Ala	Se	r	Ile 195	Thr	Pro	Phe	Ala	Ile 200	Ala	Gly	Phe	Gln	Ala 205	Leu	Thr	Ala
	Leu	Se 21	r ! 0	Thr	Thr	Gļu	Asp	Pro 215	Thr	Arg	Ala	Ser	Ile 220	Pro	Phe	Asp	Lys
40	Asp 225	Ar	g <i>I</i>	Asn	Gly	Phe	Val 230	Met	Gly	Glu	Gly	Ser 235	Gly	Met	Leu	Val	Leu 240
	Glu	Se	rI	eu	Glu	His 245	Ala	Glu	Lys	Arg	Gly 250	Ala	Thr	Ile	Leu	Ala 255	Glu
45	Val	Va.	l G	Зly	Tyr 260	Gly	Asn	Thr	Cys	Asp 265	Ala	Tyr	His	Met	Thr 270	Ser	Pro
50	His	Pro	9 G 2	lu 75	Gly	Gln	Gly	Ala	Ile 280	Lys [.]	Ala	Ile	Lys	Leu 285	Ala	Leu	Glu
	Glu	Ala 290	ı G	lu :	Ile	Ser	Pro	Glu 295	Gln	Val	Ala	Tyr	Val	Asn	Ala	His	Gly

Thr Ser Thr Pro Ala Asn Glu Lys Gly Glu Ser Gly Ala Ile Val Ala 305

Val Leu Gly Lys Glu Val Pro Val Ser Ser Thr Lys Ser Phe Thr Gly

55

325	330	335

His Leu Leu Gly Ala Ala Gly Ala Val Glu Ala Ile Val Thr Ile Glu 340 345 350

Ala Met Arg His Asn Phe Val Pro Met Thr Ala Gly Thr Ser Glu Val 355 360 365

Ser Asp Tyr Ile Glu Ala Asn Val Val Tyr Gly Gln Gly Leu Glu Lys 370 375 380

Glu Ile Pro Tyr Ala Ile Ser Asn Thr Phe Gly Phe Gly Gly His Asn 385 390 395 400

15 Ala Val Leu Ala Phe Lys Arg Trp Glu Asn Arg 405 410

45

Leu Gly Glu Leu Leu Ser Asp Pro Asp Val Val Ser Asp Thr Lys Arg 20 25 30

Phe Met Glu Leu Ser Lys Glu Glu Ala Ser Asn Arg Asp Thr Val Ile 35 40 45

Ala Tyr Arg Glu Tyr Lys Gln Val Leu Gln Asn Ile Val Asp Ala Glu
50 55 60

Glu Met Ile Lys Glu Ser Gly Gly Asp Ala Asp Leu Glu Glu Leu Ala 65 70 75 80

40 Lys Gln Glu Leu Lys Asp Ala Lys Ala Glu Lys Glu Glu Tyr Glu Glu 85 90 95

Lys Leu Lys Ile Leu Leu Leu Pro Lys Asp Pro Asn Asp Asp Lys Asn 100 105 110

Ile Ile Leu Glu Ile Arg Gly Ala Ala Gly Gly Asp Glu Ala Ala Leu 115 120 125

Phe Ala Gly Asp Leu Leu Thr Met Tyr Gln Lys Tyr Ala Glu Ala Gln 130 135 140

Gly Trp Arg Phe Glu Val Met Glu Ala Ser Met Asn Gly Val Gly Gly 155 160

55 Phe Lys Glu Val Val Ala Met Val Ser Gly Gln Ser Val Tyr Ser Lys 165 170 175

	Le	eu I	Lys	T	/r (1	81u 180	Se	r G]	L y .	Ala	Hi	.s A	rg 85	Va]	l Gl	n A	rg	۷a		co V 90	'al	Thr
. 5	G1	.u \$	Ser	G1 19	n (Ίу	Ar	g Va	1	His	Th 20	r S O	er	Thr	al Al	аТ	hr	Va: 20:		eu V	al	Met
	Pr	0 (31u 210	Va	1 G	lu	Gli	ı Va	1 (Glu 215	Ту	r A	sp	Ile	As,	р Р: 2:	ro 20	Lys	s As	p L	eu	Arg
10	Va 22	1 A 5	dsp	Il	e T	yr	His	3 Al 23	a 8 0	Ser	Gl	у А.	la	Gly	G1:	y G. 5	ln	Asr	ı Va	1 A	sn	Lys 240
15	· Va	1 A	la	Th	r A	la	Val 245	. Ar	g I	le	Va.	1 H:	is	Leu 250	Pro	o Tì	ır	Asr	ı Il		ys 55	Vaļ
	Glı	u M	et	Gl	n G. 2	lu 60	Glu	Ar	g I	'hr	Glı	n G] 26	ln 55	Lys	Asr	ı Ar	g	Glu	1 Т у 27		la	Met
20	Lys	3 I	le	11e 275	e Ai	rg	Ala	Ar	g V	'al	Ala 280	a As	ъ	His	Phe	Al		Gln 285		e Al	La	Gln
	Asp	9 G. 2:	lu 90	Glr	n As	gp.	Ala	Glı	1 A 2	rg 95.	Ьys	Se	r	Thr	Ile	G1 30		Thr	Gl ₃	/ As	p .	Arg
25	Ser 305	G.	lu	Arç	, Il	.e 2	Arg	Thr 310	T)	yr	Asn	Ph	e :	Pro	Gln 315	As	n Â	Arg	Va]	L Th		Asp 320
30	His	Aı	g	Ile	G1	y 1	Leu 325	Thr	. Le	eu	Gln	Lу	s 1	Leu 330	Asp	Th	r I	le	Let	Se 33		Gly
	Lys	Le	u.	Asp	G1 34	น โ 0	/al	Val	As	sp.	Ala	Le:	u 1 5	Val	Leu	Туз	c A	sp	Gln 350		r (Sln
35	Lys	Le	u	Glu 355	Gl	u I	eu	Asn	Γ?	/s					•				-			
.40	<210 <211 <212 <213	L> 2>.	559 PR3	9 ['	coco	occ	us	pne	ımo	nia	ae e											
45	<400 Met 1)> ; Ala	201 a T	Yyr	Thr	: L	eu : 5	Lys	Pr	o G	Slu	Glu	V	al (Gly	Val	Pl	ne i	Ala	Ile		ly
	Gly	Leu	1 G	ly	Glu 20	1 I.	le (Gly	Ьу.	s A	sn	Thr 25	T	yr G	Sly	Ile	G]		Tyr 30	Gln	A	sp
50	Glu	Ile	e I	le 35	Ile	Va	al A	Asp	Ala	a G	ly 40	Ile	Ly	ys P	he :	Pro		.u <i>P</i> 5	Asp	Asp	Le	eu
55	Leu	G1y 50	I	le.	Asp	Ty	r V	al	Ile 55	P.	ro i	Asp	T	r S	er '	Fyr 60	IJ	e V	/al	Asp	As	sn
	Ile 1 65	Asp	A:	rg	Val	Ьy	s A	la 70	Val	. Le	eu]	le	Th	r H	is (Sly	Hi	s G	lu .	Asp		.s 0

	I.	le G	Sly (Sly	Ile	Pr 8	o P	he 1	Leu	Le	eu I	уys	Gl: 90	n Ai O	la 1	Asn	Va	1 P:	ro	11e 95	Tyr
5	A.	La G	ly F	ro	Leu 100	Al	a L	eu A	lla	Le	eu] 1	1e .05	Arg	g Gl	ly I	Lys	Le		lu l0	Glu	His
10		УL	eu L 1	eu 15	Arg	As	n A	la I	ys	Le 12	u T O	'yr	Glu	1 I l	e A	Asn	Hi. 12		sn '	Thr	Glu
		u T 1	hr P 30	he :	Lys	As	n Le	eu L	ys 35	Al	а Т	hr	Phe	Ph		rg 40	Th	r Th	ır l	His	Ser
15	I1 14	e P: 5	ro G	lu 1	Pro	Lei	u Gl 15	у I 0	le	Va.	l I	le	His	Th		ro	Glr	ı Gl	уІ	ys	Ile 160
	Va	1 C	ys Ti	hr (Sly	Asp 165	Ph	e L	уs	Phe	e A	sp	Phe 170	Th	r P	ro	Va]	. Gl		31u .75	Pro
20	Al	a As	sp Le	eu F	lis .80	Arc	j Me	t A	la	 Ala	1 Le	eu 35	Gly	Gl	u G	lu	Gly	Va 19		eu	Cys
25	Lėı	ı Le	eu Se 19	er A	sp	Ser	Th	r As	sn	Ala 200	G]	lu '	Val	Pro	o Tl		Phe 205	Th:	r A	sn	Ser
23	Glı	ı Ьу 21	s Va 0	ıl V	al	Gly	Gl	ດ S∈ 21	er .5	Ile	Ме	et 1	Lys	Ile	22 22		Gln	Gl	γI	le	Glu
30	Gl ₃ 225	Ar	g Il	e I	le	Phe	Ala 230	a Se	r	Phe	Al	a S	Ser	Asn 235		e l	Phe	Arg	j L		Gln 240
	Gln	Al	a Th	r G	lu i	Ala 245	Ala	ı Va	1 1	ւչ	Th	r (Sly 250	Arg	Ly	s]	le	Ala		al :	Phe
35	Gly	Ar	g Se	r Me	et (60	Glu	Lys	Al	a I	le	Va. 26	1 A 5	Isn	Gly	Il	e A	dsp	Leu 270		Ly :	fyr
40	Ile	Lys	275 275	a Pr	o I	Ъуs	Gly	Th	r F 2	he 80	Ile	e G	lu .	Pro	Ası		lu 85	Ile	LУ	s P	Asp
	Tyr	Pro 290	Ala	a G1	.у С	Slu	Val	Let 295	1 I	le	Let	ı C	ys '	Thr	G1 <u>5</u> 300		er	Gln	Gl	уG	lu
45	Pro 305	Met	Ala	Al	a I	eu	Ser 310	Arg	j I	le	Ala	ı A:	sn (31y 315	Thr	: Н.	is	Arg	Gl	_	al 20
	Gln	Leu	Gln	Pr	o G 3	ly 25	Asp	Thr	V	al	Ile	Pl 33	ne S 30	Ser	Ser	: Se	er i	Pro	I1 33		ro
50	Gly	Asn	Thr	Th.	rs O	er `	Val	Asn	Ly	ys :	Leu 345	IJ	.e A	sn	Ile	1]		Ser 350	G1:	u A	la
55	Gly	Val	Glu 355	Va.	l I	le 1	His	Gly	Ъ <u>у</u>	/s 7 50	Val	As	n A	sn	Ile	Ні 36	.s I	hr	Sei	c G	Ly
	His	Gly 370	Gly	Glr	n GI	ln (Slu	Gln 375	ьу	s I	Seu	Ме	t L	eu (Cys	Le	u I	le	Lys	Pı	0

	38	S T	yr .	Pne	Met	Pr	o Va 39	11 H:	is G	Sly	Glu	Туг	39!	g Me 5	t Gl	n Ly	rs Va	1 His 400
5	Al.	a G	ly 1	Leu	Ala	Va:	1 As 5	p Ti	nr G	ly	Val	Glu 410	L <u>y</u> s	s As	p As	n _. Il	e Phe 415	e Ile
10		t S	er A	Asn	Gly 420	Ası	o Va	l Le	eu A	la	Leu 425	Thr	Ala	a As	p Se	r Al 43] Ile
•	Ala	a GJ	Ly F	lis 135	Phe	Ası	n Al	a Gl	.n A 4	sp 40	Ile	Tyr	Val	. Ası	0 Gl:		n Arg	, Ile
15	Gl	7 G] 45	lu I 50	le	Gly	Ala	Ala	a Va 45	1 L	eu .	Lys	Asp	Arg	Arg 460) Lei	ı Ser	Glu
	Asp 465	G1	.y V	al	Val	Leu	Ala 470	a Va)	1 A	la '	Thr	Val	Asp 475	Ph∈	E Lys	s Sei	Gln	Met 480
20						400						490					Met 495	
25					300					5	05					510		
			٦.	13					52	U					525		Val	
30		55(535)					540			Thr	Glu
	Arg 545	Glı	ı Pr	o I	le.	Ile	Ile 550	Pro	Me	t I	le 1		Thr 555	Pro	Asp	Glu	Glu	
35	<210 <211 <212	> 4	50															
40	<213 <400	> s	tre	pto	coco	cus	pnet	mon	iae									
				u V	al G	Slu (5	Glu	Leu	Arg	γ Va	ıl G	ln E 10	ro (Gln	Asp	Ile	Leu i	Ala
45	Glu	Gln	Se	r Va	al L 20	eu (Gly	Ala	Ile	Ph 2	e I 5	le A	sp (Glu	Ser	Lys 30	Leu '	Val
50	Phe '	Val	Arg 35	g G.	lu T	yr]	(le	Glu	Ser 40	Ar	g_A	sp P	he I	Phe :	Lys ' 45	Tyr	Ala H	lis
	Arg I	Seu 50	Ιlε	e Ph	ne G	ln A	la 1	Met 55	Val	As	p Le	eu S	er A	sp 2 60	Arg (Gly A	Asp A	la
55	Ile A		Ala	Th	r T	hr V	al 2 70	Arg	Thr	Ile	e Le	eu As	sp A 75	sn (Gln (Sly A		eu 80
	Gln A	sn	Ile	Gl	y Gl	lуL	eu S	Ger '	Tyr	Let	ı Va	l GI	lu I	le V	al A	lsn S	Ser V	al

85	90	95

												9	U						95	
5		co T	hr S	Ser i	Ala 100	Asn	Ala	a Gl	u T	yr	Tyr 105	Ala	а Ьу	s I	le	Val	. Al		lu Ly	s
	Al	a M	et L	eu 1	Arg	Arg	Let	1 Il	.e A	la 20	Lys	Let	ı Th	r G.		Ser 125		l As	sn Gli	n
10	Al	.a T	yr G 30	lu A	Ala	Ser	Glr	13	o A. 5	la.	Asp	Glu	ıIl		le 1	Ala	G1	n Al	la Glı	1
	Ly 14	s G. 5	ly L	eu 1	le.	Asp	Val 150	. Se	r Gl	lu i	Asn	Ala	15:	n A1 5	g s	Ser	G1	y Ph	ne Lys 160	
15	As	n I	le A	rg A	sp '	Val 165	Leu	Ası	n Le	eu A	Asn	Phe 170	Gly	y As	n I	Seu	Gl	u Al 17	a Arg 5	ī
20				_	80					L	.85						190)	g Asp	
	Leı	ı As	р Ні 19	is M 95	et 1	hr	Thr	Gly	, Le 20	u H O	lis	Glu	Glu	ı Gl		eu 05	Ile	e Il	e Leu	
25	Ala	21	a Ar O	g P	ro A	la	Val	Gly 215	, Ьу	s T	hr	Ala	Phe	Al. 22	a L O	eu	Asn	Ile	e Ala	
•	245	,					230						235						Leu 240	
30					2	45						250						255		
35				. 20						20	55					:	270		Glu	
			21.	J					280)					28	35			Ile	
40	٠	230						295						300					Arg	
45	505					3	10						315						Ile 320	
45	Asp				32						3	30						335		
50	Glu			340	,					34	5					3	50			
	Lys		333					•	360						365	5		•		
55							3	/5					3	380						
	Ile (Slu	Gln	Asp	Ala	a As	p I	le V	/al	Ala	Ph	e L	eu 1	yr	Arg	As	sp A	Asp	Tyr	

385 390 395 400 Tyr Glu Arg Gly Gly Glu Glu Glu Gly Ile Pro Asn Asn Lys Val 410 Glu Val Ile Ile Glu Lys Asn Arg Ser Gly Ala Arg Gly Thr Val Glu Leu Ile Val Gln Lys Glu Tyr Asn Lys Phe Ser Ser Ile Ser Lys Arg Glu Ala 450 15 <210> 203 <211> 699 <212> PRT <213> Streptococcus pneumoniae 20 <400> 203 Met Ala Thr Ala Thr Lys Lys Lys Ser Thr Val Lys Lys Asn Leu Val Ile Val Glu Ser Pro Ala Lys Ala Lys Thr Ile Glu Lys Tyr Leu Gly Arg Asn Tyr Lys Val Leu Ala Ser Val Gly His Ile Arg Asp Leu 30 Lys Lys Ser Ser Met Ser Val Asp Ile Glu Asn Asn Tyr Glu Pro Gln Tyr Ile Asn Ile Arg Gly Lys Gly Pro Leu Ile Asn Asp Leu Lys Lys 35 70 Glu Ala Lys Lys Ala Asn Lys Val Phe Leu Ala Ser Asp Pro Asp Arg Glu Gly Glu Ala Ile Ser Trp His Leu Ala His Ile Leu Asn Leu Asp 40 105 Glu Asn Asp Ala Asn Arg Val Val Phe Asn Glu Ile Thr Lys Asp Ala 120 -45 Val Lys Asn Ala Phe Lys Glu Pro Arg Lys Ile Asp Met Asp Leu Val 135 Asp Ala Gln Gln Ala Arg Arg Ile Leu Asp Arg Leu Val Gly Tyr Ser 50 155 Ile Ser Pro Ile Leu Trp Lys Lys Val Lys Lys Gly Leu Ser Ala Gly Arg Val Gln Ser Ile Ala Leu Lys Leu Ile Ile Asp Arg Glu Asn Glu 55

185

	1	le 2	Asn	19:	a Př 5	ne Gi	ln P.	ro G	lu	Glu 200	Ту	r Tr	p T	hr	Val	. As;	р А] 5	la V	al	Phe
5	L	/s I 2	.ys 210	Gl	y Th	ır Ly	rs G	ln P 2	he 15	His	Ala	a Se	r P		Tyr 220		y Va	l A	sp	Gly
	22	. 5				s Le	2.	30					2	35						240
10						r Ly 24	5					25	0					2	55	
15					20						265						27	0		
				213		n Ly			2	280						285				
20		2	90			а Ту:		29	35					3	00					
	30.	,				: Mei	31	U					31	5						320
25						325)					330						33	5	
30					340						345						350			
			•	333		Arg			3	6Q						365				
35		37	U			Asp		375	•					38	30					
40	363					Ala	390		•				395	5					4	00
40						Ser 405						410						415	,	
45					420	Asp	•			4	25						430			
			4	35		Pro		•	44	0	٠.				4	45				
50	Asn	400	,	•		•		455						46	0		•			
55	Glu 465						4/0						475					•	48	0
55	Ser	Thr	T	yr A	la	Pro 485	Thr	Ile	Glı	ı Tì	nr I 4	le (90	Gln	Lys	A	rg T		Tyr 495	Va	1

	Arg Leu Ala Ala Lys Arg Phe Glu Pro Thr Glu Leu Gly Glu Ile Val 500 505 510
	sn Lys Leu Ile Val Glu Tyr Phe Pro Asp Ile Val Asn Val Thr Phe 515 520 525
	Thr Ala Glu Met Glu Gly Lys Leu Asp Asp Val Glu Val Gly Lys Glu 530 535 540
10	Gln Trp Arg Arg Val Ile Asp Ala Phe Tyr Lys Pro Phe Ser Lys Glu
15	Val Ala Lys Ala Glu Glu Glu Met Glu Lyg Ilo Gla Il
	Pro Ala Gly Phe Asp Cys Glu Val Cys Gly Ser Pro Met Val Ile Lys 580 585 590
20	Leu Gly Arg Phe Gly Lys Phe Tyr Ala Cys Ser Asn Phe Pro Asp Cys 595 600 605
25	Arg His Thr Gln Ala Ile Val Lys Glu Ile Gly Val Glu Cys Pro Ser 610 .615 620
	Cys His Gln Gly Gln Ile Ile Glu Arg Lys Thr Lys Arg Asn Arg Leu 625 630 635 640
30	Phe Tyr Gly Cys Asn Arg Tyr Pro Glu Cys Glu Phe Thr Ser Trp Asp 645 650 655
	Lys Pro Val Gly Arg Asp Cys Pro Lys Cys Gly Asn Phe Leu Met Glu 660 665 670
35	Lys Lys Val Arg Gly Gly Gly Lys Gln Val Val Cys Ser Lys Gly Asp 675 680 685
40	Tyr Glu Glu Glu Lys Met Ala Leu Cys Gln Leu 690 695
45	<210> 204 <211> 326 <212> PRT <213> Streptococcus pneumoniae
50	<pre><400> 204 Met Phe Ile Ser Ile Ser Ala Gly Ile Val Thr Phe Leu Leu Thr Leu 1</pre>
	Val Gly Ile Pro Ala Phe Ile Gln Phe Tyr Arg Lys Ala Gln Ile Thr 20 25 30
55	Gly Gln Gln Met His Glu Asp Val Lys Gln His Gln Ala Lys Ala Gly 35 40 45
	Thr Pro Thr Met Gly Gly Leu Val Phe Leu Ile Thr Ser Val Leu Val

			50					5	5				6	0			
5	U	a P 5	he	Ph∈	e Ph	e Al	a Le	u Ph O	ie Se	r Se	r Gl	n Ph	e Se 5	r As	n Ası	n Va	l Gly 80
	Ме	t I	le	Leu	Phe	e Il 8	e Le	u Va	l Le	и Ту	r Gl	y Le 0	u Va	1 G1	y Phe	e Le:	u Asp
10	As	p Pi	he	Leu	100	s Va.	l Phe	e Ar	g Ly	s Il 10	e As 5	n Gl	u Gl	y Le	u Ası 11(Lys
	Gl	n L	ys	Leu 115	Ala	Let	ı Glr	ı Le	u Le	u Gl 0	y Gl	y Va	1 Ile	Phe 12:		Lei	ı Phe
15	Ty:	r G]	Lu . 30	Arg	Gly	Gly	Asp	Me ⁻	t Lei	ı Ser	r Va	l Ph	e Gly		Gln	ı Val	. His
20	Le:	ı G1	у:	Ile	Phe	Tyr	11e	. Vai	l Phe	e Ala	a Le	u Pho 15		Lev	ı Val	Gly	Phe
	Sei	: As	n A	Ala	Val	Asn 165	Leu	Thi	: Asp	. Gl	/ Vai		Gly	/ Leu	Ala	Ser 175	
25	Ser	· Va	1 1	/al	Ile 180	Ser	Leu	Ser	: Ala	Tyr 185	Gly	/ Val	. Ile	Ala	Tyr 190	Val	Gln
	·Gly	G1	n M 1	1et 195	Asp	Ile	Leu	Leu	Val 200	Ile	Leu	Ala	Met	Ile 205	Gly	Gly	Leu
30	Leu	Se 21	r P O	he	Phe	Ile	Phe	Asn 215	His	Lys	Pro	Ala	Lys 220	Ile	Phe	Met	Gly
35	Asp 225	Va.	l G	ly	Ser	Leu	Ala 230	Leu	Gly	Gly	Met	Leu 235	Ala	Ala	Ile	Ser	Met 240
	Ala	Let	ı H	is	Gln	Glu 245	Trp	Thr	Leu	Leu	Ile 250	Ile	Gly	Ile	Val	Tyr 255	Val
40	Phe	Glu	1 T	hr (Thr 260	Ser	Val	Met	Met	Gln 265	Val	Ser	Tyr	Phe	Lys 270	Leu	Thr
	Gly	Gly	2 Ly	ys 1 75	Arg	Ile	Phe	Arg	Met 280	Thr	Pro	Val	His	His 285	His	Phe	Glu-
45	Leu	Gly 290	G]	Ly I	Leu	Ser	Gly	Lys 295	Gly	Asn	Pro	Trp	Ser 300	Glu	Trp	Lys	Val
50	Asp 305	Phe	Ph	ne E	he '	Trp	Gly 310	Val	Gly	Leu	Leu	Ala 315	Ser	Leu	Leu '		Leu 320
	Ala	Ile	Le	u T		Leu 1 325	Met										
55	<210: <211: <212:	> 69	93			•											

<213> Streptococcus pneumoniae

<4	00	>	20	25
	-	_	~ \	1:1

15

30

45

- Met Ala Arg Glu Phe Ser Leu Glu Lys Thr Arg Asn Ile Gly Ile Met
 5 1 5 10 15
 - Ala His Val Asp Ala Gly Lys Thr Thr Thr Thr Glu Arg Ile Leu Tyr
 20 25 30
- 10 Tyr Thr Gly Lys Ile His Lys Ile Gly Glu Thr His Glu Gly Ala Ser 35 40 45 .
 - Gln Met Asp Trp Met Glu Gln Glu Gln Glu Arg Gly Ile Thr Ile Thr 50 55 . 60
 - Ser Ala Ala Thr Thr Ala Gln Trp Asn Asn His Arg Val Asn Ile Ile 65 70 75 80
- Asp Thr Pro Gly His Val Asp Phe Thr Ile Glu Val Gln Arg Ser Leu 85 90 95
 - Arg Val Leu Asp Gly Ala Val Thr Val Leu Asp Ser Gln Ser Gly Val 100 105 110
- 25 Glu Pro Gln Thr Glu Thr Val Trp Arg Gln Ala Thr Glu Tyr Gly Val 115 120 125
 - Pro Arg Ile Val Phe Ala Asn Lys Met Asp Lys Ile Gly Ala Asp Phe 130 135 140
 - Leu Tyr Ser Val Ser Thr Leu His Asp Arg Leu Gln Ala Asn Ala His 145 150 155 160
- Pro Ile Gln Leu Pro Ile Gly Ser Glu Asp Asp Phe Arg Gly Ile Ile
 165 170 175
 - Asp Leu Ile Lys Met Lys Ala Glu Ile Tyr Thr Asn Asp Leu Gly Thr 180 185 190
- 40 Asp Ile Leu Glu Glu Asp Ile Pro Ala Glu Tyr Leu Asp Gln Ala Gln 195 200 205
 - Glu Tyr Arg Glu Lys Leu Ile Glu Ala Val Ala Glu Thr Asp Glu Glu 210 215 220
 - Leu Met Met Lys Tyr Leu Glu Glu Glu Glu Ile Thr Asn Glu Glu Leu 225 230 235 240
- Lys Ala Gly Ile Arg Lys Ala Thr Ile Asn Val Glu Phe Phe Pro Val 245 250 250
 - Leu Cys Gly Ser Ala Phe Lys Asn Lys Gly Val Gln Leu Met Leu Asp 260 265 270
- 55 Ala Val Ile Asp Tyr Leu Pro Ser Pro Leu Asp Ile Pro Ala Ile Lys 275 280 285

	G]	Ly] 2	le 290	Asr	ı Pı	0 A	sp T	hr	Asp 295	Al	a G	lu	Glu	ıIl	е А 3	rg 00	Pro	o A)	.a S	Ser	Asp
5	G1 30	.u (lu	Pro) Ph	e Al	la A 3	la 10	Let	ı Al	a P	he	Lys	31	е М 5	et	Thi	r As	p F	ro,	Phe 320
	Va	il G	ly	Arg	Le	u Th 32	r P	he i	Phe	Ar	g V	al	Tyr 330	Se:	r G	lу	Va]	L Le		1n 35	Ser
10	G1	y S	er	Tyr	Va 34	1 Le 0	u A	sn '	Thr	Se	r Ly 34	ys 15	Gly	Lу	s Aı	:g	Glu	Ar 35		le	Gly
15	Ar	g I	le	Leu 355	G1	n Me	t H	is 1	Ala	As:	n Se	er	Arg	Glı	n Gl		Ile 365		рТ	hr	Val
	Ту	r S 3	er 70	Gly	Ası	o Il	e Al	la A	Ala 375	Ala	a Va	11	Gly	Leu	ı Ly 38		Asp	Th	r T	hr	Thr
20	G1: 38:	у А: 5	sp	Ser	Let	ı Th	r As	p 6	lu	Lys	s Al	.a :	Lys	Ile 395		e l	Leu	Gl	1 S	er	Ile 400
	Ası	n Wa	al :	Pro	Glı	40	o Va	1 I	le	Gln	Le		Meť 410	Val	G1	u I	Pro	Lys		er L5	Lys
25	Ala	a As	g (Sln	Asp 420	Ly:	Me	t G	ly	Ile	Al 42	a I 5	Leu	Gln	Ly	s I	Leu	Ala 430		.u	Glu
30	Asp) Pr	o 1	Thr 135	Phe	Arg	y Va	l G	lu	Thr 440	As	n V	/al	Glu	Thi		31y 45	Glu	Th	ır	Val
30	Ile	Se 45	r (Sly	Met	Gly	Gl:	L L	eu 55	His	Lei	ı A	ge	Val	Let 460		al	Asp	Ar	g l	Met
35	Arg 465	Ar	g G	Slu	Phe	Lys	Va. 470	L GI	lu .	Ala	Asr	ı V		Gly 475	Ala	ı P	ro	Gln	Va		Ser 480
	Tyr	Ar	g G	lu	Thr	Phe 485	Arq	j Al	la i	Ser	Thr	G 4	ln . 90	Ala	Arg	G.	ly	Phe	Ph 49		ъуs
40	Arg	Gl	n S	er	Gly 500	Gly	Lys	; G]	.у (Gln	Phe 505	G.	ly i	Asp	Val	T		Ile 510	Gl	u E	Phe
45	Thr	Pro	5 A	sn (15	Glu	Glu	Gly	Ьy	s (31y 520	Phe	G]	lu 1	Phe	Glu		sn / 25	Ala	Ile	e V	al
.	Gly	Gl ₃ 53(/ Va	al V	Val	Pro	Arg	G1 53	u E 5	Phe	Ile	Pr	co I		Val 540	G]	Lu I	Lуs	Gly	/ L	eu
50	Val 545	Glu	ı Se	er N	1et	Ala	Asn 550	G1	у۷	al	Leu	Al		Sly 555	Tyr	Pr	o 1	1et	Va]		sp 60
	Val	Lys	Al	la I	ys	Leu 565	Tyr	As	p G	ly,	Ser	Ту 57	r H O	is i	Asp	۷a	1 · P		Ser 575		er
55	Glu	Thr	Al	.a P 5	he 80	Lys	Ile	Ala	a A	la s	Ser 585	Le	u S	er I	Leu	Lу		lu 90	Ala	A.	la

Lys Ser Ala Gln Pro Ala Ile Leu Glu Pro Met Met Leu Val Thr Ile Thr Val Pro Glu Glu Asn Leu Gly Asp Val Met Gly His Val Thr Ala 5 615 Arg Arg Gly Arg Val Asp Gly Met Glu Ala His Gly Asn Ser Gln Ile 630 10 Val Arg Ala Tyr Val Pro Leu Ala Glu Met Phe Gly Tyr Ala Thr Val 650 Leu Arg Ser Ala Ser Gln Gly Arg Gly Thr Phe Met Met Val Phe Asp 15 His Tyr Glu Asp Val Pro Lys Ser Val Gln Glu Glu Ile Lys Lys 680 Asn Lys Gly Glu Asp 20 690 <210> 206 <211> 408 25 <212> PRT <213> Streptococcus pneumoniae <400> 206 Met Pro Asn Tyr Asn Ile Pro Phe Ser Pro Pro Asp Ile Thr Glu Ala 30 Glu Ile Ala Glu Val Ala Asp Thr Leu Arg Ser Gly Trp Ile Thr Thr 25 Gly Pro Lys Thr Lys Glu Leu Glu Arg Arg Leu Ser Leu Tyr Thr Gln Thr Pro Lys Thr Val Cys Leu Asn Ser Ala Thr Ala Ala Leu Glu Leu 40 Ile Leu Arg Val Leu Glu Val Gly Pro Gly Asp Glu Val Ile Val Pro Ala Met Thr Tyr Thr Ala Ser Cys Ser Val Ile Thr His Val Gly Ala

45

Thr Pro Val Met Val Asp Ile Gln Ala Asp Thr Phe Glu Met Asp Tyr

50 Asp Leu Leu Glu Gln Ala Ile Thr Glu Lys Thr Lys Val Ile Ile Pro 120

55

Val Glu Leu Ala Gly Ile Val Cys Asp Tyr Asp Arg Leu Phe Gln Val

Val Glu Lys Lys Arg Asp Phe Phe Thr Ala Ser Ser Lys Trp Gln Lys

		a Pr	ie As	in Ar	g II 16	e Va: 5	1 11	e Va	l Sei	17	p Sei 0	r Ala	a Hi	s Al	a Le 17	u Gly 5
5	Se	r Th	r Ty	r Ly 18	s Gl	y Glr	n Pr	o Se	r Gl ₃	7 Se:	r Ile	e Ala	a As _l	Phe 19		r Ser
10		e Se	r Ph 19	e Hi 5	s Ala	a Val	. Ly:	s Ası 200	n Phe	Thi	Thr	Ala	Glu 205		/ Gl	y Ser
	Ala	a Th 21	r Tr O	р Гу	s Ala	a Asn	215	o Val	l Ile	Asp	Asp	Glu 220		Met	Ту	Lys
15	Gl: 225	u Ph	e Gl:	n Ile	e Leu	Ser 230	Leu	ı His	Gly	Gln	Thr 235		Asp	Ala	Leu	Ala 240
	Lys	s Me	t Gli	n Lei	245	Ser	Trp	Glu	Tyr	Aşp 250	Ile	Val	Thr	Pro	Ala 255	
20	Lys	Cy:	s Asr	n Met 260	Thr	Asp	Ile	Met	Ala 265	Ser	Leu	Gly	Leu	Val 270	Gln	Leu
25	Asp	Arg	7 Tyr 275	Pro	Ser	Leu	Leu	Gln 280	Arg	Arg	Lys	Asp	Ile 285	Val	Asp	Arg
	Tyr	Asp 290	Ser	Gly	Phe	Ala	Gly 295	Ser	Arg	Ile	His	Pro 300	Leu	Ala	His	Lys
30	Thr 305	Glu	Thr	Val	Glu	Ser 310	Ser	Arg	His	Leu	Tyr 315	Ile	Thr	Arg	Val	Glu 320
					Glu 325	ķ				330					335	_
35				340	Ser				345					350		
40			335	•	Leu		- 30	360			•	,	365			
		370			Asn		375					380				
45	383					390			Glu :	fhr	Phe 1 395	Lys í	Thr '	Val :		Glu 400
	Lys	Val	Leu	Thr	Leu 405	Ser I	ys :	Lys								
50	<210 <211 <212	> 32 > PR	5 T								-					
55	<213: <400: Met 3	> 20	7		cus p Asp P				sp A	sn I	le A	la A	la G	ı ln L	ys I	'hr

		1				5	5					1	0					1	5
5		r G	ln G	lu I	Seu 20	Asr	ı Va	l Pi	ne L	ys	Asn 25	Th	г Ту	r As	n T	hr 1	Phe 30		s Lys
		t G	lu G	lu I 35	eu	Glr	As:	p G]	lu V	al 40	Glu	Ile	e Le	u Le		sp 1 45	?he	Le	u Ala
10	Gl	u As	sp G 50	lu S	er	Val	. Hi		ip G. 5	lu	Leu	Va]	L Al		n L	eu <i>I</i>	Ala	Glı	ı Leu
	As 6	p Ly 5	/S I	le M	et	Thr	Se:	r Ty O	r G	lu	Met	Thr	Le 7		u Le	eu S	er	Glı	Pro 80
15	Ту	r As	р Н:	is A	sn .	Asn 85	Ala	a Il	e Le	eu :	Glu	Ile 90	Hi:	s Pr	o Gl	ly S	er	Gly 95	Gly
20	Th	r Gl	u Al	la G	ln . 00	Asp	Trp	Gl.	y As	p i	Met 105	Leu	Let	ı Ar	g Me		yr 10	Thr	Arg
	Туз	Gl	y As 11	in A.	la 1	Lys	Gly	Pho	e Ly 12	s \ 0	/al	Glu	Va]	. Le	As د 12		yr	Gln	Ala
25	Gly	13	p G1 0	u A	La (Gly	Ile	Lys 135	s Se	r (/al	Thr	Leu	Ser 140		e G.	lu	Gly	Pro
	Asn 145	Al	а Ту	r Gl	Ly I	Leu	Leu 150	Lys	s Se	r G	lu	Met	Gly 155		. Hi	s Ai	rg	Leu	Val 160
30	Arg	Ile	e Se	r Pr	:o E	Phe 165	Asp	Ser	Ala	a L		Arg 170	Arg	His	Th	r Se		Phe 175	Thr
35	Ser	Val	G1	u Va 18	1 M	let	Pro	Glu	Lei	1 A	.sp 85	Asp	Thr	Ile	Glı	ע Va 19		Glu	Ile
	Arg	Glu	19:	As 5	рI	le	Lys	Met	Asp 200))	hr 1	Phe	Arg	Ser	G1 <u>y</u> 205		у	Ala	Gly
40	Gly	Gln 210	Ası	ı Va	1 A	sn :	Lys	Val 215	Ser	T	hr (31y	Val	Arg 220	Let	Th	rļ	His	Ile
				/ Il		-	230						235				•		240
45	Asn	Arg	Asp	Ar	g A.	la 1 45	Met	Lys	Met	Le		31n /	Ala	Lys	Leu	Ту		Sln 255	Met
50	Glu	Gln	Glu	Lуз 260	s Ly)	ys P	Ala	Ala	Glu	V2	1 A	sp :	Ser	Leu	Lys	G1: 270		lu .	Lys
	Lys		215						280						285				
55	Tyr	Thr 290	Met	Val	Ьу	s A	sp 1	His 295	Arg	Th	r S	er E		Glu 300	Val	Ala	G	ln V	/al
	Asp 1	Lys	Val	Met	As	p G	lv A	Asp	ī.é.:	Δ -	n (°	1., 13	ho.		7	71 -	m.		

305 310 315 320

Lys Trp Arg Ile Ser 325

5

<210> 208

<211> 249

<212> PRT

10 <213> Streptococcus pneumoniae

<400> 208

Met Phe Tyr Thr Tyr Leu Arg Gly Leu Val Val Leu Leu Trp Ser

1 5 10 15

15

Ile Asn Gly Asn Ala His Tyr His Asn Thr Asp Lys Ile Pro Asn Gln 20 25 30

Asp Glu Asn Tyr Ile Leu Val Ala Pro His Arg Thr Trp Trp Asp Pro 35 40 45

Val Tyr Met Ala Phe Ala Thr Lys Pro Lys Gln Phe Ile Phe Met Ala 50 55 60

25 Lys Lys Glu Leu Phe Thr Asn Arg Ile Phe Gly Trp Trp Ile Arg Met
65 70 75 80

Cys Gly Ala Phe Pro Ile Asp Arg Glu Asn Pro Ser Ala Ser Ala Ile 85 90 95

30

45

Lys Tyr Pro Ile Asn Val Leu Lys Lys Ser Asp Arg Ser Leu Ile Met 100 105 110

Phe Pro Ser Gly Ser Arg His Ser Asn Asp Val Lys Gly Gly Ala Ala
115 120 125

Leu Ile Ala Lys Met Ala Lys Val Arg Ile Met Pro Val Thr Tyr Thr 130 135 140

Gly Pro Met Thr Leu Lys Gly Leu Ile Ser Arg Glu Arg Val Asp Met 145 150 155 160

Asn Phe Gly Asn Pro Ile Asp Ile Ser Asp Ile Lys Lys Met Asn Asp 165 170 175

Glu Gly Ile Glu Thr Val Ala Asn Arg Ile Gln Thr Glu Phe Gln Arg 180 185 190

Leu Asp Glu Glu Thr Lys Gln Trp His Asn Asp Lys Lys Pro Asn Pro 195 200 205

Leu Trp Trp Phe Ile Arg Ile Pro Ala Leu Ile Leu Ala Ile Ile Leu 210 215 220

Ala Ile Leu Thr Ile Ile Phe Ser Phe Ile Ala Ser Phe Ile Trp Asn 225 230 235 240

Pro Asp Lys Lys Arg Glu Glu Leu Ala 245

. 5	<pre><210> 209 <211> 1033 <212> PRT <213> Streptococcus pneumoniae</pre>
	<pre><400> 209 Met Ile Ala Gln Leu Asp Thr Lys Thr Val Tyr Ser Phe Met Glu Ser</pre>
15	Val Ile Ser Ile Glu Lys Tyr Val Arg Ala Ala Lys Glu Tyr Gly Tyr 20 25 30
	Thr His Leu Ala Met Met Asp Ile Asp Asn Leu Tyr Gly Ala Phe Asp 35 40 45
20	Phe Leu Glu Ile Thr Lys Lys Tyr Gly Ile His Pro Leu Leu Gly Leu 50 60
25	Glu Met Thr Val Phe Val Asp Asp Gln Gly Val Asn Leu Arg Phe Leu 65 70 75 80
	Ala Leu Ser Ser Val Gly Tyr Gln Gln Leu Met Lys Leu Ser Thr Ala 85 90 95
30	Lys Met Gln Gly Glu Lys Thr Trp Ser Val Leu Ser Gln Tyr Leu Glu 100 105 110
25	Asp Ile Ala Val Ile Val Pro Tyr Phe Asp Arg Val Glu Ser Leu Glu 115 120 125
35	Leu Gly Cys Asp Tyr Tyr Ile Gly Val Tyr Pro Glu Thr Leu Ala Ser 130 135 140
40	Glu Phe His His Pro Ile Leu Pro Leu Tyr Arg Val Asn Ala Phe Glu 145 150 155 160
	Ser Arg Asp Arg Glu Val Leu Gln Val Leu Thr Ala Ile Lys Glu Asn 165 170 175
45	Leu Pro Leu Arg Glu Val Pro Leu Arg Ser Arg Gln Asp Val Phe Ile 180 185 190
5 0	Ser Ala Ser Ser Leu Glu Lys Leu Phe Gln Glu Arg Phe Pro Gln Ala 195 200 205
50	Leu Asp Asn Leu Glu Lys Leu Ile Ser Gly Ile Ser Tyr Asp Leu Asp 210 215 220
55	Thr Ser Leu Lys Leu Pro Arg Phe Asn Pro Ala Arg Pro Ala Val Glu 225 230 235 240
	Glu Leu Arg Glu Arg Ala Glu Leu Gly Leu Val Gln Lys Gly Leu Thr 245 250 255

		Se	er L	ys G	lu T 2	yr G 60	ln As	sp Ai	g Le	u As 26	p G1	.n G1	u Le	u Se	r Va 27		e His
	5	As	р М	et G 2	ly Pi 75	he A	sp As	T q	r Ph 28	e Le 0	u Va	l Va	l Tr	p As 28		u Le	u Arg
	10	Ph	e G. 2:	ly A 90	rg S	er As	sn Gl	у Ту 29	r Ty 5	r Me	t Gl	y Me	t Gl 30		g Gl	y Se	r Ala
	10	Va 30	1 GI 5	ly s	er Le	eu Va	al Se 31	r Ту .0	r Al	a Le	u As	p Il 31	e Thi	r Gl	y Il	e As	p Pro 320
	15	Va	1 G]	lu L	ys As	n Le 32	eu Il 25	e Ph	e Gl	u Ar	g Ph 33	e Le	u Ası	n Ar	g Glı	u Ar 33	g Tyr 5
	,	Th	r Me	et Pi	co As 34	p I1	e As	p Il	e As	9 Ile 345	e Pro	o As _l	o Ile	∋ Туз	350		o Asp
	20	Pho	e Il	e Aı 35	g Ty	r Va	l Gl	y Ası	n Ly:	s Ty:	Gl	y Sei	c Lys	His 365		a Ala	a Gln
	- 25	Ile	e Va 37	1 Th 0,	r Ph	e Se	r Th	r Phe 37	e Gly 5	/ Ala	Lys	s Glr	n Ala 380		Arg	ı Ası	o Val
	23	Leu 385	ı Ly	s Ar	g Ph	e Gl	y Val	l Pro	Glu	туг	Glu	Leu 395		Ala	Ile	Tha	Lys 400
	30	Lys	Ţl	e Se	r Ph	e Ar	g Asp 5	Asr	i Leu	Lys	Ser 410		Tyr	Glu	Gly	Asn 415	Leu
		Gln	Ph	e Ar	g Gl: 420	n Gl i	n Ile	e Asn	Ser	Lys 425	Leu	Glu	Tyr	Gl'n	Lys 430		Phe
	35	Glu	Ile	Al. 43	a Cys	s Lys	s Ile	Glu	Gly 440	Tyr	Pro	Arg	Gln	Thr 445	Ser	Val	His
	40	Ala	Ala 450	a Gl	γ Val	l Val	l Ile	Ser 455	Asp	Gln	Asp	Leu	Thr 460	Asn	Tyr	Ile	Pro
	10	Leu 465	Lys	ту:	Gly	Asp	Glu 470	Ile	Pro	Leu	Thr	Gln 475	Tyr	Asp	Ala	His	Gly 480
	45	Val	Glu	Ala	Ser	Gly 485	Leu	Leu	Lys	Met	Asp 490	Phe	Leu	Gly	Leu	Arg 495	
v.		Leu	Thr	Phe	Val 500	Gln	Lys	Met	Gln	Glu 505	Leu	Leu	Ala	Glu	Ile 510	Glu	Gly
	50	Ile	His	Leu 515	Lys	Ile	Glu	Glu	Ile 520	Asp	Leu	Glu	Asp	Lys 525	Glu	Thr	Leu
	55	Asp	Leu 530	Phe	Ala	Ser	Gly	Asn 535	Thr	Lys	Gly	Ile	Phe 540	Gln	Phe	Glu	Gl'n
		Pro 545	Gly	Ala	Ile	Arg	Leu 550	Leu	Lys	Arg.		Gln 555	Pro	Val	Суѕ		Glu 560

	As	sp V	al V	al	Al	a Th 56	r T	'hr	Se	r Le	eu I	Asn	Ar 57	g Pi O	:0 G	ly	Ala	a Se		sp 75	Tyr
5	11	e A	sn A	.sn	Phe 580	e Va O	l A	la	Ar	д Ьу	s i	lis 585	Gl	y Gl	n G	lu	Glı	ı Va 59		hr	Val
10	Le	u A	sp P 5	ro 95	Va.	l Le	u G	lu	Ası	9 Il 60	e I O	eu	Ala	a Pr	o Ti	hr	Ту: 605		уІ	le	Met
	Le	u Ty 6:	lộ Yr G	ln	Gli	ı Gl	n V	al	Met 615	G1 5	n V	al	Ala	a Gl	n Ai 62	.g	Phe	al Al	a G	ly	Phe
15	Se 62	r Le 5	eu G	ly	Lys	Al	a A. 6:	sp 30	Ile	e Le	u A	rg	Arç	g Al 63	а М е 5	et	Gly	Ly	s L	ys	Asp 640
	Al	a Se	er Al	la	Met	Hi:	s G:	lu	Met	Ar	дA	la	Ser 650	Ph	e Il	.e	Gln	Gl		er 55	Leu
20	Gl	u Al	a GJ	Ļу	His 660	Th	r Va	1	Glu	ь Буз	6 A	la 65	Glu	ı Gl	n Va	1	Phe	As ₁		al	Met
25	Glı	ı Ly	s Ph 67	ie '5	Ala	G1;	· T.	r	Gly	Phe 680))	sn	Arg	Se	r Hi		Ala 585	Туз	: Al	a	Tyr
•	Sei	A1 69	а Le 0	u.	Ala	Phe	• G1	n :	Leu 695	Ala	Ty	yr	Phe	Lys	70		lis	Туг	Pr	о.	Ala
30	I1∈ 705	Ph	е Ту	r	Gln	Ile	Ме 71	t 1 0	Leu	Asn	Se	er	Ala	Asr 715		r F	Asp	Tyr	Le		11e 720
	Asp	Ala	a Le	u (Glu	Ala 725	Gl	у 1	?he	Glu	Va		Ala 730	Pro	Let	ı S	er	Ile	As 73		Thr
3,5	Ile	Pro	ту	r F	lis 740	Asp	Ly	s 1	le	Ala	As 74	n : 5	Lys	Ala	Ile	e T	yr	Leu 750	G1	уΙ	eu
40			75:	•						760						7	65				
	His	Arg 770	Pro	T	'yr	Ser	Ası	1 I 7	le 75	Glu	As	įβ	Phe	Ile	Ala 780	L	y <u>s</u>	Leu	Pro	o G	lu
45	Asn 785	Tyr	Leu	ı L	ys	Leu	Pro 790))	eu	Leu	Gl	u E	Pro	Leu 795	Val	L	ys '	Val	Gl	_	eu 00
	Phe	Asp	Ser	P	he	Glu 805	Lys	A	sn .	Arg	Glı	n I 8	ys 10	Val	Phe	As	sn I	Asn	Let 815		la
50	Asn			8.	20						825	5					8	330			
55	Ile	Tyr	Ser 835	T	rp (31n	Glu	Se	er (Glu 840	Asp	Т	rp '	Thr	Glu	G1 84		Slu	Lys	Pì	1e
•	Tyr	Met 850	Glu	G]	ln G	Slu	Leu	Le 85	eu (Sly	Ile	G.	ly V	Val	Ser	Гу	s H	lis	Pro	Le	eu

	8	1n <i>F</i> 65	41a	I16	∍ AI	a Se	r Ly 87	ys A 70 ·	la I	le	Tyr	Pro	87:	e Tl 5	nr E	Pro	11	e G	lу	Asn 880
5	Le	eu S	Ser	Glu	ı As	n Se 88	r Ту 5	r A	la I	le	Ile	Leu 890	Va.	l G1	lu V	al	Gl:	n Ly 89		Ile
10	L	ys V	'al	Ile	90	g Th O	r Ly	s Ly	ys G	ly	Glu 905	Asn	Met	: A1	a P	he	Le: 910		.n	Ala
	As	sp A	sp	Ser 915	Ly	s Ly	s Ly	s Le	eu A 9	sp 20	Val	Thr	Leu	ı Ph		er 25	Asp	o Le	u	Tyr
15	Ar	g G 9	1n 30	Val	Gly	y Gl	n Gl	u II 93	le L:	ys	Glu	Glý	Ala	Ph 94		yr	Туг	: Va	1	Lys
	G1 94	y L; 5	ys	Ile	Glr	ı Sei	95	g As O	p G	Ly i	Arg	Leu	Gln 955	Me	t I	le	Ala	Gl		Glu 960
20	Il	e A	rg	Glu	Ala	Va] 965	Ala	a Gl	u Ar	rg 1	Phe	Trp 970	Ile	Gl	n Va	al	Lys	As:		His
25	G1	u Se	er I	Asp	Gln 980	Glu	ı Ile	e Se	r Ar	g]	Ile 985	Leu	Glu	Glı	n Pl		Lys 990	Gl	y I	?ro
	Il	e Pr	o 1	Val 995	Ile	Ile	Arg	ј Ту	r Gl 100	u 0	5lu	Glu	Gln	Lys	100		Ile	Va	LS	Ser
30	Pro	о Н <u>і</u> 101	.s F	His	Phe	Val	Ala	Ly: 101!	s Se 5	r A	lsn	Glu		Glu 1020		.u 1	Lys	Let	1 A	
	G1 102	1 Il 25	e V	/al	Met	Lys	Thr 1030		е Ту	r A	rg					٠				
35	<21	.0>	210	1		÷														
	<21	1> 2>	306	5																
40					ocod	ccus	pne	umon	iae											
		0> 2 Th:			Glu	Phe	Leu	His	Phe	• G	1 11 7	vs 1	[]e	Ser	Z) ~~/	~ C	ll n	mh	m.	
	1					5						10						15		
45					20	Arg				2	25					,	30			,
50	Glu	Ser	: I.	le I 35	уs	Ser	Phe	Asn	Asp 40	G]	ln I	le S	Ger 1	Leu	Glr 45		sp	Vạl	Tł	ır
	Asp	Ile 50	Ty	ÀĖ T	eu	Pro	Leu	Ala 55	His	Le	eu I	le G	ln 1	11e 60	Tyr	Ly	ys i	Arg	Th	ır
55	Lys 65	Glu	As	sp L	eu i	Ala	Phe 70	Ser	Lys	Gl	у І.	le P	he I 75	eu	Gln	Aı	cg (Glu		r 0
	Lys	Ser	Gl	n P	ro l	Phe :	Ile	Ile	Gly	Va	1 S	er G	ly s	er	Val	Al	la V	/al	G1	у

					8	5				90)				9	5
5	Lys	s Se	r Th	r Thi	r Sei	r Arg	J Le	ı Lev	Glr 105	ı Ile	e Lei	ı Lei	ı Sei	Arg 110		r Ph
-	Thr	: Ası	P Ala	a Thi	. Val	l Glu	ı Leı	1 Val 120	Thr	Thr	Asp	Gly	/ Phe		туз	Pro
10	Asn	Gl: 130	n Thi	r Leu	ılle	e Glu	Glr 135	Gly	Ile	Leu	ı Asņ	Arg		Gly	r- Ph∈	e Pro
	Glu 145	Ser	Tyr ·	: Asp	Met	Glu 150	Ala	Leu	Leu	Asn	Phe 155	Leu	Asp	Arg	Ile	Lys
15	Asn	Gly	Gln	Asp	Val 165	Asp	Ile	Pro	Val	Tyr 170	Ser	His	Glu	Val	Tyr 175	
20	Ile	Val	Pro	Lys 180	Lys	Lys	Gln	Ser	Val 185	Lys	Ala	Ala	Asp	Phe 190	Val	Ile
	Val	Glu	Gly 195	Ile	Asn	Val	Phe	Gln 200	Asn	Pro	Gln	Asn	Asp 205	Arg	Leu	Tyr
25	Ile	Thr 210	Asp	Phe	Phe	Asp	Phe 215	Ser	Ile	Tyr	Val	Asp 220	Ala	Gly	Val	Asp
	Asp 225	Ile	Glu	Ser	Trp	Tyr 230	Leu	Asp	Arg	Phe	Leu 235	Lys	Met	Leu	Ser	Leu 240
30	Ala	Gln	Asn	Asp	Pro 245	Asp	Ser	Tyr _.	Tyr	Tyr 250	Arg	Phe	Thr	Gln	Met 255	Pro
15	Ile	Gly	Glu	Val 260	Glu	Ser	Phe	Ala	His 265	Gln	Val	Trp		Ser 270	Ile	Asn

Val Ile Leu His Lys Ser Lys Asn His Glu Ile Asp Glu Ile Tyr Leu 40 295

Leu Thr Asn Leu Gln Asn Tyr Ile Glu Pro Thr Arg Asn Arg Ala Glu

Lys Lys 305

· 275

45

<210> 211

<211> 246

<212> PRT

<213> Streptococcus pneumoniae

50 <400> 211

Met Glu Ile Ser Leu Leu Thr Asp Val Gly Gln Lys Arg Thr Asn Asn

Gln Asp Tyr Val Asn His Tyr Val Asn Arg Ala Gly Arg Thr Met Ile 55

	Ile	e Lev	ı Ala 35		Gly	Met	: Gl ₃	/ Gl ₂ 40		s Ar	g Ala	ı Gly	Ası 45		e Al	a Ser
5	Glı	ı.Met 50	: Ala	. Val	. Thr	Asp	Lev 55		Val	Ala	a Trp	Va]		Thr	Gl:	n Ile
	Asp 65		Val	Asn	GLu	Val 70		g Glu	Trp	Phe	Ala 75		туг	Leu	,G1	u Ile 80
10	Glu	ı Asn	Gln	Lys	Ile 85		Gln	Leu	Gly	90		Glu	Ala	Tyr	Arc 9	g Gly 5
15	Met	: Gly	Thr	Thr 100		Glu	Val	Leu	Ala 105		lle	Asp	Asn	Gln 110	Ala	a Ile
	Tyr	Ala	His 115	Ile	Gly	Asp	Ser	Arg 120	Ile	Gly	Leu	Ile	Arg 125		Glu	ı Glu
20	Tyr	His 130		Leu	Thr	Ser	Asp 135		Ser	Leu	Val	Asn 140		Leu	Leu	Lys
	Ala 145		Gln	Leu	Thr	Pro 150	.Glu	Glu	Ala	Glu	Ala 155	His	Pro	Gln	Lys	160
25	Ile	Ile	Thr	Gln	Ser 165	Ile	Gly	Gln	Lys	Asp 170	Glu	Ile	Gln	Pro	Asp 175	Phe
30				180	Leu				185					190		-
			195	-	Met			200					205			
35		210			Leu		215					220				
40	225				Gly	230	Asp	Asn	Ile	Thr	Val 235	Ala	Leu	Val	Ser	Met 240
40	Asn	Glu	Glu .	-	Glu 245	Glu			-							
45	<211 <212	> 21 > 27 > PR > St	6 T	ococ	cus j	oneu	moni	ae								-
	<400								• •							
50	Met 1			Gln 1	Met 1	Lys 1	Asn '	Thr	Gly	Lys 10	Arg	Ile	qzA	Leu	Ile 15	Ala
55	Asn A	Arg 1	Lys I	?ro (20	Gln S	Ser (Sln i	Arg '	Val : 25	Leu '	Tyr (Glu :	Leu .	Arg 2	Asp	Arg

Leu Lys Arg Asn Gln Phe Ile Leu Asn Asp Thr Asn Pro Asp Ile Val 35 40 45

	Ile	Sea 50		e G12	, Gly	/ Asp	G1: 5!		t Lei	ı Leı	ı Sei	r Ala		Hi	s Ly:	з Туі
5	Glu 65		n Glr	ı Leı	a Asp	Lys 70		l Ar	g Phe	e Ile	e Gly 75		His	Thi	r Gly	y His 80
10	Leu	Gl	Phe	е Туг	Thr 85		Ту	r Arq	g Asp	Phe 90		ı Let	a Asp	Lys	Let 95	
	Thr	Asn	Leu	Glr 100	Leu	Asp	Thi	: Gly	/ Ala 105		y Val	. Ser	Tyr	Pro		L Leu
15	Asn	Val	Lys 115		Phe	Leu	Glu	1 Asr 120		/ Glu	ı Val	Lys	11e		Arç	, Ala
	Leu	Asn 130		Ala	Ser	Ile	Arg		Ser	: Asp	Arg	140		Val	. Ala	Asp
20	Ile 145	Val	Ile	Asn	Gly	Val 150		Phe	Glu	Arg	Phe 155		Gly	Asp	Gly	Leu 160
25·	Thr	Val	Ser	Thr	Pro 165	Thr	Gly	Ser	Thr	Ala 170		Asn	Lys	Ser	Leu 175	_
23	Gly	Ala	Val	Leu 180	His	Pro	Thr	Ile	Glu 185		Leu	Gln	Leu	Thr 190		Ile
30	Ala	Ser	Leu 195	Asn	Asn	Arg	Val	Tyr 200		Thr	Leu	Gly	Ser 205	Ser	Ile	Ile
	Val	Pro 210	Lys	Lys	Asp	Lys	Ile 215		Leu	Ile	Pro	Thr 220	Arg	Asn	Asp	Tyr
35	His 225	Thr	Ile	Ser	Val	Asp 230	Asn	Ser	Val	Tyr	Ser 235	Phe	Arg	Asn	Ile	Glu 240
40	Arg	Ile	Glu	Tyr	Gln 245	Ile	Asp	His	His	Lys 250	Ile	His	Phe	Val	Ala 255	Thr
•	Pro	Ser	His	Thr 260	Ser	Phe	Trp	Asn	Arg 265	Val	Lys	Asp	Ala	Phe 270		Gly
45	Glu	Val	Asp 275	Glu								-				
50	<210 <211 <212 <213	> 54 > PR	0 . T	.0000	cus	pneu	moni	lae		•						
55	<400 Met 3			Glu	Ile 5	Lys	Phe	Ser	Ser	Asp 10	Ala	Arg	Ser .	Ala	Met 15	Val
	Arg (Gly	Val.	Asp	Ile :	Leu .	Ala	Asp	Thr	Val	Ĺvs	Val	Thr :	Leu	Glv	Pro

20	25	30

5	Lу	s Gl	y Ar 3	g Ası 5	n Val	l Val	l Le	u Gl		s Se:	r Phe	e Gl	y Se 4		o Le	u Il
	Th	r As 5	n As	p Gly	y Val	LThr	: Ile 5!		a Ly:	s Gl	ı Ile	G1: 60		u Gl	u As	p Hi
10	Pho 6:	e Gl 5	u As:	n Met	Gly	7 Ala 70		s Lei	ı Vai	l Sei	r Glu 75		l Ala	a Se	r Ly	s Th 8
	Ası	n As	b Ij	e Ala	a Gly 85		Gly	Thi	Thi	7h1		Thi	c Val	l Lei	u Th: 9!	
15	Ala	a Il	e Val	l Arg 100	f Glu	Gly	Ile	e Lys	105		Thr	Ala	a Gly	/ Ala		n Pro
20	Ile	e Gl	y Ile 115	e Arg	Arg	Gly	Ile	120		: Ala	Val	Ala	Ala 125		a Val	Gli
	Ala	130	u Lys O	s Asn	Asn	Ala	Ile 135		Val	Ala	Asn	Lys 140		Ala	a Ile	Ala
25	Gln 145	Va]	l Ala	a Ala	Val	Ser 150	Ser	Arg	Ser	Glu	Lys 155	Val	Gly	Glu	Tyr	11e
				Met	165					170					175	
30				Gly 180					185				•	190		
35			195	Gly				200					205			
		210		Asp			215					220			-	
40	225			Ile		230					235					240
				Pro	245					250					255	
45				Leu 260					265	•				270		•
50			275					280					285	•		
	Asp	Ile 290	Ala	Ile	Leu	Thr (Gly 295	Gly	Thr	Val		Thr 300	Glu	Asp	Leu	Gly
55	305			Lys		310					315			•		320
	Val	Thr	Val	Asp	Lys i	Asp S	Ser '	Thr	Val	Ile	Val (Glu	Gly	Ala	Gly	Asn

					325	5				330)	•			33	5
5	Pro	o G1	u Ala	a Ile 340	e Sei	C His	s Arg	y Val	Ala 345		l Ile	Ly:	s Se:	r Gli 350		e Gl
	Thi	r. Th	r Thi	r Sei	r Glu	2 Phe	e Asp	360	g Glu	ı Lys	s Leu	Glr	n Glu 36		j Le	u Al
10	Lys	370	u Sei	Gly	/ Gly	/ Val	l Ala 375	Val	Ile	e Lys	Val	. Gl ₃		a Ala	a Thi	r Gl
•	Thr 385	Gli	ı Let	Lys	Glu	Met 390		Leu	Arg	Ile	· Glu ·395		Ala	Let	ı Ası	n Ala
15	Thr	Arç	g Ala	Ala	Val 405		Glu	Gly	Ile	Val 410		Gly	Gly	Gly	Th:	
20	Leu	Ala	a Asn	Val 420	Ile	Pro	Ala	Val	Ala 425	Thr	Leu	Glu	Leu	Thr 430		, Asp
	Glu	Ala	Thr 435	Gly	Arg	Asn	Ile	Val 440	Leu	Arg	Ala	Leu	Glu 445		Pro	Va]
25	Arg	Gln 450	Ile	Ala	His	Asn	Ala 455	Gly	Phe	Glu	Gly	Ser 460	IÌe	Val	Ile	Asp
	Arg 465	Leu	Lys	Asn	Ala	Glu 470	Leu	Gly	Ile	Gly	Phe 475	Asn	Ala	Ala	Thr	Gly 480
30	Glu	Trp	Val	Asn	Met 485	Ile	Asp	Gln	Gly	Ile 490	Ile	Asp	Pro	Val	Lys 495	
35	Ser	Arg	Ser	Ala 500	Leu	Gln	Asn	Ala	Ala 505	Ser	Val	Ala	Ser	Leu 510	Ile	Leu
	Thr	Thr	Glu 515	Ala	Val	Val	Ala	Asn 520	Lys	Pro	Glu	Pro	Val 525		Pro	Ala
40	Pro	Ala 530	Met	Asp	Pro	Ser	Met 535	Met	Gly	Gly		Met 540				
45	<210 <211 <212 <213	> 48 > PF	31	ococ	cus	pneu	moni	ae								
	<400 Met		.4 Lys	Ile	Glu	Thr	Val :	Leu l	Asp	 Ile	Leu	Lvs		Asp	G] v	Len
50	1				. 5	•				10					15	
			Glu	20					25					30		
55	Val :	Ile -	Phe 3	Asp :	Ser :	[le :	Ser 1	Tyr <i>1</i> 40	Asp (Ser 1	Arg 1	ys '	Val 45	Thr (Glu .	Asp

Thr Leu Phe Phe Ala Lys Gly Ala Ala Phe Lys Lys Glu Tyr Leu Leu Ser Ala Ile Thr Gln Gly Leu Ala Trp Tyr Val Ala Glu Lys Asp Tyr 5 Glu Val Gly Ile Pro Val Ile Ile Val Asn Asp Ile Lys Lys Ala Met 10 Ser Leu Ile Ala Met Glu Phe Tyr Gly Asn Pro Gln Glu Lys Leu Lys 105 Leu Leu Ala Phe Thr Gly Thr Lys Gly Lys Thr Thr Ala Ala Tyr Phe 115 15 Ala Tyr Asn Ile Leu Ser Gln Gly His Arg Pro Ala Met Leu Ser Thr Met Asn Thr Thr Leu Asp Gly Glu Thr Phe Phe Lys Ser Ala Leu Thr 20 150 155 Thr Pro Glu Ser Ile Asp Leu Phe Asp Met Met Asn Gln Ala Val Gln 165 Asn Asp Arg Thr His Leu Ile Met Glu Val Ser Ser Gln Ala Tyr Leu 185 Val Lys Arg Val Tyr Gly Leu Thr Phe Asp Val Gly Val Phe Leu Asn 30 Ile Ser Pro Asp His Ile Gly Pro Ile Glu His Pro Ser Phe Glu Asp Tyr Phe Tyr His Lys Arg Leu Leu Met Glu Lys Ser Arg Ala Val Ile 35 235 Ile Asn Ser Asp Met Asp His Phe Ser Val Leu Lys Glu Gln Val Glu 250 40 Asp Gln Asp His Asp Phe Tyr Gly Ser Gln Phe Asp Asn Gln Ile Glu 265 Asn Ser Lys Ala Phe Ser Phe Ser Ala Thr Gly Lys Leu Ala Gly Asp 45 Tyr Asp Ile Gln Leu Ile Gly Asn Phe Asn Gln Glu Asn Ala Val Ala 295 Ala Gly Leu Ala Cys Leu Arg Leu Gly Ala Ser Leu Glu Asp Ile Lys 50 315 Lys Gly Ile Ala Ala Thr Arg Val Pro Gly Arg Met Glu Val Leu Thr 330 Gln Lys Asn Gly Ala Lys Val Phe Ile Asp Tyr Ala His Asn Gly Asp 340

Ser Leu Lys Lys Leu Ile Asn Val Val Glu Thr His Gln Thr Gly Lys 360 -Ile Ala Leu Val Leu Gly Ser Thr Gly Asn Lys Gly Glu Ser Arg Arg 5 375 Lys Asp Phe Gly Leu Leu Leu Asn Gln His Pro Glu Ile Gln Val Phe 395 10 Leu Thr Ala Asp Asp Pro Asn Tyr Glu Asp Pro Met Ala Ile Ala Asp Glu Ile Ser Ser Tyr Ile Asn His Pro Val Glu Lys Ile Ala Asp Arg 15 Gln Glu Ala Ile Lys Ala Ala Met Ala Ile Thr Asn His Glu Leu Asp Ala Val Ile Ile Ala Gly Lys Gly Ala Asp Cys Tyr Gln Ile Ile Gln 20 Gly Lys Lys Glu Ser Tyr Pro Gly Asp Thr Ala Val Ala Glu Asn Tyr 25 Leu <210> 215 30 <211> 659 <212> PRT <213> Streptococcus pneumoniae <400> 215 35 Met Ile Gln Ile Gly Lys Ile Phe Ala Gly Arg Tyr Arg Ile Val Lys Gln Ile Gly Arg Gly Gly Met Ala Asp Val Tyr Leu Ala Lys Asp Leu 40 Ile Leu Asp Gly Glu Glu Val Ala Val Lys Val Leu Arg Thr Asn Tyr Gln Thr Asp Pro Ile Ala Val Ala Arg Phe Gln Arg Glu Ala Arg Ala 45 Met Ala Asp Leu Asp His Pro His Ile Val Arg Ile Thr Asp Ile Gly 50 Glu Glu Asp Gly Gln Gln Tyr Leu Ala Met Glu Tyr Val Ala Gly Leu Asp Leu Lys Arg Tyr Ile Lys Glu His Tyr Pro Leu Ser Asn Glu Glu 55 Ala Val Arg Ile Met Gly Gln Ile Leu Leu Ala Met Arg Leu Ala His

120

٠	Th	r Ai 13	rģ GI 30	ly Il	Le Va	ıl Hi	s Ar	g As	p Le	u Ly	s Pr	o Gl 14		n Il	e Le	u Leu
. 5	Th 14	r Pi 5	o As	sp Gl	y Th	r Al 15	a Ly O	s Va	1 Th	r As	p Ph 15		y Il	e Al	a Va	l Ala 160
10	Ph	e Al	a Gl	lu Th	r Se 16	r Le 5	u Th	r Gl	n Th	r As:		r Me	t Le	u Gl	y Se. 17	r Val
	Hi	ѕ Ту	r Le	eu Se 18	r Pr 0	o Gl	u Gl	n Al	a Ard 18		y, Se	r Lys	s Ala	a Th:		l Gln
15	Se	r As	p Il 19	е Т у	r Al	a Me	t Ģl	y Il 20	e Ile	e Phe	е Туз	Glu	1 Met		Th:	r Gly
	His	3 Il 21	e Pr O	о Ту	r As _i	p Gl	y As ₁		r Ala	a Val	l Thi	220		a Lei	ı Glr	n His
20	Phe 225	G1:	n Ly	s Pr	o Lei	230	Sei	r Val	l Ile	e Ala	Glu 235		Pro	Ser	· Val	Pro 240
. 25	Glr	a Ala	a Le	u Gl	u Asr 245	ı Val	l Ile	e Ile	e Lys	Ala 250		Ala	Lys	Lys	Leu 255	Thr
	Asn	Ar	у Ту:	r Arg 260	g Ser	· Val	. Ser	Glu	Met 265		Val	Asp	Leu	Ser 270		Ser
30	Leu	Sei	275	r Ası	n Arg	Arg	Asr.	Glu 280	Ser	Lys	Leu	Ile	Phe 285		Glu	Thr
	Ser	Lys 290	Ala	a Asp	Thr	Lys	Thr 295	Leu	Pro	Lys	Val	Ser 300	Gln	Ser	Thr	Leu
35	Thr 305	Ser	Ile	Pro	Lys	Val 310	Gln	Ala	Gln	Thr	Glu 315	His	Lys	Ser	Ile	Lys 320
40	Asn	Pro	Ser	Gln	Ala 325	.Val	Thr	Glu	Glu	Thr 330	Tyr	Gln	Pro	Gln	Ala 335	Pro
	Lys	Lys	His	Arg 340	Phe	Lys	Met	Arg	Tyr 345	Leu	Ile	Leu	Leu	Ala 350	Ser	Leu
45	Val	Leu	Val 355	Ala	Ala	Ser		Ile 360	Trp	Ile	Leu	Ser	Arg 365	Thr	Pro	Ala
	Thr	Ile 370	Ala	Ile	Pro	Asp	Val 375	Ala	Gly	Gln	Thr	Val 380	Ala	Glu	Ala	Lys
50	Ala 385	Thr	Leu	Lys	Lys	Ala 390	Asn	Phe	Glu	Ile	Gly 395	Glu	Glu	Lys	Thr	Glu 400
55	Ala	Ser	Glu	Lys	Val 405	Glu	Glu	.Gly		Ile 410	Ile .	Arg	Thr	Asp	Pro 415	Gly
	Ala	Gly	Thr	Gly 420	Arg	Lys	Glu	Gly	Thr	Lys	Ile	Asn :		Val 430	Val	Ser

	261	. GT7	435		ı sei	- FIIE	e GII	440		r Asi	т ту.	r va	44		g Ly	s Sei
5	Ser	450		. Ile	e Ala	a Glu	1 Let 455		s Glı	ı Lys	ь Гу	s Va. 46		o As	p As	n Let
10	Ile 465		: Ile	Glu	ı Glu	470		se Se	c Ası	ı Glu	3 Se:		a Ala	a Gl	y Th	r Val
	Leu	Lys	Gln	Ser	Leu 485		Glu	Gly	/ Thr	Thr 490		r Ası	Le:	ı Sei	с Ly . 49:	s Ala 5
15	Thr	Gln	Ile	Val 500	Leu	Thr	Val	Ala	Lys 505		ala	a Thi	Thi	510		n Leu
	Gly	Asn	Tyr 515	Ile	Gly	Arg	Asn	Ser 520		Glu	Va]	. Il∈	Ser 525		Le	ı Lys
20	Gln	Lys 530	Lys	Val	Pro	Glu	Asn 535		Ile	Lys	Ile	Glu 540		Glu	Glu	ı Ser
· 25	Ser 545	Glu	Ser	Glu	Pro	Gly 550	Thr	Ile	Met	Lys	Gln 555		Pro	Gly	Ala	Gly 560
	Thr	Thr	Tyr	Asp	Val 565	Ser	Lys	Pro	Thr	Gln 570	Ile	Val	Leu	Thr	Val	Ala
30	Lys	Lys	Val	Thr 580	Ser	Val	Ala	Met	Pro 585	Ser	Tyr	Ile		Ser 590		Leu
,	Glu	Phe	Thr 595	Lys	Asn	Asn	Leu	Ile 600	Gln	İle	Val	Gly	Ile 605	Lys	Glu	Ala
35	Asn	Ile 610	Glu	Val	Val	Glu	Val 615	Thr	Thr	Ala	Pro	Ala 620	Gly	Ser	Ala	Glu
40	Gly 625	Met	Val	Val	Glu	Gln 630	Ser	Pro	Arg	Ala	Gly 635	Glu	Lys	Val	Asp	Leu 640
	Asn	Lys	Thr	Arg	Val 645	Lys	Ile	Ser	Ile	Tyr 650	Lys	Pro	Lys	Thr	Thr 655	Ser
45	Ala	Thr	Pro													
50	<211 <212	> PR	1	ococ	cus ;	pneu	moni	ae	•			-				
55	<400 Met :			Phe .	Asp :	Thr :	Ile	Val	Ile	Gly 10	Gly	Gly	Pro	Ala	Gly 15	Met
	Met A	Ala '	Thr :	lle :	Ser S	Ser A	Asn 1	Phe	Tyr	Gly	Gln	Lys	Thr	Leu	Leu	Ile

				20					25					30		
5	Glu	Lys	Asn 35		Lys	Leu	Gly	Lys 40	_	Leu	Ala	Gly	Thr 45	_	Gly	Gly
5	Arg	Cys 50		Val	Thr	Asn	Asn 55		Ser	Leu	Asp	Asn 60	Leu	Leu	Ala	Gly
10	Ile 65		Gly	Asn	Gly	Arg 70	Phe	Leu	Tyr	Ser	Val 75	Phe	Ser	Gln	Phe	Asp 80
	Asn	His	Asp	Ile	Ile 85	Asn	Phe	Phe	Thr	Glu 90		Gly	Val	Lys	Leu 95	ГЛS
15	Val	Glu	Asp	His 100	Gly	Arg	Val	Phe	Pro 105	Ala	Ser	Asp	Lys	Ser 110	Arg	Thr
20	Ile	Ile	Glu 115	Ala	Leu	Glu	Lys	Lys 120	Ile	Thr	Glu	Leu	Gly 125	Gly	Gln	Val
20	Ala	Thr 130	Gln	Ile	Glu	Ile	Val 135	Ser	Val	Lys	Lys	Val 140	Asp	Asp	Gln	Phe
25	Val 145	Leu	Lys	Ser	Ala	Asp 150	Gln	Thr	Phe	Thr	Cys 155	Glu	Lys	Leu	Ile	Val 160
	Thr	Thr	Gly	Gly	Lys 165	Ser	Tyr	Pro	Ser	Thr 170	Gly	Ser	Thr	Gly	Phe 175	Gly
30	His	Glu	Ile	Ala 180	Arg	His	Phe	Lys	His 185	Thr	Ile	Thr	Asp	Leu 190	Glu	Ala
35	Ala	Glu	Ser 195	Pro	Leu	Leu	Thr	Asp 200	Phe	Pro	His	Lys	Ala 205	Leu	Gln	Gly
	Ile	Ser 210	Leu	Asp	Asp	Val	Thr 215	Leu	Ser	Tyr	Gly	Lys 220	His	Val	Ile	Thr
40	His 225	Asp	Leu	Leu	Phe	Thr 230	His	Phe	Gly	Leu	Ser 235	Gly	Pro	Ala	Ala	Leu 240
	Arg	Met	Ser	Ser	Phe 245	Val	Lys	Gly	Gly	Glu 250		Leu	Ser	Leu	Asp 255	Val
45	Leu	Pro	Gln	Leu 260	Ser	Glu	Lys	Asp	Leu 265	Val	Thr	Phe	Leu	Glu 270	Glu	Asn
50	Arg	Glu	Lys 275	Ser	Leu	Lys	Asn	Ala 280	Leu	Lys	Thr	Leu	Leu 285	Pro	Glu	Arg
,,	Leu	Ala 290	Glu	Phe	Phe	Val	Gln 295	Gly	Tyr	Pro	Glu	Lys 300	Val	Lys	Gln	Leu
55	Thr 305	Glu	Lys	Glu	Arg	Glu 310	Gln	Leu	Val	Gln	Ser 315	Ile	Lys	Glu	Leu	Lys 320

Ile Pro Val Thr Gly Lys Met Ser Leu Ala Lys Ser Phe Val Thr Lys

55

325 330 Gly Gly Val Ser Leu Lys Glu Ile Asn Pro Lys Thr Leu Glu Ser Lys 345 Leu Val Pro Gly Leu His Phe Ala Gly Glu Val Met Asp Ile Asn Ala His Thr Gly Gly Phe Asn Ile Thr Ser Ala Leu Cys Thr Gly Trp Val 10 Ala Gly Ser Leu His Tyr Asp 390 15 <210> 217 <211> 231 <212> PRT <213> Streptococcus pneumoniae 20 <400> 217 Met Leu Lys Trp Glu Asp Leu Pro Val Glu Met Lys Ser Ser Glu Val 25 Glu Ser Tyr Tyr Gln Leu Val Ser Lys Arg Lys Gly Ser Leu Ile Phe Lys Arg Cys Leu Asp Trp Val Leu Ala Leu Val Leu Thr Trp Val Leu 30 Thr Ser Pro Ile Phe Leu Ile Leu Ser Ile Trp Ile Lys Leu Asp Ser Lys Gly Pro Val Ile Tyr Lys Gln Glu Arg Val Thr Gln Tyr Asn Arg 35 Arg Phe Lys Ile Trp Lys Phe Arg Thr Met Val Thr Asp Ala Asp Lys 40 Lys Gly Ser Leu Val Thr Ser Ala Asn Asp Ser Arg Ile Thr Lys Val Gly Asn Phe Ile Arg Arg Val Arg Leu Asp Glu Leu Pro Gln Leu Val 45 Asn Val Leu Lys Gly Glu Met Ser Phe Val Gly Thr Arg Pro Glu Val 135 Pro Arg Tyr Thr Glu Gln Tyr Ser Pro Glu Met Met Ala Thr Leu Leu 50 Leu Gin Ala Gly Ile Thr Ser Pro Ala Ser Ile Asn Tyr Lys Asp Glu 170 Asp Thr Ile Ile Ser Gln Met Thr Glu Lys Gly Leu Ser Val Asp Gln

185

180

Ala Tyr Val Glu His Val Leu Pro Glu Lys Met Arg Tyr Asn Leu Ala Tyr Leu Arg Glu Phe Ser Phe Phe Gly Asp Ile Lys Ile Met Phe Gln 5 215 Thr Val Phe Glu Val Leu Lys 10 <210> 218 <211> 140 <212> PRT <213> Streptococcus pneumoniae 15 <400> 218 Met Thr Ser Pro Leu Leu Glu Ser Arg Arg Gln Leu Arg Lys Cys Ala 20 Phe Gln Ala Leu Met Ser Leu Glu Phe Gly Thr Asp Val Glu Thr Ala Cys Arg Phe Ala Tyr Thr His Asp Arg Glu Tyr Thr Asp Val Gln Leu 25 Pro Ala Phe Leu Ile Asp Leu Val Ser Gly Val Gln Ala Lys Lys Glu Glu Leu Asp Lys Gln Ile Thr Gln His Leu Lys Ala Gly Trp Thr Ile 30 Glu Arg Leu Thr Leu Val Glu Arg Asn Leu Leu Arg Leu Gly Val Phe 90 . . 35 Glu Ile Thr Ser Phe Asp Thr Pro Gln Leu Val Ala Val Asn Glu Ala 100 Ile Glu Leu Ala Lys Asp Phe Ser Asp Gln Lys Ser Ala Arg Phe Ile 120 40 Asn Gly Leu Leu Ser Gln Phe Val Thr Glu Glu Gln 130 45 <210> 219 <211> 1179 <212> PRT <213> Streptococcus pneumoniae 50 <400> 219 Met Tyr Leu Lys Glu Ile Glu Ile Gln Gly Phe Lys Ser Phe Ala Asp Lys Thr Lys Val Val Phe Asp Gln Gly Val Thr Ala Val Val Gly Pro 55 20 25

Asn Gly Ser Gly Lys Ser Asn Ile Thr Glu Ser Leu Arg Trp Ala Leu

			3	5				4	0				4	5		
5	Gl	y G1 5	u Se	r Se	r Val	l Lys	5 Se:		u Ar	g Gl	y Gly	/ Lys		t Pro	o As _i	o Val
	11 6	e Ph 5	e Al	a Gl	y Thi	Glu 70	Sei	r Arq	g Lys	s Pro	5 Let 75		Ту	r Ala	a Ser	val 80
10	Va.	l Va	l Th	r Le	u Asp 85		His	s Asp	o G13	7 Phe 90		Lys	: Asp	Ala	Gl ₃ 95	/ Gln
•	Glı	ıIl	e Ar	g Val	l Glu	Arg	His	s Ile	Tyr 105		g Ser	Gly	' Asp	Ser 110		Tyr
15	Lys	3 11	e As;	o Gly	y Lys	Lys	Val	Arg 120		Arg	Asp	lle	His 125		Leu	Phe
20	Let	130	P Thi	c Gly	/ Leu	Gly	Arg 135		Ser	Phe	Ser	Ile 140	Ile	Ser	Gln	Gly
	Lys 145	Va.	l Glı	ı Glu	lle	Phe 150	Asn	Ser	Lys	Pro	Glu 155	Glu	Arg	Arg	Ala	Ile 160
25	Phe	Glı	ı Glu	Ala	Ala 165	Glу	Val	Leu	Lys	Tyr 170		Thr	Arg	Arg	Lys 175	Glu
	Thr	Glı	ı Şer	180	Leu	Gln	Gln	Thr	Gln 185	Asp	Asn	Leu	Asp	Arg 190	Leu	Glu
30	Asp	Ile	11e 195	Tyr	Glu	Leu	Asp	Asn 200	Gln	Île	Lys	Pro	Leu 205	Glu	Lys	Gln
35	Ala	Glu 210	Asn	Ala	Arg	Lys	Phe 215	Leu	Asp	Leu	Glu	Gly 220	Gln	Arg	Lys	Ala
	Ile 225	Tyr	Leu	Asp	Val	Leu 230	Val	Ala	Gln	Ile	Lys 235	Glu	Asn	Lys	Ala	Glu 240
40	Leu	Glu	Ser	Thr	Glu 245	Glu	Glu	Léu	Ala	Gln 250	Val	Gln	Glu	Leu	Leu 255	Met
	Ser	Tyr	Tyr	Gln 260	Lys	Arg	Glu	Lys	Leu 265	Glu	Gl∙u	Glu	Asn	Gln 27:0	Thr	Leu
45	Lys	Lys	Gln 275	Arg	Gln	Asp	Leu	Gln 280	Ala	Glu	Met		Lys 285	Asp	Gln	Gly
50	Ser	Leu 290	Met	Asp	Ĺeu		Ser 295 _.	Leu	Ile	Ser	Asp	Leu 300	Glu	Arg	Lys	Leu
	Ala 305	Leu	Ser	Lys	Leu	Glu 8 310	Ser	Glu	Gln		Ala 315	Leu .	Asn	Gln	Gln	Glu 320
55	Ala	Gln	Ala	Arg	Leu 2 325	Ala A	Ala	Leu		Asp 330	Lys .	Arg I	Asn		Leu 335	Ser

Lys Glu Lys Tyr Asp Lys Glu Ser Ser Leu Ala Leu Leu Glu Gly Asn

-				34	0	•			34	5				35	0	
5	Le	u Va	1 G1 35		n As	n Gl	n Ly	s Le 36		n Ar	g Le	u Gl	u Al 36		u Lei	u Leu
	Al	a Ph 37	e Se O	r As	p As	p Pro	37		n Me	t Il	e Glu	u Lei 380		u Ar	g Glı	ı Arg
10	Ph:	e Va 5	l Al	a Le	u Le	u Glr 390	n G1	u Gl	u Ala	a As	p Va 395		r Ası	n Gli	n Lei	1 Thr 400
	Ar	g Il	e Gl	u As	n Gli 40!		ı Glı	u Ası	n Sei	410		ı Let	ı Sei	r Glr	Lys 415	Gln
15	Ala	a As	p Gl	n Lei 42		ı Lys	Le	ı Lys	5 Glu 425		n Lei	ı Ala	a Thi	Ala 430	_	Glu
20	· Lys	al:	a Se:	r Gl: 5	n Glr	n Lys	Asp	9 Glu 440		ı Glu	ı Thr	Ala	ь Буз 445		Glr	val
	Glr	450		u Lei	ı Ala	a Asp	Tyr 455		n Ala	ı Ile	e Ala	Lys 460		ı Gln	Glu	Glu
25	Gln 465	Lys	s Thi	r Ser	Tyr	Gln 470		Gln	Gln	Ser	Gln 475		Phe	. Asp	Arg	Leu 480
	Asp	Sei	: Let	ı Lys	485		Gln	Ala	Arg	Ala 490		Ser	Leu	Glu	Asn 495	
30	Leu	Arç	J Asr	1 His	Ser	Asn	Phe	Tyr	Ala 505		Val	Lys	Ser	Val 510		Gln
35	Glu	Lys	Asp 515		Leu	Gly	Gly	1le 520		Gly	Ala	Val	Ser 525	Glu	His	Leu
	Thr	Phe 530		Val	Tyr	Tyr	Gln 535		Ala	Leu	Glu	Ile 540	Ala	Leu	Gly	Ala
40	Ser 545	Ser	Gln	His	Ile	Ile 550	Val	Glu	Asp	Glu	Glu 555	Ser	Ala	Thr	Lys	Ala 560
	Ile	Asp	Phe	Leu	Lys 565		Asn	Arg	Val	Gly 570		Ala	Thr	Phe	Leu 575	Pro
45	Leu	Thr	Thr	Ile 580	Lys	Ala	Arg	Thr	Ile 585		Ser	Gln	Asn	Gln 590	Asp	Ala
50	Ile	Aļa	Val 595	Ser	Pro	Gly	Phe	Leu 600	Gly	Met	Ala	Asp	Glu 605	Leu	Val	Thr
	Phe	Asp 610	Thr	Arg	Leu	Glu	Ala 615	Ile	Phe	Lys	Asn	Leu 620	Leu	Ala	Thr	Thr
55	Ala 625	Ile	Phe	Asp	Thr	Val 630	Glu	His	Ala	Arg	Glu 635	Ala	Ala	Arg	Gln	Val 640
	Arg	Tyr	Gln	Val	Arg	Met	Val,	Thr	Leu	Asp	Gly	Thr	Glu	Leu	Arg	Thr

55

																FC 1/ U.
					64	5				65	0				65	5
5	Gl	y Gl	y Se	r Ty:	r Ala	a Gly	y Gl	y Ala	ASI 665		g Gli	n Ası	n Ası	n Ser 670		e Phe
	Ile	e Ly	s Pro 67	5 Gl	u Lei	ı Glu	ı Glı	n Lei 680	ı Glr	ı Ly	s Glı	ı Ile	e Ala 689		a Asp	o Glu
10	Ala	Se. 69	r Lei 0	ı Gl	y Ser	Glu	Glu 695	ı Ala	a Ala	ı Lei	u Lys	700		ı Glr	a Asp	Gln
	Met 705	Ala	a Aļla	a Leu	1 Thr	Glu 710	Arg	g Leu	Glu	a Ala	a Ile 715		Ser	Glr	Gly	720
15	Gln	Ala	a Arç	j Il∈	9 Gln 725		Glr	n Gly	Leu	730		Ala	Туг	Gln	Glr 735	Thr
20	Ser	Glı	n Glr	740	Glu	Glu	Leu	Glu	Thr 745		ı Trp	Lys	Leu	Gln 750		Glu
	Glu	Ile	2 Asp 755	Arg	Leu	Ser	Glu	Gly 760	Asp	Trp	Gln	Ala	Asp 765		Glu	Lys
25	Cys	Glr 770	ı Glu	Ser	Leu	Ala	Thr 775		Ala	Ser	Asp	Lys 780		Asn	Leu	Glu
	Ala 785	Glu	lle	Glu	Glu	Ile 790	Lys	Ser	Asn	Lys	Asn 795	Ala	Ile	Gln	Glu	Arg 800
30	Tyr	Gln	Asn	Leu	Gln 805	Glu	Glu	Val	Ala	Gln 810		Arg	Leu	Leu	Lys 815	Thr
35	Lys	Leu	Gln	Gly 820	Gln	Lys	Arg	Tyr	Glu 825	Val	Ala	Asp	Ile	Glu 830	Arg	Leu
	Gly	Lys	Glu 835	Leu	Asp	Asn	Leu	Asn 840	Ile	Glu	Gln	Glu	Glu 845	Ile	Gln	Arg
40	Met	Leu 850	Gln	Glu	Lys	Val	Asp 855	Asn	Leu	Glu	Lys	Val 860	Asp	Thr	Glu	Leu
	Leu 865	Ser	Gln	Gln	Ala	Glu 870	Glu	Ser	Lys	Thr	Gln 875	Lys	Thr	Asn	Leu	Gln 880
45	Gln	Gly	Leu		Arg 885	Lys	Gln	Phe		Leu 890	Asp	Asp	Ile	Glu	Gly 895	Gln
50	Leu	Asp	Asp	Ile 900		Ser	His	Leu	Asp 905	Ğln	Ala	Arg	Gln	Gln 910	Asn	Glu

Glu Trp Ile Arg Lys Gln Thr Arg Ala Glu Ala Lys Lys Glu Lys Val 915 920 925

Ser Glu Arg Leu Arg His Leu Gln Asn Gln Leu Thr Asp Gln Tyr Gln 930 935 940

Ile Ser Tyr Thr Glu Ala Leu Glu Lys Ala His Glu Leu Glu Asn Leu

	945					950)				955	5				960
5	Asn	Leu	Ala	a Glu	965	n Glu	ı Val	l Glr	n Asp	970	ı Glı	ı Lys	ala Ala	ı Ile	975	_
	Leu	Gly	Pro	980	l Asr)	ı Leu	G1v	a Ala	985		Glr	туг	Glu	990		l His
10	Asn	Arg	Leu 995	Asp	Phe	e Leu	Asr	Ser 1000		Arg	Asp	Asp	1005		Ser	Ala
	Lys 1	Asn 010	Leu	Leu	Leu	Glu	Thr 1015		Thr	Glu	Met	Asn 1020		Glu	Val	. Lys
15	Glu 1025	Arg	Phe	Lys	Ser	Thr 1030	Phe	Glu	Ala		Arg 1035		Ser	Phe	Lys	Val 1040
20	Thr	Phe	Lys	Gln	Met 1045	Phe	Gly	Gly		Gln 1050		Asp	Leu		Leu 1055	
	Glu	Gly		Leu 1060		Thr	Ala		Val 1065		Ile	Ser		Gln 1070	Pro	Pro
25	Gly		Lys 1075		Gln	Ser	Leu	Asn 1080	Leu	Met	Ser		Gly 1085	Glu	Lys	Ala
	Leu 1	Ser 090	Ala	Leu	Ala		Leu 1095	Phe	Ser	Ile		Arg 1100	Val	Lys	Thr	Ile
30	Pro 1 1105	Phe	Val	Ile		Asp 1110	Glu	Val	Glu		Ala 1115	Leu	Asp	Glu		Asn 1120
35	Val 1	Lys	Arg		Gly 1125	Asp	Tyr	Leu	Asn 1	Arg 1130	Phe	Asp	Lys		Ser .135	Gln
	Phe I	Ile		Val 140	Thr	His	Arg		Gly 1145	Thr	Met	Ala		Ala 150	Asp	Ser
40	Ile T	ľyr 1	Gly 155	Val	Thr	Met	Gln 1	Glu 160	Ser	Gly	Val		Lys .165	Ile	Val	Ser
	Val I 11	Jys 170	Leu	Lys	qaA		Glu 175	Ser	Ile	Glu	Gly					
45	<210><211>	44	7		٠	•										
50	<212> <213>	St:	rept	ococ	cus	pneu	moni	ae								·
	<400> Met T 1			Arg	Val 5	Thr :	Ile	Ile	Asp	Val :	Lys .	Asp	Tyr	Val (Gly 15	Gln
55	Glu V	al 1	hr :	Ile	Gly i	Ala :	rrp	Val .	Ala A	Asn 1	Lys :	Ser (Gly :	Lys (Gly	Lys

	Ile	Ala	a Phe		ı Glr	Leu	a Arg	Asp 40		y Thi	r Ala	a Ph∈	Phe 45		Gly	/ Val
5	Ala	Phe 50		s Pro	Asn	Phe	• Val		ı Lys	s Phe	e Gly	/ Glu 60		val	. Gly	/ Leu
	Gl u 65		s Phe	e Asp	Val	11e 70		s Arg	J Let	ı Sei	Glr. 75		Thr	Ser	· Val	Tyr 80
10	Val	. Thi	Gly	/ Ile	val 85		Glu	ı Asp	Glu	Arg		Lys	Phe	Gly	Tyr 95	Glu
15	Leu	Asp) Ile	Thr 100		Ile	Glu	ı Val	. Ile 105		/ Glu	Ser	Gln	Asp 110	_	Pro
	Ile	Thr	Pro 115		Glu	His	Gly	Thr 120		Phe	Leu	Met	Asp 125		Arg	His
20	Leu	Trp		. Arg	Ser	Arg	Lys 135		Val	Ala	Val	Leu 140	Gln	Ile	Arg	Asn
	Ala 145		Ile	Tyr	Ala	Thr 150	Tyr	Glu	Phe	Phe	Asp 155	Lys	Asn	Gly	Phe	Met 160
25	Lys	Phe	Asp	Ser	Pro 165	Ile	Leu	Ser	Gly	Asn 170		Ala	Glu	Asp	Ser 175	Thr
30	Glu	Leu	Phe	Glu 180	Thr	Asp	Tyr	Phe	Gly 185		Pro	Ala	Tyr	Leu 190	Ser	Gln
	Ser	Gly	Gln 195	Leu	Tyr	Leu	Glu	Ala 200	Gly	Ala	Met	Ala	Leu 205	Gly	Arg	Val
35	Phe	Asp 210	Phe	Gly	Pro	Val	Phe 215	Arg	Ala	Glu	Lys	Ser 220	Lys	Thr	Arg	Arg
	His 225	Leu	Thr	Glu	Phe	Trp 230	Met	Met	Asp	Ala	Glu 235	Tyr	Ser	Tyr	Leu	Thr 240
40	His	Asp	-Glu	Ser	Leu 245	Asp	Leu	Gln	Glu	Ala 250	Tyr	Val	Lys	Ala	Leu 255	Leu
45	Gln	Gly	Val	Leu 260	Asp	Arg	Ala	Pro	Gln 265		Leu	Glu	Thr	Leu 270	Glu	Arg
	Asp	Thr	Glu 275	Leu	Leu	Lys	Arg	Tyr 280	Ile	Ala 	Glu	Pro	Phe 285	Lys.	Arg	Île
50	Thr	Tyr 290	Asp	Gln	Ala		Asp 295	Leu	Leu	Gln	Glu	His 300	Glu	Asn	Asp	Glu
	Asp 305	Ala	Asp	Tyr	Glu	His 310	Leu	Glu	His	Gly	Asp 315	Asp	Phe	Gly	Ser	Pro 320
55	His	Glu	Thr	Trp	Ile 325	Ser /	Asn	His		Gly 330	Val	Pro '	Thr		Val 335	Met

	As	n T	yr Pi	ro Al 34	a Al O	a Il	e Ly	s Al	a Ph 34		r Me	t Ly	s Pr	o Va 35		o Gly
, 5	As	n Pi	ro G] 35	lu Ar 55	g Va	l Le	ц Су	s Al 36		p Le	u Lei	ı Ala	a Pr		u Gl	y Tyr
	Gl	y G1 37	lu I] 70	e Il	e Gl	y Gly	y Se:		t Ar	g Gl	u Glu	Ası 380		r Ası	p Al	a Leu
10	Va 38	1 A1 5	a Ly	's Me	t As	9 Glu 390		u Gl	y Met	t As	9 Arg		Gl	туј	r Gl	u Phe 400
15	Ту	r Le	eu As	p Le	u Ar		з Ту	r Gl	y Thi	va.		His	Gly	y Gly	y Pho 41	e Gly 5
10	11	e Gl	y Il	e Gla 420		g Met	: Val	l Thi	2 Phe		a Ala	Gly	Thr	Lys 430		s Ile
20	Ar	g Gl	u Al 43	a Ile 5	e Pro	Phe	Pro	Arg 440		: Le	ı His	Arg	11e 445	-	Pro	> ,
25	<2: <2:	10> 11> 12> .3>	308 PRT	ptoco	occus	pne	umon	iae			·			٠	•	
30				ı Lys	Leu 5		Glu	Ile	Lys	Asp 10		Glu	Ile	Ser	Phe 15	-
	Glu	Gl	y Sei	Lys 20		Phe	Val	Ala	Val 25	Lys	Asn	Ala	Asn	Phe 30	Phe	Ile
35	Asn	Lys	35 35	y Glu 5	Thr	Phe	Ser	Leu 40	Val	Gly	Glu	Ser	Gly 45	Ser	Gly	Lys
40	Thr	Th:	Tle	e Gly	Arg	Ala	Ile 55	Ile	Gly	Leu	Asn	Asp 60	Thr	Ser	Asn	Gly
	Asp 65	Ile	: Ile	Phe	Asp	Gly 70	Gln	Lys	Ile	Asn	Gly 75	Lys	Lys	Ser	Arg	Glu 80
45	Gln	Ala	Ala	Glu	Leu 85	Ile	Arg	Arg	Ile	Gln 90	Met	Ile	Phe	Gln	Asp 95	Pro
	Ala	Ala	Ser	Leu 100	Asn	Glu	Arg	Ala	Thr 105	<u>V</u> al	Asp	Tyr	Ile	Ile 110	Ser	Glu
50	Gly	Leu	Tyr 115	Asn	His	Arg	Leu	Phe 120	Lys	Asp	Glụ	Glu	Glu 125	Arg	Lys	Glu
55	Lys	Val 130	Gln	Asn	Ile		Arg 135	Glu	Val	Gly		Leu 140	Ala	Glu	His	Leu
	Thr 145	Arg	Tyr	Pro	His	Glu 150	Phe -	Ser	Gly	Gly	Gln . 155	Arg	Gln	Arg	Ile	Gly 160

	Ile	e Al	.a Ar	g Al	a Le 16	u Va] 5	L Met	: Gli	n Pro	170		e Val	. I1e	∍ Ala	175	o Glu	
5	Pro	o Il	e Se	r Al. 18	a Le	u Asp	Val	. Sei	r Val	. Arq	g Ala	Gln	Va]	Leu 190		ı Leu	
10			19	5				200)				205	5		e Ala	
	His	21	p Le O	u Sei	r Vai	l Val	Arg 215	Phe	: Ile	: Ser	Asp	Arg 220		Ala	Val	Ile	
15	225	ı				≥ Val 230					235					240	
20					245				,	250				•	255		
20				260	,	Glu			265					270			
25			275			Glu		280					285			-	
	Pro	Gl ₃ 290	y His)	Tyr	Val	Trp	Ala 295	Asn	Gln	Thr	Glu	Leu 300	Ala	Arg	Tyr	Gln	
30	Lys 305	Glλ	/ Leu	Asn													
35	<210 <211 <212 <213	l> 4 ?> P	24 RT	toco	ccus	pneu	moni	ae									
40	<400 Met 1			Ser	Trp 5	Asn	Gly	Phe	Ser	Lys 10	Lys	Ser	Tyr	Gln	Glu 15	Arg	
	Leu	Glu	Leu	Leu 20	Lys	Ala	Gln .	Ala	Leu 25	Leu	Ser	Pro	Glu	Arg 30	Gln	Ala	
45	Ser	Leu	Glu 35	Lys	Asp	Glu	Gln i	Met 40	Ser	Val	Thr	Val .	Ala 45	Asp.	Gln	Leu	
50	Ser	Glu 50	Asn	Val	Val.	Gly	Thr 1	Phe	Ser	Leu	Pro '	Tyr :	Ser	Leu	Val	Pro	
	Glu ' 65	Val	Leu	Val	Asn	Gly (Gln (Glu '	Tyr !	Thr '	Val 1	Pro 1	ſyr '	Val '	Thr (Glu 80	
55 .	Glu 1	Pro	Ser	Val	Val 85	Ala A	Ala A	Ala s	Ser :	Tyr 2 90	Ala S	Ser I	ys .	Ile :	[le] 95	Lys	

Arg Ala Gly Gly Phe Thr Ala Gln Val His Gln Arg Gln Met Ile Gly

					10	0					10.	5				1	10		
	G1	n V	al.	Ala	Le	u Ty	r Gl	n I	le	Ala	Ası	n Pr	o Li	rs T.e	en A				u Lys
5				115	;	-				120				Б		25	3.1.1.1	GI	n nys
	11	e A 1	la : 30	Ser	Ly	s Ly	s Al	.a G:	lu 35	Leu	Let	ı G1	u Le	eu Al 14		sn G	ln	Al.	a Tyr
10	Pr 14	o S 5	er :	Ile	Va.	l Ly	s Ar 15	g G: 0	lу	Gly	Gly	/ Al	a Ar 15		p Le	eu H	is	Va.	l Glu 160
	Gl	n I	le 1		Gl	y Gl	u Pr 5	o As	sp :	Phe	Let	1 Va 17		1 Ту	r IJ	le H	is	Va: 175	l Asp
15	Th	r G	ln (Slu	Ala 180	a Mei	t Gl	y Al	la i	Asn	Met 185		u As	n Th	r Me		eu 90	Glı	Ala
20	Lei	ı L	/s E 1	Pro .95	Val	L Lei	ı Gl	u Gl	u 1	Leu 200	Ser	Glı	n Gl	y Gl	n Se		eu	Met	Gly
	Ile	21	eu S .0	er	Asn	туг	Al:	a Th 21	r 7 5	4sp	Ser	Lei	ı Va	1 Th:		a S	er	Cys	Arg
25	Ile 225	Al	a P	he	Arg	туг	Let 230	ı Se)	r A	arg	Gln	Lys	235		n Gl	у Аз	cg	Glu	Ile 240
	Ala	Gl	u L	ys	Ile	Ala 245	Let	ı Al	a S	er	Gln	Phe 250		a Glr	n Al	a As	q	Pro 255	Tyr
. 30	Arg	Al	a A	la	Thr 260	His	Asr	Ly	s G		Ile 265	Phe	Asr	Gly	/ Il	e As 27		Ala	Ile
35	Leu	Il	e A.	1a 75	Thr	Gly	Asn	Ası		rp 80	Arg	Ala	Ile	Glu	Ala 285		у.	Ala	His
	Ala	Pho 29	e A.	la	Ser	Arg	Asp	Gl ₃ 295	/ A:	rg '	Tyr	Gln	Gly	Leu 300		: Су	s '	ľrp	Thr
40	Leu 305	Asp	o Le	eu (Glu	Arg	Glu 310	Glu	ı Le	eu '	Val	Gly	Glu 315		Thr	Le	u I	Pro	Met 320
	Pro	Va]	L A1	.a !	Thr	Lys .325	GŢÀ	Gly	, Se	er :	Ile	Gly 330	Leu	Asn	Pro	Ar		/al 335	
45	Leu	Ser	Hi:	.s 2	Asp 340	Leu	Leu	Gly	' As		Pro 345	Ser	Ala	Arg	Glu	Le:		Ala	Gln.
50	Ile	Ile	• Va 35	1 5	Ser	Ile	Gly	Leu	A1		ln'	Asn	Phe	Ala	Ala 365	Let	ı I	ys	Ala
	Leu	Val 370	Se	r T	hr	Gly	Ile	Gln 375	G1	n G	ly i	His	Met	Lys 380	Leu	Glr	ı A	la	Lys
55	Ser 385	Leu	Al	a L	eu	Leu	Ala 390	Gly	Al	a S	er (Ser 395	Glu _.	Val	Ala	ı P		Leu 400
	Val	Glu	Ar	g L	eu	Ile	Ser	Asp	Ьγ	s T	hr E	he	Asn	Leu	Glu	Thr	A	la (Gln

405 410

415

Arg Tyr Leu Glu Asn Leu Arg Ser 420

<210> 223

<211> 262 <212> PRT

10 <213> Streptococcus pneumoniae

<400> 223

15

30

45

Met Pro Ile Thr Ser Leu Glu Ile Lys Asp Lys Thr Phe Gly Thr Arg
1 5 10 15

Phe Arg Gly Phe Asp Pro Glu Glu Val Asp Glu Phe Leu Asp Ile Val 20 25 30

Val Arg Asp Tyr Glu Asp Leu Val Arg Ala Asn His Asp Lys Asn Leu 20 35 40 45

Arg Ile Lys Ser Leu Glu Glu Arg Leu Ser Tyr Phe Asp Glu Ile Lys 50 55 60

25 Asp Ser Leu Ser Gln Ser Val Leu Ile Ala Gln Asp Thr Ala Glu Arg 65 70 75 80

Val Lys Gln Ala Ala His Glu Arg Ser Asn Asn Ile Ile His Gln Ala 85 90 95

Glu Gln Asp Ala Gln Arg Leu Leu Glu Glu Ala Lys Tyr Lys Ala Asn 100 105 110

Glu Ile Leu Arg Gln Ala Thr Asp Asn Ala Lys Lys Val Ala Val Glu 35 115 120 125

Thr Glu Glu Leu Lys Asn Lys Ser Arg Val Phe His Gln Arg Leu Lys
130 135 140

40 Ser Thr Ile Glu Ser Gln Leu Ala Ile Val Glu Ser Ser Asp Trp Glu 145 150 155 160

Asp Ile Leu Arg Pro Thr Ala Thr Tyr Leu Gln Thr Ser Asp Glu Ala 165 170 175

Phe Lys Glu Val Val Ser Glu Val Leu Gly Glu Pro Ile Pro Ala Pro 180 185 190

50 Ile Glu Glu Glu Pro Ile Asp Met Thr Arg Gln Phe Ser Gln Ala Glu 200 205

Met Ala Glu Leu Gln Ala Arg Ile Glu Val Ala Asp Lys Glu Leu Ser 210 220

55 Glu Phe Glu Ala Gln Ile Lys Gln Glu Val Glu Ala Pro Thr Pro Val 225 230 235 240

Val Ser Pro Gln Val Glu Glu Glu Pro Leu Leu Ile Gln Leu Ala Gln 245 250 255

Cys Met Lys Asn Gln Lys 260

<210> 224

<211> 575

<212> PRT

5

10

25

40

55

<213> Streptococcus pneumoniae

<400> 224

Met Ser Asn Gly Gln Leu Ile Tyr Leu Met Val Ala Ile Ala Val Ile
15 1 5 10 15

Leu Val Leu Ala Tyr Val Val Ala Ile Phe Leu Arg Lys Arg Asn Glu 20 25 30

20 Gly Arg Leu Glu Ala Leu Glu Glu Arg Lys Glu Glu Leu Tyr Asn Leu 35 40 45

Pro Val Asn Asp Glu Val Glu Ala Val Lys Asn Met His Leu Ile Gly
50 55 60

Gln Ser Gln Val Ala Phe Arg Glu Trp Asn Gln Lys Trp Val Asp Leu 65 70 75 80

Ser Leu Asn Ser Phe Ala Asp Ile Glu Asn Asn Leu Phe Glu Ala Glu 85 90 95

Gly Tyr Asn His Ser Phe Arg Phe Leu Lys Ala Ser His Gln Ile Asp 100 105 110

35 Gln Ile Glu Ser Gln Ile Thr Leu Ile Glu Glu Asp Ile Ala Ala Ile 115 120 125

Arg Asn Ala Leu Ala Asp Leu Glu Lys Gln Glu Ser Lys Asn Ser Gly 130 135 140

Arg Val Leu His Ala Leu Asp Leu Phe Glu Glu Leu Gln His Arg Val 145 150 155 160

Ala Glu Asn Ser Glu Gln Tyr Gly Gln Ala Leu Asp Glu Ile Glu Lys
165 170 175

Gln Leu Glu Asn Ile Gln Ser Glu Phe Ser Gln Phe Val Thr Leu Asn 180 185 190

50 Ser Ser Gly Asp Pro Val Glu Ala Ala Val Ile Leu Asp Asn Thr Glu 195 200 205

Asn His Ile Leu Ala Leu Ser His Ile Val Asp Arg Val Pro Ala Leu 210 215 220

Val Thr Thr Leu Ser Thr Glu Leu Pro Asp Gln Leu Gln Asp Leu Glu 225 230 235 240

	Al	a Gl	у Ту	r Ar	g Ly: 24!	s Lei 5	ı Il	e As	p Al	a As: 25		r Hi	s Ph	e Va	1 G1 25	
5	As	p Il	e Gl	u Al 26	a Aro	g Phe	e Hi:	s Le	u Le 26		r Gl	u Al	a Ph	e Ly 27		s Asn
10	G1	n Gl	u As 27	n Il 5	e Arq	g Glr	ı Leı	u Gl: 28		u Ası	p Ası	n Ala	a Gl: 28		r Glı	u Asn
	Gl	y Gl 29	n Al O	a Gl	n Glu	ı Glu	11e 295		n Ala	a Let	туз	300		e Phe	e Thi	c Arg
15	Gl: 30!	ı Il 5	e Al	a Ala	a Gln	Lys 310	Va]	l Vai	l Glı	ı Ası	1 Let 315		ı Ala	a Thi	r Lei	Pro 320
	Thi	с Ту	r Le	u Gli	325	Met	Lys	Glu	ı Asr	330 330		Let	ı Lev	Gly	7 Glu 335	_
20	Ile	e Ala	a Ar	g Let 340	ı Asn	Lys	Thr	Туг	Leu 345		Pro	Glu	Thr	350		Ser
25	His	va:	35!	g Arg	, Ile	Gln	Thr	Glu 360		Glu	Ser	Phe	Glu 365		Ala	Ile
	Va1	. Gli 370	ı Val	l Thr	Ser	Asn	Gln 375		Glu	Pro	Thr	Gln 380		Tyr	Ser	Val
30	Leu 385	Glu	ı Glı	a Asn	Leu	Glu 390	Asp	Leu	Gln	Thr	Gln 395	Leu	Lys	Asp	Ile	.Glu 400
	Asp	Glu	Glr	ılle	Ser 405	Val	Ser	Glu	Arg	Leu 410	Thr	Gln	Ile	Glu	Lys 415	_
35	Asp	Ile	Asn	Ala 420	Arg	Gln	Lys	Ala	Asn 425	Val	Tyr	Val	Asn	Arg 430	Leu	His
40	Thr	Ile	Lys 435	Arg	Tyr	Met	Glu	Lys 440	Arg	Asn	Leu	Pro	Gly 445	Ile	Pro	Gln
	Thr	Phe 450	Leu	Lys	Leu	Phe	Phe 455	Thr	·Ala	Ser	Asn	Asn 460	Thr	Glu	Asp	Leu
45	Met 465	Va1	Glu	Leu	Glu	Gln 470	Lys	Met	Ile	Asn	Ile 475	Glu	Ser	Val	Thr	Arg 480
	Val	Leu	Glu	Ile	Ala 485	Thr	Asn	Asp	Met	Glu 490	Ala	Leu	Glu	Thr	Glu 495	Thr
50	Tyr	Asn	Ile	Val 500	Gln	Tyr	Ala	Thr	Leu 505	Thr	Glu	Gln	Leu	Leu 510	Gln	Tyr
55	Ser	Asn	Arg 515	Tyr	Arg	Ser		Asp 520	Glu.	Arg	Ile	Gln	Glu 525	Ala	Phe	Asn
	Glu	Ala 530	Leu	Asp	Ile		Glu 535	Lys	Glu	Phe	Asp	Tyr 540	His	Ala	Ser	Phe

Asp Lys Ile Ser Gln Ala Leu Glu Val Ala Glu Pro Gly Val Thr Asn Arg Phe Val Thr Ser Tyr Glu Lys Thr Arg Glu Thr Ile Arg Phe 565 570 <210> 225 10 <211> 800 <212> PRT <213> Streptococcus pneumoniae <400> 225 15 Met Leu Ile Ser Tyr Lys Trp Leu Lys Glu Leu Val Asp Ile Asp Val Pro Ser Gln Glu Leu Ala Glu Lys Met Ser Thr Thr Gly Ile Glu Val 20 Glu Gly Val Glu Ser Pro Ala Ala Gly Leu Ser Lys Ile Val Val Gly Glu Val Leu Ser Cys Glu Asp Val Pro Glu Thr His Leu His Val Cys . 25 Gln Val Asn Val Gly Glu Glu Arg Gln Ile Val Cys Gly Ala Pro 30 Asn Val Arg Ala Gly Ile Lys Val Met Val Ala Leu Pro Gly Ala Arg Ile Ala Asp Asn Tyr Lys Ile Lys Lys Gly Lys Ile Arg Gly Leu Glu 35 -Ser Leu Gly Met Ile Cys Ser Leu Gly Glu Leu Gly Ile Ser Asp Ser Val Val Pro Lys Glu Phe Ala Asp Gly Ile Gln Ile Leu Pro Glu Asp 40 130 Ala Val Pro Gly Glu Glu Val Phe Ser Tyr Leu Asp Leu Asp Glu 150 155 45 Ile Ile Glu Leu Ser Ile Thr Pro Asn Arg Ala Asp Ala Leu Ser Met 170 Cys Gly Val Ala His Glu Val Ala Ala Ile Tyr Asp Lys Ala Val Asn 50 Phe Lys Glu Phe Thr Leu Thr Glu Thr Asn Glu Ala Ala Ala Asp Ala 200 Leu Ser Val Ser Ile Glu Thr Asp Lys Ala Pro Tyr Tyr Ala Ala Arg 55 210 215 Ile Leu Asp Asn Val Thr Ile Ala Pro Ser Pro Gln Trp Leu Gln Asn

	22	5				23	0				23	5				240
5	Le	u Le	eu Me	et As	n Gl 24	u Gl _: 5	y Il	e Ar	g Pr	o Il 25	e As O	n As	n Va	1 Va	1 As 25	p Val 5
	Th	r As	sn Ty	r Il 26	e Le	u Lei	л Ту	r Phe	e Gl; 26	y Gl 5	n Pr	o Me	t Hi	s Al 27		e Asp
10	Le	u As	sp As 27	n Ph	e Gl	u Gly	/ Th	r Asp 280		e Ar	g Va.	l Ar	g Gl: 28:		a Ar	g.Ala
	G1	y G] 29	u Ly 0	s Le	u Vai	l Thr	29!		o Gly	y Gl	u Gl	u Ard 300		p Lei	ı Ası	o Val
15	Ası 305	n As	p Le	u Vai	l Ile	310		l Ala	a Asp	Ly:	s Pro 315		l Ala	a Lei	ı Ala	Gly 320
20	Va]	l Me	t Gl	y Gly	y Glr 325	n Ala	Thi	c Glu	ı Ile	33(ı Lys	Se1	Ser	335	y Val
	Val	Le	u Gl	u Ala 340	a Ala	val	Ph∈	e Asn	Gly 345		s Ser	: Ile	Arç	J Lys 350		Ser
25	Gly	/ Ar	g Let 35!	u Asr	Leu	Arg	Ser	Glu 360		Ser	Ser	Arg	Phe 365		Lys	Gly
	Ile	370	n Val	l Ala	Thr	Val	Asn 375		Ala	Leu	Asp	Ala 380		Ala	Ser	Leu
30	Ile 385	Ala	a Glu	ı Leu	Ala	Gly 390	Ala	Thr	Val		Lys 395		Ile	Val	Ser	Ala 400
35	Gly	Glı	ı Lev	a Asp	Thr 405	Ser	Asp	Val	Glu	Val 410		Ser	Thr	Leu	Ala 415	Asp
	Val	Asn	Arg	y Val 420	Leu	Gly	Thr	Glu	Leu 425	Ser	Tyr	Ala	Asp	Val 430	Glu	Asp
40	Val	Phe	435	Arg	Leu	Gly	Phe	Gly 440	Leu	Ser	Gly	Asn	Ala 445	Asp	Ser	Phe
,	Thr	Val 450	Arg	Val	Pro	Arg	Arg 455	Arg	Trp	Asp	Ile	Thr 460	Ile	Glu	Ala	Asp
45	Leu 465	Phe	Glu	Glu	Ile	Ala 470	Arg	Ile	Tyr	Gly	Tyr 475	Asp	Arg	Leu	Pro	Thr 480
50	Ser	Leu	Pro	Lys	Asp 485	Asp	Gly	Thr	Ala	Gly 490	Glu	Leu	Thr	Ala	Thr 495	Gln
	Lys	Leu	Arg	Arg 500	Gln	Val .	Arg		Ile 505	Ala	Glu	Gly	Ala	Gly 510	Leu	Thr
55	Glu	Ile	Ile 515	Thr	Tyr	Thr :	Leu	Thr 520	Thr	Pro	Glu		Ala 525	Val	Glu	Phe
	Thr	A 1 a	Gle	Pro	Sor	Aen i	ĭ.a.ı	ምክ _ም /	C3	T	N/_ L	m	D		m.	

		53	0				53	5				540)			
5	As ₁	Arı	g Se	r Vai	l Lei	Arg 550	g Gli	n Asr	n Met	t Ile	Ser 555		, V Ile	e Lei	ı Ası	p Thi 560
	Val	l Ala	а Ту	r Ası	n Val 565	L Ala	Arq	g Lys	s Ası	1 Lys 570		ı Leı	ı Ala	i Ļet	ту: 57!	
10	Il€	e Gly	y Lys	5 Val	Phe	Glu	Glṛ	n Thr	Gly 585	/ Asr	Pro	Lys	Glu	Glu 590		ı Pro
	Asr	ı Glı	1 Ile 595	e Asr	ser	Phe	Ala	Phe 600	Ala	Leu	Thr	Gly	Leu 605		Ala	i Glu
15	Lys	Asp 610	Phe	e Gln	Thr	Ala	Ala 615		Pro	Val	Asp	Phe 620		Tyr	Ala	Lys
G1 62 20	Gly 625	Ile	Leu	Glu	Ala	Leu 630	Phe	Thr	Arg	Leu	Gly 635	Leu	Gln	Val	Thr	Tyr 640
	Thr	Ala	Thr	Ser	Glu 645	Ile	Ala	Ser	Leu	His 650	Pro	Gly	Arg	Thr	Ala 655	
25	Ile	Ser	Leu	Gly 660	Asp	Gln	Val	Leu	Gly 665	Phe	Leu	Gly	Gln	Val 670	His	Pro
	Val	Thr	Ala 675	Lys	Ala	Tyr	Asp	Ile 680	Pro	Glu	Thr	Tyr	Val 685	Ala	Glu	Leu
30	Asn	Leu 690	Ser	Ala	Ile	Glu	Ala 695	Ala	Leú	Gln	Pro	Ala 700	Thr	Pro	Phe	Val
35	Glu 705	Ile	Thr	Lys	Phe	Pro 710	Ala	Val	Ser	Arg	Asp 715	Val	Ala	Leu	Leu	Leu 720
	Lys	Ala	Glu	Val	Thr 725	His	Gln	Glu	Val	Val 730	Asp	Ála	Ile	Gln	Ala 735	Ala
40	Gly	Val	Lys	Arg 740	Leu	Thr	Asp	Ile	Lys 745	Leu	Phe	Asp	Val	Phe 750	Ser	Gly
	Glu	Lys	Leu 755	Gly	Leu	Gly		Lys 760	Ser	Met	Ala	Tyr	Ser 765	Leu	Thr	Phe
15	Gln	Asn 770	Pro	Glu	Asp		Leu 775	Thr	Asp	Glu	Glu	Val 780	Ala	Arg	Tyr	Met
60	Glu 785	Lys	Ile	Gln	Ala	Ser : 790	Leu	Glu	Glu		Val . 795	Asn	Ala	Glu	Val	Arg 800

55 <210> 226 <211> 180 <212> PRT

<213> Streptococcus pneumoniae

- 4	00.	~~~
< 4	00>	226

Met Leu Glu Asn Asp Ile Lys Lys Val Leu Val Ser His Asp Glu Ile

1 10 15

Thr Glu Ala Ala Lys Lys Leu Gly Ala Gln Leu Thr Lys Asp Tyr Ala
20 25 30

- 10 Gly Lys Asn Pro Ile Leu Val Gly Ile Leu Lys Gly Ser Ile Pro Phe 35 40 45
 - Met Ala Glu Leu Val Lys His Ile Asp Thr His Ile Glu Met Asp Phe 50 55 60
 - Met Met Val Ser Ser Tyr His Gly Gly Thr Ala Ser Ser Gly Val Ile 65 70 75 80
- Asn Ile Lys Gln Asp Val Thr Gln Asp Ile Lys Gly Arg His Val Leu 85 90 95
 - Phe Val Glu Asp Ile Ile Asp Thr Gly Gln Thr Leu Lys Asn Leu Arg 100 105 110
- 25 Asp Met Phe Lys Ala Arg Glu Ala Ala Ser Val Lys Ile Ala Thr Leu 115 120 125
 - Leu Asp Lys Pro Glu Gly Arg Val Val Glu Ile Glu Ala Asp Tyr Thr 130 135 140
 - Cys Phe Thr Ile Pro Asn Glu Phe Val Val Gly Tyr Gly Leu Asp Tyr 145 150 155 160
- Lys Glu Asn Tyr Arg Asn Leu Pro Tyr Ile Gly Val Leu Lys Glu Glu 155 170 175

Val Tyr Ser Asn 180

40 .

30

15